FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Mirkovic, K Thwing, J Diack, PA Dahl, BA Reynolds, MG Rodier, G Sanyang, Y Tshioko, F Yoti, Z AF Mirkovic, Kelsey Thwing, Julie Diack, Papa Amadou Dahl, Benjamin A. Reynolds, Mary G. Rodier, Guenael Sanyang, Yaya Tshioko, Florimond Yoti, Zabulon CA Univ Hosp Fann TI Importation and Containment of Ebola Virus Disease - Senegal, August-September 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Mirkovic, Kelsey] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Mirkovic, Kelsey] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Thwing, Julie] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Diack, Papa Amadou] Senegal Minist Hlth & Social Welf, Brazzaville, Congo. [Dahl, Benjamin A.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. [Reynolds, Mary G.] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Rodier, Guenael] WHO, Reg Off Europe, Brazzaville, Congo. [Sanyang, Yaya; Tshioko, Florimond; Yoti, Zabulon] WHO, Reg Off Africa, Brazzaville, Congo. RP Mirkovic, K (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM kmirkovic@cdc.gov NR 2 TC 11 Z9 13 U1 0 U2 29 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 3 PY 2014 VL 63 IS 39 BP 873 EP 874 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1WG UT WOS:000342573900006 PM 25275333 ER PT J AU Segula, D Frosch, AP SanJoaquin, M Taulo, D Skarbinski, J Mathanga, DP Allain, TJ Molyneux, M Laufer, MK Heyderman, RS AF Segula, Dalitso Frosch, Anne P. SanJoaquin, Miguel Taulo, Dalitso Skarbinski, Jacek Mathanga, Don P. Allain, Theresa J. Molyneux, Malcolm Laufer, Miriam K. Heyderman, Robert S. TI Prevalence and spectrum of illness among hospitalized adults with malaria in Blantyre, Malawi SO MALARIA JOURNAL LA English DT Article DE Malaria; Severe malaria; Prostration; Malawi; Rapid diagnostic tests; Hyperparasitaemia; Malaria epidemiology; Adult ID SUB-SAHARAN AFRICA; CEREBRAL MALARIA; INTERVENTIONS; POSTMORTEM; ADMISSIONS; INFECTION; DIAGNOSIS; TANZANIA; IMMUNITY; DISEASE AB Background: As control interventions are rolled out, the burden of malaria may shift from young children to older children and adults as acquisition of immunity is slowed and persistence of immunity is short-lived. Data for malaria disease in adults are difficult to obtain because of co-morbid conditions and because parasitaemia may be asymptomatic. Regular surveys of adult admissions to a hospital in Malawi were conducted to characterize the clinical spectrum of malaria and to establish a baseline to monitor changes that occur in future. Methods: In 2011-2012, at Queen Elizabeth Hospital, Blantyre, four separated one-week surveys in the peak malaria transmission period (wet season) and three one-week surveys in the low transmission period (dry season) were conducted using rapid diagnostic tests (RDT) with confirmation of parasitaemia by microscopy. All adults (aged >= 15) being admitted to the adult medical wards regardless of the suspected diagnosis, were enrolled. Participants with a positive malaria test underwent a standardized physical examination and laboratory tests. Malaria syndromes were characterized by reviewing charts and laboratory results on discharge. Results: 765 adult admissions were screened. 63 (8.2%) were RDT-positive with 61 (8.0%) positive by microscopy. Over the course of the seven study weeks, two patients were judged to have incidental parasitaemia, 31 (4.1%) had uncomplicated malaria and 28 (3.7%) had severe malaria. Both uncomplicated and severe malaria cases were more common in the rainy season than the dry season. Prostration (22/28 cases) and hyperparasitaemia (>250,000 parasites/mu l) (9/28) were the most common features of severe malaria. Jaundice (4/28), severe anaemia (2/28), hyperlactataemia (2/28), shock (1/28) and haemoglobinuria (1/28) were less commonly seen, and no patient had severe metabolic derangement or organ failure. There were no deaths attributable to malaria. Conclusion: In this study of adults admitted to hospital in southern Malawi, an area with year-round transmission of Plasmodium falciparum, classical metabolic and organ complications of malaria were not encountered. Prostration and hyperparasitaemia were more common indicators of severity in patients admitted with malaria, none of whom died. These data will provide a baseline for monitoring trends in the frequency and clinical patterns of severe malaria in adults. C1 [Segula, Dalitso; SanJoaquin, Miguel; Taulo, Dalitso; Molyneux, Malcolm; Heyderman, Robert S.] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Program, Blantyre, Malawi. [Segula, Dalitso; Allain, Theresa J.; Molyneux, Malcolm] Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi. [Frosch, Anne P.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Skarbinski, Jacek] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Mathanga, Don P.] Univ Malawi, Coll Med, Malaria Alert Ctr, Blantyre, Malawi. [Laufer, Miriam K.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Heyderman, Robert S.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. RP Segula, D (reprint author), Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Program, POB 30096, Blantyre, Malawi. EM dalitsosegula@gmail.com FU Center for Disease Control (CDC) through the Malaria Alert Center FX We would like to thank all patients who participated in the study and the study nurses Harriet Chilonda, Margret Chikopa, Nellie Manda, Bertha Mekiseni and Mercy Emana who helped in the enrolling and management of these patients. We would also like to thank Mike Moore and Patrick Mphasa (Laboratory staff) for processing slides and the blood samples. This study was funded through a core grant to the Malawi Liverpool Wellcome Trust (MLW) Clinical Research Programme and a grant from the Center for Disease Control (CDC) through the Malaria Alert Center. NR 20 TC 1 Z9 1 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD OCT 2 PY 2014 VL 13 AR 391 DI 10.1186/1475-2875-13-391 PG 6 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AU6KJ UT WOS:000345711800001 PM 25277278 ER PT J AU Bailey, RL Saldanha, LG Gahche, JJ Dwyer, JT AF Bailey, Regan L. Saldanha, Leila G. Gahche, Jaime J. Dwyer, Johanna T. TI Estimating caffeine intake from energy drinks and dietary supplements in the United States SO NUTRITION REVIEWS LA English DT Review DE beverages; caffeine; dietary supplements; energy; energy drinks AB No consistent definition exists for energy products in the United States. These products have been marketed and sold as beverages (conventional foods), energy shots (dietary supplements), and in pill or tablet form. Recently, the number of available products has surged, and formulations have changed to include caffeine. To help characterize the use of caffeine-containing energy products in the United States, three sources of data were analyzed: sales data, data from federal sources, and reports from the Drug Abuse Warning Network. These data indicate that sales of caffeine-containing energy products and emergency room visits involving their consumption appear to be increasing over time. Data from the National Health and Nutrition Examination Survey (NHANES) 2007-2010 indicate that 2.7% [standard error (SE) 0.2%] of the US population >= 1 year of age used a caffeine-containing energy product, providing approximately 150-200 mg/day of caffeine per day in addition to caffeine from traditional sources like coffee, tea, and colas. The highest usage of these products was among males between the ages of 19 and 30 years (7.6%, SE 1.0). Although the prevalence of caffeine-containing energy product use remains low overall in the US population, certain subgroups appear to be using these products in larger amounts. Several challenges remain in determining the level of caffeine exposure from and accurate usage patterns of caffeine-containing energy products. Published 2014. This article is a U.S. Government work and is in the public domain in the USA C1 [Bailey, Regan L.; Saldanha, Leila G.; Dwyer, Johanna T.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Gahche, Jaime J.] CDC, Natl Hlth & Nutr Examinat Survey Planning Branch, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Bailey, RL (reprint author), NIH, Off Dietary Supplements, 6100 Execut Blvd MSC 7517,Room 3B01, Bethesda, MD 20892 USA. EM baileyr@mail.nih.gov OI Dwyer, Johanna/0000-0002-0783-1769 FU Office of Dietary Supplement at the National Institutes of Health FX This work was fully funded by the Office of Dietary Supplement at the National Institutes of Health. NR 14 TC 10 Z9 10 U1 11 U2 71 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0029-6643 EI 1753-4887 J9 NUTR REV JI Nutr. Rev. PD OCT PY 2014 VL 72 SU 1 SI SI BP 9 EP 13 DI 10.1111/nure.12138 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CB9PR UT WOS:000349964500002 PM 25293539 ER PT J AU Iturriza-Gomara, M Lopman, B AF Iturriza-Gomara, Miren Lopman, Benjamin TI Norovirus in healthcare settings SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE hospital; norovirus; risk factors; transmission ID FECAL MICROBIOTA TRANSPLANTATION; CLOSTRIDIUM-DIFFICILE INFECTION; VIRAL GASTROENTERITIS; UNITED-STATES; NOSOCOMIAL TRANSMISSION; INTESTINAL MICROBIOTA; EXCESS MORTALITY; GII.4 NOROVIRUS; HAND SANITIZERS; NORWALK VIRUS AB Purpose of review To provide an overview of the burden of norovirus disease in healthcare settings and the factors responsible for outbreaks in these institutions; to assess progress on interventions aimed at reducing the burden of norovirus disease. Recent findings Norovirus outbreaks in healthcare settings are driven by confluence of viral diversity, the built environment, and host factors. Some of these characteristics may be modifiable and the target of successful interventions. Summary Most norovirus outbreaks in hospital and residential care institutions are associated with a particular genotype, known as GII.4. The persistence of norovirus is associated with strain diversity, which is driven by immune evasion and viral adaptation to interaction with a variety of human histo-blood group antigens. The healthcare environment presents serious challenges for control, both because of the physical structure of the built space and the high levels of contact among patient populations who may have compromised hygiene. Increased vulnerability among the populations in healthcare institutions is likely to be multifactorial and may include the following: nutritional status, immunodeficiency or senescence, chronic inflammation, and microbiome alterations. Current control measures are based on general infection control principles, and treatment is mainly supportive and nonspecific. Vaccines and antiviral agents are being developed with promising results, but none are currently available. C1 [Iturriza-Gomara, Miren] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 7BE, Merseyside, England. [Iturriza-Gomara, Miren] Univ Liverpool, NIHR Hlth Protect Res Unit Gastrointestinal Infec, Liverpool L69 7BE, Merseyside, England. [Lopman, Benjamin] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP Iturriza-Gomara, M (reprint author), Univ Liverpool, Inst Infect & Global Hlth, Clin Infect Microbiol & Immunol Dept, 8 West Derby St, Liverpool L69 7BE, Merseyside, England. EM M.Iturriza-Gomara@liverpool.ac.uk FU Wellcome Trust; National Institute for Health Research Health Protection Research Unit in Gastrointestinal Infections at the University of Liverpool FX M.I.G. receives support from The Wellcome Trust and the National Institute for Health Research Health Protection Research Unit in Gastrointestinal Infections at the University of Liverpool. NR 76 TC 14 Z9 15 U1 1 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0951-7375 EI 1473-6527 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD OCT PY 2014 VL 27 IS 5 BP 437 EP 443 DI 10.1097/QCO.0000000000000094 PG 7 WC Infectious Diseases SC Infectious Diseases GA AZ7FK UT WOS:000348384400006 PM 25101555 ER PT J AU Felix, SE Mack, K AF Felix, Sausan El Burai Mack, Karin TI Prescription drug monitoring programs in the United States of America SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH LA Spanish DT Article DE analgesics, opioid; substance-related disorders; drug overdose; prescription drugs; drug monitoring; United States ID PATTERNS; DEATHS AB discuss actions that could help reduce the problem, with particular attention to the characteristics of prescription drug monitoring programs (PDMPs). These programs consist of state-level databases that monitor controlled substances. The information compiled in the databases is at the disposal of authorized persons (e.g., physicians, pharmacists, and other health-care providers) and may be used only for professional purposes. Suppliers can use such information to prevent interaction with other drugs or therapeutic duplication, or to identify drug-search behavior. Law enforcement agencies can use these programs to identify improper drug prescription or dispensing patterns, or drug diversion. Since the late 1990s, the number of opioid analgesic overdose deaths has quadrupled in the United States of America (from 4 030 deaths in 1999 to 16 651 in 2010). The objectives of this article are to provide an overview of the problem of prescription drug overdose in the United States and to C1 [Felix, Sausan El Burai] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30333 USA. [Mack, Karin] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Anal Res & Practice Integrat DARPI, Atlanta, GA USA. RP Felix, SE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30333 USA. EM sausan.elburaifelix@upr.edu NR 21 TC 1 Z9 1 U1 1 U2 3 PU PAN AMER HEALTH ORGANIZATION PI WASHINGTON PA 525 23RD ST NW, WASHINGTON, DC 20037 USA SN 1020-4989 J9 REV PANAM SALUD PUBL JI Rev. Panam. Salud Publica PD OCT PY 2014 VL 36 IS 4 BP 270 EP 276 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AY5WU UT WOS:000347640700009 ER PT J AU Chemnasiri, T Varangrat, A Chaikummao, S Chitwarakorn, A Holtz, TH AF Chemnasiri, Tareerat Varangrat, Anchalee Chaikummao, Supaporn Chitwarakorn, Anupong Holtz, Timothy H. TI Why Young MSM Do Not Use Condoms Consistently: A Qualitative Exploration SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Chemnasiri, Tareerat; Varangrat, Anchalee; Chaikummao, Supaporn; Holtz, Timothy H.] Thailand MOPH US CDC Collaborat, Nonthaburi, Thailand. [Chitwarakorn, Anupong] Thailand Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Holtz, Timothy H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA P30.02 BP A199 EP A199 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774402141 ER PT J AU Clark, M Pereira, L Clark, J Johnson, T Pau, CP Friend, D Smith, J Kiser, P AF Clark, Meredith Pereira, Lara Clark, Justin Johnson, Todd Pau, Chou-Pong Friend, David Smith, James Kiser, Patrick TI Tenofovir Reservoir Intravaginal Rings Provide Superior Pharmacokinetics and Higher Sustained Drug Levels than Tenofovir Matrix Rings SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Clark, Meredith; Friend, David] CONRAD Eastern Virginia Med Sch, Arlington, VA USA. [Pereira, Lara] LifeSource Biomed LLC, Moffett Field, CA USA. [Clark, Justin; Johnson, Todd] Univ Utah, Salt Lake City, UT USA. [Pau, Chou-Pong; Smith, James] Ctr Dis Control & Prevent, Div HIV & AIDS Prevent, Atlanta, GA USA. [Kiser, Patrick] Northwestern Univ, Evanston, IL USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA OA03.03 BP A12 EP A12 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774400016 ER PT J AU Dobard, C Taylor, A Sharma, S Chuong, D Pau, CP Rohan, L McGowan, I Heneine, W AF Dobard, Charles Taylor, Andrew Sharma, Sunita Dinh Chuong Pau, Chou-Pong Rohan, Lisa McGowan, Ian Heneine, Walid TI Rectal Specific Gels Containing Maraviroc and/or Tenofovir Protect against Rectal SHIV Transmission in a Macaque Model SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Dobard, Charles; Taylor, Andrew; Sharma, Sunita; Dinh Chuong; Pau, Chou-Pong; Heneine, Walid] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rohan, Lisa; McGowan, Ian] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA OA03.06 LB BP A13 EP A14 PG 5 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774400019 ER PT J AU Fouda, G Pollara, J McGuire, E Rountree, W Overman, G Tegha, G Kamwendo, D Kumwenda, J Nelson, J Liao, L Ellington, S King, C Jamieson, D Van der Horst, C Kourtis, A Tomaras, G Ferrari, G Permar, S AF Fouda, Genevieve Pollara, Justin McGuire, Erin Rountree, Wesley Overman, Glenn Tegha, Gerald Kamwendo, Deborah Kumwenda, Jacob Nelson, Julie Liao, Larry Ellington, Sascha King, Caroline Jamieson, Denise Van der Horst, Charlie Kourtis, Athena Tomaras, Georgia Ferrari, Guido Permar, Sallie TI Association of HIV-1 Env Antibody Responses with Postnatal Mother-to-Child Transmission of HIV-1 via Breastfeeding SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Fouda, Genevieve; Pollara, Justin; McGuire, Erin; Rountree, Wesley; Overman, Glenn; Liao, Larry; Tomaras, Georgia; Ferrari, Guido; Permar, Sallie] Duke Human Vaccine Inst, Durham, NC USA. [Tegha, Gerald; Kamwendo, Deborah; Kumwenda, Jacob] Univ N Carolina, Malawi Project, Lilongwe, Malawi. [Nelson, Julie; Van der Horst, Charlie] Univ N Carolina, Chapel Hill, NC USA. [Ellington, Sascha; King, Caroline; Jamieson, Denise; Kourtis, Athena] Ctr Dis Control & Prevent, Atlanta, GA USA. RI Tomaras, Georgia/J-5041-2016 NR 0 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA P03.05 LB BP A99 EP A100 PG 2 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774401056 ER PT J AU Greene, E Gamble, T Tolley, EE Pack, AP Stanton, J Taylor, J Shelus, V Leider, J El-Sadr, W Branson, B AF Greene, Elizabeth Gamble, Theresa Tolley, Elizabeth E. Pack, Allison P. Stanton, Jill Taylor, Jamilah Shelus, Victoria Leider, Jason El-Sadr, Wafaa Branson, Bernard CA HPTN 065 Study Team TI The Impact of Implementing a Financial Incentive Program for Viral Suppression on the Clinic Environment: A Qualitative Substudy of HPTN 065 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Greene, Elizabeth; Gamble, Theresa; Tolley, Elizabeth E.; Pack, Allison P.; Stanton, Jill; Taylor, Jamilah; Shelus, Victoria] FHI 360, Durham, NC USA. [Leider, Jason] Jacobi Med Ctr, New York, NY USA. [El-Sadr, Wafaa] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA. [El-Sadr, Wafaa] Harlem Hosp Med Ctr, New York, NY USA. [Branson, Bernard] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA P06.03 BP A104 EP A105 PG 3 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774401068 ER PT J AU Lertpruek, S Wimonsate, W Pattanasin, S Satumay, K Sukwicha, W Tongtoyai, J Pancharoen, K Chitwarakorn, A Holtz, TH AF Lertpruek, Sirirat Wimonsate, Wipas Pattanasin, Sarika Satumay, Kesinee Sukwicha, Wichuda Tongtoyai, Jaray Pancharoen, Kanokpan Chitwarakorn, Anupong Holtz, Timothy H. TI Trends and Factors Associated with Unprotected Anal Intercourse among Young Men Who Have Sex with Men in Bangkok, Thailand, 2006-2013 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Lertpruek, Sirirat; Wimonsate, Wipas; Pattanasin, Sarika; Satumay, Kesinee; Sukwicha, Wichuda; Tongtoyai, Jaray; Pancharoen, Kanokpan; Holtz, Timothy H.] Thailand MoPH US CDC Collaborat, Nonthaburi, Thailand. [Chitwarakorn, Anupong] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Holtz, Timothy H.] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA P13.11 BP A134 EP A134 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774401145 ER PT J AU Pattanasin, S Wasinrapee, P Tongtoyai, J Chonwattana, W Sriporn, A Luechai, P Sukwicha, W Chitwarakorn, A Holtz, TH Curlin, M AF Pattanasin, Sarika Wasinrapee, Punneeporn Tongtoyai, Jaray Chonwattana, Wannee Sriporn, Anuwat Luechai, Pikunchai Sukwicha, Wichuda Chitwarakorn, Anupong Holtz, Timothy H. Curlin, Marcel TI Number Needed to Screen for Chlamydial and Gonococcal Infection among Asymptomatic Men Who Have Sex with Men in Bangkok, Thailand, 2006-2010 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Pattanasin, Sarika; Wasinrapee, Punneeporn; Tongtoyai, Jaray; Chonwattana, Wannee; Sriporn, Anuwat; Luechai, Pikunchai; Sukwicha, Wichuda; Holtz, Timothy H.; Curlin, Marcel] Thailand MoPH US CDC Collaborat, Nonthaburi, Thailand. [Chitwarakorn, Anupong] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Holtz, Timothy H.; Curlin, Marcel] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA P49.12 BP A280 EP A281 PG 2 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774404003 ER PT J AU Rutvisuttinunt, W Leelawiwat, W Chinnawirotpisan, P Mueanpai, F Kongpechsatit, O Klungthong, C O'Connell, R de Souza, M Yoon, IK Curlin, M Fernandez, S AF Rutvisuttinunt, Wiriya Leelawiwat, Wanna Chinnawirotpisan, Piyawan Mueanpai, Famui Kongpechsatit, Oranuch Klungthong, Chonticha O'Connell, Robert de Souza, Mark Yoon, In-Kyu Curlin, Marcel Fernandez, Stefan TI Metagenomics Analysis of Plasma in HIV-infected Men Who Have Sex with Men in Bangkok, Thailand SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Rutvisuttinunt, Wiriya; Chinnawirotpisan, Piyawan; Klungthong, Chonticha; Yoon, In-Kyu; Fernandez, Stefan] Armed Forces Res Inst Med Sci, Dept Virol, Bangkok 10400, Thailand. [Leelawiwat, Wanna; Mueanpai, Famui; Kongpechsatit, Oranuch; Curlin, Marcel] Thai Minist Publ Hlth US Ctr Dis Prevent Collabor, Nonthaburi, Thailand. [O'Connell, Robert] Armed Forces Res Inst Med Sci, Dept Retrovirol, Bangkok 10400, Thailand. [de Souza, Mark] Thai Red Cross AIDS Res Ctr, South East Asian Res Collaborat Hawaii, Bangkok, Thailand. [Curlin, Marcel] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA P25.08 BP A184 EP A184 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774402104 ER PT J AU Thienkrua, W Pattanasin, S Chemnasiri, T Varangrat, A Sukwicha, W Chaikummao, S Hengprasert, S Chitwarakorn, A Holtz, TH AF Thienkrua, Warunee Pattanasin, Sarika Chemnasiri, Tareerat Varangrat, Anchalee Sukwicha, Wichuda Chaikummao, Supaporn Hengprasert, Sumetha Chitwarakorn, Anupong Holtz, Timothy H. TI High HIV Incidence in Young Men Who Have Sex with Men Engaged in Sex Parties, Factors Associated with Sex Party, Bangkok MSM Cohort Study, 2006-2014 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Thienkrua, Warunee; Pattanasin, Sarika; Chemnasiri, Tareerat; Varangrat, Anchalee; Sukwicha, Wichuda; Chaikummao, Supaporn; Hengprasert, Sumetha; Holtz, Timothy H.] Thailand MoPH US CDC Collaborat, Nonthaburi, Thailand. [Chitwarakorn, Anupong] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Holtz, Timothy H.] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA P36.11 BP A217 EP A217 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774403011 ER PT J AU Thurman, AR Jacot, TA Melendez, J Kimble, TD Snead, MC Jamshidi, R Wheeless, A Archer, DF Schwartz, JL Doncel, GF Mauck, C AF Thurman, Andrea R. Jacot, Terry A. Melendez, Johan Kimble, Thomas D. Snead, Margaret Christine Jamshidi, Roxanne Wheeless, Angie Archer, David F. Schwartz, Jill L. Doncel, Gustavo F. Mauck, Christine TI Assessment of the Vaginal Residence Time of Biomarkers of Semen Exposure SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Thurman, Andrea R.; Jacot, Terry A.; Kimble, Thomas D.; Archer, David F.; Schwartz, Jill L.; Doncel, Gustavo F.; Mauck, Christine] Eastern Virginia Med Sch, CONRAD, Norfolk, VA 23501 USA. [Melendez, Johan; Jamshidi, Roxanne] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Snead, Margaret Christine] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Wheeless, Angie] FHI 360, Res Triangle Pk, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA P23.15 BP A172 EP A172 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774402073 ER PT J AU Wimonsate, W Pattanasin, S Sriporn, A Luechai, P Satumay, K Tippanonth, N Promda, N Varangrat, A Chitwarakorn, A Holtz, TH AF Wimonsate, Wipas Pattanasin, Sarika Sriporn, Anuwat Luechai, Pikunchai Satumay, Kesinee Tippanonth, Narongritt Promda, Nutthawoot Varangrat, Anchalee Chitwarakorn, Anupong Holtz, Timothy H. TI Multiple HIV Counselling Sessions and Safe Sex Practice Helped Bangkok Men Who Have Sex with Men Stay HIV-uninfected: Thailand 2006-2014 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Wimonsate, Wipas; Pattanasin, Sarika; Sriporn, Anuwat; Luechai, Pikunchai; Satumay, Kesinee; Tippanonth, Narongritt; Promda, Nutthawoot; Varangrat, Anchalee; Holtz, Timothy H.] Thailand MoPH US CDC Collaborat, Nonthaburi, Thailand. [Chitwarakorn, Anupong] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Holtz, Timothy H.] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA OA07.05 BP A23 EP A23 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774400042 ER PT J AU Wimonsate, W Chaikummao, S Sriporn, A Luechai, P Satumay, K Winaitham, S Yafant, S Pattanasin, S Chitwarakorn, A Holtz, TH AF Wimonsate, Wipas Chaikummao, Supaporn Sriporn, Anuwat Luechai, Pikunchai Satumay, Kesinee Winaitham, Santi Yafant, Somsak Pattanasin, Sarika Chitwarakorn, Anupong Holtz, Timothy H. TI Young Thai Men who Have Sex with Men and a Voluntary HIV Testing Service, Bangkok, 2005-2013 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Wimonsate, Wipas; Chaikummao, Supaporn; Sriporn, Anuwat; Luechai, Pikunchai; Satumay, Kesinee; Winaitham, Santi; Yafant, Somsak; Pattanasin, Sarika; Holtz, Timothy H.] Thailand MoPH US CDC Collaborat, Nonthaburi, Thailand. [Chitwarakorn, Anupong] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Holtz, Timothy H.] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA P09.13 BP A114 EP A115 PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774401093 ER PT J AU Dentinger, C Prussing, C Khosa, P Balter, S AF Dentinger, Catherine Prussing, Catharine Khosa, Perminder Balter, Sharon TI Two Acute Hepatitis C Virus Infections Following Outpatient Endoscopy Procedures SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Prussing, Catharine; Khosa, Perminder; Balter, Sharon] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Dentinger, Catherine] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 1550 BP S457 EP S457 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383101762 ER PT J AU Barbour, KE Murphy, L Theis, KA Helmick, CG Hootman, J Stevens, JA AF Barbour, Kamil E. Murphy, Louise Theis, Kristina A. Helmick, Charles G. Hootman, Jennifer Stevens, Judy A. TI The Association Between Doctor-Diagnosed Arthritis and Falls and Fall Injuries Among Middle-Aged and Older Adults. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Barbour, Kamil E.] CDC, Atlanta, GA 30333 USA. [Murphy, Louise; Theis, Kristina A.; Helmick, Charles G.; Hootman, Jennifer; Stevens, Judy A.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 72 BP S30 EP S30 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384900073 ER PT J AU Brick, M Odom, E Brady, TJ McPhillips-Tangum, C Oliver, A Heyl, D Hefelfinger, J AF Brick, Mari Odom, Erica Brady, Teresa J. McPhillips-Tangum, Carol Oliver, Angela Heyl, Dana Hefelfinger, Jennifer TI What Do State Legislators Think about Arthritis? Results of Focus Groups with State Legislators. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Brick, Mari] Natl Assoc Chron Dis Directors, Voorheesville, NY USA. [Odom, Erica; Brady, Teresa J.; Oliver, Angela] Ctr Dis Control & Prevent, Atlanta, GA USA. [McPhillips-Tangum, Carol] Exper HealthCare Grp LLC, Atlanta, GA USA. [Hefelfinger, Jennifer] Natl Assoc Chron Dis Directors, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2011 BP S883 EP S883 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384904161 ER PT J AU Cisternas, MG Murphy, L Pasta, DJ Solomon, DH Helmick, CG AF Cisternas, Miriam G. Murphy, Louise Pasta, David J. Solomon, Daniel H. Helmick, Charles G. TI Annual Medical Care Expenditures Among US Adults with Osteoarthritis, 2008-2011 SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Cisternas, Miriam G.] MGC Data Serv, Carlsbad, CA USA. [Murphy, Louise; Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pasta, David J.] DMA Corp, Palo Alto, CA USA. [Solomon, Daniel H.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 980 BP S436 EP S436 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384902086 ER PT J AU Cisternas, MG Murphy, L Pasta, DJ Yelin, EH Helrnick, C AF Cisternas, Miriam G. Murphy, Louise Pasta, David J. Yelin, Edward H. Helrnick, Charles TI Annual Medical Care Expenditures Among US Adults with Gout, 2005-2011. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Cisternas, Miriam G.] MGC Data Serv, W Columbia, SC 29169 USA. [Murphy, Louise; Helrnick, Charles] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pasta, David J.] DMA Corp, Toronto, ON, Canada. [Yelin, Edward H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 888 BP S393 EP S393 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384901432 ER PT J AU Dall'era, M Snipes, K Cisternas, M Gordon, C Helmick, CG AF Dall'era, Maria Snipes, Kurt Cisternas, Miriam Gordon, C. Helmick, Charles G. TI Preliminary Population- Based Incidence and Prevalence Estimates of SLE: The California Lupus Surveillance Project SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Dall'era, Maria] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Snipes, Kurt] Calif Dept Publ Hlth, Sacramento, CA USA. [Cisternas, Miriam] MGC Data Serv, San Diego, CA USA. [Gordon, C.] Univ Birmingham Sch Med, Birmingham B15 2TT, W Midlands, England. [Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2788 BP S1217 EP S1218 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384906024 ER PT J AU Hefelfinger, J Brady, TJ Berktold, J Goldstein, M Bonilla, E Brick, M Odom, E Oliver, A Cowan, P AF Hefelfinger, Jennifer Brady, Teresa J. Berktold, Jennifer Goldstein, Marc Bonilla, Erika Brick, Mari Odom, Erica Oliver, Angela Cowan, Penney TI Reaching out to Physical Therapists: Results of a Survey on Physical Therapists Preferences for Learning about Evidence-Based Community Programs. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Hefelfinger, Jennifer] Natl Assoc Chron Dis Directors, Atlanta, GA USA. [Brady, Teresa J.; Odom, Erica; Oliver, Angela] Ctr Dis Control & Prevent, Atlanta, GA USA. [Berktold, Jennifer; Bonilla, Erika] Westat Corp, Rockville, MD USA. [Goldstein, Marc] Amer Phys Therapy Assoc, Alexandria, VA USA. [Brick, Mari] Natl Assoc Chron Dis Directors, Voorheesville, NY USA. [Cowan, Penney] Amer Chron Pain Assoc, Rocklin, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2010 BP S882 EP S883 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384904160 ER PT J AU Kelley, GA Kelley, KS Hootman, J AF Kelley, George A. Kelley, Kristi S. Hootman, Jennifer TI Effects of Exercise on Depressive Symptoms in Adults with Arthritis: A Systematic Review with Meta-Analysis. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Kelley, George A.; Kelley, Kristi S.] W Virginia Univ, Morgantown, WV 26506 USA. [Hootman, Jennifer] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 67 BP S28 EP S28 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384900068 ER PT J AU McDougall, J Helmick, CG Lim, SS Gordon, C Ferucci, E AF McDougall, John, Jr. Helmick, Charles G. Lim, S. Sam Gordon, Caroline Ferucci, Elizabeth TI Impact of Provider Specialty on the Diagnosis and Management of Systemic Lupus Erythematosus in the American Indian/Alaska Native Population. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [McDougall, John, Jr.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lim, S. Sam] Emory Univ, Sch Med, Div Rheumatol, Atlanta, GA USA. [Gordon, Caroline] Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect, Rheumatol Res Grp, Birmingham, W Midlands, England. [Ferucci, Elizabeth] Alaska Native Med Ctr, Anchorage, AK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2624 BP S1148 EP S1148 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384905301 ER PT J AU Theis, KA Cisternas, M Murphy, L AF Theis, Kristina A. Cisternas, Miriam Murphy, Louise TI Does Arthritis Status Predict Starting or Stopping Work over a 2-Year Period? SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Theis, Kristina A.; Murphy, Louise] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cisternas, Miriam] MGC Data Serv, San Diego, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 1092 BP S482 EP S482 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384902197 ER PT J AU Brinker, K Head, CA Johnson, CY Funk, RH AF Brinker, Kimberly Head, Catherine A. Johnson, Candice Y. Funk, Renee H. TI Injuries and Illnesses Among American Red Cross Responders-United States, 2008-2012 SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE responders; volunteers; occupational health; injuries; illnesses AB Objective: Occupational injury and illness rates for volunteer responders have not been well documented. We analyzed data specific to volunteers from the American Red Cross (ARC). Methods: Data collected by the ARC between 2008 and 2012 were analyzed to identify disaster factors associated with responder injuries and illnesses. We focused on disaster-relief operation (DRO) level (indicating operational costs, ranging from 3 [lower] to 5+ [higher]); disaster type; region; and year. We calculated injury and illness rates and estimated rate ratios (RR) with 95% CI, using negative binomial regression. Also, we analyzed a total of 113 disasters. Results: Hurricanes had the highest rates of injuries (14/1000 responders) and illnesses (18/1000 responders). In the adjusted model for injuries, RRs were higher for DRO levels 4 (3.6 [CI, 2.0-6.7]) and 5+ (4.9 [CI, 2.2-11.0]) than for level 3. In the adjusted model for illnesses, RRs also were higher for DRO levels 4 (4.4 [CI, 2.6-7.3]) and 5+ (8.6 [CI, 4.1-17.7]) than for level 3. Conclusions: Higher DRO levels were a significant predictor of greater rates of occupational injuries and illnesses. Careful selection of responders, including volunteers, has been warranted for deployments to such disasters. C1 [Brinker, Kimberly; Johnson, Candice Y.; Funk, Renee H.] NIOSH, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Head, Catherine A.] Amer Red Cross, Washington, DC 20006 USA. RP Brinker, K (reprint author), NIOSH, Ctr Dis Control & Prevent, Off Director, Emergency Preparedness & Response Off, 1600 Clifton Rd NE,Mailstop E-20, Atlanta, GA 30333 USA. EM kbrinker@cdc.gov NR 11 TC 2 Z9 2 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1935-7893 EI 1938-744X J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD OCT PY 2014 VL 8 IS 5 BP 404 EP 410 DI 10.1017/dmp.2014.99 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AX9RT UT WOS:000347240400005 PM 25351536 ER PT J AU Mortensen, ME Caudill, SP Caldwell, KL Ward, CD Jones, RL AF Mortensen, Mary E. Caudill, Samuel P. Caldwell, Kathleen L. Ward, Cynthia D. Jones, Robert L. TI Total and methyl mercury in whole blood measured for the first time in the US population: NHANES 2011-2012 SO ENVIRONMENTAL RESEARCH LA English DT Article DE Blood mercury; Mercury species; Methyl mercury; NHANES; Biomonitoring ID FISH CONSUMPTION; ORGANIC MERCURY; METHYLMERCURY; EXPOSURE; WOMEN; HAIR; AGE; THIMEROSAL AB Background: Despite the public health and toxicologic interest in methyl mercury (MeHg) and ethyl mercury (EHg), these mercury species have been technically difficult to measure in large population studies. Methods: Using NHANES 2011-2012 data, we calculated reference ranges and examined demographic factors associated with specific mercury species concentrations and the ratio of MeHg to THg. We conducted several multiple regression analyses to examine factors associated with MeHg concentrations and also with the ratio of MeHg to THg. Results: Asians had the highest geometric mean concentrations for MeHg, 1.58 mu g/L (95% CI 1.29, 1.93) and THg, 1.86 mu g/L (1.58, 2.19), followed by non-Hispanic blacks with MeHg, 0.52 mu g/L (0.39, 0.68) and THg, 0.68 mu g/L (0.54, 0.85). Greater education attainment in adults and male sex were associated with higher MeHg and THg concentrations. Race/ethnicity, age, and sex were significant predictors of MeHg concentrations, which increased with age and were highest in Asians in all age categories, followed by non-Hispanic blacks. Mexican Americans had the lowest adjusted MeHg concentrations. The ratio of MeHg to THg was highest in Asians, varied by racial/ethnic group, and increased with age in a non-linear fashion. The amount of increase in the MeHg to THg ratio with age depended on the initial ratio, with a greater increase as age increased. Of the overall population, 3.05% (95% CI 1.77, 4.87) had MeHg concentrations >5.8 mu g/L (a value that corresponds to the U.S. EPA reference dose). The prevalence was highest in Asians at 15.85% (95% CI 11.85, 20.56), increased with age, reaching a maximum of 9.26% (3.03, 20.42) at ages 60-69 years. Females 16-44 years old had a 1.76% (0.82-3.28) prevalence of MeHg concentrations >5.8 mu g/L Conclusions: Asians, males, older individuals, and adults with greater educational attainment had higher MeHg concentrations. The ratio of MeHg to THg varied with racial/ethnic group, increased with age, and was nonlinear. U.S. population reference values for MeHg and the ratio of MeHg to THg can assist in more precise assessment of public health risk from MeHg consumed in seafood. Published by Elsevier Inc C1 [Mortensen, Mary E.; Caudill, Samuel P.; Caldwell, Kathleen L.; Ward, Cynthia D.; Jones, Robert L.] Natl Ctr Environm Hlth, Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA 30341 USA. RP Mortensen, ME (reprint author), Natl Ctr Environm Hlth, Ctr Dis Control & Prevent, Div Sci Lab, MS F-20,4770 Buford Highway, Atlanta, GA 30341 USA. EM MMortensen@cdc.gov NR 37 TC 10 Z9 11 U1 2 U2 19 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD OCT PY 2014 VL 134 SI SI BP 257 EP 264 DI 10.1016/j.envres.2014.07.019 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AX3CB UT WOS:000346817100035 PM 25173092 ER PT J AU Zhou, Y Jerrett, M AF Zhou, Ying Jerrett, Michael TI Linking Exposure and Health in Environmental Public Health Tracking SO ENVIRONMENTAL RESEARCH LA English DT Editorial Material C1 [Zhou, Ying] CDC, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Environm Hlth Tracking Branch, Atlanta, GA 30333 USA. [Jerrett, Michael] Univ Calif Berkeley, Sch Publ Hlth, Dept Environm Hlth Sci, Berkeley, CA 94720 USA. RP Zhou, Y (reprint author), 4770 Buford Hwy,MS F-60, Atlanta, GA 30341 USA. EM yzhou2@cdc.gov NR 0 TC 0 Z9 1 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD OCT PY 2014 VL 134 SI SI BP 453 EP 453 DI 10.1016/j.envres.2014.08.001 PG 1 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AX3CB UT WOS:000346817100060 PM 25261952 ER PT J AU Strosnider, H Zhou, Y Balluz, L Qualters, J AF Strosnider, Heather Zhou, Ying Balluz, Lina Qualters, Judith TI Engaging academia to advance the science and practice of environmental public health tracking SO ENVIRONMENTAL RESEARCH LA English DT Article DE Environmental public health tracking; Surveillance; Air pollution; Drinking water; Environmental health ID EMERGENCY-DEPARTMENT VISITS; AIR-POLLUTION EXPOSURE; SPATIAL EPIDEMIOLOGY; UNITED-STATES; SURVEILLANCE; NETWORK; ASSOCIATION; PROGRAM; QUALITY; DIRECTIONS AB Public health agencies at the federal, state, and local level are responsible for implementing actions and policies that address health problems related to environmental hazards. These actions and policies can be informed by integrating or linking data on health, exposure, hazards, and population. The mission of the Centers for Disease Control and Prevention's National Environmental Public Health Tracking Program (Tracking Program) is to provide information from a nationwide network of integrated health, environmental hazard, and exposure data that drives actions to improve the health of communities. The Tracking Program and federal, state, and local partners collect, integrate, analyze, and disseminate data and information to inform environmental public health actions. However, many challenges exist regarding the availability and quality of data, the application of appropriate methods and tools to link data, and the state of the science needed to link and analyze health and environmental data. The Tracking Program has collaborated with academia to address key challenges in these areas. The collaboration has improved our understanding of the uses and limitations of available data and methods, expanded the use of existing data and methods, and increased our knowledge about the connections between health and environment. Valuable working relationships have been forged in this process, and together we have identified opportunities and improvements for future collaborations to further advance the science and practice of environmental public health tracking. Published by Elsevier Inc. C1 [Strosnider, Heather; Zhou, Ying; Balluz, Lina] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Environm Hlth Tracking Branch, Atlanta, GA 30333 USA. [Qualters, Judith] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA 30333 USA. RP Strosnider, H (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Environm Hlth Tracking Branch, 1600 Clifton Rd,MS F60, Atlanta, GA 30333 USA. EM HStrosnider@cdc.gov; YZhou2@cdc.gov; LBalluz@cdc.gov; JQualters@cdc.gov FU Intramural CDC HHS [CC999999] NR 44 TC 0 Z9 1 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD OCT PY 2014 VL 134 SI SI BP 474 EP 481 DI 10.1016/j.envres.2014.04.039 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AX3CB UT WOS:000346817100064 PM 25038624 ER PT J AU Asaithambi, G Tong, X George, MG Tsai, AW Peacock, JM Luepker, RV Lakshminarayan, K AF Asaithambi, Ganesh Tong, Xin George, Mary G. Tsai, Albert W. Peacock, James M. Luepker, Russell V. Lakshminarayan, Kamakshi TI Acute Stroke Reperfusion Therapy Trends in the Expanded Treatment Window Era SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES LA English DT Article DE Expanded time window; ischemic stroke; thrombolysis; trend analysis ID ACUTE ISCHEMIC-STROKE; PLASMINOGEN-ACTIVATOR; TIME WINDOW; ENDOVASCULAR TREATMENT; THROMBOLYSIS; ALTEPLASE; POPULATION; REGISTRY; STATES; TRIAL AB Background: The American Heart Association / American Stroke Association (AHA/ASA) recommended an expansion of the time window for acute ischemic stroke (AIS) reperfusion with intravenous (IV) recombinant tissue plasminogen activator (rt-PA) from 3 to 4.5 hours after symptom onset. We examine rates of IV and intra-arterial (IA) reperfusion before and after the recommendations to track guideline adoption in community practice. Methods: Patients with AIS in the Paul Coverdell National Acute Stroke Registry spanning years 2007-2012 were identified. Trends in rates of IV rt-PA versus IA therapy were examined. Outcomes included symptomatic intracerebral hemorrhage (sICH), in-hospital mortality, ability to ambulate at discharge, and discharge destination. Results: From 2007 to 2012, there were 182,235 AIS patients (median age, 72 years; 51.5% women) in the database at the time of analysis. AIS patients receiving IV rt-PA increased significantly from 3.7% in 2007 to 5.1% in 2012 in the <3 hours time window and from .2% in 2007 to 1.3% in 2012 in the 3-4.5 hours time window (P < .001 for both). There was also a significant increase in the rate of IA therapy between 2007 and 2012 (P < .001). There was a significant decrease in the rate of sICH among patients who received any reperfusion between 2007 and 2012. Conclusions: There was a trend for increased utilization of IV rt-PA in the 0-3 hours and the 3-4.5 hours time windows, which began around the same time as the publication of AHA/ASA recommendations in 2009. This increase was associated with an increase in IA treatment rates along with a decrease in overall sICH rates for patients receiving any reperfusion. C1 [Asaithambi, Ganesh] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32610 USA. [Tong, Xin; George, Mary G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tsai, Albert W.; Peacock, James M.] Minnesota Dept Hlth, St Paul, MN USA. [Luepker, Russell V.; Lakshminarayan, Kamakshi] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Lakshminarayan, Kamakshi] Univ Minnesota, Sch Med, Dept Neurol, Minneapolis, MN 55455 USA. RP Asaithambi, G (reprint author), Univ Florida, Coll Med, Dept Neurol, HSC Box 100236, Gainesville, FL 32610 USA. EM ganesh785@gmail.com OI George, Mary/0000-0003-2270-6402 FU Minnesota Stroke Registry, Paul Coverdell National Acute Stroke Registry: Centers for Disease Control and Prevention [U58 DP000857]; Institutional Review Board [0803E29268]; National Institutes of Health [K23NS051377] FX The authors do not report any conflicts of interest for this article. This work was supported by the Minnesota Stroke Registry, part of the Paul Coverdell National Acute Stroke Registry: Centers for Disease Control and Prevention U58 DP000857 and Institutional Review Board 0803E29268. K.L. has been supported by National Institutes of Health grant K23NS051377. NR 14 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1052-3057 EI 1532-8511 J9 J STROKE CEREBROVASC JI J. Stroke Cerebrovasc. Dis. PD OCT PY 2014 VL 23 IS 9 BP 2316 EP 2321 DI 10.1016/j.jstrokecerebrovasdis.2014.04.023 PG 6 WC Neurosciences; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AU5MA UT WOS:000345649900019 PM 25156783 ER PT J AU Ford, DC Merrick, MT Parks, SE Breiding, MJ Gilbert, LK Edwards, VJ Dhingra, SS Barile, JP Thompson, WW AF Ford, Derek C. Merrick, Melissa T. Parks, Sharyn E. Breiding, Matthew J. Gilbert, Leah K. Edwards, Valerie J. Dhingra, Satvinder S. Barile, John P. Thompson, William W. TI Examination of the Factorial Structure of Adverse Childhood Experiences and Recommendations for Three Subscale Scores SO PSYCHOLOGY OF VIOLENCE LA English DT Article DE ACEs; adverse childhood experiences; child abuse; child maltreatment; factor analysis ID TESTING MEASUREMENT INVARIANCE; FACTOR-ANALYSIS FRAMEWORK; STRESSFUL LIFE EVENTS; OF-FIT INDEXES; SEXUAL ABUSE; HOUSEHOLD DYSFUNCTION; MULTIPLE FORMS; MENTAL-HEALTH; DEPRESSION; ADULTS AB Objective: The purpose of the current investigation is to assess and validate the factor structure of the Behavioral Risk Factor Surveillance System's (BRFSS) Adverse Childhood Experience (ACE) module. Method: ACE data available from the 2009 BRFSS survey were fit using exploratory factor analysis (EFA) to estimate an initial factorial structure. The exploratory solution was then validated using confirmatory factor analysis (CFA) with data from the 2010 BRFSS survey. Lastly, ACE factors were tested for measurement invariance using multiple group factor analysis. Results: EFA results suggested that a 3-factor solution adequately fit the data. Examination of factor loadings and item content suggested the factors represented the following construct areas: Household Dysfunction, Emotional/Physical Abuse, and Sexual Abuse. Subsequent CFA results confirmed the 3-factor solution and provided preliminary support for estimation of an overall latent ACE score summarizing the responses to all available items. Measurement invariance was supported across both gender and age. Conclusions: Results of this study provides support for the use of the current ACE module scoring algorithm, which uses the sum of the number of items endorsed to estimate exposure. However, the results also suggest potential benefits to estimating 3 separate composite scores to estimate the specific effects of exposure to Household Dysfunction, Emotional/Physical Abuse, and Sexual Abuse. C1 [Ford, Derek C.; Dhingra, Satvinder S.] Northrop Grumman, Atlanta, GA USA. [Ford, Derek C.; Edwards, Valerie J.; Dhingra, Satvinder S.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Control, Atlanta, GA 30341 USA. [Ford, Derek C.; Merrick, Melissa T.; Parks, Sharyn E.; Breiding, Matthew J.; Gilbert, Leah K.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Barile, John P.] Univ Hawaii Manoa, Dept Psychol, Honolulu, HI 96822 USA. [Thompson, William W.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. RP Ford, DC (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway Northeast,Mailstop F-63, Atlanta, GA 30341 USA. EM wsn4@cdc.gov RI Barile, John/F-9456-2015 OI Barile, John/0000-0003-4098-0640 FU Intramural CDC HHS [CC999999] NR 54 TC 6 Z9 6 U1 1 U2 5 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 2152-0828 EI 2152-081X J9 PSYCHOL VIOLENCE JI Psychol. Violence PD OCT PY 2014 VL 4 IS 4 SI SI BP 432 EP 444 DI 10.1037/a0037723 PG 13 WC Psychology, Clinical; Criminology & Penology; Family Studies SC Psychology; Criminology & Penology; Family Studies GA AU6GD UT WOS:000345700800006 PM 26430532 ER PT J AU Davis, KC Parrott, DJ George, WH Tharp, AT Hall, GCN Stappenbeck, CA AF Davis, Kelly Cue Parrott, Dominic J. George, William H. Tharp, Andra Teten Hall, Gordon C. Nagayama Stappenbeck, Cynthia A. TI Studying Sexual Aggression: A Review of the Evolution and Validity of Laboratory Paradigms SO PSYCHOLOGY OF VIOLENCE LA English DT Article DE behavioral analogues; laboratory paradigms; sexual aggression; sexual assault ID VIOLENCE PREVENTION PROGRAM; IMPLICIT ASSOCIATION TEST; ALCOHOL-CONSUMPTION; GENDER-DIFFERENCES; DATE RAPE; BYSTANDER INTERVENTION; IMPOSITIONAL BEHAVIOR; CONSTRUCT-VALIDITY; ACQUAINTANCE RAPE; SOCIAL NORMS AB Objective: Researchers have endeavored for decades to develop and implement experimental assessments of sexual aggression and its precursors to capitalize on the many scientific advantages offered by laboratory experiments, such as rigorous control of key variables and identification of causal relationships. The purpose of this review is to provide an overview of and commentary on the evolution of these laboratory-based methods. Conclusions: To date, two primary types of sexual aggression laboratory studies have been developed: those that involve behavioral analogues of sexual aggression and those that assess postulated precursors to sexually aggressive behavior. Although the study of sexual aggression in the laboratory is fraught with methodological challenges, validity concerns, and ethical considerations, advances in the field have resulted in greater methodological rigor, more precise dependent measures, and improved experimental validity, reliability, and realism. Because highly effective sexual aggression prevention strategies remain elusive, continued laboratory-based investigation of sexual aggression coupled with translation of critical findings to the development and modification of sexual aggression prevention programs remains an important task for the field. C1 [Davis, Kelly Cue] Univ Washington, Sch Social Work, Seattle, WA 98195 USA. [Parrott, Dominic J.] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA. [George, William H.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Tharp, Andra Teten] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Hall, Gordon C. Nagayama] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA. [Stappenbeck, Cynthia A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Davis, KC (reprint author), Univ Washington, Sch Social Work, Box 354900, Seattle, WA 98195 USA. EM kcue@uw.edu NR 76 TC 5 Z9 5 U1 6 U2 17 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 2152-0828 EI 2152-081X J9 PSYCHOL VIOLENCE JI Psychol. Violence PD OCT PY 2014 VL 4 IS 4 SI SI BP 462 EP 476 DI 10.1037/a0037662 PG 15 WC Psychology, Clinical; Criminology & Penology; Family Studies SC Psychology; Criminology & Penology; Family Studies GA AU6GD UT WOS:000345700800008 ER PT J AU Gomes, GAD Kokubun, E Mieke, GI Ramos, LR Pratt, M Parra, DC Simoes, E Florindo, AA Bracco, M Cruz, D Malta, D Lobelo, F Hallal, PC AF de Oliveira Gomes, Grace Angelica Kokubun, Eduardo Mieke, Gregore Iven Ramos, Luiz Roberto Pratt, Michael Parra, Diana C. Simoes, Eduardo Florindo, Alex A. Bracco, Mario Cruz, Danielle Malta, Deborah Lobelo, Felipe Hallal, Pedro C. TI Characteristics of physical activity programs in the Brazilian primary health care system SO CADERNOS DE SAUDE PUBLICA LA English DT Article DE Motor Activity; Developing Countries; Primary Health Care; Family Health ID RANDOMIZED CONTROLLED-TRIAL; LATIN-AMERICA; ACTIVITY INTERVENTIONS; EXERCISE; OBESITY; ADULTS; LIFE; PRESCRIPTION; NORTHEAST; PROMOTION AB The aim of this study was to describe the characteristics of programs that promote physical activity in the public primary care system by region of Brazil, subject to the presence or absence of multidisciplinary primary care teams (NASF). We conducted a cross sectional and population-based telephone survey of the health unit coordinators from 1,251 health care units. Coordinators were asked about the presence and characteristics of physical activity programs. Four out of ten health units reported having a physical activity intervention program, the most common involving walking groups. Most of the activities were performed in the morning, once or twice a week, and in sessions of 30 minutes or more. Physical education professionals were primarily responsible for directing the activities. Interventions occurred in the health unit itself or in adjacent community spaces. In general, these characteristics were similar between units with or without NASF, but varied substantially across regions. These findings will guide future physical activity policies and programs within primary care in Brazil. C1 [de Oliveira Gomes, Grace Angelica] Univ Fed Sao Carlos, Dept Gerontol, BR-13565905 Sao Carlos, SP, Brazil. [de Oliveira Gomes, Grace Angelica; Kokubun, Eduardo] Univ Estadual Paulista, Nucleo Atividade Fis Esporte & Saude, Rio Claro, Brazil. [Mieke, Gregore Iven; Hallal, Pedro C.] Univ Fed Pelotas, Grp Estudos Epidemiol Atividade Fis, Pelotas, Brazil. [Ramos, Luiz Roberto] Univ Fed Sao Paulo, Sao Paulo, Brazil. [Pratt, Michael; Lobelo, Felipe] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Parra, Diana C.; Simoes, Eduardo] Washington Univ, George Warren Brown Sch Social Work, St Louis, MO 63130 USA. [Florindo, Alex A.] Univ Sao Paulo, Escola Artes Ciencias & Humanidades, Sao Paulo, Brazil. [Bracco, Mario] Hosp Israelita Albert Einstein, Sao Paulo, Brazil. [Cruz, Danielle; Malta, Deborah] Minist Saude, Brasilia, DF, Brazil. [Lobelo, Felipe] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Gomes, GAD (reprint author), Univ Fed Sao Carlos, Dept Gerontol, Rod Washington Luis Km 235, BR-13565905 Sao Carlos, SP, Brazil. EM graceaogomes@yahoo.com.br RI Parra, Diana/B-7761-2015; Hallal, Pedro/A-3249-2011; Kokubun, Eduardo/A-3298-2013; Malta, Deborah/H-7880-2012 OI Parra, Diana/0000-0002-9797-6231; Hallal, Pedro/0000-0003-1470-6461; Kokubun, Eduardo/0000-0002-9404-3444; Malta, Deborah/0000-0002-8214-5734 FU Centers for Disease Control and Prevention's Prevention Research Centers Program [U48/DP001903] FX The authors wish to thank all members of the GUIA team and the participating health care unit professionals. This study was funded through the Centers for Disease Control and Prevention's Prevention Research Centers Program contract U48/DP001903 (Applying Evidence-Physical Activity Recommendations in Brazil). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 49 TC 2 Z9 3 U1 2 U2 12 PU CADERNOS SAUDE PUBLICA PI RIO DE JANIERO PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL SN 0102-311X EI 1678-4464 J9 CAD SAUDE PUBLICA JI Cad. Saude Publica PD OCT PY 2014 VL 30 IS 10 BP 2155 EP 2168 DI 10.1590/0102-311X00085713 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AT5EK UT WOS:000344966000015 PM 25388318 ER PT J AU O'Connor, S O'Connor, PF Feng, HA Ashley, K AF O'Connor, S. O'Connor, P. F. Feng, H. A. Ashley, K. TI Gravimetric analysis of particulate matter using air samplers housing internal filtration capsules SO GEFAHRSTOFFE REINHALTUNG DER LUFT LA English DT Article ID PERFORMANCE AB An evaluation was carried out to investigate the suitability of polyvinyl chloride (PVC) internal capsules, housed within air sampling devices, for gravimetric analysis of airborne particles collected in workplaces. Experiments were carried out using blank PVC capsules and PVC capsules spiked with 0,1 to 4 mg of National Institute of Standards and Technology Standard Reference Material (R) (NIST SRM) 1648 (Urban Particulate Matter) and Arizona Road Dust (Air Cleaner Test Dust). The capsules were housed within plastic closed-face cassette (CFCs) samplers. A method detection limit (MDL) of 0,075 mg per sample was estimated. Precision S-r at 0,5 to 4 mg per sample was 0,031 and the estimated bias was 0,058. Weight stability over 28 days was verified for both blanks and spiked capsules. Independent laboratory testing on blanks and field samples verified long-term weight stability as well as sampling and analysis precision and bias estimates. An overall precision estimate (S) over cap (r)t of 0,059 was obtained. An accuracy measure of +/- 15,5% was found for the gravimetric method using PVC internal capsules. C1 [O'Connor, S.; O'Connor, P. F.; Feng, H. A.; Ashley, K.] NIOSH, Ctr Dis Control & Prevent, US Dept Hlth & Human Serv, Cincinnati, OH 45226 USA. RP O'Connor, S (reprint author), NIOSH, Ctr Dis Control & Prevent, US Dept Hlth & Human Serv, Cincinnati, OH 45226 USA. FU Intramural CDC HHS [CC999999] NR 17 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER-V D I VERLAG GMBH & CO KG PI DUSSELDORF PA VDI-PLATZ 1, D-40468 DUSSELDORF, GERMANY SN 0949-8036 EI 1436-4891 J9 GEFAHRST REINHALT L JI Gefahrst. Reinhalt. Luft PD OCT PY 2014 VL 74 IS 10 BP 403 EP 410 PG 8 WC Engineering, Environmental; Engineering, Civil; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA AT9SS UT WOS:000345267000002 PM 26435581 ER PT J AU Nyaga, MM Stucker, KM Esona, MD Jere, KC Mwinyi, B Shonhai, A Tsolenyanu, E Mulindwa, A Chibumbya, JN Adolfine, H Halpin, RA Roy, S Stockwell, TB Berejena, C Seheri, ML Mwenda, JM Steele, AD Wentworth, DE Mphahlele, MJ AF Nyaga, Martin M. Stucker, Karla M. Esona, Mathew D. Jere, Khuzwayo C. Mwinyi, Bakari Shonhai, Annie Tsolenyanu, Enyonam Mulindwa, Augustine Chibumbya, Julia N. Adolfine, Hokororo Halpin, Rebecca A. Roy, Sunando Stockwell, Timothy B. Berejena, Chipo Seheri, Mapaseka L. Mwenda, Jason M. Steele, A. Duncan Wentworth, David E. Mphahlele, M. Jeffrey TI Whole-genome analyses of DS-1-like human G2P[4] and G8P[4] rotavirus strains from Eastern, Western and Southern Africa SO VIRUS GENES LA English DT Article DE Rotavirus; Whole-genome analyses; G8P[4]; G2P[4] ID GROUP-A ROTAVIRUSES; SEQUENCE-ANALYSIS; GENOTYPE; G9; CLASSIFICATION; REASSORTMENT; G8; DIVERSITY; CHILDREN; REVEALS AB Group A rotaviruses (RVAs) with distinct G and P genotype combinations have been reported globally. We report the genome composition and possible origin of seven G8P[4] and five G2P[4] human RVA strains based on the genetic evolution of all 11 genome segments at the nucleotide level. Twelve RVA ELISA positive stool samples collected in the representative countries of Eastern, Southern and West Africa during the 2007-2012 surveillance seasons were subjected to sequencing using the Ion Torrent PGM and Illumina MiSeq platforms. A reference-based assembly was performed using CLC Bio's clc_ref_assemble_long program, and full-genome consensus sequences were obtained. With the exception of the neutralising antigen, VP7, all study strains exhibited the DS-1-like genome constellation (P[4]-I2-R2-C2-M2-A2N2-T2-E2-H2) and clustered phylogenetically with reference strains having a DS-1-like genetic backbone. Comparison of the nucleotide and amino acid sequences with selected global cognate genome segments revealed nucleotide and amino acid sequence identities of 81.7-100 % and 90.6-100 %, respectively, with NSP4 gene segment showing the most diversity among the strains. Bayesian analyses of all gene sequences to estimate the time of divergence of the lineage indicated that divergence times ranged from 16 to 44 years, except for the NSP4 gene where the lineage seemed to arise in the more distant past at an estimated 203 years ago. However, the long-term effects of changes found within the NSP4 genome segment should be further explored, and thus we recommend continued whole-genome analyses from larger sample sets to determine the evolutionary mechanisms of the DS-1-like strains collected in Africa. C1 [Nyaga, Martin M.; Esona, Mathew D.; Jere, Khuzwayo C.; Seheri, Mapaseka L.; Steele, A. Duncan; Mphahlele, M. Jeffrey] Univ Limpopo, Dept Virol, South African Med Res Council, UL Diarrhoeal Pathogens Res Unit MRC DPRU, ZA-0204 Pretoria, South Africa. [Nyaga, Martin M.; Esona, Mathew D.; Jere, Khuzwayo C.; Seheri, Mapaseka L.; Steele, A. Duncan; Mphahlele, M. Jeffrey] Natl Hlth Lab Serv, ZA-0204 Pretoria, South Africa. [Stucker, Karla M.; Halpin, Rebecca A.; Stockwell, Timothy B.; Wentworth, David E.] J Craig Venter Inst, Rockville, MD USA. [Esona, Mathew D.; Roy, Sunando] CDC, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, NCIRD, Atlanta, GA 30333 USA. [Jere, Khuzwayo C.] Univ Liverpool, Dept Clin Infect Microbiol & Immunol, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [Mwinyi, Bakari] Kenyatta Natl Hosp, Nairobi, Kenya. [Shonhai, Annie; Berejena, Chipo] Univ Zimbabwe, Dept Med Microbiol, Virol Sect, Harare, Zimbabwe. [Tsolenyanu, Enyonam] Sylvanus Olympio Teaching Hosp Lome, Dept Paediat, Lome, Togo. [Mulindwa, Augustine] Mulago Natl Referral Hosp, Kampala, Uganda. [Chibumbya, Julia N.] Univ Teaching Hosp, Virol Lab, Lusaka, Zambia. [Adolfine, Hokororo] Bugando Med Ctr, Mwanza, Tanzania. [Mwenda, Jason M.] WHO, Reg Off Africa, Brazzaville, Rep Congo. [Steele, A. Duncan] Bill & Melinda Gates Fdn, Global Hlth Program, Enter & Diarrhoeal Dis Programme, Seattle, WA USA. RP Mphahlele, MJ (reprint author), Univ Limpopo, Dept Virol, South African Med Res Council, UL Diarrhoeal Pathogens Res Unit MRC DPRU, Medunsa Campus, ZA-0204 Pretoria, South Africa. EM jeffrey.mphahlele@ul.ac.za OI Jere, Khuzwayo/0000-0003-3376-8529; Wentworth, David/0000-0002-5190-980X FU South African Medical Research Council; Poliomyelitis Research Foundation in South Africa; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200900007C] FX This project was funded by the South African Medical Research Council, the Poliomyelitis Research Foundation in South Africa, and federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract number HHSN272200900007C. We thank Lorens Maake, Kebareng Rakau, Nonkululeko Magagula and Ina Peenze for technical assistance at the MRC/Diarrhoeal Pathogens Research Unit. We also thank the Virology Group at the JCVI, especially Asmik Akopov, Nadia Fedorova and Susmita Shrivastava for their technical assistance in the laboratory and bioinformatics support. In addition, we thank all of the sample collection teams from the different countries that were involved in this study. NR 36 TC 7 Z9 7 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0920-8569 EI 1572-994X J9 VIRUS GENES JI Virus Genes PD OCT PY 2014 VL 49 IS 2 BP 196 EP 207 DI 10.1007/s11262-014-1091-7 PG 12 WC Genetics & Heredity; Virology SC Genetics & Heredity; Virology GA AT7CL UT WOS:000345094000003 PM 24952422 ER PT J AU Smith, DB Simmonds, P Jameel, S Emerson, SU Harrison, TJ Meng, XJ Okamoto, H Van der Poel, WHM Purdy, MA AF Smith, Donald B. Simmonds, Peter Jameel, Shahid Emerson, Suzanne U. Harrison, Tim J. Meng, Xiang-Jin Okamoto, Hiroaki Van der Poel, Wim H. M. Purdy, Michael A. CA Int Comm Taxonomy Viruses TI Consensus proposals for classification of the family Hepeviridae SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID HEPATITIS-E VIRUS; GENETIC-VARIABILITY; PHYLOGENETIC ANALYSIS; MOLECULAR-CLONING; WILD RATS; C VIRUS; HEV; GENOTYPE; CHINA; RECOMBINATION AB The family Hepeviridae consists of positive-stranded RNA viruses that infect a wide range of mammalian species, as well as chickens and trout. A subset of these viruses infects humans and can cause a self-limiting acute hepatitis that may become chronic in immunosuppressed individuals. Current published descriptions of the taxonomical divisions within the family Hepeviridae are contradictory in relation to the assignment of species and genotypes. Through analysis of existing sequence information, we propose a taxonomic scheme in which the family is divided into the genera Orthohepevirus (all mammalian and avian hepatitis E virus (HEV) isolates) and Piscihepevirus (cutthroat trout virus). Species within the genus Orthohepevirus are designated Orthohepevirus A (isolates from human, pig, wild boar, deer, mongoose, rabbit and camel), Orthohepevirus B (isolates from chicken), Orthohepevirus C (isolates from rat, greater bandicoot, Asian musk shrew, ferret and mink) and Orthohepevirus D (isolates from bat). Proposals are also made for the designation of genotypes within the human and rat HEVs. This hierarchical system is congruent with hepevirus phylogeny, and the three classification levels (genus, species and genotype) are consistent with, and reflect discontinuities in the ranges of pairwise distances between amino acid sequences. Adoption of this system would include the avoidance of host names in taxonomic identifiers and provide a logical framework for the assignment of novel variants. C1 [Smith, Donald B.; Simmonds, Peter] Univ Edinburgh, Ctr Immun Infect & Evolut, Edinburgh, Midlothian, Scotland. [Jameel, Shahid] Wellcome Trust DBT India Alliance, Hyderabad, Andhra Pradesh, India. [Emerson, Suzanne U.] NIAID, Mol Hepatitis Sect, NIH, Bethesda, MD 20892 USA. [Harrison, Tim J.] UCL, London, England. [Meng, Xiang-Jin] Virginia Polytech Inst & State Univ, Coll Vet Med, Blacksburg, VA 24061 USA. [Okamoto, Hiroaki] Jichi Med Univ, Sch Med, Dept Infect & Immun, Div Virol, Shimotsuke, Tochigi, Japan. [Van der Poel, Wim H. M.] Univ Wageningen & Res Ctr, Cent Vet Inst, Lelystad, Netherlands. [Purdy, Michael A.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD TB Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Smith, DB (reprint author), Univ Edinburgh, Ctr Immun Infect & Evolut, Edinburgh, Midlothian, Scotland. EM D.B.Smith@ed.ac.uk RI Okamoto, Hiroaki/H-4371-2011 OI Okamoto, Hiroaki/0000-0003-0827-0964 FU Wellcome Trust FX We are grateful to Dr Patrick Woo for sharing the camel HEV isolate complete genome sequences ahead of general release. This research was supported by a grant from The Wellcome Trust to the Centre for Immunity, Infection and Evolution at the University of Edinburgh. This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy. Use of trade names is for identification only and does not imply endorsement by the US Department of Health and Human Services, the Public Health Service, or the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The authors declare that they have no conflict of interest. NR 39 TC 117 Z9 118 U1 4 U2 13 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 EI 1465-2099 J9 J GEN VIROL JI J. Gen. Virol. PD OCT PY 2014 VL 95 BP 2223 EP 2232 DI 10.1099/vir.0.068429-0 PN 10 PG 10 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA AT4LW UT WOS:000344911900013 PM 24989172 ER PT J AU Frosch, AEP Laufer, MK Mathanga, DP Takala-Harrison, S Skarbinski, J Claassen, CW Dzinjalamala, FK Plowe, CV AF Frosch, Anne E. P. Laufer, Miriam K. Mathanga, Don P. Takala-Harrison, Shannon Skarbinski, Jacek Claassen, Cassidy W. Dzinjalamala, Fraction K. Plowe, Christopher V. TI Return of Widespread Chloroquine-Sensitive Plasmodium falciparum to Malawi SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE malaria; Plasmodium falciparum; chloroquine; resistance; PfCRT; Malawi; Africa ID RESISTANCE TRANSPORTER GENE; SOUTHERN MOZAMBIQUE; MALARIA; HAPLOTYPES AB Background. The return of chloroquine-sensitive Plasmodium falciparum to the limited area of Blantyre, Malawi, has been well demonstrated in several studies. Methods. To characterize chloroquine susceptibility over a wide geographic area, infants and children aged 6-59 months were selected using 2-stage cluster sampling in 8 Malawian districts. Pyrosequencing of the pfcrt gene codon 76 region was performed for children with asexual parasitemia. Results. Of 7145 children, 1150 had microscopic asexual parasitemia, and sequencing was performed in 685, of whom 1 had a chloroquine-resistant genotype. Conclusions. Systematic countrywide sampling demonstrates that the chloroquine pfcrt genotype has reached near-fixation, raising the possibility of reintroducing chloroquine for malaria prevention and treatment. C1 [Frosch, Anne E. P.; Laufer, Miriam K.; Takala-Harrison, Shannon; Claassen, Cassidy W.; Plowe, Christopher V.] Univ Maryland, Sch Med, Howard Hughes Med Inst, Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Frosch, Anne E. P.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Skarbinski, Jacek] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Mathanga, Don P.] Univ Malawi, Coll Med, Malaria Alert Ctr, Blantyre, Malawi. [Dzinjalamala, Fraction K.] Univ Malawi, Coll Med, Dept Pharmacol, Blantyre, Malawi. RP Plowe, CV (reprint author), Univ Maryland, Sch Med, Ctr Vaccine Dev, 685 W Baltimore St,HSF1-480, Baltimore, MD 21201 USA. EM cplowe@medicine.umaryland.edu FU United States President's Malaria Initiative, US Agency for International Development; Centers for Disease Control and Prevention (CDC); CDC [5 U01 CI000189]; Malaria Alert Centre, University of Malawi College of Medicine [5 U01 CI000189]; Doris Duke Charitable Foundation; Howard Hughes Medical Institute FX This work was supported by the United States President's Malaria Initiative, US Agency for International Development, under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention (CDC) and through a Cooperative Agreement (No. 5 U01 CI000189) between the CDC and the Malaria Alert Centre, University of Malawi College of Medicine; and by the Doris Duke Charitable Foundation and the Howard Hughes Medical Institute to (awards to C. V. P.). NR 15 TC 19 Z9 19 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2014 VL 210 IS 7 BP 1110 EP 1114 DI 10.1093/infdis/jiu216 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AT0ED UT WOS:000344609100015 PM 24723474 ER PT J AU Thurtle, N Greig, J Cooney, L Amitai, Y Ariti, C Brown, MJ Kosnett, MJ Moussally, K Sani-Gwarzo, N Akpan, H Shanks, L Dargan, PI AF Thurtle, Natalie Greig, Jane Cooney, Lauren Amitai, Yona Ariti, Cono Brown, Mary Jean Kosnett, Michael J. Moussally, Krystel Sani-Gwarzo, Nasir Akpan, Henry Shanks, Leslie Dargan, Paul I. TI Description of 3,180 Courses of Chelation with Dimercaptosuccinic Acid in Children <= 5 y with Severe Lead Poisoning in Zamfara, Northern Nigeria: A Retrospective Analysis of Programme Data SO PLOS MEDICINE LA English DT Article ID BLOOD LEAD; MESO-2,3-DIMERCAPTOSUCCINIC ACID; 2,3-DIMERCAPTOSUCCINIC ACID; UNITED-STATES; SUCCIMER; THERAPY; CHILDHOOD; DMSA; ENCEPHALOPATHY; INTOXICATION AB Background: In 2010, Medecins Sans Frontieres (MSF) discovered extensive lead poisoning impacting several thousand children in rural northern Nigeria. An estimated 400 fatalities had occurred over 3 mo. The US Centers for Disease Control and Prevention (CDC) confirmed widespread contamination from lead-rich ore being processed for gold, and environmental management was begun. MSF commenced a medical management programme that included treatment with the oral chelating agent 2,3-dimercaptosuccinic acid (DMSA, succimer). Here we describe and evaluate the changes in venous blood lead level (VBLL) associated with DMSA treatment in the largest cohort of children <= 5 y of age with severe paediatric lead intoxication reported to date to our knowledge. Methods and Findings: In a retrospective analysis of programme data, we describe change in VBLL after DMSA treatment courses in a cohort of 1,156 children <= 5 y of age who underwent between one and 15 courses of chelation treatment. Courses of DMSA of 19 or 28 d duration administered to children with VBLL >= 45 mu g/dl were included. Impact of DMSA was calculated as end-course VBLL as a percentage of pre-course VBLL (ECP). Mixed model regression with nested random effects was used to evaluate the relative associations of covariates with ECP. Of 3,180 treatment courses administered, 36% and 6% of courses commenced with VBLL >= 80 mu g/dl and >= 120 mu g/dl, respectively. Overall mean ECP was 74.5% (95% CI 69.7%-79.7%); among 159 inpatient courses, ECP was 47.7% (95% CI 39.7%-57.3%). ECP after 19-d courses (n = 2,262) was lower in older children, first-ever courses, courses with a longer interval since a previous course, courses with more directly observed doses, and courses with higher pre-course VBLLs. Low haemoglobin was associated with higher ECP. Twenty children aged <= 5 y who commenced chelation died during the period studied, with lead poisoning a primary factor in six deaths. Monitoring of alanine transaminase (ALT), creatinine, and full blood count revealed moderate ALT elevation in,2.5% of courses. No clinically severe adverse drug effects were observed, and no laboratory findings required discontinuation of treatment. Limitations include that this was a retrospective analysis of clinical data, and unmeasured variables related to environmental exposures could not be accounted for. Conclusions: Oral DMSA was a pharmacodynamically effective chelating agent for the treatment of severe childhood lead poisoning in a resource-limited setting. Re-exposure to lead, despite efforts to remediate the environment, and non-adherence may have influenced the impact of outpatient treatment. C1 [Thurtle, Natalie; Cooney, Lauren; Moussally, Krystel; Shanks, Leslie; Dargan, Paul I.] Med Sans Frontieres, Amsterdam, Netherlands. [Greig, Jane] Med Sans Frontieres, London, England. [Amitai, Yona] Bar Ilan Univ, Dept Management, Ramat Gan, Israel. [Ariti, Cono] London Sch Hyg & Trop Med, London WC1, England. [Brown, Mary Jean] Ctr Dis Control & Prevent, Hlth Homes Lead Poisoning Prevent Program, Natl Ctr Environm Hlth, Atlanta, GA USA. [Kosnett, Michael J.] Univ Colorado, Sch Med, Dept Med, Div Clin Pharmacol & Toxicol, Denver, CO USA. [Sani-Gwarzo, Nasir] Fed Minist Hlth, Dept Publ Hlth, Abuja, Nigeria. [Akpan, Henry] Fed Minist Hlth, Abuja, Nigeria. [Akpan, Henry] Fed Minist Commun Technol, Abuja, Nigeria. [Dargan, Paul I.] Guys & St Thomas NHS Fdn Trust, London, England. RP Thurtle, N (reprint author), Med Sans Frontieres, Amsterdam, Netherlands. EM Jane.Greig@london.msf.org OI Greig, Jane/0000-0003-2732-0023 FU MSF operations FX This study was funded as part of MSF operations. Lundbeck donated some DMSA, but had no role in the treatment programme or in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this presentation have not been formally disseminated by the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry and should not be construed to represent any agency determination or policy. NR 59 TC 2 Z9 2 U1 2 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD OCT PY 2014 VL 11 IS 10 AR 1001739 DI 10.1371/journal.pmed.1001739 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA AS7UU UT WOS:000344460900001 ER PT J AU Duggal, NK Bosco-Lauth, A Bowen, RA Wheeler, SS Reisen, WK Felix, TA Mann, BR Romo, H Swetnam, DM Barrett, ADT Brault, AC AF Duggal, Nisha K. Bosco-Lauth, Angela Bowen, Richard A. Wheeler, Sarah S. Reisen, William K. Felix, Todd A. Mann, Brian R. Romo, Hannah Swetnam, Daniele M. Barrett, Alan D. T. Brault, Aaron C. TI Evidence for Co-evolution of West Nile Virus and House Sparrows in North America SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID UNITED-STATES; NEW-YORK; ALPHA/BETA-INTERFERON; HOST SELECTION; AVIAN HOSTS; VIRULENCE; TRANSMISSION; BIRDS; MOSQUITOS; STRAINS AB West Nile virus (WNV) has been maintained in North America in enzootic cycles between mosquitoes and birds since it was first described in North America in 1999. House sparrows (HOSPs; Passer domesticus) are a highly competent host for WNV that have contributed to the rapid spread of WNV across the U.S.; however, their competence has been evaluated primarily using an early WNV strain (NY99) that is no longer circulating. Herein, we report that the competence of wild HOSPs for the NY99 strain has decreased significantly over time, suggesting that HOSPs may have developed resistance to this early WNV strain. Moreover, recently isolated WNV strains generate higher peak viremias and mortality in contemporary HOSPs compared to NY99. These data indicate that opposing selective pressures in both the virus and avian host have resulted in a net increase in the level of host competence of North American HOSPs for currently circulating WNV strains. C1 [Duggal, Nisha K.; Bosco-Lauth, Angela; Romo, Hannah; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Bosco-Lauth, Angela; Bowen, Richard A.; Romo, Hannah] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA. [Wheeler, Sarah S.; Reisen, William K.] Univ Calif Davis, Ctr Vectorborne Dis, Davis, CA 95616 USA. [Felix, Todd A.] USDA, Lakewood, CO USA. [Mann, Brian R.; Swetnam, Daniele M.; Barrett, Alan D. T.] Univ Texas Med Branch, Dept Pathol & Microbiol, Galveston, TX 77555 USA. [Mann, Brian R.; Swetnam, Daniele M.; Barrett, Alan D. T.] Univ Texas Med Branch, Dept Immunol, Galveston, TX 77555 USA. RP Duggal, NK (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. EM abrault@cdc.gov FU APHL Emerging Infectious Disease postdoctoral fellowship; ASM Infectious Disease postdoctoral fellowship FX NKD was supported by an APHL Emerging Infectious Disease postdoctoral fellowship, and ABL was supported by an ASM Infectious Disease postdoctoral fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 10 Z9 10 U1 1 U2 21 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2014 VL 8 IS 10 AR e3262 DI 10.1371/journal.pntd.0003262 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AS9WJ UT WOS:000344589000068 PM 25357248 ER PT J AU Hunsperger, EA Yoksan, S Buchy, P Nguyen, VC Sekaran, SD Enria, DA Vazquez, S Cartozian, E Pelegrino, JL Artsob, H Guzman, MG Olliaro, P Zwang, J Guillerm, M Kliks, S Halstead, S Peeling, RW Margolis, HS AF Hunsperger, Elizabeth A. Yoksan, Sutee Buchy, Philippe Vinh Chau Nguyen Sekaran, Shamala Devi Enria, Delia A. Vazquez, Susana Cartozian, Elizabeth Pelegrino, Jose L. Artsob, Harvey Guzman, Maria G. Olliaro, Piero Zwang, Julien Guillerm, Martine Kliks, Susie Halstead, Scott Peeling, Rosanna W. Margolis, Harold S. TI Evaluation of Commercially Available Diagnostic Tests for the Detection of Dengue Virus NS1 Antigen and Anti-Dengue Virus IgM Antibody SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID LINKED IMMUNOSORBENT ASSAYS; NONSTRUCTURAL PROTEIN NS1; RAPID DETECTION; INFECTION; KIT; SURVEILLANCE; CORRELATE; PCR AB Commercially available diagnostic test kits for detection of dengue virus (DENV) non-structural protein 1 (NS1) and anti-DENV IgM were evaluated for their sensitivity and specificity and other performance characteristics by a diagnostic laboratory network developed by World Health Organization (WHO), the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) and the Pediatric Dengue Vaccine Initiative (PDVI). Each network laboratory contributed characterized serum specimens for the panels used in the evaluation. Microplate enzyme-linked immunosorbent assay (ELISA) and rapid diagnostic test (RDT formats) were represented by the kits. Each ELISA was evaluated by 2 laboratories and RDTs were evaluated by at least 3 laboratories. The reference tests for IgM anti-DENV were laboratory developed assays produced by the Armed Forces Research Institute for Medical Science (AFRIMS) and the Centers for Disease Control and Prevention (CDC), and the NS1 reference test was reverse transcriptase polymerase chain reaction (RT-PCR). Results were analyzed to determine sensitivity, specificity, inter-laboratory and inter-reader agreement, lot-to-lot variation and ease-of-use. NS1 ELISA sensitivity was 60-75% and specificity 71-80%; NS1 RDT sensitivity was 38-71% and specificity 76-80%; the IgM anti-DENV RDTs sensitivity was 30-96%, with a specificity of 86-92%, and IgM anti-DENV ELISA sensitivity was 96-98% and specificity 78-91%. NS1 tests were generally more sensitive in specimens from the acute phase of dengue and in primary DENV infection, whereas IgM anti-DENV tests were less sensitive in secondary DENV infections. The reproducibility of the NS1 RDTs ranged from 92-99% and the IgM anti-DENV RDTs from 88-94%. C1 [Hunsperger, Elizabeth A.; Cartozian, Elizabeth; Margolis, Harold S.] Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR 00920 USA. [Yoksan, Sutee] Mahidol Univ, Ctr Vaccine Dev, Bangkok 10700, Thailand. [Buchy, Philippe] Inst Pasteur, Phnom Penh, Cambodia. [Vinh Chau Nguyen] Cho Quan Hosp, Hosp Trop Dis, Ho Chi Minh City, Vietnam. [Sekaran, Shamala Devi] Univ Malaya, Dept Med Microbiol, Kuala Lumpur, Malaysia. [Enria, Delia A.] Inst Nacl Enfermedades Virales Humanas Dr Julio I, Pergamino, Argentina. [Vazquez, Susana; Pelegrino, Jose L.; Guzman, Maria G.] Inst Med Trop Pedro Kouri, Havana, Cuba. [Artsob, Harvey] Publ Hlth Agcy Canada, Winnipeg, MB, Canada. [Olliaro, Piero; Guillerm, Martine; Peeling, Rosanna W.] WHO, Special Programme Res & Training Trop Dis TDR, UNICEF, UNDP,World Bank, CH-1211 Geneva, Switzerland. [Kliks, Susie; Halstead, Scott] Pediat Dengue Vaccine Initiat, Seoul, South Korea. RP Hunsperger, EA (reprint author), Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR 00920 USA. EM enh4@cdc.gov RI Pelegrino Martinez de la Cotera, Jose Luis/F-9040-2016 OI Pelegrino Martinez de la Cotera, Jose Luis/0000-0003-0833-653X FU UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR); Pediatrics Dengue Vaccine Initiative (PDVI) FX This study was supported financially and coordinated by the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) and Pediatrics Dengue Vaccine Initiative (PDVI). The funders of this project were involved in the study design and the preparation of the manuscript. NR 29 TC 20 Z9 20 U1 3 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2014 VL 8 IS 10 AR e3171 DI 10.1371/journal.pntd.0003171 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AS9WJ UT WOS:000344589000010 PM 25330157 ER PT J AU Kreppel, KS Caminade, C Telfer, S Rajerison, M Rahalison, L Morse, A Baylis, M AF Kreppel, Katharina S. Caminade, Cyril Telfer, Sandra Rajerison, Minoarison Rahalison, Lila Morse, Andy Baylis, Matthew TI A Non-Stationary Relationship between Global Climate Phenomena and Human Plague Incidence in Madagascar SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID EL-NINO; DENGUE EPIDEMICS; WAVELET ANALYSIS; AIR-TEMPERATURE; TIME-SERIES; VARIABILITY; RAINFALL; OUTBREAKS; HUMIDITY; DYNAMICS AB Background: Plague, a zoonosis caused by Yersinia pestis, is found in Asia and the Americas, but predominantly in Africa, with the island of Madagascar reporting almost one third of human cases worldwide. Plague's occurrence is affected by local climate factors which in turn are influenced by large-scale climate phenomena such as the El Nino Southern Oscillation (ENSO). The effects of ENSO on regional climate are often enhanced or reduced by a second large-scale climate phenomenon, the Indian Ocean Dipole (IOD). It is known that ENSO and the IOD interact as drivers of disease. Yet the impacts of these phenomena in driving plague dynamics via their effect on regional climate, and specifically contributing to the foci of transmission on Madagascar, are unknown. Here we present the first analysis of the effects of ENSO and IOD on plague in Madagascar. Methodology/principal findings: We use a forty-eight year monthly time-series of reported human plague cases from 1960 to 2008. Using wavelet analysis, we show that over the last fifty years there have been complex non-stationary associations between ENSO/IOD and the dynamics of plague in Madagascar. We demonstrate that ENSO and IOD influence temperature in Madagascar and that temperature and plague cycles are associated. The effects on plague appear to be mediated more by temperature, but precipitation also undoubtedly influences plague in Madagascar. Our results confirm a relationship between plague anomalies and an increase in the intensity of ENSO events and precipitation. Conclusions/significance: This work widens the understanding of how climate factors acting over different temporal scales can combine to drive local disease dynamics. Given the association of increasing ENSO strength and plague anomalies in Madagascar it may in future be possible to forecast plague outbreaks in Madagascar. The study gives insight into the complex and changing relationship between climate factors and plague in Madagascar. C1 [Kreppel, Katharina S.; Caminade, Cyril; Baylis, Matthew] Univ Liverpool, LUCINDA Grp, Inst Infect & Global Hlth, Dept Epidemiol & Populat Hlth, Neston, England. [Caminade, Cyril; Morse, Andy] Univ Liverpool, Sch Environm Sci, Dept Geog & Planning, Liverpool L69 3BX, Merseyside, England. [Telfer, Sandra] Univ Aberdeen, Inst Biol & Environm Sci, Aberdeen, Scotland. [Rajerison, Minoarison] Inst Pasteur Madagascar, Unite Peste, Antananarivo, Madagascar. [Rahalison, Lila] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. [Baylis, Matthew] Univ Liverpool, Hlth Protect Res Unit Emerging & Zoonot Infect, Neston, England. RP Kreppel, KS (reprint author), Univ Liverpool, LUCINDA Grp, Inst Infect & Global Hlth, Dept Epidemiol & Populat Hlth, Neston, England. EM Katharina.Kreppel@glasgow.ac.uk OI cyril, caminade/0000-0002-3846-7082; Baylis, Matthew/0000-0003-0335-187X FU Leverhulme Trust Research Leadership Award [F/0025/AC]; University of Liverpool; BBSRC [ISIS 1813] FX The analysis of the study was supported by the Leverhulme Trust Research Leadership Award F/0025/AC: "Predicting the effects of climate change on infectious diseases of animals" (awarded to MB). Funding for KSK was provided by a University of Liverpool PhD studentship award and for MB by BBSRC award ISIS 1813, "Climate change and the future of plague in Madagascar." The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 5 Z9 6 U1 3 U2 38 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2014 VL 8 IS 10 AR e3155 DI 10.1371/journal.pntd.0003155 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AS9WJ UT WOS:000344589000009 PM 25299064 ER PT J AU Ledermann, JP Guillaumot, L Yug, L Saweyog, SC Tided, M Machieng, P Pretrick, M Marfel, M Griggs, A Bel, M Duffy, MR Hancock, WT Ho-Chen, T Powers, AM AF Ledermann, Jeremy P. Guillaumot, Laurent Yug, Lawrence Saweyog, Steven C. Tided, Mary Machieng, Paul Pretrick, Moses Marfel, Maria Griggs, Anne Bel, Martin Duffy, Mark R. Hancock, W. Thane Tai Ho-Chen Powers, Ann M. TI Aedes hensilli as a Potential Vector of Chikungunya and Zika Viruses SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID MOSQUITO-BORNE INFECTIONS; FEDERATED STATES; YAP STATE; DENGUE-FEVER; EPIDEMIC; MICRONESIA; OUTBREAK; NIGERIA; ALBOPICTUS; STRAINS AB An epidemic of Zika virus (ZIKV) illness that occurred in July 2007 on Yap Island in the Federated States of Micronesia prompted entomological studies to identify both the primary vector(s) involved in transmission and the ecological parameters contributing to the outbreak. Larval and pupal surveys were performed to identify the major containers serving as oviposition habitat for the likely vector(s). Adult mosquitoes were also collected by backpack aspiration, light trap, and gravid traps at select sites around the capital city. The predominant species found on the island was Aedes (Stegomyia) hensilli. No virus isolates were obtained from the adult field material collected, nor did any of the immature mosquitoes that were allowed to emerge to adulthood contain viable virus or nucleic acid. Therefore, laboratory studies of the probable vector, Ae. hensilli, were undertaken to determine the likelihood of this species serving as a vector for Zika virus and other arboviruses. Infection rates of up to 86%, 62%, and 20% and dissemination rates of 23%, 80%, and 17% for Zika, chikungunya, and dengue-2 viruses respectively, were found supporting the possibility that this species served as a vector during the Zika outbreak and that it could play a role in transmitting other medically important arboviruses. C1 [Ledermann, Jeremy P.; Griggs, Anne; Duffy, Mark R.; Powers, Ann M.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Guillaumot, Laurent] Inst Pasteur Nouvelle Caledonie, URE Entomol Med, Noumea, New Caledonia. [Yug, Lawrence; Tided, Mary] Dept Hlth Serv, Div Publ Hlth, Environm Hlth Serv, Ponape, Micronesia. [Saweyog, Steven C.; Machieng, Paul] Dept Hlth & Social Affairs, Natl Food Safety Program, Ponape, Micronesia. [Pretrick, Moses] Dept Hlth Educ & Social Affairs, Ponape, Micronesia. [Marfel, Maria; Bel, Martin; Hancock, W. Thane] Waab Community Hlth Ctr, Yap, Micronesia. [Tai Ho-Chen] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Field Assignments Branch, Atlanta, GA USA. RP Ledermann, JP (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. EM APowers@cdc.gov FU United States Government, Dept. of Health and Human Services, Centers for Disease Control and Prevention FX This study was funded by the United States Government, Dept. of Health and Human Services, Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 54 Z9 57 U1 4 U2 55 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2014 VL 8 IS 10 AR e3188 DI 10.1371/journal.pntd.0003188 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AS9WJ UT WOS:000344589000015 PM 25299181 ER PT J AU Salyer, SJ Ellis, EM Salomon, C Bron, C Juin, S Hemme, RR Hunsperger, E Jentes, ES Magloire, R Tomashek, KM Desormeaux, AM Munoz-Jordan, JL Etienne, L Beltran, M Sharp, TM Moffett, D Tappero, J Margolis, HS Katz, MA AF Salyer, Stephanie J. Ellis, Esther M. Salomon, Corvil Bron, Christophe Juin, Stanley Hemme, Ryan R. Hunsperger, Elizabeth Jentes, Emily S. Magloire, Roc Tomashek, Kay M. Desormeaux, Anne Marie Munoz-Jordan, Jorge L. Etienne, Lesly Beltran, Manuela Sharp, Tyler M. Moffett, Daphne Tappero, Jordan Margolis, Harold S. Katz, Mark A. TI Dengue Virus Infections among Haitian and Expatriate Non-governmental Organization Workers - Leogane and Port-au-Prince, Haiti, 2012 SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; AEDES-AEGYPTI; FEVER; TRAVELERS; AMERICA; TRANSMISSION; ALBOPICTUS; DIAGNOSIS; BURDEN AB In October 2012, the Haitian Ministry of Health and the US CDC were notified of 25 recent dengue cases, confirmed by rapid diagnostic tests (RDTs), among non-governmental organization (NGO) workers. We conducted a serosurvey among NGO workers in Leogane and Port-au-Prince to determine the extent of and risk factors for dengue virus infection. Of the total 776 staff from targeted NGOs in Leogane and Port-au-Prince, 173 (22%; 52 expatriates and 121 Haitians) participated. Anti-dengue virus (DENV) IgM antibody was detected in 8 (15%) expatriates and 9 (7%) Haitians, and DENV non-structural protein 1 in one expatriate. Anti-DENV IgG antibody was detected in 162 (94%) participants (79% of expatriates; 100% of Haitians), and confirmed by microneutralization testing as DENV-specific in 17/34 (50%) expatriates and 42/42 (100%) Haitians. Of 254 pupae collected from 68 containers, 65% were Aedes aegypti; 27% were Ae. albopictus. Few NGO workers reported undertaking mosquito-avoidance action. Our findings underscore the risk of dengue in expatriate workers in Haiti and Haitians themselves. C1 [Salyer, Stephanie J.; Ellis, Esther M.; Jentes, Emily S.; Moffett, Daphne; Tappero, Jordan] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Ellis, Esther M.; Hemme, Ryan R.; Hunsperger, Elizabeth; Tomashek, Kay M.; Munoz-Jordan, Jorge L.; Beltran, Manuela; Sharp, Tyler M.; Margolis, Harold S.] Ctr Dis Control & Prevent, San Juan, PR USA. [Salomon, Corvil; Magloire, Roc; Desormeaux, Anne Marie] Minist Publ Hlth & Populat, Port Au Prince, Haiti. [Bron, Christophe] Int Federat Red Cross & Red Crescent Soc, Port Au Prince, Haiti. [Juin, Stanley; Katz, Mark A.] Ctr Dis Control & Prevent, Port Au Prince, Haiti. [Etienne, Lesly] Haitian Red Cross, Port Au Prince, Haiti. RP Salyer, SJ (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM wig9@cdc.gov OI Salyer, Stephanie/0000-0001-7679-2006 FU United States Centers for Disease Control and Prevention FX This work was supported by the United States Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 2 Z9 2 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2014 VL 8 IS 10 AR e3269 DI 10.1371/journal.pntd.0003269 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AS9WJ UT WOS:000344589000073 PM 25356592 ER PT J AU Tomashek, KM Biggerstaff, BJ Ramos, MM Perez-Guerra, CL Rivera, EJG Sun, W AF Tomashek, Kay M. Biggerstaff, Brad J. Ramos, Mary M. Perez-Guerra, Carmen L. Rivera, Enid J. Garcia Sun, Wellington TI Physician Survey to Determine How Dengue Is Diagnosed, Treated and Reported in Puerto Rico SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID PLATELET TRANSFUSION; CONTROLLED-TRIAL; FEVER; DEATHS; RATES; CARE AB Dengue is a major cause of morbidity in Puerto Rico and is well-known to its physicians. Early case identification and timely initiation of treatment for patients with severe dengue can reduce medical complications and mortality. To determine clinical management and reporting practices, and assess knowledge of dengue and its management, a survey was sent to 2,512 physicians with a medical license in Puerto Rico. Of the 2,313 physicians who received the survey, 817 (35%) completed the questionnaire. Of the respondents, 708 were currently practicing medicine; 138 were board certified (Group 1), 282 were board eligible (Group 2), and 288 had not finished residency (Group 3). Although respondents clinically diagnosed, on average, 12 cases of dengue in the preceding three months, 31% did not report any suspected cases to public health officials while about half (56%) reported all cases. Overall, 29% of respondents correctly identified early signs of shock and 48% identified severe abdominal pain and persistent vomiting as warning signs for severe dengue with the proportion of correct respondents highest in Group 1. Reportedly about sixty percent (57%) appropriately never give corticosteroids or prophylactic platelet transfusions to dengue patients. One third (30%) of respondents correctly identified administration of intravenous colloid solution as the best treatment option for dengue patients with refractory shock and elevated hematocrit after an initial trial of intravenous crystalloids, and nearly one half (46%) correctly identified administration of a blood transfusion as the best option for dengue patients with refractory shock and decreased hematocrit after a trial of intravenous crystalloids. Even though dengue has been endemic in Puerto Rico for nearly 4 decades, knowledge of dengue management is still limited, compliance with WHO treatment guidelines is suboptimal, and underreporting is significant. These findings were used to design a post graduate training course to improve the clinical management of dengue. C1 [Tomashek, Kay M.; Ramos, Mary M.; Perez-Guerra, Carmen L.; Sun, Wellington] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, San Juan, PR USA. [Biggerstaff, Brad J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO USA. [Rivera, Enid J. Garcia] Puerto Rico Dept Hlth, San Juan, PR USA. RP Tomashek, KM (reprint author), NIAID, OCRR, DMID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM kay.tomashek@nih.gov NR 37 TC 4 Z9 4 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2014 VL 8 IS 10 AR e3192 DI 10.1371/journal.pntd.0003192 PG 8 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AS9WJ UT WOS:000344589000016 PM 25299251 ER PT J AU Yadava, A Hall, CE Sullivan, JS Nace, D Williams, T Collins, WE Ockenhouse, CF Barnwell, JW AF Yadava, Anjali Hall, Cysha E. Sullivan, Joann S. Nace, Douglas Williams, Tyrone Collins, William E. Ockenhouse, Christian F. Barnwell, John W. TI Protective Efficacy of a Plasmodium vivax Circumsporozoite Protein-Based Vaccine in Aotus nancymaae Is Associated with Antibodies to the Repeat Region SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID RECOMBINANT MALARIA VACCINE; MULTIPLE ANTIGEN CONSTRUCT; MONKEYS; IMMUNOGENICITY; IMMUNIZATION; PEPTIDES; EPITOPE; MAP AB We have previously reported that Vivax Malaria Protein 001 (VMP001), a vaccine candidate based on the circumsporozoite protein of Plasmodium vivax, is immunogenic in mice and rhesus monkeys in the presence of various adjuvants. In the present study, we evaluated the immunogenicity and efficacy of VMP001 formulated with a TLR9 agonist in a water-in-oil emulsion. Following immunization, the vaccine efficacy was assessed by challenging Aotus nancymaae monkeys with P. vivax sporozoites. Monkeys from both the low-and high-dose vaccine groups generated strong humoral immune responses to the vaccine (peak median titers of 291,622), and its subunits (peak median titers to the N-term, central repeat and C-term regions of 22,188; 66,120 and 179,947, respectively). 66.7% of vaccinated monkeys demonstrated sterile protection following challenge. Protection was associated with antibodies directed against the central repeat region. The protected monkeys had a median anti-repeat titer of 97,841 compared to 14,822 in the non-protected monkeys. This is the first report demonstrating P. vivax CSP vaccine-induced protection of Aotus monkeys challenged with P. vivax sporozoites. C1 [Yadava, Anjali; Hall, Cysha E.; Ockenhouse, Christian F.] Walter Reed Army Inst Res, Malaria Vaccine Branch, Mil Malaria Res Program, Silver Spring, MD 20910 USA. [Sullivan, Joann S.; Nace, Douglas; Williams, Tyrone; Collins, William E.; Barnwell, John W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Yadava, A (reprint author), Walter Reed Army Inst Res, Malaria Vaccine Branch, Mil Malaria Res Program, Silver Spring, MD 20910 USA. EM Anjali.Yadava.Civ@mail.mil FU Military Infectious Diseases Research Program, Maryland; Centers for Disease Control, Atlanta FX This work was supported by intramural funding from the Military Infectious Diseases Research Program, Maryland and the Centers for Disease Control, Atlanta. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 7 Z9 7 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2014 VL 8 IS 10 AR e3268 DI 10.1371/journal.pntd.0003268 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AS9WJ UT WOS:000344589000072 PM 25329054 ER PT J AU Cauda, E Sheehan, M Gussman, R Kenny, L Volkwein, J AF Cauda, Emanuele Sheehan, Maura Gussman, Robert Kenny, Lee Volkwein, Jon TI An Evaluation of Sharp Cut Cyclones for Sampling Diesel Particulate Matter Aerosol in the Presence of Respirable Dust SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE cyclone; diesel particulate matter; DPMS; mining; sampler ID AERODYNAMIC PARTICLE SIZER; LUNG-CANCER; EXHAUST; MINERS; PENETRATION AB Two prototype cyclones were the subjects of a comparative research campaign with a diesel particulate matter sampler (DPMS) that consists of a respirable cyclone combined with a downstream impactor. The DPMS is currently used in mining environments to separate dust from the diesel particulate matter and to avoid interferences in the analysis of integrated samples and direct-reading monitoring in occupational environments. The sampling characteristics of all three devices were compared using ammonium fluorescein, diesel, and coal dust aerosols. With solid spherical test aerosols at low particle loadings, the aerodynamic size-selection characteristics of all three devices were found to be similar, with 50% penetration efficiencies (d(50)) close to the design value of 0.8 mu m, as required by the US Mine Safety and Health Administration for monitoring occupational exposure to diesel particulate matter in US mining operations. The prototype cyclones were shown to have 'sharp cut' size-selection characteristics that equaled or exceeded the sharpness of the DPMS. The penetration of diesel aerosols was optimal for all three samplers, while the results of the tests with coal dust induced the exclusion of one of the prototypes from subsequent testing. The sampling characteristics of the remaining prototype sharp cut cyclone (SCC) and the DPMS were tested with different loading of coal dust. While the characteristics of the SCC remained constant, the deposited respirable coal dust particles altered the size-selection performance of the currently used sampler. This study demonstrates that the SCC performed better overall than the DPMS. C1 [Cauda, Emanuele; Volkwein, Jon] NIOSH, Off Mine Safety & Hlth Res, Ctr Dis Control & Prevent, Pittsburgh, PA 15236 USA. [Sheehan, Maura] W Chester Univ, Dept Hlth, Environm Hlth Program, W Chester, PA 19383 USA. [Gussman, Robert] BGI Inc, Waltham, MA 02451 USA. [Kenny, Lee] Hlth & Safety Execut, Sheffield S3 8NH, S Yorkshire, England. RP Cauda, E (reprint author), NIOSH, Off Mine Safety & Hlth Res, Ctr Dis Control & Prevent, 626 Cochrans Mill Rd, Pittsburgh, PA 15236 USA. EM ecauda@cdc.gov FU Intramural CDC HHS [CC999999] NR 29 TC 1 Z9 1 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 EI 1475-3162 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD OCT PY 2014 VL 58 IS 8 BP 995 EP 1005 DI 10.1093/annhyg/meu045 PG 11 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA AS4IW UT WOS:000344239100007 PM 25060240 ER PT J AU Sirois, PA Pridjian, G McRae, S Hinckley, AF Rasmussen, SA Kissinger, P Buekens, P Hayes, EB O'Leary, DR Swan, KF Xiong, X Wesson, DM AF Sirois, Patricia A. Pridjian, Gabriella McRae, Scott Hinckley, Alison F. Rasmussen, Sonja A. Kissinger, Patricia Buekens, Pierre Hayes, Edward B. O'Leary, Daniel R. Swan, Kenneth F. Xiong, Xu Wesson, Dawn M. TI Developmental Outcomes in Young Children Born to Mothers with West Nile Illness during Pregnancy SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE West Nile virus; pregnancy; infancy; early childhood development ID VIRUS INFECTION; UNITED-STATES; DISEASE AB Background: West Nile virus (WNV) infection is associated with acute morbidity and mortality in adults and children. Information on the effects of maternal WNV illness during pregnancy on early childhood development is limited. This study was designed to examine the relationship between maternal WNV illness during pregnancy and birth and developmental outcomes at age 3 years. Methods: Mother-child participants were identified using a national surveillance registry for women with WNV illness during pregnancy. Maternal and infant health data and relevant family characteristics were obtained through medical record reviews and maternal questionnaires. All infants received ophthalmologic examinations. Child development was evaluated at age 3 years using the Bayley Scales of Infant and Toddler Development-Third Edition (Bayley-III). Results: As a group, the children's (N = 11) birth weight, head circumference, and infant ophthalmologic examination results were within age expectations; one child was born preterm gestational age 36 weeks). Mean (SD) age at the time of Bayley-III testing was 36.7 (3.8) months. The group's mean performance on the Bayley-III was at or above age level in all domains, but one child showed a mild delay in the Adaptive domain. The variability observed in this sample (1/53 [1.9%] Domain scores < -22.0 SDs) was consistent with expectations based upon the distribution of Bayley-III Domain scores in the general population. Conclusion: Maternal WNV infection does not appear to be associated with global developmental delays in young children. These results are preliminary, however, and require confirmation in future research. (C) 2014 Wiley Periodicals, Inc. C1 [Sirois, Patricia A.; Pridjian, Gabriella; McRae, Scott; Kissinger, Patricia; Buekens, Pierre; Swan, Kenneth F.; Xiong, Xu; Wesson, Dawn M.] Tulane Univ, New Orleans, LA 70112 USA. [Hinckley, Alison F.; Hayes, Edward B.; O'Leary, Daniel R.] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Sirois, PA (reprint author), Tulane Univ, Sch Med, 1430 Tulane Ave,TW-41, New Orleans, LA 70112 USA. EM psirois@tulane.edu FU Tulane University [5 U01 DD000026]; Centers for Disease Control and Prevention (National Center on Birth Defects and Developmental Disabilities) [5 U01 DD000026]; Centers for Disease Control and Prevention (National Center for Emerging and Zoonotic Infectious Diseases) [5 U01 DD000026] FX This study was funded through a cooperative agreement (No. 5 U01 DD000026) between Tulane University and the Centers for Disease Control and Prevention (National Center on Birth Defects and Developmental Disabilities and National Center for Emerging and Zoonotic Infectious Diseases). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors have no conflicts of interest or funding to disclose. NR 17 TC 4 Z9 4 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD OCT PY 2014 VL 100 IS 10 BP 792 EP 796 DI 10.1002/bdra.23297 PG 5 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA AS5YT UT WOS:000344343100008 PM 25196266 ER PT J AU Williams, D Basavarajappay, MS Rasmussen, SA Morris, S Mattison, D AF Williams, Denita Basavarajappay, Mallikarjuna S. Rasmussen, Sonja A. Morris, Suzanne Mattison, Donald CA Anim Models Pregnancy Working Grp TI Highlights from the United States Food and Drug Administration's Public Workshop on the Development of Animal Models of Pregnancy to Address Medical Countermeasures in an "At-Risk" Population of Pregnant Women: Influenza as a Case Study SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE animal models; influenza; oseltamivir phosphate; oseltamivir carboxylate; medical countermeasures; pregnancy ID PHARMACOKINETICS; OSELTAMIVIR AB The U.S. Food and Drug Administration (FDA) and other federal agencies partner to ensure that medical countermeasures (e. g., drug therapies and vaccines) are available for public health emergencies (FDA, 2014). Despite continuing progress, providing medical countermeasures and treatment guidelines for certain populations (e. g., pregnant women) is challenging due to the lack of clinical and/or animal data. Thus, a workshop was convened to discuss animal models of pregnancy for the evaluation of disease progression and medical countermeasures. (C) 2014 Wiley Periodicals, Inc. C1 [Williams, Denita; Basavarajappay, Mallikarjuna S.] US FDA, Div Biochem Toxicol, Natl Ctr Toxicol Res, Jefferson, AR USA. [Williams, Denita] Huntingdon Life Sci Inc, Somerset, NJ USA. [Rasmussen, Sonja A.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Morris, Suzanne] US FDA, Div Genet & Mol Toxicol, Natl Ctr Toxicol Res, Jefferson, AR USA. [Mattison, Donald] Risk Sci Int, Ottawa, ON, Canada. [Mattison, Donald] Univ Ottawa, Ottawa, ON, Canada. RP Williams, D (reprint author), 100 Mettlers Rd, Somerset, NJ 08873 USA. EM williamsd@princeton.huntingdon.com FU NCTR; FDA; U.S. Department of Energy FX Authors Williams and Basavarajappa were supported by appointments to the Postgraduate Research Program at the NCTR administered by the Oak Ridge Institute for Science Education through an interagency agreement between FDA and the U.S. Department of Energy. The views in this study do not represent those of the U.S. Food and Drug Administration or the U.S. Centers for Disease Control and Prevention. NR 16 TC 1 Z9 1 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD OCT PY 2014 VL 100 IS 10 BP 806 EP 810 DI 10.1002/bdra.23319 PG 5 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA AS5YT UT WOS:000344343100011 PM 25296888 ER PT J AU Rehman, IU Vaughan, G Purdy, MA Xia, GL Forbi, JC Rossi, LMG Butt, S Idrees, M Khudyakov, YE AF Rehman, Irshad Ur Vaughan, Gilberto Purdy, Michael A. Xia, Guo-liang Forbi, Joseph C. Goncalves Rossi, Livia Maria Butt, Sadia Idrees, Muhammad Khudyakov, Yury E. TI Genetic history of hepatitis C virus in Pakistan SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Hepatitis C Virus; Genetic diversity; Pakistan ID INJECTING DRUG-USERS; MOLECULAR PHYLOGENIES; GENOTYPES; EPIDEMIC; 3A; PHYLOGEOGRAPHY; TRANSMISSION; AFGHANISTAN; INFECTIONS; EXTINCTION AB Hepatitis C virus (HCV) genotype 3a accounts for similar to 80% of HCV infections in Pakistan, where similar to 10 million people are HCV-infected. Here, we report analysis of the genetic heterogeneity of HCV NS3 and NS5b subgenomic regions from genotype 3a variants obtained from Pakistan. Phylogenetic analyses showed that Pakistani genotype 3a variants were as genetically diverse as global variants, with extensive intermixing. Bayesian estimates showed that the most recent ancestor for genotype 3a in Pakistan was last extant in similar to 1896-1914 C.E. (range: 1851-1932). This genotype experienced a population expansion starting from similar to 1905 to similar to 1970 after which the effective population leveled. Death/birth models suggest that HCV 3a has reached saturating diversity with decreasing turnover rate and positive extinction. Taken together, these observations are consistent with a long and complex history of HCV 3a infection in Pakistan. Published by Elsevier B.V. C1 [Rehman, Irshad Ur; Butt, Sadia; Idrees, Muhammad] Univ Punjab, Genome Ctr Mol Diag & Res, Natl Ctr Excellence Mol Biol, Div Mol Virol & Mol Diagnost, Lahore, Pakistan. [Vaughan, Gilberto; Purdy, Michael A.; Xia, Guo-liang; Forbi, Joseph C.; Goncalves Rossi, Livia Maria; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Goncalves Rossi, Livia Maria] Sao Paulo State Univ, Inst Biosci Language & Exact Sci, Dept Biol, Sao Jose do Rio Pretos, SP, Brazil. RP Vaughan, G (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd,NE,Mailstop A33, Atlanta, GA USA. EM GVaughan@cdc.gov RI idrees, muhammad/F-4415-2015; OI Idrees, Muhammad/0000-0001-5783-1372 NR 44 TC 1 Z9 1 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 EI 1567-7257 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD OCT PY 2014 VL 27 BP 318 EP 324 DI 10.1016/j.meegid.2014.08.005 PG 7 WC Infectious Diseases SC Infectious Diseases GA AS0EU UT WOS:000343951900037 ER PT J AU Grosse, SD Sarafoglou, K AF Grosse, Scott D. Sarafoglou, Kyriakie TI Does Newborn Screening Have 100% Sensitivity to Detect Salt-Wasting Congenital Adrenal Hyperplasia? A Word of Caution SO JAMA PEDIATRICS LA English DT Letter C1 [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Birth Defects Ctr & Dev Disbil, Atlanta, GA 30333 USA. [Sarafoglou, Kyriakie] Univ Minnesota Amplatz Child Hosp, Div Endocrinol, Dept Pediat, Minneapolis, MN 55455 USA. RP Grosse, SD (reprint author), Ctr Dis Control & Prevent, Natl Birth Defects Ctr & Dev Disbil, 1600 Clifton Rd NE Mail Stop E87, Atlanta, GA 30333 USA. EM sgrosse@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD OCT PY 2014 VL 168 IS 10 BP 970 EP 971 PG 9 WC Pediatrics SC Pediatrics GA AT1NC UT WOS:000344699800030 PM 25285869 ER PT J AU Naumann, RB West, BA Sauber-Schatz, EK AF Naumann, Rebecca B. West, Bethany A. Sauber-Schatz, Erin K. TI AT WHAT AGE DO YOU THINK YOU WILL STOP DRIVING? VIEWS OF OLDER US ADULTS SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID DRIVERS C1 [Naumann, Rebecca B.; West, Bethany A.; Sauber-Schatz, Erin K.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Naumann, RB (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. NR 10 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2014 VL 62 IS 10 BP 1999 EP 2001 DI 10.1111/jgs.13050 PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AS6QA UT WOS:000344386400041 PM 25333545 ER PT J AU Levings, JL Cogswell, ME Gunn, JP AF Levings, Jessica L. Cogswell, Mary E. Gunn, Janelle Peralez TI Are Reductions in Population Sodium Intake Achievable? SO NUTRIENTS LA English DT Editorial Material DE sodium; salt; blood pressure; population salt reduction; sodium reduction in the food supply; salt intake and health; salt taste preference ID SALT REDUCTION; DIETARY-SODIUM; UNITED-STATES; TABLE SALT; CONSUMPTION; FOODS; CHEESE AB The vast majority of Americans consume too much sodium, primarily from packaged and restaurant foods. The evidence linking sodium intake with direct health outcomes indicates a positive relationship between higher levels of sodium intake and cardiovascular disease risk, consistent with the relationship between sodium intake and blood pressure. Despite communication and educational efforts focused on lowering sodium intake over the last three decades data suggest average US sodium intake has remained remarkably elevated, leading some to argue that current sodium guidelines are unattainable. The IOM in 2010 recommended gradual reductions in the sodium content of packaged and restaurant foods as a primary strategy to reduce US sodium intake, and research since that time suggests gradual, downward shifts in mean population sodium intake are achievable and can move the population toward current sodium intake guidelines. The current paper reviews recent evidence indicating: (1) significant reductions in mean population sodium intake can be achieved with gradual sodium reduction in the food supply, (2) gradual sodium reduction in certain cases can be achieved without a noticeable change in taste or consumption of specific products, and (3) lowering mean population sodium intake can move us toward meeting the current individual guidelines for sodium intake. C1 [Levings, Jessica L.; Cogswell, Mary E.; Gunn, Janelle Peralez] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. RP Levings, JL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,Mailstop F72, Atlanta, GA 30341 USA. EM jlevings@cdc.gov; mcogswell@cdc.gov; jperalez@cdc.gov NR 27 TC 1 Z9 1 U1 0 U2 7 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2072-6643 J9 NUTRIENTS JI Nutrients PD OCT PY 2014 VL 6 IS 10 BP 4354 EP 4361 DI 10.3390/nu6104354 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AS6FP UT WOS:000344360200019 PM 25325254 ER PT J AU Skuladottir, H Wilcox, AJ Ma, C Lammer, EJ Rasmussen, SA Werler, MM Shaw, GM Carmichael, SL AF Skuladottir, Hildur Wilcox, Allen J. Ma, Chen Lammer, Edward J. Rasmussen, Sonja A. Werler, Martha M. Shaw, Gary M. Carmichael, Suzan L. TI Corticosteroid Use and Risk for Orofacial Clefts EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material AB Orofacial clefts are one of the most common birth defects, with a worldwide prevalence of 1.7 per 1000 live births. Epidemiologic studies have reported inconsistent results regarding an association between corticosteroid use in early pregnancy and delivering an infant with an orofacial cleft. Although corticosteroids are used in women of reproductive age for many common conditions, the safety of these medications during pregnancy is uncertain. The authors previously reported that maternal corticosteroid use was associated with an increased risk for cleft lip with or without palate (CLP) but not cleft palate only (CPO) in deliveries in 1997 to 2002. Since that report, the pertinent population has more than doubled, allowing the largest study of corticosteroids and clefts to date. The aim of the present study was to assess the association using larger and more recent data from the National Birth Defects Prevention Study (NBDPS). Information on deliveries in 1997 to 2009 was collected from 10 centers. Infants or fetuses with CLP or CPO were considered cases and analyzed separately. Cases were considered isolated if there were no accompanying major unrelated birth defects or as nonisolated if more than 1 additional major unrelated defect was present. Live-born control infants without birth defects were randomly selected from birth records. Mothers were interviewed by telephone 6 weeks to 24 months after delivery. The mothers were asked whether they had specific medical conditions before or during pregnancy and what medications were used to treat them. The focus was on periconceptional corticosteroid use by any administration route and component that occurred between 4 weeks before and 12 weeks after conception. Outcomes were an association with specific timing of exposure, mode of administration, or corticosteroid component. Logistic regression models were used to estimate odds ratios (ORs) and their 95% confidence intervals (CIs). Adjustments were made for covariates, including maternal race/ethnicity, education, intake of folic acid, smoking, and study center. Results were presented for deliveries from January 2003 through December 2009 and for pooled data for deliveries from October 1997 through December 2009. From 2003 to 2009, the NBDPS enrolled mothers of 1577 children with CLP, 795 children with CPO, and 5922 control children. A total of 1402 (89%) of the CLP cases and 631 (79%) of the CPO cases were isolated. Any use of corticosteroids 4 weeks before through 12 weeks after conception was reported by mothers of 35 infants (2.3%) with CLP (OR, 1.0; 95% CI, 0.7-1.4), mothers of 13 infants (1.7%) with CPO (OR, 0.7; 95% CI, 0.4-1.2), and mothers of 137 control infants (2.4%). No association was found with route of administration or components of corticosteroids. When earlier and recent data were combined, the cohort included mothers of 2731 infants with CLP, 1429 infants with CPO, and 10,063 controls, delivered in 1997 to 2009. Mothers of 69 infants (2.6%) with CLP (OR, 1.2; 95% CI, 0.9-1.6), 19 infants (1.3%) with CPO (OR, 0.6; 95% CI, 0.4-1.0), and 214 controls (2.1%) reported using any corticosteroids during the specified period. No association was found for route of administration or component of corticosteroid in the combined data, except for prednisone (OR, 1.9; 95% CI, 1.0-3.7). For CLP, ORs ranged from 2.8 (95% CI, 1.3-5.9) for exposures only during weeks 1 to 4 and 5 to 8 after conception to 0.5 (95% CI, 0.1-1.6) for exposures during weeks 9 to 12. Recent data from the NBDPS did not support an association between maternal corticosteroid use during early pregnancy and delivering an infant with an orofacial cleft. These data may help patients and clinicians in making their risk-benefit decisions for using corticosteroids during the first trimester. C1 [Skuladottir, Hildur] Haukeland Hosp, Dept Plast Surg, Bergen, Norway. [Skuladottir, Hildur] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway. [Wilcox, Allen J.] NIEHS, NIH, Durham, NC USA. [Ma, Chen; Shaw, Gary M.; Carmichael, Suzan L.] Stanford Univ, Dept Pediat, Div Neonatol & Dev Med, Sch Med, Stanford, CA 94305 USA. [Lammer, Edward J.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Werler, Martha M.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. RP Skuladottir, H (reprint author), Haukeland Hosp, Dept Plast Surg, Bergen, Norway. NR 4 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD OCT PY 2014 VL 69 IS 10 BP 573 EP 575 DI 10.1097/01.ogx.0000456345.09228.f3 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AS7RS UT WOS:000344453200003 ER PT J AU Goodman, RA Bunnell, R Posner, SF AF Goodman, Richard A. Bunnell, Rebecca Posner, Samuel F. TI What is "community health"? Examining the meaning of an evolving field in public health SO PREVENTIVE MEDICINE LA English DT Editorial Material DE Community health; Community; Public health science; Public health practice ID NORTH-KARELIA PROJECT; CARDIOVASCULAR-DISEASE; PREVENTION; EDUCATION AB In this commentary, We review definition frameworks for community health and examine factors having core relevance to shaping the meaning of this term and growing field. We conclude by suggesting a potential framework for conceptualizing and advancing this field of public health practice through improved understanding of the meaning, scope, and science of community health. Published by Elsevier Inc. C1 [Goodman, Richard A.; Posner, Samuel F.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Director, Atlanta, GA 30341 USA. [Goodman, Richard A.] US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Atlanta, GA USA. [Bunnell, Rebecca] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA. RP Goodman, RA (reprint author), Ctr Dis Control & Prevent, Mailstop K45,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM rag4@cdc.gov OI Posner, Samuel/0000-0003-1574-585X NR 15 TC 3 Z9 3 U1 3 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2014 VL 67 SU 1 BP S58 EP S61 DI 10.1016/j.ypmed.2014.07.028 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AS3YL UT WOS:000344210900011 PM 25069043 ER PT J AU Soler, RE Whitten, KL Ottley, PG AF Soler, Robin E. Whitten, Kathleen L. Ottley, Phyllis G. TI Communities putting prevention to work: Local evaluation of community-based strategies designed to make healthy living easier SO PREVENTIVE MEDICINE LA English DT Editorial Material DE Chronic disease; Obesity; Tobacco use; Second hand smoke exposure; Physical activity; Public health; Evaluation ID PHYSICAL-ACTIVITY; INTERVENTION; ENVIRONMENTS; AFTERSCHOOL; COUNTY; IMPACT; FOOD AB This introduction is an overview of the articles presented in this supplement that describe implementation and evaluation activities conducted as part of the Centers for Disease Control and Prevention's (CDC's) Communities Putting Prevention to Work (CPPW) initiative. CPPW was one of the largest federal investments ever to combat chronic diseases in the United States. CPPW supported high-impact, jurisdiction-wide policy, systems, and "environmental changes to improve health by increasing access to physical activity and healthy foods, and by decreasing tobacco use and exposure to secondhand smoke. The articles included in this supplement describe implementation and evaluation efforts of strategies implemented as part of CPPW by local awardees. This supplement is intended to guide the evidence base for public health interventions on the basis of jurisdiction-wide policy and environmental-level improvements and to encourage rigorous evaluation of the public health interventions. Published by Elsevier Inc. C1 [Soler, Robin E.] Ctr Dis Control & Prevent, Div Community Hlth, Chamblee, GA 30341 USA. [Whitten, Kathleen L.; Ottley, Phyllis G.] ICF Int, Publ Hlth & Survey Res Div, Atlanta, GA USA. RP Soler, RE (reprint author), Ctr Dis Control & Prevent, Res Surveillance & Evaluat Branch, Div Community Hlth, CDC Warehouse, 3719 North Peachtree Rd,Bldg 100, Chamblee, GA 30341 USA. EM rsoler@cdc.gov FU Intramural CDC HHS [CC999999] NR 30 TC 2 Z9 2 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2014 VL 67 SU 1 BP S1 EP S3 DI 10.1016/j.ypmed.2014.08.020 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AS3YL UT WOS:000344210900001 PM 25150384 ER PT J AU Ramos, LR Malta, DC Gomes, GAD Bracco, MM Florindo, AA Mielke, GI Parra, DC Lobelo, F Simoes, EJ Hallal, PC AF Ramos, Luiz Roberto Malta, Deborah Carvalho de Oliveira Gomes, Grace Angelica Bracco, Mario M. Florindo, Alex Antonio Mielke, Gregore Iven Parra, Diana C. Lobelo, Felipe Simoes, Eduardo J. Hallal, Pedro Curi TI Prevalence of health promotion programs in primary health care units in Brazil SO REVISTA DE SAUDE PUBLICA LA English DT Article DE Health Programs and Plans; Health Centers; Health Promotion; Primary Health Care; Health Surveys ID PHYSICAL-ACTIVITY INTERVENTIONS; LATIN-AMERICA; POPULATION AB OBJECTIVE: Assessment of prevalence of health promotion programs in primary health care units within Brazil's health system. METHODS: We conducted a cross-sectional descriptive study based on telephone interviews with managers of primary care units. Of a total 42,486 primary health care units listed in the Brazilian Unified Health System directory, 1,600 were randomly selected. Care units from all five Brazilian macroregions were selected proportionally to the number of units in each region. We examined whether any of the following five different types of health promotion programs was available: physical activity; smoking cessation; cessation of alcohol and illicit drug use; healthy eating; and healthy environment. Information was collected on the kinds of activities offered and the status of implementation of the Family Health Strategy at the units. RESULTS: Most units (62.0%) reported having in place three health promotion programs or more and only 3.0% reported having none. Healthy environment (77.0%) and healthy eating (72.0%) programs were the most widely available; smoking and alcohol use cessation were reported in 54.0% and 42.0% of the units. Physical activity programs were offered in less than 40.0% of the units and their availability varied greatly nationwide, from 51.0% in the Southeast to as low as 21.0% in the North. The Family Health Strategy was implemented in most units (61.0%); however, they did not offer more health promotion programs than others did. CONCLUSIONS: Our study showed that most primary care units have in place health promotion programs. Public policies are needed to strengthen primary care services and improve training of health providers to meet the goals of the agenda for health promotion in Brazil. C1 [Ramos, Luiz Roberto] Univ Fed Sao Paulo, Dept Med Prevent, Sao Paulo, Brazil. [Malta, Deborah Carvalho] Minist Saude, Secretaria Vigilancia Epidemiol, Brasilia, DF, Brazil. [de Oliveira Gomes, Grace Angelica] Univ Estadual Sao Paulo, Nucleo Atividade Fis Esporte & Saude, Rio Claro, SP, Brazil. [Bracco, Mario M.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil. [Florindo, Alex Antonio] Univ Sao Paulo, Escola Artes Ciencias & Humanidades, Sao Paulo, Brazil. [Mielke, Gregore Iven] Univ Fed Pelotas, Programa Posgrad Epidemiol, Pelotas, RS, Brazil. [Parra, Diana C.] Washington Univ, George Warren Brown Sch Social Work, Prevent Res Ctr St Louis, St Louis, MO 63130 USA. [Lobelo, Felipe] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Simoes, Eduardo J.] Univ Missouri, Sch Med, Dept Hlth Management & Informat, Columbia, MO USA. [Hallal, Pedro Curi] Univ Fed Pelotas, Fac Educ Fis, Pelotas, RS, Brazil. RP Ramos, LR (reprint author), Setor Estudos Envelhecimento, Rua Dr Bacelar 384, BR-04026000 Sao Paulo, Brazil. EM lrr@uol.com.br RI Parra, Diana/B-7761-2015; Hallal, Pedro/A-3249-2011; Malta, Deborah/H-7880-2012; Mielke, Gregore/E-2141-2014; OI Simoes, Eduardo/0000-0003-4371-4305; Parra, Diana/0000-0002-9797-6231; Hallal, Pedro/0000-0003-1470-6461; Malta, Deborah/0000-0002-8214-5734; Mielke, Gregore/0000-0002-3043-2715; Lobelo, Felipe/0000-0003-4185-7193 FU Centers for Disease Control and Prevention's Prevention Research Centers Program [U48/DP001903] FX This study was supported by the Centers for Disease Control and Prevention's Prevention Research Centers Program contract U48/DP001903 (Applying Evidence-Physical Activity Recommendations in Brazil). NR 23 TC 4 Z9 8 U1 2 U2 8 PU REVISTA DE SAUDE PUBLICA PI SAO PAULO PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO, BRAZIL SN 0034-8910 EI 1518-8787 J9 REV SAUDE PUBL JI Rev. Saude Publica PD OCT PY 2014 VL 48 IS 5 BP 837 EP 844 DI 10.1590/S0034-8910.2014048005249 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AS7ZA UT WOS:000344469200015 PM 25372175 ER PT J AU Wilson, TE Fraser-White, M Williams, KM Pinto, A Agbetor, F Camilien, B Henny, K Browne, RC Gousse, Y Taylor, T Brown, H Taylor, R Joseph, MA AF Wilson, Tracey E. Fraser-White, Marilyn Williams, Kim M. Pinto, Angelo Agbetor, Francis Camilien, Brignel Henny, Kirk Browne, Ruth C. Gousse, Yolene Taylor, Tonya Brown, Humberto Taylor, Raekiela Joseph, Michael A. TI BARBERSHOP TALK WITH BROTHERS: USING COMMUNITY-BASED PARTICIPATORY RESEARCH TO DEVELOP AND PILOT TEST A PROGRAM TO REDUCE HIV RISK AMONG BLACK HETEROSEXUAL MEN SO AIDS EDUCATION AND PREVENTION LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; AFRICAN-AMERICAN MEN; PROSTATE-CANCER EDUCATION; BEHAVIORAL INTERVENTIONS; UNITED-STATES; HEALTH-PROMOTION; PUERTO-RICO; EFFICACY; STIGMA; METAANALYSIS AB There is a need for feasible, evidence-based interventions that support HIV risk reduction among heterosexual Black men. In this article, we describe the process for development of the Barbershop Talk With Brothers (BTWB) program and evaluation. The BTWB program is a theoretically grounded and community-based HIV prevention program that seeks to improve individual skills and motivation to decrease sexual risk, and that builds men's interest in and capacity for improving their community's health. Formative data collection included barbershop observations and barber focus groups, brief behavioral risk assessments of men in barbershops, and focus groups and individual interviews. Based on this information and in consultation with our steering committee, we developed the BTWB program and accompanying program evaluation. From April through November 2011, 80 men were recruited and completed a baseline assessment of a pilot test of the program; 78 men completed the program and 71 completed a 3-month assessment. The pilot evaluation procedures were feasible to implement, and assessments of pre- and post-test measures indicate that key behavioral outcomes and proposed mediators of those outcomes changed in hypothesized directions. Specifically, attitudes and self-efficacy toward consistent condom use improved, and respondents reported lower levels of sexual risk behavior from baseline to follow-up (all p < 0.05). Perceptions of community empowerment also increased (p = 0.06). While HIV stigma decreased, this difference did not reach statistical significance. Our approach to community-engaged program development resulted in an acceptable, feasible approach to reaching and educating heterosexual Black men about HIV prevention in community settings. C1 [Wilson, Tracey E.; Joseph, Michael A.] Suny Downstate Med Ctr, Sch Publ Hlth, Brooklyn, NY 11203 USA. [Fraser-White, Marilyn; Agbetor, Francis; Camilien, Brignel; Browne, Ruth C.; Brown, Humberto] Arthur Ashe Inst Urban Hlth, Brooklyn, NY USA. [Williams, Kim M.; Henny, Kirk; Taylor, Raekiela] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pinto, Angelo] Correct Assoc New York, New York, NY USA. [Gousse, Yolene; Taylor, Tonya] Suny Downstate Med Ctr, STAR Program, Coll Med, Brooklyn, NY 11203 USA. [Wilson, Tracey E.; Fraser-White, Marilyn; Browne, Ruth C.; Gousse, Yolene; Joseph, Michael A.] Brooklyn Hlth Dispar Ctr, Brooklyn, NY USA. RP Wilson, TE (reprint author), Suny Downstate Med Ctr, Sch Publ Hlth, Mail Stop Code 43,450 Clarkson Ave, Brooklyn, NY 11203 USA. EM Tracey.Wilson@downstate.edu OI Henny, Kirk/0000-0002-0886-8651 FU NCHHSTP CDC HHS [PS000691, UR6 PS000691]; NIMHD NIH HHS [P20 MD006875, P20MD006875] NR 49 TC 3 Z9 3 U1 1 U2 12 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0899-9546 EI 1943-2755 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD OCT PY 2014 VL 26 IS 5 BP 383 EP 397 PG 15 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA AS2SL UT WOS:000344129700001 PM 25299804 ER PT J AU Kahn, HS Gu, QP Bullard, KM Freedman, DS Ahluwalia, N Ogden, CL AF Kahn, Henry S. Gu, Qiuping Bullard, Kai McKeever Freedman, David S. Ahluwalia, Namanjeet Ogden, Cynthia L. TI Population Distribution of the Sagittal Abdominal Diameter (SAD) from a Representative Sample of US Adults: Comparison of SAD, Waist Circumference and Body Mass Index for Identifying Dysglycemia SO PLOS ONE LA English DT Article ID SUBCUTANEOUS ADIPOSE-TISSUE; SIMPLE ANTHROPOMETRIC INDEXES; X-RAY ABSORPTIOMETRY; CARDIOVASCULAR RISK; COMPUTED-TOMOGRAPHY; INSULIN-RESISTANCE; VISCERAL FAT; HEART-DISEASE; MEN; OBESITY AB Background: The sagittal abdominal diameter (SAD) measured in supine position is an alternative adiposity indicator that estimates the quantity of dysfunctional adipose tissue in the visceral depot. However, supine SAD's distribution and its association with health risk at the population level are unknown. Here we describe standardized measurements of SAD, provide the first, national estimates of the SAD distribution among US adults, and test associations of SAD and other adiposity indicators with prevalent dysglycemia. Methods and Findings: In the 2011-2012 National Health and Nutrition Examination Survey, supine SAD was measured ("abdominal height") between arms of a sliding-beam caliper at the level of the iliac crests. From 4817 non-pregnant adults (age >= 20; response rate 88%) we used sample weights to estimate SAD's population distribution by sex and age groups. SAD's population mean was 22.5 cm [95% confidence interval 22.2-22.8]; median was 21.9 cm [21.6-22.4]. The mean and median values of SAD were greater for men than women. For the subpopulation without diagnosed diabetes, we compared the abilities of SAD, waist circumference (WC), and body mass index (BMI, kg/m(2)) to identify prevalent dysglycemia (HbA1c >= 5.7%). For age-adjusted, logistic-regression models in which sex-specific quartiles of SAD were considered simultaneously with quartiles of either WC or BMI, only SAD quartiles 3 (p<0.05 vs quartile 1) and 4 (p<0.001 vs quartile 1) remained associated with increased dysglycemia. Based on continuous adiposity indicators, analyses of the area under the receiver operating characteristic curve (AUC) indicated that the dysglycemia model fit for SAD (age-adjusted) was 0.734 for men (greater than the AUC for WC, p<0.001) and 0.764 for women (greater than the AUC for WC or BMI, p<0.001). Conclusions: Measured inexpensively by bedside caliper, SAD was associated with dysglycemia independently of WC or BMI. Standardized SAD measurements may enhance assessment of dysfunctional adiposity. C1 [Kahn, Henry S.; Bullard, Kai McKeever] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Gu, Qiuping; Ahluwalia, Namanjeet; Ogden, Cynthia L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth & Nutr Examinat Surveys, Hyattsville, MD 20782 USA. [Freedman, David S.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Kahn, HS (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM hkahn@cdc.gov OI Kahn, Henry/0000-0003-2533-1562 NR 49 TC 5 Z9 5 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 1 PY 2014 VL 9 IS 10 AR e108707 DI 10.1371/journal.pone.0108707 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AR6ZM UT WOS:000343729600056 PM 25272003 ER PT J AU Courtney, B Hodge, JG Toner, ES Roxland, BE Penn, MS Devereaux, AV Dichter, JR Kissoon, N Christian, MD Powell, T AF Courtney, Brooke Hodge, James G., Jr. Toner, Eric S. Roxland, Beth E. Penn, Matthew S. Devereaux, Asha V. Dichter, Jeffrey R. Kissoon, Niranjan Christian, Michael D. Powell, Tia CA Task Force Mass Critical Care TI Legal Preparedness Care of the Critically Ill and Injured During Pandemics and Disasters: CHEST Consensus Statement SO CHEST LA English DT Article ID PUBLIC-HEALTH EMERGENCIES; MASS CRITICAL-CARE; LIABILITY; CHALLENGES; STANDARDS; LESSONS; CRISIS; SANDY; LAWS AB BACKGROUND: Significant legal challenges arise when health-care resources become scarce and population-based approaches to care are implemented during severe disasters and pandemics. Recent emergencies highlight the serious legal, economic, and health impacts that can be associated with responding in austere conditions and the critical importance of comprehensive, collaborative health response system planning. This article discusses legal suggestions developed by the American College of Chest Physicians (CHEST) Task Force for Mass Critical Care to support planning and response efforts for mass casualty incidents involving critically ill or injured patients. The suggestions in this chapter are important for all of those involved in a pandemic or disaster with multiple critically ill or injured patients, including front-line clinicians, hospital administrators, and public health or government officials. METHODS: Following the CHEST Guidelines Oversight Committee's methodology, the Legal Panel developed 35 key questions for which specific literature searches were then conducted. The literature in this field is not suitable to provide support for evidence-based recommendations. Therefore, the panel developed expert opinion-based suggestions using a modified Delphi process resulting in seven final suggestions. RESULTS: Acceptance is widespread for the health-care community's duty to appropriately plan for and respond to severe disasters and pandemics. Hospitals, public health entities, and clinicians have an obligation to develop comprehensive, vetted plans for mass casualty incidents involving critically ill or injured patients. Such plans should address processes for evacuation and limited appeals and reviews of care decisions. To legitimize responses, deter independent actions, and trigger liability protections, mass critical care (MCC) plans should be formally activated when facilities and practitioners shift to providing MCC. Adherence to official MCC plans should contribute to protecting hospitals and practitioners who act in good faith from liability. Finally, to address anticipated staffing shortages during severe and prolonged disasters and pandemics, governments should develop approaches to formally expand the availability of qualified health-care workers, such as through using official foreign medical teams. CONCLUSIONS: As a fundamental element of health-care and public health emergency planning and preparedness, the law underlies critical aspects of disaster and pandemic responses. Effective responses require comprehensive advance planning efforts that include assessments of complex legal issues and authorities. Recent disasters have shown that although law is a critical response tool, it can also be used to hold health-care stakeholders who fail to appropriately plan for or respond to disasters and pandemics accountable for resulting patient or staff harm. Claims of liability from harms allegedly suffered during disasters and pandemics cannot be avoided altogether. However, appropriate planning and legal protections can help facilitate sound, consistent decision-making and support response participation among health-care entities and practitioners. CHEST 2014; 146 (4_Suppl): e134S-e144S C1 [Courtney, Brooke] US FDA, Off Counterterrorism & Emerging Threats, Off Commissioner, Silver Spring, MD USA. [Hodge, James G., Jr.] Arizona State Univ, Sandra Day OConnor Coll Law, Tempe, AZ USA. [Toner, Eric S.] Univ Pittsburgh, Med Ctr, UPMC Ctr Hlth Secur, Baltimore, MD USA. [Roxland, Beth E.] NYU, Sch Law, Langone Med Ctr, New York, NY 10003 USA. [Penn, Matthew S.] Ctr Dis Control & Prevent, Publ Hlth Law Program, Off State Tribal Local & Terr Support, Atlanta, GA USA. [Devereaux, Asha V.] Sharp Hosp, Coronado, CA USA. [Dichter, Jeffrey R.] Allina Hlth, Minneapolis, MN USA. [Dichter, Jeffrey R.] Aurora Healthcare, Milwaukee, WI USA. [Kissoon, Niranjan] Univ British Columbia, BC Childrens Hosp, Vancouver, BC V5Z 1M9, Canada. [Kissoon, Niranjan] Univ British Columbia, Sunny Hill Hlth Ctr, Vancouver, BC V5Z 1M9, Canada. [Christian, Michael D.] Canadian Armed Forces, Royal Canadian Med Serv, Toronto, ON, Canada. [Christian, Michael D.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. [Powell, Tia] Albert Einstein Coll Med, Montefiore Med Ctr, New York, NY USA. RP Christian, MD (reprint author), Univ Toronto, Mt Sinai Hosp, Royal Canadian Air Force, 600 Univ Ave,Rm 18-232-1, Toronto, ON M4X 1P4, Canada. EM michael.christian@utoronto.ca OI West, T Eoin/0000-0001-5503-7204 FU Centers of Disease Control and Prevention [1U90TP00591-01]; Department of Health and Human Services from the Office of Preparedness of Emergency Operations [1 - HFPEP070013-01-00]; University of California-Davis FX This publication was supported by the Cooperative Agreement Number 1U90TP00591-01 from the Centers of Disease Control and Prevention, and through a research sub award agreement through the Department of Health and Human Services [Grant 1 - HFPEP070013-01-00] from the Office of Preparedness of Emergency Operations. In addition, this publication was supported by a grant from the University of California-Davis. NR 72 TC 0 Z9 0 U1 1 U2 4 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2014 VL 146 IS 4 SU S BP E134S EP E144S DI 10.1378/chest.14-0741 PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AR4RN UT WOS:000343574100009 PM 25144203 ER PT J AU Devereaux, AV Tosh, PK Hick, JL Hanfling, D Geiling, J Reed, MJ Uyeki, TM Shah, UA Fagbuyi, DB Skippen, P Dichter, JR Kissoon, N Christian, MD Upperman, JS AF Devereaux, Asha V. Tosh, Pritish K. Hick, John L. Hanfling, Dan Geiling, James Reed, Mary Jane Uyeki, Timothy M. Shah, Umair A. Fagbuyi, Daniel B. Skippen, Peter Dichter, Jeffrey R. Kissoon, Niranjan Christian, Michael D. Upperman, Jeffrey S. CA Task Force Mass Critical Care TI Engagement and Education Care of the Critically Ill and Injured During Pandemics and Disasters: CHEST Consensus Statement SO CHEST LA English DT Article ID PUBLIC-HEALTH PREPAREDNESS; MASS CASUALTY INCIDENTS; EMERGENCY PREPAREDNESS; COMMUNITY ENGAGEMENT; CORE COMPETENCES; MANAGEMENT; MEDICINE; SYSTEMS; REGIONALIZATION; INFORMATION AB BACKGROUND: Engagement and education of ICU clinicians in disaster preparedness is fragmented by time constraints and institutional barriers and frequently occurs during a disaster. We reviewed the existing literature from 2007 to April 2013 and expert opinions about clinician engagement and education for critical care during a pandemic or disaster and off er suggestions for integrating ICU clinicians into planning and response. The suggestions in this article are important for all of those involved in a pandemic or large-scale disaster with multiple critically ill or injured patients, including front-line clinicians, hospital administrators, and public health or government officials. METHODS: A systematic literature review was performed and suggestions formulated according to the American College of Chest Physicians (CHEST) Consensus Statement development methodology. We assessed articles, documents, reports, and gray literature reported since 2007. Following expert-informed sorting and review of the literature, key priority areas and questions were developed. No studies of sufficient quality were identified upon which to make evidence-based recommendations. Therefore, the panel developed expert opinion-based suggestions using a modified Delphi process. RESULTS: Twenty-three suggestions were formulated based on literature-informed consensus opinion. These suggestions are grouped according to the following thematic elements: (1) situational awareness, (2) clinician roles and responsibilities, (3) education, and (4) community engagement. Together, these four elements are considered to form the basis for effective ICU clinician engagement for mass critical care. CONCLUSIONS: The optimal engagement of the ICU clinical team in caring for large numbers of critically ill patients due to a pandemic or disaster will require a departure from the routine independent systems operating in hospitals. An effective response will require robust information systems; coordination among clinicians, hospitals, and governmental organizations; pre-event engagement of relevant stakeholders; and standardized core competencies for the education and training of critical care clinicians. CHEST 2014; 146 (4_Suppl): e118S-e133S C1 [Devereaux, Asha V.] Sharp Hosp, Coronado, CA USA. [Tosh, Pritish K.] Mayo Clin, Rochester, MN USA. [Hick, John L.] Univ Minnesota, Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Hanfling, Dan] Inova Hlth Syst, Falls Church, VA USA. [Hanfling, Dan] George Washington Univ, Washington, DC USA. [Geiling, James] VA Med Ctr, White River Jct, VT USA. [Geiling, James] Geisel Sch Med Dartmouth, Hanover, NH USA. [Reed, Mary Jane] Temple Sch Med, Geisinger Med Ctr, Danville, PA USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Shah, Umair A.] Harris Cty Publ Hlth & Environm Serv, Houston, TX USA. [Fagbuyi, Daniel B.] George Washington Univ, Childrens Natl Med Ctr, Washington, DC USA. [Skippen, Peter; Kissoon, Niranjan] Univ British Columbia, BC Childrens Hosp, Vancouver, BC V5Z 1M9, Canada. [Dichter, Jeffrey R.] Allina Hlth, Minneapolis, MN USA. [Dichter, Jeffrey R.] Aurora Healthcare, Milwaukee, WI USA. [Kissoon, Niranjan] Univ British Columbia, Sunny Hill Hlth Ctr, Vancouver, BC V5Z 1M9, Canada. [Christian, Michael D.] Canadian Armed Forces, Royal Canadian Med Serv, Toronto, ON, Canada. [Christian, Michael D.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. [Upperman, Jeffrey S.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA. RP Devereaux, AV (reprint author), 1224 10th Pl 205, Coronado, CA 92118 USA. EM ashadevereaux@icloud.com OI West, T Eoin/0000-0001-5503-7204 FU Centers of Disease Control and Prevention [1U90TP00591-01]; Department of Health and Human Services from the Office of Preparedness of Emergency Operations [1 - HFPEP070013-01-00]; University of California-Davis FX This publication was supported by the Cooperative Agreement Number 1U90TP00591-01 from the Centers of Disease Control and Prevention, and through a research sub award agreement through the Department of Health and Human Services [Grant 1 - HFPEP070013-01-00] from the Office of Preparedness of Emergency Operations. In addition, this publication was supported by a grant from the University of California-Davis. NR 102 TC 0 Z9 0 U1 2 U2 7 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2014 VL 146 IS 4 SU S BP E118S EP E133S DI 10.1378/chest.14-0740 PG 16 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AR4RN UT WOS:000343574100008 PM 25144161 ER PT J AU Geiling, J Burkle, FM Amundson, D Dominguez-Cherit, G Gomersall, CD Lim, ML Luyckx, V Sarani, B Uyeki, TM West, TE Christian, MD Devereaux, AV Dichter, JR Kissoon, N AF Geiling, James Burkle, Frederick M., Jr. Amundson, Dennis Dominguez-Cherit, Guillermo Gomersall, Charles D. Lim, Matthew L. Luyckx, Valerie Sarani, Babak Uyeki, Timothy M. West, T. Eoin Christian, Michael D. Devereaux, Asha V. Dichter, Jeffrey R. Kissoon, Niranjan CA Task Force Mass Critical Care TI Resource-Poor Settings: Infrastructure and Capacity Building Care of the Critically Ill and Injured During Pandemics and Disasters: CHEST Consensus Statement SO CHEST LA English DT Article ID MIDDLE-INCOME COUNTRIES; EMERGENCY TRIAGE ASSESSMENT; INTENSIVE-CARE; DISTRICT HOSPITALS; SEPSIS MANAGEMENT; LIMITED SETTINGS; DEVELOPING-WORLD; HEALTH SYSTEMS; SOUTH-AFRICA; CHILDREN AB BACKGROUND: Planning for mass critical care (MCC) in resource-poor or constrained settings has been largely ignored, despite their large populations that are prone to suffer disproportionately from natural disasters. Addressing MCC in these settings has the potential to help vast numbers of people and also to inform planning for better-resourced areas. METHODS: The Resource-Poor Settings panel developed five key question domains; defining the term resource poor and using the traditional phases of disaster (mitigation/preparedness/response/recovery), literature searches were conducted to identify evidence on which to answer the key questions in these areas. Given a lack of data upon which to develop evidence-based recommendations, expert-opinion suggestions were developed, and consensus was achieved using a modified Delphi process. RESULTS: The five key questions were then separated as follows: definition, infrastructure and capacity building, resources, response, and reconstitution/recovery of host nation critical care capabilities and research. Addressing these questions led the panel to off er 33 suggestions. Because of the large number of suggestions, the results have been separated into two sections: part 1, Infrastructure/Capacity in this article, and part 2, Response/Recovery/Research in the accompanying article. CONCLUSIONS: Lack of, or presence of, rudimentary ICU resources and limited capacity to enhance services further challenge resource-poor and constrained settings. Hence, capacity building entails preventative strategies and strengthening of primary health services. Assistance from other countries and organizations is needed to mount a surge response. Moreover, planning should include when to disengage and how the host nation can provide capacity beyond the mass casualty care event. CHEST 2014; 146 (4_Suppl): e156S-e167S C1 [Geiling, James] VA Med Ctr, White River Jct, VT USA. [Geiling, James] Geisel Sch Med Dartmouth, Hanover, NH 03755 USA. [Burkle, Frederick M., Jr.] Harvard Univ, Harvard Humanitarian Initiat, Cambridge, MA 02138 USA. [Burkle, Frederick M., Jr.] Woodrow Wilson Int Ctr Scholars, Washington, DC 20560 USA. [Amundson, Dennis] Scripps Mem Hosp, Encinitas, CA USA. [Amundson, Dennis] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Dominguez-Cherit, Guillermo] Univ Nacl Autonoma Mexico, Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City 04510, DF, Mexico. [Gomersall, Charles D.] Chinese Univ Hong Kong, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China. [Lim, Matthew L.] Dept Hlth & Human Serv, Off Global Affairs, Washington, DC USA. [Luyckx, Valerie] Univ Alberta, Int Soc Nephrol, Edmonton, AB, Canada. [Sarani, Babak] George Washington Univ, Washington, DC USA. [Uyeki, Timothy M.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [West, T. Eoin] Univ Washington, Sch Med, Seattle, WA USA. [Christian, Michael D.] Canadian Armed Forces, Royal Canadian Med Serv, Toronto, ON, Canada. [Christian, Michael D.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. [Devereaux, Asha V.] Sharp Hosp, Coronado, CA USA. [Dichter, Jeffrey R.] Allina Hlth, Minneapolis, MN USA. [Dichter, Jeffrey R.] Aurora Healthcare, Milwaukee, WI USA. [Kissoon, Niranjan] Univ British Columbia, British Columbia Childrens Hosp, Vancouver, BC V5Z 1M9, Canada. [Kissoon, Niranjan] Univ British Columbia, Sunny Hill Hlth Ctr, Vancouver, BC V5Z 1M9, Canada. RP Geiling, J (reprint author), Geisel Sch Med Dartmouth, 1 Rope Ferry Rd,HB 7900, Hanover, NH 03755 USA. EM James.Geiling@Dartmouth.edu RI Gomersall, Charles/J-1540-2012; OI Gomersall, Charles/0000-0002-8494-8063; Dominguez-Cherit, Guillermo/0000-0003-1403-4415; West, T Eoin/0000-0001-5503-7204 FU Centers of Disease Control and Prevention [1U90TP00591-01]; Department of Health and Human Services from the Office of Preparedness of Emergency Operations [1 - HFPEP070013-01-00]; University of California-Davis FX This publication was supported by the Cooperative Agreement Number 1U90TP00591-01 from the Centers of Disease Control and Prevention, and through a research sub award agreement through the Department of Health and Human Services [Grant 1 - HFPEP070013-01-00] from the Office of Preparedness of Emergency Operations. In addition, this publication was supported by a grant from the University of California-Davis. NR 73 TC 1 Z9 1 U1 2 U2 10 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2014 VL 146 IS 4 SU S BP E156S EP E167S DI 10.1378/chest.14-0744 PG 12 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AR4RN UT WOS:000343574100011 PM 25144337 ER PT J AU Geiling, J Burkle, FM West, TE Uyeki, TM Amundson, D Dominguez-Cherit, G Gomersall, CD Lim, ML Luyckx, V Sarani, B Christian, MD Devereaux, AV Dichter, JR Kissoon, N AF Geiling, James Burkle, Frederick M., Jr. West, T. Eoin Uyeki, Timothy M. Amundson, Dennis Dominguez-Cherit, Guillermo Gomersall, Charles D. Lim, Matthew L. Luyckx, Valerie Sarani, Babak Christian, Michael D. Devereaux, Asha V. Dichter, Jeffrey R. Kissoon, Niranjan CA Task Force Mass Critical Care TI Resource-Poor Settings: Response, Recovery, and Research Care of the Critically Ill and Injured During Pandemics and Disasters: CHEST Consensus Statement SO CHEST LA English DT Article ID MIDDLE-INCOME COUNTRIES; PUBLIC-HEALTH; MEDICAL-CARE; POSTEARTHQUAKE HAITI; EMERGENCY; AUSTERE; SYSTEMS; PREPAREDNESS; SERVICES; PROFESSIONALIZATION AB BACKGROUND: Planning for mass critical care in resource-poor and constrained settings has been largely ignored, despite large, densely crowded populations who are prone to suffer disproportionately from natural disasters. As a result, disaster response has been suboptimal and in many instances hampered by lack of planning, education and training, information, and communication. METHODS: The Resource-Poor Settings panel developed five key question domains; defining the term resource poor and using the traditional phases of the disaster cycle (mitigation/preparedness/response/recovery). Literature searches were conducted to identify evidence to answer the key questions in these areas. Given a lack of data on which to develop evidence-based recommendations, expert-opinion suggestions were developed, and consensus was achieved using a modified Delphi process. RESULTS: The five key questions were as follows: definition, capacity building and mitigation, what resources can we bring to bear to assist/surge, response, and reconstitution and recovery of host nation critical care capabilities. Addressing these led the panel to off er 33 suggestions. Because of the large number of suggestions, the results have been separated into two sections: part I, Infrastructure/Capacity in the accompanying article, and part II, Response/Recovery/Research in this article. CONCLUSIONS: A lack of rudimentary ICU resources and capacity to enhance services plagues resource-poor or constrained settings. Capacity building therefore entails preventative strategies and strengthening of primary health services. Assistance from other countries and organizations is oft en needed to mount a surge response. Moreover, the disengagement of these responding groups and host country recovery require active planning. Future improvements in all phases require active research activities. CHEST 2014; 146 (4_Suppl): e168S-e177S C1 [Geiling, James] VA Med Ctr, White River Jct, VT USA. [Geiling, James] Geisel Sch Med Dartmouth, Hanover, NH 03755 USA. [Burkle, Frederick M., Jr.] Harvard Univ, Harvard Humanitarian Initiat, Cambridge, MA 02138 USA. [Burkle, Frederick M., Jr.] Woodrow Wilson Int Ctr Scholars, Washington, DC 20560 USA. [West, T. Eoin] Univ Washington, Sch Med, Seattle, WA USA. [Uyeki, Timothy M.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Amundson, Dennis] Scripps Mem Hosp, Encinitas, CA USA. [Amundson, Dennis] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Dominguez-Cherit, Guillermo] Univ Nacl Autonoma Mexico, Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City 04510, DF, Mexico. [Gomersall, Charles D.] Chinese Univ Hong Kong, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China. [Lim, Matthew L.] Dept Hlth & Human Serv, Off Global Affairs, Washington, DC USA. [Luyckx, Valerie] Univ Alberta, Int Soc Nephrol, Edmonton, AB, Canada. [Sarani, Babak] George Washington Univ, Washington, DC USA. [Christian, Michael D.] Canadian Armed Forces, Royal Canadian Med Serv, Toronto, ON, Canada. [Christian, Michael D.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. [Devereaux, Asha V.] Sharp Hosp, Coronado, CA USA. [Dichter, Jeffrey R.] Allina Hlth, Minneapolis, MN USA. [Dichter, Jeffrey R.] Aurora Healthcare, Milwaukee, WI USA. [Kissoon, Niranjan] Univ British Columbia, British Columbia Childrens Hosp, Vancouver, BC V5Z 1M9, Canada. [Kissoon, Niranjan] Univ British Columbia, Sunny Hill Hlth Ctr, Vancouver, BC V5Z 1M9, Canada. RP Geiling, J (reprint author), Geisel Sch Med Dartmouth, 1 Rope Ferry Rd,HB 7900, Hanover, NH 03755 USA. EM James.Geiling@Dartmouth.edu RI Gomersall, Charles/J-1540-2012; OI Gomersall, Charles/0000-0002-8494-8063; West, T Eoin/0000-0001-5503-7204; Dominguez-Cherit, Guillermo/0000-0003-1403-4415 FU Centers of Disease Control and Prevention [1U90TP00591-01]; Department of Health and Human Services from the Office of Preparedness of Emergency Operations [1 - HFPEP070013-01-00]; University of California-Davis FX This publication was supported by the Cooperative Agreement Number 1U90TP00591-01 from the Centers of Disease Control and Prevention, and through a research sub award agreement through the Department of Health and Human Services grant Number 1 - HFPEP070013-01-00 from the Office of Preparedness of Emergency Operations. In addition, this publication was supported by a grant from the University of California-Davis. NR 62 TC 0 Z9 0 U1 0 U2 6 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2014 VL 146 IS 4 SU S BP E168S EP E177S DI 10.1378/chest.14-0745 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AR4RN UT WOS:000343574100012 PM 25144410 ER PT J AU Tseng, HF Tartof, S Harpaz, R Luo, Y Sy, LS Hetcher, RC Jacobsen, SJ AF Tseng, Hung Fu Tartof, Sara Harpaz, Rafael Luo, Yi Sy, Lina S. Hetcher, Rulin C. Jacobsen, Steven J. TI Vaccination Against Zoster Remains Effective in Older Adults Who Later Undergo Chemotherapy SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE chemotherapy; immunosuppression; vaccine effectiveness; zoster vaccine ID PREVENT HERPES-ZOSTER; RHEUMATOID-ARTHRITIS; POSTHERPETIC NEURALGIA; VARICELLA-ZOSTER; RISK; INFECTION; TRANSPLANT; POPULATION; DISEASE; COHORT AB Background. Approximately 40% of adults develop invasive cancer during their lifetimes, many of whom require chemotherapy. Herpes zoster (HZ) is common and often severe in patients undergoing chemotherapy, yet there are no data regarding whether these patients retain specific protection against HZ if they had previously received zoster vaccine. We conducted a study to determine whether zoster vaccine was effective in patients who subsequently underwent chemotherapy. Methods. The cohort study consisted of Kaiser Permanente Southern California members aged >= 60 years treated with chemotherapy. The exposure variable was receipt of zoster vaccine prior to initiation of chemotherapy. Incident HZ cases were identified using International Classification of Diseases, Ninth Revision diagnostic codes. HZ incidence rates were calculated; hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression models. Results. There were 91 and 583 HZ cases in the vaccinated and unvaccinated cohorts, respectively, yielding an incidence rate of 12.87 (95% CI, 10.48-15.80) vs 22.05 (95% CI, 20.33-23.92) per 1000 person-years. Thirty-month cumulative incidence was 3.28% in the vaccinated group and 5.34% in the unvaccinated group (P < .05). The adjusted HR for HZ was 0.58 (95% CI,.46-.73) and showed no significant variation by age, sex, or race. HZ incidence rates remained increased in the small subgroup of persons receiving zoster vaccine within 60 days before chemotherapy, but this was the only group affected by indication bias. No vaccinated patients underwent hospitalization for HZ, compared with 6 unvaccinated patients. Conclusions. Zoster vaccine continues to protect against HZ if recipients later undergo chemotherapy. Our findings provide an additional rationale for offering zoster vaccine to indicated adults while they are immunocompetent. C1 [Tseng, Hung Fu; Tartof, Sara; Luo, Yi; Sy, Lina S.; Hetcher, Rulin C.; Jacobsen, Steven J.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Harpaz, Rafael] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. RP Tseng, HF (reprint author), Kaiser Permanente, So Calif Permanente Med Grp, Dept Res & Evaluat, 100 S Robles Ave,2nd Floor, Pasadena, CA 91101 USA. EM hung-fu.x.tseng@kp.org OI Jacobsen, Steven/0000-0002-8174-8533 FU Kaiser Permanente Southern California internal research fund FX This study was supported by the Kaiser Permanente Southern California internal research fund. NR 24 TC 19 Z9 20 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2014 VL 59 IS 7 BP 913 EP 919 DI 10.1093/cid/ciu498 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AR2JY UT WOS:000343411900002 PM 25097079 ER PT J AU Livio, S Strockbine, NA Panchalingam, S Tennant, SM Barry, EM Marohn, ME Antonio, M Hossain, A Mandomando, I Ochieng, JB Oundo, JO Qureshi, S Ramamurthy, T Tamboura, B Adegbola, RA Hossain, MJ Saha, D Sen, S Faruque, AS Alonso, PL Breiman, RF Zaidi, AKM Sur, D Sow, SO Berkeley, LY O'Reilly, CE Mintz, ED Biswas, K Cohen, D Farag, TH Nasrin, D Wu, YK Blackwelder, WC Kotloff, KL Nataro, JP Levine, MM AF Livio, Sofie Strockbine, Nancy A. Panchalingam, Sandra Tennant, Sharon M. Barry, Eileen M. Marohn, Mark E. Antonio, Martin Hossain, Anowar Mandomando, Inacio Ochieng, John B. Oundo, Joseph O. Qureshi, Shahida Ramamurthy, Thandavarayan Tamboura, Boubou Adegbola, Richard A. Hossain, Mohammed Jahangir Saha, Debasish Sen, Sunil Faruque, Abu Syed Golam Alonso, Pedro L. Breiman, Robert F. Zaidi, Anita K. M. Sur, Dipika Sow, Samba O. Berkeley, Lynette Y. O'Reilly, Ciara E. Mintz, Eric D. Biswas, Kousick Cohen, Dani Farag, Tamer H. Nasrin, Dilruba Wu, Yukun Blackwelder, William C. Kotloff, Karen L. Nataro, James P. Levine, Myron M. TI Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE serotyping; Shigella; shigellosis; vaccines ID SHIGA BACILLUS DYSENTERY; FLEXNERI 2A; DIARRHEAL DISEASE; ORAL IMMUNIZATION; DEVELOPING-COUNTRIES; ENTEROTOXIN GENES; SERUM ANTIBODIES; YOUNG-CHILDREN; O-ANTIGEN; IN-VITRO AB Background. Shigella, a major diarrheal disease pathogen worldwide, is the target of vaccine development. The Global Enteric Multicenter Study (GEMS) investigated burden and etiology of moderate-to-severe diarrheal disease in children aged <60 months and matched controls without diarrhea during 3 years at 4 sites in Africa and 3 in Asia. Shigella was 1 of the 4 most common pathogens across sites and age strata. GEMS Shigella serotypes are reviewed to guide vaccine development. Methods. Subjects' stool specimens/rectal swabs were transported to site laboratories in transport media and plated onto xylose lysine desoxycholate and MacConkey agar. Suspect Shigella colonies were identified by biochemical tests and agglutination with antisera. Shigella isolates were shipped to the GEMS Reference Laboratory (Baltimore, MD) for confirmation and serotyping of S. flexneri; one-third of isolates were sent to the Centers for Disease Control and Prevention for quality control. Results. Shigella dysenteriae and S. boydii accounted for 5.0% and 5.4%, respectively, of 1130 Shigella case isolates; S. flexneri comprised 65.9% and S. sonnei 23.7%. Five serotypes/subserotypes comprised 89.4% of S. flexneri, including S. flexneri 2a, S. flexneri 6, S. flexneri 3a, S. flexneri 2b, and S. flexneri 1b. Conclusions. A broad-spectrum Shigella vaccine must protect against S. sonnei and 15 S. flexneri serotypes/subserotypes. A quadrivalent vaccine with O antigens from S. sonnei, S. flexneri 2a, S. flexneri 3a, and S. flexneri 6 can provide broad direct coverage against these most common serotypes and indirect coverage against all but 1 (rare) remaining subserotype through shared S. flexneri group antigens. C1 [Livio, Sofie; Panchalingam, Sandra; Tennant, Sharon M.; Barry, Eileen M.; Marohn, Mark E.; Sen, Sunil; Berkeley, Lynette Y.; Farag, Tamer H.; Nasrin, Dilruba; Wu, Yukun; Blackwelder, William C.; Kotloff, Karen L.; Nataro, James P.; Levine, Myron M.] Univ Maryland Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Strockbine, Nancy A.] Ctr Dis Control & Prevent, Escherichia & Shigella Reference Unit, Enter Dis Lab Branch, Atlanta, GA USA. [Strockbine, Nancy A.; O'Reilly, Ciara E.; Mintz, Eric D.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Antonio, Martin; Adegbola, Richard A.; Hossain, Mohammed Jahangir; Saha, Debasish] Med Res Council Unit United Kingdom, Fajara, Gambia. [Hossain, Anowar; Faruque, Abu Syed Golam] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Mandomando, Inacio; Alonso, Pedro L.] Ctr Invest Saude Manhica, Manhica, Mozambique. [Mandomando, Inacio; Breiman, Robert F.] Univ Barcelona, Hosp Clinic, Ctr Recerca Salut Int Barcelona, E-08007 Barcelona, Spain. [Ochieng, John B.; Oundo, Joseph O.; Breiman, Robert F.] Ctr Dis Control & Prevent, Kenya Med Res Inst, Kisumu, Kenya. [Qureshi, Shahida; Zaidi, Anita K. M.] Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan. [Ramamurthy, Thandavarayan; Sur, Dipika] Natl Inst Cholera & Enter Dis, Kolkata, India. [Tamboura, Boubou; Sow, Samba O.] Ctr Dev Vaccins Mali, Bamako, Mali. [Breiman, Robert F.] US Ctr Dis Control & Prevent, Global Dis Detect Div, Kenya Off, Nairobi, Kenya. [Sur, Dipika] PATH, New Delhi, India. [Berkeley, Lynette Y.] US FDA, Rockville, MD 20857 USA. [Biswas, Kousick] US Dept Vet Affairs, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA. [Cohen, Dani] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, Ramat Aviv, Israel. RP Levine, MM (reprint author), Univ Maryland Sch Med, Ctr Vaccine Dev, 685 West Baltimore St, Baltimore, MD 21201 USA. EM mlevine@medicine.umaryland.edu FU Bill & Melinda Gates Foundation [38774] FX This work was supported by grant 38774 from the Bill & Melinda Gates Foundation to M. M. L. NR 46 TC 51 Z9 52 U1 2 U2 16 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2014 VL 59 IS 7 BP 933 EP 941 DI 10.1093/cid/ciu468 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AR2JY UT WOS:000343411900005 PM 24958238 ER PT J AU Spradling, PR Tong, X Rupp, LB Moorman, AC Lu, M Teshale, EH Gordon, SC Vijayadeva, V Boscarino, JA Schmidt, MA Holmberg, SD AF Spradling, Philip R. Tong, Xin Rupp, Loralee B. Moorman, Anne C. Lu, Mei Teshale, Eyasu H. Gordon, Stuart C. Vijayadeva, Vinutha Boscarino, Joseph A. Schmidt, Mark A. Holmberg, Scott D. CA Chronic Hepatitis Cohort Study TI Trends in HCV RNA Testing Among HCV Antibody-Positive Persons in Care, 2003-2010 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE diagnosis; hepatitis C virus; infection; testing ID C VIRUS-INFECTION; HEPATITIS-C; UNITED-STATES AB Background. A test for hepatitis C virus (HCV) RNA is essential to identify persons with active, or current, HCV infection. We assessed trends in HCV RNA testing following a positive HCV antibody result among persons in 4 large healthcare organizations. Methods. Data collected from adults with >= 2 clinical encounters during 2003-2010 were analyzed to determine the frequency of, interval between, and factors associated with having an RNA test after a first positive HCV antibody test. Results. From 2003-2010, 5860 persons had a positive antibody test, of whom 3570 (60.9%) had a follow-up RNA test. During this period, the annual frequency of persons with an eventual RNA test did not change significantly; however, the fraction of persons who had the follow-up RNA test within 6 months improved significantly, from 45% in 2003 to 57% in 2010 (P < .001, for trend). Persons born during 1945-1965, men, and those with annual income <$30 000 (by census geocode) were less likely to have had a follow-up RNA test done within 6 months of a positive antibody test. Conclusions. Less than two-thirds of persons with a positive HCV antibody test had a follow-up RNA test. Rapid ascertainment of HCV infection status with reflex testing to RNA is critical to identify persons eligible for treatment. C1 [Spradling, Philip R.; Tong, Xin; Moorman, Anne C.; Teshale, Eyasu H.; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Rupp, Loralee B.; Lu, Mei; Gordon, Stuart C.] Henry Ford Hlth Syst, Detroit, MI USA. [Vijayadeva, Vinutha] Kaiser Permanente, Honolulu, HI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Portland, OR USA. RP Spradling, PR (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, MS G37,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM pspradling@cdc.gov FU CDC Foundation; AbbVie; Janssen Pharmaceuticals, Inc.; Vertex Pharmaceuticals; Genentech (Roche Group); Bristol-Myers Squibb FX CHeCS is funded by the CDC Foundation, which currently receives grants from AbbVie, Janssen Pharmaceuticals, Inc., and Vertex Pharmaceuticals. Past funders include Genentech, a member of the Roche Group; and Bristol-Myers Squibb. NR 13 TC 9 Z9 9 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2014 VL 59 IS 7 BP 976 EP 981 DI 10.1093/cid/ciu509 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AR2JY UT WOS:000343411900011 PM 24991025 ER PT J AU Forrester, JD Mead, P AF Forrester, Joseph D. Mead, Paul TI Third-Degree Heart Block Associated With Lyme Carditis: Review of Published Cases SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE atrioventricular conduction block; heart block; Lyme carditis; Lyme disease ID EMERGENCY-DEPARTMENT; BORRELIA-BURGDORFERI; DISEASE; MYOCARDITIS; BABESIOSIS; TICK AB Lyme carditis is an uncommon manifestation of Lyme disease that most commonly involves some degree of atrioventricular conduction blockade. Third-degree conduction block is the most severe form and can be fatal if untreated. Systematic review of the medical literature identified 45 published cases of third-degree conduction block associated with Lyme carditis in the United States. Median patient age was 32 years, 84% of patients were male, and 39% required temporary pacing. Recognizing patient groups more likely to develop third-degree heart block associated with Lyme carditis is essential to providing prompt and appropriate therapy. C1 [Forrester, Joseph D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Div Sci Educ & Profess Dev, Atlanta, GA USA. [Forrester, Joseph D.; Mead, Paul] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Forrester, JD (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM xdd2@cdc.gov NR 47 TC 7 Z9 7 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2014 VL 59 IS 7 BP 996 EP 1000 DI 10.1093/cid/ciu411 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AR2JY UT WOS:000343411900015 PM 24879781 ER PT J AU Xu, FJ Tong, X Leidner, AJ AF Xu, Fujie Tong, Xin Leidner, Andrew J. TI Hospitalizations And Costs Associated With Hepatitis C And Advanced Liver Disease Continue To Increase SO HEALTH AFFAIRS LA English DT Article ID UNITED-STATES; VIRUS-INFECTION; VIRAL-HEPATITIS; MORTALITY; SOFOSBUVIR; CARE; BURDEN; COHORT; PREVALENCE; LEDIPASVIR AB Disease burden models have predicted worsening morbidity of liver disease caused by hepatitis C in the United States. The aim of this study was to determine the trend in hospitalizations caused by hepatitis C and advanced liver disease. We analyzed data for the period 2004-11 from the Nationwide Inpatient Sample, the largest nationwide all-payer hospital inpatient care database. Hospitalization rates for hepatitis C per 100,000 people increased significantly from 4.76 in 2004-05 to 13.81 in 2010-11-an increase of 190 percent. Hospitalization rates for advanced liver disease also increased, particularly for hepatorenal syndrome (93 percent) and portal hypertension (62 percent). Hepatitis C was the principal diagnosis for 64,867 hospitalizations in 2010-11, resulting in a total charge of $3.5 billion. We found nationwide trends in increasing morbidity and medical costs for advanced liver disease associated with hepatitis C. Our findings suggest that hepatitis C is a public health problem and has been growing in magnitude in recent years. Stakeholders and policy makers should implement both recommended screenings for people born in the period 1945-65 and more effective treatment for hepatitis C, which have the potential to reverse the rising morbidity and costs of hepatitis C. C1 [Xu, Fujie] Ctr Dis Control & Prevent CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Tong, Xin; Leidner, Andrew J.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Xu, FJ (reprint author), Ctr Dis Control & Prevent CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM fax1@cdc.gov NR 32 TC 15 Z9 15 U1 0 U2 6 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD OCT PY 2014 VL 33 IS 10 BP 1728 EP 1735 DI 10.1377/hlthaff.2014.0096 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AR2IE UT WOS:000343406500005 PM 25288416 ER PT J AU Goldstein, IM Kostova, D Foltz, JL Kenney, GM AF Goldstein, Ian M. Kostova, Deliana Foltz, Jennifer L. Kenney, Genevieve M. TI The Impact Of Recent CHIP Eligibility Expansions On Children's Insurance Coverage, 2008-12 SO HEALTH AFFAIRS LA English DT Article ID HEALTH-INSURANCE; PUBLIC INSURANCE; CROWD-OUT; MEDICAID; PRIVATE; PREMIUMS AB Following the reauthorization of the Children's Health Insurance Program (CHIP) in 2009, fifteen states raised their CHIP income eligibility thresholds to further reduce uninsurance among children. We examined the impact of these expansions on uninsurance, public insurance, and private insurance among children who became newly eligible for CHIP after the expansions. Using a difference-in-differences approach, we estimated that the expansions reduced uninsurance by 1.1 percentage points among the newly eligible, cutting their uninsurance rate by nearly 15 percent. Public coverage increased by 2.9 percentage points, with variations in take-up among the states. A better understanding of these state-level differences in take-up could inform efforts to enroll children who remain uninsured but are eligible for CHIP. CHIP is up for reauthorization in 2015, and further funding will be needed to maintain the program, which provides insurance to children who might not have access to affordable private coverage. C1 [Goldstein, Ian M.] Univ Colorado, Denver, CO 80202 USA. [Kostova, Deliana] Ctr Dis Control & Prevent, CDC, Atlanta, GA USA. [Foltz, Jennifer L.] CDC, Atlanta, GA 30333 USA. [Kenney, Genevieve M.] Urban Inst, Ctr Hlth Policy, Washington, DC 20037 USA. RP Goldstein, IM (reprint author), Univ Colorado, Denver, CO 80202 USA. EM iangoldstein1@gmail.com FU Centers for Disease Control and Prevention (CDC) - External Medical Affairs, Pfizer Inc. FX Ian Goldstein received funding from the CDC Experience, a one-year fellowship in applied epidemiology at the Centers for Disease Control and Prevention (CDC) made possible by a public-private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer Inc. The authors acknowledge Brook Belay and Heidi Blanck for their help in the development of this project, as well as Jared Fox for additional insights on the manuscript. Jennifer Foltz and Genevieve Kenney are co-senior authors for this project. The findings and conclusions in this report are those of the authors and do not necessarily reflect the official position of the CDC. [Published online September 24, 2014.] NR 25 TC 1 Z9 1 U1 0 U2 2 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD OCT PY 2014 VL 33 IS 10 BP 1861 EP 1867 DI 10.1377/hlthaff.2014.0208 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AR2IE UT WOS:000343406500022 PM 25253261 ER PT J AU Escoffery, C Rodgers, K Kegler, MC Haardorfer, R Howard, D Roland, KB Wilson, KM Castro, G Rodriguez, J AF Escoffery, Cam Rodgers, Kirsten Kegler, Michelle C. Haardoerfer, Regine Howard, David Roland, Katherine B. Wilson, Katherine M. Castro, Georgina Rodriguez, Juan TI Key informant interviews with coordinators of special events conducted to increase cancer screening in the United States SO HEALTH EDUCATION RESEARCH LA English DT Article ID HEALTH FAIRS; PROMOTE BREAST; PREVENTION AB Special events such as health fairs, cultural festivals and charity runs are commonly employed in the community to increase cancer screening; however, little is known about their effectiveness. The purpose of this study is to assess the activities, screening outcomes, barriers and recommendations of special events to increase breast, cervical and colorectal cancer screening. In-depth interviews were conducted nationally with 51 coordinators of events in June to September 2012. Health fairs and screening days were the most common events conducted, primarily for breast cancer education. Goals were to increase awareness of cancer screening and reach special populations. Evidence-based Community Guide strategies to increase cancer screening employed were: small media, reducing structural barriers, one-on-one education or group education. For each event that provided screening on-site or through referral, a mean of 35 breast, 28 cervical and 19 colorectal cancer screenings were reported. Coordinators made recommendations for further evaluation of special events, and most plan to conduct another special event. These data are novel and provide baseline documentation of activities and recommendations for a commonly used community-based cancer screening intervention that lacks evidence of effectiveness. Additional research to better understand the use of special events for increasing cancer screening is warranted. C1 [Escoffery, Cam; Rodgers, Kirsten; Kegler, Michelle C.; Haardoerfer, Regine] Ctr Dis Control & Prevent, Dept Behav Sci & Hlth Educ, Atlanta, GA 30341 USA. [Howard, David] Ctr Dis Control & Prevent, Dept Hlth Policy & Management, Atlanta, GA 30341 USA. [Roland, Katherine B.; Wilson, Katherine M.; Castro, Georgina; Rodriguez, Juan] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Escoffery, C (reprint author), Ctr Dis Control & Prevent, Dept Behav Sci & Hlth Educ, Atlanta, GA 30341 USA. EM cescoff@sph.emory.edu FU Intramural CDC HHS [FSX3]; NCCDPHP CDC HHS [U48DP001909-02, U48 DP001909] NR 27 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1153 EI 1465-3648 J9 HEALTH EDUC RES JI Health Educ. Res. PD OCT PY 2014 VL 29 IS 5 BP 730 EP 739 DI 10.1093/her/cyu042 PG 10 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA AR2KL UT WOS:000343414000002 PM 25134886 ER PT J AU Palella, FJ Armon, C Buchacz, K Chmiel, JS Novak, RM D'Aquila, RT Brooks, JT AF Palella, Frank J., Jr. Armon, Carl Buchacz, Kate Chmiel, Joan S. Novak, Richard M. D'Aquila, Richard T. Brooks, John T. CA HOPS Investigators TI Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS) SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE ARV; antiretroviral resistance; viraemia ID IMMUNODEFICIENCY-VIRUS TYPE-1; OPTIMIZED BACKGROUND THERAPY; REVERSE-TRANSCRIPTASE; DRUG-RESISTANCE; VIRAL REPLICATION; MOTIVATE 1; MUTATIONS; FITNESS; TRIALS; INFECTION AB Background: Identifying factors associated with mortality for HIV-infected patients with persistent viraemia despite antiretroviral (ARV) therapy may inform diagnostic and treatment strategies. Methods: We analysed data from viraemic triple-ARV-class-experienced HIV Outpatient Study patients seen during 1 January 1999 to 31 December 2012 who, despite treatment that included ARVs from three major drug classes [nucleoside analogue reverse transcriptase inhibitors, non-nucleoside analogue reverse transcriptase inhibitors and protease inhibitors (PIs)], had plasma HIV RNA levels [viral load (VL)] >1000 copies/mL ['triple ARV class failure' (TCF)]. The baseline was defined as the date of meeting the TCF criteria during 1999-2008. We identified factors associated with mortality using Cox regression. Results: Of 597 patients who met the TCF criteria (median follow-up after baseline 4.9 years), 115 (19.3%) died. Baseline factors associated with mortality were age per 10 years [hazard ratio (HR) 1.61, 95% CI 1.28-2.02], risk of HIV from use of injection drugs (HR 1.81, 95% CI 1.10-2.98), CD4+T cell count <200 cells/mm(3) (HR 3.68, 95% CI 2.41-5.62), VL >= 5.0 log(10) copies/mL (HR 2.91, 95% CI 1.88-4.49) and receiving a first combination ARV therapy regimen that was PI-based (HR 2.44, 95% CI 1.47-4.06); receiving a novel ARV agent during follow-up (HR 0.45, 95% CI 0.22-0.93) was protective. Genotypic resistance testing results were available for 274 (45.9%) of the TCF patients, of whom 47 (17.2%) died. In this group, factors associated with death were increasing age (HR 1.94, 95% CI 1.36-2.78, per 10 year increment), risk of HIV from use of injection drugs (HR 2.71, 95% CI 1.37-5.39), baseline VL >= 5.0 log(10) copies/mL (HR 5.35, 95% CI 2.82-10.1) and receiving PI-based first combination ARV therapy regimen (HR 3.20, 95% CI 1.25-8.17). No HIV mutations or combinations of mutations were significantly associated with survival. Conclusions: Factors significantly associated with mortality risk among TCF patients who received ongoing ARV therapy included traditional clinical predictors but not the presence, type or number of HIV genetic mutations. The use of novel ARV drugs by these ARV therapy-experienced patients was associated with an improved survival. C1 [Palella, Frank J., Jr.; Chmiel, Joan S.; D'Aquila, Richard T.] Northwestern Univ, Chicago, IL 60611 USA. [Armon, Carl] Cerner Corp, Vienna, VA USA. [Buchacz, Kate; Brooks, John T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Novak, Richard M.] Univ Illinois, Chicago, IL USA. RP Palella, FJ (reprint author), Northwestern Univ, Chicago, IL 60611 USA. EM f-palella@northwestern.edu FU Centers for Disease Control and Prevention [200-2001-00133, 200-2006-18797, 200-2011-41872] FX This work was supported by contracts 200-2001-00133, 200-2006-18797 and 200-2011-41872 from the Centers for Disease Control and Prevention. NR 28 TC 5 Z9 5 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD OCT PY 2014 VL 69 IS 10 BP 2826 EP 2834 DI 10.1093/jac/dku190 PG 9 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA AR1DP UT WOS:000343322700029 PM 24942257 ER PT J AU Ocasio, MA Fleming, LE Hollenbeck, J Fernandez, CA LeBlanc, WG Lin, J Martinez, AJC Kachan, D Christ, SL Sestito, JP Lee, DJ AF Ocasio, Manuel A. Fleming, Lora E. Hollenbeck, Julie Fernandez, Cristina A. LeBlanc, William G. Lin, Jenelle Martinez, Alberto J. Caban Kachan, Diana Christ, Sharon L. Sestito, John P. Lee, David J. TI The Health of Young US Workers SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID SELF-REPORTED HEIGHT; NATIONAL-HEALTH; INTERVIEW SURVEY; UNITED-STATES; WEIGHT; VALIDITY AB Objectives: To provide an overview of the health status of young US workers across four domains: functional health, physical and psychological health, health behavior, and health care utilization. Methods: Pooled data from the 2004 to 2010 National Health Interview Survey were analyzed for 11,279 US workers aged 18 to 24 years, representing an estimated 16.9 million workers annually. Thirty-nine health indicators were examined and compared across nine occupational groups. Results: Compared with other occupational groups, craft workers and laborers and helpers had the highest prevalence of risky health behaviors, including current smoking and risky drinking, as well as fewer reported visits to a primary care physician in the past year. Conclusions: Young workers engage in risky health behaviors, and may benefit from targeted workplace interventions to mitigate the potentially negative long-term effects on health and well-being. C1 [Ocasio, Manuel A.; Fernandez, Cristina A.; LeBlanc, William G.; Lin, Jenelle; Martinez, Alberto J. Caban; Kachan, Diana; Lee, David J.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA. [Fleming, Lora E.; Hollenbeck, Julie] Univ Exeter, Sch Med, European Ctr Environm & Human Hlth, Truro, Cornwall, England. [Martinez, Alberto J. Caban] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, Boston, MA 02115 USA. [Christ, Sharon L.] Purdue Univ, Dept Human Dev & Family Studies, W Lafayette, IN 47907 USA. [Sestito, John P.] NIOSH, Div Surveillance Hlth Evaluat & Field Studies, Cincinnati, OH 45226 USA. RP Ocasio, MA (reprint author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Clin Res Bldg,Rm 1075,1120 NW 14th St, Miami, FL 33136 USA. EM mocasio@med.miami.edu FU NIOSH [R01 0H003915]; National Institute on Aging [F30AG040886]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [T32 AR055885] FX This study was funded in part through the NIOSH Grant number R01 0H003915. Funding was also provided to the European Centre for Environment and Human Health at the University of Exeter Medical School through the European Union Convergence Program (European Regional Development Fund and European Social Fund), National Institute on Aging grant #F30AG040886 (Trainee: Kachan), and from the National Institute of Arthritis and Musculoskeletal and Skin Diseases grant T32 AR055885 (PI: Katz) to the Clinical Orthopedic and Musculoskeletal Education and Training Program at Brigham and Women's Hospital, Harvard Medical School and Harvard School of Public Health (Trainee: Caban-Martinez). NR 34 TC 0 Z9 0 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD OCT PY 2014 VL 56 IS 10 BP 1011 EP 1018 DI 10.1097/JOM.0000000000000256 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR4YE UT WOS:000343591300008 PM 25285823 ER PT J AU Ganova-Raeva, L Ben Ayed, Y Punkova, L Do, D Dalton, H Yury, K AF Ganova-Raeva, L. Ben Ayed, Y. Punkova, L. Do, D. Dalton, H. Yury, K. TI Cryptic HBV, HCV and HEV infection in presumed nonA-E hepatitis SO JOURNAL OF VIRAL HEPATITIS LA English DT Meeting Abstract CT Viral Hepatitis Congress CY OCT 09-11, 2014 CL Frankfurt, GERMANY ID A-E HEPATITIS C1 [Ganova-Raeva, L.; Punkova, L.; Yury, K.] CDC, Atlanta, GA 30333 USA. [Ben Ayed, Y.] Inst Pasteur Tunis, Tunis, Tunisia. [Do, D.] Vabiotech, Hanoi, Vietnam. [Dalton, H.] Royal Cornwall Hosp, Truro, England. NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1352-0504 EI 1365-2893 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD OCT PY 2014 VL 21 SU 2 SI SI MA P34 BP 40 EP 41 DI 10.1111/jvh.12333_33 PG 4 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA AR7DA UT WOS:000343738800063 ER PT J AU Snead, MC Black, CM Kourtis, AP AF Snead, Margaret Christine Black, Carolyn M. Kourtis, Athena P. TI The Use of Biomarkers of Semen Exposure in Sexual and Reproductive Health Studies SO JOURNAL OF WOMENS HEALTH LA English DT Article ID PROSTATE-SPECIFIC ANTIGEN; REPORTED CONDOM USE; RANDOMIZED CONTROLLED-TRIAL; CHAIN-REACTION DETECTION; Y-CHROMOSOME SEQUENCES; FEMALE CONDOM; VAGINAL FLUID; CLINICAL-TRIALS; TRANSMITTED INFECTION; POTENTIAL BIOMARKER AB Biomarkers of semen exposure have been used in studies investigating the safety and efficacy of barrier methods of contraception. They have been used as objective indicators of semen exposure when studying sexual behaviors and in human immunodeficiency virus/sexually transmitted infection research interventions where participants are advised to avoid unprotected sex. Semen biomarkers have also been used to assess or validate self-reported sexual behaviors or condom use in reproductive health settings. Prostate-specific antigen (PSA) and Y chromosome DNA (Yc-DNA) have each been evaluated in the past as semen biomarkers and are the most widely used in the field. While both are considered reliable for evaluating exposure to semen, each has unique characteristics. In this report, we summarize the literature and provide some considerations for reproductive health researchers who are interested in using PSA or Yc-DNA as semen biomarkers. We also synthesize our previous published work on the optimal conditions of collecting and storing specimens and assay performance in the presence of other vaginal products that may influence various assays. Semen biomarkers are innovative and promising tools to further study and better understand women's reproductive and sexual health and behavior. More research is needed to better understand the strengths, limitations, and optimal performance conditions of specific assays in vivo. C1 [Snead, Margaret Christine; Kourtis, Athena P.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Black, Carolyn M.] Ctr Dis Control & Prevent, Div Sci Resources, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30341 USA. RP Snead, MC (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,F74, Atlanta, GA 30341 USA. EM msnead@cdc.gov FU Intramural CDC HHS [CC999999] NR 44 TC 1 Z9 1 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD OCT 1 PY 2014 VL 23 IS 10 BP 787 EP 791 DI 10.1089/jwh.2014.5018 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AR0DT UT WOS:000343237900004 PM 25268551 ER PT J AU Flax, VL Adair, LS Allen, LH Tegha, G Jamieson, DJ Bentley, ME AF Flax, Valerie L. Adair, Linda S. Allen, Lindsay H. Tegha, Gerald Jamieson, Denise J. Bentley, Margaret E. TI Protease Inhibitor-Based Highly Active Antiretroviral Therapy Is Associated with Decreased Plasma Folate and Increased Transferrin Receptor Concentrations in Lactating HIV-Infected Women SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Flax, Valerie L.; Adair, Linda S.; Bentley, Margaret E.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. [Allen, Lindsay H.] ARS, Western Human Nutr Res Ctr, USDA, Davis, CA USA. [Tegha, Gerald] Univ N Carolina, Project Malawi, Chapel Hill, NC 27515 USA. [Jamieson, Denise J.] Ctr Dis Control & Prevent, DeKalb County, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD OCT 1 PY 2014 VL 23 IS 10 MA P-23 BP 858 EP 858 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AR0DT UT WOS:000343237900037 ER PT J AU Posner, SF Goodman, RA AF Posner, Samuel F. Goodman, Richard A. TI Multimorbidity at the Local Level: Implications and Research Directions SO MAYO CLINIC PROCEEDINGS LA English DT Editorial Material ID CLINICAL-PRACTICE GUIDELINES; MULTIPLE CHRONIC CONDITIONS C1 [Posner, Samuel F.; Goodman, Richard A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Posner, SF (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy MS F-80, Atlanta, GA 30341 USA. EM shp5@cdc.gov OI Posner, Samuel/0000-0003-1574-585X NR 13 TC 5 Z9 5 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD OCT PY 2014 VL 89 IS 10 BP 1321 EP 1323 DI 10.1016/j.mayocp.2014.08.007 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AR0BW UT WOS:000343230500005 PM 25220410 ER PT J AU King, BA Homa, DM Dube, SR Babb, SD AF King, Brian A. Homa, David M. Dube, Shanta R. Babb, Stephen D. TI Exposure to Secondhand Smoke and Attitudes Toward Smoke-Free Workplaces Among Employed U.S. Adults: Findings From the National Adult Tobacco Survey SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID CURRENT CIGARETTE-SMOKING; CROSS-SECTIONAL SURVEY; UNITED-STATES; FREE LEGISLATION; US; IMPLEMENTATION; POLICIES; HOSPITALIZATIONS; ASSOCIATION; RESTAURANTS AB Introduction: This study assessed the prevalence and correlates of secondhand smoke (SHS) exposure and attitudes toward smoke-free workplaces among employed U. S. adults. Methods: Data came from the 2009-2010 National Adult Tobacco Survey, a landline and cellular telephone survey of adults aged >= 18 years in the United States and the District of Columbia. National and state estimates of past 7-day workplace SHS exposure and attitudes toward indoor and outdoor smoke-free workplaces were assessed among employed adults. National estimates were calculated by sex, age, race/ethnicity, education, annual household income, sexual orientation, U. S. region, and smoking status. Results: Among employed adults who did not smoke cigarettes, 20.4% reported past 7-day SHS exposure at their workplace (state range: 12.4% [Maine] to 30.8% [Nevada]). Nationally, prevalence of exposure was higher among males, those aged 18-44 years, non-Hispanic Blacks, Hispanics, and non-Hispanic American Indians/Alaska natives compared to non-Hispanic Whites, those with less education and income, those in the western United States, and those with no smoke-free workplace policy. Among all employed adults, 83.8% and 23.2% believed smoking should never be allowed in indoor and outdoor areas of workplaces, respectively. Conclusions: One-fifth of employed U. S. adult nonsmokers are exposed to SHS in the workplace, and disparities in exposure exist across states and subpopulations. Most employed adults believe indoor areas of workplaces should be smoke free, and nearly one-quarter believe outdoor areas should be smoke free. Efforts to protect employees from SHS exposure and to educate the public about the dangers of SHS and benefits of smoke-free workplaces could be beneficial. C1 [King, Brian A.; Homa, David M.; Dube, Shanta R.; Babb, Stephen D.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP King, BA (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F-79, Atlanta, GA 30341 USA. EM baking@cdc.gov FU Intramural CDC HHS [CC999999] NR 41 TC 6 Z9 6 U1 2 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD OCT PY 2014 VL 16 IS 10 BP 1307 EP 1318 DI 10.1093/ntr/ntu069 PG 12 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA AR6CS UT WOS:000343671300004 PM 24812025 ER PT J AU Breck, A Goodman, K Dunn, L Stephens, RL Dawkins, N Dixon, B Jernigan, J Kakietek, J Lesesne, C Lessard, L Nonas, C O'Dell, SA Osuji, TA Bronson, B Xu, Y Khan, LK AF Breck, Andrew Goodman, Ken Dunn, Lillian Stephens, Robert L. Dawkins, Nicola Dixon, Beth Jernigan, Jan Kakietek, Jakub Lesesne, Catherine Lessard, Laura Nonas, Cathy O'Dell, Sarah Abood Osuji, Thearis A. Bronson, Bernice Xu, Ye Khan, Laura Kettel TI Evaluation Design of New York City's Regulations on Nutrition, Physical Activity, and Screen Time in Early Child Care Centers SO PREVENTING CHRONIC DISEASE LA English DT Article ID OBSERVATIONAL SYSTEM; MEASUREMENT ISSUES; FOOD-INTAKE; RELIABILITY AB This article describes the multi-method cross-sectional design used to evaluate New York City Department of Health and Mental Hygiene's regulations of nutrition, physical activity, and screen time for children aged 3 years or older in licensed group child care centers. The Center Evaluation Component collected data from a stratified random sample of 176 licensed group child care centers in New York City. Compliance with the regulations was measured through a review of center records, a facility inventory, and interviews of center directors, lead teachers, and food service staff. The Classroom Evaluation Component included an observational and biometric study of a sample of approximately 1,400 children aged 3 or 4 years attending 110 child care centers and was designed to complement the center component at the classroom and child level. The study methodology detailed in this paper may aid researchers in designing policy evaluation studies that can inform other jurisdictions considering similar policies. C1 [Breck, Andrew; Bronson, Bernice] Ctr Dis Control & Prevent, Natl Fdn, Atlanta, GA 30341 USA. [Goodman, Ken; Stephens, Robert L.; Dawkins, Nicola; Kakietek, Jakub; Lesesne, Catherine; O'Dell, Sarah Abood; Osuji, Thearis A.; Xu, Ye] ICF Int, Atlanta, GA USA. [Dunn, Lillian] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Dixon, Beth] NYU, New York, NY USA. [Jernigan, Jan; Khan, Laura Kettel] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Lessard, Laura] Arcadia Univ, Glenside, CA USA. RP Khan, LK (reprint author), Ctr Dis Control & Prevent, Off Director, Div Nutr Phys Act & Obes, 4770 Buford Hwy,MS K-24, Atlanta, GA 30341 USA. EM LDK7@cdc.gov FU Robert Wood Johnson Foundation (RWJF) [65425] FX The project was funded by grant no. 65425 from the Robert Wood Johnson Foundation (RWJF) to the National Foundation for the Centers for Disease Control and Prevention. Technical assistance was provided by the CDC National Center for Chronic Disease Prevention and Health Promotion, Division of Nutrition, Physical Activity, and Obesity. ICF International served as the lead contractor for the study in conjunction with the DOHMH. Dr Dixon served as a consultant on the project. Special thanks for their support and contributions to the study go to Laura Leviton, RWJF; Tamara Dumanovsky, DOHMH; and Julia Ruben and David Cotton, ICF International. NR 16 TC 3 Z9 3 U1 0 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2014 VL 11 AR E184 DI 10.5888/pcd11.130431 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XM UT WOS:000343522500003 PM 25321635 ER PT J AU Kakietek, J Osuji, TA O'Dell, SA Breck, A Khan, LK AF Kakietek, Jakub Osuji, Thearis A. O'Dell, Sarah Abood Breck, Andrew Khan, Laura Kettel TI Compliance With New York City's Beverage Regulations and Beverage Consumption Among Children in Early Child Care Centers SO PREVENTING CHRONIC DISEASE LA English DT Article ID SUGAR-SWEETENED BEVERAGES; NUTRITION PRACTICES; MEALTIME ENVIRONMENTS; OBESITY PREVENTION; UNITED-STATES; FOODS; ASSOCIATION; OVERWEIGHT; SETTINGS; SCHOOLS AB Introduction This article examines the association between the New York City regulations on beverages served in child care centers and beverage consumption among enrolled children. The regulations include requirements related to beverages served to children throughout the day. Methods Beverage consumption data were collected on 636 children enrolled in 106 group child care centers in New York City. Data on compliance with the regulations were collected through direct observation, interviews with center staff, and a site inventory. Logistic regression for rare events was used to test associations between compliance with the regulations and beverage consumption. Results Compliance with the regulations was associated with lower odds of children consuming milk with more than 1% fat content and sugar-sweetened beverages during meals and snacks. There was not a significant relationship between compliance with the regulations and children's consumption of water. Conclusion The findings suggest a strong, direct relationship between what a center serves and what a child consumes, particularly regarding consumption of higher-fat milk and sugar-sweetened beverages. Therefore, policies governing the types of beverages served in child care centers may increase children's consumption of more healthful beverages and reduce the consumption of less healthful ones. C1 [Kakietek, Jakub; Osuji, Thearis A.; O'Dell, Sarah Abood] ICF Int, Atlanta, GA 30329 USA. [Breck, Andrew] CDC Fdn, Atlanta, GA USA. [Khan, Laura Kettel] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Kakietek, J (reprint author), ICF Int, Three Corp Sq,Suite 370, Atlanta, GA 30329 USA. EM jKakietek@icfi.com FU Robert Wood Johnson Foundation [65425] FX The project was funded by grant no. 65425 from the Robert Wood Johnson Foundation to the CDC Foundation. Technical assistance was provided by the CDC National Center for Chronic Disease Prevention and Health Promotion Division of Nutrition, Physical Activity, and Obesity. ICF International served as the lead contractor for the study in conjunction with the New York City Department of Health and Mental Hygiene. Beth Dixon served as a consultant on the project. NR 37 TC 4 Z9 4 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2014 VL 11 AR E180 DI 10.5888/pcd11.130430 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XM UT WOS:000343522500002 PM 25321631 ER PT J AU Kakietek, J Dunn, L O'Dell, SA Jernigan, J Khan, LK AF Kakietek, Jakub Dunn, Lillian O'Dell, Sarah Abood Jernigan, Jan Khan, Laura Kettel TI Training and Technical Assistance for Compliance With Beverage and Physical Activity Components of New York City's Regulations for Early Child Care Centers SO PREVENTING CHRONIC DISEASE LA English DT Article ID NUTRITION; ADOLESCENTS; DELAWARE; OBESITY; POLICY AB Introduction In 2006, the New York City Department of Health and Mental Hygiene (DOHMH) passed regulations for child care centers that established standards for beverages provided to children and set a minimum amount of time for daily physical activity. DOHMH offered several types of training and technical assistance to support compliance with the regulations. This article analyzes the association between training and technical assistance provided and compliance with the regulations in a sample of 174 group child care centers. Methods Compliance was measured by using a site inventory of beverages stored on premises and a survey of centers' teachers regarding the amount of physical activity provided. Training and technical assistance measures were based on the DOHMH records of training and technical assistance provided to the centers in the sample and on a survey of center directors. Ordinal logistic regression was used to assess the association between training and technical assistance measures and compliance with the regulations. Results Measures of training related to physical activity the center received: the number of staff members who participated in Sport, Play and Active Recreation for Kids (SPARK) and other training programs in which a center participated were associated with better compliance with the physical activity regulations. Neither training nor technical assistance were associated with compliance with the regulations related to beverages. Conclusion Increased compliance with regulations pertaining to physical activity was not related to compliance with beverage regulations. Future trainings should be targeted to the specific regulation requirements to increase compliance. C1 [Kakietek, Jakub; O'Dell, Sarah Abood] ICF Int, Washington, DC 20006 USA. [Dunn, Lillian] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Jernigan, Jan; Khan, Laura Kettel] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Kakietek, J (reprint author), ICF Int, 1725 1 St NW 1000, Washington, DC 20006 USA. EM jKakietek@icfi.com FU Robert Wood Johnson Foundation [65425] FX The project was funded by grant no. 65425 from the Robert Wood Johnson Foundation to the CDC Foundation. Technical assistance was provided by CDC's Center for Chronic Disease Prevention and Health Promotion, Division of Nutrition, Physical Activity, and Obesity. ICF International was the lead contractor for the study in conjunction with the New York City DOHMH. Beth Dixon was a consultant on the project. NR 15 TC 2 Z9 2 U1 0 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2014 VL 11 AR E177 DI 10.5888/pcd11.130434 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XM UT WOS:000343522500006 PM 25321628 ER PT J AU King, BA Peck, RM Babb, SD AF King, Brian A. Peck, Richard M. Babb, Stephen D. TI National and State Cost Savings Associated With Prohibiting Smoking in Subsidized and Public Housing in the United States SO PREVENTING CHRONIC DISEASE LA English DT Article ID SECONDHAND SMOKE; FREE POLICIES; EXPOSURE; RESIDENTS; ATTITUDES AB Introduction Despite progress in implementing smoke-free laws in indoor public places and workplaces, millions of Americans remain exposed to secondhand smoke at home. The nation's 80 million multiunit housing residents, including the nearly 7 million who live in subsidized or public housing, are especially susceptible to secondhand smoke infiltration between units. Methods We calculated national and state costs that could have been averted in 2012 if smoking were prohibited in all US subsidized housing, including public housing: 1) secondhand smoke-related direct health care, 2) renovation of smoking-permitted units; and 3) smoking-attributable fires. Annual cost savings were calculated by using residency estimates from the Department of Housing and Urban Development and cost data reported elsewhere. Data were adjusted for inflation and variations in state costs. National and state estimates (excluding Alaska and the District of Columbia) were calculated by cost type. Results Prohibiting smoking in subsidized housing would yield annual cost savings of $496.82 million (range, $258.96-$843.50 million), including $310.48 million ($154.14-$552.34 million) in secondhand smoke-related health care, $133.77 million ($75.24-$209.01 million) in renovation expenses, and $52.57 million ($29.57-$82.15 million) in smoking-attributable fire losses. By state, cost savings ranged from $0.58 million ($0.31-$0.94 million) in Wyoming to $124.68 million ($63.45-$216.71 million) in New York. Prohibiting smoking in public housing alone would yield cost savings of $152.91 million ($79.81-$259.28 million); by state, total cost savings ranged from $0.13 million ($0.07-$0.22 million) in Wyoming to $57.77 million ($29.41-$100.36 million) in New York. Conclusion Prohibiting smoking in all US subsidized housing, including public housing, would protect health and could generate substantial societal cost savings. C1 [King, Brian A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Peck, Richard M.] Univ Illinois, Chicago, IL USA. [Babb, Stephen D.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP King, BA (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Highway,MS F-79, Atlanta, GA 30341 USA. EM baking@cdc.gov NR 30 TC 5 Z9 5 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2014 VL 11 AR E171 DI 10.5888/pcd11.140222 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XM UT WOS:000343522500018 PM 25275808 ER PT J AU Lessard, L Lesesne, C Kakietek, J Breck, A Jernigan, J Dunn, L Nonas, C O'Dell, SA Stephens, RL Xu, Y Khan, LK AF Lessard, Laura Lesesne, Catherine Kakietek, Jakub Breck, Andrew Jernigan, Jan Dunn, Lillian Nonas, Cathy O'Dell, Sarah Abood Stephens, Robert L. Xu, Ye Khan, Laura Kettel TI Measurement of Compliance With New York City's Regulations on Beverages, Physical Activity, and Screen Time in Early Child Care Centers SO PREVENTING CHRONIC DISEASE LA English DT Article ID OBESITY PREVENTION; NUTRITION AB Introduction Policy interventions designed to change the nutrition environment and increase physical activity in child care centers are becoming more common, but an understanding of the implementation of these interventions is yet to be developed. The objective of this study was to explore the extent and consistency of compliance with a policy intervention designed to promote nutrition and physical activity among licensed child care centers in New York City. Methods We used a multimethod cross-sectional approach and 2 independent components of data collection (Center Evaluation Component and Classroom Evaluation Component). The methods were designed to evaluate the impact of regulations on beverages served, physical activity, and screen time at child care centers. We calculated compliance scores for each evaluation component and each regulation and percentage agreement between compliance in the center and classroom components. Results Compliance with certain requirements of the beverage regulations was high and fairly consistent between components, whereas compliance with the physical activity regulation varied according to the data collection component. Compliance with the regulation on amount and content of screen time was high and consistent. Conclusion Compliance with the physical activity regulation may be a more fluid, day-to-day issue, whereas compliance with the regulations on beverages and television viewing may be easier to control at the center level. Multiple indicators over multiple time points may provide a more complete picture of compliance - especially in the assessment of compliance with physical activity policies. C1 [Lessard, Laura] Arcadia Univ, Glenside, PA 19038 USA. [Lesesne, Catherine; Kakietek, Jakub; O'Dell, Sarah Abood; Stephens, Robert L.; Xu, Ye] ICF Int, Atlanta, GA USA. [Breck, Andrew] Ctr Dis Control & Prevent, Natl Fdn, Atlanta, GA USA. [Jernigan, Jan; Khan, Laura Kettel] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dunn, Lillian] New York City Dept Educ, New York, NY USA. [Nonas, Cathy] New York City Dept Hlth & Mental Hyg, New York, NY USA. RP Lessard, L (reprint author), Arcadia Univ, 450 S Easton Rd, Glenside, PA 19038 USA. EM LessardL@Arcadia.edu FU Robert Wood Johnson Foundation [65425] FX The project was funded by grant no. 65425 from the Robert Wood Johnson Foundation to the National Foundation for the Centers for Disease Control and Prevention. Technical assistance was provided by the National Center for Chronic Disease Prevention and Health Promotion's Division of Nutrition, Physical Activity, and Obesity at the Centers for Disease Control and Prevention. ICF International served as the lead contractor for the study in conjunction with the New York City Department of Health and Mental Hygiene. Beth Dixon served as a consultant on the project. The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or any of the other project agencies. NR 9 TC 8 Z9 8 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2014 VL 11 AR E183 DI 10.5888/pcd11.130433 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XM UT WOS:000343522500005 PM 25321634 ER PT J AU Maxwell, AE Hannon, PA Escoffery, C Vu, T Kohn, M Vernon, SW DeGroff, A AF Maxwell, Annette E. Hannon, Peggy A. Escoffery, Cam Thuy Vu Kohn, Marlana Vernon, Sally W. DeGroff, Amy TI Promotion and Provision of Colorectal Cancer Screening: A Comparison of Colorectal Cancer Control Program Grantees and Nongrantees, 2011-2012 SO PREVENTING CHRONIC DISEASE LA English DT Article ID CLIENT-DIRECTED INTERVENTIONS; HEALTH-CARE PROVIDERS; UNITED-STATES; INCREASE RECOMMENDATION; PREVENTIVE SERVICES; SYSTEMATIC REVIEWS; BREAST; DELIVERY AB Introduction Since 2009, the Centers for Disease Control and Prevention (CDC) has awarded nearly $95 million to 29 states and tribes through the Colorectal Cancer Control Program (CRCCP) to fund 2 program components: 1) providing colorectal cancer (CRC) screening to uninsured and underinsured low-income adults and 2) promoting population-wide CRC screening through evidence-based interventions identified in the Guide to Community Preventive Services (Community Guide). CRCCP is a new model for disseminating and promoting use of evidence-based interventions. If the program proves successful, CDC may adopt the model for future cancer control programs. The objective of our study was to compare the colorectal cancer screening practices of recipients of CRCCP funding (grantees) with those of nonrecipients (nongrantees). Methods We conducted parallel Web-based surveys in 2012 with CRCCP grantees (N = 29) and nongrantees (N = 24) to assess promotion and provision of CRC screening, including the use of evidence-based interventions. Results CRCCP grantees were significantly more likely than nongrantees to use Community Guide-recommended evidence-based interventions (mean, 3.14 interventions vs 1.25 interventions, P <.001) and to use patient navigation services (eg, transportion or language translation services) (72% vs 17%, P <.001) for promoting CRC screening. Both groups were equally likely to use other strategies. CRCCP grantees were significantly more likely to provide CRC screening than were nongrantees (100% versus 50%, P <.001). Conclusion Results suggest that CRCCP funding and support increases use of evidence-based interventions to promote CRC screening, indicating the program's potential to increase population-wide CRC screening rates. C1 [Maxwell, Annette E.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Maxwell, Annette E.] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Hannon, Peggy A.; Thuy Vu; Kohn, Marlana] Univ Washington, Seattle, WA 98195 USA. [Escoffery, Cam] Emory Univ, Atlanta, GA 30322 USA. [Vernon, Sally W.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [DeGroff, Amy] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Maxwell, AE (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, 650 Charles Young Dr South,A2-125 CHS,Box 956900, Los Angeles, CA 90095 USA. EM amaxwell@ucla.edu FU CDC; National Cancer Institute through the Cancer Prevention and Control Research Network, a network within CDC's Prevention Research Center Program (University of California at Los Angeles) [U48 DP001934]; National Cancer Institute through the Cancer Prevention and Control Research Network, a network within CDC's Prevention Research Center Program (University of Washington) [U48DP001911]; National Cancer Institute through the Cancer Prevention and Control Research Network, a network within CDC's Prevention Research Center Program (Emory University) [U48DP001909]; National Cancer Institute through the Cancer Prevention and Control Research Network, a network within CDC's Prevention Research Center Program (University of Texas at Houston) [U48DP001949] FX The authors thank CRCCP and the National Breast and Cervical Cancer Early Detection Program grantees for their participation in the survey. This publication was supported by CDC and the National Cancer Institute through the Cancer Prevention and Control Research Network, a network within CDC's Prevention Research Centers Program (University of California at Los Angeles, U48 DP001934; University of Washington, U48DP001911; Emory University, U48DP001909; University of Texas at Houston, U48DP001949). NR 27 TC 0 Z9 0 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2014 VL 11 AR E170 DI 10.5888/pcd11.140183 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XM UT WOS:000343522500013 PM 25275807 ER PT J AU Nonas, C Silver, LD Khan, LK Leviton, L AF Nonas, Cathy Silver, Lynn D. Khan, Laura Kettel Leviton, Laura TI Rationale for New York City's Regulations on Nutrition, Physical Activity, and Screen Time in Early Child Care Centers SO PREVENTING CHRONIC DISEASE LA English DT Article ID OBESITY; PREVALENCE; CONSUMPTION; PREVENTION; OVERWEIGHT; HEALTH AB Childhood obesity is associated with health risks in childhood, and it increases the risk of adult obesity, which is associated with many chronic diseases. Therefore, implementing policies that may prevent obesity at young ages is important. In 2007, the New York City Department of Health and Mental Hygiene implemented new regulations for early childhood centers to increase physical activity, limit screen time, and provide healthful beverage offerings (ie, restrict sugar-sweetened beverages for all children, restrict whole milk for those older than 2 years, restrict juice to beverages that are 100% juice and limit serving of juice to only 6 ounces per day, and make water available and accessible at all times). This article explains why these amendments to the Health Code were created, how information about these changes was disseminated, and what training programs were used to help ensure implementation, particularly in high-need neighborhoods. C1 [Nonas, Cathy] New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA. [Silver, Lynn D.] Inst Publ Hlth, Oakland, CA USA. [Khan, Laura Kettel] Ctr Dis Control & Prevent, Atlanta, GA USA. [Leviton, Laura] Robert Wood Johnson Fdn, Princeton, NJ 08540 USA. RP Nonas, C (reprint author), New York City Dept Hlth & Mental Hyg, 42-09 28th St,CN 46, Queens, NY 11101 USA. EM cnonas@health.nyc.gov FU Robert Wood Johnson Foundation [65425] FX The project was funded by grant no. 65425 from the Robert Wood Johnson Foundation to the National Foundation for CDC. Technical assistance was provided by CDC's National Center for Chronic Disease Prevention and Health Promotion, Division of Nutrition, Physical Activity, and Obesity. ICF International was the lead contractor for the study in conjunction with the NYC DOHMH. Beth Dixon was a consultant on the project. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC or any of the other project agencies. NR 32 TC 4 Z9 4 U1 1 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2014 VL 11 AR E182 DI 10.5888/pcd11.130435 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XM UT WOS:000343522500007 PM 25321633 ER PT J AU Nonas, C Silver, LD Khan, LK AF Nonas, Cathy Silver, Lynn D. Khan, Laura Kettel TI Insights and Implications for Health Departments From the Evaluation of New York City's Regulations on Nutrition, Physical Activity, and Screen Time in Child Care Centers SO PREVENTING CHRONIC DISEASE LA English DT Article ID PARENTS; US AB In 2006, the New York City Department of Health and Mental Hygiene, seeking to address the epidemic of childhood obesity, issued new regulations on beverages, physical activity, and screen time in group child care centers. An evaluation was conducted to identify characteristics of New York City child care centers that have implemented these regulations and to examine how varying degrees of implementation affected children's behaviors. This article discusses results of this evaluation and how findings can be useful for other public health agencies. Knowing the characteristics of centers that are more likely to comply can help other jurisdictions identify centers that may need additional support and training. Results indicated that compliance may improve when rules established by governing agencies, national standards, and local regulatory bodies are complementary or additive. Therefore, the establishment of clear standards for obesity prevention for child care providers can be a significant public health achievement. C1 [Nonas, Cathy] New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA. [Silver, Lynn D.] Inst Publ Hlth, Oakland, CA USA. [Khan, Laura Kettel] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Nonas, C (reprint author), New York City Dept Hlth & Mental Hyg, 42-09 28th St,CN 46, Queens, NY 11101 USA. EM cnonas@health.nyc.gov FU Robert Wood Johnson Foundation [65425] FX This project was funded by grant no. 65425 from the Robert Wood Johnson Foundation to the National Foundation for the Centers for Disease Control and Prevention (CDC). Technical assistance was provided by the CDC National Center for Chronic Disease Prevention and Health Promotion Division of Nutrition, Physical Activity, and Obesity. ICF International served as the lead contractor for the study in conjunction with the New York City DOHMH. Beth Dixon served as a consultant on the project. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC or any of the other project agencies. NR 12 TC 1 Z9 1 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2014 VL 11 AR E178 DI 10.5888/pcd11.130429 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XM UT WOS:000343522500001 PM 25321629 ER PT J AU Sekhobo, JP Edmunds, LS Dalenius, K Jernigan, J Davis, CF Giddings, M Lesesne, C Khan, LK AF Sekhobo, Jackson P. Edmunds, Lynn S. Dalenius, Karen Jernigan, Jan Davis, Christopher F. Giddings, Mark Lesesne, Catherine Khan, Laura Kettel TI Neighborhood Disparities in Prevalence of Childhood Obesity Among Low-Income Children Before and After Implementation of New York City Child Care Regulations SO PREVENTING CHRONIC DISEASE LA English DT Article ID PRESCHOOL-AGED CHILDREN; STATE WIC PROGRAM; BODY-MASS INDEX; UNITED-STATES; ADOLESCENTS; HEALTH; PREVENTION; VALIDITY; COUNTY; TRENDS AB Introduction New York City Article 47 regulations, implemented in 2007, require licensed child care centers to improve the nutrition, physical activity, and television-viewing behaviors of enrolled children. To supplement an evaluation of the Article 47 regulations, we conducted an exploratory ecologic study to examine changes in childhood obesity prevalence among low-income preschool children enrolled in the Nutrition Program for Women, Infants, and Children (WIC) in New York City neighborhoods with or without a district public health office. We conducted the study 3 years before (from 2004 through 2006) and after (from 2008 through 2010) the implementation of the regulations in 2007. Methods We used an ecologic, time-trend analysis to compare 3-year cumulative obesity prevalence among WIC-enrolled preschool children during 2004 to 2006 and 2008 to 2010. Outcome data were obtained from the New York State component of the Centers for Disease Control and Prevention's Pediatric Nutrition Surveillance System. Results Early childhood obesity prevalence declined in all study neighborhoods from 2004-2006 to 2008-2010. The greatest decline occurred in Manhattan high-risk neighborhoods where obesity prevalence decreased from 18.6% in 2004-2006 to 15.3% in 2008-2010. The results showed a narrowing of the gap in obesity prevalence between high-risk and low-risk neighborhoods in Manhattan and the Bronx, but not in Brooklyn. Conclusion The reductions in early childhood obesity prevalence in some high-risk and low-risk neighborhoods in New York City suggest that progress was made in reducing health disparities during the years just before and after implementation of the 2007 regulations. Future research should consider the built environment and markers of differential exposure to known interventions and policies related to childhood obesity prevention. C1 [Sekhobo, Jackson P.] New York State Dept Hlth, Div Nutr, Menands, NY 12204 USA. [Edmunds, Lynn S.; Giddings, Mark] New York State Dept Hlth, Albany, NY USA. [Dalenius, Karen; Jernigan, Jan; Khan, Laura Kettel] Ctr Dis Control & Prevent, Atlanta, GA USA. [Davis, Christopher F.] SUNY Albany, Sch Publ Hlth, Albany, NY USA. [Lesesne, Catherine] ICF Int, Atlanta, GA USA. RP Sekhobo, JP (reprint author), New York State Dept Hlth, Div Nutr, 150 Broadway, Menands, NY 12204 USA. EM Jackson.Sekhobo@health.ny.gov FU Robert Wood Johnson Foundation (RWJF) [65425] FX The evaluation of the New York City Department of Health and Mental Hygiene's regulations for beverages, physical activity, and screen time for children aged 3 years or older in licensed, group child care centers was funded by grant no. 65425 from the Robert Wood Johnson Foundation (RWJF) to the CDC Foundation. Technical assistance was provided by CDC's National Center for Chronic Disease Prevention and Health Promotion's Division of Nutrition, Physical Activity, and Obesity. ICF International was the lead contractor for the study in conjunction with the New York City Department of Health and Mental Hygiene (DHMH). Beth Dixon was a consultant on the project. We thank Laura Leviton, RWJF; Tamara Dumanovsky, New York City DHMH; and Julia Ruben and David Cotton, ICF International for their support and contributions to the study. The findings and conclusions of this paper are those of the authors and do not necessarily reflect the official views of CDC. NR 25 TC 2 Z9 2 U1 5 U2 16 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2014 VL 11 AR E181 DI 10.5888/pcd11.140152 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XM UT WOS:000343522500010 PM 25321632 ER PT J AU Stephens, RL Xu, Y Lesesne, CA Dunn, L Kakietek, J Jernigan, J Khan, LK AF Stephens, Robert L. Xu, Ye Lesesne, Catherine A. Dunn, Lillian Kakietek, Jakub Jernigan, Jan Khan, Laura Kettel TI Relationship Between Child Care Centers' Compliance With Physical Activity Regulations and Children's Physical Activity, New York City, 2010 SO PREVENTING CHRONIC DISEASE LA English DT Article ID OBESITY PREVENTION; STATE REGULATIONS; PRESCHOOLERS; INTERVENTIONS; ENVIRONMENT; PREVALENCE AB Introduction Physical activity may protect against overweight and obesity among preschoolers, and the policies and characteristics of group child care centers influence the physical activity levels of children who attend them. We examined whether children in New York City group child care centers that are compliant with the city's regulations on child physical activity engage in more activity than children in centers who do not comply. Methods A sample of 1,352 children (mean age, 3.39 years) served by 110 group child care centers in low - income neighborhoods participated. Children's anthropometric data were collected and accelerometers were used to measure duration and intensity of physical activity. Multilevel generalized linear regression modeling techniques were used to assess the effect of center - and child - level factors on child - level physical activity. Results Centers' compliance with the regulation of obtaining at least 60 minutes of total physical activity per day was positively associated with children's levels of moderate to vigorous physical activity (MVPA); compliance with the regulation of obtaining at least 30 minutes of structured activity was not associated with increased levels of MVPA. Children in centers with a dedicated outdoor play space available also spent more time in MVPA. Boys spent more time in MVPA than girls, and non - Hispanic black children spent more time in MVPA than Hispanic children. Conclusion To increase children's level of MVPA in child care, both time and type of activity should be considered. Further examination of the role of play space availability and its effect on opportunities for engaging in physical activity is needed. C1 [Stephens, Robert L.; Xu, Ye; Lesesne, Catherine A.; Kakietek, Jakub] ICF Int, Atlanta, GA 30329 USA. [Dunn, Lillian] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Jernigan, Jan; Khan, Laura Kettel] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Stephens, RL (reprint author), ICF Int, Three Corp Sq,Suite 370, Atlanta, GA 30329 USA. EM Robert.Stephens@icfi.com FU Robert Wood Johnson Foundation [65425] FX The project was funded by grant no. 65425 from the Robert Wood Johnson Foundation to the National Foundation for the Centers for Disease Control and Prevention (CDC). Technical assistance was provided by the CDC National Center for Chronic Disease Prevention and Health Promotion Division of Nutrition, Physical Activity, and Obesity. ICF International was lead contractor in conjunction with the NYC DOHMH. Beth Dixon served as a consultant. NR 22 TC 10 Z9 10 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2014 VL 11 AR E179 DI 10.5888/pcd11.130432 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XM UT WOS:000343522500004 PM 25321630 ER PT J AU Vaughan, AS Kramer, MR Casper, M AF Vaughan, Adam S. Kramer, Michael R. Casper, Michele TI Geographic Disparities in Declining Rates of Heart Disease Mortality in the Southern United States, 1973-2010 SO PREVENTING CHRONIC DISEASE LA English DT Editorial Material C1 [Vaughan, Adam S.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Vaughan, Adam S.; Kramer, Michael R.; Casper, Michele] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kramer, Michael R.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Vaughan, AS (reprint author), Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM asvaugh@emory.edu FU NICHD NIH HHS [K01 HD074726, K01HD074726] NR 6 TC 3 Z9 3 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2014 VL 11 AR E185 DI 10.5888/pcd11.140203 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XM UT WOS:000343522500014 PM 25340357 ER PT J AU Agaku, IT King, BA AF Agaku, Israel T. King, Brian A. TI Validation of Self-Reported Smokeless Tobacco Use by Measurement of Serum Cotinine Concentration Among US Adults SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE biomarkers; cotinine; epidemiologic methods; smokeless tobacco; smoking; snuff; tobacco ID UNITED-STATES; CIGARETTE-SMOKING; ETHNIC-DIFFERENCES; URINARY COTININE; SECONDHAND SMOKE; EXPOSURE; NONSMOKERS; NICOTINE; ADOLESCENTS; PRODUCTS AB Although investigators have assessed the relationship between self-reported cigarette smoking and biomarker levels, the validity of self-reported information on smokeless tobacco (SLT) use is uncertain. We used aggregated data from the 2003-2004, 2005-2006, 2007-2008, and 2009-2010 administrations of the National Health and Nutrition Examination Survey (NHANES) to compare self-reported SLT use with serum concentrations of cotinine, a metabolite of nicotine, among US adults aged a parts per thousand yen18 years. Receiver operating characteristic analysis was used to determine the optimal serum cotinine cutpoint for discriminating SLT users from nonusers of tobacco, and concordance analysis was used to compare self-reported SLT use with cotinine levels. Among the 30,298 adult respondents who completed the NHANES during 2003-2010, 418 reported having exclusively used SLT and no other type of tobacco (cigarettes, cigars, or pipes) during the past 5 days, while 23,457 reported not using any tobacco. The optimal cotinine cutpoint for discriminating SLT users from non-tobacco users was 3.0 ng/mL (sensitivity = 97.0%, specificity = 93.0%), which was comparable to a revised cutpoint recommended for identifying adult cigarette smokers. Concordance with cotinine was 96.4% and 93.7% for self-reported SLT use and tobacco nonuse, respectively. These findings indicate that self-reported SLT use among adults correlates highly with serum cotinine levels and that the optimal cutpoint for minimizing misclassification of self-reported use is a serum cotinine concentration of 3.0 ng/mL. C1 [Agaku, Israel T.; King, Brian A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Agaku, Israel T.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, Atlanta, GA 30341 USA. RP Agaku, IT (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F-79, Atlanta, GA 30341 USA. EM iagaku@cdc.gov FU Intramural CDC HHS [CC999999] NR 35 TC 6 Z9 6 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD OCT 1 PY 2014 VL 180 IS 7 BP 749 EP 754 DI 10.1093/aje/kwu182 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ8DU UT WOS:000343054500010 PM 25125690 ER PT J AU Meijer, A Rebelo-de-Andrade, H Correia, V Besselaar, T Drager-Dayal, R Fry, A Gregory, V Gubareva, L Kageyama, T Lackenby, A Lo, J Odagiri, T Pereyaslov, D Siqueira, MM Takashita, E Tashiro, M Wang, D Wong, S Zhang, W Daniels, RS Hurt, AC AF Meijer, Adam Rebelo-de-Andrade, Helena Correia, Vanessa Besselaar, Terry Drager-Dayal, Renu Fry, Alicia Gregory, Vicky Gubareva, Larisa Kageyama, Tsutomu Lackenby, Angie Lo, Janice Odagiri, Takato Pereyaslov, Dmitriy Siqueira, Marilda M. Takashita, Emi Tashiro, Masato Wang, Dayan Wong, Sun Zhang, Wenqing Daniels, Rod S. Hurt, Aeron C. TI Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013 SO ANTIVIRAL RESEARCH LA English DT Article DE Influenza virus; Antiviral resistance; Neuraminidase inhibitors; Oseltamivir; Global analysis; Normalization using fold-change data ID OSELTAMIVIR-RESISTANT; A(H1N1) VIRUSES; UNITED-STATES; B VIRUSES; H1N1; EMERGENCE; INFECTION; VARIANTS; SEASON AB Emergence of influenza viruses with reduced susceptibility to neuraminidase inhibitors (NAIs) is sporadic, often follows exposure to NAIs, but occasionally occurs in the absence of NAI pressure. The emergence and global spread in 2007/2008 of A(H1N1) influenza viruses showing clinical resistance to oseltamivir due to neuraminidase (NA) H275Y substitution, in the absence of drug pressure, warrants continued vigilance and monitoring for similar viruses. Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 11387 viruses collected by WHO-recognized National Influenza Centres (NIC) between May 2012 and May 2013 to determine 50% inhibitory concentration (IC50) data for oseltamivir, zanamivir, peramivir and laninamivir. The data were evaluated using normalized IC50 fold-changes rather than raw IC50 data. Nearly 90% of the 11,387 viruses were from three WHO regions: Western Pacific, the Americas and Europe. Only 0.2% (n = 27) showed highly reduced inhibition (HRI) against at least one of the four NAIs, usually oseltamivir, while 0.3% (n = 39) showed reduced inhibition (RI). NA sequence data, available from the WHO CCs and from sequence databases (n = 3661), were screened for amino acid substitutions associated with reduced NAI susceptibility. Those showing HRI were A(H1N1)pdm09 with NA H275Y (n = 18), A(H3N2) with NA E119V (n = 3) or NA R292K (n = 1) and B/Victoria-lineage with NA H273Y (n = 2); amino acid position numbering is A subtype and B type specific. Overall, approximately 99% of circulating viruses tested during the 2012-2013 period were sensitive to all four NAIs. Consequently, these drugs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections. (C) 2014 The Authors. Published by Elsevier B.V. C1 [Meijer, Adam] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Rebelo-de-Andrade, Helena; Correia, Vanessa] Inst Natl Saude, P-1649016 Lisbon, Portugal. [Rebelo-de-Andrade, Helena; Correia, Vanessa] Univ Lisbon, Fac Farm, P-1699 Lisbon, Portugal. [Besselaar, Terry; Drager-Dayal, Renu; Zhang, Wenqing] WHO, Global Influenza Programme, CH-1211 Geneva 27, Switzerland. [Fry, Alicia; Gubareva, Larisa] Ctr Dis Control & Prevent, Collaborating Ctr Surveillance Epidemiol & Contro, WHO, Atlanta, GA USA. [Gregory, Vicky; Daniels, Rod S.] Natl Inst Med Res, MRC, Collaborating Ctr Reference & Res Influenza, WHO, London NW7 1AA, England. [Kageyama, Tsutomu; Odagiri, Takato; Takashita, Emi; Tashiro, Masato] Natl Inst Infect Dis, Collaborating Ctr Reference & Res Influenza, WHO, Tokyo 2080011, Japan. [Lackenby, Angie] Publ Hlth England Colindale, London NW9 5EQ, England. [Lo, Janice; Wong, Sun] Publ Hlth Lab Ctr, Kowloon, Hong Kong, Peoples R China. [Pereyaslov, Dmitriy] WHO, Reg Off Europe, Div Communicable Dis Hlth Secur & Environm, DK-2100 Copenhagen O, Denmark. [Siqueira, Marilda M.] Fiocruz MS, IOC, Resp Viruses Lab, BR-21045900 Rio De Janeiro, Brazil. [Wang, Dayan] Chinese Ctr Dis Control & Prevent, Collaborating Ctr Reference & Res Influenza, Chinese Natl Influenza Ctr, Natl Inst Viral Dis Control & Prevent,WHO, Beijing 102206, Peoples R China. [Hurt, Aeron C.] VIDRL, Peter Doherty Inst Infect & Immun, Collaborating Ctr Reference & Res Influenza, WHO, Melbourne, Vic 3000, Australia. [Hurt, Aeron C.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic 3010, Australia. RP Meijer, A (reprint author), Natl Inst Publ Hlth & Environm, POB 1, NL-3720 BA Bilthoven, Netherlands. EM adam.meijer@rivm.nl; h.rebelo.andrade@insa.min-saude.pt; vanessa.correia@insa.min-saude.pt; besselaart@who.int; rdragerdayal@gmail.com; agfl@cdc.gov; vgregor@nimr.mrc.ac.uk; LGubareva@CDC.gov; tkage@nih.go.jp; Angie.Lackenby@phe.gov.uk; janicelo@dh.gov.hk; todagiri@nih.go.jp; PDM@euro.who.int; mmsiq@ioc.fiocruz.br; emitaka@nih.go.jp; mtashiro@nih.go.jp; dayanwang@cnic.org.cn; ro_phls1@dh.gov; zhangw@who.int; rdaniel@nimr.mrc.ac.uk; Aeron.Hurt@influenzacentre.org RI Rebelo-de-Andrade, Helena/E-1871-2014; iMed.ULisboa, iMed.ULisboa/C-6292-2014; iMed.ULisboa, HPI /B-4239-2014; OI Rebelo-de-Andrade, Helena/0000-0002-0138-0944; iMed.ULisboa, HPI /0000-0001-5934-0198; Correia, Vanessa/0000-0002-1619-1900; Hurt, Aeron/0000-0003-1826-4314 FU British Medical Research Council [U117512723]; Australian Government, Department of Health; Ministry of Health, Labour and Welfare, Japan - Japan FX We thank all laboratories, mostly NICs of the WHO GISRS (http://www.who.int/influenza/gisrs_laboratory/national_influenza_centre s/list/en/), which contributed to this global analysis by submitting influenza virus positive samples (clinical specimens or virus isolates) to WHO CCs for detailed characterisation. We gratefully acknowledge the authors, originating and submitting laboratories of the 372 sequences unique to the GISAID database, additional to those of the 2826 sequences submitted to the GISAID database by the authors of this paper and the 233 sequences imported by GISAID from public databases (Supplementary Table 3), and the 230 sequences retrieved from NCBI-IVR, that were included in this global analysis. The London WHO CC is funded by the British Medical Research Council through programme U117512723. The Melbourne WHO CC is supported by the Australian Government, Department of Health. The Tokyo WHO CC is supported by Grants-in-Aid for Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labour and Welfare, Japan - Japan. NR 32 TC 25 Z9 27 U1 1 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 EI 1872-9096 J9 ANTIVIR RES JI Antiviral Res. PD OCT PY 2014 VL 110 BP 31 EP 41 DI 10.1016/j.antiviral.2014.07.001 PG 11 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA AR1NT UT WOS:000343352600004 PM 25043638 ER PT J AU Santos, R Mota, J Okely, AD Pratt, M Moreira, C Coelho-e-Silva, MJ Vale, S Sardinha, LB AF Santos, Rute Mota, Jorge Okely, Anthony David Pratt, Michael Moreira, Carla Coelho-e-Silva, Manuel Joao Vale, Susana Sardinha, Luis B. TI The independent associations of sedentary behaviour and physical activity on cardiorespiratory fitness SO BRITISH JOURNAL OF SPORTS MEDICINE LA English DT Article ID HEALTH-RELATED FITNESS; BED REST; FEMALE ADOLESCENTS; AEROBIC FITNESS; METABOLIC RISK; UNITED-STATES; YOUTH; CHILDREN; TELEVISION; TIME AB Background During childhood and adolescence, both physical activity (PA) and sedentary behaviour seem to influence cardiorespiratory fitness (CRF); however, the combined association of PA and sedentary behaviour remains to be understood. We analysed the combined association of objectively measured sedentary behaviour and moderate-to-vigorous intensity PA (MVPA) on CRF in Portuguese children and adolescents. Methods The sample comprised 2506 Portuguese healthy children and adolescents aged 10-18 years, from a cross-sectional school-based study (2008). PA and sedentary behaviour were assessed with accelerometry. Participants were classified as meeting current PA guidelines for youth versus not meeting, and as low versus high sedentary (according to the median value of sedentary time/day by age and gender), and then grouped as follows: Low active-high sedentary; low active-low sedentary; high active-high sedentary; high active-low sedentary. CRF was assessed with the FITNESSGRAM 20 m shuttle-run test. Binary logistic regression models were constructed to verify the relationship between high CRF and the combined influence of MVPA/sedentary behaviour, adjusting for age, gender, body mass index and accelerometer wear time. Results Participants classified as high active/low sedentary (OR=1.81; 95% CI 1.21 to 2.69), as well as those classified as low active/low sedentary (OR=1.27; 95% CI 1.01 to 1.61) were more likely to be fit, compared with those from the low-active/high-sedentary group. Conclusion MVPA and sedentary behaviour may act independently in their relation with CRF, and that MVPA levels may not overcome the deleterious influence of high-sedentary time in maximising CRF. C1 [Santos, Rute; Mota, Jorge; Moreira, Carla; Vale, Susana] Univ Porto, Res Ctr Phys Act Hlth & Leisure, P-4200450 Oporto, Portugal. [Santos, Rute] Maia Inst Higher Educ, Maia, Portugal. [Okely, Anthony David] Univ Wollongong, Interdisciplinary Educ Res Inst, Wollongong, NSW, Australia. [Pratt, Michael] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Coelho-e-Silva, Manuel Joao] Univ Coimbra, Fac Sport Sci & Phys Educ, Res Ctr Anthropol & Hlth, Coimbra, Portugal. [Sardinha, Luis B.] Univ Tecn Lisboa, Fac Human Kinet, Exercise & Hlth Lab, Lisbon, Portugal. RP Santos, R (reprint author), Univ Porto, Res Ctr Phys Act Hlth & Leisure, Rua Dr Placido Costa 91, P-4200450 Oporto, Portugal. EM rutemarinasantos@hotmail.com RI mota, jorge/B-2980-2013; OI mota, jorge/0000-0001-7571-9181; Moreira, Carla/0000-0003-1039-6320; Coelho-e-Silva, Manuel/0000-0003-4512-7331; Sardinha, Luis/0000-0002-6230-6027; Santos, Rute/0000-0002-7604-5753; Vale, Susana/0000-0002-1703-9361 FU FCT [BD/44422/2008, PTDC/DES/098309/2008, BPD/65180/2009, SAB/1025/2010] FX This study was supported by FCT grants: BD/44422/2008; PTDC/DES/098309/2008; BPD/65180/2009; SAB/1025/2010. NR 61 TC 27 Z9 27 U1 1 U2 36 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0306-3674 EI 1473-0480 J9 BRIT J SPORT MED JI Br. J. Sports Med. PD OCT PY 2014 VL 48 IS 20 BP 1508 EP 1512 DI 10.1136/bjsports-2012-091610 PG 6 WC Sport Sciences SC Sport Sciences GA AQ8UV UT WOS:000343111200010 PM 23410883 ER PT J AU Lipkin, EW Schwartz, AV Anderson, AM Davis, C Johnson, KC Gregg, EW Bray, GA Berkowitz, R Peters, AL Hodges, A Lewis, C Kahn, SE AF Lipkin, Edward W. Schwartz, Ann V. Anderson, Andrea M. Davis, Cralen Johnson, Karen C. Gregg, Edward W. Bray, George A. Berkowitz, Robert Peters, Anne L. Hodges, Amelia Lewis, Cora Kahn, Steven E. CA Look AHEAD Res Grp TI The Look AHEAD Trial: Bone Loss at 4-Year Follow-up in Type 2 Diabetes SO DIABETES CARE LA English DT Article ID X-RAY ABSORPTIOMETRY; OBESE OLDER-ADULTS; LIFE-STYLE INTERVENTION; WEIGHT-LOSS; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; LUMBAR SPINE; EXERCISE; ROSIGLITAZONE AB OBJECTIVE To determine whether an intensive lifestyle intervention (ILI) designed to sustain weight loss and improve physical fitness in overweight or obese persons with type 2 diabetes was associated with bone loss after 4 years of follow-up. RESEARCH DESIGN AND METHODS This randomized controlled trial of intensive weight loss compared an ILI with a diabetes support and education (DSE) group among 1,309 overweight or obese subjects. Bone mineral density was assessed at baseline and after 1 year and 4 years of intervention. RESULTS ILI was effective in producing significant weight loss (5.3% vs. 1.8% in ILI and DSE, respectively; P < 0.01) and increased fitness (6.4% vs. -0.8%) at year 4. Inmen, ILI participants had a greater rate of bone loss during the first year (-1.66% vs. -0.09% per year in ILI and DSE, respectively). Differences between groups were diminished by one-half after 4 years (-0.88% vs. -0.05% per year in ILI and DSE, respectively) but remained significant (P < 0.01). The difference in rate of hip bone loss between groups over 4 years was related to increased weight loss in ILI. Among women, the rate of bone loss did not differ between ILI and DSE after 4 years. CONCLUSIONS A 4-year weight loss intervention was significantly associated with a modest increase in bone loss at the hip in men but not in women. C1 [Lipkin, Edward W.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Lipkin, Edward W.; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Schwartz, Ann V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Anderson, Andrea M.; Davis, Cralen; Hodges, Amelia] Wake Forest Univ Hlth Sci, Div Publ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA. [Johnson, Karen C.] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Berkowitz, Robert] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Peters, Anne L.] Univ So Calif, Keck Sch Med, Dept Med, Div Endocrinol, Los Angeles, CA 90033 USA. [Lewis, Cora] Univ Alabama Birmingham, Dept Prevent Med, Birmingham, AL USA. RP Lipkin, EW (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. EM ewl@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 FU Department of Health and Human Services through National Institutes of Health [DK-57136, DK-57149, DK-56990, DK-57177, DK-57171, DK-57151, DK-57182, DK-57131, DK-57002, DK-57078, DK57154, DK-57178, DK-57219, DK-57008, DK-57135, DK-56992]; Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; Johns Hopkins Medical Institutions Bayview General Clinical Research Center (GCRC) [M01-RR-02719]; Massachusetts General Hospital Mallinckrodt GCRC; Massachusetts Institute of Technology GCRC [M01-RR-01066]; University of Colorado Health Sciences Center GCRC [M01-RR-00051]; Clinical Nutrition Research Unit [P30-DK-48520]; University of Tennessee at Memphis GCRC [M01-RR-0021140]; University of Pittsburgh GCRC [M01-RR-000056]; Clinical Translational Research Center - Clinical and Translational Science Award [UL1-RR-024153]; National Institutes of Health [DK-046204]; VA Puget Sound Health Care System Medical Research Service; Department of Veterans Affairs; Frederic C. Bartter GCRC [M01-RR-01346] FX This study is supported by the Department of Health and Human Services through the following cooperative agreements from the National Institutes of Health: DK-57136, DK-57149, DK-56990, DK-57177, DK-57171, DK-57151, DK-57182, DK-57131, DK-57002, DK-57078, DK57154, DK-57178, DK-57219, DK-57008, DK-57135, and DK-56992. The following federal agencies have contributed support: National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; Office of Research on Women's Health; and the Centers for Disease Control and Prevention. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service (IHS) provided personnel, medical oversight, and use of facilities. The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the IHS or other funding sources.; Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (GCRC) (M01-RR-02719), the Massachusetts General Hospital Mallinckrodt GCRC and the Massachusetts Institute of Technology GCRC (M01-RR-01066), the University of Colorado Health Sciences Center GCRC (M01-RR-00051) and Clinical Nutrition Research Unit (P30-DK-48520), the University of Tennessee at Memphis GCRC (M01-RR-0021140), the University of Pittsburgh GCRC (M01-RR-000056), the Clinical Translational Research Center funded by a Clinical and Translational Science Award (UL1-RR-024153) and a National Institutes of Health grant (DK-046204), the VA Puget Sound Health Care System Medical Research Service, the Department of Veterans Affairs, and the Frederic C. Bartter GCRC (M01-RR-01346). NR 36 TC 5 Z9 5 U1 1 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2014 VL 37 IS 10 BP 2822 EP 2829 DI 10.2337/dc14-0762 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AR4UM UT WOS:000343582400037 PM 25048381 ER PT J AU Whyatt, RM Perzanowski, MS Just, AC Rundle, AG Donohue, KM Calafat, AM Hoepner, LA Perera, FP Miller, RL AF Whyatt, Robin M. Perzanowski, Matthew S. Just, Allan C. Rundle, Andrew G. Donohue, Kathleen M. Calafat, Antonia M. Hoepner, Lori A. Perera, Frederica P. Miller, Rachel L. TI Asthma in Inner-City Children at 5-11 Years of Age and Prenatal Exposure to Phthalates: The Columbia Center for Children's Environmental Health Cohort SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID POLYCYCLIC AROMATIC-HYDROCARBONS; BISPHENOL-A EXPOSURE; EXHALED NITRIC-OXIDE; TRANSPLACENTAL EXPOSURE; TEMPORAL VARIABILITY; CHILDHOOD ASTHMA; DNA METHYLATION; PREGNANT-WOMEN; TOBACCO-SMOKE; URBAN COHORT AB BACKGROUND: Studies suggest that phthalate exposures may adversely affect child respiratory health. OBJECTIVES: We evaluated associations between asthma diagnosed in children between 5 and 11 years of age and prenatal exposures to butylbenzyl phthalate (BBzP), di-n-butyl phthalate (DnBP), di(2-ethylhexyl) phthalate (DEHP), and diethyl phthalate (DEP). METHODS: Phthalate metabolites were measured in spot urine collected from 300 pregnant innercity women. Children were examined by an allergist or pulmonologist based on the first parental report of wheeze, other respiratory symptoms, and/or use of asthma rescue/controller medication in the preceding 12 months on repeat follow-up questionnaires. Standardized diagnostic criteria were used to classify these children as either having or not having current asthma at the time of the physician examination. Children without any report of wheeze or the other asthma-like symptoms were classified as nonasthmatics at the time of the last negative questionnaire. Modified Poisson regression analyses were used to estimate relative risks (RR) controlling for specific gravity and potential confounders. RESULTS: Of 300 children, 154 (51%) were examined by a physician because of reports of wheeze, other asthma-like symptoms, and/or medication use; 94 were diagnosed with current asthma and 60 without current asthma. The remaining 146 children were classified as nonasthmatic. Compared with levels in nonasthmatics, prenatal metabolites of BBzP and DnBP were associated with a history of asthma-like symptoms (p < 0.05) and with the diagnosis of current asthma: RR = 1.17 (95% CI: 1.01, 1.35) and RR = 1.25 (95% CI: 1.04, 1.51) per natural log-unit increase, respectively. Risk of current asthma was > 70% higher among children with maternal prenatal BBzP and DnBP metabolite concentrations in the third versus the first tertile. CONCLUSION: Prenatal exposure to BBzP and DnBP may increase the risk of asthma among innercity children. However, because this is the first such finding, results require replication. C1 [Whyatt, Robin M.; Perzanowski, Matthew S.; Hoepner, Lori A.; Perera, Frederica P.; Miller, Rachel L.] Columbia Univ, Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA. [Just, Allan C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Rundle, Andrew G.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA. [Donohue, Kathleen M.; Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care, New York, NY USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Pediat, Div Allergy & Immunol, New York, NY USA. RP Whyatt, RM (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, Dept Environm Hlth Sci, 722 W 168th St, New York, NY 10032 USA. EM rmw5@columbia.edu RI Rundle, Andrew/A-5282-2009; OI Rundle, Andrew/0000-0003-0211-7707; Just, Allan/0000-0003-4312-5957 FU National Institute of Environmental Health Sciences (NIEHS); U.S. Environmental Protection Agency (EPA) [NIEHS/EPA P01 ES09600/RD83214101, NIEHS R01ES014393, R01ES13163, P30ES009089]; U.S. EPA grants [R82702701, RD83214101] FX Funding was provided by the National Institute of Environmental Health Sciences (NIEHS) and the U.S. Environmental Protection Agency (EPA) (NIEHS/EPA P01 ES09600/RD83214101 and NIEHS R01ES014393, R01ES13163, and P30ES009089). This publication was made possible in part by U.S. EPA grants R82702701 and RD83214101. NR 55 TC 17 Z9 18 U1 4 U2 23 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2014 VL 122 IS 10 BP 1141 EP 1146 DI 10.1289/ehp.1307670 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA AQ9BO UT WOS:000343136200029 PM 25230320 ER PT J AU Zhou, FF Wu, S Klena, JD Huang, HH AF Zhou, F. F. Wu, S. Klena, J. D. Huang, H. H. TI Clinical characteristics of Clostridium difficile infection in hospitalized patients with antibiotic-associated diarrhea in a university hospital in China SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES LA English DT Article ID MOLECULAR EPIDEMIOLOGY; RISK-FACTORS; PREVENTION; IDENTIFICATION; BERBERINE; STRAINS AB The purpose of this study was to identify clinical characteristics of Clostridium difficile infection (CDI) in patients with antibiotic-associated diarrhea (AAD). A prospective study was conducted among patients hospitalized in Fudan University Hospital Huashan from August 1, 2012 to July 31, 2013. Toxigenic C. difficile isolates were characterized by PCR ribotyping and multilocus sequence typing. AAD developed in 1.0 % (206/20437) of the antibiotic-treated hospitalized patients and toxigenic C. difficile was isolated from 30.6 % (63/206) of patients with AAD. The frequency of AAD was highest in the intensive care unit (10.7 %); however the proportion of CDI in AAD was highest in the Geriatric Unit (38 %). AAD ranged in severity from mild to moderate. One case with pseudomembranous colitis was identified. Use of carbapenems was found to significantly increase the risk of CDI (OR, 2.31; 95 % CI, 1.22-4.38; p=0.011). Patient demographics, presumed risk factors, clinical manifestations and laboratory findings revealed no significant difference between patients with CDI and non-C. difficile AAD. Over 90 % of the patients with CDI or non-C. difficile AAD were cured. Two patients had CDI recurrence. Ribotype H was the dominant (18.8 %) genotype, followed by ribotype 012 and ribotype 017. C. difficile plays a significant role in AAD in our setting in China. Because the severity of diarrhea ranges from mild to moderate, it is difficult for Chinese clinicians to identify CDI from AAD patients, therefore CDI should be included in the routine differential diagnoses for hospitalized patients presenting with AAD. C1 [Zhou, F. F.; Wu, S.; Huang, H. H.] Fudan Univ, Huashan Hosp, Inst Antibiot, Shanghai 200040, Peoples R China. [Klena, J. D.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. RP Huang, HH (reprint author), Fudan Univ, Huashan Hosp, Inst Antibiot, Shanghai 200040, Peoples R China. EM drhaihuihuang@163.com FU National Natural Science Foundation of China [30973594, 81101292]; Shanghai Pujiang Programme [10PJ1401800] FX This work was supported by a grant from the National Natural Science Foundation of China (no. 30973594 and no. 81101292) and Shanghai Pujiang Programme (no. 10PJ1401800). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 31 TC 4 Z9 4 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0934-9723 EI 1435-4373 J9 EUR J CLIN MICROBIOL JI Eur. J. Clin. Microbiol. Infect. Dis. PD OCT PY 2014 VL 33 IS 10 BP 1773 EP 1779 DI 10.1007/s10096-014-2132-9 PG 7 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA AQ9CM UT WOS:000343139000013 PM 24820293 ER PT J AU Bosco-Lauth, A Harmon, JR Lash, RR Weiss, S Langevin, S Savage, HM Godsey, MS Burkhalter, K Root, JJ Gidlewski, T Nicholson, WL Brault, AC Komar, N AF Bosco-Lauth, Angela Harmon, Jessica R. Lash, R. Ryan Weiss, Sonja Langevin, Stanley Savage, Harry M. Godsey, Marvin S., Jr. Burkhalter, Kristen Root, J. Jeffrey Gidlewski, Thomas Nicholson, William L. Brault, Aaron C. Komar, Nicholas TI West Nile Virus Isolated from a Virginia Opossum (Didelphis virginiana) in Northwestern Missouri, USA, 2012 SO JOURNAL OF WILDLIFE DISEASES LA English DT Article ID SQUIRRELS SCIURUS-NIGER; EXPERIMENTAL-INFECTION; VIREMIAS SUFFICIENT; SEROLOGIC EVIDENCE; MAMMALS AB We describe the isolation of West Nile virus (WNV; Flaviviridae, Flavivirus) from blood of a Virginia opossum (Didelphis virginiana) collected in northwestern Missouri, USA in August 2012. Sequencing determined that the virus was related to lineage la WNV02 strains. We discuss the role of wildlife in WNV disease epidemiology. C1 [Bosco-Lauth, Angela; Savage, Harry M.; Godsey, Marvin S., Jr.; Burkhalter, Kristen; Brault, Aaron C.; Komar, Nicholas] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arboviral Dis Branch, Ft Collins, CO 80521 USA. [Harmon, Jessica R.; Lash, R. Ryan; Weiss, Sonja; Nicholson, William L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. [Langevin, Stanley] Sandia Natl Labs, Livermore, CA 94550 USA. [Root, J. Jeffrey; Gidlewski, Thomas] USDA, Natl Wildlife Res Ctr, Ft Collins, CO 80521 USA. RP Bosco-Lauth, A (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Arboviral Dis Branch, 3156 Rampart Rd,Foothills Campus, Ft Collins, CO 80521 USA. EM mopargal@rams.colostate.edu FU US Department of Energy's National Nuclear Security Administration [DE-AC04-94AL85000] FX Sandia National Laboratories is a multi-program laboratory managed and operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the US Department of Energy's National Nuclear Security Administration under contract DE-AC04-94AL85000. NR 16 TC 0 Z9 0 U1 1 U2 14 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 EI 1943-3700 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD OCT PY 2014 VL 50 IS 4 BP 976 EP 978 DI 10.7589/2013-11-295 PG 3 WC Veterinary Sciences SC Veterinary Sciences GA AQ8LB UT WOS:000343075900037 PM 25098303 ER PT J AU Houston, KA Henley, SJ Li, J White, MC Richards, TB AF Houston, Keisha A. Henley, S. Jane Li, Jun White, Mary C. Richards, Thomas B. TI Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009 SO LUNG CANCER LA English DT Article DE Histologic type; Lung cancer; Time trend; Incidence; Tumor registry; Surveillance ID SQUAMOUS-CELL CARCINOMA; CIGARETTE-SMOKING; PATHOLOGICAL CLASSIFICATION; CHANGING EPIDEMIOLOGY; TOBACCO USE; TIME TREND; ADENOCARCINOMA; WOMEN; RISK; SURVEILLANCE AB Objective: The examination of lung cancer by histology type is important for monitoring population trends that have implications for etiology and prevention, screening and clinical diagnosis, prognosis and treatment. We provide a comprehensive description of recent histologic lung cancer incidence rates and trends in the USA using combined population-based registry data for the entire nation. Materials and methods: Histologic lung cancer incidence data was analyzed from CDC's National Program of Cancer Registries (NPCR) and the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program. Standardized rates and trends were calculated for men and women by age, race/ethnicity, and U.S. Census region. Rate ratios were examined for differences in rates between men and women, and annual percent change was calculated to quantify changes in incidence rates over time. Results: Trend analysis demonstrate that overall rates have decreased, but incidence has remained stable for women aged 50 or older. Adenocarcinoma and squamous cell carcinoma were the two most common histologic subtypes. Adenocarcinoma rates continued to increase in men and women, and squamous cell rates increased in women only. All histologic subtype rates for white women exceeded rates for black women. Histologic rates for black men exceeded those for white men, except for small cell carcinoma. The incidence rate for Hispanics was nearly half the rate for blacks and whites. Conclusion: The continuing rise in incidence of lung adenocarcinoma, the rise of squamous cell cancer in women, and differences by age, race, ethnicity and region points to the need to better understand factors acting in addition to, or in synergy with, cigarette smoking that may be contributing to observed differences in lung cancer histology. Published by Elsevier Ireland Ltd. C1 [Houston, Keisha A.; Henley, S. Jane; Li, Jun; White, Mary C.; Richards, Thomas B.] Ctr Dis Control & Prevent CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30341 USA. RP Houston, KA (reprint author), Div Canc Prevent & Control, Epidemiol & Appl Res Branch, CDC 4770 Buford Highway NE,F-76 Chamblee, Atlanta, GA 30341 USA. EM kahouston@cdc.gov; shenley@cdc.gov; jli14@cdc.gov; mcwhite@cdc.gov; trichards@cdc.gov RI White, Mary C./C-9242-2012 OI White, Mary C./0000-0002-9826-3962 NR 57 TC 35 Z9 35 U1 0 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 EI 1872-8332 J9 LUNG CANCER JI Lung Cancer PD OCT PY 2014 VL 86 IS 1 BP 22 EP 28 DI 10.1016/j.lungcan.2014.08.001 PG 7 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AR2CK UT WOS:000343391000004 PM 25172266 ER PT J AU Lovegrove, MC Mathew, J Hampp, C Governale, L Wysowski, DK Budnitz, DS AF Lovegrove, Maribeth C. Mathew, Justin Hampp, Christian Governale, Laura Wysowski, Diane K. Budnitz, Daniel S. TI Emergency Hospitalizations for Unsupervised Prescription Medication Ingestions by Young Children SO PEDIATRICS LA English DT Article DE poisoning; unintentional overdose; pediatric hospitalization; buprenorphine; opioids; sulfonylureas; prescription drugs; drug packaging ID POISON DATA SYSTEM; AMERICAN ASSOCIATION; DEPARTMENT VISITS; EXPOSURES; SURVEILLANCE; OVERDOSES; DRUGS AB BACKGROUND: Emergency department visits and subsequent hospitalizations of young children after unsupervised ingestions of prescription medications are increasing despite widespread use of child-resistant packaging and caregiver education efforts. Data on the medications implicated in ingestions are limited but could help identify prevention priorities and intervention strategies. METHODS: We used nationally representative adverse drug event data from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project and national retail pharmacy prescription data from IMS Health to estimate the frequency and rates of emergency hospitalizations for unsupervised prescription medication ingestions by young children (2007-2011). RESULTS: On the basis of 1513 surveillance cases, 9490 estimated emergency hospitalizations (95% confidence interval: 6420-12 560) occurred annually in the United States for unsupervised prescription medication ingestions among children aged <6 years from 2007 through 2011; 75.4% involved 1- or 2-year old children. Opioids (17.6%) and benzodiazepines (10.1%) were the most commonly implicated medication classes. The most commonly implicated active ingredients were buprenorphine (7.7%) and clonidine (7.4%). The top 12 active ingredients, alone or in combination with others, were implicated in nearly half (45.0%) of hospitalizations. Accounting for the number of unique patients who received dispensed prescriptions, the hospitalization rate for unsupervised ingestion of buprenorphine products was significantly higher than rates for all other commonly implicated medications and 97-fold higher than the rate for oxycodone products (200.1 vs 2.1 hospitalizations per 100 000 unique patients). CONCLUSIONS: Focusing unsupervised ingestion prevention efforts on medications with the highest hospitalization rates may efficiently achieve large public health impact. C1 [Lovegrove, Maribeth C.; Budnitz, Daniel S.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Mathew, Justin; Hampp, Christian; Governale, Laura; Wysowski, Diane K.] US FDA, Ctr Drug Evaluat & Res, Off Surveillance & Epidemiol, Silver Spring, MD USA. [Governale, Laura] AstraZeneca, Patient Safety, Gaithersburg, MD USA. RP Lovegrove, MC (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,Mailstop A-24, Atlanta, GA 30333 USA. EM mlovegrove@cdc.gov FU Intramural CDC HHS [CC999999] NR 31 TC 13 Z9 13 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD OCT PY 2014 VL 134 IS 4 BP E1009 EP E1016 DI 10.1542/peds.2014-0840 PG 8 WC Pediatrics SC Pediatrics GA AQ9CV UT WOS:000343140500010 PM 25225137 ER PT J AU Siegel, DA King, J Tai, E Buchanan, N Ajani, UA Li, J AF Siegel, David A. King, Jessica Tai, Eric Buchanan, Natasha Ajani, Umed A. Li, Jun TI Cancer Incidence Rates and Trends Among Children and Adolescents in the United States, 2001-2009 SO PEDIATRICS LA English DT Article DE adolescent; cancer; children; incidence; pediatric ID RENAL-CELL CARCINOMA; CHILDHOOD-CANCER; THYROID-CANCER; PEDIATRIC MELANOMA; RISK-FACTORS; EPIDEMIOLOGY; REGISTRY; SURVEILLANCE; SURVIVAL; NATION AB OBJECTIVES: Cancer continues to be the leading disease-related cause of death among children and adolescents in the United States. More current information is needed to describe recent cancer trends and identify demographic and geographic variations. METHODS: We analyzed data from the National Program of Cancer Registries and Surveillance, Epidemiology, and End Results statewide registries representing 94.2% of the US population to identify cancers diagnosed among persons aged 0 to 19 years during 2001-2009. Age-adjusted rates and annual percentage change for trends were calculated. Data were stratified by age, gender, race, ethnicity, and geography. RESULTS: We identified 120 137 childhood and adolescent cancer cases during 2001-2009 with an age-adjusted incidence rate of 171.01 per million. The overall rate of all cancers combined remained stable over time (annual percent change [APC], 0.3%; 95% confidence interval [CI], -0.1 to 0.7). There was an increase in the overall cancer trend among African American children and adolescents (APC, 1.3%; 95% CI, 0.2 to 2.5). An increasing trend for thyroid cancer was observed among both genders (APC, 4.9%; 95% CI, 3.2 to 6.6) and specifically among adolescents and those in the Northeast, South, and West regions of the United States. Renal carcinoma incidence was increasing significantly overall (APC, 5.4%; 95% CI, 2.8 to 8.1). Extracranial and extragonadal germ cell tumors and melanoma were both significantly decreasing. CONCLUSIONS: This study reports the novel finding that renal carcinoma rates are increasing among children and adolescents. This study confirms that thyroid cancer rates are increasing and further describes rising cancer rates among African Americans. C1 [Siegel, David A.] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA. [King, Jessica] Ctr Dis Control & Prevent, Canc Surveillance Branch, Atlanta, GA 30341 USA. [Tai, Eric] Ctr Dis Control & Prevent, Comprehens Canc Control Branch, Atlanta, GA 30341 USA. [Buchanan, Natasha; Li, Jun] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30341 USA. [Ajani, Umed A.] Ctr Dis Control & Prevent, OSELS, Atlanta, GA 30341 USA. RP Li, J (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy,MS K55, Atlanta, GA 30341 USA. EM ffa2@cdc.gov FU Intramural CDC HHS [CC999999] NR 49 TC 24 Z9 24 U1 1 U2 16 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD OCT PY 2014 VL 134 IS 4 BP E945 EP E955 DI 10.1542/peds.2013-3926 PG 11 WC Pediatrics SC Pediatrics GA AQ9CV UT WOS:000343140500003 PM 25201796 ER PT J AU Staples, JE Diallo, M Janusz, KB Manengu, C Lewis, RF Perea, W Yactayo, S Sall, AA AF Staples, J. Erin Diallo, Mawlouth Janusz, Kristen B. Manengu, Casimir Lewis, Rosamund F. Perea, William Yactayo, Sergio Sall, Amadou A. CA RCA Risk Assessment Team TI Yellow fever risk assessment in the Central African Republic SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE LA English DT Article DE Aedes mosquitos; Central African Republic; Enzyme-linked immunosorbent assay; Reverse transcriptase polymerase chain reaction; Yellow fever; Yellow fever virus ID SEROLOGICAL SURVEY; SOUTHEAST; ARBOVIRUSES; PREVALENCE; ANTIBODIES; NIGERIA; VIRUS; ASSAY AB Background: Starting in 2008, the Central African Republic (CAR) experienced an unprecedented number of reported yellow fever (YF) cases. A risk assessment of YF virus (YFV) activity was conducted to estimate potential disease risk and vaccine needs. Methods: A multistage cluster sampling design was used to sample humans, non-human primates, and mosquitoes in distinct ecologic zones. Humans and non-human primates were tested for YFV-specific antibodies; mosquitoes were tested for YFV RNA. Results: Overall, 13.3% (125/938) of humans were found to have naturally-acquired YFV antibodies. Antibody levels were higher in zones in the southern and south central regions of CAR. All sampled non-human primates (n = 56) were known YFV reservoirs; one tested positive for YFV antibodies. Several known YF vectors were identified including Aedes africanus, Ae. aegypti, Ae. luteocephalus, and Ae. simpsoni. Several more urban locations were found to have elevated Breateau and Container indices for Ae. aegypti. Conclusions: A country-wide assessment of YF risk found YFV to be endemic in CAR. The potential for future YF cases and outbreaks, however, varied by ecologic zone. Improved vaccination coverage through mass campaign and childhood immunization was recommended to mitigate the YF risk. C1 [Staples, J. Erin; Janusz, Kristen B.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO 80521 USA. [Diallo, Mawlouth; Sall, Amadou A.] Inst Pasteur, Dakar, Senegal. [Manengu, Casimir] WHO, Bangui 1416, Cent Afr Republ. [Lewis, Rosamund F.; Perea, William; Yactayo, Sergio] WHO, CH-1211 Geneva 27, Switzerland. RP Staples, JE (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO 80521 USA. EM estaples@cdc.gov FU World Health Organization FX This work was supported by the World Health Organization. NR 31 TC 1 Z9 1 U1 1 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0035-9203 EI 1878-3503 J9 T ROY SOC TROP MED H JI Trans. Roy. Soc. Trop. Med. Hyg. PD OCT PY 2014 VL 108 IS 10 BP 608 EP 615 DI 10.1093/trstmh/tru086 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AQ8FI UT WOS:000343059300004 PM 24947520 ER PT J AU Deshpande, BR Rao, SR Jentes, ES Hills, SL Fischer, M Gershman, MD Brunette, GW Ryan, ET LaRocque, RC AF Deshpande, Bhushan R. Rao, Sowmya R. Jentes, Emily S. Hills, Susan L. Fischer, Marc Gershman, Mark D. Brunette, Gary W. Ryan, Edward T. LaRocque, Regina C. CA Global TravEpiNet Consortium TI Use of Japanese Encephalitis Vaccine in US Travel Medicine Practices in Global TravEpiNet SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID YELLOW-FEVER; RISK; RECOMMENDATIONS; ASIA AB Few data regarding the use of Japanese encephalitis (JE) vaccine in clinical practice are available. We identified 711 travelers at higher risk and 7,578 travelers at lower risk for JE who were seen at US Global TravEpiNet sites from September of 2009 to August of 2012. Higher-risk travelers were younger than lower-risk travelers (median age = 29 years versus 40 years, P < 0.001). Over 70% of higher-risk travelers neither received JE vaccine during the clinic visit nor had been previously vaccinated. In the majority of these instances, clinicians determined that the JE vaccine was not indicated for the higher-risk traveler, which contradicts current recommendations of the Advisory Committee on Immunization Practices. Better understanding is needed of the clinical decision-making regarding JE vaccine in US travel medicine practices. C1 [Deshpande, Bhushan R.] Tufts Univ, Sch Arts & Sci, Medford, MA 02155 USA. [Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Jentes, Emily S.; Gershman, Mark D.; Brunette, Gary W.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Hills, Susan L.; Fischer, Marc] Ctr Dis Control & Prevent, Div Vector Borne Dis, Atlanta, GA USA. [Ryan, Edward T.; LaRocque, Regina C.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. RP LaRocque, RC (reprint author), Massachusetts Gen Hosp, Div Infect Dis, GRJ 504,55 Fruit St, Boston, MA 02114 USA. EM bhushan.deshpande@tufts.edu; srrao@partners.org; efj8@cdc.gov; shills@cdc.gov; mxf2@cdc.gov; dvj8@cdc.gov; fvd3@cdc.gov; etryan@partners.org; rclarocque@partners.org OI Vinetz, Joseph/0000-0001-8344-2004 FU US Centers for Disease Control and Prevention [U19CI000514, U01CK000175] FX This work was supported by US Centers for Disease Control and Prevention Grants U19CI000514 and U01CK000175. NR 12 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2014 VL 91 IS 4 BP 694 EP 698 DI 10.4269/ajtmh.14-0062 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AQ6XQ UT WOS:000342957600008 PM 25070999 ER PT J AU Charles, M Vilbrun, SC Koenig, SP Hashiguchi, LM Mabou, MM Ocheretina, O Pape, JW AF Charles, Macarthur Vilbrun, Stalz Charles Koenig, Serena P. Hashiguchi, Lauren M. Mabou, Marie Marcelle Ocheretina, Oksana Pape, Jean W. TI Treatment Outcomes for Patients with Multidrug-Resistant Tuberculosis in Post-Earthquake Port-au-Prince, Haiti SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID THERAPY; MANAGEMENT AB We report outcomes and 12-month survival for the first cohort of patients to undergo multidrug-resistant tuberculosis (MDR-TB) treatment after the earthquake in Haiti. From March 3, 2010 to March 28, 2013, 110 patients initiated treatment of laboratory-confirmed MDR-TB at the Groupe Haftien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO) Center in Port-au-Prince, Haiti. Twenty-seven patients (25%) were human immunodeficiency virus (HIV)-positive. As of October 31, 2013, 95 (86%) patients were either cured or alive on treatment, 4 (4%) patients defaulted, and 11 (10%) patients died. Culture conversion occurred by 30 days in 14 (13%) patients, 60 days in 49 (45%) patients, and 90 days in 81 (74%) patients. The probabilities of survival to 12 months were 96% (95% confidence interval [95% CI] = 89-99) and 85% (95% CI = 64-94) for HIV-negative and -positive patients, respectively. Despite adverse conditions, outcomes for patients with MDR-TB are highly encouraging. Major efforts are underway to scale up community directly observed therapy and expand care to other regions of Haiti. C1 [Charles, Macarthur] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Atlanta, GA 30333 USA. [Vilbrun, Stalz Charles; Hashiguchi, Lauren M.; Mabou, Marie Marcelle; Pape, Jean W.] Ctr GHESKIO, Port Au Prince, Haiti. [Koenig, Serena P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Ocheretina, Oksana] Weill Cornell Med Coll, Ctr Global Hlth, Div Infect Dis, New York, NY USA. RP Charles, M (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Atlanta, GA 30333 USA. EM makchuk@gmail.com; stalzsog@yahoo.com; skoenig@partners.org; lhashiguchi@gmail.com; mmabou@gheskio.org; ocheretina@yahoo.com; jwpape@gheskio.org FU Mentored Patient-Oriented Research Career Development Award [K23 AI073190]; Robert Wood Johnson's Amos Medical Faculty Development Award [63526]; International Training and Education Center for Health (I-TECH) [HA000047]; Centers for Disease Control and Prevention; Global Fund for AIDS, Tuberculosis, and Malaria; US President's Emergency Fund for AIDS Relief; Fogarty International Center; [R01AI104344] FX Support for the Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO) Multidrug-Resistant Tuberculosis Program was obtained from the Centers for Disease Control and Prevention, the Global Fund for AIDS, Tuberculosis, and Malaria, the US President's Emergency Fund for AIDS Relief, and the Fogarty International Center. M.C. received support from the Mentored Patient-Oriented Research Career Development Award (K23 AI073190) and from the Robert Wood Johnson's Amos Medical Faculty Development Award (63526). S.P.K. received support from Research Project Grant R01AI104344. O.O. received support from the International Training and Education Center for Health (I-TECH) Grant Number HA000047. NR 33 TC 6 Z9 6 U1 0 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2014 VL 91 IS 4 BP 715 EP 721 DI 10.4269/ajtmh.14-0161 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AQ6XQ UT WOS:000342957600012 PM 25071001 ER PT J AU Blum, LS Dentz, H Chingoli, F Chilima, B Warne, T Lee, C Hyde, T Gindler, J Sejvar, J Mintz, ED AF Blum, Lauren S. Dentz, Holly Chingoli, Felix Chilima, Benson Warne, Thomas Lee, Carla Hyde, Terri Gindler, Jacqueline Sejvar, James Mintz, Eric D. TI Formative Investigation of Acceptability of Typhoid Vaccine during a Typhoid Fever Outbreak in Neno District, Malawi SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID DYSENTERY; ZIMBABWE; WATER AB Typhoid fever affects an estimated 22 million people annually and causes 216,000 deaths worldwide. We conducted an investigation in August and September 2010 to examine the acceptability of typhoid vaccine in Neno District, Malawi where a typhoid outbreak was ongoing. We used qualitative methods, including freelisting exercises, key informant and in-depth interviews, and group discussions. Respondents associated illness with exposure to "bad wind," and transmission was believed to be airborne. Typhoid was considered extremely dangerous because of its rapid spread, the debilitating conditions it produced, the number of related fatalities, and the perception that it was highly contagious. Respondents were skeptical about the effectiveness of water, sanitation, and hygiene (WaSH) interventions. The perceived severity of typhoid and fear of exposure, uncertainty about the effectiveness of WaSH measures, and widespread belief in the efficacy of vaccines in preventing disease resulted in an overwhelming interest in receiving typhoid vaccine during an outbreak. C1 [Dentz, Holly] Emory Univ, Ctr Global Safe Water, Atlanta, GA 30322 USA. [Chingoli, Felix] Neno Dist Hlth Off, Neno, Malawi. [Chilima, Benson] Minist Hlth, Lilongwe, Malawi. [Warne, Thomas] Ctr Dis Control & Prevent, Pretoria, South Africa. [Lee, Carla; Hyde, Terri; Gindler, Jacqueline] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. [Sejvar, James; Mintz, Eric D.] Ctr Dis Control & Prevent, Natl Ctr Emerging Infect & Zoonot Dis, Atlanta, GA USA. RP Blum, LS (reprint author), 2130 Dakar Pl, Dulles, VA 20189 USA. EM laurensblum@yahoo.com; hollydentz@gmail.com; fchingoli@gmail.com; bchilima2@yahoo.com; warnet@sa.cdc.gov; cell@cdc.gov; tkh4@cdc.gov; jsg5@cdc.gov; zea3@cdc.gov; edm1@cdc.gov FU Division of Global Disease Detection and Emergency Response, CGH, CDC FX The investigation was funded by the Division of Global Disease Detection and Emergency Response, CGH, CDC. NR 36 TC 0 Z9 0 U1 1 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2014 VL 91 IS 4 BP 729 EP 737 DI 10.4269/ajtmh.14-0067 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AQ6XQ UT WOS:000342957600014 PM 25002303 ER PT J AU Doker, TJ Quinn, CL Salehi, ED Sherwood, JJ Benoit, TJ Elrod, MG Gee, JE Shadomy, SV Bower, WA Hoffmaster, AR Walke, HT Blaney, DD DiOrio, MS AF Doker, Thomas J. Quinn, Celia L. Salehi, Ellen D. Sherwood, Joshua J. Benoit, Tina J. Elrod, Mindy Glass Gee, Jay E. Shadomy, Sean V. Bower, William A. Hoffmaster, Alex R. Walke, Henry T. Blaney, David D. DiOrio, Mary S. CA Melioidosis Invest Team TI Case Report: Fatal Burkholderia pseudomallei Infection Initially Reported as a Bacillus Species, Ohio, 2013 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID TROPICAL NORTHERN AUSTRALIA; INDIRECT-HEMAGGLUTINATION; MELIOIDOSIS; EPIDEMIOLOGY; SOIL AB A fatal case of melioidosis was diagnosed in Ohio one month after culture results were initially reported as a Bacillus species. To identify a source of infection and assess risk in patient contacts, we abstracted patient charts; interviewed physicians and contacts; genetically characterized the isolate; performed a Burkholderia pseudomallei antibody indirect hemagglutination assay on household contacts and pets to assess seropositivity; and collected household plant, soil, liquid, and insect samples for culturing and real-time polymerase chain reaction testing. Family members and pets tested were seronegative for B. pseudomallei. Environmental samples were negative by real-time polymerase chain reaction and culture. Although the patient never traveled internationally, the isolate genotype was consistent with an isolate that originated in Southeast Asia. This investigation identified the fifth reported locally acquired non-laboratory melioidosis case in the contiguous United States. Physicians and laboratories should be aware of this potentially emerging disease and refer positive cultures to a Laboratory Response Network laboratory. C1 [Doker, Thomas J.; Quinn, Celia L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Salehi, Ellen D.; DiOrio, Mary S.] Ohio Dept Hlth, Columbus, OH 43266 USA. [Sherwood, Joshua J.] Pike Cty Gen Hlth Dist, Waverly, OH USA. [Benoit, Tina J.; Elrod, Mindy Glass; Gee, Jay E.; Shadomy, Sean V.; Bower, William A.; Hoffmaster, Alex R.; Walke, Henry T.; Blaney, David D.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Bacterial Special Pathogens Branch, Atlanta, GA 30333 USA. RP Doker, TJ (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM thomas.doker@gmail.com; fyq6@cdc.gov; ellen.salehi@odh.ohio.gov; jsherwood@pike-health.org; tbenoit@cdc.gov; welrod@cdc.gov; xzg4@cdc.gov; sshadomy@cdc.gov; wbower@cdc.gov; ahoffmaster@cdc.gov; hwalke@cdc.gov; dblaney@cdc.gov; mary.diorio@odh.ohio.gov FU Wellcome Trust FX This publication made use of the Multi-Locus Sequence Typing website (http://www.mlst.net) at Imperial College London. This website was developed by David Aanensen and funded by the Wellcome Trust. We would like to thank the members of the Melioidosis Investigation Team: Aaron Adams, Kristen Baker, Karen Baransi, Timothy R. Cassity, Janet Curtin, Mary Daniels, Sietske de Fijter, Ruth Montavon, Kathy Mullins, Amy Murphy, Eric St Germain, Marcia Waibel, and Nancy Zikri. NR 24 TC 7 Z9 7 U1 3 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2014 VL 91 IS 4 BP 743 EP 746 DI 10.4269/ajtmh.14-0172 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AQ6XQ UT WOS:000342957600016 PM 25092821 ER PT J AU Rodriguez, NMP Galloway, R Blau, DM Traxler, R Bhatnagar, J Zaki, SR Rivera, A Torres, JV Noyd, D Santiago-Albizu, XE Garcia, BR Tomashek, KM Bower, WA Sharp, TM AF Rodriguez, Nicole M. Perez Galloway, Renee Blau, Dianna M. Traxler, Rita Bhatnagar, Julu Zaki, Sherif R. Rivera, Aidsa Torres, Jose V. Noyd, David Santiago-Albizu, Xavier E. Garcia, Brenda Rivera Tomashek, Kay M. Bower, William A. Sharp, Tyler M. TI Case Report: Case Series of Fatal Leptospira spp./Dengue Virus Co-Infections-Puerto Rico, 2010-2012 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID DENGUE SHOCK SYNDROME; CONTROLLED-TRIAL; FEBRILE ILLNESS; EPIDEMIC; OUTBREAK; THERAPY; DISEASE AB Co-infection with pathogens that cause acute febrile illness creates a diagnostic challenge as a result of overlapping clinical manifestations. Here, we describe four fatal cases of Leptospira species/dengue virus co-infection in Puerto Rico. Although all patients sought care early, antibiotic administration was delayed for most. Steroids were administered to all patients, in most cases before antibiotics. These cases show the need for clinicians evaluating patients in or recently returned from the tropics with acute febrile illness to consider both dengue and leptospirosis. Furthermore, they illustrate the need for nucleic acid- or antigen-based rapid diagnostic tests to enable timely patient diagnosis and management. In particular, antibiotic therapy should be initiated early for patients with suspected leptospirosis, and steroids should not be administered to patients with suspected dengue. C1 [Rodriguez, Nicole M. Perez; Rivera, Aidsa; Noyd, David; Tomashek, Kay M.; Sharp, Tyler M.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Dengue Branch, San Juan, PR 00920 USA. [Galloway, Renee; Traxler, Rita; Bower, William A.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Bacterial Special Pathogens Branch, Atlanta, GA USA. [Blau, Dianna M.; Bhatnagar, Julu; Zaki, Sherif R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Infect Dis Pathol Branch, Atlanta, GA USA. [Santiago-Albizu, Xavier E.] San Lucas Episcopal Hosp, Ponce, PR USA. [Torres, Jose V.] Puerto Rico Inst Forens Sci, Medicolegal & Toxicol Investigat Div, Carparra Hts Stn, San Juan, PR 00920 USA. [Garcia, Brenda Rivera] Med Ctr Area, Puerto Rico Dept Hlth, Epidemiol & Res Off, San Juan, PR USA. RP Sharp, TM (reprint author), Ctr Dis Control & Prevent, Dengue Branch, 1324 Calle Canada, San Juan, PR 00920 USA. EM xhp4@cdc.gov; zu10@cdc.gov; bvv1@cdc.gov; gna9@cdc.gov; zrn1@cdc.gov; sxz1@cdc.gov; erj2@cdc.gov; JVTorres@icf.gobierno.pr; wyfl@cdc.gov; xsantiagoal@yahoo.com; brendarivera@salud.pr.gov; kct9@cdc.gov; wab4@cdc.gov; tsharp@cdc.gov NR 38 TC 4 Z9 4 U1 0 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2014 VL 91 IS 4 BP 760 EP 765 DI 10.4269/ajtmh.14-0220 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AQ6XQ UT WOS:000342957600019 ER PT J AU McQuiston, JH Wiedeman, C Singleton, J Carpenter, LR McElroy, K Mosites, E Chung, I Kato, C Morris, K Moncayo, AC Porter, S Dunn, J AF McQuiston, Jennifer H. Wiedeman, Caleb Singleton, Joseph Carpenter, L. Rand McElroy, Kristina Mosites, Emily Chung, Ida Kato, Cecilia Morris, Kevin Moncayo, Abelardo C. Porter, Susan Dunn, John TI Inadequacy of IgM Antibody Tests for Diagnosis of Rocky Mountain Spotted Fever SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID RICKETTSIA; CALIFORNIA; ASSAY AB Among 13 suspected Rocky Mountain spotted fever (RMSF) cases identified through an enhanced surveillance program in Tennessee, antibodies to Rickettsia rickettsii were detected in 10 (77%) patients using a standard indirect immunofluorescent antibody (IFA) assay. Immunoglobulin M (IgM) antibodies were observed for 6 of 13 patients (46%) without a corresponding development of IgG, and for 3 of 10 patients (30%) at least 1 year post-onset. However, recent infection with a spotted fever group rickettsiae could not be confirmed for any patient, based on a lack of rising antibody titers in properly timed acute and convalescent serologic specimens, and negative findings by polymerase chain reaction testing. Case definitions used in national surveillance programs lack specificity and may capture cases that do not represent current rickettsial infections. Use of IgM antibodies should be reconsidered as a basis for diagnosis and public health reporting of RMSF and other spotted fever group rickettsiae in the United States. C1 Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vectorborne Dis, Atlanta, GA USA. Tennessee Dept Hlth, Nashville, TN USA. RP McQuiston, JH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A30, Atlanta, GA 30333 USA. EM fzh7@cdc.gov NR 14 TC 5 Z9 5 U1 0 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2014 VL 91 IS 4 BP 767 EP 770 DI 10.4269/ajtmh.14-0123 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AQ6XQ UT WOS:000342957600021 PM 25092818 ER PT J AU Venkatesan, M Gadalla, NB Stepniewska, K Dahal, P Nsanzabana, C Moriera, C Price, RN Martensson, A Rosenthal, PJ Dorsey, G Sutherland, CJ Guerin, P Davis, TME Menard, D Adam, I Ademowo, G Arze, C Baliraine, FN Berens-Riha, N Bjorkman, A Borrmann, S Checchi, F Desai, M Dhorda, M Djimde, AA El-Sayed, BB Eshetu, T Eyase, F Falade, C Faucher, JF Froberg, G Grivoyannis, A Hamour, S Houze, S Johnson, J Kamugisha, E Kariuki, S Kiechel, JR Kironde, F Kofoed, PE LeBras, J Malmberg, M Mwai, L Ngasala, B Nosten, F Nsobya, SL Nzila, A Oguike, M Otienoburu, SD Ogutu, B Ouedraogo, JB Piola, P Rombo, L Schramm, B Some, AF Thwing, J Ursing, J Wong, RPM Zeynudin, A Zongo, I Plowe, CV Sibley, CH AF Venkatesan, Meera Gadalla, Nahla B. Stepniewska, Kasia Dahal, Prabin Nsanzabana, Christian Moriera, Clarissa Price, Ric N. Martensson, Andreas Rosenthal, Philip J. Dorsey, Grant Sutherland, Colin J. Guerin, Philippe Davis, Timothy M. E. Menard, Didier Adam, Ishag Ademowo, George Arze, Cesar Baliraine, Frederick N. Berens-Riha, Nicole Bjorkman, Anders Borrmann, Steffen Checchi, Francesco Desai, Meghna Dhorda, Mehul Djimde, Abdoulaye A. El-Sayed, Badria B. Eshetu, Teferi Eyase, Frederick Falade, Catherine Faucher, Jean-Francois Froberg, Gabrielle Grivoyannis, Anastasia Hamour, Sally Houze, Sandrine Johnson, Jacob Kamugisha, Erasmus Kariuki, Simon Kiechel, Jean-Rene Kironde, Fred Kofoed, Poul-Erik LeBras, Jacques Malmberg, Maja Mwai, Leah Ngasala, Billy Nosten, Francois Nsobya, Samuel L. Nzila, Alexis Oguike, Mary Otienoburu, Sabina Dahlstrom Ogutu, Bernhards Ouedraogo, Jean-Bosco Piola, Patrice Rombo, Lars Schramm, Birgit Some, A. Fabrice Thwing, Julie Ursing, Johan Wong, Rina P. M. Zeynudin, Ahmed Zongo, Issaka Plowe, Christopher V. Sibley, Carol Hopkins CA WWARN AL & ASAQ Mol Marker Study TI Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for P-falciparum Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PLUS SULFADOXINE-PYRIMETHAMINE; PFMDR1 COPY NUMBER; UNCOMPLICATED MALARIA; IN-VIVO; DRUG-RESISTANCE; PLASMODIUM-FALCIPARUM-PFMDR1 ALLELES; DIHYDROARTEMISININ-PIPERAQUINE; COMBINATION THERAPIES; TYROSINE-86 ALLELE; TANZANIAN CHILDREN AB Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) and P. falciparum multidrug resistance 1 (pfmdr1) genes are associated with decreased sensitivity to amodiaquine and lumefantrine, but effects of these polymorphisms on therapeutic responses to artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) have not been clearly defined. Individual patient data from 31 clinical trials were harmonized and pooled by using standardized methods from the WorldWide Antimalarial Resistance Network. Data for more than 7,000 patients were analyzed to assess relationships between parasite polymorphisms in pfcrt and pfmdr1 and clinically relevant outcomes after treatment with AL or ASAQ. Presence of the pfmdr1 gene N86 (adjusted hazards ratio = 4.74, 95% confidence interval = 2.29 - 9.78, P < 0.001) and increased pfmdr1 copy number (adjusted hazards ratio = 6.52, 95% confidence interval = 2.36-17.97, P < 0.001) were significant independent risk factors for recrudescence in patients treated with AL. AL and ASAQ exerted opposing selective effects on single-nucleotide polymorphisms in pfcrt and pfmdr1. Monitoring selection and responding to emerging signs of drug resistance are critical tools for preserving efficacy of artemisinin combination therapies; determination of the prevalence of at least pfcrt K76T and pfmdr1 N86Y should now be routine. C1 [Venkatesan, Meera; Plowe, Christopher V.] Univ Maryland, Sch Med, WorldWide Antimalarial Resistance Network Mol Mod, Baltimore, MD 21201 USA. [Venkatesan, Meera; Plowe, Christopher V.] Univ Maryland, Sch Med, Howard Hughes Med Inst, Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Gadalla, Nahla B.] NIAID, NIH, Bethesda, MD 20892 USA. [Gadalla, Nahla B.] Res Inst Trop Med, Dept Epidemiol, Khartoum, Sudan. [Stepniewska, Kasia; Dahal, Prabin; Nsanzabana, Christian; Moriera, Clarissa; Price, Ric N.; Guerin, Philippe; Piola, Patrice; Sibley, Carol Hopkins] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, World Wide Antimalarial Resistance Network, Oxford, England. [Price, Ric N.] Menzies Sch Hlth Res, Global Hlth Div, Darwin, NT, Australia. [Price, Ric N.] Charles Darwin Univ, Darwin, NT 0909, Australia. [Martensson, Andreas; Bjorkman, Anders; Froberg, Gabrielle; Malmberg, Maja; Rombo, Lars; Ursing, Johan] Dept Med Solna, Infect Dis Unit, Stockholm, Sweden. [Martensson, Andreas] Karolinska Inst, Global Hlth, Dept Publ Hlth Sci, Stockholm, Sweden. [Rosenthal, Philip J.; Dorsey, Grant] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Sutherland, Colin J.; Oguike, Mary] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London WC1, England. [Davis, Timothy M. E.; Wong, Rina P. M.] Univ Western Australia, Fremantle Hosp, Sch Med & Pharmacol, Nedlands, WA 6009, Australia. [Menard, Didier] Inst Pasteur Cambodge, Malaria Mol Epidemiol Unit, Phnom Penh, Cambodia. [Adam, Ishag] Univ Khartoum, Fac Med, Khartoum, Sudan. [Ademowo, George] Univ Ibadan, Coll Med, Inst Adv Med Res & Training, Ibadan, Nigeria. [Arze, Cesar] Univ Maryland, Sch Med, Module & Inst Genome Sci, WorldWide Antimalarial Resistance Network Mol, Baltimore, MD 21201 USA. [Baliraine, Frederick N.] LeTourneau Univ, Dept Biol, Longview, TX USA. [Berens-Riha, Nicole] Univ Munich, Dept Infect Dis & Trop Med, Munich, Germany. [Borrmann, Steffen; Mwai, Leah; Nzila, Alexis] Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, Kenya. [Borrmann, Steffen] Univ Magdeburg, Sch Med, Dept Microbiol, D-39106 Magdeburg, Germany. [Checchi, Francesco] Save Children, Paris, France. [Desai, Meghna; Thwing, Julie] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA. [Dhorda, Mehul] Univ Maryland, Sch Med, WorldWide Antimalarial Resistance Network Mol Mod, Baltimore, MD 21201 USA. [Dhorda, Mehul] Epictr Uganda Res Base, Mbarara, Uganda. [Djimde, Abdoulaye A.] Univ Sci Techn & Technol Bamako, Fac Pharm, Malaria Res & Training Ctr, Bamako, Mali. [El-Sayed, Badria B.] Res Inst Trop Med, Dept Epidemiol, Khartoum, Sudan. [Eshetu, Teferi; Zeynudin, Ahmed] Jimma Univ, Med Parasitol Unit, Dept Med, Lab Sci & Pathol, Jimma, Ethiopia. [Eyase, Frederick; Ogutu, Bernhards] US Army, Res Unit Kenya Walter Reed, Kenya Med Res Inst Project, Kisumu, Kenya. [Falade, Catherine] Univ Ibadan, Dept Pharmacol & Therapeut, Ibadan, Nigeria. [Faucher, Jean-Francois] Univ Med Ctr, Dept Infect Dis, Besancon, France. [Faucher, Jean-Francois] Inst Rech Dev, Paris, France. [Grivoyannis, Anastasia] Univ Washington, Dept Med, Div Emergency Med, Seattle, WA USA. [Hamour, Sally] UCL, Ctr Nephrol, Royal Free Hosp, London, England. [Houze, Sandrine; LeBras, Jacques] Hop Xavier Bichat, AP HP, Malaria Natl Reference Ctr, Parasitol Lab, Paris, France. [Houze, Sandrine; LeBras, Jacques] Mere & Enfant Face Infect Trop, Inst Rech Dev, Paris, France. [Houze, Sandrine; LeBras, Jacques] Univ Paris 05, Sorbonne Paris Cite, PRES, Fac Pharm, Paris, France. [Johnson, Jacob] US Army, Med Res Unit Kenya, Nairobi, Kenya. [Kamugisha, Erasmus] Catholic Univ Hlth & Allied Sci Bugando, Mwanza, Tanzania. [Kariuki, Simon] Ctrs Dis Control & Prevent, Kenya Med Res Inst, Malaria Branch, Kisumu, Kenya. [Kiechel, Jean-Rene] Drugs Neglected Dis Initiat, Geneva, Switzerland. [Kironde, Fred] Makerere Univ, Coll Hlth Sci, Kampala, Uganda. [Kironde, Fred] St Augustine Int Univ, Kampala, Uganda. [Kofoed, Poul-Erik] INDEPTH Network, Projecto Saude Bandim, Bissau, Guinea Bissau. [Kofoed, Poul-Erik] Kolding Cty Hosp, Dept Pediat, Kolding, Denmark. [Ngasala, Billy] Muhimbili Univ Hlth & Allied Sci, Dept Parasitol, Dar Es Salaam, Tanzania. [Nosten, Francois] Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Oxford, England. [Nosten, Francois] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Shoklo Malaria Res Unit, Bangkok, Thailand. [Nsobya, Samuel L.] Makerere Univ, Coll Hlth Sci, Sch Biomed Sci, Dept Pathol, Kampala, Uganda. [Otienoburu, Sabina Dahlstrom] Hop Bichat Claude Bernard, Inst Med & Epidemiol Appliquee, Worldwide Antimalarial Resistance Network, F-75877 Paris 18, France. [Ouedraogo, Jean-Bosco; Some, A. Fabrice; Zongo, Issaka] Ctr Muraz, Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso. [Schramm, Birgit] Epictr, Paris, France. [Sibley, Carol Hopkins] Univ Washington, Dept Genome Sci, Seattle, WA USA. RP Sibley, CH (reprint author), Univ Washington, Dept Genome Sci, Box 355065, Seattle, WA 98195 USA. EM carol.sibley@wwarn.org RI Malmberg, Maja/H-1890-2014; guo, hong/N-7392-2014; OI Dahal, Prabin/0000-0002-2158-846X; Malmberg, Maja/0000-0002-4506-0408; SOME, Anyirekun Fabrice/0000-0002-1530-1493; Borrmann, Steffen/0000-0001-9189-4393; Ursing, Johan/0000-0002-5508-9327; GADALLA, NAHLA/0000-0002-6177-6705; Nosten, Francois/0000-0002-7951-0745; Price, Richard/0000-0003-2000-2874; Guerin, Philippe/0000-0002-6008-2963 FU Bill and Melinda Gates Foundation FX The WorldWide Antimalarial Resistance Network is supported by the Bill and Melinda Gates Foundation.Disclaimer: The opinions and assertions contained herein are the personal opinions of authors and are not to be construed as reflecting the views of the U.S. Army Medical Research Unit-Kenya or the U.S. Department of Defense. NR 68 TC 37 Z9 37 U1 1 U2 16 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2014 VL 91 IS 4 BP 833 EP 843 DI 10.4269/ajtmh.14-0031 PG 11 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AQ6XQ UT WOS:000342957600033 PM 25048375 ER PT J AU Bruxvoort, K Festo, C Kalolella, A Cairns, M Lyaruu, P Kenani, M Kachur, SP Goodman, C Schellenberg, D AF Bruxvoort, Katia Festo, Charles Kalolella, Admirabilis Cairns, Matthew Lyaruu, Peter Kenani, Mitya Kachur, S. Patrick Goodman, Catherine Schellenberg, David TI Cluster Randomized Trial of Text Message Reminders to Retail Staff in Tanzanian Drug Shops Dispensing Artemether-Lumefantrine: Effect on Dispenser Knowledge and Patient Adherence SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SUB-SAHARAN AFRICA; COMBINATION THERAPY; MALARIA TREATMENT; HEALTH-WORKERS; ANTIMALARIAL TREATMENT; RURAL TANZANIA; HOME TREATMENT; KENYA; INTERVENTIONS; AVAILABILITY AB Artemisinin combination therapies are available in private outlets, but patient adherence might be compromised by poor advice from dispensers. In this cluster randomized trial in drug shops in Tanzania, 42 of 82 selected shops were randomized to receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL). Eligible patients purchasing AL at shops in both arms were followed up at home and questioned about each dose taken. Dispensers were interviewed regarding knowledge of AL dispensing practices and receipt of the malaria-related text messages. We interviewed 904 patients and 110 dispensers from 77 shops. Although there was some improvement in dispenser knowledge, there was no difference between arms in adherence measured as completion of all doses (intervention 68.3%, control 69.8%, p [adjusted] = 0.6), or as completion of each dose at the correct time (intervention 33.1%, control 32.6%, p [adjusted] = 0.9). Further studies on the potential of text messages to improve adherence are needed. C1 London Sch Hyg & Trop Med, Dept Global Hlth & Dev, Dept Infect Dis Epidemiol, London WC1, England. London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England. Ifakara Hlth Inst, Impact Evaluat Themat Grp, Dar Es Salaam, Tanzania. US Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. RP Bruxvoort, K (reprint author), 15-17 Tavistock Pl, London WC1H 9SH, England. EM katia.bruxvoort@lshtm.ac.uk FU ACT Consortium; Bill and Melinda Gates Foundation; U.S. Centers for Disease Control and Prevention; Ifakara Health Institute FX This research was funded by the ACT Consortium, through a grant from the Bill and Melinda Gates Foundation to the London School of Hygiene and Tropical Medicine. Additional support was provided by a cooperative agreement between the U.S. Centers for Disease Control and Prevention and Ifakara Health Institute. NR 46 TC 8 Z9 8 U1 1 U2 7 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2014 VL 91 IS 4 BP 844 EP 853 DI 10.4269/ajtmh.14-0126 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AQ6XQ UT WOS:000342957600034 PM 25002300 ER PT J AU Ruisenor-Escudero, H Wirtz, AL Berry, M Mfochive-Njindan, I Paikan, F Yousufi, HA Yadav, RS Burnham, G Vu, A AF Ruisenor-Escudero, Horacio Wirtz, Andrea L. Berry, Mark Mfochive-Njindan, Iliassou Paikan, Feda Yousufi, Hussain A. Yadav, Rajpal S. Burnham, Gilbert Vu, Alexander TI Risky behavior and correlates of HIV and Hepatitis C Virus infection among people who inject drugs in three cities in Afghanistan SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE HIV; HCV; HBV; HSV; PWID; Afghanistan ID HARM REDUCTION; COINFECTION; PREVENTION; PREVALENCE; COVERAGE; THERAPY; USERS AB Background: Injecting drug use is the primary mode of HIV transmission and acquisition in Afghanistan. People who inject drugs (PWID) in the country have been characterized by high risk injecting behavior and a high burden of HCV infection. We aimed to estimate the burden of HIV, HCV, and other infectious diseases and to identify the correlates of HIV and HCV infection among PWID living in three major Afghan cities in 2009. Methods: Epidemiologic data was collected among PWID for the integrated biological and behavioral surveillance (IBBS) survey between May and August, 2009 in three Afghan cities. Data were collected using a structured questionnaire and biologic specimens to screen for HIV, HBV, HCV, syphilis, and HSV-2 using rapid testing kits. Multiple logistic regression models were constructed to identify correlates of infection. Results: Among 548 participants, pooled HIV prevalence was 7.1% (Mazar-i-Sharif: 1.0%, Kabul: 3.1%, Herat: 18.4%) and HCV prevalence was 40.3%. Almost all participants with HIV infection were co-infected with HCV (94.9%). Pooled prevalence estimates for other diseases included 7.1% for HBV, 5.5% for syphilis; and 9.3% for HSV-2. Living in Herat, ever in prison and time injecting were independently associated with HIV infection. Living in Kabul, Herat and time injecting were independently associated with HCV infection. Conclusions: There is a high and heterogeneous burden of HIV and HCV among PWID in Afghan cities. Provision of comprehensive harm reduction services to PWID in Afghanistan is warranted to reduce exposures associated with HIV and HCV infection, especially in the city of Herat. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Ruisenor-Escudero, Horacio] Michigan State Univ, Dept Psychiat, E Lansing, MI 48824 USA. [Wirtz, Andrea L.; Vu, Alexander] Johns Hopkins Med Inst, Dept Emergency Med, Baltimore, MD 21205 USA. [Wirtz, Andrea L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Ctr Publ Hlth & Human Rights, Baltimore, MD 21205 USA. [Berry, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA. [Paikan, Feda; Yousufi, Hussain A.] Minist Publ Hlth, Natl AIDS Control Program, Kabul, Afghanistan. [Yadav, Rajpal S.] ChildFund, New Delhi 110048, India. [Ruisenor-Escudero, Horacio; Mfochive-Njindan, Iliassou; Burnham, Gilbert; Vu, Alexander] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. RP Ruisenor-Escudero, H (reprint author), Michigan State Univ, Dept Psychiat, 965 E Fee Hall Suite A227, E Lansing, MI 48824 USA. EM horaciore@gmail.com OI Ruisenor-Escudero, Horacio/0000-0002-0367-6976 FU World Bank through the Afghanistan HIV/AIDS Prevention Project (AHAPP) [P101502/H328] FX The World Bank (P101502/H328) provided the funding for the implementations of the Integrated Biological and Behavioral Survey through the Afghanistan HIV/AIDS Prevention Project (AHAPP). NR 39 TC 5 Z9 5 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD OCT 1 PY 2014 VL 143 BP 127 EP 133 DI 10.1016/j.drugalcdep.2014.07.022 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA AQ5TI UT WOS:000342871100017 PM 25131717 ER PT J AU Anderson, LA Prohaska, TR AF Anderson, Lynda A. Prohaska, Thomas R. TI Fostering Engagement and Independence: Opportunities and Challenges for an Aging Society SO HEALTH EDUCATION & BEHAVIOR LA English DT Editorial Material ID HEALTH-PROMOTION C1 [Anderson, Lynda A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Anderson, Lynda A.] Emory Univ, Atlanta, GA 30322 USA. [Prohaska, Thomas R.] George Mason Univ, Fairfax, VA 22030 USA. RP Anderson, LA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F-78, Atlanta, GA 30341 USA. EM laa0@cdc.gov FU Intramural CDC HHS [CC999999]; NCHM CDC HHS [U38 HM000454] NR 24 TC 4 Z9 4 U1 1 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD OCT PY 2014 VL 41 SU 1 BP 5S EP 9S DI 10.1177/1090198114547818 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ6MW UT WOS:000342928400001 PM 25274712 ER PT J AU Anderson, LA Slonim, A Yen, IH Jones, DL Allen, P Hunter, RH Goins, RT Leith, KH Rosenberg, D Satariano, WA McPhillips-Tangum, C AF Anderson, Lynda A. Slonim, Amy Yen, Irene H. Jones, Dina L. Allen, Peg Hunter, Rebecca H. Goins, R. Turner Leith, Katherine H. Rosenberg, Dori Satariano, William A. McPhillips-Tangum, Carol TI Developing a Framework and Priorities to Promote Mobility Among Older Adults SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE concept mapping; Delphi; environmental strategies; health education; mobility; older adults ID PUBLIC-HEALTH ACTION; PROGRAMS AB Mobility, broadly defined as movement in all of its forms from ambulation to transportation, is critical to supporting optimal aging. This article describes two projects to develop a framework and a set of priority actions designed to promote mobility among community-dwelling older adults. Project 1 involved a concept-mapping process to solicit and organize action items into domains from a broad group of stakeholders to create the framework. Concept mapping uses qualitative group processes with multivariate statistical analysis to represent the ideas visually through maps. A snowball technique was used to identify stakeholders (n = 211). A 12-member steering committee developed a focus prompt, One specific action that can lead to positive change in mobility for older adults in the United States is . . . Project 2 included a Delphi technique (n = 43) with three iterations to prioritize four to six items using results from the concept mapping rating process. Project 1 resulted in 102 items across nine domains (Research to Practice, Independence and Engagement, Built Environment and Safety, Transportation, Policy, Housing and Accessibility, Community Supports, Training, and Coordinated Action). The number of items ranged from 6 to 18 per domain. Project 2 resulted in agreement on four items that reflect the importance of promoting environmental strategies through collaborative initiatives aimed at planning and best practices focusing on environmental enhancements or transit, training of professionals, and integration of mobility into state and local public health plans. These findings can be applied to support coordinated, multidisciplinary research and practice to promote mobility among older adults. C1 [Anderson, Lynda A.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Slonim, Amy] AARP, Washington, DC USA. [Yen, Irene H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Jones, Dina L.] W Virginia Univ, Morgantown, WV 26506 USA. [Allen, Peg] Washington Univ, St Louis, MO USA. [Hunter, Rebecca H.] Univ N Carolina, Chapel Hill, NC USA. [Goins, R. Turner] Western Carolina Univ, Cullowhee, NC 28723 USA. [Leith, Katherine H.] Univ S Carolina, Columbia, SC 29208 USA. [Rosenberg, Dori] Grp Hlth Res Inst, Seattle, WA USA. [Satariano, William A.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [McPhillips-Tangum, Carol] Natl Assoc Chron Dis Directors, Atlanta, GA USA. RP Anderson, LA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F-15, Atlanta, GA 30341 USA. EM laa0@cdc.gov FU Centers for Disease Control and Prevention [U58DP002759-01] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This publication was supported by Grant/Cooperative Agreement Number U58DP002759-01 from the Centers for Disease Control and Prevention to the National Association of Chronic Disease Directors. NR 23 TC 3 Z9 3 U1 2 U2 16 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD OCT PY 2014 VL 41 SU 1 BP 10S EP 18S DI 10.1177/1090198114537492 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ6MW UT WOS:000342928400002 PM 25274706 ER PT J AU Sivapalasingam, S Rajasingham, A Macy, JT Friedman, CR Hoekstra, RM Ayers, T Gold, B Quick, RE AF Sivapalasingam, Sumathi Rajasingham, Anu Macy, Jonathan T. Friedman, Cindy R. Hoekstra, Robert M. Ayers, Tracy Gold, Benjamin Quick, Robert E. TI Recurrence of Helicobacter pylori Infection in Bolivian Children and Adults After a Population-Based "Screen and Treat" Strategy SO HELICOBACTER LA English DT Article DE Helicobacter pylori; seroprevalence; treatment; prevention; reinfection ID C-13-UREA BREATH TEST; GASTRIC-CANCER; SUCCESSFUL ERADICATION; RISK; GUIDELINES; DIAGNOSIS; THERAPY; ARTICLE; OCCURS; RATES AB BackgroundStrategies to prevent gastric cancer by decreasing Helicobacter pylori infections in high-prevalence, low-income countries could include a population-based screen and treat eradication program. MethodsWe tested residents of two rural villages for H.pylori infection using urea breath test (UBT), treated infected persons using directly observed therapy (DOT), retested for cure, and retested after 1year later for H.pylori infection. FindingsWe tested 1,065 (92%) of 1153 residents from two villages in rural Bolivia. Baseline H.pylori prevalence was 80% (95% confidence interval [CI]: 78-84). Age-specific cure rates were similar (92%) after DOT. Among those cured, 12% (95% CI: 8-15) had recurrent infection. Age-specific annual H.pylori recurrence rates for combined villages were 20% (95% CI: 10-29) in persons <5years, 20% (95% CI: 10-29) in 5-9years, 8% (95% CI: 1-15) in 10-14years, and 8% (95% CI: 4-12) in persons 15years. Compared with the referent population, those 15years, recurrent infections were significantly more likely in children <5years (odds ratios [OR] 2.7, 95% CI: 1.2-5.8) and 5-9years (OR 2.7, 95% CI: 1.4-5.1). InterpretationChildren <10years had high H.pylori recurrence rates following a population-based screen and treat program; this H.pylori eradication strategy may not be feasible in high-prevalence, low-income settings. C1 [Sivapalasingam, Sumathi; Rajasingham, Anu; Macy, Jonathan T.; Friedman, Cindy R.; Hoekstra, Robert M.; Ayers, Tracy; Quick, Robert E.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Gold, Benjamin] Childrens Ctr Digest Healthcare, Atlanta, GA USA. RP Sivapalasingam, S (reprint author), 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA. EM Sumathi.sivapalasingam@gmail.com OI Ayers, Tracy/0000-0003-4140-3263 FU U.S Centers for Disease Control and Prevention FX This study was funded by U.S Centers for Disease Control and Prevention. NR 24 TC 5 Z9 5 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1083-4389 EI 1523-5378 J9 HELICOBACTER JI Helicobacter PD OCT PY 2014 VL 19 IS 5 BP 343 EP 348 DI 10.1111/hel.12137 PG 6 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA AQ7JK UT WOS:000342989000003 PM 24830916 ER PT J AU Sriram, K Jefferson, AM Lin, GX Afshari, A Zeidler-Erdely, PC Meighan, TG McKinney, W Jackson, M Cumpston, A Cumpston, JL Leonard, HD Frazer, DG Antonini, JM AF Sriram, Krishnan Jefferson, Amy M. Lin, Gary X. Afshari, Aliakbar Zeidler-Erdely, Patti C. Meighan, Terence G. McKinney, Walter Jackson, Mark Cumpston, Amy Cumpston, Jared L. Leonard, Howard D. Frazer, David G. Antonini, James M. TI Neurotoxicity following acute inhalation of aerosols generated during resistance spot weld-bonding of carbon steel SO INHALATION TOXICOLOGY LA English DT Article DE Aerosols; manganese; neurotoxicity; occupational exposure; Parkinson's disease; volatile organic compounds; welding; welding fume ID BLOOD-BRAIN-BARRIER; CHRONIC TOLUENE ABUSE; NECROSIS-FACTOR-ALPHA; RAT OLFACTORY-BULB; PARKINSONS-DISEASE; MANGANESE EXPOSURE; DOPAMINERGIC NEUROTOXICITY; NEUROLOGICAL SYMPTOMS; TYROSINE-HYDROXYLASE; ORGANIC-SOLVENTS AB Welding generates complex metal aerosols, inhalation of which is linked to adverse health effects among welders. An important health concern of welding fume (WF) exposure is neurological dysfunction akin to Parkinson's disease (PD). Some applications in manufacturing industry employ a variant welding technology known as "weld-bonding" that utilizes resistance spot welding, in combination with adhesives, for metal-to-metal welding. The presence of adhesives raises additional concerns about worker exposure to potentially toxic components like Methyl Methacrylate, Bisphenol A and volatile organic compounds (VOCs). Here, we investigated the potential neurotoxicological effects of exposure to welding aerosols generated during weld-bonding. Male Sprague-Dawley rats were exposed (25 mg/m(3) targeted concentration; 4 h/day X 13 days) by whole-body inhalation to filtered air or aerosols generated by either weld-bonding with sparking (high metal, low VOCs; HM) or without sparking (low metal; high VOCs; LM). Fumes generated under these conditions exhibited complex aerosols that contained both metal oxide particulates and VOCs. LM aerosols contained a greater fraction of VOCs than HM, which comprised largely metal particulates of ultrafine morphology. Short-term exposure to LM aerosols caused distinct changes in the levels of the neurotransmitters, dopamine (DA) and serotonin (5-HT), in various brain areas examined. LM aerosols also specifically decreased the mRNA expression of the olfactory marker protein (Omp) and tyrosine hydroxylase (Th) in the olfactory bulb. Consistent with the decrease in Th, LM also reduced the expression of dopamine transporter (Slc6a3; Dat), as well as, dopamine D2 receptor (Drd2) in the olfactory bulb. In contrast, HM aerosols induced the expression of Th and dopamine D5 receptor (Drd5) mRNAs, elicited neuroinflammation and blood-brain barrier-related changes in the olfactory bulb, but did not alter the expression of Omp. Our findings divulge the differential effects of LM and HM aerosols in the brain and suggest that exposure to weld-bonding aerosols can potentially elicit neurotoxicity following a short-term exposure. However, further investigations are warranted to determine if the aerosols generated by weld-bonding can contribute to persistent long-term neurological deficits and/or neurodegeneration. C1 [Sriram, Krishnan; Jefferson, Amy M.; Lin, Gary X.; Afshari, Aliakbar; Zeidler-Erdely, Patti C.; Meighan, Terence G.; McKinney, Walter; Jackson, Mark; Cumpston, Amy; Cumpston, Jared L.; Leonard, Howard D.; Frazer, David G.; Antonini, James M.] NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA. RP Sriram, K (reprint author), NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd MS L-3014, Morgantown, WV 26505 USA. EM kos4@cdc.gov FU Intramural CDC HHS [CC999999] NR 76 TC 4 Z9 4 U1 1 U2 5 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0895-8378 EI 1091-7691 J9 INHAL TOXICOL JI Inhal. Toxicol. PD OCT PY 2014 VL 26 IS 12 BP 720 EP 732 DI 10.3109/08958378.2014.954654 PG 13 WC Toxicology SC Toxicology GA AQ7NR UT WOS:000343005100003 PM 25265048 ER PT J AU Otieno, FO Ndivo, R Oswago, S Ondiek, J Pals, S McLellan-Lemal, E Chen, RT Chege, W Gray, KM AF Otieno, Fredrick Odhiambo Ndivo, Richard Oswago, Simon Ondiek, Johnson Pals, Sherri McLellan-Lemal, Eleanor Chen, Robert T. Chege, Wairimu Gray, Kristen Mahle TI Evaluation of syndromic management of sexually transmitted infections within the Kisumu Incidence Cohort Study SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE Kenya; sexually transmitted infection; STIs; diagnosis; syndromic management; Kisumu ID RANDOMIZED CONTROLLED-TRIAL; IMPROVED TREATMENT SERVICES; PARTNER NOTIFICATION; RURAL TANZANIA; HIV-INFECTION; RISK-FACTORS; DISEASES; KENYA; TRANSMISSION; SYPHILIS AB While laboratory aetiological diagnosis is considered the gold standard for diagnosis and management of sexually transmitted infections (STIs), syndromic management has been presented as a simplified and affordable approach for STI management in limited resource settings. STI signs and symptoms were collected using staff-administered computer-assisted personal interview and audio computer-assisted self-interview. Participants underwent a medical examination and laboratory testing for common STIs. The performance of syndromic management was assessed on the agreement between interviewing methods as well as accurate diagnosis. We screened 846 participants, of whom 88 (10.4%) received syndromic STI diagnosis while 272 (32.2%) received an aetiological diagnosis. Agreement between syndromic and aetiological diagnoses was very poor (overall kappa=0.09). The most prevalent STI was herpes simplex virus type 2 and the percentage of persons with any STI was higher among women (48.6%) than men (15.6%, p<0.0001). Agreement between audio computer-assisted self-interview and computer-assisted personal interview interviewing methods for syndromic diagnosis of STIs ranged from poor to good. Our findings suggest that syndromic management of STIs is not a sufficient tool for STI diagnosis in this setting; development and improvement of STI diagnostic capabilities through laboratory confirmation is needed in resource-limited settings. C1 [Otieno, Fredrick Odhiambo; Ndivo, Richard; Oswago, Simon; Ondiek, Johnson] Kenya Med Res Inst KEMRI, CDC Program, Ctr Global Hlth Res, Kisumu, Kenya. [Pals, Sherri; McLellan-Lemal, Eleanor; Chen, Robert T.; Chege, Wairimu; Gray, Kristen Mahle] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Ctr Dis Control & Prevent, Off Infect Dis, Div HIV AIDS Prevent, Atlanta, GA USA. RP Otieno, FO (reprint author), KEMRI CDC Res & Publ Hlth Collaborat, Off Kisumu Busia Rd,POB 1578-40100, Kisumu, Kenya. EM FOtieno@kemricdc.org FU Centers for Disease Control and Prevention, Office of Infectious Diseases, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention, Atlanta, Georgia FX This research was funded by Centers for Disease Control and Prevention, Office of Infectious Diseases, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention, Atlanta, Georgia. NR 51 TC 3 Z9 3 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD OCT PY 2014 VL 25 IS 12 BP 851 EP 859 DI 10.1177/0956462414523260 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ5CO UT WOS:000342821500003 PM 24516075 ER PT J AU Dubey, JP Verma, SK Ferreira, LR Oliveira, S Cassinelli, AB Ying, Y Kwok, OCH Tuo, W Chiesa, OA Jones, JL AF Dubey, J. P. Verma, S. K. Ferreira, L. R. Oliveira, S. Cassinelli, A. B. Ying, Y. Kwok, O. C. H. Tuo, W. Chiesa, O. A. Jones, J. L. TI Detection and Survival of Toxoplasma gondii in Milk and Cheese from Experimentally Infected Goats SO JOURNAL OF FOOD PROTECTION LA English DT Article ID UNITED-STATES; CELL CULTIVATION; PREGNANT COWS; CAPTURE ELISA; CAT BIOASSAY; RAW CAPRINE; DAIRY GOATS; PCR METHODS; OOCYSTS; MICE AB The consumption of unpasteurized goat cheese and goat's milk has been suggested as a risk factor for toxoplasmosis in humans. In the present study, detection and survival of Toxoplasma gondii in milk and cheese was studied by bioassay in mice (milk) and in cats (cheese). Eight goats were inoculated orally with 300 to 10,000 oocysts of T. gondii strain TgGoatUS26. Milk samples were collected daily up to 30 days postinoculation and bioassayed in mice and cats. For mouse bioassay, 50 ml of milk samples were centrifuged, and the sediment was inoculated subcutaneously into mice. Mice were tested for T. gondii infection by seroconversion and by the demonstration of parasites. By mouse bioassay, T. gondii was detected in milk from all eight goats. The T. gondii excretion in milk was intermittent. For cat bioassay, 400 ml (100 ml or more from each goat) of milk from four goats from 6 to 27 days postinoculation were pooled daily, and cheese was made using rennin. Ten grams of cheese was fed daily to four cats, and cat feces were examined for oocyst shedding. One cat fed cheese shed oocysts 7 to 11 days after consuming cheese. Attempts were made to detect T. gondii DNA in milk of four goats; T. gondii was detected by PCR more consistently, but there was no correlation between detection of viable T. gondii by bioassay in mice and T. gondii DNA by PCR. Results indicate that T. gondii can be excreted in goat's milk and can survive in fresh cheese made by cold-enzyme treatment. To prevent transmission to humans or animals, milk should not be consumed raw. Raw fresh goat cheese made by cold-enzyme treatment of unpasteurized milk also should not be consumed. C1 [Dubey, J. P.; Verma, S. K.; Ferreira, L. R.; Oliveira, S.; Cassinelli, A. B.; Ying, Y.; Kwok, O. C. H.; Tuo, W.] ARS, USDA, Beltsville Agr Res Ctr, Anim Parasit Dis Lab, Beltsville, MD 20705 USA. [Chiesa, O. A.] US FDA, Div Appl Vet Res, Res Off, Ctr Vet Med, Laurel, MD 20708 USA. [Jones, J. L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Dubey, JP (reprint author), ARS, USDA, Beltsville Agr Res Ctr, Anim Parasit Dis Lab, Bldg 1001, Beltsville, MD 20705 USA. EM jitender.dubey@ars.usda.gov NR 44 TC 4 Z9 5 U1 0 U2 19 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD OCT PY 2014 VL 77 IS 10 BP 1747 EP 1753 DI 10.4315/0362-028X.JFP-14-167 PG 7 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA AQ6AB UT WOS:000342888600012 PM 25285492 ER PT J AU Fang, J Wheaton, AG Ayala, C AF Fang, Jing Wheaton, Anne G. Ayala, Carma TI Sleep duration and history of stroke among adults from the USA SO JOURNAL OF SLEEP RESEARCH LA English DT Article DE age; cerebrovascular disease; hours; NHIS; sex ID CORONARY-HEART-DISEASE; CARDIOVASCULAR EVENTS; ASSOCIATION; WOMEN; RISK; MORTALITY; COHORT; IMPACT AB Although short sleep duration is related to chronic conditions, such as hypertension, diabetes and obesity, the association with stroke is less well known. Using 2006-2011 National Health Interview Surveys, we assessed the association between self-reported duration of sleep and prevalence of stroke stratifying by age and sex. Of the 154 599 participants aged 18 years or older, 29.2%, 61.8% and 9.0% reported they sleep <= 6, 7-8 and >= 9 h per day, respectively. Corresponding age-standardized prevalence of stroke were 2.78%, 1.99% and 5.21% (P < 0.001). Logistic regression models showed a higher prevalence of stroke among those who slept <= 6 or >= 9 h a day compared with those who slept 7-8 h, after adjusting for sociodemographic, behavioural and health characteristics. Further stratifying by age and sex showed that the association of duration of sleep and stroke differed among different age or sex groups. Among young adults (18-44 years), a higher prevalence of stroke was found among women with short sleep. Higher prevalence of stroke was found among middle-aged men and women reporting short or long sleep duration. Among older adults (> 65 years), higher prevalence of stroke was found only among those who slept >= 9 h. In this national sample of adults, the association between duration of sleep and stroke varied by sex and age. Although there was an association of short sleep duration with stroke, we also observed the association of long sleep duration with stroke, especially among those aged 65 years or older. C1 [Fang, Jing; Ayala, Carma] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Wheaton, Anne G.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30341 USA. RP Fang, J (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS K-47, Atlanta, GA 30341 USA. EM jfang@cdc.gov FU Intramural CDC HHS [CC999999] NR 32 TC 6 Z9 6 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1105 EI 1365-2869 J9 J SLEEP RES JI J. Sleep Res. PD OCT PY 2014 VL 23 IS 5 BP 531 EP 537 DI 10.1111/jsr.12160 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AQ7PV UT WOS:000343012400007 PM 24815229 ER PT J AU Gissy, JJ Johnson, T Fox, DJ Kumar, A Ciafaloni, E Kim, S Yang, M van Essen, AJ Finkel, RS AF Gissy, J. J. Johnson, T. Fox, D. J. Kumar, A. Ciafaloni, E. Kim, S. Yang, M. van Essen, A. J. Finkel, R. S. TI The age of ambulation in boys with Duchenne muscular dystrophy and its use as an end-point in clinical trials SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 19th International Congress of the World-Muscle-Society CY OCT 07-11, 2014 CL Berlin, GERMANY SP World Muscle Soc C1 [Gissy, J. J.; Johnson, T.] Univ Cent Florida Coll Med, Orlando, FL USA. [Fox, D. J.; Kumar, A.] New York State Dept Hlth, Albany, NY 12237 USA. [Ciafaloni, E.] Univ Rochester, Sch Med, Rochester, NY 14627 USA. [Kim, S.] Ctr Dis Control, Atlanta, GA 30333 USA. [Yang, M.] Childrens Hosp Colorado, Aurora, CO USA. [van Essen, A. J.] Univ Groningen, Groningen, Netherlands. [Finkel, R. S.] Nemours Childrens Hosp, Orlando, FL 32827 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2014 VL 24 IS 9-10 MA T.P.2 BP 860 EP 861 DI 10.1016/j.nmd.2014.06.225 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AQ5SZ UT WOS:000342870200222 ER PT J AU Tepper, NK Boulet, SL Whiteman, MK Monsour, M Marchbanks, PA Hooper, WC Curtis, KM AF Tepper, Naomi K. Boulet, Sheree L. Whiteman, Maura K. Monsour, Michael Marchbanks, Polly A. Hooper, W. Craig Curtis, Kathryn M. TI Postpartum Venous Thromboembolism: Incidence and Risk Factors Reply SO OBSTETRICS AND GYNECOLOGY LA English DT Letter ID UNITED-STATES C1 [Tepper, Naomi K.; Boulet, Sheree L.; Whiteman, Maura K.; Monsour, Michael; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. [Hooper, W. Craig] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA USA. RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 EI 1873-233X J9 OBSTET GYNECOL JI Obstet. Gynecol. PD OCT PY 2014 VL 124 IS 4 BP 838 EP 839 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AQ4GZ UT WOS:000342753000031 PM 25244449 ER PT J AU Richardson, AS Dietz, WH Gordon-Larsen, P AF Richardson, A. S. Dietz, W. H. Gordon-Larsen, P. TI The association between childhood sexual and physical abuse with incident adult severe obesity across 13 years of the National Longitudinal Study of Adolescent Health SO PEDIATRIC OBESITY LA English DT Article DE Childhood maltreatment; severe obesity; United States; young adult ID BODY-MASS INDEX; FOR-DISEASE-CONTROL; 30-YEAR FOLLOW-UP; YOUNG-ADULTS; UNITED-STATES; US ADULTS; SOCIOECONOMIC-STATUS; RISK BEHAVIORS; GROWTH CHARTS; PREVALENCE AB What is already known about this subject Severe obesity prevalence in adults has close to doubled from the 1990s to 2010 and is expected to double again by 2030. Over 3million reports of child maltreatment were received by child protective services in 2008. While clinic and population-based studies have found high rates of adult psychological distress among severely obese individuals, little is known about how the experience of abuse during childhood relates to the risk of severe obesity later in life. What this study addsUsing data from a nationally representative, longitudinal study, we found that incidence rates and 13-year risk of developing severe obesity in adulthood varied by abuse type. We found significantly higher risk of incident severe obesity in non-minority females and males who experienced the combined occurrence of sexual and physical abuse during childhood, relative to individuals with no history of abuse. In addition to other social and emotional risks, exposure to sexual and physical abuse during childhood may increase risk of severe obesity later in life. BackgroundSevere obesity has increased, yet childhood antecedents of adult severe obesity are not well understood. ObjectiveEstimate adult-onset severe obesity risk in individuals with history of childhood physical and/or sexual abuse compared with those who did not report abuse. MethodsLongitudinal analysis of participants from the US National Longitudinal Study of Adolescent Health (n=10774) wave II (1996; aged 12-22 years) followed through wave IV (2008-2009; aged 24-34 years). New cases of adult-onset severe obesity (body mass index [BMI]40kg/m(2) using measured height and weight) in individuals followed over 13 years who were not severely obese during adolescence (BMI <120% of 95th percentile Centers for Disease Control and Prevention National Center for Health Statistics growth curves). ResultsThe combined occurrence of self-reported sexual and physical abuse during childhood was associated with an increased risk of incident severe obesity in adulthood in non-minority females (hazard ratio [HR; 95% Confidence Interval]=2.5; 1.3, 4.8) and males (HR=3.6; 1.5, 8.5) compared with individuals with no history of abuse. ConclusionIn addition to other social and emotional risks, exposure to sexual and physical abuse during childhood may increase risk of severe obesity later in life. Consideration of the confluence of childhood abuse might be considered as part of preventive and therapeutic approaches to address severe obesity. C1 [Richardson, A. S.; Gordon-Larsen, P.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC 27516 USA. [Richardson, A. S.; Gordon-Larsen, P.] Univ N Carolina, Sch Med, Chapel Hill, NC 27516 USA. [Richardson, A. S.; Gordon-Larsen, P.] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC USA. [Dietz, W. H.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. RP Gordon-Larsen, P (reprint author), Univ N Carolina, Carolina Populat Ctr, 123 West Franklin St CB 8120, Chapel Hill, NC 27516 USA. EM pglarsen@unc.edu FU National Institutes of Health [R01HD057194]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [P01-HD31921]; Carolina Population Center [R24 HD050924] FX This work was funded by the National Institutes of Health grant R01HD057194. We thank Ms. Frances Dancy, BS, UNC Carolina Population Center for her helpful administrative assistance. This research uses data from Add Health, a program project directed by Kathleen Mullan Harris and designed by J. Richard Udry, Peter S. Bearman and Kathleen Mullan Harris at the University of North Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, with cooperative funding from 23 other federal agencies and foundations. Special acknowledgement is due to Ronald R. Rindfuss and Barbara Entwisle for assistance in the original design. Information on how to obtain the Add Health data files is available on the Add Health website (http://www.cpc.unc.edu/projects/addhealth). We also are grateful to the Carolina Population Center (R24 HD050924) for general support. NR 80 TC 14 Z9 14 U1 1 U2 23 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-6310 EI 2047-6302 J9 PEDIATR OBES JI Pediatr. Obes. PD OCT PY 2014 VL 9 IS 5 BP 351 EP 361 DI 10.1111/j.2047-6310.2013.00196.x PG 11 WC Pediatrics SC Pediatrics GA AQ7KA UT WOS:000342991900013 PM 24115589 ER PT J AU Reefhuis, J in 't Woud, SG van Rooij, I van Gelder, M Olney, R Carmichael, S Roeleveld, N AF Reefhuis, Jennita in 't Woud, Sander Groen van Rooij, Iris van Gelder, Marleen Olney, Richard Carmichael, Suzan Roeleveld, Nel TI Medications and Other Risk Factors for 2nd and 3rd Degree Hypospadias in the National Birth Defects Prevention Study, 1997-2009 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Reefhuis, Jennita; in 't Woud, Sander Groen; Olney, Richard] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [in 't Woud, Sander Groen; van Rooij, Iris; van Gelder, Marleen; Roeleveld, Nel] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands. [Carmichael, Suzan] Stanford Univ, Berkeley, CA USA. RI Roeleveld, Nel/B-4242-2008 OI Roeleveld, Nel/0000-0002-3390-4466 NR 0 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2014 VL 23 SU 1 SI SI MA 41 BP 23 EP 23 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AQ4JZ UT WOS:000342763600042 ER PT J AU Ailes, E Gilboa, S Gill, S Broussard, C Crider, K Berry, RJ Carter, T Hobbs, C Reefhuis, J AF Ailes, Elizabeth Gilboa, Suzanne Gill, Simerpal Broussard, Cheryl Crider, Krista Berry, R. J. Carter, Tonia Hobbs, Charlotte Reefhuis, Jennita TI Association between Antibiotic Use and Birth Defects Among Women Who Had Urinary Tract Infections in the First Trimester of Pregnancy SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Ailes, Elizabeth; Gilboa, Suzanne; Broussard, Cheryl; Crider, Krista; Berry, R. J.; Reefhuis, Jennita] Ctr Dis Control & Prevent, NCBDDD, Atlanta, GA USA. [Gill, Simerpal] Duchesnay Inc, Blainville, PQ, Canada. [Carter, Tonia] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. [Hobbs, Charlotte] Univ Arkansas, Coll Med, Med Ctr, Little Rock, AR 72205 USA. NR 0 TC 0 Z9 0 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2014 VL 23 SU 1 SI SI MA 574 BP 303 EP 303 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AQ4JZ UT WOS:000342763600570 ER PT J AU Broussard, CS Frey, MT Hernandez-Diaz, S Greene, MF Chambers, CD Sahin, L Sharp, BAC Honein, MA AF Broussard, Cheryl S. Frey, Meghan T. Hernandez-Diaz, Sonia Greene, Michael F. Chambers, Christina D. Sahin, Leyla Sharp, Beth A. Collins Honein, Margaret A. TI Developing a Systematic Approach to Safer Medication Use during Pregnancy: Summary of a Centers for Disease Control and Prevention-Convened Meeting SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Broussard, Cheryl S.; Frey, Meghan T.; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Frey, Meghan T.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Greene, Michael F.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Greene, Michael F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Chambers, Christina D.] Univ Calif San Francisco, Dept Pediat, La Jolla, CA USA. [Chambers, Christina D.] Univ Calif San Francisco, Dept Family & Prevent Med, La Jolla, CA USA. [Sahin, Leyla] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Sharp, Beth A. Collins] Agcy Healthcare Res & Qual, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2014 VL 23 SU 1 SI SI MA 594 BP 315 EP 315 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AQ4JZ UT WOS:000342763600590 ER PT J AU Tseng, HF Tartof, S Lewin, B Hales, C Sy, L Harpaz, R Bialek, S Reddy, K Huang, PY Zhang, J Anand, S Bauer, EM Chang, J Jacobsen, S AF Tseng, Hung Fu Tartof, Sara Lewin, Bruno Hales, Craig Sy, Lina Harpaz, Rafael Bialek, Stephanie Reddy, Kavya Huang, Po-ying Zhang, Jeff Anand, Sean Bauer, Erin Mary Chang, Jennifer Jacobsen, Steven TI Effectiveness of Herpes Zoster Vaccination for Prevention of Post-Herpetic Neuralgia among Individuals with Herpes Zoster SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Tseng, Hung Fu; Tartof, Sara; Sy, Lina; Anand, Sean; Jacobsen, Steven] Kaiser Permanente, Res & Evaluat, Pasadena, CA USA. [Hales, Craig; Harpaz, Rafael; Bialek, Stephanie] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Lewin, Bruno; Reddy, Kavya; Huang, Po-ying; Zhang, Jeff; Bauer, Erin Mary; Chang, Jennifer] Kaiser Permanente, Los Angeles Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2014 VL 23 SU 1 SI SI MA 663 BP 354 EP 355 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AQ4JZ UT WOS:000342763600658 ER PT J AU Farr, SL Hutchings, YL Ondersma, SJ Creanga, AA AF Farr, Sherry L. Hutchings, Yalonda L. Ondersma, Steven J. Creanga, Andreea A. TI Brief interventions for illicit drug use among peripartum women SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE brief interventions; illicit drugs; postpartum; pregnant ID COMPUTER-DELIVERED INTERVENTIONS; SUBSTANCE-ABUSE; RANDOMIZED-TRIAL; PRETREATMENT CHANGE; URBAN CHILDREN; TOBACCO USE; METAANALYSIS; DEPENDENCE; ALCOHOL; RISK AB We review the evidence and identify limitations of the current literature on the effectiveness of brief interventions (<= 5 intervention sessions) on illicit drug use, treatment enrollment/retention, and pregnancy outcomes among pregnant and postpartum women; and consider this evidence in the context of the broader brief intervention literature. Among 4 published studies identified via systematic review and meeting a priori quality criteria, we found limited, yet promising evidence of the benefit of brief interventions to reduce illicit drug use among postpartum women. Two of the 4 randomized controlled trials tested similar computer-delivered single-session interventions; both demonstrate effects on postpartum drug use. Neither of the 2 randomized controlled trials that assessed treatment use found differences between intervention and control groups. Studies examining brief interventions for smoking and alcohol use among pregnant women, and for illicit drug use in the general adult population, have shown small but statistically significant results of the effectiveness of such interventions. Larger studies, those that examine the effect of assessment alone on illicit drug use, and those that use technology-delivered brief interventions are needed to assess the effectiveness of brief interventions for drug use in the peripartum period. C1 [Farr, Sherry L.; Hutchings, Yalonda L.; Creanga, Andreea A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. [Ondersma, Steven J.] Wayne State Univ, Dept Med, Detroit, MI 48202 USA. RP Farr, SL (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. NR 35 TC 1 Z9 1 U1 1 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2014 VL 211 IS 4 BP 336 EP 343 DI 10.1016/j.ajog.2014.04.005 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AQ1VR UT WOS:000342572200005 PM 24721261 ER PT J AU Marsh, CA Cragan, JD Alverson, CJ Correa, A AF Marsh, Courtney A. Cragan, Janet D. Alverson, C. J. Correa, Adolfo TI Casecontrol analysis of maternal prenatal analgesic use and cardiovascular malformations: Baltimore-Washington Infant Study SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE analgesics; birth defects; cardiovascular malformations; congenital heart defects; pregnancy ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; VENTRICULAR SEPTAL-DEFECTS; OVER-THE-COUNTER; DEVELOPMENTAL TOXICITY; PREGNANCY; RISK; HEART; RATS; ACETAMINOPHEN; PRESCRIPTION AB OBJECTIVE: We sought to assess maternal prenatal use of analgesics and risk of cardiovascular malformations (CVM) in the offspring. STUDY DESIGN: Data from the Baltimore-Washington Infant Study, a population-based case-control investigation of CVM, were used to examine selected isolated CVM diagnoses and maternal analgesic use during the periconceptional period (3 months before and after conception). We compared case and control infants on frequency of maternal use of analgesics and estimated adjusted odds ratios (adjORs) and 95% confidence intervals (CI) with logistic regression models for specific CVM phenotypes. RESULTS: Frequency of periconceptional use of any analgesic was 52% among control mothers and 53% among case mothers. Analyses by CVM diagnoses identified an association of tetralogy of Fallot with maternal acetaminophen use (adjOR, 1.6; 95% CI, 1.1-2.3) and dextrotransposition of the great arteries with intact ventricular septum with maternal nonsteroidal antiinflammatory drug use (adjOR, 3.2; 95% CI, 1.2-8.7). CONCLUSION: Analgesic use during the periconceptional period was not associated with CVM in the aggregate or with most phenotypes of CVM examined. Associations with 2 phenotypes of CVM may have occurred by chance. These findings warrant corroboration and further study, including further evaluation of the observed associations, the dose of analgesic taken, more specific timing of analgesic use, and indications for use. C1 [Marsh, Courtney A.] Univ Kansas, Sch Med, Dept Obstet & Gynecol, Kansas City, KS USA. [Cragan, Janet D.; Alverson, C. J.] Emory Univ, NCBDDD, Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. [Correa, Adolfo] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. RP Marsh, CA (reprint author), Univ Kansas, Med Ctr, Dept Obstet & Gynecol, 3901 Rainbow Blvd,Fifth Floor DELP, Kansas City, KS 66160 USA. EM cmarsh2@kumc.edu FU National Heart, Lung, and Blood Institute [R-37 HL25629]; Centers for Disease Control and Prevention Experience Applied Epidemiology Fellowship, Pfizer Inc. FX The Baltimore-Washington Infant Study was funded through National Heart, Lung, and Blood Institute R-37 HL25629. This project was funded through the Centers for Disease Control and Prevention Experience Applied Epidemiology Fellowship, Pfizer Inc. NR 30 TC 1 Z9 1 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2014 VL 211 IS 4 AR 404.e1 DI 10.1016/j.ajog.2014.03.054 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AQ1VR UT WOS:000342572200029 PM 24681289 ER PT J AU Saraiya, M Benard, VB Greek, AA Steinau, M Patel, S Massad, LS Sawaya, GF Unger, ER AF Saraiya, Mona p Benard, Vicki B. Greek, April A. Steinau, Martin Patel, Sonya Massad, L. Stewart Sawaya, George F. Unger, Elizabeth R. TI Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE cotesting; genotying; HPV testing; Pap test; underserved populations ID QUALIFIED HEALTH CENTERS; AMERICAN-CANCER-SOCIETY; CERVICAL-CANCER; CONSENSUS GUIDELINES; HUMAN-PAPILLOMAVIRUS; SCREENING-TESTS; CYTOLOGY; BELIEFS AB OBJECTIVE: The primary cervical cancer screening strategy for women over age 30 is high-risk human papillomavirus (HPV) testing combined with Papanicolaou (Pap) testing (cotesting) every 5 years. This combination strategy is a preventive service that is required by the Affordable Care Act to be covered with no cost-sharing by most health insurance plans. The cotesting recommendation was made based entirely on prospective data from an insured population that may have a lower proportion of women with HPV positive and Pap negative results (ie, discordant results). The discordant group represents a very difficult group to manage. If the frequency of discordant results among underserved women is higher, health care providers may perceive the cotesting strategy to be a less favorable screening strategy than traditional Pap testing every 3 years. STUDY DESIGN: The Centers for Disease Control and Prevention's Cervical Cancer Study was conducted at 15 clinics in 6 federally qualified health centers across Illinois. Providers at these clinics were given the option of cotesting for routine cervical cancer screening. Type-specific HPV detection was performed on residual extracts using linear array. RESULTS: Pap test results were abnormal in 6.0% and HPV was positive in 7.2% of the underserved women screened in this study (mean age, 45.1 years). HPV prevalence decreased with age, from 10.3% among 30- to 39-year-olds to 4.5% among 50- to 60-year-olds. About 5% of the women had a combination of a positive HPV test and normal Pap test results; HPV 16/18 was identified in 14% of discordant women. CONCLUSION: The rate of discordant results among underserved women was similar to those reported throughout the US in a variety of populations. Typing for HPV 16/18 appears to assist in the management in a small proportion of women with discordant results. C1 [Saraiya, Mona p; Benard, Vicki B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA USA. [Steinau, Martin; Patel, Sonya; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Greek, April A.] Battelle Hlth & Analyt, Seattle, WA USA. [Massad, L. Stewart] Washington Univ, St Louis Sch Med, Dept Obstet & Gynecol, St Louis, MO USA. [Sawaya, George F.] Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. RP Saraiya, M (reprint author), 4770 Buford Hwy, Atlanta, GA 30341 USA. EM msaraiya@cdc.gov FU United States Government [0006, 200-2002-00573] FX This manuscript was written in the course of employment by the United States Government with support from services provided by a contract with Battelle (200-2002-00573, Task Order no. 0006) and is not subject to copyright in the United States. Qiagen and Roche Molecular Diagnostics provided in-kind support for testing reagents through the CDC Foundation. Diane Manninen, PhD was the project manager from Battelle. NR 21 TC 0 Z9 0 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2014 VL 211 IS 4 AR 354.e1 DI 10.1016/j.ajog.2014.05.001 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AQ1VR UT WOS:000342572200008 PM 24813971 ER PT J AU Nowalk, MP Lin, CCJ Hannibal, K Reis, EC Gallik, G Moehling, KK Huang, HH Allred, NJ Wolfson, DH Zimmerman, RK AF Nowalk, Mary Patricia Lin, Chyongchiou Jeng Hannibal, Kristin Reis, Evelyn C. Gallik, Gregory Moehling, Krissy K. Huang, Hsin-Hui Allred, Norma J. Wolfson, David H. Zimmerman, Richard K. TI Increasing Childhood Influenza Vaccination A Cluster Randomized Trial SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID YOUNG-CHILDREN; HEALTH CENTERS; IMMUNIZATION; INTERVENTIONS; COMMUNITY; TOOLKIT; RATES; URBAN; CARE AB Background: Since the 2008 inception of universal childhood influenza vaccination, national rates have risen more dramatically among younger children than older children and reported rates across racial/ethnic groups are inconsistent. Interventions may be needed to address age and racial disparities to achieve the recommended childhood influenza vaccination target of 70%. Purpose: To evaluate an intervention to increase childhood influenza vaccination across age and racial groups. Methods: In 2011-2012, a total of 20 primary care practices treating children were randomly assigned to the intervention and control arms of a cluster randomized controlled trial to increase childhood influenza vaccination uptake using a toolkit and other strategies including early delivery of donated vaccine, in-service staff meetings, and publicity. Results: The average vaccination differences from pre-intervention to the intervention year were significantly larger in the intervention arm (n=10 practices) than the control arm (n=10 practices); for children aged 9-18 years (11.1 pct pts intervention vs 4.3 pct pts control, p<0.05); for non-white children (16.7 pct pts intervention vs 4.6 pct pts control, p<0.001); and overall (9.9 pct pts intervention vs 4.2 pct pts control, p<0.01). In multi-level modeling that accounted for person- and practice-level variables and the interactions among age, race, and intervention, the likelihood of vaccination increased with younger age group (6-23 months); white race; commercial insurance; the practice's pre-intervention vaccination rate; and being in the intervention arm. Estimates of the interaction terms indicated that the intervention increased the likelihood of vaccination for nonwhite children in all age groups and white children aged 9-18 years. Conclusions: A multi-strategy intervention that includes a practice improvement toolkit can significantly improve influenza vaccination uptake across age and racial groups without targeting specific groups, especially in practices with large percentages of minority children. (C) 2014 American Journal of Preventive Medicine. All rights reserved. C1 [Nowalk, Mary Patricia; Lin, Chyongchiou Jeng; Moehling, Krissy K.; Huang, Hsin-Hui; Zimmerman, Richard K.] Dept Family Med, Pittsburgh, PA 15213 USA. [Hannibal, Kristin; Reis, Evelyn C.] Dept Pediat, Pittsburgh, PA USA. [Gallik, Gregory] Univ Pittsburgh, Sch Med, Shadyside Family Hlth Ctr, Pittsburgh, PA USA. [Wolfson, David H.] Childrens Community Pediat, Pittsburgh, PA USA. [Allred, Norma J.] CDC, Atlanta, GA 30333 USA. RP Nowalk, MP (reprint author), Dept Family Med, 3518 5th Ave, Pittsburgh, PA 15213 USA. EM tnowalk@pitt.edu OI Zimmerman, Richard/0000-0001-5941-6092 FU CDC [U01 IP000321]; NIH [UL1 RR024153, UL1TR000005]; Merck and Co., Inc.; Pfizer, Inc.; MedImmune, LLC; Sanofi Pasteur FX This investigation was supported by a grant (No. U01 IP000321) from CDC. The views expressed herein are those of those authors and not those of the funding agency. The project was also supported by the NIH through Grants UL1 RR024153 and UL1TR000005.; Dr. Nowalk has received research funding from Merck and Co., Inc., Pfizer, Inc., and MedImmune, LLC, and consults for MedImmune, LLC. Dr. Lin has received research funding from Merck and Co., Inc., Pfizer, Inc., and Sanofi Pasteur and consults for MedImmune, LLC. Dr. Huang has received research funding from Merck and Co., Inc., and Sanofi Pasteur. Dr. Zimmerman has received research funding from Merck and Co., Inc., Pfizer, Inc., Sanofi Pasteur and MedImmune, LLC, and consulted for MedImmune, LLC. Drs. Hannibal, Reis, Gallik, Allred, and Wolfson have no financial relationships relevant to this article to disclose. Ms. Moehling has no financial relationships relevant to this article to disclose. NR 16 TC 3 Z9 3 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2014 VL 47 IS 4 BP 435 EP 443 DI 10.1016/j.amepre.2014.07.003 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AP9GJ UT WOS:000342386700010 PM 25113138 ER PT J AU Syamlal, G Mazurek, JM Dube, SR AF Syamlal, Girija Mazurek, Jacek M. Dube, Shanta R. TI Gender Differences in Smoking Among US Working Adults SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; CURRENT CIGARETTE-SMOKING; UNITED-STATES; OCCUPATIONAL EXPOSURES; LUNG-CANCER; WORKPLACE POLICIES; PROSPECTIVE COHORT; RISK-FACTOR; WORKERS; HEALTH AB Background: Cigarette smoking remains a leading cause of morbidity and mortality. Although gender differences in cigarette smoking in the U.S. population have been documented, information on these differences among working adults is limited. Purpose: To describe the current smoking prevalence by gender among working U.S. adults and examine gender differences in smoking by occupation. Methods: The 2004-2011 National Health Interview Survey data for adults aged >= 18 years that were working in the week prior to the interview (N=132,215) were analyzed in 2013. Current cigarette smokers were those who smoked at least 100 cigarettes in their lifetime and currently smoke every day or some days. Results: During 2004-2011, an estimated 22.8% of men workers and 18.3% of women workers were current smokers. Of the current smokers, women workers had higher odds of being an everyday smoker (prevalence OR [POR]=1.17, 95% CI=1.09, 1.26); having poor self-rated emotional health (POR=1.28, 95% CI=1.15, 1.41); and having chronic obstructive pulmonary disease (POR=2.45, 95% CI=2.14, 2.80), heart disease (POR=1.27, 95% CI=1.12, 1.45), and current asthma (POR=2.21, 95% CI=1.96, 2.49) compared with men workers. Women in "supervisors, construction, and extraction" (38.9%) occupations and men in "extraction" (40.5%) occupations had the highest smoking prevalence. Conclusion: Among working adults, women had lower prevalence of smoking than men, yet women who smoke were more likely than men to have adverse health outcomes, including self-rated poorer physical and emotional health. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Syamlal, Girija; Mazurek, Jacek M.] NIOSH, Div Resp Dis Studies, CDC, Morgantown, WV 26505 USA. [Dube, Shanta R.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Dube, Shanta R.] Georgia State Univ, Sch Publ Hlth, Div Epidemiol & Biostat, Atlanta, GA 30303 USA. RP Syamlal, G (reprint author), 1095 Willowdale Rd,Mail Stop HG 900-2, Morgantown, WV 26505 USA. EM gsyamlal@cdc.gov FU Intramural CDC HHS [CC999999] NR 35 TC 9 Z9 9 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2014 VL 47 IS 4 BP 467 EP 475 DI 10.1016/j.amepre.2014.06.013 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AP9GJ UT WOS:000342386700014 PM 25049215 ER PT J AU Lindsey, NP Lehman, JA Staples, JE Fischer, M AF Lindsey, Nicole P. Lehman, Jennifer A. Staples, J. Erin Fischer, Marc TI West Nile Virus and Other Arboviral Diseases-United States, 2013 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material ID ENCEPHALITIS; USA AB This report identifies the major causes of neuroinvasive arboviral disease in the United States, an important piece of information when considering meningoencephalitis for both donors and recipients. C1 [Lindsey, Nicole P.; Lehman, Jennifer A.; Staples, J. Erin; Fischer, Marc] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Lindsey, NP (reprint author), CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM nplindsey@cdc.gov NR 9 TC 0 Z9 0 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD OCT PY 2014 VL 14 IS 10 BP 2422 EP 2426 DI 10.1111/ajt.12997 PG 5 WC Surgery; Transplantation SC Surgery; Transplantation GA AQ3BI UT WOS:000342663300031 ER PT J AU Grotegut, CA Kuklina, EV Anstrom, KJ Heine, RP Callaghan, WM Myers, ER James, AH AF Grotegut, C. A. Kuklina, E. V. Anstrom, K. J. Heine, R. P. Callaghan, W. M. Myers, E. R. James, A. H. TI Factors associated with the change in prevalence of cardiomyopathy at delivery in the period 2000-2009: a population-based prevalence study SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY LA English DT Article DE Cardiomyopathy; hypertension; mortality; nationwide inpatient sample; pregnancy ID PREGNANCY-RELATED MORTALITY; SEVERE OBSTETRIC MORBIDITY; PERIPARTUM HEART-FAILURE; UNITED-STATES; HOSPITALIZATIONS; DISORDERS; DIAGNOSES; ACCURACY; RISK AB ObjectiveCardiomyopathy (CM) at delivery is increasing in prevalance. The objective of this study was to determine which medical conditions are attributable to this increasing prevalance. DesignPopulation prevalence study from 2000 to 2009. SettingThe Nationwide Inpatient Sample (NIS). SamplePregnant women admitted for delivery were identified in the NIS for the years 2000-2009. MethodsTemporal trends in pre-existing medical conditions and in medical and obstetric complications at delivery admissions were determined by linear regression. The change in the prevalence of CM among all pregnant women was compared with the change in the prevalance of CM among pregnant women without pre-existing conditions or complications. Main outcome measurePrevalence of CM. ResultsThe prevalence of CM increased from 0.25 per 1000 deliveries in 2000 to 0.43 per 1000 deliveries in 2009 (P<0.0001). Women with chronic hypertension had increased odds of developing CM compared with women without chronic hypertension (odds ratio, OR, 13.2; 95% confidence interval, 95%CI, 12.5-13.7). The linear increase in chronic hypertension over the 10-year period was the single identified pre-existing medical condition that explained the increasing prevalence of CM at delivery (P=0.005 for the differences in slopes for linear trends). ConclusionsPregnant women with chronic hypertenion are at an increased risk for CM at delivery, and the increasing prevalence of chronic hypertension is an important factor associated with the increasing prevalence of CM at the time of delivery. Among women without chronic hypertension, the prevalence of CM at delivery did not change during the time period. C1 [Grotegut, C. A.; Heine, R. P.] Duke Univ, Dept Obstet & Gynecol, Div Maternal Fetal Med, Durham, NC 27710 USA. [Kuklina, E. V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Anstrom, K. J.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27710 USA. [Callaghan, W. M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Myers, E. R.] Duke Univ, Dept Obstet & Gynecol, Div Clin & Epidemiol Res, Durham, NC 27710 USA. [James, A. H.] Univ Virginia, Dept Obstet & Gynecol, Div Maternal Fetal Med, Charlottesville, VA USA. RP Grotegut, CA (reprint author), Duke Univ, Dept Obstet & Gynecol, Div Maternal Fetal Med, Durham, NC 27710 USA. EM chad.grotegut@duke.edu FU Division of Maternal-Fetal Medicine, Duke University; Eunice Kennedy Shriver National Institute of Child Health & Human Development [K12-HD-043446] FX This project was funded in part by the Division of Maternal-Fetal Medicine, Duke University and by the Eunice Kennedy Shriver National Institute of Child Health & Human Development, under award number K12-HD-043446, to C. A. G. as a Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Scholar. The findings and conclusions in this report are those of the authors, and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 32 TC 5 Z9 5 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1470-0328 EI 1471-0528 J9 BJOG-INT J OBSTET GY JI BJOG PD OCT PY 2014 VL 121 IS 11 BP 1386 EP 1394 DI 10.1111/1471-0528.12726 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AQ3CU UT WOS:000342667300009 PM 24661593 ER PT J AU Halpern, MT Romaire, MA Haber, SG Tangka, FK Sabatino, SA Howard, DH AF Halpern, Michael T. Romaire, Melissa A. Haber, Susan G. Tangka, Florence K. Sabatino, Susan A. Howard, David H. TI Impact of State-Specific Medicaid Reimbursement and Eligibility Policies on Receipt of Cancer Screening SO CANCER LA English DT Article DE Medicaid; access to health care; cancer screening; health insurance reimbursement; health care disparities; colonoscopy; mammography; Papanicolaou test ID HEALTH-INSURANCE; PHYSICIAN PARTICIPATION; FINANCIAL INCENTIVES; UNITED-STATES; CARE; ACCESS; DIAGNOSIS; STAGE; BENEFICIARIES; ASSOCIATION AB BACKGROUND: Although state Medicaid programs cover cancer screening, Medicaid beneficiaries are less likely to be screened for cancer and are more likely to present with tumors of an advanced stage than are those with other insurance. The current study was performed to determine whether state Medicaid eligibility and reimbursement policies affect the receipt of breast, cervical, and colon cancer screening among Medicaid beneficiaries. METHODS: Cross-sectional regression analyses of 2007 Medicaid data from 46 states and the District of Columbia were performed to examine associations between state-specific Medicaid reimbursement/eligibility policies and receipt of cancer screening. The study sample included individuals aged 21 years to 64 years who were enrolled in fee-for-service Medicaid for at least 4 months. Subsamples eligible for each screening test were: Papanicolaou test among 2,136,511 patients, mammography among 792,470 patients, colonoscopy among 769,729 patients, and fecal occult blood test among 753,868 patients. State-specific Medicaid variables included median screening test reimbursement, income/financial asset eligibility requirements, physician copayments, and frequency of eligibility renewal. RESULTS: Increases in screening test reimbursement demonstrated mixed associations (positive and negative) with the likelihood of receiving screening tests among Medicaid beneficiaries. In contrast, increased reimbursements for office visits were found to be positively associated with the odds of receiving all screening tests examined, including colonoscopy (odds ratio [OR], 1.07; 95% confidence interval [95% CI], 1.06-1.08), fecal occult blood test (OR, 1.09; 95% CI, 1.08-1.10), Papanicolaou test (OR, 1.02; 95% CI, 1.02-1.03), and mammography (OR, 1.02; 95% CI, 1.02-1.03). Effects of other state-specific Medicaid policies varied across the screening tests examined. CONCLUSIONS: Increased reimbursement for office visits was consistently associated with an increased likelihood of being screened for cancer, and may be an important policy tool for increasing screening among this vulnerable population. (C) 2014 American Cancer Society. C1 [Halpern, Michael T.] RTI Int, Washington, DC 20005 USA. [Romaire, Melissa A.] RTI Int, Res Triangle Pk, NC USA. [Haber, Susan G.] RTI Int, Waltham, MA USA. [Tangka, Florence K.; Sabatino, Susan A.] US Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Howard, David H.] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. RP Halpern, MT (reprint author), RTI Int, Div Hlth Serv & Social Policy Res, 701 13th St NW,750, Washington, DC 20005 USA. EM mhalpern@rti.org FU Centers for Disease Control and Prevention [200-2008-27958, 15] FX Funded by the Centers for Disease Control and Prevention contract 200-2008-27958 task order 15. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 51 TC 7 Z9 8 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD OCT 1 PY 2014 VL 120 IS 19 BP 3016 EP 3024 DI 10.1002/cncr.28704 PG 9 WC Oncology SC Oncology GA AQ2PP UT WOS:000342630000014 PM 25154930 ER PT J AU Karaceper, MD Brownell, M Casey, R Chakraborty, P Coyle, D Dodds, L Feigenbaum, A Fell, D Grosse, S Guttmann, A Laberge, AM Mhanni, A Miller, F Nakhla, M Rockman-Greenberg, C Sparkes, R Vallance, H Wilson, B Wilson, K Potter, BK AF Karaceper, Maria D. Brownell, Marni Casey, Robin Chakraborty, Pranesh Coyle, Doug Dodds, Linda Feigenbaum, Annette Fell, Deshayne Grosse, Scott Guttmann, Astrid Laberge, Anne-Marie Mhanni, Aziz Miller, Fiona Nakhla, Meranda Rockman-Greenberg, Cheryl Sparkes, Rebecca Vallance, Hilary Wilson, Brenda Wilson, Kumanan Potter, Beth K. TI The epidemiology and health service impact of medium-chain acyl-CoA dehydrogenase deficiency among affected children and those with false positive newborn screening results in Ontario SO CLINICAL BIOCHEMISTRY LA English DT Meeting Abstract C1 [Karaceper, Maria D.; Coyle, Doug; Wilson, Brenda; Potter, Beth K.] Univ Ottawa, Ottawa, ON, Canada. [Brownell, Marni] Manitoba Ctr Hlth Policy, Winnipeg, MB, Canada. [Casey, Robin; Sparkes, Rebecca] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada. [Chakraborty, Pranesh] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada. [Dodds, Linda] Dalhousie Univ, Halifax, NS, Canada. [Feigenbaum, Annette] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Fell, Deshayne] BORN Ontario, Ottawa, ON, Canada. [Grosse, Scott] Ctr Dis Control & Prevent, Atlanta, GA USA. [Guttmann, Astrid] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Laberge, Anne-Marie] Hop St Justine, Montreal, PQ H3T 1C5, Canada. [Mhanni, Aziz; Rockman-Greenberg, Cheryl] Univ Manitoba, Winnipeg, MB, Canada. [Miller, Fiona] Univ Toronto, Toronto, ON, Canada. [Nakhla, Meranda] Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada. [Vallance, Hilary] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Wilson, Kumanan] Inst Clin Evaluat Sci, Ottawa, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0009-9120 EI 1873-2933 J9 CLIN BIOCHEM JI Clin. Biochem. PD OCT PY 2014 VL 47 IS 15 BP 132 EP + DI 10.1016/j.clinbiochem.2014.07.025 PG 2 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AQ5CS UT WOS:000342822100027 ER PT J AU Degeberg, RA Ojodu, J Greene, CR Cordovado, SN Cuthbert, CD AF Degeberg, Ruhiyyih A. Ojodu, Jelili Greene, Christopher R. Cordovado, Suzanne N. Cuthbert, Carla D. TI Describing the utility of the newborn screening Molecular Assessment Program (MAP) in US Public Health Laboratories SO CLINICAL BIOCHEMISTRY LA English DT Meeting Abstract C1 [Degeberg, Ruhiyyih A.; Ojodu, Jelili] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Greene, Christopher R.; Cordovado, Suzanne N.; Cuthbert, Carla D.] Ctr Dis Control & Prevent, Newborn Screening Mol Biol Branch, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0009-9120 EI 1873-2933 J9 CLIN BIOCHEM JI Clin. Biochem. PD OCT PY 2014 VL 47 IS 15 BP 136 EP 136 DI 10.1016/j.clinbiochem.2014.07.035 PG 1 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AQ5CS UT WOS:000342822100037 ER PT J AU Greene, CN Cuthbert, CD Cordovado, SK AF Greene, Christopher N. Cuthbert, Carla D. Cordovado, Suzanne K. TI Newborn Screening Molecular Assessment Program for quality improvement SO CLINICAL BIOCHEMISTRY LA English DT Meeting Abstract C1 [Greene, Christopher N.; Cuthbert, Carla D.; Cordovado, Suzanne K.] Ctr Dis Control & Prevent, Newborn Screening Mol Biol Branch, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0009-9120 EI 1873-2933 J9 CLIN BIOCHEM JI Clin. Biochem. PD OCT PY 2014 VL 47 IS 15 BP 136 EP 136 DI 10.1016/j.clinbiochem.2014.07.036 PG 1 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AQ5CS UT WOS:000342822100038 ER PT J AU Bonilla, DL Cole-Porse, C Kjemtrup, A Osikowicz, L Kosoy, M AF Bonilla, Denise L. Cole-Porse, Charsey Kjemtrup, Anne Osikowicz, Lynn Kosoy, Michael TI Risk Factors for Human Lice and Bartonellosis among the Homeless, San Francisco, California, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ARTHROPOD-BORNE DISEASES; BODY LICE; HEAD LICE; QUINTANA; PEOPLE AB Homeless persons in San Francisco, California, USA, have been shown to have head and body lice infestations and Bartonella quintana infections. We surveyed a self-selected population of homeless persons in San Francisco to assess infestations of head and body lice, risks of having body lice, and presence of B. quintana in lice. A total of 203 persons who reported itching were surveyed during 2008-2010 and 2012: 60 (30%) had body lice, 10 (4.9%) had head lice, and 6 (3.0%) had both. B. quintana was detected in 10 (15.9%) of 63 body lice pools and in 6 (37.5%) of 16 head lice pools. Variables significantly associated (p <= 0.05) with having body lice in this homeless population included male sex, African-American ethnicity, and sleeping outdoors. Our study findings suggest that specific segments of the homeless population would benefit from information on preventing body lice infestations and louseborne diseases. C1 [Bonilla, Denise L.] Calif Dept Publ Hlth, Richmond, CA 94804 USA. [Cole-Porse, Charsey; Kjemtrup, Anne] Calif Dept Publ Hlth, Sacramento, CA USA. [Osikowicz, Lynn; Kosoy, Michael] Ctr Dis Control & Prevent, Ft Collins, CO USA. RP Bonilla, DL (reprint author), Calif Dept Publ Hlth, Vector Borne Dis Sect, 850 Marina Bay Pkwy, Richmond, CA 94804 USA. EM dbonilla@cdph.ca.gov OI Kjemtrup, Anne/0000-0002-5788-7621 NR 23 TC 3 Z9 3 U1 2 U2 9 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2014 VL 20 IS 10 BP 1645 EP 1651 DI 10.3201/eid2010.131655 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ1ER UT WOS:000342525200005 PM 25280380 ER PT J AU Gray, MD Lampel, KA Strockbine, NA Fernandez, RE Melton-Celsa, AR Maurelli, AT AF Gray, Miranda D. Lampel, Keith A. Strockbine, Nancy A. Fernandez, Reinaldo E. Melton-Celsa, Angela R. Maurelli, Anthony T. TI Clinical Isolates of Shiga Toxin 1a-Producing Shigella flexneri with an Epidemiological Link to Recent Travel to Hispaniola SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ESCHERICHIA-COLI STRAINS; III SECRETION SYSTEM; BACTERIOPHAGE; PATHOGENS; VIRULENCE; RELEASE; PHAGES AB Shiga toxins (Stx) are cytotoxins involved in severe human intestinal disease. These toxins are commonly found in Shigella dysenteriae serotype 1 and Shiga-toxin producing Escherichia colt; however, the toxin genes have been found in other Shigella species. We identified 26 Shigella flexneri serotype 2 strains isolated by public health laboratories in the United States during 2001-2013, which encode the Shiga toxin 1a gene (stx(1a)). These strains produced and released Stx1 a as measured by cytotoxicity and neutralization assays using anti-Stx/Stx1a antiserum. The release of Stx1a into culture supernatants increased approximate to 100-fold after treatment with mitomycin C, suggesting that stx(1a) is carried by a bacteriophage. Infectious phage were found in culture supernatants and increased approximate to 1,000-fold with mitonnycin C. Whole-genome sequencing of several isolates and PCR analyses of. all strains confirmed that stx(1a) was carried by a lambdoid bacteriophage. Furthermore, all patients who reported foreign travel had recently been to Hispaniola, suggesting that emergence of these novel strains is associated with that region. C1 [Gray, Miranda D.; Fernandez, Reinaldo E.; Melton-Celsa, Angela R.; Maurelli, Anthony T.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Lampel, Keith A.] US FDA, College Pk, MD USA. [Strockbine, Nancy A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Maurelli, AT (reprint author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, F Edward Hebert Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM anthony.maurelli@usuhs.edu FU National Institute of Allergy and Infectious Diseases [R01AI24656, AI020148] FX This work was supported by grants R01AI24656 and AI020148 from the National Institute of Allergy and Infectious Diseases. NR 16 TC 11 Z9 11 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2014 VL 20 IS 10 BP 1669 EP 1677 DI 10.3201/eid2010.140292 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ1ER UT WOS:000342525200008 PM 25271406 ER PT J AU McElroy, AK Erickson, BR Flietstra, TD Rollin, PE Nichol, ST Towner, JS Spiropoulou, CF AF McElroy, Anita K. Erickson, Bobbie R. Flietstra, Timothy D. Rollin, Pierre E. Nichol, Stuart T. Towner, Jonathan S. Spiropoulou, Christina F. TI Biomarker Correlates of Survival in Pediatric Patients with Ebola Virus Disease SO EMERGING INFECTIOUS DISEASES LA English DT Article ID HEMORRHAGIC-FEVER; CEREBRAL MALARIA; INFECTION; RANTES; CHILDREN; AGE; UGANDA; INFLAMMATION; PROTECTION; RESPONSES AB Outbreaks of Ebola virus disease (EVD) occur spo-radically in Africa and are associated with high case-fatality rates. Historically, children have been less affected than adults. The 2000-2001 Sudan virus associated EVD outbreak in the Gulu district of Uganda resulted in 55 pediatric and 161 adult laboratory-confirmed cases. We used a series of multiplex assays to measure the concentrations of 55 serum analytes in specimens from patients from that outbreak to identify biomarkers specific to pediatric disease. Pediatric patients who survived had higher levels of the chemokine regulated on activation, normal T-cell expressed and secreted marker and lower levels of plasminogen activator inhibitor 1, soluble intracellular adhesion molecule, and soluble vascular cell adhesion molecule than did pediatric patients who died. Adult patients had similar levels of these analytes regardless of outcome. Our findings suggest that children with EVD may benefit from different treatment regimens than those for adults. C1 [McElroy, Anita K.] Emory Univ, Atlanta, GA 30322 USA. [McElroy, Anita K.; Erickson, Bobbie R.; Flietstra, Timothy D.; Rollin, Pierre E.; Nichol, Stuart T.; Towner, Jonathan S.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP McElroy, AK (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G14, Atlanta, GA 30333 USA. EM gsz5@cdc.gov FU PIDS/St. Jude Fellowship Award; Atlanta Pediatric Scholars Award (National Institutes of Health) [K12 HD072245]; National Institutes of Health FX A.K.M is supported by the PIDS/St. Jude Fellowship Award and the Atlanta Pediatric Scholars Award (National Institutes of Health K12 HD072245). This work was performed while she held a National Institutes of Health Loan Repayment Award. NR 40 TC 27 Z9 27 U1 0 U2 39 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2014 VL 20 IS 10 BP 1683 EP 1690 DI 10.3201/eid2010.140430 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ1ER UT WOS:000342525200010 PM 25279581 ER PT J AU Griffing, SM Villegas, L Udhayakumar, V AF Griffing, Sean M. Villegas, Leopoldo Udhayakumar, Venkatachalam TI Malaria Control and Elimination,Venezuela, 1800s-1970s SO EMERGING INFECTIOUS DISEASES LA English DT Review ID VENEZUELA; ERADICATION; AMERICA AB Venezuela had the highest number of human malaria cases in Latin American before 1936. During 1891-1920, malaria was endemic to >600,000 km(2) of this country; malaria death rates led to major population decreases during 1891-1920. No pathogen, including the influenza virus that caused the 1918 pandemic, caused more deaths than malaria during 1905-1945. Early reports of malaria eradication in Venezuela helped spark the world's interest in global eradication. We describe early approaches to malaria epidemiology in Venezuela and how this country developed an efficient control program and an approach to eradication. Arnoldo Gabaldon was a key policy maker during this development process. He directed malaria control in Venezuela from the late 1930s to the end of the 1970s and contributed to malaria program planning of the World Health Organization. We discuss how his efforts helped reduce the incidence of malaria in Venezuela and how his approach diverged from World Health Organization guidelines. C1 [Griffing, Sean M.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Villegas, Leopoldo] ICF Int, Calverton, MD USA. [Villegas, Leopoldo] Ctr Invest Campo Dr Francesco Vitanza, Bolivar, Venezuela. RP Griffing, SM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D67, Atlanta, GA 30333 USA. EM sean.griffing@gmail.com FU National Science Foundation Graduate Research Fellowship FX S.M.G. was supported by a National Science Foundation Graduate Research Fellowship. NR 35 TC 2 Z9 2 U1 2 U2 13 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2014 VL 20 IS 10 BP 1697 EP 1704 DI 10.3201/eid2010.130917 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ1ER UT WOS:000342525200012 PM 25396258 ER PT J AU Marks, M Chi, KH Vahi, V Pillay, A Sokana, O Pavluck, A Mabey, DC Chen, CY Solomon, AW AF Marks, Michael Chi, Kai-Hua Vahi, Ventis Pillay, Allan Sokana, Oliver Pavluck, Alex Mabey, David C. Chen, Cheng Y. Solomon, Anthony W. TI Haemophilus ducreyi Associated with Skin Ulcers among Children, Solomon Islands SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFECTION; YAWS AB During a survey of yaws prevalence in the Solomon Islands, we collected samples from skin ulcers of 41 children. Using PCR, we identified Haemophilus ducreyi infection in 13 (32%) children. PCR-positive and PCR-negative ulcers were phenotypically indistinguishable. Emergence of H. ducreyi as a cause of nongenital ulcers may affect the World Health Organization's yaws eradication program. C1 [Marks, Michael; Mabey, David C.; Solomon, Anthony W.] London Sch Hyg & Trop Med, London WC1, England. [Marks, Michael; Mabey, David C.; Solomon, Anthony W.] Hosp Trop Dis, London NW1 0PE, England. [Chi, Kai-Hua; Pillay, Allan; Chen, Cheng Y.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Vahi, Ventis; Sokana, Oliver] Minist Hlth & Med Serv, Honiara, Solomon Islands. [Pavluck, Alex] Task Force Global Hlth, Atlanta, GA USA. RP Marks, M (reprint author), London Sch Hyg & Trop Med, Dept Clin Res, Fac Infect & Trop Dis, Room 359,Keppel St, London WC1, England. EM michael.marks@lshtm.ac.uk OI Mabey, David/0000-0002-0031-8276; Marks, Michael/0000-0002-7585-4743; Solomon, Anthony/0000-0001-7101-6649 FU United Kingdom's Department for International Development, through the Global Trachoma Mapping grant; Wellcome Trust Clinical PhD Fellowship [WT102807] FX This study was funded by the United Kingdom's Department for International Development, through the Global Trachoma Mapping grant to Sightsavers and a Wellcome Trust Clinical PhD Fellowship (WT102807) to M.M.A. W.S. is a Wellcome Trust Intermediate Clinical Fellow (098521) at the London School of Hygiene & Tropical Medicine. NR 16 TC 25 Z9 25 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2014 VL 20 IS 10 BP 1705 EP 1707 DI 10.3201/eid2010.140573 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ1ER UT WOS:000342525200013 PM 25271477 ER PT J AU Koul, PA Broor, S Saha, S Barnes, J Smith, C Shaw, M Chadha, M Lal, RB AF Koul, Parvaiz A. Broor, Shobha Saha, Siddhartha Barnes, John Smith, Catherine Shaw, Michael Chadha, Mandeep Lal, Renu B. TI Differences in Influenia Seasonality by Latitude, Northern India SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ASIA AB The seasonality of influenza in the tropics complicates vaccination timing. We investigated influenza seasonality in northern India and found influenza positivity peaked in Srinagar (34.09 degrees N) in January-March but peaked in New Delhi (28.66 degrees N) in July-September. Srinagar should consider influenza vaccination in October-November, but New Delhi should vaccinate in May-June. C1 [Koul, Parvaiz A.] Sheri Kashmir Inst Med Sci, Srinagar 190011, Jammu & Kashmir, India. [Broor, Shobha] All India Inst Med Sci, New Delhi, India. [Saha, Siddhartha; Barnes, John; Smith, Catherine; Shaw, Michael; Lal, Renu B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chadha, Mandeep] Natl Inst Virol, Pune, Maharashtra, India. RP Koul, PA (reprint author), Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar 190011, Jammu & Kashmir, India. EM parvaizk@gmail.com FU US Centers for Disease Control and Prevention (Atlanta, GA, USA) [5U51IP 000333] FX This study was supported in part by cooperative agreement 5U51IP 000333 from the US Centers for Disease Control and Prevention (Atlanta, GA, USA). NR 15 TC 11 Z9 11 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2014 VL 20 IS 10 BP 1723 EP 1726 DI 10.3201/eid2010.140431 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ1ER UT WOS:000342525200018 PM 25279651 ER PT J AU Foytich, KR Deshazer, G Esona, MD Liu, A Wang, YH Tu, XM Jiang, BM AF Foytich, Kimberly R. Deshazer, Garland Esona, Mathew D. Liu, Angela Wang, Yuhuan Tu, Xinming Jiang, Baoming TI Identification of New Provisional Simian Adenovirus Species from Captive Monkeys, China SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 [Foytich, Kimberly R.; Deshazer, Garland; Esona, Mathew D.; Liu, Angela; Wang, Yuhuan; Jiang, Baoming] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Tu, Xinming] Chinese Acad Med Sci, Beijing 100730, Peoples R China. RP Jiang, BM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G04, Atlanta, GA 30329 USA. EM bxj4@cdc.gov NR 8 TC 2 Z9 2 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2014 VL 20 IS 10 BP 1758 EP 1759 DI 10.3201/eid2010.131255 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ1ER UT WOS:000342525200027 PM 25271868 ER PT J AU Amman, BR Nyakarahuka, L McElroy, AK Dodd, KA Sealy, TK Schuh, AJ Shoemaker, TR Balinandi, S Atimnedi, P Kaboyo, W Nichol, ST Towner, JS AF Amman, Brian R. Nyakarahuka, Luke McElroy, Anita K. Dodd, Kimberly A. Sealy, Tara K. Schuh, Amy J. Shoemaker, Trevor R. Balinandi, Stephen Atimnedi, Patrick Kaboyo, Winyi Nichol, Stuart T. Towner, Jonathan S. TI Marburgvirus Resurgence in Kitaka Mine Bat Population after Extermination Attempts, Uganda SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID HEMORRHAGIC-FEVER C1 [Amman, Brian R.; McElroy, Anita K.; Dodd, Kimberly A.; Sealy, Tara K.; Schuh, Amy J.; Nichol, Stuart T.; Towner, Jonathan S.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Nyakarahuka, Luke] Uganda Virus Res Inst, Entebbe, Uganda. [McElroy, Anita K.] Emory Univ, Atlanta, GA 30322 USA. [Dodd, Kimberly A.] Univ Calif Davis, Davis, CA 95616 USA. [Shoemaker, Trevor R.; Balinandi, Stephen] Ctr Dis Control & Prevent, Entebbe, Uganda. [Atimnedi, Patrick] Uganda Wildlife Author, Kampala, Uganda. [Kaboyo, Winyi] Uganda Minist Hlth, Kampala, Uganda. RP Towner, JS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G14, Atlanta, GA 30329 USA. EM jit8@cdc.gov FU NICHD NIH HHS [K12 HD072245] NR 10 TC 16 Z9 17 U1 1 U2 16 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2014 VL 20 IS 10 BP 1761 EP 1764 DI 10.3201/eid2010.140696 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ1ER UT WOS:000342525200029 PM 25272104 ER PT J AU Edouard, S Bhengsri, S Dowell, SF Watt, G Parola, P Raoult, D AF Edouard, Sophie Bhengsri, Saithip Dowell, Scott F. Watt, George Parola, Philippe Raoult, Didier TI Two Human Cases of Rickettsia felis Infection, Thailand SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID FEVER; AFRICA C1 [Edouard, Sophie; Parola, Philippe; Raoult, Didier] Aix Marseille Univ, F-13385 Marseille 5, France. [Bhengsri, Saithip; Watt, George] Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Nonthaburi, Thailand. [Dowell, Scott F.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Raoult, D (reprint author), Aix Marseille Univ, Fac Med, 27 Bd Jean Moulin, F-13385 Marseille 5, France. EM didier.raoult@gmail.com NR 10 TC 10 Z9 10 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2014 VL 20 IS 10 BP 1780 EP 1781 DI 10.3201/eid2010.140905 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ1ER UT WOS:000342525200039 PM 25272251 ER PT J AU Breedlove, B AF Breedlove, Byron TI A Fragile Dignity Despite Their Rags and Tatters SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E41, Atlanta, GA 30329 USA. EM wbb1@cdc.gov OI Breedlove, Byron/0000-0002-1026-1963 NR 3 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2014 VL 20 IS 10 BP 1784 EP 1785 DI 10.3201/eid2010.AC2010 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ1ER UT WOS:000342525200040 ER PT J AU Serdula, MK Nichols, EK Aburto, NJ Masa'd, H Obaid, B Wirth, J Tarawneh, M Barham, R Hijawi, B Sullivan, KM AF Serdula, M. K. Nichols, E. K. Aburto, N. J. Masa'd, H. Obaid, B. Wirth, J. Tarawneh, M. Barham, R. Hijawi, B. Sullivan, K. M. CA Jordan Fortification Working Grp TI Micronutrient status in Jordan: 2002 and 2010 SO EUROPEAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID FLOUR FORTIFICATION PROGRAMS; NEURAL-TUBE DEFECTS; WHEAT-FLOUR; FOLATE; ASSAY; SERUM; IRON AB BACKGROUND/OBJECTIVES: Two national surveys were conducted in Jordan in 2002 and 2010 to investigate the micronutrient status in women and children. To determine the prevalence of anemia, iron and folate deficiency among women and children in 2010 and compare with the prevalence of anemia and iron deficiency in 2002. SUBJECTS/METHODS: A nationally representative survey was conducted in 2002 (1023 women, 15-49 years Of 1059 children, 12-59 months of age) and a second survey in 2010 (2035 women; 940 children). Venous blood samples were used to measure hemoglobin, ferritin and red blood cell folate (the latter on a subsample of 393 women). RESULTS: Among women in 2010, the prevalence of folate deficiency and insufficiency was 13.6% and 82.9%, respectively. Geometric mean serum ferritin was higher in 2010 compared with 2002 (21.3 ng/ml vs 18.3, P=0.01); there was no significant change in the prevalence of iron deficiency (35.1% vs 38.7%, P=0.17), iron deficiency anemia (19.1% vs 20.0%, P=0.61) or anemia (29.2% vs 29.3%, P=0.96). Among children, a significantly lower prevalence was observed in 2010 compared with 2002 for iron deficiency (13.7% vs 26.2% P < 0.001) and iron deficiency anemia (4.8% vs 10.1%, P < 0.001); a nonsignificant lower prevalence was observed for anemia (16.6% vs 20.2%, P=0.09). CONCLUSIONS: In 2010, approximately one of seven women was folate deficient and six out of seven were folate insufficient for the prevention of neural tube defects. Between 2002 and 2010, significant improvement was observed in the prevalence of iron deficiency in children, but not in women. C1 [Serdula, M. K.; Nichols, E. K.; Aburto, N. J.; Sullivan, K. M.] Ctr Dis Control & Prevent CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Nichols, E. K.; Aburto, N. J.] US Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Masa'd, H.; Tarawneh, M.; Barham, R.; Hijawi, B.] Minist Hlth, Dept Noncommunicable Dis, Amman, Jordan. [Obaid, B.] Dept Stat, Amman, Jordan. [Wirth, J.] Global Alliance Improved Nutr, Geneva, Switzerland. [Wirth, J.] GroundWork LLC, Crans Pres Celigny, Switzerland. [Sullivan, K. M.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. RP Serdula, MK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, 4770 Buford Highway,MS F77, Atlanta, GA 30341 USA. EM mks1@cdc.gov FU GAIN; Government of Jordan Ministry of Health (MOH); UNICEF Jordan office FX The 2010 survey was funded through a grant agreement between GAIN and the Government of Jordan Ministry of Health (MOH) and a Memorandum of Understanding between GAIN and the CDC. Additional support was provided by the UNICEF Jordan office. We would especially like to acknowledge Nadera Al-Shareff and Rubs Nabulsi for their help in the laboratory and lab technicians Gaia Alwandan, Lamees Janineh and Shefa Saleh for their dedicated work. We acknowledge Adnan Ishaq and Mohammad Anees for their contributions during the early stage of survey preparations. Finally, we are grateful to Adel M Belbeisi, Usha Mandava, Wissam Qarqash, Nicolas Tsikhlakis and Barbara Macdonald for their invaluable support throughout the survey. NR 15 TC 0 Z9 0 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0954-3007 EI 1476-5640 J9 EUR J CLIN NUTR JI Eur. J. Clin. Nutr. PD OCT PY 2014 VL 68 IS 10 BP 1124 EP 1128 DI 10.1038/ejcn.2014.100 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AQ4BC UT WOS:000342736200008 PM 24986824 ER PT J AU Boulet, SL Mehta, A Kissin, DM Warner, L Jamieson, DJ AF Boulet, S. L. Mehta, A. Kissin, D. M. Warner, L. Jamieson, D. J. TI TRENDS IN THE USE OF ICSI: INDICATIONS AND PREGNANCY OUTCOMES, UNITED STATES 1996-2011. SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 18-22, 2014 CL Honolulu, HI SP Amer Soc Reprod Med C1 [Boulet, S. L.; Kissin, D. M.; Warner, L.; Jamieson, D. J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mehta, A.] Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD OCT PY 2014 VL 102 IS 3 SU S MA O-195 BP E67 EP E67 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AQ0VG UT WOS:000342500200196 ER PT J AU Gannon, JR Williams, L Warner, L O'Neil, ME Aston, K Carrell, DT Grigorescu, V Jamieson, D Eisenberg, M Hotaling, JM AF Gannon, J. R. Williams, L. Warner, L. O'Neil, M. E. Aston, K. Carrell, D. T. Grigorescu, V. Jamieson, D. Eisenberg, M. Hotaling, J. M. TI BACK-UP CONTRACEPTION AFTER VASECTOMY: INSIGHTS FROM THE PREGNANCY RISK ASSESSMENT MONITORING SYSTEM (PRAMS), 2007-2010. SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 18-22, 2014 CL Honolulu, HI SP Amer Soc Reprod Med C1 [Gannon, J. R.; Aston, K.; Carrell, D. T.; Hotaling, J. M.] Univ Utah, Div Urol, Salt Lake City, UT USA. [Williams, L.; Warner, L.; O'Neil, M. E.; Grigorescu, V.; Jamieson, D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Eisenberg, M.] Stanford Univ, Dept Urol, Palo Alto, CA 94304 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD OCT PY 2014 VL 102 IS 3 SU S MA O-318 BP E109 EP E109 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AQ0VG UT WOS:000342500200324 ER PT J AU Gaskins, AJ Lawson, CC Rich-Edwards, JW Missmer, SA Laden, F Chavarro, JE AF Gaskins, A. J. Lawson, C. C. Rich-Edwards, J. W. Missmer, S. A. Laden, F. Chavarro, J. E. TI OCCUPATIONAL USE OF HIGH LEVEL DISINFECTANTS AND TIME TO PREGNANCY AMONG NURSES. SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 18-22, 2014 CL Honolulu, HI SP Amer Soc Reprod Med C1 [Gaskins, A. J.; Rich-Edwards, J. W.; Missmer, S. A.; Laden, F.; Chavarro, J. E.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Lawson, C. C.] NIOSH, Cincinnati, OH USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD OCT PY 2014 VL 102 IS 3 SU S MA O-310 BP E107 EP E107 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AQ0VG UT WOS:000342500200316 ER PT J AU Kissin, DM Zhang, Y Boulet, SL Fountain, C Bearman, P Schieve, L Yeargin-Allsopp, M Jamieson, DJ AF Kissin, D. M. Zhang, Y. Boulet, S. L. Fountain, C. Bearman, P. Schieve, L. Yeargin-Allsopp, M. Jamieson, D. J. TI ASSOCIATION OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT AND PARENTAL INFERTILITY DIAGNOSIS WITH AUTISM IN ART-CONCEIVED CHILDREN. SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 18-22, 2014 CL Honolulu, HI SP Amer Soc Reprod Med C1 [Kissin, D. M.; Zhang, Y.; Boulet, S. L.; Jamieson, D. J.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Fountain, C.] Fordham Univ, Dept Sociol, New York, NY 10023 USA. [Bearman, P.] Columbia Univ, Dept Sociol, New York, NY 10027 USA. [Schieve, L.; Yeargin-Allsopp, M.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD OCT PY 2014 VL 102 IS 3 SU S MA O-46 BP E17 EP E17 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AQ0VG UT WOS:000342500200047 ER PT J AU Perkins, KM Boulet, SL Kissin, DM Jamieson, DJ AF Perkins, K. M. Boulet, S. L. Kissin, D. M. Jamieson, D. J. TI RISK OF ECTOPIC PREGNANCY ASSOCIATED WITH ASSISTED REPRODUCTIVE TECHNOLOGY (ART), UNITED STATES, 2001-2011. SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 18-22, 2014 CL Honolulu, HI SP Amer Soc Reprod Med C1 [Perkins, K. M.; Boulet, S. L.; Kissin, D. M.; Jamieson, D. J.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD OCT PY 2014 VL 102 IS 3 SU S MA O-112 BP E38 EP E39 PG 2 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AQ0VG UT WOS:000342500200113 ER PT J AU Sunderam, S Kissin, DM Crawford, S Jamieson, DJ Barfield, WD AF Sunderam, S. Kissin, D. M. Crawford, S. Jamieson, D. J. Barfield, W. D. TI STATE-SPECIFIC OVERVIEW OF 2011 US ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT OUTCOMES AND CONTRIBUTION TO MULTIPLE-BIRTH, LOW BIRTH WEIGHT, AND PRETERM INFANTS. SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT 70th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 18-22, 2014 CL Honolulu, HI SP Amer Soc Reprod Med C1 [Sunderam, S.; Kissin, D. M.; Crawford, S.; Jamieson, D. J.; Barfield, W. D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Chamblee, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD OCT PY 2014 VL 102 IS 3 SU S MA P-548 BP E318 EP E319 PG 2 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AQ0VG UT WOS:000342500201303 ER PT J AU Reid, AJ Blake, DP Ansari, HR Billington, K Browne, HP Bryant, J Dunn, M Hung, SS Kawahara, F Miranda-Saavedra, D Malas, TB Mourier, T Naghra, H Nair, M Otto, TD Rawlings, ND Rivailler, P Sanchez-Flores, A Sanders, M Subramaniam, C Tay, YL Woo, Y Wu, XK Barrell, B Dear, PH Doerig, C Gruber, A Ivens, AC Parkinson, J Rajandream, MA Shirley, MW Wan, KL Berriman, M Tomley, FM Pain, A AF Reid, Adam J. Blake, Damer P. Ansari, Hifzur R. Billington, Karen Browne, Hilary P. Bryant, Josephine Dunn, Matt Hung, Stacy S. Kawahara, Fumiya Miranda-Saavedra, Diego Malas, Tareq B. Mourier, Tobias Naghra, Hardeep Nair, Mridul Otto, Thomas D. Rawlings, Neil D. Rivailler, Pierre Sanchez-Flores, Alejandro Sanders, Mandy Subramaniam, Chandra Tay, Yea-Ling Woo, Yong Wu, Xikun Barrell, Bart Dear, Paul H. Doerig, Christian Gruber, Arthur Ivens, Alasdair C. Parkinson, John Rajandream, Marie-Adele Shirley, Martin W. Wan, Kiew-Lian Berriman, Matthew Tomley, Fiona M. Pain, Arnab TI Genomic analysis of the causative agents of coccidiosis in domestic chickens SO GENOME RESEARCH LA English DT Article ID PARASITE PLASMODIUM-FALCIPARUM; EIMERIA-TENELLA; TOXOPLASMA-GONDII; PROTEIN-KINASES; APICOMPLEXA; EXPRESSION; VIRULENCE; EVOLUTION; ALIGNMENT; APICOPLAST AB Global production of chickens has trebled in the past two decades and they are now the most important source of dietary animal protein worldwide. Chickens are subject to many infectious diseases that reduce their performance and productivity. Coccidiosis, caused by apicomplexan protozoa of the genus Eimeria, is one of the most important poultry diseases. Understanding the biology of Eimeria parasites underpins development of new drugs and vaccines needed to improve global food security. We have produced annotated genome sequences of all seven species of Eimeria that infect domestic chickens, which reveal the full extent of previously described repeat-rich and repeat-poor regions and show that these parasites possess the most repeat-rich proteomes ever described. Furthermore, while no other apicomplexan has been found to possess retrotransposons, Eimeria is home to a family of chromoviruses. Analysis of Eimeria genes involved in basic biology and host-parasite interaction highlights adaptations to a relatively simple developmental life cycle and a complex array of co-expressed surface proteins involved in host cell binding. C1 [Reid, Adam J.; Browne, Hilary P.; Bryant, Josephine; Dunn, Matt; Naghra, Hardeep; Otto, Thomas D.; Sanders, Mandy; Barrell, Bart; Rajandream, Marie-Adele; Berriman, Matthew] Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England. [Blake, Damer P.; Tomley, Fiona M.] Univ London Royal Vet Coll, N Mymms AL9 7TA, Herts, England. [Blake, Damer P.; Billington, Karen; Rivailler, Pierre; Subramaniam, Chandra; Wu, Xikun; Tomley, Fiona M.] Pirbright Inst, Compton Lab, Newbury RG20 7NN, Berks, England. [Ansari, Hifzur R.; Malas, Tareq B.; Nair, Mridul; Woo, Yong; Pain, Arnab] King Abdullah Univ Sci & Technol, Computat Biosci Res Ctr, Biol Environm Sci & Engn Div, Jeddah 239556900, Saudi Arabia. [Hung, Stacy S.; Parkinson, John] Hosp Sick Children, Program Mol Struct & Funct, Toronto, ON M5G 1X8, Canada. [Hung, Stacy S.; Parkinson, John] Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada. [Hung, Stacy S.; Parkinson, John] Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1X8, Canada. [Kawahara, Fumiya] Nippon Inst Biol Sci, Ome, Tokyo 1980024, Japan. [Miranda-Saavedra, Diego] Univ Newcastle, Sch Med, Inst Cellular Med, Fibrosis Labs, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England. [Mourier, Tobias] Univ Copenhagen, Ctr GeoGenet, Nat Hist Museum Denmark, DK-1350 Copenhagen, Denmark. [Naghra, Hardeep] Univ Nottingham, Ctr Biomol Sci, Sch Life Sci, Nottingham NG7 2RD, England. [Rawlings, Neil D.] European Bioinformat Inst, Hinxton CB10 1SA, Cambs, England. [Rivailler, Pierre] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Sanchez-Flores, Alejandro] Univ Nacl Autonoma Mexico, Inst Biotechnol, Unidad Univ Apoyo Bioinformat, Cuernavaca 62210, Morelos, Mexico. [Tay, Yea-Ling; Wan, Kiew-Lian] Univ Kebangsaan Malaysia, Fac Sci & Technol, Sch Biosci & Biotechnol, UKM Bangi 43600, Selangor DE, Malaysia. [Tay, Yea-Ling; Wan, Kiew-Lian] Malaysia Genome Inst, Kajang 43000, Selangor DE, Malaysia. [Wu, Xikun] Amgen Ltd, Uxbridge UB8 1DH, Middx, England. [Dear, Paul H.] MRC, Mol Biol Lab, Cambridge CB2 0QH, England. [Doerig, Christian] Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia. [Gruber, Arthur] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, BR-05508000 Sao Paulo, Brazil. [Ivens, Alasdair C.] Univ Edinburgh, Ctr Immun Infect & Evolut, Sch Biol Sci, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland. [Shirley, Martin W.] Pirbright Inst, Pirbright Lab, Woking GU24 0NF, Surrey, England. RP Reid, AJ (reprint author), Wellcome Trust Sanger Inst, Genome Campus, Hinxton CB10 1SA, Cambs, England. EM ar11@sanger.ac.uk; ftomley@rvc.ac.uk; arnab.pain@kaustedu.sa RI Gruber, Arthur/B-4711-2011; Mourier, Tobias/C-1164-2015; Dear, Paul/A-1162-2012; Institute, Pirbright/K-4476-2014; Pain, Arnab/L-5766-2015; Rawlings, Neil/M-5566-2013; OI Ansari, Hifzur Rahman/0000-0002-0646-1743; Otto, Thomas/0000-0002-1246-7404; Parkinson, John/0000-0001-9815-1189; Mourier, Tobias/0000-0003-2727-1903; Doerig, Christian/0000-0002-3188-094X; Sanchez-Flores, Alejandro/0000-0003-0476-3139; Pain, Arnab/0000-0002-1755-2819; Naghra, Hardeep/0000-0003-3335-4617; Reid, Adam/0000-0002-5926-7768; Rawlings, Neil/0000-0001-5557-7665; Browne, Hilary/0000-0002-1305-2470 FU BBSRC [S17413, S19705/6]; Wellcome Trust; King Abdullah University of Science and Technology (KAUST); Ministry of Science, Technology and Innovation, Malaysia [07-05-16-MGI-GMB10]; Universiti Kebangsaan Malaysia [DIP-2012-21]; Canadian Institute for Health Research (CIHR) [MOP84556] FX The work was funded by BBSRC grants S17413 and S19705/6, Wellcome Trust core funding to Wellcome Trust Sanger Institute (WTSI), and faculty baseline funding from the King Abdullah University of Science and Technology (KAUST). We thank Mike Quail, Karen Mungall, Carol Churcher, and members of the core DNA pipelines for sequencing at WTSI and Bioscience core laboratories for sequencing operations at KAUST. We acknowledge Martin Aslett from WTSI for data submission and Dora Harvey and Fionnadh Carroll from the Institute for Animal Health for technical assistance. K.-L.W. would like to acknowledge funding from the Ministry of Science, Technology and Innovation, Malaysia (Project No. 07-05-16-MGI-GMB10) and the Universiti Kebangsaan Malaysia (Project No. DIP-2012-21). J.P. and S.S.H. were funded by the Canadian Institute for Health Research (CIHR #MOP84556). NR 60 TC 36 Z9 37 U1 2 U2 12 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1088-9051 EI 1549-5469 J9 GENOME RES JI Genome Res. PD OCT PY 2014 VL 24 IS 10 BP 1676 EP 1685 DI 10.1101/gr.168955.113 PG 10 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA AQ1LL UT WOS:000342542800011 PM 25015382 ER PT J AU Yang, QH Yuan, KM Gregg, EW Loustalot, F Fang, J Hong, YL Merritt, R AF Yang, Quanhe Yuan, Keming Gregg, Edward W. Loustalot, Fleetwood Fang, Jing Hong, Yuling Merritt, Robert TI Trends and Clustering of Cardiovascular Health Metrics Among US Adolescents 1988-2010 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Adolescents; Cardiovascular health; Trends of risk factors; Prevention; Health disparities ID NUTRITION EXAMINATION SURVEY; RISK BEHAVIOR SURVEILLANCE; BODY-MASS INDEX; NATIONAL-HEALTH; UNITED-STATES; METABOLIC SYNDROME; HEART-DISEASE; CHILDREN; CHILDHOOD; PREVALENCE AB Purpose: American Heart Association recently published a set of seven cardiovascular (CV) health metrics for adults and children, emphasizing importance of preventing CV risk factors. Although CV disease risk factors have generally improved in adults, there is concern that this has not been true among adolescents. The present study examined trends and disparities of CV health metrics among U. S. adolescents. Methods: We used data from a series of National Health and Nutrition Examination Survey (1988-1994, 1999-2004, and 2005-2010) including 11,233 adolescents aged 12-17 years. We estimated prevalence and mean score of CV health metrics and examined the disparities in mean score by sex, race/ethnicity, educational attainment, and poverty-income ratio. Results: The prevalence of nonsmoking and healthy diet increased from 1988 through 2010, while the prevalence of normal body mass index and physical activity decreased, resulting in an unchanged distribution of overall CV health scores since 1988. The prevalence of adolescents meeting all seven CV health metrics was low, 3.5% (95% confidence interval [CI] 2.2-5.4), 4.0% (95% CI 3.3-4.8), and 4.0% (95% CI 2.9-5.3) in National Health and Nutrition Examination Survey 1988-1994, 1999-2004, and 2005-2010, respectively. The disparities in adjusted mean scores persisted between non-Hispanic whites and non-Hispanic blacks, families/households with >12 versus <12 years of education, and poverty-income ratio of >3 versus <3 (p<.05). Conclusions: The proportion of adolescents achieving all seven CV health metrics was low and remained unchanged during 1988-2010. The disparities in mean CV health score persisted among adolescents. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Yang, Quanhe; Yuan, Keming; Loustalot, Fleetwood; Fang, Jing; Hong, Yuling; Merritt, Robert] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. RP Yang, QH (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford HWY,MailStop F-72, Atlanta, GA 30341 USA. EM qay0@cdc.gov NR 40 TC 5 Z9 5 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2014 VL 55 IS 4 BP 513 EP 520 DI 10.1016/j.jadohealth.2014.03.013 PG 8 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA AQ3HV UT WOS:000342683400008 PM 24746492 ER PT J AU Dittus, PJ De Rosa, CJ Jeffries, RA Afifi, AA Cumberland, WG Chung, EQ Martinez, E Kerndt, PR Ethier, KA AF Dittus, Patricia J. De Rosa, Christine J. Jeffries, Robin A. Afifi, Abdelmonem A. Cumberland, William G. Chung, Emily Q. Martinez, Esteban Kerndt, Peter R. Ethier, Kathleen A. TI The Project Connect Health Systems Intervention: Linking Sexually Experienced Youth to Sexual and Reproductive Health Care SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Adolescent; STD; HIV; Reproductive health; Adolescent health services ID CONTRACEPTIVE USE; CHLAMYDIA; SERVICES; PREGNANCY; GONORRHEA; BEHAVIOR; ACCESS; IMPACT; WOMEN AB Purpose: To evaluate a health systems intervention to increase adolescents' receipt of high-quality sexual and reproductive health care services. Methods: Quasi experimental design. Twelve high schools in a large public school district were matched into pairs. Within each pair, schools were assigned to condition so that no control school shared a geographic border with an intervention school. Five yearly surveys (T1, T2,., T5) were administered from 2005 to 2009 (N = 29,823) to students in randomly selected classes in grades 9-12. Community-based providers of high-quality sexual and reproductive health care services were listed on a referral guide for use by school nurses to connect adolescents to care. Results: Statistically significant effects were found for intervention school females on three outcomes, relative to controls. Relative to T1, receipt of birth control in the past year was greater at T4 (adjusted odds ratio [AOR] = 1.85; 95% confidence interval [CI], 1.09-3.15) and T5 (AOR = 2.22; 95% CI, 1.32-3.74). Increases in sexually transmitted disease testing and/or treatment in the past year were greater in T1-T3 (AOR = 1.78; 95% CI, 1.05-3.02), T1-T4 (AOR = 1.73; 95% CI, 1.01-2.97), T1-T5 (AOR = 1.97; 95% CI, 1.17-3.31), and T2-T5 (AOR = 1.76; 95% CI, 1.06-2.91). Increases in ever receiving an HIV test were greater in T1-T4 (AOR = 2.14; 95% CI, 1.08-4.26). Among males, no intervention effects were found. Conclusions: A school-based structural intervention can improve female adolescents' receipt of services. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Dittus, Patricia J.; Ethier, Kathleen A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [De Rosa, Christine J.; Jeffries, Robin A.; Chung, Emily Q.; Martinez, Esteban] Los Angeles Cty Dept Publ Hlth, Div HIV & STD Programs, Los Angeles, CA USA. [De Rosa, Christine J.; Jeffries, Robin A.; Martinez, Esteban] Univ So Calif, Inst Hlth Promot & Dis Prevent Res, Los Angeles, CA USA. [Afifi, Abdelmonem A.; Cumberland, William G.] Univ Calif Los Angeles, Dept Biostat, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Kerndt, Peter R.] Los Angeles Cty Dept Publ Hlth, TB Control Program, Los Angeles, CA USA. RP Dittus, PJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-44, Atlanta, GA 30333 USA. EM pdittus@cdc.gov RI Donatello, Robin/A-5297-2009 OI Donatello, Robin/0000-0001-8487-5995 FU Centers for Disease Control and Prevention [U30/CCU922283-01] FX This research was supported by a cooperative agreement from the Centers for Disease Control and Prevention (U30/CCU922283-01). NR 25 TC 7 Z9 7 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2014 VL 55 IS 4 BP 528 EP 534 DI 10.1016/j.jadohealth.2014.04.005 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA AQ3HV UT WOS:000342683400010 PM 24856358 ER PT J AU Tyburski, EA Gillespie, SE Stoy, WA Mannino, RG Weiss, AJ Siu, AF Bulloch, RH Thota, K Cardenas, A Session, W Khoury, HJ O'Connor, S Bunting, ST Boudreaux, J Forest, CR Gaddh, M Leong, T Lyon, LA Lam, WA AF Tyburski, Erika A. Gillespie, Scott E. Stoy, William A. Mannino, Robert G. Weiss, Alexander J. Siu, Alexa F. Bulloch, Rayford H. Thota, Karthik Cardenas, Anyela Session, Wilena Khoury, Hanna J. O'Connor, Siobhan Bunting, Silvia T. Boudreaux, Jeanne Forest, Craig R. Gaddh, Manila Leong, Traci Lyon, L. Andrew Lam, Wilbur A. TI Disposable platform provides visual and color-based point-of-care anemia self-testing SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID IRON-DEFICIENCY ANEMIA; HEMOGLOBIN; SCALE; PREVALENCE; TETRAMETHYLBENZIDINE; SCHISTOSOMIASIS; ACCURACY; CRITIQUE; CHILDREN AB BACKGROUND. Anemia, or low blood hemoglobin (Hgb) levels, afflicts 2 billion people worldwide. Currently, Hgb levels are typically measured from blood samples using hematology analyzers, which are housed in hospitals, clinics, or commercial laboratories and require skilled technicians to operate. A reliable, inexpensive point-of-care (POC) Hgb test would enable cost-effective anemia screening and chronically anemic patients to self-monitor their disease. We present a rapid, stand-alone, and disposable POC anemia test that, via a single drop of blood, outputs color-based visual results that correlate with Hgb levels. METHODS. We tested blood from 238 pediatric and adult patients with anemia of varying degrees and etiologies and compared hematology analyzer Hgb levels with POC Hgb levels, which were estimated via visual interpretation using a color scale and an optional smartphone app for automated analysis. RESULTS. POC Hgb levels correlated with hematology analyzer Hgb levels (r = 0.864 and r = 0.856 for visual interpretation and smartphone app, respectively), and both POC test methods yielded comparable sensitivity and specificity for detecting any anemia (n = 178) (<11 g/dl) (sensitivity: 90.2% and 91.1%, specificity: 83.7% and 79.2%, respectively) and severe anemia (n = 10) (<7 g/dl) (sensitivity: 90.0% and 100%, specificity: 94.6% and 93.9%, respectively). CONCLUSIONS. These results demonstrate the feasibility of this POC color-based diagnostic test for self-screening/self-monitoring of anemia. C1 [Tyburski, Erika A.; Stoy, William A.; Mannino, Robert G.; Weiss, Alexander J.; Siu, Alexa F.; Thota, Karthik; Lam, Wilbur A.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA. [Tyburski, Erika A.; Stoy, William A.; Mannino, Robert G.; Weiss, Alexander J.; Siu, Alexa F.; Thota, Karthik; Lam, Wilbur A.] Emory Univ, Atlanta, GA 30322 USA. [Tyburski, Erika A.; Mannino, Robert G.; Boudreaux, Jeanne; Lam, Wilbur A.] Childrens Healthcare Atlanta, Aflac Canc Ctr, Atlanta, GA USA. [Tyburski, Erika A.; Mannino, Robert G.; Boudreaux, Jeanne; Lam, Wilbur A.] Childrens Healthcare Atlanta, Blood Disorders Serv, Atlanta, GA USA. [Tyburski, Erika A.; Gillespie, Scott E.; Mannino, Robert G.; Boudreaux, Jeanne; Lam, Wilbur A.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Tyburski, Erika A.; Stoy, William A.; Mannino, Robert G.; Forest, Craig R.; Lyon, L. Andrew; Lam, Wilbur A.] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA. [Tyburski, Erika A.; Mannino, Robert G.; Session, Wilena; Khoury, Hanna J.; Gaddh, Manila; Lam, Wilbur A.] Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA. [Bulloch, Rayford H.; Lyon, L. Andrew] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Cardenas, Anyela; Bunting, Silvia T.] Childrens Healthcare Atlanta, Dept Pathol, Atlanta, GA USA. [O'Connor, Siobhan] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Forest, Craig R.] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA. [Leong, Traci] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA. RP Lam, WA (reprint author), Emory Childrens Ctr, 2015 Uppergate Dr,Room 448, Atlanta, GA 30332 USA. EM wilbur.lam@emory.edu RI Lyon, Andrew/A-4082-2009 OI Lyon, Andrew/0000-0001-7828-7345 FU FDA [P50FD004193]; Georgia Research Alliance; Children's Healthcare of Atlanta; Georgia Center of Innovation for Manufacturing; InVenture Prize; Ideas to Serve competitions at the Georgia Institute of Technology FX We thank the following funding sources: the FDA-funded Atlantic Pediatric Device Consortium (P50FD004193), the Georgia Research Alliance for phase 1 venture funding, the Children's Healthcare of Atlanta-sponsored summer internship program, the Georgia Center of Innovation for Manufacturing, and the InVenture Prize and the Ideas to Serve competitions at the Georgia Institute of Technology. We thank the physicians and nurse practitioners of the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta and the physicians and nurse practitioners of the Winship Cancer Institute at Emory University who assisted with the collection of clinical samples. We also thank the Global Center for Medical Innovation (GCMI) for all prototype iteration and production. We thank M. Byrd, N. Hotaling, M. McKinnon, and M. Platt for initial discussions, advice, and help with initial experiments. We also thank C.R. Fantz for assistance in POC testing and stability assessment. We finally thank the entirety of the Lam lab, including Y. Sakurai, E.T. Hardy, D.R. Myers, H.A. Gole, Y. Qiu, B. Ahn, R. Tran, J. Ciciliano, and M. Fay for thoughtful discussions. NR 30 TC 7 Z9 7 U1 2 U2 10 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD OCT PY 2014 VL 124 IS 10 BP 4387 EP 4394 DI 10.1172/JCI76666 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AQ2WG UT WOS:000342649900034 PM 25157824 ER PT J AU Leung, J Lopez, AS Tootell, E Baumrind, N Mohle-Boetani, J Leistikow, B Harriman, KH Preas, CP Cosentino, G Bialek, SR Marin, M AF Leung, Jessica Lopez, Adriana S. Tootell, Elena Baumrind, Nikki Mohle-Boetani, Janet Leistikow, Bruce Harriman, Kathleen H. Preas, Christopher P. Cosentino, Giorgio Bialek, Stephanie R. Marin, Mona TI Challenges With Controlling Varicella in Prison Settings: Experience of California, 2010 to 2011 SO JOURNAL OF CORRECTIONAL HEALTH CARE LA English DT Article DE varicella; chicken pox; prison; outbreak; costs ID OUTBREAK; SUSCEPTIBILITY; CHICKENPOX; HISTORY; ADULTS; TRANSMISSION; INFECTION; RECRUITS; VALIDITY; FACILITY AB This article describes the epidemiology of varicella in one state prison in California during 2010 and 2011, control measures implemented, and associated costs. Eleven varicella cases were reported, of which nine were associated with two outbreaks. One outbreak consisted of three cases and the second consisted of six cases with two generations of spread. Among exposed inmates serologically tested, 98% (643/656) were varicella-zoster virus seropositive. The outbreaks resulted in > 1,000 inmates exposed, 444 staff exposures, and > $160,000 in costs. The authors documented the challenges and costs associated with controlling and managing varicella in a prison setting. A screening policy for evidence of varicella immunity for incoming inmates and staff and vaccination of susceptible persons has the potential to mitigate the impact of future outbreaks and reduce resources necessary to manage cases and outbreaks. C1 [Leung, Jessica; Lopez, Adriana S.; Bialek, Stephanie R.; Marin, Mona] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Tootell, Elena; Baumrind, Nikki; Mohle-Boetani, Janet; Leistikow, Bruce] Calif Correct Hlth Care Serv, Elk Grove, CA USA. [Harriman, Kathleen H.; Preas, Christopher P.; Cosentino, Giorgio] Calif Dept Publ Hlth, Los Angeles, CA USA. RP Leung, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Mail Stop A-34, Atlanta, GA 30333 USA. EM jleung@cdc.gov FU Intramural CDC HHS [CC999999] NR 29 TC 3 Z9 3 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1078-3458 EI 1940-5200 J9 J CORRECT HEALTH CAR JI J. Correct. Health Care PD OCT PY 2014 VL 20 IS 4 BP 292 EP 301 DI 10.1177/1078345814541535 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ3BL UT WOS:000342663600004 PM 25201912 ER PT J AU Kersh, EN Henning, T Vishwanathan, SA Morris, M Butler, K Adams, DR Guenthner, P Srinivasan, P Smith, J Radzio, J Garcia-Lerma, JG Dobard, C Heneine, W McNicholl, J AF Kersh, Ellen N. Henning, Tara Vishwanathan, Sundaram A. Morris, Monica Butler, Katherine Adams, Debra R. Guenthner, Patricia Srinivasan, Priya Smith, James Radzio, Jessica Garcia-Lerma, J. Gerardo Dobard, Charles Heneine, Walid McNicholl, Janet TI SHIV susceptibility changes during the menstrual cycle of pigtail macaques SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Article DE HIV acquisition; HIV risk; hormonal contraception; menstrual cycle; mucosal immunity; reproductive hormone ID ACTIVE ANTIRETROVIRAL THERAPY; T-CELL DEPLETION; VIRUS-INFECTED PATIENTS; MICROBIAL TRANSLOCATION; HIV-INFECTION; COLLAGEN DEPOSITION; TYPE-1 INFECTION; RHESUS MACAQUES; LYMPHOID-TISSUE; SIV INFECTION AB Background Hormonal changes during menstrual cycling may affect susceptibility to HIV. Methods We determined the simian human immunodeficiency virus (SHIV) acquisition time point in 43 cycling pigtail macaques infected by repeated vaginal virus exposures initiated randomly in the cycle. Results SHIV infection was first detected in the follicular phase in 38 macaques (88%), and in the luteal phase in five macaques (12%), indicating a statistically significant timing difference. Assuming a 7-day eclipse phase, most infections occurred during or following a high-progesterone period associated with menstruation, vaginal epithelium thinning, and suppressed mucosal immunity. Conclusions This raises questions whether other high-progesterone conditions (pregnancy, hormonal contraception) similarly affect HIV risk. C1 [Kersh, Ellen N.; Henning, Tara; Vishwanathan, Sundaram A.; Morris, Monica; Butler, Katherine; Adams, Debra R.; Guenthner, Patricia; Srinivasan, Priya; Smith, James; Radzio, Jessica; Garcia-Lerma, J. Gerardo; Dobard, Charles; Heneine, Walid; McNicholl, Janet] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Kersh, EN (reprint author), 1600 Clifton Rd NE,MS A25,Bldg 17,Rm 3229, Atlanta, GA 30333 USA. EM egk6@cdc.gov FU NIAID NIH HHS [Y01 AI000681-02]; PHS HHS [Y1-A1-0681-02] NR 29 TC 23 Z9 24 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 BP 310 EP 316 DI 10.1111/jmp.12124 PG 7 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700004 PM 24779484 ER PT J AU Engel, RM Morris, M Henning, T Ritter, JM Jones, TL Dietz, S Ayers, J Vishwanathan, SA Jenkins, L Zaki, S Wildemeersch, D Garber, D Powell, N Hendry, RM McNicholl, J Kersh, EN AF Engel, Robyn M. Morris, Monica Henning, Tara Ritter, Jana M. Jones, Tara L. Dietz, Sharon Ayers, Jessica Vishwanathan, Sundaram A. Jenkins, Leecresia Zaki, Sherif Wildemeersch, Dirk Garber, David Powell, Nathaniel Hendry, R. Michael McNicholl, Janet Kersh, Ellen N. TI Evaluation of pigtail macaques as a model for the effects of copper intrauterine devices on HIV infection SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Article DE contraception; non-human primate; Simian-Human Immunodeficiency Virus (SHIV); susceptibility; transmission risk ID CD4(+) T-CELLS; REAL-TIME; VIRUS; ASSAY; XENOTRANSPLANTATION; IMMUNOTHERAPY; COMPATIBILITY; COMBINATION; ACTIVATION; EXPRESSION AB Background Long-acting, hormonal contraception may increase HIV risk. Copper intrauterine devices (IUDs) could serve as non-hormonal alternatives. We pilot a pigtail macaque model for evaluating HIV susceptibility factors during copper IUD use. Methods Frameless and flexible GyneFix (R) copper IUDs were surgically implanted into three SHIVSF162p3-positive macaques via hysterotomy and monitored for up to 4 months. Four macaques served as non-IUD controls. Results All animals retained the devices without complications. No consistent change in vaginal viral RNA or inflammatory cytokines was seen. Two animals had altered menstrual cycles and experienced marked thinning of vaginal epithelium after IUD insertion. Histological examination of uterine tissue at necropsy revealed endometrial ulceration and lymphocytic inflammation with glandular loss at sites of direct IUD contact. Conclusions Although the need for insertion surgery could limit its usefulness, this model will allow studies on copper IUDs and SHIV shedding, disease progression, and HIV susceptibility factors. C1 [Engel, Robyn M.; Dietz, Sharon; Ayers, Jessica; Powell, Nathaniel] CDC, Anim Resources Branch, Div Sci Resources, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Morris, Monica] Total Solut, Atlanta, GA USA. [Henning, Tara; Vishwanathan, Sundaram A.; Jenkins, Leecresia; Garber, David; Hendry, R. Michael; McNicholl, Janet; Kersh, Ellen N.] CDC, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, Atlanta, GA 30333 USA. [Ritter, Jana M.; Jones, Tara L.; Zaki, Sherif] CDC, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Wildemeersch, Dirk] Gynecol Outpatient Clin, Ghent, Belgium. [Wildemeersch, Dirk] IUD Training Ctr, Ghent, Belgium. RP Kersh, EN (reprint author), 1600 Clifton Rd NE MS A25, Atlanta, GA 30333 USA. EM ekersh@cdc.gov FU NIAID NIH HHS [Y01 AI000681-02]; PHS HHS [Y1-A1-0681-02] NR 30 TC 3 Z9 3 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 BP 349 EP 359 DI 10.1111/jmp.12096 PG 11 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700008 PM 24372425 ER PT J AU Pereira, LE Makarova, N Dobard, C Aubert, RD Srinivasan, P McNicholl, J Smith, JM AF Pereira, Lara E. Makarova, Natalia Dobard, Charles Aubert, Rachael D. Srinivasan, Priya McNicholl, Janet Smith, James M. TI Development and optimization of a non-enzymatic method of leukocyte isolation from macaque tissues SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Article DE collagenase digestion; flow cytometry; Macaca nemestrina; Medimachine ID INTRAUTERINE-DEVICES; HIV ACQUISITION; CHEMOPROPHYLAXIS; CONTRACEPTION; TRANSMISSION; DISEASES; VIRUS; MODEL AB Background and Methods Cell isolation from macaque tissues involves laborious enzymatic digestion. The Medimachine provides a simpler, quicker nonenzymatic method, yielding 1.5-5 million cells/g of vaginal or rectal tissue from pigtailed macaques. Results and Conclusions Flow cytometry analysis of the two methods revealed similar levels of cell viability and most major cell lineage and activation markers. C1 [Pereira, Lara E.] LifeSource Biomed LLC, Mountain View, CA USA. [Makarova, Natalia; Dobard, Charles; Aubert, Rachael D.; Srinivasan, Priya; McNicholl, Janet; Smith, James M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Smith, JM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Bldg 17,Mailstop A25,1600 Clifton Rd, Atlanta, GA 30333 USA. EM ajo9@cdc.gov NR 24 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 BP 360 EP 363 DI 10.1111/jmp.12121 PG 4 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700009 PM 25379593 ER PT J AU Srinivasan, P Dinh, C Zhang, J Pau, CP McNicholl, JM Lo, YT Herold, BC Teller, R Kiser, P Smith, JM AF Srinivasan, Priya Dinh, Chuong Zhang, Jining Pau, Chou-Pong McNicholl, Janet M. Lo, Yungtai Herold, Betsy C. Teller, Ryan Kiser, Patrick Smith, James M. TI Pharmacokinetic evaluation of tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed macaques after 6 months of continuous use SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Article DE HIV microbicide; non-human primates; pre-exposure prophylaxis; sustained release ID ANIMAL-MODELS; COLLAGENASE; TISSUE; CELLS; TRANSMISSION; LYMPHOCYTES; MOLECULES; INFECTION; SAFETY; CD14 AB Background and Methods A reservoir intravaginal ring (IVR) eluting tenofovir disoproxil fumarate (TDF) was evaluated for 6 months of continuous use in normally cycling female pigtailed macaques with monthly IVR exchanges to define pharmacokinetics and safety. Results and Conclusions Tenofovir levels in vaginal secretions and tissue remained consistent for 6 months with no adverse safety concerns. C1 [Srinivasan, Priya; Pau, Chou-Pong; McNicholl, Janet M.; Smith, James M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dinh, Chuong; Zhang, Jining] Total Solut Inc, Atlanta, GA USA. [Lo, Yungtai] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Herold, Betsy C.] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA. [Herold, Betsy C.] Albert Einstein Coll Med, Dept Microbiol Immunol, Bronx, NY 10467 USA. [Teller, Ryan; Kiser, Patrick] Univ Utah, Dept Bioengn, Salt Lake City, UT USA. RP Smith, JM (reprint author), 1600,Clifton Rd NE,MS A25, Atlanta, GA 30329 USA. EM ajo9@cdc.gov FU NCATS NIH HHS [UL1 TR001073]; NIAID NIH HHS [U19 AI103461, U19 AI076980] NR 23 TC 5 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 BP 364 EP 369 DI 10.1111/jmp.12119 PG 6 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700010 PM 25379594 ER PT J AU Morris, M Aubert, RD Butler, K Henning, T Mitchell, J Jenkins, L Garber, D McNicholl, J Kersh, EN AF Morris, Monica Aubert, Rachael D. Butler, Katherine Henning, Tara Mitchell, James Jenkins, Leecresia Garber, David McNicholl, Janet Kersh, Ellen N. TI Preclinical evaluation of the immunomodulatory lymphocyte trafficking drug FTY720 for HIV prevention in the female genital mucosa of macaques SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Article DE FTY720; genital mucosa; SHIV ID HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; PROTECTION; INFECTION AB FTY720 has been shown to reduce inflammatory cytokines and immune cells in the genital mucosa of macaques. This pilot study examined the ability of FTY720 to inhibit HIV acquisition. Systemic treatment with FTY720 failed to prevent or delay vaginal SHIV transmission. C1 [Morris, Monica] Total Solut, Atlanta, GA USA. [Aubert, Rachael D.; Butler, Katherine; Henning, Tara; Mitchell, James; Jenkins, Leecresia; Garber, David; McNicholl, Janet; Kersh, Ellen N.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Kersh, EN (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS A25,Bldg 17,Rm 3229, Atlanta, GA 30333 USA. EM egk6@cdc.gov FU NIAID NIH HHS [Y01 AI000681-02]; PHS HHS [Y1-A1-0681-02] NR 15 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 BP 370 EP 373 DI 10.1111/jmp.12120 PG 4 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700011 PM 25379595 ER PT J AU Kersh, EN Henning, T Vishwanathan, SA Morris, M Butler, K Adams, DR Guenthner, P Srinivasan, P Smith, J Radzio, J Garcia-Lerma, JG Dobard, C Heneine, W Hendry, RM McNicholl, J AF Kersh, Ellen N. Henning, Tara Vishwanathan, S. Ajay Morris, Monica Butler, Katherine Adams, Debra R. Guenthner, Patricia Srinivasan, Priya Smith, James Radzio, Jessica Garcia-Lerma, J. Gerardo Dobard, Charles Heneine, Walid Hendry, R. Michael McNicholl, Janet TI SHIV SUSCEPTIBILITY CHANGES DURING THE MENSTRUAL CYCLE OF PIGTAIL MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Kersh, Ellen N.; Henning, Tara; Vishwanathan, S. Ajay; Morris, Monica; Butler, Katherine; Adams, Debra R.; Guenthner, Patricia; Srinivasan, Priya; Smith, James; Radzio, Jessica; Garcia-Lerma, J. Gerardo; Dobard, Charles; Heneine, Walid; Hendry, R. Michael; McNicholl, Janet] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 MA 34 BP 392 EP 393 PG 2 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700047 ER PT J AU Radzio, J Hanley, K Mitchell, J Ellis, S Deyounks, F Jenkins, LT Heneine, W Garcia-Lerma, JG AF Radzio, Jessica Hanley, Krisztina Mitchell, James Ellis, Shanon Deyounks, Frank Jenkins, Leecresia T. Heneine, Walid Garcia-Lerma, J. Gerardo TI MONTHLY 3 MG DEPOT-MEDROXYPROGESTERONE ACETATE (DMPA) SUPPRESSES PROGESTERONE AND RECAPITULATES PLASMA MPA EXPOSURES IN WOMEN SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Radzio, Jessica; Mitchell, James; Ellis, Shanon; Deyounks, Frank; Jenkins, Leecresia T.; Heneine, Walid; Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hanley, Krisztina] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 MA 53 BP 400 EP 401 PG 2 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700066 ER PT J AU Dobard, CW Sharma, S Taylor, A Wang, L Chuong, D Pau, CP Hanson, D Rohan, L McGowan, I Heneine, W AF Dobard, Charles W. Sharma, Sunita Taylor, Andrew Wang, Lin Chuong, Dinh Pau, Chou-Pong Hanson, Debra Rohan, Lisa McGowan, Ian Heneine, Walid TI RECTAL GEL CONTAINING MARAVIROC PROTECTS AGAINST RECTAL SHIV TRANSMISSION IN A MACAQUE MODEL SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Dobard, Charles W.; Sharma, Sunita; Chuong, Dinh; Pau, Chou-Pong; Heneine, Walid] Ctr Dis Control & Prevent, Branch Lab, Atlanta, GA USA. [Taylor, Andrew] Total Solut Inc, Madison, AL USA. [Wang, Lin; Rohan, Lisa; McGowan, Ian] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA USA. [Hanson, Debra] Ctr Dis Control & Prevent, Quantitat Sci & Data Management Branch, Div HIV AIDs Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 MA 55 BP 401 EP 401 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700068 ER PT J AU Garber, DA Johnson, CH Ritter, JM Skinner, BL Drew, CP Blaney, D Dietz, SM Engel, RM Gee, JE Elrod, MG Jones, TL Vinson, PE Dhara, VR Hoffmaster, AR Zaki, SR Lathrop, G Hendry, RM McNicholl, JM AF Garber, David A. Johnson, Crystal H. Ritter, Jana M. Skinner, Brianna L. Drew, Clifton P. Blaney, David Dietz, Sharon M. Engel, Robyn M. Gee, Jay E. Elrod, Mindy G. Jones, T. L. Vinson, Paul E. Dhara, V. Ramana Hoffmaster, Alex R. Zaki, Sherif R. Lathrop, George Hendry, R. Michael McNicholl, Janet M. TI BURKHOLDERIA PSEUDOMALLEI INFECTION OF PIGTAIL MACAQUES IMPORTED FROM INDONESIA TO CDC SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Garber, David A.; Hendry, R. Michael; McNicholl, Janet M.] Ctr Dis Control & Prevent, Div HIV AIDs Prevent, Branch Lab, Atlanta, GA USA. [Johnson, Crystal H.; Skinner, Brianna L.; Dietz, Sharon M.; Engel, Robyn M.; Lathrop, George] Ctr Dis Control & Prevent, Div Sci Resources, Anim Resources Branch, Atlanta, GA USA. [Ritter, Jana M.; Drew, Clifton P.; Jones, T. L.; Zaki, Sherif R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Infect Dis Pathol Branch, Atlanta, GA USA. [Blaney, David; Gee, Jay E.; Elrod, Mindy G.; Hoffmaster, Alex R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Bacterial Special Pathogens Branch, Atlanta, GA USA. [Vinson, Paul E.; Dhara, V. Ramana] Ctr Dis Control & Prevent, Environm Safety Hlth & Compliance Off, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 MA 113 BP 425 EP 425 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700126 ER PT J AU Engel, RM Morris, M Henning, T Ritter, JM Zaki, S Jones, T Dietz, S Ayers, J Vishwanathan, A Jenkins, L Garber, D Powell, N Wildemeersch, D Hendry, RM McNicholl, J Kersh, EN AF Engel, Robyn M. Morris, Monica Henning, Tara Ritter, Jana M. Zaki, Sherif Jones, Tara Dietz, Sharon Ayers, Jessica Vishwanathan, Ajay Jenkins, Leecresia Garber, David Powell, Nathanial Wildemeersch, Dirk Hendry, R. Michael McNicholl, Janet Kersh, Ellen N. TI EVALUATION OF PIGTAIL MACAQUES (MACACA NEMESTRINA) AS A MODEL FOR THE EFFECTS OF COPPER INTRAUTERINE DEVICES (IUDS) ON HIV INFECTION SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Engel, Robyn M.; Henning, Tara; Ritter, Jana M.; Zaki, Sherif; Jones, Tara; Dietz, Sharon; Ayers, Jessica; Vishwanathan, Ajay; Jenkins, Leecresia; Garber, David; Powell, Nathanial; McNicholl, Janet; Kersh, Ellen N.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Morris, Monica] Total Solut, Atlanta, GA USA. [Wildemeersch, Dirk] Contrel, Gynecol Outpatient Clin, Ghent, Belgium. [Wildemeersch, Dirk] IUD Training Ctr, Ghent, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 MA 120 BP 427 EP 428 PG 2 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700133 ER PT J AU Massud, I Dinh, C Martin, A Mitchell, J Jenkins, L Pau, CP Heneine, W Garcia-Lerma, JG AF Massud, Ivana Dinh, Chuong Martin, Amy Mitchell, James Jenkins, Leecresia Pau, Chou-Pong Heneine, Walid Garcia-Lerma, J. Gerardo TI PHARMACOKINETIC PROFILE OF ORAL ELVITEGRAVIR IN RHESUS MACAQUES AND ANTIVIRAL ACTIVITY IN RECTAL SECRETIONS SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Massud, Ivana; Dinh, Chuong; Martin, Amy; Mitchell, James; Jenkins, Leecresia; Pau, Chou-Pong; Heneine, Walid; Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 MA 122 BP 428 EP 428 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700135 ER PT J AU Pereira, LE Makarova, N Dobard, C Aubert, RD Srinivasan, P McNicholl, J Smith, J AF Pereira, Lara E. Makarova, Natalia Dobard, Charles Aubert, Rachael D. Srinivasan, Priya McNicholl, Janet Smith, James TI DEVELOPMENT AND OPTIMIZATION OF A NONENZYMATIC METHOD OF LEUKOCYTE ISOLATION FROM MACAQUE TISSUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Pereira, Lara E.] Lifesource Biomed LLC, Moffett Field, CA USA. [Makarova, Natalia; Dobard, Charles; Aubert, Rachael D.; Srinivasan, Priya; McNicholl, Janet; Smith, James] Ctr Dis Control & Prevent, Div HIV AIDs Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 MA 121 BP 428 EP 428 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700134 ER PT J AU Srinivasan, P Teller, RS Rastogi, R Dinh, C Zhang, JN Pau, CP McNicholl, JM Hendry, RM Mesquita, P Herold, BC Kiser, P Smith, JM AF Srinivasan, Priya Teller, Ryan S. Rastogi, Rachna Dinh, Chuong Zhang, Jining Pau, Chou-Pong McNicholl, Janet M. Hendry, R. Michael Mesquita, Pedro Herold, Betsy C. Kiser, Patrick Smith, James M. TI PHARMACOKINETIC EVALUATION OF TENOFOVIR DISOPROXIL FUMARATE RELEASED FROM AN INTRAVAGINAL RING IN PIG-TAILED MACAQUES AFTER 6 MONTHS OF CONTINUOUS USE SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Srinivasan, Priya; Dinh, Chuong; Zhang, Jining; Pau, Chou-Pong; McNicholl, Janet M.; Hendry, R. Michael; Smith, James M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Teller, Ryan S.; Rastogi, Rachna; Kiser, Patrick] Univ Utah, Dept Bioengn, Salt Lake City, UT USA. [Mesquita, Pedro; Herold, Betsy C.] Albert Einstein Coll Med, Dept Pediat & Microbiol Immunol, Bronx, NY 10467 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 MA 123 BP 428 EP 429 PG 2 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700136 ER PT J AU Aubert, RD Morris, M Butler, K Henning, T Mitchell, J Jenkins, L Garber, D Hendry, M McNicholl, J Kersh, E AF Aubert, Rachael D. Morris, Monica Butler, Katherine Henning, Tara Mitchell, James Jenkins, Leecresia Garber, David Hendry, Michael McNicholl, Janet Kersh, Ellen TI PRECLINICAL EVALUATION OF THE IMMUNOMODULATORY LYMPHOCYTE TRAFFICKING DRUG FTY720 FOR HIV PREVENTION IN THE FEMALE GENITAL MUCOSA OF MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Aubert, Rachael D.; Butler, Katherine; Henning, Tara; Mitchell, James; Jenkins, Leecresia; Garber, David; Hendry, Michael; McNicholl, Janet; Kersh, Ellen] Ctr Dis Control, Branch Lab, Div HIV AIDs Prevent, Natl Ctr HIV AIDs Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Morris, Monica] Total Solut, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2014 VL 43 IS 5 MA 124 BP 429 EP 429 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AQ3EZ UT WOS:000342673700137 ER PT J AU Buser, MC Murray, HE Scinicariello, F AF Buser, Melanie C. Murray, H. Edward Scinicariello, Franco TI Association of Urinary Phenols with Increased Body Weight Measures and Obesity in Children and Adolescents SO JOURNAL OF PEDIATRICS LA English DT Article ID ENDOCRINE DISRUPTORS; EXPOSURE; POPULATION; CHEMICALS; OBESOGENS; BIRTH AB Objective To examine the association of urinary levels of the environmental phenol pesticides 2,5-dichlorophenol, 2,4-dichlorophenol, and triclosan with body weight outcomes in children and adolescent participants in the National Health and Nutrition Examination Survey 2007-2010. Study design We performed multivariate linear and multinomial logistic regressions to analyze the association of body mass index (BMI) z-score, waist circumference (WC), and obesity with urinary pesticide concentration in children and adolescents. Results After adjustment for covariates, we found a statistically significant positive association (P < .05) between both 2,5-dichlorophenol and 2,4-dichlorophenol with BMI z-score, WC, and obesity in children and adolescents. After stratification by age, the significant associations remained only in adolescents (ages 12-19). No associations were found between triclosan and any of the body weight outcomes. Conclusions We found an association between dichlorophenols and increased body weight measures (BMI z-score, WC, and obesity) in adolescents. However, further studies, such as a longitudinal study, are needed to confirm and elucidate on our findings. C1 [Buser, Melanie C.; Murray, H. Edward; Scinicariello, Franco] Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA. RP Scinicariello, F (reprint author), Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, 4770 Buford Hwy,MS F57, Atlanta, GA 30341 USA. EM fes6@cdc.gov NR 26 TC 9 Z9 9 U1 0 U2 10 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD OCT PY 2014 VL 165 IS 4 BP 744 EP 749 DI 10.1016/j.jpeds.2014.06.039 PG 6 WC Pediatrics SC Pediatrics GA AQ3LD UT WOS:000342694200021 PM 25063718 ER PT J AU Veselsky, SL Walker, TY Fenlon, N Teo, CG Murphy, TV AF Veselsky, Steven L. Walker, Tanja Y. Fenlon, Nancy Teo, Chong-Gee Murphy, Trudy V. TI Discrepant Hepatitis B Surface Antigen Results in Pregnant Women Screened to Identify Hepatitis B Virus Infection SO JOURNAL OF PEDIATRICS LA English DT Article ID TRANSMISSION; RECOMMENDATIONS; IMMUNIZATION; VACCINATION; PREVENTION; PREVALENCE; NEWBORN; INFANTS; PROGRAM; MOTHERS AB Objective To resolve discrepant hepatitis B surface antigen (HBsAg) results for pregnant women screened for hepatitis B virus (HBV) infection. Study design A case was defined as discrepant HBsAg (reactive followed by non-reactive) result during the same pregnancy. The Centers for Disease Control and Prevention examined a convenience sample of cases passively reported by US Perinatal Hepatitis B Prevention Programs. Using a standard form, available results were obtained for hepatitis B tests and vaccination histories. Results were independently reviewed by 3 viral hepatitis experts and a clinical virologist to resolve discrepancies. The initial HBsAg result was classified as probable true positive, probable false positive, or unresolved. Results From April 2009-December 2011, 142 (75.9%) of 187 reported discrepant cases met the case definition. Of the 142 initial reactive HBsAg results, 113 (79.5%) were laboratory-confirmed, and 89 (62.7%) were resolved. Among these 89 cases, the initial test was a probable true positive in 14 (15.7%), and a false positive in 75 (84.3%). Total antibody to hepatitis B core antigen was positive for 11 (78.6%) of the true positive cases and negative for 67 (89.3%) of the false positive cases. True positives included 2 cases of resolving acute HBV infection and one case recently given hepatitis B vaccination. Conclusions In this retrospective analysis of discrepant HBsAg-reactive screening results from pregnant women, the majority were false positives, but true positives occurred. Testing for total hepatitis B core antibody, an indicator of past or current HBV infection, was useful for resolving discrepancies. C1 [Veselsky, Steven L.; Walker, Tanja Y.; Teo, Chong-Gee; Murphy, Trudy V.] US Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, Atlanta, GA USA. [Fenlon, Nancy] US Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Veselsky, SL (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, MSE-30,1600 Clifton Rd, Atlanta, GA 30333 USA. EM wos6@cdc.gov FU Research Participation Program at the Centers for Disease Control and Prevention [12FED1209578] FX Supported by the Research Participation Program at the Centers for Disease Control and Prevention, administered by the Oak Ridge Institute for Science and Education through an interagency agreement (ORISE Interagency Agreement [12FED1209578]) between the US Department of Energy and the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the Centers for Disease Control and Prevention. The authors declare no conflicts of interest. NR 23 TC 2 Z9 2 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD OCT PY 2014 VL 165 IS 4 BP 773 EP 778 DI 10.1016/j.jpeds.2014.06.043 PG 6 WC Pediatrics SC Pediatrics GA AQ3LD UT WOS:000342694200026 PM 25063719 ER PT J AU Looker, AC AF Looker, A. C. TI Hemoglobin and hip fracture risk in older non-Hispanic white adults SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Epidemiology; Hemoglobin; Hip fracture risk ID BONE-MINERAL DENSITY; IRON-DEFICIENCY DECREASES; UNITED-STATES; NATIONAL-HEALTH; ANEMIA; POPULATION; PREVALENCE; MORTALITY; MOBILITY; WOMEN AB The relationship between hemoglobin and hip fracture was examined in older non-Hispanic white adults from the third National Health and Nutrition Examination Survey (NHANES III). Both low and high hemoglobin values were associated with increased hip fracture risk before and after adjusting for selected risk factors. The few studies to date that have examined the relationship between hemoglobin and fracture risk have focused on low hemoglobin values. The present study examined hip fracture risk across the hemoglobin distribution in older non-Hispanic white adults from the third National Health and Nutrition Examination Survey (NHANES III, 1988-1994). Hemoglobin was measured using a Coulter S-plus Jr.A (R) (Coulter Electronics, Hialeah, FL) in 2,122 non-Hispanic whites age 65 years and older. Hip fracture cases were identified using linked Medicare and mortality records obtained through 2007. Cox proportional hazards models were used to assess the best-fitting model and to estimate the hazards ratio (HR) for hip fracture by hemoglobin decile before and after adjusting for selected confounders. There were 239 hip fracture cases in the analytic sample. The best fitting model was quadratic. When compared to values in the middle of the distribution, those with hemoglobin in the lowest and highest deciles had increased hip fracture risk (HRlowest decile = 2.96, 95 % confidence interval (CI) 1.44-6.08; HRhighest decile = 2.06, 95 % CI 1.09-3.92) after adjusting for age and sex. Both HRs remained significant after adjusting for additional confounders (HRlowest decile = 2.24, 95 % CI 1.09-3.92; HRhighest decile = 2.37, 95 % CI 1.35-4.16). Both low and high hemoglobin values were associated with increased hip fracture risk. The mechanism underlying the relationship is not clear, but there were some suggestions that it may differ for low versus high hemoglobin. C1 Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Looker, AC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Room 4310,3311 Toledo Rd, Hyattsville, MD 20782 USA. EM ALooker@cdc.gov FU Intramural CDC HHS [CC999999] NR 42 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD OCT PY 2014 VL 25 IS 10 BP 2389 EP 2398 DI 10.1007/s00198-014-2769-3 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP9YT UT WOS:000342438800005 PM 24938506 ER PT J AU Joyce, BT Berman, R Lau, DT AF Joyce, Brian T. Berman, Rebecca Lau, Denys T. TI Formal and informal support of family caregivers managing medications for patients who receive end-of-life care at home: A cross-sectional survey of caregivers SO PALLIATIVE MEDICINE LA English DT Article DE Hospices; caregivers; medication therapy management; social support ID OLDER-ADULTS; HOSPICE PATIENTS; NEGATIVE IMPACT; PALLIATIVE CARE; COMMUNITY; EXPERIENCES; BARRIERS; NEEDS; RISK; MANAGEMENT AB Background: Managing medications is a complex responsibility of family caregivers caring for end-of-life patients. This study characterizes caregivers with and without formal/informal support managing medications for patients who receive end-of-life care at home. Aim: To explore factors related to caregivers' support with managing medications for end-of-life home hospice patients. Design: A convenience-sampled, cross-sectional telephone survey. Setting/participants: Computer-assisted telephone interviews were administered to 120 caregivers managing medications, who were referred by five Chicago-based home hospice services. We measured caregivers' additional formal (paid) and informal (unpaid) support with managing medications, and caregiver/patient socio-demographic, relational, and health characteristics. Results: While 47 (39%) had no additional support with managing medications, 27 (22.5%) had formal support, 37 (31%) informal, and 9 (7.5%) both. Seven caregivers (19%) with formal and 13 (31%) with informal support reported disagreements concerning treatment plans. Caregivers lacking formal support tended to be racial/ethnic minorities, live with the patient in their home, or report greater emotional burden. Caregivers with formal support tended to report higher education/income, lower mutuality, or care for a patient with over 6 months' hospice enrollment. Caregivers lacking informal support tended to be spousal caregivers, live with the patient, or have experience caring for another dying person. Conclusion: Our study suggests that high proportions of caregivers may not have support managing medications for patients receiving hospice care at home. More research should examine whether the observed variations in obtaining support indicate disparities or unmet needs among caregivers. Disagreement about treatment with formal/informal support also warrants further investigation. C1 [Joyce, Brian T.] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA. [Berman, Rebecca] CJE SeniorLife, Leonard Schanfield Res Inst, Chicago, IL USA. [Lau, Denys T.] Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Lau, Denys T.] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA. RP Lau, DT (reprint author), Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 3315, Hyattsville, MD 20782 USA. EM DLau1@cdc.gov FU United States National Institute on Aging [K01AG027295] FX At the time when this research was conducted, Dr Denys T Lau was affiliated with the University of Illinois at Chicago, College of Pharmacy. This work was supported by the United States National Institute on Aging (Grant Number K01AG027295 to Principal Investigator: Denys T Lau). NR 56 TC 2 Z9 2 U1 2 U2 21 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0269-2163 EI 1477-030X J9 PALLIATIVE MED JI Palliat. Med. PD OCT PY 2014 VL 28 IS 9 BP 1146 EP 1155 DI 10.1177/0269216314535963 PG 10 WC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal SC Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine GA AQ1WA UT WOS:000342573200008 PM 24854033 ER PT J AU Edelman, EJ Gordon, KS Hogben, M Crystal, S Bryant, K Justice, AC Fiellin, DA AF Edelman, E. J. Gordon, K. S. Hogben, M. Crystal, S. Bryant, K. Justice, A. C. Fiellin, D. A. CA VACS Project Team TI Sexual Partner Notification of HIV Infection Among a National United States-Based Sample of HIV-Infected Men SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Sexual partners; Sexually transmitted diseases/prevention and control; Disease notification ID REFERRAL SERVICES; HEALTH; EXPERIENCES; ATTITUDES; STD AB Limited data exist on whether sexual partner notification practices among HIV-infected men, particularly those who have sex with men (MSM), vary by HIV viral load. We examined factors associated with complete (all partners) versus incomplete partner notification in 760 HIV-infected individuals across the United States, 49 % of whom were MSM. Thirty-four percent reported incomplete partner notification. Incomplete partner notification was more likely among black men, MSM, and those reporting casual partners and non-condom use. Partner notification practices did not vary by HIV viral load except among those with casual partners in whom a detectable viral load was associated with incomplete partner notification. Increased sexual partner notification among HIV-infected men, especially MSM, is needed. C1 [Edelman, E. J.; Justice, A. C.; Fiellin, D. A.] Yale Univ, Yale Sch Med, New Haven, CT 06520 USA. [Edelman, E. J.; Justice, A. C.; Fiellin, D. A.] Yale Univ, Ctr Interdisciplinary Res AIDS, New Haven, CT 06520 USA. [Gordon, K. S.; Justice, A. C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Hogben, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Crystal, S.] Rutgers State Univ, New Brunswick, NJ 08903 USA. [Bryant, K.] NIAAA, Bethesda, MD USA. RP Edelman, EJ (reprint author), Yale Univ, Yale Sch Med, POB 208025, New Haven, CT 06520 USA. EM ejennifer.edelman@yale.edu OI Fiellin, David/0000-0002-4006-010X FU NIAAA NIH HHS [U01 AA013566, U01 AA020790, U10 AA013566, U10-AA13566, U24 AA020794]; NIDA NIH HHS [K12 DA033312, K12DA033312-01A1] NR 20 TC 4 Z9 4 U1 1 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2014 VL 18 IS 10 BP 1898 EP 1903 DI 10.1007/s10461-014-0799-7 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AP9UF UT WOS:000342425000006 PM 24858394 ER PT J AU Heeren, GA Icard, LD O'Leary, A Jemmott, JB Ngwane, Z Mtose, X AF Heeren, G. Anita Icard, Larry D. O'Leary, Ann Jemmott, John B., III Ngwane, Zolani Mtose, Xoliswa TI Protective Factors and HIV Risk Behavior Among South African Men SO AIDS AND BEHAVIOR LA English DT Article DE South Africa; Men; Protective factors; Condom use; Human immunodeficiency virus ID CONDOM-USE; REDUCTION INTERVENTION; HIV/AIDS; WOMEN; SEX; COMMUNICATION; METAANALYSIS; INVOLVEMENT; PREVENTION; MEDIATION AB The primary mode of HIV transmission in South Africa is heterosexual sexual behavior. HIV prevention research specifically focusing on men in South Africa is limited. We assessed self-reported HIV risk behaviors in 1,181 men ages 18 to 45 years in randomly selected neighborhoods in Eastern Cape Province, South Africa. Older men were less likely to report having multiple partners. Religiosity was a protective factor for condom use and unprotected sex with steady partners. Discussing using condoms was a protective factor for condom use and unprotected sex with both steady and casual partners. Having a child was associated with decreased condom use with steady partners and employment was associated with decreased condom use with casual partners. The findings suggest the need for HIV risk-reduction behavioral interventions tailored for South African men with regard to age, religiosity, and types of sexual partners. Implications for the development of such interventions are discussed. C1 [Heeren, G. Anita; Jemmott, John B., III] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Icard, Larry D.] Temple Univ, Coll Hlth Profess & Social Work, Philadelphia, PA 19122 USA. [O'Leary, Ann] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jemmott, John B., III] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. [Ngwane, Zolani] Haverford Coll, Dept Anthropol, Haverford, PA 19041 USA. [Mtose, Xoliswa] Univ Ft Hare, Fac Educ, East London, South Africa. RP Jemmott, JB (reprint author), Univ Penn, Perelman Sch Med, Dept Psychiat, 3535 Market St,Suite 520, Philadelphia, PA 19104 USA. EM jjemmott@asc.upenn.edu FU NIAID NIH HHS [P30 AI045008]; NICHD NIH HHS [R01 HD053270]; NIMH NIH HHS [R01 MH065867] NR 38 TC 2 Z9 2 U1 1 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2014 VL 18 IS 10 BP 1991 EP 1997 DI 10.1007/s10461-014-0767-2 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AP9UF UT WOS:000342425000015 PM 24722765 ER PT J AU Ahluwalia, N Herrick, K Moshfegh, A Rybak, M AF Ahluwalia, Namanjeet Herrick, Kirsten Moshfegh, Alanna Rybak, Michael TI Caffeine intake in children in the United States and 10-y trends: 2001-2010 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID ENERGY DRINK CONSUMPTION; YOUNG-CHILDREN; ADOLESCENTS; ADULTS; CHILDHOOD; HEALTH; SLEEP; US AB Background: Because of the increasing concern of the potential adverse effects of caffeine intake in children, recent estimates of caffeine consumption in a representative sample of children are needed. Objectives: We provide estimates of caffeine intake in children in absolute amounts (mg) and in relation to body weight (mg/kg) to examine the association of caffeine consumption with sociodemographic factors and describe trends in caffeine intake in children in the United States. Design: We analyzed caffeine intake in 3280 children aged 2-19 y who participated in a 24-h dietary recall as part of the NHANES, which is a nationally representative survey of the US population with a cross-sectional design, in 2009-2010. Trends over time between 2001 and 2010 were examined in 2-19-y-old children (n = 18,530). Analyses were conducted for all children and repeated for caffeine consumers. Results: In 2009-2010, 71% of US children consumed caffeine on a given day. Median caffeine intakes for 2-5-, 6-11-, and 12-19-y olds were 1.3, 4.5, and 13.6 mg, respectively, and 4.7, 9.1, and 40.6 mg, respectively, in caffeine consumers. Non-Hispanic black children had lower caffeine intake than that of non-Hispanic white counterparts. Caffeine intake correlated positively with age; this association was independent of body weight. On a given day, 10% of 12-19-y-olds exceeded the suggested maximum caffeine intake of 2.5 mg/kg by Health Canada. A significant linear trend of decline in caffeine intake (in mg or mg/kg) was noted overall for children aged 2-19 y during 2001-2010. Specifically, caffeine intake declined by 3.0 and 4.6 mg in 2-5- and 6-11-y-old caffeine consumers, respectively; no change was noted in 12-19-y-olds. Conclusion: A majority of US children including preschoolers consumed caffeine. Caffeine intake was highest in 12-19-y-olds and remained stable over the 10-y study period in this age group. C1 [Ahluwalia, Namanjeet; Herrick, Kirsten] CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Rybak, Michael] Natl Ctr Environm Hlth, Atlanta, GA USA. [Moshfegh, Alanna] USDA ARS, Food Surveys Res Grp, Beltsville Human Nutr Res Ctr, Beltsville, MD 20705 USA. RP Ahluwalia, N (reprint author), CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4110, Hyattsville, MD 20782 USA. EM naman.ahluwalia@cdc.gov OI Rybak, Michael/0000-0003-1650-8581 NR 44 TC 8 Z9 8 U1 3 U2 18 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD OCT PY 2014 VL 100 IS 4 BP 1124 EP 1132 DI 10.3945/ajcn.113.082172 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AP7OT UT WOS:000342267300019 PM 25240076 ER PT J AU Blackley, DJ Retzer, KD Hubler, WG Hill, RD Laney, AS AF Blackley, David J. Retzer, Kyla D. Hubler, Warren G. Hill, Ryan D. Laney, A. Scott TI Injury Rates on New and Old Technology Oil and Gas Rigs Operated by the Largest United States Onshore Drilling Contractor SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE oil and gas extraction; drilling contractors; domestic energy; occupational injuries; engineering controls AB BackgroundOccupational fatality rates among oil and gas extraction industry and specifically among drilling contractor workers are high compared to the U.S. all-industry average. There is scant literature focused on non-fatal injuries among drilling contractors, some of which have introduced engineering controls to improve rig efficiency and reduce injury risk. MethodsWe compared injury rates on new and old technology rigs operated by the largest U.S. drilling contractor during 2003-2012, stratifying by job type and grouping outcomes by injury severity and body part affected. ResultsSix hundred seventy-one injuries were recorded over 77.4 million person-hours. The rate on new rigs was 66% of that on old rigs. Roughnecks had lower injury rates on new rigs, largely through reduced limb injury rates. New rigs had lower rates in each non-fatal injury severity category. ConclusionsFor this company, new technology rigs appear to provide a safer environment for roughnecks. Future studies could include data from additional companies. Am. J. Ind. Med. 57:1188-1192, 2014. (c) 2014 Wiley Periodicals, Inc. C1 [Blackley, David J.; Laney, A. Scott] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Blackley, David J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA USA. [Retzer, Kyla D.] NIOSH, Western States Off, Oil & Gas Extract Program, Ctr Dis Control & Prevent, Denver, CO USA. [Hubler, Warren G.] Helmerich & Payne Int Drilling Co, Hlth Safety & Environm Div, Tulsa, OK USA. [Hill, Ryan D.] NIOSH, Off Director, Oil & Gas Sector Program, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Blackley, DJ (reprint author), NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. EM dblackley@cdc.gov FU Intramural CDC HHS [CC999999] NR 9 TC 1 Z9 1 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD OCT PY 2014 VL 57 IS 10 BP 1188 EP 1192 DI 10.1002/ajim.22356 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP7UD UT WOS:000342281300013 PM 25164118 ER PT J AU Masterson, EA Tak, S Themann, CL Wall, DK Groenewold, MR Deddens, JA Calvert, GM AF Masterson, Elizabeth A. Tak, SangWoo Themann, Christa L. Wall, David K. Groenewold, Matthew R. Deddens, James A. Calvert, Geoffrey M. TI Prevalence of Hearing Loss in the United States by Industry (vol 56, pg 670, 2013) SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Correction C1 [Masterson, Elizabeth A.; Themann, Christa L.; Wall, David K.; Groenewold, Matthew R.; Deddens, James A.; Calvert, Geoffrey M.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Tak, SangWoo] Massachusetts Dept Publ Hlth, Boston, MA USA. RP Masterson, EA (reprint author), NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. NR 1 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD OCT PY 2014 VL 57 IS 10 BP 1193 EP 1193 DI 10.1002/ajim.22308 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP7UD UT WOS:000342281300014 ER PT J AU Roberge, RJ Kim, JH Powell, JB AF Roberge, Raymond J. Kim, Jung-Hyun Powell, Jeffrey B. TI N95 respirator use during advanced pregnancy SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Pregnancy; Respiratory protective equipment; Physiological response; Subjective response; Fetal heart rate ID FILTERING FACEPIECE RESPIRATORS; HEALTH-CARE WORKERS; GAS MASK; PHYSIOLOGICAL IMPACT; SURGICAL MASK; RESPONSES; DISEASE; PULMONARY AB Background: To determine the physiological and subjective effects of wearing an N95 filtering facepiece respirator (N95 FFR) in advanced stages of pregnancy. Methods: Healthy pregnant women (n = 22) and nonpregnant women (n = 22) had physiological and subjective measurements taken with and without wearing an N95 FFR during exercise and postural sedentary activities over a 1-hour period. Results: There were no differences between the pregnant and nonpregnant women with respect to heart rate, respiratory rate, oxygen saturation, transcutaneous carbon dioxide level, chest wall temperature, aural temperature, and subjective perceptions of exertion and thermal comfort. No significant effect on fetal heart rate was noted. Conclusions: Healthy pregnant women wearing an N95 FFR for 1 hour during exercise and sedentary activities did not exhibit any significant differences in measured physiological and subjective responses compared with nonpregnant women. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Roberge, Raymond J.; Kim, Jung-Hyun; Powell, Jeffrey B.] NIOSH, Ctr Dis Control & Prevent, US Natl Personal Protect Technol Lab, Pittsburgh, PA USA. RP Roberge, RJ (reprint author), Natl Personal Protect Technol Lab, 636 Cochrans Mill Rd, Pittsburgh, PA 15236 USA. EM dtn0@cdc.gov FU National Personal Protective Technology Laboratory/National Institute for Occupational Safety and Health FX Funded by internal operating funds of the National Personal Protective Technology Laboratory/National Institute for Occupational Safety and Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. Mention of product names does not imply endorsement. NR 37 TC 6 Z9 6 U1 0 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT PY 2014 VL 42 IS 10 BP 1097 EP 1100 DI 10.1016/j.ajic.2014.06.025 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AP9FZ UT WOS:000342385700015 PM 25278401 ER PT J AU Lin, AE Krikov, S Riehle-Colarusso, T Frias, JL Belmont, J Anderka, M Geva, T Getz, KD Botto, LD AF Lin, Angela E. Krikov, Sergey Riehle-Colarusso, Tiffany Frias, Jaime L. Belmont, John Anderka, Marlene Geva, Tal Getz, Kelly D. Botto, Lorenzo D. CA Natl Birth Defects Prevention TI Laterality Defects in the National Birth Defects Prevention Study (1998-2007): Birth Prevalence and Descriptive Epidemiology SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE asplenia; cardiovascular malformations; congenital heart defects; dextrocardia; heterotaxy; isomerism; laterality defects; malposition; prevalence; race/ethnic disparities; situs ambiguous; situs inversus ID CONGENITAL HEART-DISEASE; PRIMARY CILIARY DYSKINESIA; ANOMALIES; HETEROTAXIA; CLASSIFICATION; ASYMMETRY; DIAGNOSIS; NEWBORNS; ATLANTA AB Little is known epidemiologically about laterality defects. Using data from the National Birth Defects Prevention Study (NBDPS), a large multi-site case-control study of birth defects, we analyzed prevalence and selected characteristics in children born with laterality defects born from 1998 to 2007. We identified 517 nonsyndromic cases (378 heterotaxy, 73.1%; 139 situs inversus totalis [SIT], 26.9%) resulting in an estimated birth prevalence of 1.1 per 10,000 live births (95% confidence interval 1.0-1.2). Prevalence did not differ significantly across sites, over time, or by inclusion of pregnancy termination. Laterality defects were more common among preterm cases compared to term cases, and in children born to mothers who were non-white or younger than 20 years compared to white mothers or those age 25-29 years. The distribution of associated cardiac and extra-cardiac defects, excluding the expected heterotaxy anomalies, varied by type of laterality defect. Cases with heterotaxy were significantly more likely than those with SIT to have double outlet right ventricle, atrioventricular canal defects, pulmonary stenosis, non-tetralogy of Fallot pulmonary atresia with ventricular septal defect, totally and partially anomalous pulmonary venous return; also more likely to have orofacial clefts, esophageal atresia, bowel atresias, and omphalocele, though not reaching statistical significance. Relatively more common among cases with SIT were Dandy-Walker malformation, anotia/microtia, and limb deficiency. The similarity in the demographic characteristics of heterotaxy and SIT supports the hypothesis that they are part of a continuum of abnormal left-right axis patterning. These findings on laterality defects may help guide clinical care, future research, and prevention strategies. (C) 2014 Wiley Periodicals, Inc. C1 [Lin, Angela E.] MassGen Hosp Children, Boston, MA 02114 USA. [Lin, Angela E.; Anderka, Marlene; Getz, Kelly D.] Massachusetts Ctr Birth Defects Res & Prevent, Boston, MA USA. [Krikov, Sergey; Botto, Lorenzo D.] Univ Utah, Dept Pediat, Div Med Genet, Salt Lake City, UT USA. [Riehle-Colarusso, Tiffany; Frias, Jaime L.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Frias, Jaime L.] McKing Consulting Corp, Fairfax, VA USA. [Belmont, John] Baylor Coll Med, Houston, TX 77030 USA. [Geva, Tal] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA. RP Lin, AE (reprint author), MassGen Hosp Children, 185 Cambridge St,CPZN 2222, Boston, MA 02114 USA. EM lin.angela@mgh.harvard.edu FU Centers for Disease Control and Prevention Centers of Excellence Award [U50/CCU925286] FX Grant sponsor: Centers for Disease Control and Prevention Centers of Excellence Award No.; Grant number: U50/CCU925286. NR 35 TC 17 Z9 18 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD OCT PY 2014 VL 164 IS 10 BP 2581 EP 2591 DI 10.1002/ajmg.a.36695 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA AP7TM UT WOS:000342279600026 PM 25099286 ER PT J AU Rossen, LM Talih, M AF Rossen, Lauren M. Talih, Makram TI Social determinants of disparities in weight among US children and adolescents SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Epidemiologic methods; Health status disparities; Multilevel analysis; Propensity score; Obesity; Residence characteristics; Social determinants of health ID BODY-MASS INDEX; NEIGHBORHOOD SOCIOECONOMIC-STATUS; UNITED-STATES; RESIDENTIAL SEGREGATION; EXTREME OBESITY; RACIAL/ETHNIC DISPARITIES; ETHNIC DISPARITIES; HEALTH DISPARITIES; BUILT ENVIRONMENT; PHYSICAL-ACTIVITY AB Purpose: To explore whether contextual variables attenuate disparities in weight among 18,639 US children and adolescents aged 2 to 18 years participating in the National Health and Nutrition Examination Survey, 2001 to 2010. Methods: Disparities were assessed using the Symmetrized Renyi Index, a new measure that summarizes disparities in the severity of a disease, as well as the prevalence, across multiple population groups. Propensity score subclassification was used to ensure covariate balance between racial and ethnic subgroups and account for individual-level and contextual covariates. Results: Before propensity score subclassification, significant disparities were evident in the prevalence of overweight and/or obesity and the degree of excess weight among overweight/obese children and adolescents. After propensity score subclassification, racial/ethnic disparities in the prevalence and severity of excess weight were completely attenuated within matched groups, indicating that racial and ethnic differences were explained by social determinants such as neighborhood socioeconomic and demographic factors. Conclusions: The limited overlap in covariate distributions between various racial/ethnic subgroups warrants further attention in disparities research. The attenuation of disparities within matched groups suggests that social determinants such as neighborhood socioeconomic factors may engender disparities in weight among US children and adolescents. Published by Elsevier Inc. C1 [Rossen, Lauren M.; Talih, Makram] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, Hyattsville, MD 20782 USA. RP Rossen, LM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, Infant Child & Womens Hlth Stat Branch, 3311 Toledo Rd,Room 6121, Hyattsville, MD 20782 USA. EM lrossen@cdc.gov FU Intramural CDC HHS [CC999999] NR 92 TC 10 Z9 10 U1 7 U2 30 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD OCT PY 2014 VL 24 IS 10 BP 705 EP 713 DI 10.1016/j.annepidem.2014.07.010 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP8KY UT WOS:000342329100001 PM 25174287 ER PT J AU Gupta, S Granich, R Date, A Lepere, P Hersh, B Gouws, E Samb, B AF Gupta, S. Granich, R. Date, A. Lepere, P. Hersh, B. Gouws, E. Samb, B. TI Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Review DE ART; IPT; HIV testing; Three I's for HIV/TB ID ANTIRETROVIRAL THERAPY; TUBERCULOSIS; INFECTION; PREVALENCE; IMPACT AB Issuance of national policy guidance is a critical step to ensure quality HIV-TB (human immunodeficiency virus-tuberculosis) coordination and programme implementation. From the database of the Joint United Nations Programme on HIV/AIDS (UNAIDS), we reviewed 62 national HIV and TB guidelines from 23 high-burden countries for recommendations on HIV testing for TB patients, criteria for initiating antiretroviral therapy (ART) and the Three I's for HIV/TB (isoniazid preventive treatment [IPT], intensified TB case finding and TB infection control). We used UNAIDS country-level programme data to determine the status of implementation of existing guidance. Of the 23 countries representing 89% of the global HIV-TB burden, Brazil recommends ART irrespective of CD4 count for all people living with HIV, and four (17%) countries recommend ART at the World Health Organization (WHO) 2013 guidelines level of CD4 count <= 500 cells/mm(3) for asymptomatic persons. Nineteen (83%) countries are consistent with WHO 2013 guidelines and recommend ART for HIV-positive TB patients irrespective of CD4 count. IPT is recommended by 16 (70%) countries, representing 67% of the HIV-TB burden; 12 recommend symptom-based screening alone for IPT initiation. Guidelines from 15 (65%) countries with 79% of the world's HIV-TB burden include recommendations on HIV testing and counselling for TB patients. Although uptake of ART, HIV testing for TB patients, TB screening for people living with HIV and IPT have increased significantly, progress is still limited in many countries. There is considerable variance in the timing and content of national policies compared with WHO guidelines. Missed opportunities to implement new scientific evidence and delayed adaptation of existing WHO guidance remains a key challenge for many countries. C1 [Gupta, S.; Granich, R.; Lepere, P.; Samb, B.] Joint United Nations Programme HIV AIDS UNAIDS, Special Initiat, CH-1211 Geneva 27, Switzerland. [Date, A.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Hersh, B.] UNAIDS, Global Financing Mech & Collaborat Div, Geneva, Switzerland. [Gouws, E.] UNAIDS, Reg Support Team, Johannesburg, South Africa. RP Gupta, S (reprint author), Joint United Nations Programme HIV AIDS UNAIDS, Ave Appia 20, CH-1211 Geneva 27, Switzerland. EM somyagupta17@gmail.com NR 39 TC 16 Z9 16 U1 1 U2 12 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD OCT PY 2014 VL 18 IS 10 BP 1149 EP 1158 DI 10.5588/ijtld.13.0889 PG 10 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA AP7PU UT WOS:000342270000005 PM 25216827 ER PT J AU Gupta, S Abimbola, T Date, A Suthar, AB Bennett, R Sangrujee, N Granich, R AF Gupta, S. Abimbola, T. Date, A. Suthar, A. B. Bennett, R. Sangrujee, N. Granich, R. TI Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE isoniazid; Xpert (R) MTB/RIF; intensified TB case finding; economic analysis ID ANTIRETROVIRAL THERAPY; PRIMARY-CARE; TUBERCULOSIS; DIAGNOSIS; ADULTS; TRIAL AB OBJECTIVE: To evaluate the cost-effectiveness of the Three I's for HIV/TB (human immunodeficiency virus/tuberculosis): antiretroviral therapy (ART), intensified TB case finding (ICF), isoniazid preventive treatment (IPT), and TB infection control (IC). METHODS: Using a 3-year decision-analytic model, we estimated the cost-effectiveness of a base scenario (55% ART coverage at CD4 count <= 350 cells/mm(3)) and 19 strategies that included one or more of the following: 1) 90% ART coverage, 2) IC and 3) ICF using four-symptom screening and 6- or 36-month IPT. The TB diagnostic algorithm included 1) sputum smear microscopy with chest X-ray, and 2) Xpert (R) MTB/RIF. RESULTS: In resource-constrained settings with a high burden of HIV and TB, the most cost-effective strategies under both diagnostic algorithms included 1) 55% ART coverage and IC, 2) 55% ART coverage, IC and 36-month IPT, and 3) expanded ART at 90% coverage with IC and 36-month IPT. The latter averted more TB cases than other scenarios with increased ART coverage, IC, 6-month IPT and/or IPT for tuberculin skin test positive individuals. The cost-effectiveness results did not change significantly under the sensitivity analyses. CONCLUSION: Expanded ART to 90% coverage, IC and a 36-month IPT strategy averted most TB cases and is among the cost-effective strategies. C1 [Gupta, S.; Granich, R.] Joint United Nations Programme HIV AIDS, Geneva, Switzerland. [Abimbola, T.; Date, A.; Sangrujee, N.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Suthar, A. B.] Univ Stellenbosch, South African Ctr Epidemiol Modelling & Anal, Cape Town, South Africa. RP Gupta, S (reprint author), Joint United Nations Programme HIV AIDS UNAIDS, Ave Appia 20, CH-1211 Geneva 27, Switzerland. EM somyagupta17@gmail.com FU Intramural CDC HHS [CC999999] NR 29 TC 4 Z9 4 U1 1 U2 6 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD OCT PY 2014 VL 18 IS 10 BP 1159 EP 1165 DI 10.5588/ijtld.13.0571 PG 7 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA AP7PU UT WOS:000342270000006 PM 25216828 ER PT J AU Rasberry, CN Cheung, K Buckley, R Dunville, R Daniels, B Cook, D Robin, L Dean, B AF Rasberry, Catherine N. Cheung, Karen Buckley, Rebekah Dunville, Richard Daniels, Brandy Cook, Deborah Robin, Leah Dean, Blair TI Indicators of asthma control among students in a rural, school-based asthma management program SO JOURNAL OF ASTHMA LA English DT Article DE Asthma; asthma control; schools; children; education; evaluation; pediatrics; youth ID CONTROL QUESTIONNAIRE; VALIDATION; TRIAL AB Objective: The evaluation sought to determine if a comprehensive, school-based asthma management program in a small, rural school district helped students improve asthma control. Methods: To determine if students in the asthma program demonstrated better asthma control than students in a comparison school district, the evaluation team used a quasi-experimental, cross-sectional design and administered questionnaires assessing asthma control (which included FEV1 measurement) to 456 students with asthma in the intervention and comparison districts. Data were analyzed for differences in asthma control between students in the two districts. To determine if students in the intervention experienced increased asthma control between baseline and follow-up, the evaluation team used a one-group retrospective design. Program records for 323 students were analyzed for differences in percent of predicted forced expiratory volume in one second (FEV1) between baseline and follow-up. Results: Students with asthma in the intervention district exhibited significantly better asthma control than students with asthma in the comparison district. Percent of predicted FEV1 did not change significantly between baseline and follow-up for the intervention participants; however, post hoc analyses revealed students with poorly controlled asthma at baseline had significantly higher FEV1 scores at follow-up, and students with well-controlled asthma at baseline had significantly lower FEV1 scores at follow-up. Conclusions: Findings suggest that the comprehensive school-based program led to improvements in asthma control for students with poorly controlled asthma at baseline, and school-based programs need mechanisms for tracking students with initially well-controlled asthma to ensure they maintain control. C1 [Rasberry, Catherine N.; Dunville, Richard; Robin, Leah] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Adolescent, Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Rasberry, Catherine N.; Dunville, Richard; Robin, Leah] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Sch Hlth, Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Cheung, Karen; Daniels, Brandy; Dean, Blair] ICF Int Publ Hlth & Survey Res Div, Atlanta, GA USA. [Buckley, Rebekah] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Ctr Dis Control & Prevent, Atlanta, GA USA. [Cook, Deborah] Kennett Publ Sch, Kennett, MO USA. RP Rasberry, CN (reprint author), Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Adolescent, Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-75, Atlanta, GA 30329 USA. EM CRasberry@cdc.gov RI Rasberry, Catherine/P-1984-2016 OI Rasberry, Catherine/0000-0001-8256-6961 FU Centers for Disease Control and Prevention's (CDC) Division of Adolescent and School Health (DASH) [200-2009-30503]; ICF International FX Technical assistance for this evaluation was funded by the Centers for Disease Control and Prevention's (CDC) Division of Adolescent and School Health (DASH) under contract #200-2009-30503 with ICF International. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 24 TC 3 Z9 3 U1 0 U2 4 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 EI 1532-4303 J9 J ASTHMA JI J. Asthma PD OCT PY 2014 VL 51 IS 8 BP 876 EP 885 DI 10.3109/02770903.2014.913620 PG 10 WC Allergy; Respiratory System SC Allergy; Respiratory System GA AP6QT UT WOS:000342203100012 PM 24730771 ER PT J AU Baltazar, CS Raposo, C Jani, IV Shodell, D Correia, D da Silva, CG Kalou, M Patel, H Parekh, B AF Baltazar, Cynthia Sema Raposo, Cristina Jani, Ilesh V. Shodell, Daniel Correia, Della da Silva, Cristiane Goncalves Kalou, Mireille Patel, Hetal Parekh, Bharat TI Evaluation of Performance and Acceptability of Two Rapid Oral Fluid Tests for HIV Detection in Mozambique SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID DIAGNOSTIC-ACCURACY; INFECTION; AFRICA AB Simplified HIV testing based on oral fluid (OF) may allow the expansion of HIV infection counseling and testing (CT) while reducing the risk due to exposure to needles and blood collection. This study evaluated the performance and acceptability of two OF tests (the OraQuick Advance Rapid HIV-1/2 and the Chembio DPP HIV-1/2) from May to September 2009 in two CT sites in Maputo City, Mozambique, compared with results for the national testing algorithm. OF testing was conducted in parallel with whole blood-based testing according to the national HIV algorithm. Blood samples were collected as dried blood spot (DBS) specimens from all participants for quality assurance. HIV infection results were delivered according to the national algorithm. According to the national HIV algorithm, 512 (30.5%) samples were reactive, 1,151 (68.7%) were nonreactive, and 13 (0.8%) were discordant. All discordant cases were retested with an enzyme immunoassay followed by Western blotting, and five (38.5%) were confirmed as HIV positive. The OraQuick OF test showed 518 (30.9%) reactive samples and 1,158 (69.1%) nonreactive samples, with a sensitivity and specificity of 99.8% and 99.8%, respectively. The Chembio DPP OF test showed 519 (31.0%) reactive samples and 1,157 (69.0%) nonreactive samples with a sensitivity and specificity of 100% and 99.8%, respectively. The participants perceived blood testing (49.9%) to be more accurate than OF testing (46.8%). The OF tests showed high performance for the diagnosis of HIV infection when examined individually and in an algorithm, compared with results according to the national testing algorithm. C1 [Baltazar, Cynthia Sema; Jani, Ilesh V.] Inst Nacl Saude, Maputo, Mozambique. [Raposo, Cristina; Shodell, Daniel; Correia, Della] CDC, Maputo, Mozambique. [da Silva, Cristiane Goncalves] FUJB, Maputo, Mozambique. [Kalou, Mireille; Patel, Hetal; Parekh, Bharat] CDC, Atlanta, GA 30333 USA. RP Shodell, D (reprint author), CDC, Maputo, Mozambique. EM dshodell@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR); Mozambican Ministry of Health; Jhpiego [U2G/PS001542]; Centers for Disease Control and Prevention (CDC) FX This work was supported by funds from the President's Emergency Plan for AIDS Relief (PEPFAR), through the Centers for Disease Control and Prevention (CDC) and implementing partners the Mozambican Ministry of Health and Jhpiego, under the terms of cooperative agreement no. U2G/PS001542. The findings and conclusions presented are those of the authors and do not necessarily represent the official position of the supporting institutions. NR 20 TC 4 Z9 4 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2014 VL 52 IS 10 BP 3544 EP 3548 DI 10.1128/JCM.01098-14 PG 5 WC Microbiology SC Microbiology GA AP9AX UT WOS:000342371700005 ER PT J AU Bowden, KE Williams, MM Cassiday, PK Milton, A Pawloski, L Harrison, M Martin, SW Meyer, S Qin, X DeBolt, C Tasslimi, A Syed, N Sorrell, R Tran, M Hiatt, B Tondella, ML AF Bowden, Katherine E. Williams, Margaret M. Cassiday, Pamela K. Milton, Andrea Pawloski, Lucia Harrison, Marsenia Martin, Stacey W. Meyer, Sarah Qin, Xuan DeBolt, Chas Tasslimi, Azadeh Syed, Nusrat Sorrell, Ronald Tran, Mike Hiatt, Brian Tondella, Maria Lucia TI Molecular Epidemiology of the Pertussis Epidemic in Washington State in 2012 SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID IMMUNIZATION PRACTICES ACIP; DEFICIENT BORDETELLA-PERTUSSIS; PERTACTIN-NEGATIVE VARIANTS; TANDEM-REPEAT ANALYSIS; UNITED-STATES; ADVISORY-COMMITTEE; PREVENTING TETANUS; TEMPORAL TRENDS; DIVERSITY; STRAINS AB Although pertussis disease is vaccine preventable, Washington State experienced a substantial rise in pertussis incidence beginning in 2011. By June 2012, the reported cases reached 2,520 (37.5 cases per 100,000 residents), a 1,300% increase compared with the same period in 2011. We assessed the molecular epidemiology of this statewide epidemic using 240 isolates collected from case patients reported from 19 of 39 Washington counties during 2012 to 2013. The typing methods included pulsed-field gel electrophoresis (PFGE), multilocus variable number tandem repeat analysis (MLVA), multilocus sequence typing (MLST), and pertactin gene (prn) mutational analysis. Using the scheme PFGE-MLVA-MLST-prn mutations-Prn deficiency, the 240 isolates comprised 65 distinct typing profiles. Thirty-one PFGE types were found, with the most common types, CDC013 (n = 51), CDC237 (n = 44), and CDC002 (n = 42), accounting for 57% of them. Eleven MLVA types were observed, mainly comprising type 27 (n = 183, 76%). Seven MLST types were identified, with the majority of the isolates typing as prn2-ptxP3-ptxA1-fim3-1 (n = 157, 65%). Four different prn mutations accounted for the 76% of isolates exhibiting pertactin deficiency. PFGE provided the highest discriminatory power (D = 0.87) and was found to be a more powerful typing method than MLVA and MLST combined (D = 0.67). This study provides evidence for the continued predominance of MLVA 27 and prn2-ptxP3-ptxA1 alleles, along with the reemergence of the fim3-1 allele. Our results indicate that the Bordetella pertussis population causing this epidemic was diverse, with a few molecular types predominating. The PFGE, MLVA, and MLST profiles were consistent with the predominate types circulating in the United States and other countries. For prn, several mutations were present in multiple molecular types. C1 [Bowden, Katherine E.; Williams, Margaret M.; Cassiday, Pamela K.; Milton, Andrea; Pawloski, Lucia; Harrison, Marsenia; Martin, Stacey W.; Meyer, Sarah; Tondella, Maria Lucia] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Qin, Xuan] Seattle Childrens Hosp, Seattle, WA USA. [DeBolt, Chas; Tasslimi, Azadeh] Washington State Dept Hlth, Communicable Dis Epidemiol, Shoreline, WA USA. [Syed, Nusrat; Sorrell, Ronald; Tran, Mike; Hiatt, Brian] Washington State Dept Hlth, Publ Hlth Labs, Off Microbiol, Shoreline, WA USA. RP Tondella, ML (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM mlt5@cdc.gov OI Bowden, Katherine/0000-0002-7877-8205 NR 42 TC 19 Z9 20 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2014 VL 52 IS 10 BP 3549 EP 3557 DI 10.1128/JCM.01189-14 PG 9 WC Microbiology SC Microbiology GA AP9AX UT WOS:000342371700006 PM 25031439 ER PT J AU Duong, YT Mavengere, Y Patel, H Moore, C Manjengwa, J Sibandze, D Rasberry, C Mlambo, C Li, Z Emel, L Bock, N Moore, J Nkambule, R Justman, J Reed, J Bicego, G Ellenberger, DL Nkengasong, JN Parekh, BS AF Duong, Yen T. Mavengere, Yvonne Patel, Hetal Moore, Carole Manjengwa, Julius Sibandze, Dumile Rasberry, Christopher Mlambo, Charmaine Li, Zhi Emel, Lynda Bock, Naomi Moore, Jan Nkambule, Rejoice Justman, Jessica Reed, Jason Bicego, George Ellenberger, Dennis L. Nkengasong, John N. Parekh, Bharat S. TI Poor Performance of the Determine HIV-1/2 Ag/Ab Combo Fourth-Generation Rapid Test for Detection of Acute Infections in a National Household Survey in Swaziland SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ACUTE HIV-INFECTION; IMMUNODEFICIENCY-VIRUS-INFECTION; P24 ANTIGEN; NUCLEIC-ACID; TRANSMISSION; ASSAY; RNA; AMPLIFICATION; IMMUNOASSAYS; PREVENTION AB Fourth-generation HIV rapid tests (RTs) claim to detect both p24 antigen (Ag) and HIV antibodies (Ab) for early identification of acute infections, important for targeting prevention and reducing HIV transmission. In a nationally representative household survey in Swaziland, 18,172 adults, age 18 to 49 years, received home-based HIV rapid testing in 2010 and 2011. Of the 18,172 individuals, 5,822 (32.0%) were Ab positive (Ab(+)) by the Determine HIV-1/2 Ab/Ab combo test, and 5,789 (99.4%) of those were confirmed to be reactive in the Uni-Gold test. Determine combo identified 12 individuals as having acute infections (Ag+/Ab negative [Ab(-)]); however, none had detectable HIV-1 RNA and 8 of 12 remained HIV negative at their 6-week follow-up visit (4 were lost to follow-up). All RT-nonreactive samples were pooled and tested by nucleic acid amplification testing (NAAT) to identify acute infections. NAAT identified 13 (0.1%) of the 12,338 HIV antibody-negative specimens as HIV RNA positive, with RNA levels ranging from 300 to >10,000,000 copies/ml. However, none of them were Ag+ by Determine combo. Follow-up testing of 12 of the 13 NAAT-positive individuals at 6 months demonstrated 12 seroconversions (1 individual was lost to follow-up). Therefore, the Determine combo test had a sensitivity of 0% (95% confidence interval, 0 to 28) and positive predictive value of 0% for the detection of acute infections. The ability of the 4th-generation Determine combo to detect antigen was very poor in Swaziland. Thus, the Determine combo test does not add any value to the current testing algorithm; rather, it adds additional costs and complexity to HIV diagnosis. The detection of acute HIV infections may need to rely on other testing strategies. C1 [Duong, Yen T.; Patel, Hetal; Moore, Carole; Rasberry, Christopher; Bock, Naomi; Moore, Jan; Reed, Jason; Ellenberger, Dennis L.; Nkengasong, John N.; Parekh, Bharat S.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Mavengere, Yvonne; Manjengwa, Julius; Mlambo, Charmaine; Justman, Jessica] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA. [Li, Zhi; Emel, Lynda] Fred Hutchison Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent SCHARP, Seattle, WA USA. [Sibandze, Dumile; Nkambule, Rejoice] Minist Hlth, Mbabane, Swaziland. [Bicego, George] Ctr Dis Control & Prevent, Mbabane, Swaziland. RP Parekh, BS (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA. EM bparekh@cdc.gov FU Ministry of Health; Centers for Disease Control and Prevention [5U2GPS002005] FX We thank all the participants of SHIMS and would like to acknowledge the hard working SHIMS field staff, the laboratory staff at the National Reference Laboratory in Mbabane, Swaziland, and the invaluable contribution of the laboratory staff from the International Laboratory Branch in the Division of Global HIV/AIDS at CDC Atlanta who provided training and other technical support to the study. We also thank the Ministry of Health for their support and acknowledge the efforts of many from ICAP, Maromi/EpiCentre, and SCHARP who contributed to the success of the study.; This publication was supported by Cooperative Agreement no. 5U2GPS002005 from the Centers for Disease Control and Prevention. NR 40 TC 13 Z9 13 U1 2 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2014 VL 52 IS 10 BP 3743 EP 3748 DI 10.1128/JCM.01989-14 PG 6 WC Microbiology SC Microbiology GA AP9AX UT WOS:000342371700029 PM 25122853 ER PT J AU Molins, CR Sexton, C Young, JW Ashton, LV Pappert, R Beard, CB Schriefer, ME AF Molins, Claudia R. Sexton, Christopher Young, John W. Ashton, Laura V. Pappert, Ryan Beard, Charles B. Schriefer, Martin E. TI Collection and Characterization of Samples for Establishment of a Serum Repository for Lyme Disease Diagnostic Test Development and Evaluation SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID BORRELIA-BURGDORFERI; ERYTHEMA MIGRANS; AMERICAN-COLLEGE; CROSS-REACTIVITY; SEROLOGIC TESTS; CRITERIA; CLASSIFICATION; FIBROMYALGIA; ARTHRITIS; PROTEINS AB Serological assays and a two-tiered test algorithm are recommended for laboratory confirmation of Lyme disease. In the United States, the sensitivity of two-tiered testing using commercially available serology-based assays is dependent on the stage of infection and ranges from 30% in the early localized disease stage to near 100% in late-stage disease. Other variables, including subjectivity in reading Western blots, compliance with two-tiered recommendations, use of different first-and second-tier test combinations, and use of different test samples, all contribute to variation in two-tiered test performance. The availability and use of sample sets from well-characterized Lyme disease patients and controls are needed to better assess the performance of existing tests and for development of improved assays. To address this need, the Centers for Disease Control and Prevention and the National Institutes of Health prospectively collected sera from patients at all stages of Lyme disease, as well as healthy donors and patients with look-alike diseases. Patients and healthy controls were recruited using strict inclusion and exclusion criteria. Samples from all included patients were retrospectively characterized by two-tiered testing. The results from two-tiered testing corroborated the need for novel and improved diagnostics, particularly for laboratory diagnosis of earlier stages of infection. Furthermore, the two-tiered results provide a baseline with samples from well-characterized patients that can be used in comparing the sensitivity and specificity of novel diagnostics. Panels of sera and accompanying clinical and laboratory testing results are now available to Lyme disease serological test users and researchers developing novel tests. C1 [Molins, Claudia R.; Sexton, Christopher; Young, John W.; Pappert, Ryan; Beard, Charles B.; Schriefer, Martin E.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Ashton, Laura V.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. RP Schriefer, ME (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. EM mms7@cdc.gov FU National Institutes of Health; [Y1-A1-8362-01] FX We thank the National Institutes of Health for their support for this project under interagency title CDC-NIH Lyme Disease Clinical Sample Repository and funding number Y1-A1-8362-01. NR 31 TC 11 Z9 11 U1 2 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2014 VL 52 IS 10 BP 3755 EP 3762 DI 10.1128/JCM.01409-14 PG 8 WC Microbiology SC Microbiology GA AP9AX UT WOS:000342371700031 PM 25122862 ER PT J AU Spradling, PR Bulkow, L Teshale, EH Negus, S Homan, C Simons, B McMahon, BJ AF Spradling, Philip R. Bulkow, Lisa Teshale, Eyasu H. Negus, Susan Homan, Chriss Simons, Brenna McMahon, Brian J. TI Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection SO JOURNAL OF HEPATOLOGY LA English DT Article DE Hepatitis B; Aminotransferase levels; Immune active disease; Nonalcoholic fatty liver disease ID FATTY LIVER-DISEASE; UNITED-STATES; NATURAL-HISTORY; ALASKA NATIVES; RISK-FACTORS; MANAGEMENT; EPIDEMIOLOGY; STEATOSIS; WORKSHOP AB Background & Aims: Information delineating the possible causes for elevated serum aminotransferase activity among persons with chronic hepatitis B virus (HBV) infection is limited. Methods: We analysed data collected from a population-based cohort of persons with chronic HBV infection followed from 2001 to 2010 to determine the frequency and causes of elevated aminotransferase activity. Any elevation concurrent with an HBV DNA level >= 2000 IU/ml was attributed to immune active hepatitis B. Participant medical charts were reviewed by expert clinical staff to determine the presence of additional or alternative attributable causes. For each participant, a serum aminotransferase elevation could be attributed to more than one cause. Results: Among 1090 persons with chronic HBV infection, the mean follow-up was 7.7 years and the median age in 2001 was 39 (range 19-96) years; 634 (58.2%) had >= 1 elevated aminotransferase level during follow-up and 438 (69.1%) of persons with >= 1 elevation had at least one cause assigned for the elevation. The most common causes of aminotransferase elevations were immune active hepatitis B (48.4%), alcohol consumption (30.8%), and non-alcoholic fatty liver disease (NAFLD) (24.7%). Among participants with HBV DNA levels persistently less than 2000 IU/ml, the most common causes were NAFLD or alcohol consumption. Conclusions: In this population-based cohort of persons with chronic HBV infection, the prevalence of elevated aminotransferase activity was high and attributable to immune active chronic hepatitis B in approximately half of the cases; however, NAFLD or alcohol consumption were also common causes for enzyme elevations. These findings underscore the importance of monitoring HBV DNA levels, in addition to aminotransferase activity, among persons with chronic HBV infection so that appropriate interventions, including antiviral therapy, are utilised. Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver. C1 [Spradling, Philip R.; Teshale, Eyasu H.] Ctr Dis Control & Prevent CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Bulkow, Lisa; McMahon, Brian J.] Ctr Dis Control & Prevent CDC, Arctic Invest Program, Div Preparedness & Emerging Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Negus, Susan; Homan, Chriss; Simons, Brenna; McMahon, Brian J.] Alaska Nat Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. RP Spradling, PR (reprint author), 1600 Clifton Rd,MS G-37, Atlanta, GA 30333 USA. EM pspradling@cdc.gov FU Division of Viral Hepatitis at the Centers for Disease Control and Prevention FX All funding was provided by the Division of Viral Hepatitis at the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 25 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD OCT PY 2014 VL 61 IS 4 BP 785 EP 791 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AP7IY UT WOS:000342252200013 PM 24911461 ER PT J AU Pride, KR Geissler, AL Kolasa, MS Robinson, B Van Houten, C McClinton, R Bryan, K Murphy, T AF Pride, Kerry R. Geissler, Aimee L. Kolasa, Maureen S. Robinson, Byron Van Houten, Clay McClinton, Reginald Bryan, Katie Murphy, Tracy TI Assessment of Vaccine Exemptions Among Wyoming School Children, 2009 and 2011 SO JOURNAL OF SCHOOL NURSING LA English DT Article DE vaccines; Wyoming; schools; immunization ID IMMUNIZATION REQUIREMENTS; UNITED-STATES; PHILOSOPHICAL EXEMPTIONS; NONMEDICAL EXEMPTIONS; COVERAGE; PERTUSSIS; POLICIES; PARENTS; REFUSAL; IMPACT AB During 2010-2011, varicella vaccination was an added requirement for school entrance in Wyoming. Vaccination exemption rates were compared during the 2009-2010 and 2011-2012 school years, and impacts of implementing a new childhood vaccine requirement were evaluated. All public schools, grades K-12, were required to report vaccination status of enrolled children for the 2009-2010 and 2011-2012 school years to the Wyoming Department of Health. Exemption data were analyzed by exemption category, vaccine, county, grade, and rurality. The proportion of children exempt for >= 1 vaccine increased from 1.2% (1,035/87,398) during the 2009-2010 school year to 1.9% (1,678/89,476) during 2011-2012. In 2011, exemptions were lowest (1.5%) in urban areas and highest (2.6%) in the most rural areas, and varicella vaccine exemptions represented 67.1% (294/438) of single vaccination exemptions. Implementation of a new vaccination requirement for school admission led to an increased exemption rate across Wyoming. C1 [Pride, Kerry R.; Geissler, Aimee L.; Van Houten, Clay; McClinton, Reginald; Bryan, Katie; Murphy, Tracy] Ctr Dis Control & Prevent, Wyoming State Dept Publ Hlth, Atlanta, GA USA. [Kolasa, Maureen S.] Ctr Dis Control & Prevent, Hlth Serv Res & Evaluat Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Robinson, Byron] Ctr Dis Control & Prevent, Div Appl Sci, Sci Educ & Profess Dev Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. RP Pride, KR (reprint author), Wyoming State Dept Publ Hlth, 6101 Yellowstone Rd,Suite 510, Cheyenne, WY 82002 USA. EM hgp3@cdc.gov NR 30 TC 1 Z9 1 U1 1 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1059-8405 EI 1546-8364 J9 J SCH NURS JI J. Sch. Nurs. PD OCT PY 2014 VL 30 IS 5 BP 332 EP 339 DI 10.1177/1059840513518439 PG 8 WC Nursing SC Nursing GA AP7CI UT WOS:000342234900005 PM 24407317 ER PT J AU Lungren, MP Donlan, RM Kankotia, R Paxton, BE Falk, I Christensen, D Kim, CY AF Lungren, Matthew P. Donlan, Rodney M. Kankotia, Ravi Paxton, Ben E. Falk, Irene Christensen, Diana Kim, Charles Y. TI Bacteriophage K Antimicrobial-Lock Technique for Treatment of Staphylococcus aureus Central Venous Catheter-Related Infection: A Leporine Model Efficacy Analysis SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID BLOOD-STREAM INFECTION; ANTIBIOTIC-LOCK; PHAGE THERAPY; IN-VIVO; EPIDERMIDIS; BACTEREMIA; PREVENTION; BIOFILMS AB Purpose: To determine whether a bacteriophage antimicrobial-lock technique can reduce bacterial colonization and biofilm formation on indwelling central venous catheters in a rabbit model. Materials and Methods: Cuffed central venous catheters were inserted into the jugular vein of female New Zealand White rabbits under image guidance. Catheters were inoculated for 24 hours with broth culture of methicillin-sensitive Staphylococcus aureus. The inoculum was aspirated, and rabbits were randomly assigned to two equal groups for 24 hours: (i) untreated controls (heparinized saline lock), (ii) bacteriophage antimicrobial-lock (staphylococcal bacteriophage K.; propagated titer > 10(8)/mL). Blood cultures were obtained via peripheral veins, and the catheters were removed for quantitative culture and scanning electron microscopy. Results: Mean colony-forming units (CFU) per cm(2) of the distal catheter segment, as a measure of biofilm, were significantly decreased in experimental animals compared with controls (control, 1.2 x 10(5) CFU/cm(2); experimental, 7.6 x 10(3); P = .016). Scanning electron microscopy demonstrated that biofilms were present on the surface of five of five control catheters but only one of five treated catheters (P = .048). Blood culture results were not significantly different between the groups. Conclusions: In a rabbit model, treatment of infected central venous catheters with a bacteriophage antimicrobial-lock technique significantly reduced bacterial colonization and biofilm presence. Our data represent a preliminary step toward use of bacteriophage therapy for prevention and treatment of central venous catheter-associated infection. C1 [Lungren, Matthew P.] Stanford Univ, Med Ctr, Dept Radiol, Palo Alto, CA 94304 USA. [Donlan, Rodney M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Donlan, Rodney M.; Paxton, Ben E.; Falk, Irene; Christensen, Diana; Kim, Charles Y.] Duke Univ, Med Ctr, Dept Radiol, Intervent Radiol Translat Res Lab, Durham, NC 27710 USA. RP Lungren, MP (reprint author), Stanford Univ, Med Ctr, Dept Radiol, 725 Welch Rd,Room 1690 MC 5913, Palo Alto, CA 94304 USA. EM mlungren@gmail.com RI Kim, Charles/P-3729-2015 OI Kim, Charles/0000-0002-8687-1522 FU Society of Interventional Radiology (SIR); American Society for Parenteral and Enteral Nutrition (ASPEN) FX The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention (CDC). This study was funded in part by grants from the Society of Interventional Radiology (SIR) and the American Society for Parenteral and Enteral Nutrition (ASPEN). NR 30 TC 0 Z9 1 U1 3 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD OCT PY 2014 VL 25 IS 10 BP 1627 EP 1632 DI 10.1016/j.jvir.2014.06.009 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA AQ0OQ UT WOS:000342483000020 PM 25088065 ER PT J AU Abo, H Okamoto, K Anraku, M Otsuki, N Sakata, M Icenogle, J Zheng, Q Kurata, T Kase, T Komase, K Takeda, M Mori, Y AF Abo, H. Okamoto, K. Anraku, M. Otsuki, N. Sakata, M. Icenogle, J. Zheng, Q. Kurata, T. Kase, T. Komase, K. Takeda, M. Mori, Y. TI Development of an improved RT-LAMP assay for detection of currently circulating rubella viruses SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Rubella; Diagnosis; RT-LAMP ID MEDIATED ISOTHERMAL AMPLIFICATION; NONSTRUCTURAL PROTEINS; RAPID DETECTION; DIAGNOSIS; GENOME; FEVER; RNA AB Rubella virus is the causative agent of rubella. The symptoms are usually mild, and characterized by a maculopapular rash and fever. However, rubella infection in pregnant women sometimes can result in the birth of infants with congenital rubella syndrome (CRS). Global efforts have been made to reduce and eliminate CRS. Although a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) assay for detection of rubella virus has been reported, the primers contained several mismatched nucleotides with the genomes of currently circulating rubella virus strains. In the present study, a new RT-LAMP assay was established. The detection limit of this assay was 100-1000 PFU/reaction of viruses for all rubella genotypes, except for genotype 2C, which is not commonly found in the current era. Therefore, the new RI-LAMP assay can successfully detect all current rubella virus genotypes, and does not require sophisticated devices like TaqMan real-time PCR systems. This assay should be a useful assay for laboratory diagnosis of rubella and CRS. (C) 2014 Elsevier B.V. All rights reserved. C1 [Abo, H.; Okamoto, K.; Anraku, M.; Otsuki, N.; Sakata, M.; Komase, K.; Takeda, M.; Mori, Y.] Natl Inst Infect Dis, Lab Rubella, Dept Virol 3, Murayama Branch, Tokyo 2080011, Japan. [Icenogle, J.; Zheng, Q.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpes Virus Lab Branch, Div Viral Dis, Atlanta, GA 30333 USA. [Kurata, T.; Kase, T.] Osaka Prefectural Inst Publ Hlth, Div Virol, Dept Infect Dis, Higashinari Ku, Osaka 5370025, Japan. RP Okamoto, K (reprint author), Natl Inst Infect Dis, Lab Rubella, Dept Virol 3, Murayama Branch, 4-7-1 Gakuen, Tokyo 2080011, Japan. EM k-okmt@nih.go.jp FU Ministry of Health, Labour and Welfare, Science Research [H24-Iyaku-Ippan-008, H25-Shinko-Ippan-010] FX This work was supported by Grants-in-Aid from the Ministry of Health, Labour and Welfare, Science Research Grant(s) (H24-Iyaku-Ippan-008 and H25-Shinko-Ippan-010). We thank Dr. P. Rota and all members of Measles, Mumps, Rubella and Herpes Virus Laboratory Branch, Division of Viral Diseases, Centers for Disease Control and Prevention, for their helpful discussions. NR 23 TC 2 Z9 2 U1 0 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD OCT PY 2014 VL 207 BP 73 EP 77 DI 10.1016/j.jviromet.2014.06.013 PG 5 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA AP7GR UT WOS:000342246300012 PM 24972365 ER PT J AU Markowitz, LE Hariri, S AF Markowitz, Lauri E. Hariri, Susan TI Postlicensure monitoring of HPV vaccination programmes SO LANCET INFECTIOUS DISEASES LA English DT Editorial Material ID HUMAN-PAPILLOMAVIRUS VACCINE; GENITAL WARTS; YOUNG-WOMEN; PREVALENCE; INFECTION; TRIAL C1 [Markowitz, Lauri E.; Hariri, Susan] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Markowitz, LE (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM lem2@cdc.gov NR 15 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD OCT PY 2014 VL 14 IS 10 BP 904 EP 905 DI 10.1016/S1473-3099(14)70871-0 PG 2 WC Infectious Diseases SC Infectious Diseases GA AP7HY UT WOS:000342249600005 PM 25107681 ER PT J AU Collier, MG Khudyakov, YE Selvage, D Adams-Cameron, M Epson, E Cronquist, A Jervis, RH Lamba, K Kimura, AC Sowadsky, R Hassan, R Park, SY Garza, E Elliott, AJ Rotstein, DS Beal, J Kuntz, T Lance, SE Dreisch, R Wise, ME Nelson, NP Suryaprasad, A Drobeniuc, J Holmberg, SD Xu, FJ AF Collier, Melissa G. Khudyakov, Yury E. Selvage, David Adams-Cameron, Meg Epson, Erin Cronquist, Alicia Jervis, Rachel H. Lamba, Katherine Kimura, Akiko C. Sowadsky, Rick Hassan, Rashida Park, Sarah Y. Garza, Eric Elliott, Aleisha J. Rotstein, David S. Beal, Jennifer Kuntz, Thomas Lance, Susan E. Dreisch, Rebecca Wise, Matthew E. Nelson, Noele P. Suryaprasad, Anil Drobeniuc, Jan Holmberg, Scott D. Xu, Fujie CA Hepatitis A Outbreak Invest Team TI Outbreak of hepatitis A in the USA associated with frozen pomegranate arils imported from Turkey: an epidemiological case study SO LANCET INFECTIOUS DISEASES LA English DT Article ID IMMUNIZATION PRACTICES ACIP; MULTISTATE OUTBREAK; SEMIDRIED TOMATOES; MOLECULAR EPIDEMIOLOGY; ADVISORY-COMMITTEE; VIRUS-INFECTION; UNITED-STATES; RECOMMENDATIONS; PREVENTION; SURVIVAL AB Background In May, 2013, an outbreak of symptomatic hepatitis A virus infections occurred in the USA. Federal, state, and local public health officials investigated the cause of the outbreak and instituted actions to control its spread. We investigated the source of the outbreak and assessed the public health measures used. Methods We interviewed patients, obtained their shopping information, and did genetic analysis of hepatitis A virus recovered from patients' serum and stool samples. We tested products for the virus and traced supply chains. Findings Of 165 patients identified from ten states, 69 (42%) were admitted to hospital, two developed fulminant hepatitis, and one needed a liver transplant; none died. Illness onset occurred from March 31 to Aug 12, 2013. The median age of patients was 47 years (IQR 35-58) and 91 (55%) were women. 153 patients (93%) reported consuming product B from retailer A. 40 patients (24%) had product B in their freezers, and 113 (68%) bought it according to data from retailer A. Hepatitis A virus genotype IB, uncommon in the Americas, was recovered from specimens from 117 people with hepatitis A virus illness. Pomegranate arils that were imported from Turkey-where genotype IB is common-were identified in product B. No hepatitis A virus was detected in product B. Interpretation Imported frozen pomegranate arils were identified as the vehicle early in the investigation by combining epidemiology-with data from several sources-genetic analysis of patient samples, and product tracing. Product B was removed from store shelves, the public were warned not to eat product B, product recalls took place, and postexposure prophylaxis with both hepatitis A virus vaccine and immunoglobulin was provided. Our findings show that modern public health actions can help rapidly detect and control hepatitis A virus illness caused by imported food. Our findings show that postexposure prophylaxis can successfully prevent hepatitis A illness when a specific product is identified. Imported food products combined with waning immunity in some adult populations might make this type of intervention necessary in the future. Funding US Centers for Disease Control and Prevention, US Food and Drug Administration, and US state and local public health departments. C1 [Collier, Melissa G.; Khudyakov, Yury E.; Nelson, Noele P.; Suryaprasad, Anil; Drobeniuc, Jan; Holmberg, Scott D.; Xu, Fujie] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA. [Epson, Erin] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Lance, Susan E.; Wise, Matthew E.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Selvage, David; Adams-Cameron, Meg] New Mexico Dept Hlth, Santa Fe, NM USA. [Epson, Erin; Cronquist, Alicia; Jervis, Rachel H.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Lamba, Katherine; Kimura, Akiko C.] Calif Dept Publ Hlth, Sacramento, CA USA. [Sowadsky, Rick] Nevada Div Publ & Behav Hlth, Carson City, NV USA. [Hassan, Rashida] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Park, Sarah Y.] Hawaii State Dept Hlth, Honolulu, HI USA. [Garza, Eric] Texas Dept State Hlth Serv, Austin, TX USA. [Elliott, Aleisha J.; Rotstein, David S.; Beal, Jennifer; Kuntz, Thomas; Lance, Susan E.; Dreisch, Rebecca] US FDA, Silver Spring, MD USA. [Elliott, Aleisha J.] Oakridge Inst Sci & Educ, Oakridge, TN USA. RP Collier, MG (reprint author), Div Viral Hepatitis, CDC Mailstop G-37, Atlanta, GA 30329 USA. EM mgcollier@cdc.gov FU US Centers for Disease Control and Prevention; US Food and Drug Administration; US state public health department; US local public health department FX US Centers for Disease Control and Prevention, US Food and Drug Administration, and US state and local public health departments. NR 26 TC 31 Z9 31 U1 2 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD OCT PY 2014 VL 14 IS 10 BP 976 EP 981 DI 10.1016/S1473-3099(14)70883-7 PG 6 WC Infectious Diseases SC Infectious Diseases GA AP7HY UT WOS:000342249600038 PM 25195178 ER PT J AU Mirabelli, MC Beavers, SF Chatterjee, AB AF Mirabelli, Maria C. Beavers, Suzanne F. Chatterjee, Arjun B. TI Active Asthma and the Prevalence of Physician-Diagnosed COPD SO LUNG LA English DT Article DE Adult; Asthma; COPD; Epidemiology; Respiratory health; Surveillance ID OBSTRUCTIVE PULMONARY-DISEASE; WORK-RELATED ASTHMA; CALL-BACK-SURVEY; OVERLAP SYNDROME; ONSET ASTHMA; RISK-FACTOR; HEALTH; ADULTS; POPULATION; PREDICTORS AB Despite the considerable overlap of asthma and chronic obstructive pulmonary disease (COPD), the extent to which the two diagnoses are the manifestations of the same disease remains unresolved. We conducted these analyses to evaluate the role of active asthma in the prevalence of physician-diagnosed COPD. From 2006 through 2010, 74,209 adults aged 18-99 years and with a history of asthma participated in the Behavioral Risk Factor Surveillance System (BRFSS) Asthma Call-back Survey and responded to interview-administered questionnaires via telephone. We used publicly available data from 71,639 (97%) participants to identify respondents with and without active manifestations of asthma and self-reported, physician-diagnosed COPD. We generated population-weighted estimates of physician-diagnosed COPD prevalence and conducted linear regression to estimate associations between active asthma status and the prevalence of COPD among current smokers, former smokers, and lifetime nonsmokers separately. Physician-diagnosed COPD was reported in an estimated 29% of the population with any history of asthma, including both active and inactive asthma. Age-specific prevalences of physician-diagnosed COPD were consistently higher among adults with active asthma than adults without active asthma. Compared to inactive asthma, active asthma was associated with an 8.3% [95 % confidence interval (CI) 6.1, 10.5] higher prevalence of physician-diagnosed COPD among lifetime nonsmokers, a 20.6% (95 % CI 18.0, 23.3) higher prevalence among former smokers, and a 26.7% (95 % CI 22.5, 30.9) higher prevalence among current smokers. Among adults with a history of asthma, active manifestations of asthma may play an important role in the epidemiology of COPD. C1 [Mirabelli, Maria C.; Beavers, Suzanne F.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Chatterjee, Arjun B.] Wake Forest Sch Med, Dept Internal Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC USA. RP Mirabelli, MC (reprint author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway NE,Mailstop F-60, Atlanta, GA 30341 USA. EM zif7@cdc.gov OI Mirabelli, Maria/0000-0002-3540-0085 FU Intramural CDC HHS [CC999999] NR 40 TC 8 Z9 9 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0341-2040 EI 1432-1750 J9 LUNG JI Lung PD OCT PY 2014 VL 192 IS 5 BP 693 EP 700 DI 10.1007/s00408-014-9609-2 PG 8 WC Respiratory System SC Respiratory System GA AP9XD UT WOS:000342434000012 PM 24952247 ER PT J AU Phillips, KL Schieve, LA Visser, S Boulet, S Sharma, AJ Kogan, MD Boyle, CA Yeargin-Allsopp, M AF Phillips, Keydra L. Schieve, Laura A. Visser, Susanna Boulet, Sheree Sharma, Andrea J. Kogan, Michael D. Boyle, Coleen A. Yeargin-Allsopp, Marshalyn TI Prevalence and Impact of Unhealthy Weight in a National Sample of US Adolescents with Autism and Other Learning and Behavioral Disabilities SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Obesity; Overweight; Underweight; Developmental disability; Children; Concurrent medical conditions; Autism ID CHRONIC HEALTH CONDITIONS; BODY-MASS INDEX; CHILDHOOD OVERWEIGHT; DEVELOPMENTAL-DISABILITIES; UNITED-STATES; CHILDREN; OBESITY; RISK; ASTHMA; ADULTS AB We estimated the prevalence of obesity, overweight, and underweight among US adolescents with and without autism and other learning and behavioral developmental disabilities (DDs) and assessed the health consequences of obesity among adolescents with DDs. From the 2008 to 2010 National Health Interview Survey, we selected 9,619 adolescents ages 12-17 years. Parent respondents reported weight, height, presence of DDs and health conditions. We calculated body mass index (BMI) and defined obesity, overweight, and underweight as a parts per thousand yen95th, a parts per thousand yen85th to < 95th, and < 5th percentiles, respectively, using established criteria. We created mutually-exclusive DD subgroups using the following order of precedence: autism; intellectual disability; attention-deficit-hyperactivity-disorder; learning disorder/other developmental delay. We compared BMI outcomes among adolescents in each DD group versus adolescents without DDs using multivariable logistic regression. Socio-demographic factors and birthweight were included as confounders. Estimates were weighted to reflect the US population. Both obesity and underweight prevalences were higher among adolescents with than without DDs [adjusted prevalence ratios (aPR) 1.5 (1.25-1.75) and 1.5 (1.01-2.20), respectively]. Obesity was elevated among adolescents with all DD types, and was highest among the autism subgroup [aPR 2.1 (1.44-3.16)]. Adolescents with either a DD or obesity had higher prevalences of common respiratory, gastrointestinal, dermatological and neurological conditions/symptoms than nonobese adolescents without DDs. Adolescents with both DDs and obesity had the highest estimates for most conditions. Obesity is high among adolescents with autism and other DDs and poses added chronic health risks. Obesity prevention and management approaches for this vulnerable population subgroup need further consideration. C1 [Phillips, Keydra L.; Schieve, Laura A.; Visser, Susanna; Boulet, Sheree; Boyle, Coleen A.; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Sharma, Andrea J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Kogan, Michael D.] Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, Rockville, MD USA. RP Schieve, LA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mailstop E-86, Atlanta, GA 30333 USA. EM lschieve@cdc.gov OI Sharma, Andrea/0000-0003-0385-0011 FU Intramural CDC HHS [CC999999] NR 45 TC 20 Z9 23 U1 6 U2 26 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD OCT PY 2014 VL 18 IS 8 BP 1964 EP 1975 DI 10.1007/s10995-014-1442-y PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP6HW UT WOS:000342179300021 PM 24553796 ER PT J AU Tong, VT Hutchings, Y Farr, SL D'Angelo, D Babb, S AF Tong, Van T. Hutchings, Yalonda Farr, Sherry L. D'Angelo, Denise Babb, Stephen TI State-specific estimates of complete smoke-free home rules among postpartum women, 2010 SO PREVENTIVE MEDICINE LA English DT Article DE Environmental tobacco smoke; Secondhand smoke; Tobacco; Reproductive health; Pregnancy; Infant; Home ID ASSESSMENT MONITORING-SYSTEM; UNITED-STATES; EXPOSURE; PREGNANCY AB Background: Secondhand smoke exposure increases an infant's risk of morbidity and mortality. We provide state-specific estimates for and characterize postpartum women with complete smoke-free home rules. Methods: Data were analyzed from 26 states and New York City (n = 37,698) from the 2010 Pregnancy Risk Assessment Monitoring System, a population-based survey of women who recently delivered live-born infants. We calculated state-specific estimates of complete rules and assessed associations between complete rules and selected characteristics. Results: Overall, 93.6% (95% CI: 93.1-94.1) of women with recent live births had complete smoke-free home rules (86.8% [West Virginia] to 98.6% [Utah]). Demographic groups with the lowest percentage of rules were women who smoked during pregnancy/postpartum (77.6%), were non-Hispanic Black (86.8%), never initiated breastfeeding (86.8%), <20 years of age (87.1%), <$15,000 annual income (87.6%), <12 years of education (88.6%), unmarried (88.6%), initiated prenatal care late/had no prenatal care (88.8%), had Medicaid coverage (89.7%), had an unintended pregnancy (90.3%), and enrolled in WIC (90.6%). Conclusions: Prevalence of complete smoke-free home rules was high among women with recent live births; however, disparities exist by state and among certain sub-populations. Women, particularly smokers, should be educated during and after pregnancy about secondhand smoke and encouraged to maintain 100% smoke-free homes. Published by Elsevier Inc. C1 [Tong, Van T.; Hutchings, Yalonda; Farr, Sherry L.; D'Angelo, Denise] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Babb, Stephen] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. RP Tong, VT (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, NCCDPHP, 4770 Buford Hwy NE,MS F74, Atlanta, GA 30341 USA. EM vtong@cdc.gov FU Intramural CDC HHS [CC999999] NR 19 TC 1 Z9 1 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2014 VL 67 BP 24 EP 27 DI 10.1016/j.ypmed.2014.06.030 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AP7KD UT WOS:000342255300005 PM 24983888 ER PT J AU Goldstein, IM Foltz, JL Onufrak, S Belay, B AF Goldstein, Ian M. Foltz, Jennifer L. Onufrak, Stephen Belay, Brook TI Health-promoting environments in U.S. medical facilities: Physician perceptions, DocStyles 2012 SO PREVENTIVE MEDICINE LA English DT Article DE Health facility environment; Hospital; Food; Physical activity; Breastfeeding ID CHILDRENS HOSPITALS; UNITED-STATES; FAST-FOOD; INTERVENTIONS; OBESITY; POLICY; PREVALENCE; OVERWEIGHT; NUTRITION AB Objective. Medical facilities are natural leaders for health promotion because of their mission, influence, and reach. We sought to determine the frequency of physicians reporting supportive, health-promoting environments in their facility and identify characteristics of physicians and medical practices associated with support. Methods. We analyzed a sample of 1485 U.S. primary care physicians in DocStyles 2012 survey. Physicians rated their facility's support for healthy nutrition, physical activity, and lactation environments. Frequencies and adjusted odds ratios for supportive environments (rated "Good" or "Very Good") were assessed by select characteristics. Results. The frequency of physicians reporting supportive environments was 70.0% for nutrition, 60.0% for physical activity, 76.0% for lactation, and 40.4% for all 3 environments combined. Supportive nutrition [odds ratio: 2.91 (1.49-5.66)] and physical activity [2.13 (1.19-3.83)] environments were associated with physicians seeing upper middle class to affluent patients versus poor patients. Supportive lactation environments were associated with pediatricians [3.35 (2.14-5.25)] and obstetricians/gynecologists [3.39 (2.15-5.33)] versus internists. Conclusions. Less than half of physicians reported their facility supportive of all these environments, suggesting there are many missed opportunities for U.S. medical facilities to promote wellness. Facilities serving poor patients and those staffed by internists and family/general practitioners may represent one area of need. (C) 2014 Elsevier Inc. All rights reserved. C1 [Goldstein, Ian M.; Foltz, Jennifer L.; Onufrak, Stephen; Belay, Brook] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Goldstein, Ian M.] Ctr Dis Control & Prevent, CDC Experience Appl Epidemiol Fellowship, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. [Goldstein, Ian M.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Foltz, Jennifer L.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. RP Goldstein, IM (reprint author), 12631 E 17th Ave,B177, Aurora, CO 80045 USA. EM iangoldstein1@gmail.com FU CDC Experience; CDC Foundation from External Medical Affairs, Pfizer Inc. FX Ian Goldstein received funding from The CDC Experience, a one-year fellowship in applied epidemiology at the Centers for Disease Control and Prevention made possible by a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer Inc. Neither of these entities had any involvement in the study design; collection, analysis and interpretation of data; the writing of the manuscript; or the decision to submit the manuscript for publication. NR 29 TC 0 Z9 0 U1 1 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2014 VL 67 BP 65 EP 70 DI 10.1016/j.ypmed.2014.06.031 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AP7KD UT WOS:000342255300010 PM 25008218 ER PT J AU Kharbanda, EO Vazquez-Benitez, G Lipkind, H Naleway, AL Klein, NP Cheetham, TC Hambidge, SJ Vellozzi, C Nordin, JD AF Kharbanda, Elyse O. Vazquez-Benitez, Gabriela Lipkind, Heather Naleway, Allison L. Klein, Nicola P. Cheetham, T. Craig Hambidge, Simon J. Vellozzi, Claudia Nordin, James D. TI Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink Sites SO PREVENTIVE MEDICINE LA English DT Article DE Pertussis; Pregnancy; Vaccine coverage ID IMMUNIZATION PRACTICES ACIP; INACTIVATED INFLUENZA VACCINE; ADVISORY-COMMITTEE; PREVENTING TETANUS; INFANT PERTUSSIS; DIPHTHERIA; TDAP; RECOMMENDATIONS; WOMEN; ADOLESCENTS AB Objective. In response to widespread pertussis outbreaks and infant deaths, in 2010, the California Department of Health (CDPH) and in 2011 the Advisory Committee on Immunization Practices (ACIP) advised that the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine be administered during pregnancy. The goals of this study were to describe Tdap coverage among pregnant women following these recommendations. Methods. In this observational cohort study, we utilized electronic medical record and claims data from seven Vaccine Safety Datalink sites to identify pregnancies and Tdap administrations. All Tdap doses were classified as pre-pregnancy, during pregnancy or post-pregnancy/postpartum. For pregnancies ending in a live birth, we evaluated factors associated with Tdap vaccination. Results. Among 289,141 live births at the California VSD sites, receipt of Tdap during pregnancy increased substantially in the years 2010, 2011, and 2012, when coverage was 15.9, 30.0 and 19.5%, respectively. Among 82,398 women with live births at the Oregon, Washington, Colorado, Wisconsin and Minnesota VSD sites, receipt of Tdap during pregnancy first increased in 2012, at 16.0%. Women receiving early prenatal care and other vaccine(s) during pregnancy had higher Tdap coverage. Conclusion. We observed substantial increases in Tdap coverage during pregnancy following CDPH and ACIP recommendations. (C) 2014 Elsevier Inc. All rights reserved. C1 [Kharbanda, Elyse O.; Vazquez-Benitez, Gabriela; Nordin, James D.] HealthPartners Inst Educ & Res, Minneapolis, MN 55425 USA. [Lipkind, Heather] Yale Univ, Dept Obstet & Gynecol, New Haven, CT USA. [Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Klein, Nicola P.] Kaiser Permanente No Calif, Vaccine Study Ctr, Oakland, CA USA. [Cheetham, T. Craig] Kaiser Permanente So Calif, Pasadena, CA 91101 USA. [Hambidge, Simon J.] Kaiser Permanente Inst Hlth Res, Denver, CO USA. [Hambidge, Simon J.] Denver Hlth Community Hlth Serv, Denver, CO USA. [Vellozzi, Claudia] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual & Promot, Atlanta, GA USA. RP Kharbanda, EO (reprint author), HealthPartners Inst Educ & Res, POB 1524,MS 21111R, Minneapolis, MN 55425 USA. EM Elyse.o.kharbanda@healthpartners.com OI Naleway, Allison/0000-0001-5747-4643 FU Centers for Disease Control and Prevention [200-2012-53526] FX This study was funded by the Centers for Disease Control and Prevention, Contract 200-2012-53526. Dr. Claudia Vellozzi is employed by the funder and a collaborator on this research. Dr. Vellozzi assisted with study design, interpretation of findings and the decision to submit this article for publication. This paper did undergo the CDC clearance process. NR 20 TC 21 Z9 21 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2014 VL 67 BP 316 EP 319 DI 10.1016/j.ypmed.2014.05.025 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AP7KD UT WOS:000342255300049 PM 24952094 ER PT J AU Pohl, HR Jones, DE Holler, JS Murray, HE AF Pohl, H. R. Jones, D. E. Holler, J. S. Murray, H. E. TI Public health decisions: Actions and consequences SO REGULATORY TOXICOLOGY AND PHARMACOLOGY LA English DT Article DE Chemical regulations; Insecticides; Gasoline additives; Wood preservatives; Risk management decisions ID VOLATILE ORGANIC-COMPOUNDS; TERTIARY-BUTYL ETHER; MALARIA CONTROL; HUMAN EXPOSURE; DDT; BLOOD; PENTACHLOROPHENOL; CONTAMINATION; CREOSOTE; WORKERS AB The goal of public health is to promote the best possible health for the whole population. Public health issues are numerous and can be unbelievably complex in form, scope, and possible consequence. Most public health decisions involve assessing several different options, weighing the respective benefits and risks of those options, and making difficult decisions that hopefully provide the greatest benefit to the affected populations. Many risk management decisions involve a variety of societal factors which modify risk assessment choices. The purpose of this paper is to point out difficulties in making decisions that impact public health. The intent of such decisions is to improve public health, but as illustrated in the paper, there can be unintended adverse consequences. Such unplanned issues require continued attention and efforts for responsible officials in the protection of environmental public health. This article presents examples of such events, when in the past, it was necessary to assess and regulate a number of potentially hazardous chemicals commonly used as insecticides, gasoline additives, and wood preservatives. Published by Elsevier Inc. C1 [Pohl, H. R.; Jones, D. E.; Holler, J. S.; Murray, H. E.] Agcy Toxic Subst & Dis Registry, US Dept HHS, Atlanta, GA USA. RP Pohl, HR (reprint author), ATSDR, 1600 Clifton Rd,MS F57, Atlanta, GA 30329 USA. EM hpohl@cdc.gov NR 80 TC 1 Z9 1 U1 1 U2 29 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0273-2300 EI 1096-0295 J9 REGUL TOXICOL PHARM JI Regul. Toxicol. Pharmacol. PD OCT 1 PY 2014 VL 70 IS 1 BP 363 EP 369 DI 10.1016/j.yrtph.2014.07.023 PG 7 WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology SC Legal Medicine; Pharmacology & Pharmacy; Toxicology GA AQ0OI UT WOS:000342482200039 PM 25092130 ER PT J AU Beymer, MR Llata, E Stirland, AM Weinstock, HS Wigen, CL Guerry, SL Mejia, E Bolan, RK AF Beymer, Matthew R. Llata, Eloisa Stirland, Ali M. Weinstock, Hillard S. Wigen, Christine L. Guerry, Sarah L. Mejia, Everardo Bolan, Robert K. TI Evaluation of Gonorrhea Test of Cure at 1 Week in a Los Angeles Community-Based Clinic Serving Men Who Have Sex With Men SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID DISEASES-TREATMENT-GUIDELINES; ACID AMPLIFICATION TESTS; NEISSERIA-GONORRHOEAE; GONOCOCCAL INFECTIONS; CHLAMYDIA-TRACHOMATIS; PHARYNGEAL GONORRHEA; UNITED-STATES; NO LONGER; SUSCEPTIBILITY; APPROPRIATE AB Background: Because of the decreasing susceptibility of Neisseria gonorrhoeae to cephalosporin therapy, the Centers for Disease Control and Prevention recommends test of cure (TOC) 1 week after gonorrhea (GC) treatment if therapies other than ceftriaxone are used. In addition, the Centers for Disease Control and Prevention asks clinicians, particularly those caring for men who have sex with men (MSM) on the west coast, to consider retesting all MSM at 1 week. However, it is unclear if this is acceptable to providers and patients or if nucleic acid amplification tests (NAATs) are useful for TOC at 7 days. Methods: Between January and July 2012, MSM with GC were advised to return 1 week after treatment for TOC using NAAT. A multi-variate logistic regression model was used to determine demographic and behavioral differences between MSM who returned for follow-up and MSM who did not. Results: Of 737 men with GC, 194 (26.3%) returned between 3 and 21 days of treatment. Individuals who returned were more likely to have no GC history (P = 0.0001) and to report no initial symptoms (P = 0.02) when compared with individuals who did not return for TOC. Of those who returned, 0% of urethral samples, 7.4% of rectal samples, and 5.3% of pharyngeal samples were NAAT positive at TOC. Conclusions: Although TOC may be an important strategy in reducing complications and the spread of GC, low return rates may make implementation challenging. If implemented, extra efforts should be considered to enhance return rates among individuals with a history of GC. If TOCs are recommended at 1 week and NAATs are used, the interpretation of positive results, particularly those from extragenital sites, may be difficult. C1 [Beymer, Matthew R.; Mejia, Everardo; Bolan, Robert K.] Los Angeles LGBT Ctr, Los Angeles, CA 90028 USA. [Beymer, Matthew R.] Univ Calif Los Angeles, Dept Community Hlth Sci, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Llata, Eloisa; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Div STD Prevent NCCHSTP, Epidemiol & Surveillance Branch, Atlanta, GA USA. [Stirland, Ali M.; Wigen, Christine L.; Guerry, Sarah L.] Cty Los Angeles, Dept Publ Hlth, Los Angeles, CA USA. RP Beymer, MR (reprint author), Los Angeles LGBT Ctr, McDonald Wright Bldg,1625 N Schrader Blvd, Los Angeles, CA 90028 USA. EM mbeymer@lalgbtcenter.org NR 27 TC 4 Z9 4 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2014 VL 41 IS 10 BP 595 EP 600 DI 10.1097/OLQ.0000000000000190 PG 6 WC Infectious Diseases SC Infectious Diseases GA AP9CI UT WOS:000342375600006 PM 25211254 ER PT J AU Steiner, RJ Swartzendruber, AL Rose, E DiClemente, RJ AF Steiner, Riley J. Swartzendruber, Andrea L. Rose, Eve DiClemente, Ralph J. TI Monitoring Knowledge Among Family, Sexually Transmitted Infections, and Sexual Partnership Characteristics of African American Adolescent Females SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID BEHAVIORS; RISK AB Among 284 African American girls aged 14 to 17 years, frequent family monitoring knowledge was associated with a reduced likelihood of sexually transmitted infections (STIs) and having a casual sex partner but was not associated with other partnership characteristics. Family monitoring may offer an additional STI prevention opportunity for this vulnerable population. C1 [Steiner, Riley J.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Swartzendruber, Andrea L.; Rose, Eve; DiClemente, Ralph J.] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Steiner, RJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE Mailstop E-75, Atlanta, GA 30329 USA. EM rsteiner@cdc.gov FU National Institute of Mental Health [5R01 MH070537]; Emory Center for AIDS Research [P30 AI050409]; Atlanta Clinical & Translational Science Institute [UL1TR000454]; Center for Contextual Genetics Prevention [P03 DA027827]; National Institute on Alcohol Abuse and Alcoholism [F32AA022058] FX This research was supported by a grant from the National Institute of Mental Health (5R01 MH070537) to the fourth author. Additional support was provided by the Emory Center for AIDS Research (P30 AI050409), the Atlanta Clinical & Translational Science Institute (UL1TR000454), and the Center for Contextual Genetics & Prevention (P03 DA027827). Andrea Swartzendruber was supported by National Institute on Alcohol Abuse and Alcoholism Grant No. F32AA022058. NR 19 TC 2 Z9 2 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2014 VL 41 IS 10 BP 601 EP 604 DI 10.1097/OLQ.0000000000000188 PG 4 WC Infectious Diseases SC Infectious Diseases GA AP9CI UT WOS:000342375600007 PM 25211255 ER PT J AU Lewis, FMT Newman, DR Anschuetz, GL Mettey, A Asbel, L Salmon, ME AF Lewis, Felicia M. T. Newman, Daniel R. Anschuetz, Greta L. Mettey, Aaron Asbel, Lenore Salmon, Melinda E. TI Partner Meeting Place Is Significantly Associated With Gonorrhea and Chlamydia in Adolescents Participating in a Large High School Sexually Transmitted Disease Screening Program SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID PUBLIC HIGH-SCHOOLS; NEISSERIA-GONORRHOEAE; SENSATION SEEKING; RISK BEHAVIORS; INFECTIONS; STD; TRACHOMATIS; PREVALENCE; FEMALES; CONSEQUENCES AB Background: From 2003 to 2012, the Philadelphia High School STD Screening Program screened 126,053 students, identifying 8089 Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (GC) infections. We examined sociodemographic and behavioral factors associated with CT/GC diagnoses among a sample of this high-risk population. Methods: Standardized interviews were given to infected students receiving in-school CT/GC treatment (2009-2012) and to uninfected students calling for results (2011-2012). Sex-stratified multivariable logistic models were created to examine factors independently associated with a CT/GC diagnosis. A simple risk index was developed using variables significant on multivariable analysis. Results: A total of 1489 positive and 318 negative students were interviewed. Independent factors associated with a GC/CT diagnosis among females were black race (adjusted odds ratio [AOR], 2.27; confidence interval, 1.12-4.58), history of arrest (AOR, 2.26; 1.22-4.21), higher partner number (AOR, 1.75; 1.05-2.91), meeting partners in own neighborhood (AOR, 1.92; 1.29-2.86), and meeting partners in venues other than own school, neighborhood, or through friends ("all other"; AOR, 9.44; 3.70-24.09). For males, factors included early sexual debut (AOR, 1.99; 1.21-3.26) and meeting partners at "all other" venues (AOR, 2.76; 1.2-6.4); meeting through friends was protective (AOR, 0.63; 0.41-0.96). Meeting partners at own school was protective for both sexes (males: AOR, 0.33; 0.20-0.55; females: AOR, 0.65; 0.44-0.96). Conclusions: Although factors associated with a GC/CT infection differed between males and females in our sample, partner meeting place was associated with infection for both sexes. School-based screening programs could use this information to target high-risk students for effective interventions. C1 [Lewis, Felicia M. T.; Newman, Daniel R.; Salmon, Melinda E.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Lewis, Felicia M. T.; Anschuetz, Greta L.; Mettey, Aaron; Asbel, Lenore; Salmon, Melinda E.] Philadelphia Dept Publ Hlth, STD Control Program, Philadelphia, PA 19146 USA. RP Lewis, FMT (reprint author), Philadelphia Dept Publ Hlth, 500 S Broad St, Philadelphia, PA 19146 USA. EM Felicia.lewis@phila.gov NR 28 TC 1 Z9 1 U1 3 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2014 VL 41 IS 10 BP 605 EP 610 DI 10.1097/OLQ.0000000000000189 PG 6 WC Infectious Diseases SC Infectious Diseases GA AP9CI UT WOS:000342375600008 PM 25211256 ER PT J AU Cramer, R Leichliter, JS Gift, TL AF Cramer, Ryan Leichliter, Jami S. Gift, Thomas L. TI Are Safety Net Sexually Transmitted Disease Clinical and Preventive Services Still Needed in a Changing Health Care System? SO SEXUALLY TRANSMITTED DISEASES LA English DT Editorial Material ID UNITED-STATES; COVERAGE; TRENDS C1 [Cramer, Ryan; Leichliter, Jami S.; Gift, Thomas L.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Cramer, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA. EM rcramer@cdc.gov NR 27 TC 6 Z9 6 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2014 VL 41 IS 10 BP 628 EP 630 DI 10.1097/OLQ.0000000000000187 PG 3 WC Infectious Diseases SC Infectious Diseases GA AP9CI UT WOS:000342375600013 PM 25211261 ER PT J AU Luo, FJ Stone, DM Tharp, AT AF Luo, Feijun Stone, Deborah M. Tharp, Andra T. TI Physical Dating Violence Victimization Among Sexual Minority Youth SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID RISK BEHAVIOR SURVEILLANCE; HIGH-SCHOOL-STUDENTS; UNITED-STATES; SAME-SEX; PARTNER VIOLENCE; ADOLESCENTS; GAY; HEALTH; ASSOCIATIONS; PREVENTION AB Objectives. We examined (1) whether sexual minority youths (SMYs) are at increased risk for physical dating violence victimization (PDVV) compared with non-SMYs, (2) whether bisexual youths have greater risk of PDVV than lesbian or gay youths, (3) whether youths who have had sexual contact with both sexes are more susceptible to PDVV than youths with same sex-only sexual contact, and (4) patterns of PDVV among SMYs across demographic groups. Methods. Using 2 measures of sexual orientation, sexual identity and sexual behavior, and compiling data from 9 urban areas that administered the Youth Risk Behavior Surveys from 2001 to 2011, we conducted logistic regression analyses to calculate odds of PDVV among SMYs across demographic sub-samples. Results. SMYs have significantly increased odds of PDVV compared with non-SMYs. Bisexual youths do not have significantly higher odds of PDVV than gay or lesbian youths, but youths who had sexual contact with both-sexes possess significantly higher odds of PDVV than youths with same sex-only sexual contact. These patterns hold for most gender, grade, and racial/ethnic subgroups. Conclusions. Overall, SMYs have greater odds of PDVV versus non-SMYs. Among SMYs, youths who had sexual contact with both sexes have greater odds of PDVV than youths with same sex-only sexual contact. Prevention programs that consider sexual orientation, support tolerance, and teach coping and conflict resolution skills could reduce PDVV among SMYs. C1 [Luo, Feijun] Ctr Dis Control & Prevent, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Stone, Deborah M.; Tharp, Andra T.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Stone, DM (reprint author), 4770 Buford Highway NE,MS F 64, Atlanta, GA 30341 USA. EM Dstone3@cdc.gov FU Intramural CDC HHS [CC999999] NR 35 TC 6 Z9 6 U1 2 U2 14 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2014 VL 104 IS 10 BP E66 EP E73 DI 10.2105/AJPH.2014.302051 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1XG UT WOS:000341865000011 PM 25121813 ER PT J AU Polis, CB Phillips, SJ Curtis, KM Westreich, DJ Steyn, PS Raymond, E Hannaford, P Turner, AN AF Polis, Chelsea B. Phillips, Sharon J. Curtis, Kathryn M. Westreich, Daniel J. Steyn, Petrus S. Raymond, Elizabeth Hannaford, Philip Turner, Abigail Norris TI Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence SO CONTRACEPTION LA English DT Review DE Hormonal contraception; DMPA; Injectable contraception; Oral contraception; HIV acquisition; Systematic review ID IMMUNODEFICIENCY-VIRUS TYPE-1; SEXUALLY-TRANSMITTED-DISEASES; MEDROXYPROGESTERONE ACETATE; SOUTH-AFRICA; SEX WORKERS; COMPETING RISKS; CONDOM-USE; INFECTION; TRANSMISSION; COHORT AB Whether use of various types of hormonal contraception (HC) affect risk of HIV acquisition is a critical question for women's health. For this systematic review, we identified 22 studies published by January 15, 2014 which met inclusion criteria; we classified thirteen studies as having severe methodological limitations, and nine studies as "informative but with important limitations". Overall, data do not support an association between use of oral contraceptives and increased risk of HIV acquisition. Uncertainty persists regarding whether an association exists between depot-medroxyprogesterone acetate (DMPA) use and risk of HIV acquisition. Most studies suggested no significantly increased HIV risk with norethisterone enanthate (NET-EN) use, but when assessed in the same study, point estimates for NET-EN tended to be larger than for DMPA, though 95% confidence intervals overlapped substantially. No data have suggested significantly increased risk of HIV acquisition with use of implants, though data were limited. No data are available on the relationship between use of contraceptive patches, rings, or hormonal intrauterine devices and risk of HIV acquisition. Women choosing progestin-only injectable contraceptives such as DMPA or NET-EN should be informed of the current uncertainty regarding whether use of these methods increases risk of HIV acquisition, and like all women at risk of HIV, should be empowered to access and use condoms and other HIV preventative measures. Programs, practitioners, and women urgently need guidance on how to maximize health with respect to avoiding both unintended pregnancy and HIV given inconclusive or limited data for certain HC methods. Published by Elsevier Inc. C1 [Polis, Chelsea B.] US Agcy Int Dev, Off Populat & Reprod Hlth, Washington, DC 20004 USA. [Polis, Chelsea B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA. [Phillips, Sharon J.; Steyn, Petrus S.] WHO, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland. [Curtis, Kathryn M.] CDC, Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. [Westreich, Daniel J.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Raymond, Elizabeth] Gynu Hlth Projects, New York, NY 10010 USA. [Hannaford, Philip] Univ Aberdeen, Ctr Primary Acad Care, Aberdeen, Scotland. [Turner, Abigail Norris] Ohio State Univ, Dept Internal Med, Div Infect Dis, Columbus, OH 43210 USA. RP Polis, CB (reprint author), 1201 Penn Ave NW,Suite 315, Washington, DC 20004 USA. EM cpolis@usaid.gov OI Phillips, Sharon/0000-0001-7157-4122; Polis, Chelsea/0000-0002-1031-7074 NR 87 TC 41 Z9 42 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD OCT PY 2014 VL 90 IS 4 BP 360 EP 390 DI 10.1016/j.contraception.2014.07.009 PG 31 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AP5KL UT WOS:000342118000004 PM 25183264 ER PT J AU Schultz, L Lowe, TJ Srinivasan, A Neilson, D Pugliese, G AF Schultz, Leslie Lowe, Timothy J. Srinivasan, Arjun Neilson, Dwight Pugliese, Gina TI Economic Impact of Redundant Antimicrobial Therapy in US Hospitals SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID INFECTIOUS-DISEASES SOCIETY; CLOSTRIDIUM-DIFFICILE INFECTION; HEALTH-CARE EPIDEMIOLOGY; STAPHYLOCOCCUS-AUREUS INFECTIONS; CLINICAL-PRACTICE GUIDELINES; MEDICAL-CENTERS; AMERICA IDSA; STEWARDSHIP; DIAGNOSIS; CHILDREN AB BACKGROUND. Overutilization of antimicrobial therapy places patients at risk for harm and contributes to antimicrobial resistance and escalating healthcare costs. Focusing on redundant or duplicate antimicrobial therapy is 1 recommended strategy to reduce overutilization and its attendant effects on patient safety and hospital costs. OBJECTIVE. This study explored the incidence and economic impact of potentially redundant antimicrobial therapy. METHODS. We conducted a retrospective analysis of inpatient administrative data drawn from 505 nonfederal US hospitals. All hospitalized patients discharged between January 1, 2008, and December 31, 2011, were eligible for study inclusion. Potentially redundant antimicrobial therapy was identified from pharmacy records and was defined as patients receiving treatment with overlapping antibiotic spectra for 2 or more consecutive days. RESULTS. We found evidence of potentially inappropriate, redundant antimicrobial coverage for 23 different antimicrobial combinations in 394 of the 505 (78%) hospitals, representing a total of 32,507 cases. High-frequency redundancies were observed in 3 antianaerobic regimens, accounting for 22,701 (70%) of the cases. Of these, metronidazole and piperacillin-tazobactam accounted for 53% (n = 17,326) of all potentially redundant cases. Days of redundant therapy totaled 148,589, representing greater than $12 million in potentially avoidable healthcare costs. CONCLUSIONS. Our study suggests that there may be pervasive use of redundant antimicrobial therapy within US hospitals. Appropriate use of antimicrobials may reduce the risk of harm to patients and lower healthcare costs. C1 [Schultz, Leslie; Pugliese, Gina] Premier, Premier Safety Inst, Charlotte, NC 28277 USA. [Lowe, Timothy J.; Neilson, Dwight] Premier Healthcare Alliance, Charlotte, NC USA. [Srinivasan, Arjun] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Lowe, TJ (reprint author), Premier, 13034 Ballantyne Corp Pl, Charlotte, NC 28277 USA. EM timothy_lowe@premierinc.com NR 39 TC 9 Z9 9 U1 1 U2 8 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD OCT PY 2014 VL 35 IS 10 BP 1229 EP 1235 DI 10.1086/678066 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AP2XF UT WOS:000341938600002 PM 25203175 ER PT J AU Septimus, EJ Hayden, MK Kleinman, K Avery, TR Moody, J Weinstein, RA Hickok, J Lankiewicz, J Gombosev, A Haffenreffer, K Kaganov, RE Jernigan, JA Perlin, JB Platt, R Huang, SS AF Septimus, Edward J. Hayden, Mary K. Kleinman, Ken Avery, Taliser R. Moody, Julia Weinstein, Robert A. Hickok, Jason Lankiewicz, Julie Gombosev, Adrijana Haffenreffer, Katherine Kaganov, Rebecca E. Jernigan, John A. Perlin, Jonathan B. Platt, Richard Huang, Susan S. TI Does Chlorhexidine Bathing in Adult Intensive Care Units Reduce Blood Culture Contamination? A Pragmatic Cluster-Randomized Trial SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID COAGULASE-NEGATIVE STAPHYLOCOCCI; SKIN; INFECTION AB OBJECTIVE. To determine rates of blood culture contamination comparing 3 strategies to prevent intensive care unit (ICU) infections: screening and isolation, targeted decolonization, and universal decolonization. DESIGN. Pragmatic cluster-randomized trial. SETTING. Forty-three hospitals with 74 ICUs; 42 of 43 were community hospitals. PATIENTS. Patients admitted to adult ICUs from July 1, 2009, to September 30, 2011. METHODS. After a 6-month baseline period, hospitals were randomly assigned to 1 of 3 strategies, with all participating adult ICUs in a given hospital assigned to the same strategy. Arm 1 implemented methicillin-resistant Staphylococcus aureus (MRSA) nares screening and isolation, arm 2 targeted decolonization (screening, isolation, and decolonization of MRSA carriers), and arm 3 conducted no screening but universal decolonization of all patients with mupirocin and chlorhexidine (CHG) bathing. Blood culture contamination rates in the intervention period were compared to the baseline period across all 3 arms. RESULTS. During the 6-month baseline period, 7,926 blood cultures were collected from 3,399 unique patients: 1,099 sets in arm 1, 928 in arm 2, and 1,372 in arm 3. During the 18-month intervention period, 22,761 blood cultures were collected from 9,878 unique patients: 3,055 sets in arm 1, 3,213 in arm 2, and 3,610 in arm 3. Among all individual draws, for arms 1, 2, and 3, the contamination rates were 4.1%, 3.9%, and 3.8% for the baseline period and 3.3%, 3.2%, and 2.4% for the intervention period, respectively. When we evaluated sets of blood cultures rather than individual draws, the contamination rate in arm 1 (screening and isolation) was 9.8% (N = 108 sets) in the baseline period and 7.5% (N = 228) in the intervention period. For arm 2 (targeted decolonization), the baseline rate was 8.4% (N = 78) compared to 7.5% (N = 241) in the intervention period. Arm 3 (universal decolonization) had the greatest decrease in contamination rate, with a decrease from 8.7% (N = 119) contaminated blood cultures during the baseline period to 5.1% (N = 184) during the intervention period. Logistic regression models demonstrated a significant difference across the arms when comparing the reduction in contamination between baseline and intervention periods in both unadjusted (P =.02) and adjusted (P =.02) analyses. Arm 3 resulted in the greatest reduction in blood culture contamination rates, with an unadjusted odds ratio (OR) of 0.56 (95% confidence interval [CI], 0.044-0.71) and an adjusted OR of 0.55 (95% CI, 0.43-0.71). CONCLUSION. In this large cluster-randomized trial, we demonstrated that universal decolonization with CHG bathing resulted in a significant reduction in blood culture contamination. C1 [Septimus, Edward J.; Moody, Julia; Hickok, Jason; Perlin, Jonathan B.] Hosp Corp Amer, Nashville, TN USA. [Septimus, Edward J.] Texas A&M Univ, Coll Med, Texas A&M Hlth Sci Ctr, Houston, TX USA. [Hayden, Mary K.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Kleinman, Ken; Avery, Taliser R.; Lankiewicz, Julie; Haffenreffer, Katherine; Kaganov, Rebecca E.; Platt, Richard] Harvard Univ, Sch Med, Boston, MA USA. [Kleinman, Ken; Avery, Taliser R.; Lankiewicz, Julie; Haffenreffer, Katherine; Kaganov, Rebecca E.; Platt, Richard] Harvard Univ, Harvard Pilgrim Hlth Care Inst, Boston, MA 02115 USA. [Weinstein, Robert A.] Cook Cty Hlth & Hosp Syst, Chicago, IL USA. [Gombosev, Adrijana; Huang, Susan S.] Univ Calif Irvine, Sch Med, Orange, CA 92668 USA. [Jernigan, John A.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Jernigan, John A.] CDC Prevent Epictr Program, Chicago, IL USA. RP Septimus, EJ (reprint author), 4257 Albans St, Houston, TX 77005 USA. EM edward.septimus@hcahealthcare.com FU Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, as part of the Developing Evidence to Inform Decisions about Effectiveness program [HHSA290201000008I, HHSA29032007T]; Centers for Disease Control and Prevention (CDC) Prevention Epicenters Program [1U01 CI000344] FX This project was funded by the Healthcare-Associated Infections Program under contracts HHSA290201000008I and HHSA29032007T from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, as part of the Developing Evidence to Inform Decisions about Effectiveness program, and the Centers for Disease Control and Prevention (CDC) Prevention Epicenters Program (1U01 CI000344 to R.P.). The REDUCE MRSA study received approval from the Harvard Pilgrim Health Care institutional review board. NR 20 TC 8 Z9 8 U1 3 U2 11 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD OCT PY 2014 VL 35 SU 3 BP S17 EP S22 DI 10.1086/677822 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AP2XP UT WOS:000341939700004 PM 25222893 ER PT J AU Braun, JM Froehlich, T Kalkbrenner, A Pfeiffer, CM Fazili, Z Yolton, K Lanphear, BP AF Braun, Joseph M. Froehlich, Tanya Kalkbrenner, Amy Pfeiffer, Christine M. Fazili, Zia Yolton, Kimberly Lanphear, Bruce P. TI Brief Report: Are Autistic-Behaviors in Children Related to Prenatal Vitamin Use and Maternal Whole Blood Folate Concentrations? SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism spectrum disorders; Folate; Pregnancy; Prenatal vitamins ID FOLIC-ACID SUPPLEMENTS; TOBACCO-SMOKE EXPOSURE; ONE-CARBON METABOLISM; SPECTRUM DISORDERS; EARLY-PREGNANCY; RISK; REPRODUCIBILITY; QUESTIONNAIRE; ASSOCIATION; VALIDITY AB Prenatal multivitamin/folic acid supplement use may reduce the risk of autism spectrum disorders. We investigated whether 2nd trimester prenatal vitamin use and maternal whole blood folate (WBF) concentrations were associated with Social Responsiveness Scale (SRS) scores at 4-5 years of age in a prospective cohort of 209 mother-child pairs. After confounder adjustment, children born to women taking prenatal vitamins weekly/daily (n = 179) had lower odds of clinically elevated SRS scores (odds ratio 0.26; 95 % confidence interval 0.08, 0.89) than those who rarely/never took them (n = 30). WBF concentrations were not associated with SRS scores. The lack of association between WBF and autistic-behaviors may be due to the timing of biomarker measures relative to critical periods of brain development, confounding, or other modifying factors. C1 [Braun, Joseph M.] Brown Univ, Dept Epidemiol, Sch Publ Hlth, Providence, RI 02912 USA. [Froehlich, Tanya; Yolton, Kimberly] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA. [Kalkbrenner, Amy] Univ Wisconsin, Zilber Sch Publ Hlth, Milwaukee, WI 53201 USA. [Pfeiffer, Christine M.; Fazili, Zia] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Lanphear, Bruce P.] Simon Fraser Univ, Fac Hlth & Sci, Burnaby, BC V5A 1S6, Canada. [Lanphear, Bruce P.] BC Childrens & Womens Hosp, Child & Family Res Inst, Vancouver, BC V5Z 4H48, Canada. RP Braun, JM (reprint author), Brown Univ, Dept Epidemiol, Sch Publ Hlth, Providence, RI 02912 USA. EM joseph_braun_1@brown.edu FU NCATS NIH HHS [UL1 TR001425]; NIEHS NIH HHS [P01 ES11261, R00 ES020346, R01 ES014575, R01 ES020349] NR 28 TC 4 Z9 4 U1 0 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 EI 1573-3432 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD OCT PY 2014 VL 44 IS 10 BP 2602 EP 2607 DI 10.1007/s10803-014-2114-x PG 6 WC Psychology, Developmental SC Psychology GA AP6TX UT WOS:000342211800021 PM 24710813 ER PT J AU Dunne, EF Markowitz, LE Taylor, LD Unger, ER Wheeler, CM AF Dunne, Eileen F. Markowitz, Lauri E. Taylor, La'shan D. Unger, Elizabeth R. Wheeler, Cosette M. TI Human papilloma virions in the laboratory SO JOURNAL OF CLINICAL VIROLOGY LA English DT Review DE Laboratory safety; Human papillomavirus; HPV; HPV vaccines ID EPITHELIAL-CELL DIFFERENTIATION; HPV TYPES; INFECTION; VACCINE; NEUTRALIZATION; TYPE-16; WOMEN; DNA AB Carcinogenic human papillomaviruses (HPV) can cause cervical, vaginal, vulvar, penile, anal, and oropharyngeal cancers. Non-carcinogenic HPVs can cause anogenital warts and recurrent respiratory papillomatosis. Currently, few research laboratories propagate, isolate or generate papilloma virions. However, there have been questions about potential exposure and risk in this setting. In this brief note, we discuss the use of wild type and laboratory-generated virions in research laboratories, potential routes of laboratory exposure, and considerations for HPV vaccination of laboratory personnel. (C) 2014 Elsevier B.V. All rights reserved. C1 [Dunne, Eileen F.; Markowitz, Lauri E.; Taylor, La'shan D.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Taylor, La'shan D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Fellow EIS, Atlanta, GA USA. [Unger, Elizabeth R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Wheeler, Cosette M.] Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87313 USA. [Wheeler, Cosette M.] Univ New Mexico, Hlth Sci Ctr, Dept Obstet & Gynecol, Albuquerque, NM 87313 USA. RP Wheeler, CM (reprint author), Univ New Mexico, Hlth Sci Ctr, Dept Pathol, MSC 02-1670, Albuquerque, NM 87313 USA. EM cwheeler@salud.unm.edu FU National Institute of Allergy and Infectious Diseases (NIAID) [U19AI084081] FX CMW efforts were funded by an award from the National Institute of Allergy and Infectious Diseases (NIAID U19AI084081 to CMW). NR 24 TC 1 Z9 2 U1 0 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD OCT PY 2014 VL 61 IS 2 BP 196 EP 198 DI 10.1016/j.jcv.2014.06.014 PG 3 WC Virology SC Virology GA AP4MY UT WOS:000342052300003 PM 25088765 ER PT J AU Kodani, M Mixson-Hayden, T Drobeniuc, J Kamili, S AF Kodani, Maja Mixson-Hayden, Tonya Drobeniuc, Jan Kamili, Saleem TI Rapid and sensitive approach to simultaneous detection of genomes of hepatitis A, B, C, D and E viruses SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Simultaneous pathogen detection; Real-time PCR; Hepatitis; Microfluidics ID TAQMAN ARRAY CARD; PCR ASSAY; INFECTION; EPIDEMIOLOGY AB Background: Five viruses have been etiologically associated with viral hepatitis. Nucleic acid testing (NAT) remains the gold standard for diagnosis of viremic stages of infection. NAT methodologies have been developed for all hepatitis viruses; however, a NAT-based assay that can simultaneously detect all five viruses is not available. Objectives: We designed TaqMan card-based assays for detection of HAV RNA, HBV DNA, HCV RNA, HDV RNA and HEV RNA. Study design: The performances of individual assays were evaluated on TaqMan Array Cards (TAC) for detecting five viral genomes simultaneously. Sensitivity and specificity were determined by testing 329 NAT-tested clinical specimens. Results: All NAT-positive samples for HCV (n = 32), HDV (n = 28) and HEV (n = 14) were also found positive in TAC (sensitivity, 100%). Forty-three of 46 HAV-NAT positive samples were also positive in TAC (sensitivity, 94%), while 36 of 39 HBV-NAT positive samples were positive (sensitivity, 92%). No false-positives were detected for HBV (n = 32), HCV (n = 36), HDV (n = 30), and HEV (n = 31) NAT-negative samples (specificity 100%), while 38 of 41 HAV-NAT negative samples were negative by TAC (specificity 93%). Conclusions: TAC assay was concordant with corresponding individual NATs for hepatitis A-E viral genomes and can be used for their detection simultaneously. The TAC assay has potential for use in hepatitis surveillance, for screening of donor specimens and in outbreak situations. Wider availability of TAC-ready assays may allow for customized assays, for improving acute jaundice surveillance and for other purposes for which there is need to identify multiple pathogens rapidly. Published by Elsevier B.V. C1 [Kodani, Maja; Mixson-Hayden, Tonya; Drobeniuc, Jan; Kamili, Saleem] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div Viral Hepatitis, Atlanta, GA 30329 USA. RP Kodani, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div Viral Hepatitis, Atlanta, GA 30329 USA. EM mkodani@cdc.gov FU CDC FX Internal CDC funding. NR 20 TC 7 Z9 8 U1 2 U2 18 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD OCT PY 2014 VL 61 IS 2 BP 260 EP 264 DI 10.1016/j.jcv.2014.06.027 PG 5 WC Virology SC Virology GA AP4MY UT WOS:000342052300014 PM 25081939 ER PT J AU Youngpairoj, AS Curtis, KA Wells, SK Pau, CP Granade, TC Owen, SM AF Youngpairoj, Ae S. Curtis, Kelly A. Wells, Susan K. Pau, Chou-Pong Granade, Timothy C. Owen, S. Michele TI Reference panel of cloned HIV-2 plasmid DNA for nucleic acid assay development, evaluation, and quality monitoring SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE HIV-2; Clone; Plasmid; HIV-2 group; Real-time PCR; NAT ID IMMUNODEFICIENCY-VIRUS TYPE-2; PROTEASE INHIBITORS; UNITED-STATES; VIRAL LOAD; INFECTION; SUBTYPE; IDENTIFICATION; SUSCEPTIBILITY; RESISTANCE; SEQUENCE AB Background: Currently, no FDA-approved HIV-2 nucleic acid assay is commercially available in the United States, although several laboratories have developed in-house assays to confirm HIV-2 infections. A major limitation in the development of novel HIV-2 diagnostic assays is the lack of reference materials that can be used to evaluate, optimize, and monitor assay performance. Study design: Eleven viral stocks of HIV-2 isolates from various West African countries, including the Ivory Coast, Senegal, and Guinea-Bissau, were used to clone the entire LTR and pol regions from each virus. Results: We successfully cloned, sequenced, and group classified 22 HIV-2 DNA plasmids including 11 full length LTR (similar to 849 bp) and 11 pol (similar to 2995 bp) sequences. There were eight HIV-2 group A and three group B in both the LTR and pol regions. Conclusions: This reference panel provides a robust, quantifiable, renewable, and non-infectious set of reagents that can be used for the development and evaluation of new HIV-2 molecular diagnostic assays and quality assurance and quality control reagents for use in the clinical laboratories. Published by Elsevier B.V. C1 [Youngpairoj, Ae S.; Curtis, Kelly A.; Wells, Susan K.; Pau, Chou-Pong; Granade, Timothy C.; Owen, S. Michele] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Branch Lab, Atlanta, GA 30333 USA. RP Youngpairoj, AS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A25, Atlanta, GA 30333 USA. EM ads8@cdc.gov NR 39 TC 0 Z9 0 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD OCT PY 2014 VL 61 IS 2 BP 293 EP 297 DI 10.1016/j.jcv.2014.06.028 PG 5 WC Virology SC Virology GA AP4MY UT WOS:000342052300022 PM 25066885 ER PT J AU Crews, JE Chou, CF Zhang, XZ Zack, MM Saaddine, JB AF Crews, John E. Chou, Chiu-Fang Zhang, Xinzhi Zack, Matthew M. Saaddine, Jinan B. TI Health-Related Quality of Life Among People Aged >= 65 Years with Self-reported Visual Impairment: Findings from the 2006-2010 Behavioral Risk Factor Surveillance System SO OPHTHALMIC EPIDEMIOLOGY LA English DT Article DE Aging; Behavioral Risk Factor Surveillance System; health related quality of life; vision impairment ID NURSING-HOME RESIDENTS; EYE CARE UTILIZATION; BLUE MOUNTAINS EYE; UNITED-STATES; FUNCTIONAL STATUS; OLDER-ADULTS; MACULAR DEGENERATION; VISION IMPAIRMENT; FUNCTION QUESTIONNAIRE; DIABETES-MELLITUS AB Purpose: To examine the association between health-related quality of life (HRQoL) and visual impairment among people aged >= 65 years. Methods: We used cross-sectional data from the 2006-2010 Behavioral Risk Factor Surveillance System to examine six HRQoL measures: self-reported health, physically unhealthy days, mentally unhealthy days, activity limitation days, life satisfaction, and disability. Visual impairment was categorized as no, a little, and moderate/severe. We examined the association between self-reported visual impairment and HRQoL using logistic regression accounting for the survey's complex design. Results: People with self-reported moderate/severe visual impairment had more frequent (>= 14) physically unhealthy days, mentally unhealthy days, and activity limitation days in the last 30 days compared to those reporting a little or no visual impairment. After controlling for all covariates (age, sex, marital status, race/ethnicity, education, income, diabetes, heart disease, stroke, heart attack, body mass index, leisure time activity, smoking, and medical care cost concerns) and comparing to those with no self-reported visual impairment, people reporting a little visual impairment were more likely to have fair/poor health (odds ratio, OR, 1.2, 95% confidence interval, CI, 1.1-1.3), life dissatisfaction (OR 1.6, 95% CI 1.3-2.0), and disability (OR 1.5, 95% CI 1.3-1.6), and those with self-reported moderate/severe visual impairment had more fair/poor health (OR 1.8, 95% CI 1.6-2.0), life dissatisfaction (OR 2.3, 95% CI 1.8-2.9), and disability (OR 2.0, 95% CI 1.8-2.2). They also had more frequent physically unhealthy days (OR 1.9, 95% CI 1.7-2.1), mentally unhealthy days (OR 1.8, 95% CI 1.5-2.1), and activity limitations days (OR 1.9, 95% CI 1.6-2.2). Conclusion: Poor HRQoL is strongly associated with the severity of self-reported visual impairment among people aged >= 65 years. C1 [Crews, John E.; Chou, Chiu-Fang; Zhang, Xinzhi; Zack, Matthew M.; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Crews, JE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM Jcrews@cdc.gov FU Centers for Disease Control and Prevention FX Financial support was provided by the Centers for Disease Control and Prevention. NR 70 TC 11 Z9 11 U1 0 U2 15 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0928-6586 EI 1744-5086 J9 OPHTHAL EPIDEMIOL JI Ophthalmic Epidemiol. PD OCT PY 2014 VL 21 IS 5 BP 287 EP 296 DI 10.3109/09286586.2014.926556 PG 10 WC Ophthalmology SC Ophthalmology GA AP3RP UT WOS:000341995200003 PM 24955821 ER PT J AU Toprak, D Soysal, A Torunoglu, MA Turgut, M Turkoglu, S Pimenta, FC Carvalho, MD Wang, X Mayer, L Altinkanat, G Soyletir, G Mete, B Bakir, M AF Toprak, Demet Soysal, Ahmet Torunoglu, Mehmet Ali Turgut, Mehmet Turkoglu, Salih Pimenta, Fabiana Cristina Carvalho, Maria da Gloria Wang, Xin Mayer, Leonard Altinkanat, Gulsen Soyletir, Guner Mete, Birgul Bakir, Mustafa CA Turkish Meningitis Study Grp TI PCR-BASED NATIONAL BACTERIAL MENINGITIS SURVEILLANCE IN TURKEY YEARS 2006 TO 2009 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE surveillance; bacterial; meningitis; Turkey ID STREPTOCOCCUS-PNEUMONIAE; NEISSERIA-MENINGITIDIS; DISEASE; ASSAYS AB Polymerase chain reaction-based surveillance for bacterial meningitis including 841 children revealed 246 with bacterial DNA in cerebrospinal fluid samples of which 53% were Streptococcus pneumoniae, 19% Neisseria meningitidis, and 16% Haemophilus influenzae type b. The most common S. pneumoniae serotypes/serogroups were 1, 19F, 6A/6B, 23F, 5, 14, 18 and 19A. Among 47 meningococci, 86% were serogroup B, 6% serogroup C, 3% serogroup A, 3% serogroup X and 3% serogroup W. C1 [Toprak, Demet; Turkish Meningitis Study Grp] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Med,Div Pulm Med, Cambridge, MA 02138 USA. [Soysal, Ahmet; Bakir, Mustafa] Marmara Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, Istanbul, Turkey. [Torunoglu, Mehmet Ali] Turkish Minist Hlth, Dept Infect Dis, Adiyaman, Turkey. [Turgut, Mehmet] Adiyaman Univ, Fac Med, Dept Pediat, Adiyaman, Turkey. [Turkoglu, Salih] Istanbul Univ, Istanbul Fac Med, Dept Microbiol, Istanbul, Turkey. [Pimenta, Fabiana Cristina; Carvalho, Maria da Gloria] Ctr Dis Control & Prevent, Streptococcus Lab, Resp Dis Branch, Atlanta, GA USA. [Wang, Xin; Mayer, Leonard] Ctr Dis Control & Prevent, Meningitis Lab, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA USA. [Altinkanat, Gulsen; Soyletir, Guner] Marmara Univ, Sch Med, Dept Clin Microbiol, Istanbul, Turkey. [Mete, Birgul] Istanbul Univ, Cerrahpasa Med Sch, Dept Clin Microbiol, Istanbul, Turkey. RP Bakir, M (reprint author), Marmara Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, Mimar Sinan Caddesi,Fevzi Cakmak Mah, Istanbul, Turkey. EM mustafabakir65@gmail.com RI altinkanat gelmez, gulsen/Q-2516-2015 FU Turkish Scientific and Technical Research Institute (TUBITAK) [107S337] FX This study is supported by the Turkish Scientific and Technical Research Institute (TUBITAK), Grant no: 107S337. NR 13 TC 5 Z9 5 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD OCT PY 2014 VL 33 IS 10 BP 1087 EP 1089 DI 10.1097/INF.0000000000000378 PG 3 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA AP6PC UT WOS:000342198700023 PM 25361189 ER PT J AU Matsumoto, RR Seminerio, MJ Turner, RC Robson, MJ Nguyen, L Miller, DB O'Callaghan, JP AF Matsumoto, Rae R. Seminerio, Michael J. Turner, Ryan C. Robson, Matthew J. Nguyen, Linda Miller, Diane B. O'Callaghan, James P. TI Methamphetamine-induced toxicity: An updated review on issues related to hyperthermia SO PHARMACOLOGY & THERAPEUTICS LA English DT Review DE Autonomic nervous system; Hyperthermia; Methamphetamine; Reactive oxygen species; Thermoregulation; Toxicity ID INDUCED DOPAMINERGIC NEUROTOXICITY; SIGMA-RECEPTOR ANTAGONIST; HEAT-SHOCK-PROTEIN; BODY-TEMPERATURE; BRAIN HYPERTHERMIA; STRIATAL DOPAMINE; MESSENGER-RNA; RAT-BRAIN; IN-VIVO; THERMOREGULATORY RESPONSES AB Reports of methamphetamine-related emergency room visits suggest that elevated body temperature is a universal presenting symptom, with lethal overdoses generally associated with extreme hyperthermia. This review summarizes the available information on methamphetamine toxicity as it pertains to elevations in body temperature. First, a brief overview of thermoregulatory mechanisms is presented. Next, central and peripheral targets that have been considered for potential involvement in methamphetamine hyperthermia are discussed. Finally, future areas of investigation are proposed, as further studies are needed to provide greater insight into the mechanisms that mediate the alterations in body temperature elicited by methamphetamine. (C) 2014 Elsevier Inc. All rights reserved. C1 [Matsumoto, Rae R.; Seminerio, Michael J.; Robson, Matthew J.; Nguyen, Linda] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA. [Matsumoto, Rae R.; Turner, Ryan C.; Nguyen, Linda] W Virginia Univ, Sch Med, Ctr Neurosci, Morgantown, WV 26506 USA. [Seminerio, Michael J.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Turner, Ryan C.] W Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA. [Robson, Matthew J.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA. [Miller, Diane B.; O'Callaghan, James P.] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Morgantown, WV 26505 USA. RP Matsumoto, RR (reprint author), W Virginia Univ, Sch Pharm, 1 Med Ctr Dr, Morgantown, WV 26506 USA. EM rmatsumoto@hsc.wvu.edu RI Robson, Matthew/H-3127-2013 OI Robson, Matthew/0000-0002-3277-3062 FU National Institutes of Health [DA013978, GM081741, NS007491] FX Some of the studies described herein and the authors were supported by grants from the National Institutes of Health (DA013978, GM081741, NS007491). NR 154 TC 9 Z9 10 U1 1 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0163-7258 J9 PHARMACOL THERAPEUT JI Pharmacol. Ther. PD OCT PY 2014 VL 144 IS 1 BP 28 EP 40 DI 10.1016/j.pharmthera.2014.05.001 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AP7NL UT WOS:000342263900003 PM 24836729 ER PT J AU Xu, X Malarcher, A O'Halloran, A Kruger, J AF Xu, Xin Malarcher, Ann O'Halloran, Alissa Kruger, Judy TI Does every US smoker bear the same cigarette tax? SO ADDICTION LA English DT Article DE Behavior; cigarette smoking; pass-through rate; prices; smoking; taxes ID 4 COUNTRY SURVEY; PRICE-MINIMIZATION STRATEGIES; SMOKING-CESSATION; PURCHASE PATTERNS; UNITED-STATES; BEHAVIORS; TAXATION; REDUCTIONS; AVOIDANCE; INDUSTRY AB Aims To evaluate state cigarette excise tax pass-through rates for selected price-minimizing strategies. Design Multivariate regression analysis of current smokers from a stratified, national, dual-frame telephone survey. Setting United States. Participants A total of 16542 adult current smokers aged 18 years or older. Measurements Cigarette per pack prices paid with and without coupons were obtained for pack versus carton purchase, use of generic brands versus premium brands, and purchase from Indian reservations versus outside Indian reservations. Findings The average per pack prices paid differed substantially by price-minimizing strategy. Smokers who used any type of price-minimizing strategies paid substantially less than those who did not use these strategies (P<0.05). Premium brand users who purchased by pack in places outside Indian reservations paid the entire amount of the excise tax, together with an additional premium of 7-10 cents per pack for every $1 increase in excise tax (pass-through rate of 1.07-1.10, P<0.05). In contrast, carton purchasers, generic brand users or those who were likely to make their purchases on Indian reservations paid only 30-83 cents per pack for every $1 tax increase (pass-through rate of 0.30-0.83, P<0.05). Conclusions Many smokers in the United States are able to avoid the full impact of state excise tax on cost of smoking by buying cartons, using generic brands and buying from Indian reservations. C1 [Xu, Xin; Malarcher, Ann; Kruger, Judy] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [O'Halloran, Alissa] Ctr Dis Control & Prevent, NCCDPHP NGIS, Atlanta, GA 30341 USA. RP Xu, X (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F-79, Atlanta, GA 30341 USA. EM xinxu@cdc.gov FU Intramural CDC HHS [CC999999] NR 43 TC 4 Z9 4 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD OCT PY 2014 VL 109 IS 10 BP 1741 EP 1749 DI 10.1111/add.12630 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA AO9AO UT WOS:000341648000027 PM 24861973 ER PT J AU Toms, LML Thompson, J Rotander, A Hobson, P Calafat, AM Kato, K Ye, X Broomhall, S Harden, F Mueller, JF AF Toms, L-M. L. Thompson, J. Rotander, A. Hobson, P. Calafat, A. M. Kato, K. Ye, X. Broomhall, S. Harden, F. Mueller, J. F. TI Decline in perfluorooctane sulfonate and perfluorooctanoate serum concentrations in an Australian population from 2002 to 2011 SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Biomonitoring; Human blood serum; Perfluoroalkyl; Polyfluoroalkyl substances; PFAS ID ADULT-BLOOD DONORS; POLYFLUOROALKYL CHEMICALS; PERFLUORINATED CHEMICALS; PERFLUOROALKYL ACIDS; PERFLUOROCARBOXYLIC ACIDS; SUBSTANCES PFASS; NHANES 1999-2000; TEMPORAL TRENDS; NATIONAL-HEALTH; PREGNANT-WOMEN AB Some perfluoroalkyl and polyfluoroalkyl substances (PFASs) have become widespread pollutants detected in human and wildlife samples worldwide. The main objective of this study was to assess temporal trends of PFAS concentrations in human blood in Australia over the last decade (2002-2011), taking into consideration age and sex trends. Pooled human sera from 2002/03 (n = 26); 2008/09 (n = 24) and 2010/11 (n = 24) from South East Queensland, Australia were obtained from de-identified surplus pathology samples and compared with samples collected previously from 2006/07 (n = 84). A total of 9775 samples in 158 pools were available for an assessment of PFASs. Stratification criteria included sex and age: <16 years (2002/03 only); 0-4 (2006/07, 2008/09, 2010/11); 5-15 (2006/07, 2008/09, 2010/11); 16-30; 31-45; 46-60; and >60 years (all collection periods). Sera were analyzed using on-line solid-phase extraction coupled to high-performance liquid chromatography-isotope dilution-tandem mass spectrometry. Perfluorooctane sulfonate (PFOS) was detected in the highest concentrations ranging from 5.3-19.2 ng/ml (2008/09) to 4.4-17.4 ng/ml (2010/11). Perfluorooctanoate (PFOA) was detected in the next highest concentration ranging from 2.8-7.3 ng/ml (2008/09) to 3.1-6.5 ng/ml (2010/11). All other measured PFASs were detected at concentrations <1 ng/ml with the exception of perfluorohexane sulfonate which ranged from 12-5.7 ng/ml (08/09) and 1.4-5.4 ng/ml (10/11). The mean concentrations of both PFOS and PFOA in the 2010/11 period compared to 2002/03 were lower for all adult age groups by 56%. For 5-15 year olds, the decrease was 66% (PFOS) and 63% (PFOA) from 2002/03 to 2010/11. For 0-4 year olds the decrease from 2006/07 (when data were first available for this age group) was 50% (PFOS) and 22% (PFOA). This study provides strong evidence for decreasing serum PFOS and PFOA concentrations in an Australian population from 2002 through 2011. Age trends were variable and concentrations were higher in males than in females. Global use has been in decline since around 2002 and hence primary exposure levels are expected to be decreasing. Further biomonitoring will allow assessment of PFAS exposures to confirm trends in exposure as primary and eventually secondary sources are depleted. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Toms, L-M. L.; Harden, F.] Queensland Univ Technol, Sch Clin Sci, Brisbane, Qld 4001, Australia. [Toms, L-M. L.; Harden, F.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia. [Thompson, J.] Queensland Hlth Sci Serv, Coopers Plains, Qld 4108, Australia. [Rotander, A.; Mueller, J. F.] Univ Queensland, Natl Res Ctr Environm Toxicol, Coopers Plains, Qld 4108, Australia. [Hobson, P.] Sullivan Nicolaides Pathol, Taringa, Qld 4068, Australia. [Calafat, A. M.; Kato, K.; Ye, X.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Broomhall, S.] Dept Environm, Canberra, ACT 2601, Australia. RP Toms, LML (reprint author), Queensland Univ Technol, Sch Clin Sci, Brisbane, Qld 4001, Australia. EM leisamaree.toms@qut.edu.au RI Mueller, Jochen/C-6241-2008; Toms, Leisa-Maree/C-9530-2009; Harden, Fiona/C-2450-2011; OI Toms, Leisa-Maree/0000-0002-1444-1638; Harden, Fiona/0000-0003-4831-2292; Mueller, Jochen/0000-0002-0000-1973 FU ARC DECRA [DE120100161]; ARC Future Fellowship [FF120100546]; University of Queensland; Queensland Health; Australian Government Department of the Environment FX LMLT is funded by an ARC DECRA (DE120100161). JFM is funded by ARC Future Fellowship (FF120100546). Entox is jointly funded by the University of Queensland and Queensland Health. The authors would like to thank the Australian Government Department of the Environment for their financial support, and for allowing access to the submitted report entitled "Chemical Monitoring Initiative: Australian human blood sample collection and chemical testing". We acknowledge Brian Basden, Ayesha Patel and Lily Jia for the technical assistance in measuring the serum concentrations of PFASs. NR 55 TC 25 Z9 25 U1 8 U2 71 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD OCT PY 2014 VL 71 BP 74 EP 80 DI 10.1016/j.envint.2014.05.019 PG 7 WC Environmental Sciences SC Environmental Sciences & Ecology GA AP0IQ UT WOS:000341745100008 PM 24980755 ER PT J AU Mills, DS AF Mills, Danielle Shirk TI Building Environmental Public Health Framework for Chemical Emergencies SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 CDC, Natl Ctr Environm Hlth, Off Environm Hlth Emergencies, Chamblee, GA 30341 USA. RP Mills, DS (reprint author), CDC, Natl Ctr Environm Hlth, Off Environm Hlth Emergencies, 4770 Buford Highway,MS F-09, Chamblee, GA 30341 USA. EM dmills@cdc.gov FU Intramural CDC HHS [CC999999] NR 4 TC 0 Z9 1 U1 0 U2 0 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD OCT PY 2014 VL 77 IS 3 BP 32 EP 33 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AP3FI UT WOS:000341960600004 PM 25603652 ER PT J AU Outin, YR AF Outin, Youlanda R. TI CDC's National Environmental Public Health Tracking Network Adds Pesticide Exposure and Prospective Climate Data SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 CDC, Natl Ctr Environm Hlth, Environm Hlth Tracking Branch, Atlanta, GA 30341 USA. RP Outin, YR (reprint author), CDC, Natl Ctr Environm Hlth, Environm Hlth Tracking Branch, 4770 Buford Highway,MS F-60, Atlanta, GA 30341 USA. EM youtin@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 2 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD OCT PY 2014 VL 77 IS 3 BP 34 EP 36 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AP3FI UT WOS:000341960600005 PM 25603653 ER PT J AU Schulden, JD Painter, TM Song, BW Valverde, E Borman, MA Monroe-Spencer, K Bautista, G Saleheen, H Voetsch, AC Heffelfinger, JD AF Schulden, Jeffrey D. Painter, Thomas M. Song, Binwei Valverde, Eduardo Borman, Mary Ann Monroe-Spencer, Kyle Bautista, Greg Saleheen, Hassan Voetsch, Andrew C. Heffelfinger, James D. TI HIV Testing Histories and Risk Factors Among Migrants and Recent Immigrants Who Received Rapid HIV Testing from Three Community-Based Organizations SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE HIV; STD; Migrants; Immigrants; Rapid HIV testing; HIV prevention ID SEXUALLY-TRANSMITTED-DISEASES; INJECTION-DRUG USERS; MEXICAN MIGRANTS; UNITED-STATES; DAY LABORERS; NORTH-CAROLINA; FOREIGN-BORN; SEX WORKERS; CONDOM USE; INFECTION AB Migrants and recent immigrants in the US constitute a large population that is vulnerable to HIV. From March 2005 to February 2007, three community-based organizations conducted rapid HIV testing among migrants in five states. Participants were asked to complete a survey on sociodemographics, HIV-risk behaviors, and HIV-testing histories with the aim of understanding factors associated with HIV testing. Among 5,247 persons tested, 6 (0.1 %) were HIV-positive. Among 3,135 persons who completed surveys, more than half had never been tested for HIV previously (59 %). Participants reported high levels of HIV-risk behaviors in the past year, including 2 or more sex partners (45 %), sex while high/drunk (30 %), and transactional sex (29 %). Multivariate analysis identified several factors independently associated with decreased likelihood of prior HIV testing, including poor spoken English. Continued efforts are needed to ensure that migrant populations have improved access to HIV testing and prevention services. Understanding factors associated with migrants' lack of previous HIV testing may help focus these efforts. C1 [Schulden, Jeffrey D.] NIDA, NIH, Bethesda, MD 20892 USA. [Painter, Thomas M.; Song, Binwei; Valverde, Eduardo; Voetsch, Andrew C.; Heffelfinger, James D.] Ctr Dis Control & Prevent CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Borman, Mary Ann] United Migrant Opportun Serv, Milwaukee, WI USA. [Monroe-Spencer, Kyle; Bautista, Greg] AIDGwinnett, Lawrenceville, GA USA. [Saleheen, Hassan] Connecticut Childrens Med Ctr, Hartford, CT USA. RP Schulden, JD (reprint author), NIDA, NIH, 6001 Execut Blvd,MSC 9589, Bethesda, MD 20892 USA. EM schuldenj@nida.nih.gov NR 71 TC 5 Z9 5 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD OCT PY 2014 VL 16 IS 5 BP 798 EP 810 DI 10.1007/s10903-013-9811-y PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO9PJ UT WOS:000341687400004 PM 23512324 ER PT J AU Kumar, GS Varma, S Saenger, MS Burleson, M Kohrt, BA Cantey, P AF Kumar, Gayathri S. Varma, Selina Saenger, Michael S. Burleson, Molly Kohrt, Brandon A. Cantey, Paul TI Noninfectious Disease Among the Bhutanese Refugee Population at a United States Urban Clinic SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Bhutanese; Refugee; Chronic disease; Noninfectious disease ID DEFICIENCY; NEPAL AB A large number of Bhutanese are currently being resettled to the United States. A high prevalence of noninfectious diseases has been noted in some refugee groups, but data on the Bhutanese refugee population are lacking. A retrospective, chart review study was conducted to determine proportion of noninfectious disease among ethnically Nepali Bhutanese refugees (n = 66) seen at the Grady Refugee Clinic (GRC). GRC disease proportions included the following: 52 % of the patients were overweight/obese (n = 34), 23 % were hypertensive (n = 15), 12 % had vitamin B-12 deficiency (n = 8), 15 % had depression (n = 10), and 14 % had diabetes (n = 9). Nine (90 %) patients with depression had chronic disease compared to 30 (54 %) of the patients without depression. The study found a substantial burden of chronic disease, micronutrient deficiency, and depression in the GRC. Further research is needed to accurately describe the disease burden in refugee populations and to evaluate pre-resettlement disease prevention strategies to provide a framework for future public health interventions. C1 [Kumar, Gayathri S.; Saenger, Michael S.] Emory Univ, Dept Internal Med, Atlanta, GA 30303 USA. [Varma, Selina; Burleson, Molly] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Kohrt, Brandon A.] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. [Cantey, Paul] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Saenger, MS (reprint author), Emory Univ, Dept Internal Med, 49 Jesse Hill Jr Dr,Suite 403, Atlanta, GA 30303 USA. EM mssaeng@emory.edu NR 14 TC 6 Z9 6 U1 5 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD OCT PY 2014 VL 16 IS 5 BP 922 EP 925 DI 10.1007/s10903-013-9800-1 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO9PJ UT WOS:000341687400018 PM 23456726 ER PT J AU Shah, AY Suchdev, PS Mitchell, T Shetty, S Warner, C Oladele, A Reines, S AF Shah, Ankoor Y. Suchdev, Parminder S. Mitchell, Tarissa Shetty, Sharmila Warner, Catherine Oladele, Alawode Reines, Susan TI Nutritional Status of Refugee Children Entering DeKalb County, Georgia SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Refugee; Anemia; Malnutrition; Parasites; Dental caries ID IRON-DEFICIENCY; UNITED-STATES; ANEMIA; HEALTH; MORTALITY; GROWTH; CARIES; BURMA; RISK AB This study determines the nutritional status among refugee children entering one of the largest resettlement counties in the United States and identifies differences between incoming populations. Medical records of all newly arriving pediatric refugees (0-18 years) entering DeKalb County, Georgia between October 2010 and July 2011 were reviewed. Refugee children were grouped as African, Bhutanese, or Burmese (resettling from either Thailand or Malaysia) for comparative analysis. Approximately one in five refugees were anemic or malnourished, while a quarter had stool parasites, and nearly half had dental caries. African refugees had the highest anemia but the lowest underweight prevalence (p < 0.05). Compared to Burmese resettling from Malaysia, Burmese children from Thailand had a higher prevalence of anemia, underweight, and stool parasites (p < 0.05). Clinicians should use CDC medical screening guidelines for newly arriving pediatric refugees, as well as ensure proper nutritional support and follow-up care. C1 [Shah, Ankoor Y.] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Shah, Ankoor Y.; Suchdev, Parminder S.; Reines, Susan] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Suchdev, Parminder S.] Ctr Dis Control & Prevent, Nutr Branch, Atlanta, GA USA. [Mitchell, Tarissa; Shetty, Sharmila] Ctr Dis Control & Prevent, Immigrant Refugee & Migrant Hlth Branch, Atlanta, GA USA. [Mitchell, Tarissa; Reines, Susan] Southeast Permanente Med Grp, Atlanta, GA USA. [Warner, Catherine] Med Coll Georgia, Augusta, GA 30912 USA. [Oladele, Alawode] DeKalb Cty Board Hlth, DeKalb, GA USA. RP Shah, AY (reprint author), Childrens Natl Med Ctr, W3-5-600,111 Michigan Ave NW, Washington, DC 20010 USA. EM anshah@cnmc.org OI Suchdev, Parmi/0000-0002-0350-3469 NR 35 TC 5 Z9 5 U1 3 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD OCT PY 2014 VL 16 IS 5 BP 959 EP 967 DI 10.1007/s10903-013-9867-8 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO9PJ UT WOS:000341687400023 PM 23828627 ER PT J AU Lutfy, C Cookson, ST Talley, L Rochat, R AF Lutfy, Caitlyn Cookson, Susan T. Talley, Leisel Rochat, Roger TI Malnourished Children in Refugee Camps and Lack of Connection with Services After US Resettlement SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Refugees; Malnutrition; Anemia; United States Resettlement AB Identifying and addressing malnutrition among US-bound refugee children is an important human rights issue. Failure to address childhood malnutrition can impair cognitive development and productivity. The target population was children aged 6-59 months, originating from eight countries representing 51 % of US-resettled refugees for 2005-2011, living in 22 camps prior to potential US-resettlement. The corresponding camp-level nutritional survey data were evaluated. State Refugee Health Coordinators were surveyed on nutritional assessment, reporting and referrals for their US-refugee medical screenings. From 2004 to 2010, half of the camps (63 total surveys) had global acute malnutrition prevalence over 15 % at least once (surveys not done annually) and anemia prevalence greater than 40 %. The majority of US-refugee medical screenings included height and weight measurements but few used national or WHO standards to evaluate presence or level of malnutrition. Improve overseas camp monitoring and link these nutritional data to US-resettling refugee children to inform potential nutritional interventions. Domestically, use WHO or US growth standards for anthropometrics to determine presence of malnutrition and need for corrective action. C1 [Lutfy, Caitlyn; Cookson, Susan T.; Talley, Leisel; Rochat, Roger] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Lutfy, Caitlyn] WI HER LLC, Vienna, VA 22180 USA. [Cookson, Susan T.; Talley, Leisel] Ctr Dis Control & Prevent, Ctr Global Hlth Int Emergency & Refugee Hlth, Atlanta, GA USA. RP Lutfy, C (reprint author), WI HER LLC, Vienna, VA 22180 USA. EM Clutfy@urc-chs.com FU Intramural CDC HHS [CC999999] NR 13 TC 1 Z9 1 U1 3 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD OCT PY 2014 VL 16 IS 5 BP 1016 EP 1022 DI 10.1007/s10903-013-9796-6 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO9PJ UT WOS:000341687400032 PM 23430464 ER PT J AU Blackley, DJ Halldin, CN Wang, ML Laney, AS AF Blackley, David J. Halldin, Cara N. Wang, Mei Lin Laney, A. Scott TI Small mine size is associated with lung function abnormality and pneumoconiosis among underground coal miners in Kentucky, Virginia and West Virginia SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID PROGRESSIVE MASSIVE FIBROSIS; UNITED-STATES; WORKERS PNEUMOCONIOSIS; PREVALENCE; DETERMINANTS; DECLINES; EXPOSURE; DISEASE; ADULTS; HEALTH AB Objectives To describe the prevalence of lung function abnormality and coal workers' pneumoconiosis (CWP) by mine size among underground coal miners in Kentucky, Virginia and West Virginia. Methods During 2005-2012, 4491 miners completed spirometry and chest radiography as part of a health surveillance programme. Spirometry was interpreted according to American Thoracic Society and European Respiratory Society guidelines, and radiography per International Labour Office standards. Prevalence ratios (PR) were calculated for abnormal spirometry (obstructive, restrictive or mixed pattern using lower limits of normal derived from National Health and Nutrition Examination Survey (NHANES) III) and CWP among workers from small mines (<= 50 miners) compared with those from large mines. Results Among 3771 eligible miners, those from small mines were more likely to have abnormal spirometry (18.5% vs 13.8%, p<0.01), CWP (10.8% vs 5.2%, p<0.01) and progressive massive fibrosis (2.4% vs 1.1%, p<0.01). In regression analysis, working in a small mine was associated with 37% higher prevalence of abnormal spirometry (PR 1.37, 95% CI 1.16 to 1.61) and 2.1 times higher prevalence of CWP (95% CI 1.68 to 2.70). Conclusions More than one in four of these miners had evidence of CWP, abnormal lung function or both. Although 96% of miners in the study have worked exclusively under dust regulations implemented following the 1969 Federal Coal Mine Safety and Health Act, we observed high rates of respiratory disease including severe cases. The current approach to dust control and provision of safe work conditions for central Appalachian underground coal miners is not adequate to protect them from adverse respiratory health effects. C1 [Blackley, David J.; Halldin, Cara N.; Wang, Mei Lin; Laney, A. Scott] Ctr Dis Control & Prevent, Surveillance Branch, Div Resp Dis Studies, NIOSH, Morgantown, WV 26505 USA. [Blackley, David J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Div Sci Educ & Profess Dev, Atlanta, GA USA. RP Blackley, DJ (reprint author), Ctr Dis Control & Prevent, Surveillance Branch, Div Resp Dis Studies, NIOSH, 1095 Willowdale Rd Mail Stop HG900, Morgantown, WV 26505 USA. EM dblackley@cdc.gov OI Blackley, David/0000-0003-0997-1746 FU Intramural CDC HHS [CC999999] NR 32 TC 9 Z9 9 U1 2 U2 17 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD OCT PY 2014 VL 71 IS 10 BP 690 EP 694 DI 10.1136/oemed-2014-102224 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1SC UT WOS:000341850500006 PM 25052085 ER PT J AU Anderson, LA Egge, R AF Anderson, Lynda A. Egge, Robert TI Expanding efforts to address Alzheimer's disease: The Healthy Brain Initiative SO ALZHEIMERS & DEMENTIA LA English DT Article DE Alzheimer's disease; Healthy Brain Initiative; Road Map; Public health partnerships ID PUBLIC-HEALTH; POPULATION; STATES AB The growing burden of Alzheimer's disease underscores the importance of enhancing current public health efforts to address dementia. Public health organizations and entities have substantial opportunities to contribute to efforts underway and to add innovations to the field. The Alzheimer's Association and the Centers for Disease Control and Prevention worked with a 15-member leadership committee and hundreds of stakeholders to create The Healthy Brain Initiative: The Public Health Road Map for State and National Partnerships, 2013-2018 (Road Map). The actions in the Road Map provide a foundation for the public health community to anticipate and respond to emerging innovations and developments. It will be a challenge to harness the increasingly complex nature of public- and private-sector collaborations. We must strengthen the capacity of public health agencies, leverage partnerships, and find new ways to integrate cognitive functioning into public health efforts. Published by Elsevier Inc. on behalf of The Alzheimer's Association. C1 [Anderson, Lynda A.] Ctr Dis Control & Prevent, Hlth Aging Program, Hlth Brain Initiat, Natl Ctr Chron Dis Prevent, Atlanta, GA USA. [Anderson, Lynda A.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Egge, Robert] Alzheimers Assoc, Publ Policy, Washington, DC USA. RP Anderson, LA (reprint author), Ctr Dis Control & Prevent, Hlth Aging Program, Hlth Brain Initiat, Natl Ctr Chron Dis Prevent, Atlanta, GA USA. EM Laa0@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 1 Z9 1 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD OCT PY 2014 VL 10 IS 5 SU 1 BP S453 EP S456 DI 10.1016/j.jalz.2014.05.1748 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA CZ0WW UT WOS:000366828100024 PM 25088658 ER PT J AU Laney, AS Weissman, DN AF Laney, A. Scott Weissman, David N. TI Respiratory Diseases Caused by Coal Mine Dust SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article; Proceedings Paper CT Conference of American-College-of-Chest-Physicians on Occupational and Environmental Lung Disease 2013 CY JUN 21-23, 2013 CL Toronto, CANADA SP Amer Coll Chest Phys AB Objective: To provide an update on respiratory diseases caused by coal mine dust. Methods: This article presents the results of a literature review initially performed for an International Conference on Occupational and Environmental Lung Disease held in summer 2013. Results: Coal mine dust causes a spectrum of lung diseases collectively termed coal mine dust lung disease (CMDLD). These include Coal Workers' Pneumoconiosis, silicosis, mixed dust pneumoconiosis, dust-related diffuse fibrosis (which can be mistaken for idiopathic pulmonary fibrosis), and chronic obstructive pulmonary disease. CMDLD continues to be a problem in the United States, particularly in the central Appalachian region. Treatment of CMDLD is symptomatic. Those with end-stage disease are candidates for lung transplantation. Because CMDLD cannot be cured, prevention is critical. Conclusions: Coal mine dust remains a relevant occupational hazard and miners remain at risk for CMDLD. C1 [Laney, A. Scott; Weissman, David N.] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. RP Weissman, DN (reprint author), NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM DWeissman@cdc.gov FU Intramural CDC HHS [CC999999] NR 41 TC 7 Z9 7 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD OCT PY 2014 VL 56 IS 10 SU S BP S18 EP S22 DI 10.1097/JOM.0000000000000260 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V44HZ UT WOS:000209741400005 PM 25285970 ER PT J AU Ozturk, OD McDermott, S Mann, JR Hardin, JW Royer, JA Ouyang, LJ AF Ozturk, Orgul D. McDermott, Suzanne Mann, Joshua R. Hardin, James W. Royer, Julie A. Ouyang, Lijing TI Disparities in Health Care Utilization by Race Among Teenagers and Young Adults With Muscular Dystrophy SO MEDICAL CARE LA English DT Article DE rare conditions; disability; muscular dystrophy; health care use disparity; racial disparity AB Background: For people with muscular dystrophy (MD) health care access is crucial and utilization is expected to be high. A multidisciplinary approach is needed for optimal management of symptoms of this rare condition. Regular primary care, specialty care, therapy, and medicine use can improve quality of care and reduce need for emergency treatment and hospitalization. We analyzed health insurance and administrative data to test for racial disparities in regular care use among teenagers and young adults with MD. Methods: We used South Carolina Medicaid and other administrative data for individuals aged 15-24 years to determine annual health care utilization patterns for individuals with MD by race. We studied adolescents and young adults with MD because this age group represents a time when the condition is typically intensifying and the transition from pediatric to adult care is expected. We used Generalized Estimating Equation models to analyze longitudinal utilization data conditional on other factors that may lead to utilization differences. Results: Race is correlated with health care utilization among adolescents and young adults with MD. Blacks have lower overall utilization, and less primary care, therapy, and specialist care use but higher incidence of hospitalization and emergency treatment use compared with whites and also to other races. The most striking disparity was the use of outpatient services. Blacks utilized these services 50% less compared with whites and 70% less compared with others. Even in regression analysis, where we take into account individual unobserved factors and allow clustering at the individual level, these differences remained and were in most cases statistically significant. Conclusions: Our results indicate that there are differences in health care utilization by race even when individuals have access to the same health care benefits. This means simply offering coverage to individuals with MD may not be sufficient in eliminating health disparities. Future studies will be needed to examine other possible sources of these racial disparities, such as resource awareness, health knowledge, or access barriers such as transportation. C1 [Ozturk, Orgul D.] Univ South Carolina, Moore Sch Business, Dept Econ, 1705 Coll St, Columbia, SC 29208 USA. [McDermott, Suzanne; Hardin, James W.] Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, 1705 Coll St, Columbia, SC 29208 USA. [Mann, Joshua R.] Univ South Carolina, Sch Med, Dept Family & Prevent Med, 1705 Coll St, Columbia, SC 29208 USA. [Royer, Julie A.] South Carolina Budget & Control Board, Div Res & Stat, Columbia, SC USA. [Ouyang, Lijing] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Ozturk, OD (reprint author), Univ South Carolina, Moore Sch Business, Dept Econ, 1705 Coll St, Columbia, SC 29208 USA. EM odozturk@moore.sc.edu FU CDC FX Supported by a grant from CDC and results are presented in the Health Disparities at the Intersection of Race, Ethnicity, and Disability: A National Conference. NR 27 TC 3 Z9 3 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD OCT PY 2014 VL 52 IS 10 SU 3 BP S32 EP S39 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA V45TK UT WOS:000209838700006 PM 25215918 ER PT J AU Nelson, JC Shortreed, SM Yu, O Peterson, D Baxter, R Fireman, B Lewis, N McClure, D Weintraub, E Xu, S Jackson, LA AF Nelson, Jennifer C. Shortreed, Susan M. Yu, Onchee Peterson, Do Baxter, Roger Fireman, Bruce Lewis, Ned McClure, Dave Weintraub, Eric Xu, Stan Jackson, Lisa A. CA Vaccine Safety Datalink Project TI Integrating Database Knowledge and Epidemiological Design to Improve the Implementation of Data Mining Methods that Evaluate Vaccine Safety in Large Healthcare Databases SO STATISTICAL ANALYSIS AND DATA MINING LA English DT Review DE vaccine safety; data mining; methodology ID INACTIVATED INFLUENZA VACCINE; INSURANCE CLAIMS DATABASE; ADVERSE EVENTS; PROPENSITY SCORE; SIGNAL-DETECTION; UNITED-STATES; LOGISTIC-REGRESSION; IMMUNIZATION SAFETY; ACTIVE SURVEILLANCE; CLINICAL-DATA AB Large healthcare databases maintained by health plans have been widely used to conduct customized protocol-based epidemiological safety studies as well as targeted routine sequential monitoring of suspected adverse events for newly licensed vaccines. These databases also offer a rich data source to discover vaccine-related adverse events not known prior to licensure using data mining methods, but they remain relatively under-utilized for this purpose. Initial safety applications of data mining methods using 'big healthcare data' are promising, but stronger integration of database expertize, epidemiological design, and statistical analysis strategies are needed to better leverage the available information, reduce bias, and improve reporting transparency. We enumerate major methodological challenges in mining large healthcare databases for vaccine safety research, describe existing strategies that have been used to address these issues, and identify opportunities for methodological advancements that emphasize the importance of adapting techniques used in customized protocol-based vaccine safety assessments. Investment in such research methods and in the development of deeper collaborations between database safety experts and data mining methodologists has great potential to improve existing safety surveillance programs and further increase public confidence in the safety of newly licensed vaccines. (C) 2014 Wiley Periodicals, Inc. C1 [Nelson, Jennifer C.; Shortreed, Susan M.; Yu, Onchee; Peterson, Do; Jackson, Lisa A.] Grp Hlth Res Inst, Biostat Unit, Seattle, WA 98101 USA. [Nelson, Jennifer C.; Shortreed, Susan M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Baxter, Roger; Fireman, Bruce; Lewis, Ned] Kaiser Permanente No Calif, Vaccine Study Ctr, Oakland, CA 94612 USA. [Baxter, Roger; Fireman, Bruce; Lewis, Ned] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA. [McClure, Dave] Marshfield Clin Res Fdn, Epidemiol Res Ctr, Marshfield, WI 54449 USA. [Weintraub, Eric] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Xu, Stan] Kaiser Permanente Inst Hlth Res, Denver, CO 80231 USA. [Jackson, Lisa A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Nelson, JC (reprint author), Grp Hlth Res Inst, Biostat Unit, Seattle, WA 98101 USA. EM nelson.jl@ghc.org NR 69 TC 0 Z9 0 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1932-1864 EI 1932-1872 J9 STAT ANAL DATA MIN JI Stat. Anal. Data Min. PD OCT PY 2014 VL 7 IS 5 SI SI BP 337 EP 351 DI 10.1002/sam.11232 PG 15 WC Computer Science, Artificial Intelligence; Computer Science, Interdisciplinary Applications; Statistics & Probability SC Computer Science; Mathematics GA CV3US UT WOS:000364192400002 ER PT J AU McCarthy, CF Kelley, MA Verani, AR St Louis, ME Riley, PL AF McCarthy, Carey F. Kelley, Maureen A. Verani, Andre R. St Louis, Michael E. Riley, Patricia L. TI Development of a framework to measure health profession regulation strengthening SO EVALUATION AND PROGRAM PLANNING LA English DT Article DE Africa; Capability maturity model; Midwifery; Nursing; Regulation; Task sharing; Task shifting ID ANTIRETROVIRAL TREATMENT; SCALE-UP; CARE; COUNTRIES; SYSTEMS; AFRICA AB This paper describes the development of a framework to evaluate the progress and impact of a multi-year US government initiative to strengthen nursing and midwifery professional regulation in sub-Saharan Africa. The framework was designed as a capability maturity model, which is a stepwise series of performance levels that describe the sophistication of processes necessary to achieve an organization's objectives. A model from the field of software design was adapted to comprise the key functions of a nursing and midwifery regulatory body and describe five stages of advancing each function. The framework was used to measure the progress of five countries that received direct assistance to strengthen regulations and to benchmark the status of regulations in the 17 countries participating in the initiative. The framework captured meaningful advancements in regulatory strengthening in the five supported countries and the level of regulatory capacity in participating countries. The project uses the framework to assess yearly progress of supported countries, track the overall impact of the project on national and regional nursing regulation, and to identify national and regional priorities for regulatory strengthening. It is the first of its kind to document and measure progress toward sustainably strengthening nursing and midwifery regulation in Africa. Published by Elsevier Ltd. C1 [McCarthy, Carey F.; Verani, Andre R.; St Louis, Michael E.; Riley, Patricia L.] US Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Kelley, Maureen A.] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Lillian Carter Ctr Global Hlth & Social Responsib, Atlanta, GA 30322 USA. RP McCarthy, CF (reprint author), US Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, 1600 Clifton Rd MS E-30, Atlanta, GA 30333 USA. EM cmccarthy@cdc.gov FU Intramural CDC HHS [CC999999]; PEPFAR NR 33 TC 7 Z9 7 U1 0 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7189 EI 1873-7870 J9 EVAL PROGRAM PLANN JI Eval. Program Plan. PD OCT PY 2014 VL 46 BP 17 EP 24 DI 10.1016/j.evalprogplan.2014.04.008 PG 8 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA AO0GZ UT WOS:000340988400003 PM 24863957 ER PT J AU Wolraich, ML McKeown, RE Visser, SN Bard, D Cuffe, S Neas, B Geryk, LL Doffing, M Bottai, M Abramowitz, AJ Beck, L Holbrook, JR Danielson, M AF Wolraich, Mark L. McKeown, Robert E. Visser, Susanna N. Bard, David Cuffe, Steven Neas, Barbara Geryk, Lorie L. Doffing, Melissa Bottai, Matteo Abramowitz, Ann J. Beck, Laoma Holbrook, Joseph R. Danielson, Melissa TI The Prevalence of ADHD: Its Diagnosis and Treatment in Four School Districts Across Two States SO JOURNAL OF ATTENTION DISORDERS LA English DT Article DE ADHD; prevalence rate; school sample; community-based sample; epidemiology ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT-HYPERACTIVITY DISORDER; CLINICAL-PRACTICE GUIDELINE; PRIMARY-CARE SETTINGS; PSYCHOMETRIC PROPERTIES; MENTAL-DISORDERS; SERVICE USE; CHILDREN; PARENT; ADOLESCENTS AB Objective: To describe the epidemiology of ADHD in communities using a DSM-IVTR case definition. Method: This community-based study used multiple informants to develop and apply a DSM -IVTR-based case definition of ADHD to screening and diagnostic interview data collected for children 5-13 years of age. Teachers screened 10,427 children (66.4%) in four school districts across two states (SC and OK). ADHD ratings by teachers and parent reports of diagnosis and medication treatment were used to stratify children into high and low risk for ADHD. Parents (n = 855) of high risk and gender frequency-matched low risk children completed structured diagnostic interviews. The case definition was applied to generate community prevalence estimates, weighted to reflect the complex sampling design. Results: ADHD prevalence was 8.7% in SC and 10.6% in OK. The prevalence of ADHD medication use was 10.1% (SC) and 7.4% (OK). Of those medicated, 39.5% (SC) and 28.3% (OK) met the case definition. Comparison children taking medication had higher mean symptom counts than other comparison children. Conclusions: Our ADHD estimates are at the upper end of those from previous studies. The identification of a large proportion of comparison children taking ADHD medication suggests that our estimates may be conservative; these children were not included as cases in the case definition, although some might be effectively treated. C1 [Wolraich, Mark L.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Sect Dev & Behav Pediat, Oklahoma City, OK 73117 USA. [McKeown, Robert E.; Geryk, Lorie L.; Bottai, Matteo; Holbrook, Joseph R.] Univ S Carolina, Dept Epidemiol & Biostat, Columbia, SC 29208 USA. [Visser, Susanna N.; Danielson, Melissa] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cuffe, Steven] Univ Florida, Coll Med, Dept Psychiat, Jacksonville, FL USA. [Doffing, Melissa] Univ Colorado, Colorado Springs, CO 80907 USA. [Abramowitz, Ann J.] Emory Univ, Atlanta, GA 30322 USA. [Bard, David] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73117 USA. [Neas, Barbara] Univ Oklahoma, Biostat & Epidemiol Dept, Hlth Sci Ctr, Sch Publ Hlth, Oklahoma City, OK 73117 USA. [Beck, Laoma] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73117 USA. RP Wolraich, ML (reprint author), Univ Oklahoma, Hlth Sci Ctr, OU Child Study Ctr, 1100 NE 13th St, Oklahoma City, OK 73117 USA. EM mark-wolraich@ouhsc.edu OI McKeown, Robert/0000-0002-8829-5784; Danielson, Melissa/0000-0001-9461-0341 FU Centers for Disease Control and Prevention [U50/CCU622315-02, U84/CCU422516-02, 200-2006-18912, 200-2006-18949] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This manuscript was supported by the Centers for Disease Control and Prevention through cooperative agreements U50/CCU622315-02 and U84/CCU422516-02 and contracts 200-2006-18912 and 200-2006-18949. NR 43 TC 12 Z9 12 U1 4 U2 45 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1087-0547 EI 1557-1246 J9 J ATTEN DISORD JI J. Atten. Disord. PD OCT PY 2014 VL 18 IS 7 BP 563 EP 575 DI 10.1177/1087054712453169 PG 13 WC Psychology, Developmental; Psychiatry SC Psychology; Psychiatry GA AN8VJ UT WOS:000340883000001 PM 22956714 ER PT J AU Yusuf, HR Hooper, WC Beckman, MG Zhang, QC Tsai, J Ortel, TL AF Yusuf, Hussain R. Hooper, W. Craig Beckman, Michele G. Zhang, Qing C. Tsai, James Ortel, Thomas L. TI Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Article DE Autoimmune diseases; Autoimmune hemolytic anemia; Immune thrombocytopenic purpura; Rheumatoid arthritis; Systemic lupus erythematosus; Venous thromboembolism ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; ANTICOAGULANT; INFLAMMATION; COAGULATION; COHORT AB Previous research has suggested autoimmune diseases are risk factors for developing venous thromboembolism (VTE). We assessed whether having diagnoses of selected autoimmune diseases associated with antiphospholipid antibodies-autoimmune hemolytic anemia (AIHA), immune thrombocytopenic purpura (ITP), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE)-were associated with having a VTE diagnosis among US adult hospitalizations. A cross-sectional study was conducted using the 2010 Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. VTE and autoimmune diseases were identified using International Classification of Diseases, Ninth Revision, Clinical Modification coded diagnoses information. The percentages of hospitalizations with a VTE diagnosis among all non-maternal adult hospitalizations without any of the four autoimmune diseases of interest and among those with AIHA, ITP, RA, and SLE diagnoses were 2.28, 4.46, 3.35, 2.65 and 2.77 %, respectively. The adjusted odds ratios (OR) for having a diagnosis of VTE among non-maternal adult hospitalizations with diagnoses of AIHA, ITP, RA, and SLE were 1.25 [95 % confidence interval (CI) 1.05-1.49], 1.20 (95 % CI 1.07-1.34), 1.17 (95 % CI 1.13-1.21), and 1.23 (95 % CI 1.15-1.32), respectively, when compared to those without the corresponding conditions. The adjusted OR for a diagnosis of VTE associated with a diagnosis of any of the four autoimmune diseases was 1.20 (95 % CI 1.16-1.24). The presence of a diagnosis of AIHA, ITP, RA, and SLE was associated with an increased likelihood of having a VTE diagnosis among the group of all non-maternal adult hospitalizations. C1 [Yusuf, Hussain R.; Hooper, W. Craig; Beckman, Michele G.; Zhang, Qing C.; Tsai, James] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Ortel, Thomas L.] Duke Univ, Med Ctr, Ctr Thrombosis & Hemostasis, Durham, NC USA. RP Yusuf, HR (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS-E64, Atlanta, GA 30333 USA. EM hyusuf@cdc.gov FU Intramural CDC HHS [CC999999] NR 30 TC 6 Z9 6 U1 1 U2 9 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 EI 1573-742X J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD OCT PY 2014 VL 38 IS 3 BP 306 EP 313 DI 10.1007/s11239-014-1050-0 PG 8 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA AO1PK UT WOS:000341085300004 PM 24464552 ER PT J AU Latzman, RD Shishido, Y Latzman, NE Elkin, TD Majumdar, S AF Latzman, Robert D. Shishido, Yuri Latzman, Natasha E. Elkin, T. David Majumdar, Suvankar TI Associations Among Emergency Room Visits, Parenting Styles, and Psychopathology Among Pediatric Patients With Sickle Cell SO PEDIATRIC BLOOD & CANCER LA English DT Article DE healthcare utilization; parenting; psychopathology; sickle cell disease ID PSYCHOLOGICAL ADJUSTMENT; CONTROLLED-TRIAL; CHILDREN; DISEASE; ADOLESCENTS; FAMILY; PAIN; AUTHORITARIAN; MANAGEMENT; SCHOOL AB Background. To examine associations between frequency of emergency room (ER) visits and various parenting styles, both conjointly and interactively, and psychopathological outcomes among pediatric patients with sickle cell disease (SCD). Procedures. Ninety-eight parents/caregivers of 6- to 18-year-old patients with SCD completed instruments assessing parenting style, child psychopathology, and reported on the frequency of ER visits during the previous year. Results. ER visits were found to significantly explain Withdrawn/Depressed problems and parenting styles were found to incrementally contribute to the explanation of all forms of psychopathology. Further, Permissive parenting was found to explain Rule Breaking Behavior for those patients with low ER visit frequency but not for those with high ER visit frequency. Conclusions. Results of the current study confirm the importance of considering both the frequency of ER visits and parenting style in the explanation of psychopathology among pediatric patients with SCD. Results have important implications for both research and treatment. (C) 2014 Wiley Periodicals, Inc. C1 [Latzman, Robert D.; Shishido, Yuri] Georgia State Univ, Atlanta, GA 30307 USA. [Latzman, Natasha E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Elkin, T. David; Majumdar, Suvankar] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. RP Latzman, RD (reprint author), Georgia State Univ, Dept Psychol, POB 5010, Atlanta, GA 30307 USA. EM rlatzman@gsu.edu NR 48 TC 1 Z9 1 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD OCT PY 2014 VL 61 IS 10 BP 1822 EP 1827 DI 10.1002/pbc.25141 PG 6 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA AN4ET UT WOS:000340541100021 PM 24975124 ER PT J AU Neri, AJ Roy, J Jarrett, J Pan, Y Dooyema, C Caldwell, K Umar-Tsafe, NT Olubiyo, R Brown, MJ AF Neri, Antonio James Roy, Joannie Jarrett, Jeffery Pan, Yi Dooyema, Carrie Caldwell, Kathleen Umar-Tsafe, Nasir Tsafe Olubiyo, Ruth Brown, Mary Jean TI Analysis of a novel field dilution method for testing samples that exceed the analytic range of point-of-care blood lead analyzers SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL HEALTH RESEARCH LA English DT Article DE laboratory; lead poisoning; dilution methods ID RISK-FACTORS; CHILDREN; NIGERIA; ZAMFARA AB Investigators developed and evaluated a dilution method for the LeadCare II analyzer (LCII) for blood lead levels > 65 mu g/dL, the analyzer's maximum reporting value. Venous blood samples from lead-poisoned children were initially analyzed in the field using the dilution method. Split samples were analyzed at the US Centers for Disease Control and Prevention (CDC) laboratory using both the dilution method and inductively coupled plasma-mass spectrometry (ICP-MS). The concordance correlation coefficient of CDC LCII vs. ICP-MS values (N = 211) was 0.976 (95% confidence interval (CI) 0.970-0.981); of Field LCII vs. ICP-MS (N = 68) was 0.910 (95% CI 0.861-0.942), and CDC LCII vs. Field LCII (N = 53) was 0.721 (95% CI 0.565-0.827). Sixty percent of CDC and 54% of Field LCII values were within +/-10% of the ICP-MS value. Results from the dilution method approximated ICP-MS values and were useful for field-based decision-making. Specific recommendations for additional evaluation are provided. C1 [Neri, Antonio James; Dooyema, Carrie] US Ctr Dis Control Prevent, Atlanta, GA 30333 USA. [Roy, Joannie] Medecins Sans Frontieres OCA, Amsterdam, Netherlands. [Jarrett, Jeffery; Pan, Yi; Caldwell, Kathleen] US Ctr Dis Control & Prevent, Inorgan & Radiat Analyt Toxicol Branch, Atlanta, GA USA. [Umar-Tsafe, Nasir Tsafe] Blood Lead Inorgan Met Lab, Gusau, Nigeria. [Olubiyo, Ruth] Medecins Sans Frontieres OCA, Gusau, Nigeria. [Brown, Mary Jean] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Neri, AJ (reprint author), US Ctr Dis Control Prevent, Atlanta, GA 30333 USA. EM aneri@cdc.gov RI Roy, Joannie/O-5406-2015; OI Roy, Joannie/0000-0002-7791-6629; Jarrett, Jeffery/0000-0001-5755-3552 NR 32 TC 2 Z9 2 U1 0 U2 5 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0960-3123 EI 1369-1619 J9 INT J ENVIRON HEAL R JI Int. J. Environ. Health Res. PD OCT PY 2014 VL 24 IS 5 BP 418 EP 428 DI 10.1080/09603123.2013.857390 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AM8XL UT WOS:000340162400003 PM 24266724 ER PT J AU Reidy, DE Berke, DS Gentile, B Zeichner, A AF Reidy, Dennis E. Berke, Danielle S. Gentile, Brittany Zeichner, Amos TI Man enough? Masculine discrepancy stress and intimate partner violence SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article DE Gender role discrepancy stress; Gender role stress; Intimate partner violence; Masculinity ID GENDER-ROLE STRESS; MEN; AGGRESSION; SCALE AB Research on gender roles suggests that men who strongly adhere to traditional masculine gender norms are at increased risk for the perpetration of violent and abusive acts toward their female intimate partners. Yet, gender norms alone fail to provide a comprehensive explanation of the multifaceted construct of intimate partner violence (IPV) and there is theoretical reason to suspect that men who fail to conform to masculine roles may equally be at risk for IPV. In the present study, we assessed effect of masculine discrepancy stress, a form of distress arising from perceived failure to conform to socially-prescribed masculine gender role norms, on IPV. Six-hundred men completed online surveys assessing their experience of discrepancy stress, masculine gender role norms, and history of IPV. Results indicated that masculine discrepancy stress significantly predicted men's historical perpetration of IPV independent of other masculinity related variables. Findings are discussed in terms of potential distress engendered by masculine socialization as well as putative implications of gender role discrepancy stress for understanding and intervening in partner violence perpetrated by men. Published by Elsevier Ltd. C1 [Reidy, Dennis E.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. [Reidy, Dennis E.; Berke, Danielle S.; Gentile, Brittany; Zeichner, Amos] Univ Georgia, Dept Psychol, Athens, GA 30602 USA. RP Reidy, DE (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. EM dreidy@cdc.gov NR 34 TC 8 Z9 8 U1 2 U2 22 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD OCT PY 2014 VL 68 BP 160 EP 164 DI 10.1016/j.paid.2014.04.021 PG 5 WC Psychology, Social SC Psychology GA AK8OU UT WOS:000338688200030 ER PT J AU Cowling, BJ Ip, DKM Fang, VJ Suntarattiwong, P Olsen, SJ Levy, J Uyeki, TM Leung, GM Peiris, JSM Chotpitayasunondh, T Nishiura, H Simmerman, JM AF Cowling, Benjamin J. Ip, Dennis K. M. Fang, Vicky J. Suntarattiwong, Piyarat Olsen, Sonja J. Levy, Jens Uyeki, Timothy M. Leung, Gabriel M. Peiris, J. S. Malik Chotpitayasunondh, Tawee Nishiura, Hiroshi Simmerman, J. Mark TI Modes of Transmission of Influenza B Virus in Households SO PLOS ONE LA English DT Article ID AEROSOL TRANSMISSION; HEALTH-CARE; HONG-KONG; MORTALITY; COMMUNITY; THAILAND; BANGKOK; CONTAMINATION; VENTILATION; INFECTION AB Introduction:While influenza A and B viruses can be transmitted via respiratory droplets, the importance of small droplet nuclei "aerosols'' in transmission is controversial. Methods and Findings: In Hong Kong and Bangkok, in 2008-11, subjects were recruited from outpatient clinics if they had recent onset of acute respiratory illness and none of their household contacts were ill. Following a positive rapid influenza diagnostic test result, subjects were randomly allocated to one of three household-based interventions: hand hygiene, hand hygiene plus face masks, and a control group. Index cases plus their household contacts were followed for 7-10 days to identify secondary infections by reverse transcription polymerase chain reaction (RT-PCR) testing of respiratory specimens. Index cases with RT-PCR-confirmed influenza B were included in the present analyses. We used a mathematical model to make inferences on the modes of transmission, facilitated by apparent differences in clinical presentation of secondary infections resulting from aerosol transmission. We estimated that approximately 37% and 26% of influenza B virus transmission was via the aerosol mode in households in Hong Kong and Bangkok, respectively. In the fitted model, influenza B virus infections were associated with a 56%-72% risk of fever plus cough if infected via aerosol route, and a 23%-31% risk of fever plus cough if infected via the other two modes of transmission. Conclusions: Aerosol transmission may be an important mode of spread of influenza B virus. The point estimates of aerosol transmission were slightly lower for influenza B virus compared to previously published estimates for influenza A virus in both Hong Kong and Bangkok. Caution should be taken in interpreting these findings because of the multiple assumptions inherent in the model, including that there is limited biological evidence to date supporting a difference in the clinical features of influenza B virus infection by different modes. C1 [Cowling, Benjamin J.; Ip, Dennis K. M.; Fang, Vicky J.; Leung, Gabriel M.; Peiris, J. S. Malik] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China. [Suntarattiwong, Piyarat; Chotpitayasunondh, Tawee] Queen Sirikit Natl Inst Child Hlth, Bangkok, Thailand. [Olsen, Sonja J.; Levy, Jens] Thailand MOPH US CDC Collaborat, Influenza Program, Nonthaburi, Thailand. [Olsen, Sonja J.; Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Peiris, J. S. Malik] Univ Hong Kong, Li Ka Shing Fac Med, Influenza Res Ctr, Hong Kong, Hong Kong, Peoples R China. [Nishiura, Hiroshi] Univ Tokyo, Grad Sch Med, Bunkyo Ku, Tokyo, Japan. [Simmerman, J. Mark] Sanofi Pasteur, Epidemiol & Med Affairs, Bangkok, Thailand. RP Cowling, BJ (reprint author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China. EM bcowling@hku.hk OI Nishiura, Hiroshi/0000-0003-0941-8537 FU National Institute of Allergy and Infectious Diseases [HHSN266200700005C]; ADB [N01-AI-70005]; National Institute of General Medical Sciences [U54 GM08855]; Area of Excellence Scheme of the Hong Kong University Grants Committee [AoE/M-12/06]; United States Centers for Disease Control and Prevention [1 U01 CI000439, 5 U51 IP000345]; JST PRESTO FX This project was supported by the National Institute of Allergy and Infectious Diseases under contract no.HHSN266200700005C, ADB No. N01-AI-70005 (NIAID Centers for Excellence in Influenza Research and Surveillance), the Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences (grant no. U54 GM088558), and the Area of Excellence Scheme of the Hong Kong University Grants Committee (grant no. AoE/M-12/06). The household trials in Hong Kong and Bangkok were supported by the United States Centers for Disease Control and Prevention (cooperative nos. 1 U01 CI000439 and 5 U51 IP000345). HN received funding support from JST PRESTO. The funding bodies had no role in study design and analysis or the decision to publish, but the CDC was involved in the design of the original studies and the preparation of this manuscript. This work represents the views of the authors and does not reflect the official policy of their institutions, including the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 30 TC 1 Z9 1 U1 2 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 30 PY 2014 VL 9 IS 9 AR e108850 DI 10.1371/journal.pone.0108850 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AR6CW UT WOS:000343671700179 PM 25268241 ER PT J AU Gant, Z Gant, L Song, RG Willis, L Johnson, AS AF Gant, Zanetta Gant, Larry Song, Ruiguang Willis, Leigh Johnson, Anna Satcher TI A Census Tract-Level Examination of Social Determinants of Health among Black/African American Men with Diagnosed HIV Infection, 2005-2009-17 US Areas SO PLOS ONE LA English DT Article ID RISK BEHAVIORS; BLACK-MEN; UNITED-STATES; SEX; HIV/AIDS; EPIDEMIOLOGY; TRANSMISSION; METAANALYSIS; INVOLVEMENT; DISPARITIES AB Background: HIV disproportionately affects black men in the United States: most diagnoses are for black gay, bisexual, and other men who have sex with men (collectively referred to as MSM). A better understanding of the social conditions in which black men live and work may better explain why HIV incidence and diagnosis rates are higher than expected in this population. Methods: Using data from the National HIV Surveillance System and the US Census Bureau's American Community Survey, we examined the relationships of HIV diagnosis rates and 5 census tract-level social determinants of health variables for 21,948 black MSM and non-MSM aged >= 15 years residing in 17 areas in the United States. We examined federal poverty status, marital status, education level, employment status, and vacancy status and computed rate ratios (RRs) and prevalence odds ratios (PORs), using logistic regression with zero-inflated negative binomial modeling. Results: Among black MSM, HIV diagnosis rates decreased as poverty increased (RR: 0.54). At the time of HIV diagnosis, black MSM were less likely than black non-MSM to live in census tracts with a higher proportion below the poverty level (POR: 0.81) and with a higher proportion of vacant houses (POR: 0.86). In comparison, housing vacancy was positively associated with HIV diagnosis rates among black non-MSM (RR: 1.65). HIV diagnosis rates were higher for black MSM (RR: 2.75) and non-MSM (RR: 4.90) whose educational level was low. Rates were significantly lower for black MSM (RR: 0.06) and non-MSM (RR: 0.26) as the proportion unemployed and the proportion married increased. Conclusions: This exploratory study found differences in the patterns of HIV diagnosis rates for black MSM and non-MSM and provides insight into the transmission of HIV infection in areas that reflect substantial disadvantage in education, housing, employment, and income. C1 [Gant, Zanetta; Song, Ruiguang; Willis, Leigh; Johnson, Anna Satcher] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Gant, Larry] Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA. RP Gant, Z (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. EM zgant@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX The Centers for Disease Control and Prevention (CDC) provides funding to state and local health departments to conduct surveillance of HIV disease in accordance with their own disease reporting regulations. CDC provides technical guidance for the collection of data by the state and local health departments and data are sent to CDC for national-level analyses. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 42 TC 2 Z9 2 U1 2 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 30 PY 2014 VL 9 IS 9 AR e107701 DI 10.1371/journal.pone.0107701 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AR6CW UT WOS:000343671700045 PM 25268831 ER PT J AU Sharp, TM Mackay, AJ Santiago, GA Hunsperger, E Nilles, EJ Perez-Padilla, J Tikomaidraubuta, KS Colon, C Amador, M Chen, TH Lalita, P Munoz-Jordan, JL Barrera, R Langidrik, J Tomashek, KM AF Sharp, Tyler M. Mackay, Andrew J. Santiago, Gilberto A. Hunsperger, Elizabeth Nilles, Eric J. Perez-Padilla, Janice Tikomaidraubuta, Kinisalote S. Colon, Candimar Amador, Manuel Chen, Tai-Ho Lalita, Paul Munoz-Jordan, Jorge L. Barrera, Roberto Langidrik, Justina Tomashek, Kay M. TI Characteristics of a Dengue Outbreak in a Remote Pacific Island Chain - Republic of the Marshall Islands, 2011-2012 SO PLOS ONE LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; FEDERATED STATES; HEMORRHAGIC-FEVER; RISK-FACTORS; VIRUS; MICRONESIA; EPIDEMIC; INFECTION; THAILAND; DISEASE AB Dengue is a potentially fatal acute febrile illness caused by four mosquito-transmitted dengue viruses (DENV-1-4). Although dengue outbreaks regularly occur in many regions of the Pacific, little is known about dengue in the Republic of the Marshall Islands (RMI). To better understand dengue in RMI, we investigated an explosive outbreak that began in October 2011. Suspected cases were reported to the Ministry of Health, serum specimens were tested with a dengue rapid diagnostic test (RDT), and confirmatory testing was performed using RT-PCR and IgM ELISA. Laboratory-positive cases were defined by detection of DENV nonstructural protein 1 by RDT, DENV nucleic acid by RT-PCR, or anti-DENV IgM antibody by RDT or ELISA. Secondary infection was defined by detection of anti-DENV IgG antibody by ELISA in a laboratory-positive acute specimen. During the four months of the outbreak, 1,603 suspected dengue cases (3% of the RMI population) were reported. Of 867 (54%) laboratory-positive cases, 209 (24%) had dengue with warning signs, six (0.7%) had severe dengue, and none died. Dengue incidence was highest in residents of Majuro and individuals aged 10-29 years, and similar to 95% of dengue cases were experiencing secondary infection. Only DENV-4 was detected by RT-PCR, which phylogenetic analysis demonstrated was most closely related to a virus previously identified in Southeast Asia. Cases of vertical DENV transmission, and DENV/Salmonella Typhi and DENV/Mycobacterium leprae co-infection were identified. Entomological surveys implicated water storage containers and discarded tires as the most important development sites for Aedes aegypti and Ae. albopictus, respectively. Although this is the first documented dengue outbreak in RMI, the age groups of cases and high prevalence of secondary infection demonstrate prior DENV circulation. Dengue surveillance should continue to be strengthened in RMI and throughout the Pacific to identify and rapidly respond to future outbreaks. C1 [Sharp, Tyler M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Sharp, Tyler M.; Mackay, Andrew J.; Santiago, Gilberto A.; Hunsperger, Elizabeth; Perez-Padilla, Janice; Colon, Candimar; Amador, Manuel; Munoz-Jordan, Jorge L.; Barrera, Roberto; Tomashek, Kay M.] Ctr Dis Control & Prevent, Div Vector Borne Dis, San Juan, PR USA. [Nilles, Eric J.] WHO, Div Pacific Tech Support, Suva, Fiji. [Tikomaidraubuta, Kinisalote S.; Lalita, Paul] Majuro Hosp, Majuro, Marshall Island. [Chen, Tai-Ho] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Honolulu, HI USA. [Langidrik, Justina] Minist Hlth, Majuro, Marshall Island. RP Sharp, TM (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. EM tsharp@cdc.gov OI Nilles, Eric/0000-0001-7044-5257 FU US Centers for Disease Control and Prevention; Puerto Rico Department of Health FX This investigation was funded by the US Centers for Disease Control and Prevention and Puerto Rico Department of Health. The funders contributed to all study stages, including investigation design, data collection and analysis, decision to publish, and preparation of the report. NR 48 TC 2 Z9 2 U1 2 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 30 PY 2014 VL 9 IS 9 AR e108445 DI 10.1371/journal.pone.0108445 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AR6CW UT WOS:000343671700098 PM 25268134 ER PT J AU Ha, NS Lahiri, P Parsons, V AF Ha, Neung Soo Lahiri, Partha Parsons, Van TI Methods and results for small area estimation using smoking data from the 2008 National Health Interview Survey SO STATISTICS IN MEDICINE LA English DT Article DE generalized mixed effect model; generalized variance function; hierarchical Bayesian method; MCMC; National Health Interview Survey; random sampling error model ID CHAIN MONTE-CARLO; BAYES ESTIMATION; INFERENCE; PREDICTION AB The National Health Interview Survey, conducted by the National Center for Health Statistics, is designed to provide reliable design-based estimates for a wide range of health-related variables for national and four major geographical regions of the USA. However, state-level or substate-level estimates are likely to be unreliable because they are based on small sample sizes. In this paper, we compare the efficiency of different area-level models in estimating smoking prevalence for the 50 US states and the District of Columbia. Our study is based on survey data from the 2008 National Health Interview Survey in conjunction with a number of potentially related auxiliary variables obtained from the American Community Survey, an ongoing large complex survey conducted by the US Census. A major portion of this study is devoted to the investigation of several methods for estimating survey sampling variances needed to implement an area-level hierarchical model. Based on our findings, a hierarchical Bayesian method that uses a survey-adjusted random sampling variance model to capture the complex survey sampling variability appears to be somewhat superior to the other considered area-level models in accounting for small sample behavior of estimated survey sampling variances. Several diagnostic procedures are presented to compare the proposed methods. Copyright (C) 2014 John Wiley & Sons, Ltd. C1 [Ha, Neung Soo] Stat & Appl Math Sci Inst, Durham, NC 27709 USA. [Lahiri, Partha] Univ Maryland, Joint Program Survey Methodol, College Pk, MD 20742 USA. [Parsons, Van] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Ha, NS (reprint author), 19 TW Alexander Dr,POB 14006, Res Triangle Pk, NC 27709 USA. EM nsha2@ncsu.edu FU National Science Foundation [SES-085100]; National Institute of Health [R01 CA 129101] FX The authors would like to thank the anonymous reviewers for their valuable comments on the manuscript. The second author's research was supported in part by the National Science Foundation Grant Number SES-085100 and National Institute of Health Grant Number R01 CA 129101. NR 27 TC 0 Z9 0 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD SEP 28 PY 2014 VL 33 IS 22 BP 3932 EP 3945 DI 10.1002/sim.6219 PG 14 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA AP1JH UT WOS:000341824600012 PM 24910281 ER PT J AU Mohan, S Mutell, R Patzer, RE Holt, J Cohen, D McClellan, W AF Mohan, Sumit Mutell, Richard Patzer, Rachel E. Holt, James Cohen, David McClellan, William TI Kidney Transplantation and the Intensity of Poverty in the Contiguous United States SO TRANSPLANTATION LA English DT Article DE Spatial topography; Geographical variation; Healthcare disparities; Poverty; Renal transplantation ID NEIGHBORHOOD POVERTY; RENAL-TRANSPLANTATION; ACCESS; ESRD; DISPARITIES; DONATION; OUTCOMES; RACE AB Background. Geographic variation in kidney transplantation rates in the United States has been described previously but remains unexplained by age, race, sex, or socioeconomic status differences. Geographic variations in the concentration of poverty appear to impact end-stage renal disease care and potentially access to transplantation. Methods. We studied the impact of how spatial topography of poverty across geographical regions in the contiguous United States is associated with kidney transplantation in the 48 contiguous U.S. states. Results. We found considerable geographic variation in transplantation rates across the country that persisted across quartiles of county-level median household income and percentage minority population. Higher transplant rates were seen with increasing median household income and decreasing minority populations but were not influenced by education level. Transplantation rates in counties with poverty rates above the national average had low transplant rates, but these rates were influenced by the poverty level in the surrounding counties. Similarly, wealthy counties had higher transplant rates but were lowered in counties of relative wealth that were surrounded by less wealthy counties. Conclusions. Our results underline the geographical heterogeneity of kidney transplantation in the United States and identify regions of the country most likely to benefit from interventions that may reduce disparities in transplantation. C1 [Mohan, Sumit; Cohen, David] Columbia Univ Coll Phys & Surg, Div Nephrol, Dept Med, New York, NY 10032 USA. [Mutell, Richard] Apex Hlth Innovat, Simi Valley, CA USA. [Patzer, Rachel E.] Emory Univ, Rollins Sch Publ Hlth, Div Transplantat, Dept Surg, Atlanta, GA 30322 USA. [Patzer, Rachel E.; McClellan, William] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Holt, James] Ctr Dis Control & Prevent, Atlanta, GA USA. [McClellan, William] Emory Univ, Sch Med, Div Renal, Atlanta, GA 30322 USA. RP Mohan, S (reprint author), Columbia Univ Coll Phys & Surg, Div Nephrol, Dept Med, 622 W 168th St,PH4-124, New York, NY 10032 USA. EM sm2206@columbia.edu OI Mohan, Sumit/0000-0002-5305-9685 FU Health Resources and Services Administration [231-00-0115] FX This work was supported in part by the Health Resources and Services Administration contract 231-00-0115. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. NR 21 TC 5 Z9 5 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD SEP 27 PY 2014 VL 98 IS 6 BP 640 EP 645 DI 10.1097/TP.0000000000000125 PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA AP8YZ UT WOS:000342366600016 PM 24809750 ER PT J AU Comfort, AB van Dijk, JH Mharakurwa, S Stillman, K Johns, B Hathi, P Korde, S Craig, AS Nachbar, N Derriennic, Y Gabert, R Thuma, PE AF Comfort, Alison B. van Dijk, Janneke H. Mharakurwa, Sungano Stillman, Kathryn Johns, Benjamin Hathi, Payal Korde, Sonali Craig, Allen S. Nachbar, Nancy Derriennic, Yann Gabert, Rose Thuma, Philip E. TI Association between malaria control and paediatric blood transfusions in rural Zambia: an interrupted time-series analysis SO MALARIA JOURNAL LA English DT Article DE Malaria control; Blood transfusion; Severe malarial anaemia; Paediatric hospital admissions; Zambia; Sub-Saharan Africa; Time series ID SUB-SAHARAN AFRICA; PLASMODIUM-FALCIPARUM; ANOPHELES-ARABIENSIS; FEEDING BEHAVIOR; SOUTHERN ZAMBIA; CHILDREN; ANEMIA; IMPACT; TRANSMISSION; MORTALITY AB Background: Blood transfusions can reduce mortality among children with severe malarial anaemia, but there is limited evidence quantifying the relationship between paediatric malaria and blood transfusions. This study explores the extent to which the use of paediatric blood transfusions is affected by the number of paediatric malaria visits and admissions. It assesses whether the scale-up of malaria control interventions in a facility catchment area explains the use of paediatric blood transfusions. Methods: The study was conducted at a referral hospital for 13 rural health centres in rural Zambia. Data were used from facility and patient records covering all paediatric malaria admissions from 2000 to 2008. An interrupted time series analysis using an autoregression-moving-average model was conducted to assess the relationship between paediatric malaria outpatient visits and admissions and the use of paediatric blood transfusions. Further investigation explored whether the use of paediatric blood transfusions over time was consistent with the roll out of malaria control interventions in the hospital catchment area. Results: For each additional paediatric malaria outpatient visit, there were 0.07 additional paediatric blood transfusions (95% CI 0.01-0.13; p < 0.05). For each additional paediatric admission for severe malarial anaemia, there were 1.09 additional paediatric blood transfusions (95% CI 0.95-1.23; p < 0.01). There were 19.1 fewer paediatric blood transfusions per month during the 2004-2006 malaria control period (95% CI 12.1-26.0; p < 0.01), a 50% reduction compared to the preceding period when malaria control was relatively limited. During the 2007-2008 malaria control period, there were 27.5 fewer paediatric blood transfusions per month (95% CI 14.6-40.3; p < 0.01), representing a 72% decline compared to the period with limited malaria control. Conclusions: Paediatric admissions for severe malarial anaemia largely explain total use of paediatric blood transfusions. The reduction in paediatric blood transfusions is consistent with the timing of the malaria control interventions. Malaria control seems to influence the use of paediatric blood transfusions by reducing the number of paediatric admissions for severe malarial anaemia. Reduced use of blood transfusions could benefit other areas of the health system through greater blood availability, particularly where supply is limited. C1 [Comfort, Alison B.; Stillman, Kathryn; Johns, Benjamin; Hathi, Payal; Nachbar, Nancy; Derriennic, Yann; Gabert, Rose] Abt Associates Inc, Int Hlth Div, Cambridge, MA 02138 USA. [van Dijk, Janneke H.] Macha Res Trust, Dept Clin Res, Choma, Zambia. [Mharakurwa, Sungano] Macha Res Trust, Johns Hopkins Malaria Res Inst, Malaria Res Dept, Choma, Zambia. [Korde, Sonali] USAID, Bur Global Hlth, Presidents Malaria Initiat, Washington, DC USA. [Craig, Allen S.] Ctr Dis Control & Prevent, Ctr Global Hlth, Presidents Malaria Initiat, Div Parasit Dis & Malaria, Lusaka, Zambia. [Craig, Allen S.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. [Thuma, Philip E.] Macha Res Trust, Choma, Zambia. [Gabert, Rose] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. RP Comfort, AB (reprint author), Abt Associates Inc, Int Hlth Div, Cambridge, MA 02138 USA. EM alison_comfort@abtassoc.com FU President's Malaria Initiative via the Bureau for Global Health, US Agency for International Development [GHS-A-00-06-00010-00, AID-OAA-A-12-00080]; President's Malaria Initiative (PMI), USAID; Health Finance and Governance Project; Johns Hopkins Malaria Research Institute; US government grants; NIH [5U19AI089680]; CDC [5U2GPS001930] FX The study was a collaborative effort between researchers from the Health Systems 20/20 and Health Finance and Governance projects, Macha Research Trust, MMH. This research was made possible through support provided by the President's Malaria Initiative via the Bureau for Global Health, US Agency for International Development under terms of Cooperative Agreement No. GHS-A-00-06-00010-00 for the Health Systems 20/20 Project and Cooperative Agreement No. AID-OAA-A-12-00080 for the Health Finance and Governance Project. The opinions expressed herein are those of the author(s) and do not necessarily reflect the views of the US Agency for International Development or the US Government. We thank Scott Stewart and Jodi Charles, at USAID, for supporting this study. Thanks to the data entry staff at Macha Research Trust and nursing staff at MMH, for assisting in compilation of the paediatric admission data set, with special recognition to Patricia Muleya and Pamela Sinywimaanzi. Finally, we thank Lauren Peterson for conducting data cleaning, and Suzanne Erfurth for editing the manuscript. ABC, KS, BJ, PH, NN, YD, and RG were funded by the President's Malaria Initiative (PMI), USAID, through the Health Systems 20/20 Project, and the Health Finance and Governance Project, held by Abt Associates. PET, JHvD, and SM received support from the Johns Hopkins Malaria Research Institute and US government grants, including NIH (5U19AI089680) and CDC (5U2GPS001930). PMI was involved in the study's design and contributed to the analysis and interpretation of the study results, as well as the drafting of the final manuscript and the decision to submit the manuscript for publication. NR 32 TC 3 Z9 3 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD SEP 26 PY 2014 VL 13 AR 383 DI 10.1186/1475-2875-13-383 PG 17 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AU6KB UT WOS:000345711000001 PM 25261276 ER PT J AU Holloway, R Rasmussen, SA Zaza, S Cox, NJ Jernigan, DB AF Holloway, Rachel Rasmussen, Sonja A. Zaza, Stephanie Cox, Nancy J. Jernigan, Daniel B. TI Updated Preparedness and Response Framework for Influenza Pandemics SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID US CITIES; INTERVENTIONS; STRATEGIES; OUTBREAK; VIRUSES AB The complexities of planning for and responding to the emergence of novel influenza viruses emphasize the need for systematic frameworks to describe the progression of the event; weigh the risk of emergence and potential public health impact; evaluate transmissibility, antiviral resistance, and severity; and make decisions about interventions. On the basis of experience from recent influenza responses, CDC has updated its framework to describe influenza pandemic progression using six intervals (two prepandemic and four pandemic intervals) and eight domains. This updated framework can be used for influenza pandemic planning and serves as recommendations for risk assessment, decision-making, and action in the United States. The updated framework replaces the U.S. federal government stages from the 2006 implementation plan for the National Strategy for Pandemic Influenza (US Homeland Security Council. National strategy for pandemic influenza: implementation plan. Washington, DC: US Homeland Security Council; 2006 Available at http://www.flu.gov/planning-preparedness/fideral/pandemic-influenza-implementation.pdf). The six intervals of the updated framework are as follows: I) investigation of cases of novel influenza, 2) recognition of increased potential for ongoing transmission, 3) initiation of a pandemic wave, 4) acceleration of a pandemic wave, 5) deceleration of a pandemic wave, and 6) preparation for future pandemic waves. The following eight domains are used to organize response efforts within each interval: incident management, surveillance and epidemiology, laboratory, community mitigation, medical care and countermeasures, vaccine, risk communications, and state/local coordination. Compared with the previous US. government stages, this updated framework provides greater detail and clarity regarding the potential timing of key decisions and actions aimed at slowing the spread and mitigating the impact of an emerging pandemic. Use of this updated framework is anticipated to improve pandemic preparedness and response in the United States. Activities and decisions during a response are event-specific. These intervals serve as a reference for public health decision-making by federal, state, and local health authorities in the United States during an influenza pandemic and are not meant to be prescriptive or comprehensive. This framework incorporates information from newly developed tools for pandemic planning and response, including the Influenza Risk Assessment Tool and the Pandemic Severity Assessment Framework, and has been aligned with the pandemic phases restructured in 2013 by the World Health Organization. C1 [Zaza, Stephanie] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Cox, Nancy J.; Jernigan, Daniel B.] Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA. EM srasmussen@ccic.gov NR 22 TC 6 Z9 6 U1 0 U2 11 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1057-5987 EI 1545-8601 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD SEP 26 PY 2014 VL 63 IS 6 BP 1 EP 18 PG 18 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR7ZR UT WOS:000343796000001 PM 25254666 ER PT J AU Singh, S Bradley, H Hu, XH Skarbinski, J Hall, HI Lansky, A AF Singh, Sonia Bradley, Heather Hu, Xiaohong Skarbinski, Jacek Hall, H. Irene Lansky, Amy TI Men Living with Diagnosed HIV Who Have Sex with Men: Progress Along the Continuum of HIV Care - United States, 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Singh, Sonia; Bradley, Heather; Hu, Xiaohong; Skarbinski, Jacek; Hall, H. Irene; Lansky, Amy] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Singh, S (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM ssingh3@cdc.gov NR 10 TC 22 Z9 23 U1 1 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 26 PY 2014 VL 63 IS 38 BP 829 EP 833 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP9ON UT WOS:000342409200002 PM 25254559 ER PT J AU Torrone, E Papp, J Weinstock, H AF Torrone, Elizabeth Papp, John Weinstock, Hillard TI Prevalence of Chlamydia trachomatis Genital Infection Among Persons Aged 14-39 Years - United States, 2007-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Torrone, Elizabeth; Papp, John; Weinstock, Hillard] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Torrone, E (reprint author), CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM etorrone@cdc.gov NR 10 TC 31 Z9 34 U1 2 U2 15 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 26 PY 2014 VL 63 IS 38 BP 834 EP 838 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP9ON UT WOS:000342409200003 PM 25254560 ER PT J AU Housey, M Zhang, F Miller, C Lyon-Callo, S McFadden, J Garcia, E Potter, R AF Housey, Michelle Zhang, Fan Miller, Corinne Lyon-Callo, Sarah McFadden, Jevon Garcia, Erika Potter, Rachel TI Vaccination with Tetanus, Diphtheria, and Acellular Pertussis Vaccine of Pregnant Women Enrolled in Medicaid - Michigan, 2011-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; COVERAGE; INFLUENZA; INFANTS C1 [Housey, Michelle; Miller, Corinne; Lyon-Callo, Sarah; McFadden, Jevon; Garcia, Erika; Potter, Rachel] Michigan Dept Community Hlth, Lansing, MI 48909 USA. [Zhang, Fan] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [McFadden, Jevon] CDC, Career Epidemiol Field Officer Program, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. RP Housey, M (reprint author), Michigan Dept Community Hlth, Lansing, MI 48909 USA. EM mhousey@med.umich.edu NR 10 TC 26 Z9 26 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 26 PY 2014 VL 63 IS 38 BP 839 EP 842 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP9ON UT WOS:000342409200004 PM 25254561 ER PT J AU Li, W Tao, W Jiang, YX Diao, RN Yang, JP Xiao, LH AF Li, Wei Tao, Wei Jiang, Yanxue Diao, Ruinan Yang, Jinping Xiao, Lihua TI Genotypic Distribution and Phylogenetic Characterization of Enterocytozoon bieneusi in Diarrheic Chickens and Pigs in Multiple Cities, China: Potential Zoonotic Transmission SO PLOS ONE LA English DT Article ID VIRUS-INFECTED PATIENTS; 1ST DETECTION; ENCEPHALITOZOON-CUNICULI; MOLECULAR EPIDEMIOLOGY; GIARDIA-DUODENALIS; MICROSPORIDIOSIS; IDENTIFICATION; SWINE; HUMANS; PREVALENCE AB This study investigated diarrheic broiler and layer chickens (<50 days; n = 14) and pigs of three age groups (preweaned <30 days, weaned approximate to 30 to 60 days, and growing >60 days; n = 64) for E. bieneusi genotypes in northeast China and evaluated the potential roles of chickens and pigs in zoonotic transmission of microsporidiosis. Two 45-day-old layer chickens in city Jixi, Heilongjiang province and one 23-day-old broiler chicken in city Songyuan, Jilin province were identified to harbor a human-pathogenic E. bieneusi genotype Henan-IV and a new genotype named CC-1, respectively, by nested PCR and sequence analysis of the ribosomal internal transcribed spacer (ITS). Eleven of 64 (17.2%) duodenal mucosal specimens from pigs in city Tianjin, city Tongliao of Inner Mongolia, cities Jilin and Songyuan of Jilin province, and cities Daqing, Harbin, and Suihua of Heilongjiang province, were positive for E. bieneusi, with the infection rates of weaned pigs (35%, 7/20) significantly higher than preweaned ones (3.6%, 1/28; P<0.05). Nucleotide sequences of the ITS were obtained from 6 pig specimens, belonging to 3 known genotypes CHN7, EbpC, and Henan-IV. That the previous reports have described the occurrence of genotypes EbpC and Henan-IV in humans and EbpC in wastewater in central China and the clustering of genotypes CC-1 and CHN7 into a major phylogenetic group of E. bieneusi genotypes with zoonotic potential indicated that chickens and pigs could be potential sources of human micorsporidiosis. To our knowledge, this is the first report describing the existence of zoonotic E. bieneusi genotypes in diarrheic chickens. C1 [Li, Wei; Tao, Wei; Jiang, Yanxue; Diao, Ruinan; Yang, Jinping] Northeast Agr Univ, Coll Vet Med, Harbin, Heilongjiang, Peoples R China. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Li, W (reprint author), Northeast Agr Univ, Coll Vet Med, Harbin, Heilongjiang, Peoples R China. EM neaulw@gmail.com; lax0@cdc.gov RI Xiao, Lihua/B-1704-2013; Li, Wei/H-7214-2013 OI Xiao, Lihua/0000-0001-8532-2727; Li, Wei/0000-0002-4264-1864 FU Scientific Research Funds of Heilongjiang Provincial Education Department [1253HQ015] FX This study was supported by the Scientific Research Funds of Heilongjiang Provincial Education Department (no. 1253HQ015). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 8 Z9 8 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 25 PY 2014 VL 9 IS 9 AR e108279 DI 10.1371/journal.pone.0108279 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AT3UZ UT WOS:000344862300068 PM 25255117 ER PT J AU Monroe, BP Nakazawa, YJ Reynolds, MG Carroll, DS AF Monroe, Benjamin P. Nakazawa, Yoshinori J. Reynolds, Mary G. Carroll, Darin S. TI Estimating the geographic distribution of human Tanapox and potential reservoirs using ecological niche modeling SO INTERNATIONAL JOURNAL OF HEALTH GEOGRAPHICS LA English DT Article DE Poxvirus; Environmental niche modeling; Disease reservoir ID DISEASE; VIRUS; INFECTIONS; MONKEYS; UGANDA AB Background: Tanapox virus is a zoonotic infection that causes mild febrile illness and one to several nodular skin lesions. The disease is endemic in parts of Africa. The principal reservoir for the virus that causes Tanapox is unknown, but has been hypothesized to be a non-human primate. This study employs ecological niche modeling (ENM) to determine areas of tropical Africa suitable for the occurrence of human Tanapox and a list of hypothetical reservoirs. The resultant niche model will be a useful tool to guide medical surveillance activities in the region. Methods: This study uses the Desktop GARP software to predict regions where human Tanapox might be expected to occur based on historical human case locations and environmental data. Additional modeling of primate species, using occurrence data from museum records was performed to determine suitable disease reservoirs. Results: The final ENM predicts a potential distribution of Tanapox over much of equatorial Africa, exceeding the borders of Kenya and Democratic Republic of Congo (DRC) where it has been historically reported. Five genera of non-human primates were found to be potential reservoir taxa. Conclusions: Validity testing suggests the model created here is robust (p < 0.04). Several genera of primates were identified as having ENMs overlapping with that of Tanapox and are suggested as potential reservoirs, mainly members of the Genus Cercopithecus. The ENM modeling technique has several limitations and results should be interpreted with caution. This study may increase knowledge and engage further research in this neglected disease. C1 [Monroe, Benjamin P.; Nakazawa, Yoshinori J.; Reynolds, Mary G.; Carroll, Darin S.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. RP Monroe, BP (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd NE,Mailstop A-30, Atlanta, GA 30333 USA. EM ihd2@cdc.gov NR 29 TC 1 Z9 1 U1 1 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-072X J9 INT J HEALTH GEOGR JI Int. J. Health Geogr. PD SEP 25 PY 2014 VL 13 AR 34 DI 10.1186/1476-072X-13-34 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ2CM UT WOS:000342593100001 PM 25255815 ER PT J AU Frieden, TR Damon, I Bell, BP Kenyon, T Nichol, S AF Frieden, Thomas R. Damon, Inger Bell, Beth P. Kenyon, Thomas Nichol, Stuart TI Ebola 2014-New Challenges, New Global Response and Responsibility SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Frieden, Thomas R.; Damon, Inger; Bell, Beth P.; Kenyon, Thomas; Nichol, Stuart] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Frieden, TR (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 5 TC 83 Z9 88 U1 1 U2 74 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 25 PY 2014 VL 371 IS 13 BP 1177 EP 1180 DI 10.1056/NEJMp1409903 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA AP4WH UT WOS:000342079700002 PM 25140858 ER PT J AU Held, PK Haynes, CA De Jesus, VR Baker, MW AF Held, Patrice K. Haynes, Christopher A. De Jesus, Victor R. Baker, Mei W. TI Development of an assay to simultaneously measure orotic acid, amino acids, and acylcarnitines in dried blood spots SO CLINICA CHIMICA ACTA LA English DT Article DE Orotic acid; Ornithine transcarbamylase deficiency; Urea cycle defects; Newborn screening ID TANDEM MASS-SPECTROMETRY; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; QUANTITATIVE-ANALYSIS; RAPID-DETERMINATION; UREA CYCLE; URINE; DIAGNOSIS; QUANTIFICATION; PLASMA AB Background: Orotic aciduria in the presence of hyperammonemia is a key indicator for a defect in the urea cycle, specifically ornithine transcarbamylase (OTC) deficiency. Current newborn screening (NBS) protocols can detect several defects of the urea cycle, but screening for OTC deficiency remains a challenge due to the lack of a suitable assay. The purpose of this study was to develop a high-throughput assay to measure orotic acid in dried blood spot (DBS) specimens as an indicator for urea cycle dysfunction, which can be readily incorporated into routine NBS. Methods: Orotic acid was extracted from DBS punches and analyzed using flow-injection analysis tandem mass spectrometry (FIA-MS/MS) with negative-mode ionization, requiring <2 min/sample run time. This method was then multiplexed into a conventional newborn screening assay for analysis of amino acids, acylcarnitines, and orotic acid. Results: We describe 2 assays which can quantify orotic acid in DBS: a stand-alone method and a combined method for analysis of orotic acid, amino acids, and acylcarnitines. Both methods demonstrated orotic acid recovery of 75-85% at multiple levels of enrichment. Precision was also comparable to traditional FIA-MS/MS methods. Analysis of residual presumptively normal NBS specimens demonstrated a 5:1 signal to noise ratio and the average concentration of orotic acid was approximately 1.2 mu mol/l. The concentration of amino acids and acylcarnitines as measured by the combined method showed no significant differences when compared to the conventional newborn screening assay. In addition, retrospective analysis of confirmed patients and presumptively normal newborn screening specimens suggests potential for the methods to identify patients with OTC deficiency, as well as other urea cycle defects. Conclusion: The assays described here quantify orotic acid in DBS using a simple extraction and FIA-MS/MS analysis procedures that can be implemented into current NBS protocols. (C) 2014 Elsevier B.V. All rights reserved. C1 [Held, Patrice K.; Baker, Mei W.] Wisconsin State Lab Hyg, Madison, WI 53706 USA. [Haynes, Christopher A.; De Jesus, Victor R.] Ctr Dis Control & Prevent, Newborn Screening & Mol Biol Branch, Atlanta, GA 30341 USA. [Held, Patrice K.; Baker, Mei W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA. RP Held, PK (reprint author), Wisconsin State Lab Hyg, 465 Henry Mall, Madison, WI 53706 USA. EM patrice.held@slh.wisc.edu OI De Jesus, Victor/0000-0003-4964-538X FU Intramural CDC HHS [CC999999] NR 23 TC 1 Z9 1 U1 4 U2 19 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD SEP 25 PY 2014 VL 436 BP 149 EP 154 DI 10.1016/j.cca.2014.05.016 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AO6LH UT WOS:000341463100024 PM 24886687 ER PT J AU Wang, Y Gay, GD Botelho, JC Caudill, SP Vesper, HW AF Wang, Yuesong Gay, Gabrielle D. Botelho, Julianne Cook Caudill, Samuel P. Vesper, Hubert W. TI Total testosterone quantitative measurement in serum by LC-MS/MS SO CLINICA CHIMICA ACTA LA English DT Article DE Testosterone; Steroids; Hormone; LC-MS/MS ID TANDEM MASS-SPECTROMETRY; POSTMENOPAUSAL WOMEN; TESTICULAR CANCER; OLDER MEN; ASSAY; VALIDATION; DEFICIENCY; DIAGNOSIS; HORMONES; DIHYDROTESTOSTERONE AB Reliable measurement of total testosterone is essential for the diagnosis, treatment and prevention of a number of hormone-related diseases affecting adults and children. A mass spectrometric method for testosterone determination in human serum was carefully developed and thoroughly validated. Total testosterone from 100 mu L. serum is released from proteins with acidic buffer and isolated by two serial liquid-liquid extraction steps. The first extraction step isolates the lipid fractions from an acidic buffer solution using ethyl acetate and hexane. The organic phase is dried down and reconstituted in a basic buffer solution. The second extraction step removes the phospholipids and other components by hexane extraction. Liquid chromatography-isotopic dilution tandem mass spectrometry is used to quantify the total testosterone. The sample preparation is automatically conducted in a liquid-handling system with 96-deepwell plates. The method limit of detection is 9.71 pmol/L (0.280 ng/dL) and the method average percent bias is not significantly different from reference methods. The performance of this method has proven to be consistent with the method precision over a 2-year period ranging from 3.7 to 4.8% for quality control pools at the concentrations 0.527, 7.90 and 30.7 nmol/L (15.2, 228, and 886 ng/dL), respectively. This method provides consistently high accuracy and excellent precision for testosterone determination in human serum across all clinical relevant concentrations. Published by Elsevier B.V. C1 [Wang, Yuesong; Gay, Gabrielle D.; Botelho, Julianne Cook; Caudill, Samuel P.; Vesper, Hubert W.] Ctr Dis Control & Prevent, Div Sci Lab, Clin Chem Branch, Atlanta, GA 30341 USA. RP Vesper, HW (reprint author), Ctr Dis Control & Prevent, 4770 Buford HWY NE,MS F25, Atlanta, GA 30341 USA. EM hvesper@cdc.gov FU Intramural CDC HHS [CC999999] NR 53 TC 7 Z9 8 U1 2 U2 35 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD SEP 25 PY 2014 VL 436 BP 263 EP 267 DI 10.1016/j.cca.2014.06.009 PG 5 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AO6LH UT WOS:000341463100041 PM 24960363 ER PT J AU Wei, BNA Feng, JN Rehmani, IJ Miller, S McGuffey, JE Blount, BC Wang, LQ AF Wei, Binnian Feng, June Rehmani, Imran J. Miller, Sharyn McGuffey, James E. Blount, Benjamin C. Wang, Lanqing TI A high-throughput robotic sample preparation system and HPLC-MS/MS for measuring urinary anatabine, anabasine, nicotine and major nicotine metabolites SO CLINICA CHIMICA ACTA LA English DT Article DE Robotic; High-throughput; Biomonitoring; Biomarker; Tobacco exposure; Urinary metabolites ID TANDEM MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; SOLVENT-EXTRACTION; HUMAN PLASMA; EXPOSURE; SMOKE; NONSMOKERS; BIOMARKERS; COTININE; DRUGS AB Background: Most sample preparation methods characteristically involve intensive and repetitive labor, which is inefficient when preparing large numbers of samples from population-scale studies. Methods: This study presents a robotic system designed to meet the sampling requirements for large population-scale studies. Using this robotic system, we developed and validated a method to simultaneously measure urinary anatabine, anabasine, nicotine and seven major nicotine metabolites: 4-Hydroxy-4-(3-pyridyl)butanoic acid, cotinine-N-oxide, nicotine-N-oxide, trans-3'-hydroxycotinine, norcotinine, cotinine and nornicotine. We analyzed robotically prepared samples using high-performance liquid chromatography (HPLC) coupled with triple quadrupole mass spectrometry in positive electrospray ionization mode using scheduled multiple reaction monitoring (sMRM) with a total runtime of 8.5 min. Results: The optimized procedure was able to deliver linear analyte responses over a broad range of concentrations. Responses of urine-based calibrators delivered coefficients of determination (R-2) of >0.995. Sample preparation recovery was generally higher than 80%. The robotic system was able to prepare four 96-well plate (384 urine samples) per day, and the overall method afforded an accuracy range of 92-115%, and an imprecision of <15.0% on average. Conclusions: The validation results demonstrate that the method is accurate, precise, sensitive, robust, and most significantly labor-saving for sample preparation, making it efficient and practical for routine measurements in large population-scale studies such as the National Health and Nutrition Examination Survey (NHANES) and the Population Assessment of Tobacco and Health (PATH) study. Published by Elsevier B.V. C1 [Wei, Binnian; Feng, June; Rehmani, Imran J.; Miller, Sharyn; McGuffey, James E.; Blount, Benjamin C.; Wang, Lanqing] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30041 USA. RP Wei, BNA (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE Rd,Mail Stop F44, Atlanta, GA 30041 USA. EM bwei@cdc.gov; czf2@cdc.gov OI Wei, Binnian/0000-0003-0465-9964 FU U.S. Centers for Disease Control and Prevention (CDC) [IAG: 224-11-9006]; U.S. Food and Drug Administration (FDA) Center for Tobacco Products [IAG: 224-11-9006] FX This study was funded through an inter-agency agreement between the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) Center for Tobacco Products (IAG: 224-11-9006). We thank Connie Sosnoff, Irish Angie Frey and Elisa Restea for their valuable comments. NR 27 TC 8 Z9 8 U1 2 U2 32 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD SEP 25 PY 2014 VL 436 BP 290 EP 297 DI 10.1016/j.cca.2014.06.012 PG 8 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AO6LH UT WOS:000341463100046 PM 24968308 ER PT J AU deCastro, BR Caldwell, KL Jones, RL Blount, BC Pan, Y Ward, C Mortensen, ME AF deCastro, B. Rey Caldwell, Kathleen L. Jones, Robert L. Blount, Benjamin C. Pan, Yi Ward, Cynthia Mortensen, Mary E. TI Dietary Sources of Methylated Arsenic Species in Urine of the United States Population, NHANES 2003-2010 SO PLOS ONE LA English DT Article ID MARKET BASKET SURVEY; US POPULATION; NATIONAL-HEALTH; MONOMETHYLARSONOUS ACID; MICROBIOLOGICAL ASSAY; TRIVALENT ARSENICALS; BANGLADESHI ADULTS; DIABETES-MELLITUS; RICE CONSUMPTION; HUMAN-CELLS AB Background: Arsenic is an ubiquitous element linked to carcinogenicity, neurotoxicity, as well as adverse respiratory, gastrointestinal, hepatic, and dermal health effects. Objective: Identify dietary sources of speciated arsenic: monomethylarsonic acid (MMA), and dimethylarsinic acid (DMA). Methods: Age-stratified, sample-weighted regression of NHANES (National Health and Nutrition Examination Survey) 20032010 data (, 8,300 participants >= 6 years old) characterized the association between urinary arsenic species and the additional mass consumed of USDA-standardized food groups (24-hour dietary recall data), controlling for potential confounders. Results: For all arsenic species, the rank-order of age strata for median urinary molar concentration was children 6-11 years > adults 20-84 years > adolescents 12-19 years, and for all age strata, the rank-order was DMA > MMA. Median urinary molar concentrations of methylated arsenic species ranged from 0.56 to 3.52 mmol/mol creatinine. Statistically significant increases in urinary arsenic species were associated with increased consumption of: fish (DMA); fruits (DMA, MMA); grain products (DMA, MMA); legumes, nuts, seeds (DMA); meat, poultry (DMA); rice (DMA, MMA); rice cakes/crackers (DMA, MMA); and sugars, sweets, beverages (MMA). And, for adults, rice beverage/milk (DMA, MMA). In addition, based on US (United States) median and 90th percentile consumption rates of each food group, exposure from the following food groups was highlighted: fish; fruits; grain products; legumes, nuts, seeds; meat, poultry; and sugars, sweets, beverages. Conclusions: In a nationally representative sample of the US civilian, noninstitutionalized population, fish (adults), rice (children), and rice cakes/crackers (adolescents) had the largest associations with urinary DMA. For MMA, rice beverage/milk (adults) and rice cakes/crackers (children, adolescents) had the largest associations. C1 [deCastro, B. Rey; Caldwell, Kathleen L.; Jones, Robert L.; Blount, Benjamin C.; Pan, Yi; Ward, Cynthia; Mortensen, Mary E.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30333 USA. RP deCastro, BR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30333 USA. EM rdecastro@cdc.gov NR 84 TC 10 Z9 10 U1 0 U2 26 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 24 PY 2014 VL 9 IS 9 AR e108098 DI 10.1371/journal.pone.0108098 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ0SJ UT WOS:000342492700079 PM 25251890 ER PT J AU Vitek, CR Cakalo, JI Kruglov, YV Dumchev, KV Salyuk, TO Bozicevic, I Baughman, AL Spindler, HH Martsynovska, VA Kobyshcha, YV Abdul-Quader, AS Rutherford, GW AF Vitek, Charles R. Cakalo, Jurja-Ivana Kruglov, Yuri V. Dumchev, Konstantin V. Salyuk, Tetyana O. Bozicevic, Ivana Baughman, Andrew L. Spindler, Hilary H. Martsynovska, Violetta A. Kobyshcha, Yuri V. Abdul-Quader, Abu S. Rutherford, George W. TI Slowing of the HIV Epidemic in Ukraine: Evidence from Case Reporting and Key Population Surveys, 2005-2012 SO PLOS ONE LA English DT Article ID EUROPE AB Background: Ukraine developed Europe's most severe HIV epidemic due to widespread transmission among persons who inject drugs (PWID). Since 2004, prevention has focused on key populations; antiretroviral therapy (ART) coverage has increased. Recent data show increases in reported HIV cases through 2011, especially attributed to sexual transmission, but also signs of potential epidemic slowing. We conducted a data triangulation exercise to better analyze available data and inform program implementation. Methods and Findings: We reviewed data for 2005 to 2012 from multiple sources, primarily national HIV case reporting and integrated biobehavioral surveillance (IBBS) studies among key populations. Annually reported HIV cases increased at a progressively slower rate through 2011 with recent increases only among older, more immunosuppressed individuals; cases decreased 2.7% in 2012. Among women <25 years of age, cases attributed to heterosexual transmission and HIV prevalence in antenatal screening declined after 2008. Reported cases among young PWID declined by three-fourths. In 2011, integrated biobehavioral surveillance demonstrated decreased HIV prevalence among young members of key populations compared with 2009. HIV infection among female sex workers (FSW) remains strongly associated with a personal history of injecting drug use (IDU). Conclusions: This analysis suggests that Ukraine's HIV epidemic has slowed, with decreasing reported cases and older cases predominating among those diagnosed. Recent decreases in cases and in prevalence support decreased incidence among young PWID and women. Trends among heterosexual men and men who have sex with men (MSM) are less clear; further study and enhanced MSM prevention are needed. FSW appear to have stable prevalence with risk strongly associated with IDU. Current trends suggest the Ukrainian epidemic can be contained with enhanced prevention among key populations and increased treatment access. C1 [Vitek, Charles R.; Dumchev, Konstantin V.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Kiev, Ukraine. [Baughman, Andrew L.; Abdul-Quader, Abu S.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA. [Cakalo, Jurja-Ivana; Bozicevic, Ivana] Univ Zagreb, WHO, Collaborating Ctr HIV Surveillance, Zagreb 41000, Croatia. [Kruglov, Yuri V.; Martsynovska, Violetta A.] Minist Hlth Ukraine, Ukrainian Ctr Socially Dangerous Dis Control, Kiev, Ukraine. [Salyuk, Tetyana O.] Int HIV AIDS Alliance Ukraine, Kiev, Ukraine. [Spindler, Hilary H.; Rutherford, George W.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kobyshcha, Yuri V.] WHO, Kiev, Ukraine. RP Vitek, CR (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Kiev, Ukraine. EM cxv3@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through U.S. Centers for Disease Control and Prevention (CDC) [PS001468] FX This project has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) under the terms of grant PS001468. CDC staff listed as authors participated in study design, data analysis, and preparation of the manuscript but had no role in the funding decision. NR 34 TC 11 Z9 11 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 24 PY 2014 VL 9 IS 9 AR e103657 DI 10.1371/journal.pone.0103657 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ0SJ UT WOS:000342492700001 PM 25251080 ER PT J AU Geiss, LS Wang, J Cheng, YLJ Thompson, TJ Barker, L Li, YF Albright, AL Gregg, EW AF Geiss, Linda S. Wang, Jing Cheng, Yiling J. Thompson, Theodore J. Barker, Lawrence Li, Yanfeng Albright, Ann L. Gregg, Edward W. TI Prevalence and Incidence Trends for Diagnosed Diabetes Among Adults Aged 20 to 79 Years, United States, 1980-2012 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID BODY-MASS INDEX; US ADULTS; AMERICAN-INDIANS; NATIONAL-HEALTH; OBESITY; MELLITUS; GLUCOSE; PERFORMANCE; POPULATION; RISK AB IMPORTANCE Although the prevalence and incidence of diabetes have increased in the United States in recent decades, no studies have systematically examined long-term, national trends in the prevalence and incidence of diagnosed diabetes. OBJECTIVE To examine long-term trends in the prevalence and incidence of diagnosed diabetes to determine whether there have been periods of acceleration or deceleration in rates. DESIGN, SETTING, AND PARTICIPANTS We analyzed 1980-2012 data for 664 969 adults aged 20 to 79 years from the National Health Interview Survey (NHIS) to estimate incidence and prevalence rates for the overall civilian, noninstitutionalized, US population and by demographic subgroups (age group, sex, race/ethnicity, and educational level). MAIN OUTCOMES AND MEASURES The annual percentage change (APC) in rates of the prevalence and incidence of diagnosed diabetes (type 1 and type 2 combined). RESULTS The APC for age-adjusted prevalence and incidence of diagnosed diabetes did not change significantly during the 1980s, but each increased sharply each year during 1990-2008 before leveling off with no significant change during 2008-2012. The prevalence per 100 persons was 3.5 (95% CI, 3.2 to 3.9) in 1990, 7.9 (95% CI, 7.4 to 8.3) in 2008, and 8.3 (95% CI, 7.9 to 8.7) in 2012. The incidence per 1000 persons was 3.2 (95% CI, 2.2 to 4.1) in 1990, 8.8 (95% CI, 7.4 to 10.3) in 2008, and 7.1 (95% CI, 6.1 to 8.2) in 2012. [GRAPHICS] Trends in many demographic subpopulations were similar to these overall trends. However, incidence rates among non-Hispanic black and Hispanic adults continued to increase (for interaction, P = .03 for non-Hispanic black adults and P =.01 for Hispanic adults) at rates significantly greater than for non-Hispanic white adults. In addition, the rate of increase in prevalence was higher for adults who had a high school education or less compared with those who had more than a high school education (for interaction, P = .006 for < high school and P < .001 for high school). CONCLUSIONS AND RELEVANCE Analyses of nationally representative data from 1980 to 2012 suggest a doubling of the incidence and prevalence of diabetes during 1990-2008, and a plateauing between 2008 and 2012. However, there appear to be continued increases in the prevalence or incidence of diabetes among subgroups, including non-Hispanic black and Hispanic subpopulations and those with a high school education or less. C1 [Geiss, Linda S.; Wang, Jing; Cheng, Yiling J.; Thompson, Theodore J.; Barker, Lawrence; Li, Yanfeng; Albright, Ann L.; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. RP Geiss, LS (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Hwy NE,MS F73, Atlanta, GA 30341 USA. EM lgeiss@cdc.gov NR 39 TC 133 Z9 134 U1 4 U2 26 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 24 PY 2014 VL 312 IS 12 BP 1218 EP 1226 DI 10.1001/jama.2014.11494 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA AP3QA UT WOS:000341990600022 PM 25247518 ER PT J AU McNeil, MM Gee, J Weintraub, ES Belongia, EA Lee, GM Glanz, JM Nordin, JD Klein, NP Baxter, R Naleway, AL Jackson, LA Omer, SB Jacobsen, SJ DeStefano, F AF McNeil, Michael M. Gee, Julianne Weintraub, Eric S. Belongia, Edward A. Lee, Grace M. Glanz, Jason M. Nordin, James D. Klein, Nicola P. Baxter, Roger Naleway, Allison L. Jackson, Lisa A. Omer, Saad B. Jacobsen, Steven J. DeStefano, Frank TI The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety SO VACCINE LA English DT Review DE Surveillance; Vaccine safety; Immunization ID INACTIVATED INFLUENZA VACCINE; GUILLAIN-BARRE-SYNDROME; MEASLES-MUMPS-RUBELLA; REAL-TIME SURVEILLANCE; PROBABILITY RATIO TEST; ADVERSE EVENTS; UNITED-STATES; CHILDHOOD VACCINATIONS; IMMUNIZATION PRACTICES; PREVENTABLE DISEASES AB The Vaccine Safety Datalink (VSD) is a collaborative project between the Centers for Disease Control and Prevention (CDC) and 9 health care organizations. Established in 1990, VSD is a vital resource informing policy makers and the public about the safety of vaccines used in the United States. Large linked databases are used to identify and evaluate adverse events in over 9 million individuals annually. VSD generates rapid, important safety assessments for both routine vaccinations and emergency vaccination campaigns. VSD monitors safety of seasonal influenza vaccines in near-real time, and provided essential information on the safety of influenza A (H1N1) 2009 monovalent vaccine during the recent pandemic. VSD investigators have published important studies demonstrating that childhood vaccines are not associated with autism or other developmental disabilities. VSD prioritizes evaluation of new vaccines; searches for possible unusual health events after vaccination; monitors vaccine safety in pregnant women; and has pioneered development of biostatistical research methods. Published by Elsevier Ltd. C1 [McNeil, Michael M.; Gee, Julianne; Weintraub, Eric S.; DeStefano, Frank] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Lee, Grace M.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Glanz, Jason M.] Kaiser Permanente, Inst Hlth Res, Denver, CO USA. [Nordin, James D.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Klein, Nicola P.; Baxter, Roger] Kaiser Permanente No Calif, Vaccine Study Ctr, Oakland, CA USA. [Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Jackson, Lisa A.] Grp Hlth Cooperat Puget Sound, Seattle, WA USA. [Omer, Saad B.] Kaiser Permanente Ctr Hlth Res, Atlanta, GA USA. [Jacobsen, Steven J.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. RP McNeil, MM (reprint author), CDC, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. EM mmm2@cdc.gov OI Naleway, Allison/0000-0001-5747-4643; Jacobsen, Steven/0000-0002-8174-8533 FU CDC FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official policy or position of the Centers for Disease Control and Prevention. Use of trade names and commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention, or the U.S. Department of Health and Human Services. This study was supported by CDC and no external funding was secured. NR 69 TC 27 Z9 27 U1 2 U2 26 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 22 PY 2014 VL 32 IS 42 BP 5390 EP 5398 DI 10.1016/j.vaccine.2014.07.073 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AR1LH UT WOS:000343346200005 PM 25108215 ER PT J AU Roland, KB Benard, VB Greek, A Hawkins, NA Saraiya, M AF Roland, Katherine B. Benard, Vicki B. Greek, April Hawkins, Nikki A. Saraiya, Mona TI Primary care providers human papillomavirus vaccine recommendations for the medically underserved: A pilot study in U.S. Federally Qualified Health Centers SO VACCINE LA English DT Article DE HPV vaccine; Cervical cancer screening; Federally Qualified Health Center (FQHC); Underserved; Low-income ID CERVICAL-CANCER; UNITED-STATES; PHYSICIANS; COVERAGE; ADOLESCENTS; GUIDELINE; BELIEFS AB Introduction: In the United States, Federally Qualified Health Centers (FQHCs) are safety-net clinics that provide cervical cancer screening and human papillomavirus (HPV) vaccination to medically underserved women, some of whom may be at risk for developing cervical cancer. National guidelines recommend against using screening test results or sexual history to determine vaccine eligibility. Documenting HPV vaccine recommendations and beliefs of primary care providers in FQHCs may aid in promoting evidence-based practices and prioritizing health interventions for vulnerable populations. Methods: Between 2009 and 2010, we collected data from 98 primary care providers in 15 FQHC clinics in IL, USA using a cross-sectional survey. Questions assessed provider and practice characteristics, HPV vaccine recommendations, and provider's belief about whether their screening and management procedures would change for women who were vaccinated. Results: 93% of providers recommended the HPV vaccine, most frequently for females aged 13-26 years (98%). Some providers reported sometimes to always using HPV test results (12%), Pap test results (7%), and number of sexual partners (33%) to determine vaccine eligibility. More than half of providers (55%) reported they will not change their screening and management practices for vaccinated females, yet believe vaccination will yield fewer abnormal Pap tests (71%) and referrals for colposcopy (74%). Conclusion: Study providers routinely recommended the HPV vaccine for their patients. However, providers made fewer recommendations to vaccinate females ages 9-12 years (which includes the target age for vaccination) compared to older females, and used pre-vaccination assessments not recommended by U.S. guidelines, such as screening test results and number of sexual partners. In order to maximize the public health benefit of the HPV vaccine to prevent cervical cancer, adherence to guidelines is necessary, especially in settings that provide care to medically underserved women. Published by Elsevier Ltd. C1 [Roland, Katherine B.; Benard, Vicki B.; Hawkins, Nikki A.; Saraiya, Mona] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30341 USA. [Greek, April] Battelle Hlth & Analyt, Seattle, WA 98109 USA. RP Roland, KB (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, 4770 Buford Hwy NE,MS F-76, Atlanta, GA 30341 USA. EM kroland@cdc.gov FU Centers for Disease Control and Prevention [200-2002-00573] FX Centers for Disease Control and Prevention, Contract number 200-2002-00573, Task Order No. 0006 supported field work and data collection. NR 27 TC 7 Z9 7 U1 3 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 22 PY 2014 VL 32 IS 42 BP 5432 EP 5435 DI 10.1016/j.vaccine.2014.07.098 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AR1LH UT WOS:000343346200011 PM 25131744 ER PT J AU Vasudevan, L Labrique, AB Mehra, S Wu, L Levine, O Feikin, D Klemm, R Christian, P West, KP AF Vasudevan, Lavanya Labrique, Alain B. Mehra, Sucheta Wu, Lee Levine, Orin Feikin, Danny Klemm, Rolf Christian, Parul West, Keith P., Jr. TI Maternal determinants of timely vaccination coverage among infants in rural Bangladesh SO VACCINE LA English DT Article DE Timely vaccination; Crude vaccination; Expanded Program on Immunization (EPI); Bangladesh; Timely vaccination score; Maternal determinants; Antenatal care; Tetanus toxoid vaccination ID BETA-CAROTENE SUPPLEMENTATION; VITAMIN-A SUPPLEMENTATION; IMMUNIZATION; MORTALITY; CHILDREN; PERFORMANCE; COMPLETION; TIMELINESS; COUNTRIES; SURVIVAL AB Background: Timely vaccination, i.e., the receipt of all scheduled vaccinations in an age-appropriate fashion, is critical for the prevention of deadly diseases in infants and achievement of the UN Millennium Development Goal to reduce infant mortality. Infants, especially in rural or underprivileged settings often receive delayed vaccinations leaving them susceptible to vaccine-preventable illnesses early in the first year of life. In this study, we examined rates of timely vaccination among 24,435 infants born in Gaibandha and Rangpur rural districts of Bangladesh from 2001 to 2007. Methods: Vaccinations due by 14 weeks of age and administered through routine government immunization services were assessed using interviews with enrolled mothers between 11 and 18 weeks postpartum. We created a Timely Vaccination (TV) score to classify infants as vaccinated fully and on schedule (TV = 1) or not (TV = 0), and used multivariable logistic regression to identify maternal characteristics associated with infant's timely vaccination status. Results: Our results suggest that only 19% of infants in this cohort received scheduled vaccinations on time by 11-18 weeks postpartum. Mothers' engagement in paid employment [OR=1.13,95% CI: 1.03-1.23], receipt of tetanus toxoid vaccination [OR=1.24, 95% CI: 1.11-1.38], history of antenatal care [OR=1.22, 95% CI: 1.12-1.32], or higher socioeconomic status [OR=1.07, 95% CI: 1.03-1.11] were positively associated with timely vaccination of their infants. Mother's perception of small infant size at birth was negatively associated with timely vaccination [OR=0.89,95% CI: 0.82-0.97]. Conclusion: Timely vaccination coverage of infants in rural Gaibandha and Rangpur districts is extremely low. This analysis identifies important shortcomings associated with the 1-year vaccination benchmark of routine immunization performance and suggests the need for specific interventions based on potential maternal determinants as well as known system and programmatic barriers of timely vaccination among infants in rural Bangladesh. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Vasudevan, Lavanya] Duke Global Hlth Inst, Durham, NC USA. [Vasudevan, Lavanya; Labrique, Alain B.; Mehra, Sucheta; Wu, Lee; Levine, Orin; Feikin, Danny; Klemm, Rolf; Christian, Parul; West, Keith P., Jr.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Levine, Orin] Bill & Melinda Gates Fdn, Seattle, WA USA. [Feikin, Danny] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Labrique, AB (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. EM alabriqu@jhsph.edu FU Grand Challenges Explorations Phase I grant; Bill and Melinda Gates Foundation, Seattle WA [614]; Office of Health, Infectious Diseases and Nutrition, US Agency for International Development (USAID), Washington, DC [HRN-A-00-97-00015-00, GHS-A-00-03-00019-00]; USAID Mission, Dhaka, Bangladesh; Sight and Life Global Nutrition Research Institute, Baltimore, MD; Micronutrient Initiative/Department of Foreign Affairs, Trade and Development, Ottawa, Ontario; Nutrilite Health Institute, Access Business Group LLC, Buena Park, CA; Ministry of Health and Family Welfare, Government of Bangladesh, Dhaka FX This work was funded partly through a Grand Challenges Explorations Phase I grant to AL and LV. The funding source had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The field trial and associated studies were supported through Grant No. 614 (Global Control of Micronutrient Deficiency) from the Bill and Melinda Gates Foundation, Seattle WA; Cooperative Agreement HRN-A-00-97-00015-00 and Global Research Activity GHS-A-00-03-00019-00 between the Office of Health, Infectious Diseases and Nutrition, US Agency for International Development (USAID), Washington, DC; the USAID Mission, Dhaka, Bangladesh; the Sight and Life Global Nutrition Research Institute, Baltimore, MD; the Micronutrient Initiative/Department of Foreign Affairs, Trade and Development, Ottawa, Ontario; and the Nutrilite Health Institute, Access Business Group LLC, Buena Park, CA; and the Ministry of Health and Family Welfare, Government of Bangladesh, Dhaka. NR 31 TC 4 Z9 4 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 22 PY 2014 VL 32 IS 42 BP 5514 EP 5519 DI 10.1016/j.vaccine.2014.06.092 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AR1LH UT WOS:000343346200023 PM 25132336 ER PT J AU Maman, I Badziklou, K Landoh, ED Halatoko, AW Nzussouo, TN Defang, GN Tamekloe, TA Kennedy, PJ Thelma, W Kossi, K Issa, Z Kere, AB AF Maman, Issaka Badziklou, Kossi Landoh, Essoya D. Halatoko, Afiwa W. Nzussouo, Talla N. Defang, Gabriel N. Tamekloe, Tsidi A. Kennedy, Pamela J. Thelma, Williams Kossi, Komlan Issa, Zoulkarneiri Kere, Abiba B. TI Implementation of Influenza-like illness Sentinel Surveillance in Togo SO BMC PUBLIC HEALTH LA English DT Article DE Influenza; Human; Sentinel surveillance; Influenza-like illness (ILI); Lome commune ID EPIDEMIOLOGY; AFRICA; SEASONALITY; BRAZIL AB Background: The emergence of avian influenza A/H5N1 in 2003 as well as the pandemic influenza A (H1N1) pdm09 highlighted the need to establish influenza sentinel surveillance in Togo. The Ministry of Health decided to introduce Influenza to the list of diseases with epidemic potential. By April 2010, Togo was actively involved in influenza surveillance. This study aims to describe the implementation of ILI surveillance and results obtained from April 2010 to December 2012. Methods: Two sites were selected based on their accessibility and affordability to patients, their adequate specimen storage capacity and transportation system. Patients with ILI presenting at sentinel sites were enrolled by trained medical staff based on the World Health Organization (WHO) case definitions. Oropharyngeal and nasopharyngeal samples were collected and they were tested at the National Influenza Reference Laboratory using a U.S. Centers for Disease Control and Prevention (CDC) validated real time RT-PCR protocol. Laboratory results and epidemiological data were reported weekly and shared with all sentinel sites, Ministry of Health, Division of Epidemiology, WHO and CDC/NAMRU-3. Results: From April 2010 to December 2012, a total of 955 samples were collected with 52% of the study population aged between 0 and 4 years. Of the 955 samples, 236 (24.7%) tested positive for influenza viruses; with 136 (14.2%) positive for influenza A and 100 (10.5%) positive for influenza B. The highest influenza positive percentage (30%) was observed in 5-14 years old and patients aged 0-4 and >60 years had the lowest percentage (20%). Clinical symptoms such as cough and rhinorrhea were associated more with ILI patients who were positive for influenza type A than influenza type B. Influenza viruses circulated throughout the year with the positivity rate peaking around the months of January, May and again in October; corresponding respectively to the dry-dusty harmattan season and the long and then the short raining season. The pandemic A (H1N1) pdm09 was the predominantly circulating strain in 2010 while influenza B was the predominantly circulating strain in 2011. The seasonal A/H3N2 was observed throughout 2012 year. Conclusions: This study provides information on influenza epidemiology in the capital city of Togo. C1 [Maman, Issaka; Badziklou, Kossi; Halatoko, Afiwa W.; Kossi, Komlan; Issa, Zoulkarneiri; Kere, Abiba B.] Inst Natl Hygiene, Nat Influenza Reference Lab, Lome, Togo. [Landoh, Essoya D.; Tamekloe, Tsidi A.] Minist Hlth, Div Epidemiol, Lome, Togo. [Nzussouo, Talla N.; Thelma, Williams] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Defang, Gabriel N.] US Naval Med Res Unit 3, Dept Virol, Cairo, Egypt. [Kennedy, Pamela J.] US Ctr Dis Control & Prevent, McKing Consulting Influenza Div, Atlanta, GA USA. RP Maman, I (reprint author), Inst Natl Hygiene, Nat Influenza Reference Lab, 26 QAD Rue Nangbeto,01 Lome Sud,POB 1396, Lome, Togo. EM mamanissaka@yahoo.fr FU Ministry of Health; Division of Epidemiology; CDC; NAMRU-3 FX We would like to thank all sentinel staff at the Hopital de Be and the Military Health services for their essential role in the ILI sentinel surveillance. We are grateful to the Ministry of Health and the Division of Epidemiology for their support and coordination. We would like also express our sincere thanks to the team of the National Influenza Reference Laboratory for their efforts in collecting samples, clinical data and detection by RT-PCR of influenza viruses. We wish to thank Mr Koffi Akolly, Field Epidemiologist for designing the map of the Figure 1. The influenza sentinel surveillance was successful established with the technical and financial support of CDC and NAMRU-3. We are grateful also to CDC reviewers for their precious analyses and revision of this paper prior it's submission for publication. NR 28 TC 2 Z9 2 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD SEP 20 PY 2014 VL 14 AR 981 DI 10.1186/1471-2458-14-981 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1BO UT WOS:000342516600002 PM 25239536 ER PT J AU He, YL Landrum, MB Zaslavsky, AM AF He, Yulei Landrum, Mary Beth Zaslavsky, Alan M. TI Combining information from two data sources with misreporting and incompleteness to assess hospice-use among cancer patients: a multiple imputation approach SO STATISTICS IN MEDICINE LA English DT Article DE data augmentation; health services research; measurement error; model diagnostics; multilevel models ID MEASUREMENT-ERROR; BINARY; CARE; DISTRIBUTIONS; DISCUSSIONS; ENUMERATION; REGRESSION; VARIABLES; MODELS; LIFE AB Combining information from multiple data sources can enhance estimates of health-related measures by using one source to supply information that is lacking in another, assuming the former has accurate and complete data. However, there is little research conducted on combining methods when each source might be imperfect, for example, subject to measurement errors and/or missing data. In a multisite study of hospice-use by late-stage cancer patients, this variable was available from patients' abstracted medical records, which may be considerably underreported because of incomplete acquisition of these records. Therefore, data for Medicare-eligible patients were supplemented with their Medicare claims that contained information on hospice-use, which may also be subject to underreporting yet to a lesser degree. In addition, both sources suffered from missing data because of unit nonresponse from medical record abstraction and sample undercoverage for Medicare claims. We treat the true hospice-use status from these patients as a latent variable and propose to multiply impute it using information from both data sources, borrowing the strength from each. We characterize the complete-data model as a product of an outcome' model for the probability of hospice-use and a reporting' model for the probability of underreporting from both sources, adjusting for other covariates. Assuming the reports of hospice-use from both sources are missing at random and the underreporting are conditionally independent, we develop a Bayesian multiple imputation algorithm and conduct multiple imputation analyses of patient hospice-use in demographic and clinical subgroups. The proposed approach yields more sensible results than alternative methods in our example. Our model is also related to dual system estimation in population censuses and dual exposure assessment in epidemiology. Copyright (c) 2014 John Wiley & Sons, Ltd. C1 [He, Yulei] Ctr Dis Control & Prevent, Off Res & Methodol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Landrum, Mary Beth; Zaslavsky, Alan M.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. RP He, YL (reprint author), Ctr Dis Control & Prevent, Off Res & Methodol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM wdq7@cdc.gov FU National Cancer Institute (NCI) [U01 CA093344, U01 CA093332, U01 CA093324, U01 CA093348, U01 CA093329, U01 CA093339, U01 CA093326]; Department of Veterans Affairs [CRS 02-164] FX The findings and conclusions in this study are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The authors acknowledged the journal editors and reviewers, Meena Khare and Jennifer Madans, for their valuable input. The work of the CanCORS Consortium was supported by grants from the National Cancer Institute (NCI) to the Statistical Coordinating Center (U01 CA093344) and the NCI-supported Primary Data Collection and Research Centers (Dana-Farber Cancer Institute/Cancer Research Network U01 CA093332, Harvard Medical School/Northern California Cancer Center U01 CA093324, RAND/UCLA U01 CA093348, University of Alabama at Birmingham U01 CA093329, University of Iowa U01 CA093339, and University of North Carolina U01 CA093326) and by the Department of Veterans Affairs grant to the Durham VA Medical Center CRS 02-164. NR 31 TC 0 Z9 0 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD SEP 20 PY 2014 VL 33 IS 21 BP 3710 EP 3724 DI 10.1002/sim.6173 PG 15 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA AN2NX UT WOS:000340423700007 PM 24804628 ER PT J AU Black, CL Yue, X Ball, SW Donahue, SMA Izrael, D de Perio, MA Laney, AS Lindley, MC Graitcer, SB Lu, PJ Williams, WW Bridges, CB DiSogra, C Sokolowski, J Walker, DK Greby, SM AF Black, Carla L. Yue, Xin Ball, Sarah W. Donahue, Sara M. A. Izrael, David de Perio, Marie A. Laney, A. Scott Lindley, Megan C. Graitcer, Samuel B. Lu, Peng-jun Williams, Walter W. Bridges, Carolyn B. DiSogra, Charles Sokolowski, John Walker, Deborah K. Greby, Stacie M. TI Influenza Vaccination Coverage Among Health Care Personnel - United States, 2013-14 Influenza Season SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HOME STAFF; RESIDENTS; MORTALITY C1 [Black, Carla L.; Yue, Xin; Lindley, Megan C.; Graitcer, Samuel B.; Lu, Peng-jun; Williams, Walter W.; Bridges, Carolyn B.; Greby, Stacie M.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Ball, Sarah W.; Donahue, Sara M. A.; Izrael, David; Walker, Deborah K.] ABT Associates Inc, Cambridge, MA 02138 USA. [de Perio, Marie A.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, CDC, Washington, DC USA. [Laney, A. Scott] NIOSH, Div Resp Dis Studies, CDC, Washington, DC USA. [DiSogra, Charles; Sokolowski, John] Abt SRBI, New York, NY USA. RP Black, CL (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM cblack2@cdc.gov NR 10 TC 25 Z9 25 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 19 PY 2014 VL 63 IS 37 BP 805 EP 811 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1WC UT WOS:000342573500001 PM 25233281 ER PT J AU Lindley, MC Bridges, CB Strikas, RA Kalayil, EJ Woods, LO Pollock, D Sievert, D AF Lindley, Megan C. Bridges, Carolyn B. Strikas, Raymond A. Kalayil, Elizabeth J. Woods, LaDora O. Pollock, Daniel Sievert, Dawn TI Influenza Vaccination Performance Measurement Among Acute Care Hospital-Based Health Care Personnel - United States, 2013-14 Influenza Season SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID COVERAGE C1 [Lindley, Megan C.; Bridges, Carolyn B.; Strikas, Raymond A.; Kalayil, Elizabeth J.; Woods, LaDora O.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Pollock, Daniel; Sievert, Dawn] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Lindley, MC (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM mlindley@cdc.gov NR 9 TC 7 Z9 7 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 19 PY 2014 VL 63 IS 37 BP 812 EP 815 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1WC UT WOS:000342573500002 PM 25233282 ER PT J AU Ding, H Black, CL Ball, S Donahue, S Izrael, D Williams, WW Kennedy, ED Bridges, CB Lu, PJ Kahn, KE Grohskopf, LA Ahluwalia, IB Sokolowski, J DiSogra, C Walker, DK Greby, SM AF Ding, Helen Black, Carla L. Ball, Sarah Donahue, Sara Izrael, David Williams, Walter W. Kennedy, Erin D. Bridges, Carolyn B. Lu, Peng-Jun Kahn, Katherine E. Grohskopf, Lisa A. Ahluwalia, Indu B. Sokolowski, John DiSogra, Charles Walker, Deborah K. Greby, Stacie M. TI Influenza Vaccination Coverage Among Pregnant Women - United States, 2013-14 Influenza Season SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID DISPARITIES C1 [Ding, Helen; Black, Carla L.; Williams, Walter W.; Kennedy, Erin D.; Bridges, Carolyn B.; Lu, Peng-Jun; Kahn, Katherine E.; Greby, Stacie M.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Ball, Sarah; Donahue, Sara; Izrael, David; Walker, Deborah K.] ABT Associates Inc, Cambridge, MA 02138 USA. [Grohskopf, Lisa A.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Ahluwalia, Indu B.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Sokolowski, John; DiSogra, Charles] Abt SRBI, New York, NY USA. RP Ding, H (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM hding@cdc.gov NR 8 TC 35 Z9 35 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 19 PY 2014 VL 63 IS 37 BP 816 EP 821 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1WC UT WOS:000342573500003 PM 25233283 ER PT J AU Tomczyk, S Bennett, NM Stoecker, C Gierke, R Moore, MR Whitney, CG Hadler, S Pilishvili, T AF Tomczyk, Sara Bennett, Nancy M. Stoecker, Charles Gierke, Ryan Moore, Matthew R. Whitney, Cynthia G. Hadler, Stephen Pilishvili, Tamara TI Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >= 65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID NAIVE ADULTS; IMMUNOGENICITY; SAFETY; OLDER C1 [Tomczyk, Sara] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Tomczyk, Sara; Gierke, Ryan; Moore, Matthew R.; Whitney, Cynthia G.; Hadler, Stephen; Pilishvili, Tamara] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Bennett, Nancy M.] Advisory Comm Immunizat Practices, Pneumococcal Vaccines Working Grp, London, England. [Bennett, Nancy M.] Univ Rochester, Med Ctr, Sch Med & Dent, Rochester, NY 14642 USA. [Stoecker, Charles] Tulane Univ Publ Hlth & Trop Med, Dept Global Hlth Syst & Dev, New Orleans, LA USA. RP Pilishvili, T (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM tdp4@cdc.gov NR 16 TC 167 Z9 172 U1 0 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 19 PY 2014 VL 63 IS 37 BP 822 EP 825 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1WC UT WOS:000342573500004 PM 25233284 ER PT J AU Curtis, KA Ambrose, KM Kennedy, MS Owen, SM AF Curtis, Kelly A. Ambrose, Krystin M. Kennedy, M. Susan Owen, S. Michele TI Evaluation of Dried Blood Spots with a Multiplex Assay for Measuring Recent HIV-1 Infection SO PLOS ONE LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; POLYMERASE-CHAIN-REACTION; BED ENZYME-IMMUNOASSAY; AVIDITY INDEX; UNITED-STATES; ANTIBODIES; SPECIMENS; SEROCONVERSION AB Laboratory-based HIV tests for recent infection (TRIs), which primarily measure a specific serological biomarker(s) that distinguishes recent from long-term HIV infection, have facilitated the estimation of population-based incidence. Dried blood spots (DBS) on filter paper are an attractive sample source for HIV surveillance, given the simplified and cost-effective methods of specimen collection, storage, and shipment. Here, we evaluated the use of DBS in conjunction with an in-house multiplex TRI, the HIV-1-specific Bio-Plex assay, which measures direct antibody binding and avidity to multiple HIV-1 analytes. The assay performance was comparable between matched plasma and DBS samples from HIV-1 infected individuals obtained from diverse sources. The coefficients of variation, comparing the median antibody reactivity for each analyte between plasma and DBS, ranged from 2.78% to 9.40% and the correlation coefficients between the two sample types ranged from 0.89 to 0.97, depending on the analyte. The correlation in antibody reactivity between laboratory and site-prepared DBS for each analyte ranged from 0.87 to 0.98 and from 0.90 to 0.97 between site-prepared DBS and plasma. The correlation in assay measures between plasma and DBS indicate that the sample types can be used interchangeably with the Bio-Plex format, without negatively impacting the misclassification rate of the assay. C1 [Curtis, Kelly A.; Ambrose, Krystin M.; Kennedy, M. Susan; Owen, S. Michele] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Curtis, KA (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM czv2@cdc.gov FU Centers for Disease Control and Prevention FX This study was supported with intramural funding from the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the official view of the Centers for Disease Control and Prevention. NR 31 TC 2 Z9 2 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 18 PY 2014 VL 9 IS 9 AR e107153 DI 10.1371/journal.pone.0107153 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ6KR UT WOS:000342921200015 PM 25232736 ER PT J AU Goff, LW Thakkar, N Du, LP Chan, E Tan, BR Cardin, DB McLeod, HL Berlin, JD Zehnbauer, B Fournier, C Picus, J Wang-Gillam, A Lee, W Lockhart, AC AF Goff, Laura W. Thakkar, Nilay Du, Liping Chan, Emily Tan, Benjamin R. Cardin, Dana B. McLeod, Howard L. Berlin, Jordan D. Zehnbauer, Barbara Fournier, Chloe Picus, Joel Wang-Gillam, Andrea Lee, Wooin Lockhart, A. Craig TI Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers SO PLOS ONE LA English DT Article ID SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT SEQUENCE; PHASE-II; 1ST-LINE TREATMENT; COLORECTAL-CANCER; FOLINIC ACID; GENETIC POLYMORPHISMS; ENHANCER REGION; MESSENGER-RNA; ADJUVANT CHEMOTHERAPY AB Background: Retrospective studies indicate associations between TSER (thymidylate synthase enhancer region) genotypes and clinical outcomes in patients receiving 5-FU based chemotherapy, but well-controlled prospective validation has been lacking. Methods: In this phase II study (NCT00515216 registered through ClinicalTrials.gov, http://clinicaltrials.gov/show/NCT00515216), patients with "good risk'' TSER genotypes (at least one TSER*2 allele) were treated with FOLFOX chemotherapy to determine whether prospective patient selection can improve overall response rates (ORR) in patients with gastric and gastroesophageal junction (GEJ) cancers, compared with historical outcomes in unselected patients (estimated 43%). Results: The ORR in genotype-selected patients was 39.1% (9 partial responses out of 23 evaluable patients, 95% CI, 22.2 to 59.2), not achieving the primary objective of improving ORR. An encouraging disease control rate (DCR, consisting of partial responses and stable diseases) of 95.7% was noted and patients with homozygous TSER*2 genotype showed better tumor response. Conclusions: In this first prospective, multi-institutional study in patients with gastric or GEJ cancers, selecting patients with at least one TSER*2 allele did not improve the ORR but led to an encouraging DCR. Further studies are needed to investigate the utility of selecting patients homozygous for the TSER*2 allele and additional genomic markers in improving clinical outcomes for patients with gastric and GEJ cancers. C1 [Goff, Laura W.; Du, Liping; Chan, Emily; Cardin, Dana B.; Berlin, Jordan D.] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA. [Thakkar, Nilay; Lee, Wooin] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA. [Tan, Benjamin R.; Fournier, Chloe; Picus, Joel; Wang-Gillam, Andrea; Lockhart, A. Craig] Washington Univ, Sch Med, Dept Med, Siteman Canc Ctr, St Louis, MO 63110 USA. [McLeod, Howard L.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Zehnbauer, Barbara] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Lockhart, AC (reprint author), Washington Univ, Sch Med, Dept Med, Siteman Canc Ctr, St Louis, MO 63110 USA. EM alockhar@dom.wustl.edu OI Lee, Wooin/0000-0001-7805-869X; Thakkar, Nilay/0000-0002-2846-5796 FU National Cancer Institute, NIH [R21 CA123881, K23 CA098011]; National Center for Research resources, NIH [5 M01 RR-000095]; BJC Foundation Cancer Frontier Fund; Sanofi-Aventis FX This study was supported in part by the grants from the National Cancer Institute, NIH (R21 CA123881, K23 CA098011), the National Center for Research resources, NIH (5 M01 RR-000095). Additional funding was provided by BJC Foundation Cancer Frontier Fund and Sanofi-Aventis. The authors confirm that the funding agencies, with the exception of the NIH, had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 0 Z9 2 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 18 PY 2014 VL 9 IS 9 AR e107424 DI 10.1371/journal.pone.0107424 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ6KR UT WOS:000342921200030 PM 25232828 ER PT J AU O'Reilly, CE Taylor, EV Ayers, T Fantu, R Abayneh, SA Marston, B Molla, YB Sewnet, T Abebe, F Hoekstra, RM Quick, R AF O'Reilly, Ciara E. Taylor, Ethel V. Ayers, Tracy Fantu, Ribka Abayneh, Sisay Alemayehu Marston, Barbara Molla, Yordanos B. Sewnet, Tegene Abebe, Fitsum Hoekstra, Robert M. Quick, Robert TI Improved Health among People Living with HIV/AIDS Who Received Packages of Proven Preventive Health Interventions, Amhara, Ethiopia SO PLOS ONE LA English DT Article ID POINT-OF-USE; USE WATER-TREATMENT; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED ADULTS; COTRIMOXAZOLE PROPHYLAXIS; VIRAL LOAD; ANTIRETROVIRAL THERAPY; TREATING COINFECTIONS; COST-EFFECTIVENESS; RURAL GUATEMALA AB In 2009, basic care packages (BCP) containing health products were distributed to HIV-infected persons in Ethiopia who were clients of antiretroviral therapy clinics. To measure health impact, we enrolled clients from an intervention hospital and comparison hospital, and then conducted a baseline survey, and 7 bi-weekly home visits. We enrolled 405 intervention group clients and 344 comparison clients. Intervention clients were more likely than comparison clients to have detectable chlorine in stored water (40% vs. 1%, p<0.001), soap (51% vs. 36%, p<0.001), and a BCP water container (65% vs. 0%, p<0.001) at every home visit. Intervention clients were less likely than comparison clients to report illness (44% vs. 67%, p<0.001) or health facility visits for illness (74% vs. 95%, p<0.001), and had lower median illness scores (1.0 vs. 3.0, p<0.05). Participation in the BCP program appeared to improve reported health outcomes. C1 [O'Reilly, Ciara E.; Taylor, Ethel V.; Ayers, Tracy; Hoekstra, Robert M.; Quick, Robert] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Taylor, Ethel V.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Fantu, Ribka; Abayneh, Sisay Alemayehu] Ctr Dis Control & Prevent, Addis Ababa, Ethiopia. [Marston, Barbara] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Molla, Yordanos B.; Sewnet, Tegene; Abebe, Fitsum] Michael Dejene Publ Hlth Consultancy Serv, Addis Ababa, Ethiopia. RP O'Reilly, CE (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM bwf1@cdc.gov OI Ayers, Tracy/0000-0003-4140-3263 FU US President's Emergency Plan for AIDS Relief; Global AIDS Program; Centers for Disease Control and Prevention, Ethiopia; U.S. Agency for International Development through an Inter-Agency Agreement; U.S. Centers for Disease Control and Prevention FX Funding for the study was provided by the US President's Emergency Plan for AIDS Relief, Global AIDS Program, and Centers for Disease Control and Prevention, Ethiopia. Additional support for technical assistance was provided by the U.S. Agency for International Development through an Inter-Agency Agreement with the U.S. Centers for Disease Control and Prevention. Michael Dejene Public Health Consultancy Services was formally contracted by the Centers for Disease Control and Prevention, Ethiopia to carry out the data collection component of this study only. Co-authors YM, TS, and FA were employed by Michael Dejene Public Health Consultancy Services, Addis Ababa, Ethiopia. NR 37 TC 1 Z9 1 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 18 PY 2014 VL 9 IS 9 AR e107662 DI 10.1371/journal.pone.0107662 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ6KR UT WOS:000342921200041 PM 25233345 ER PT J AU Horton, DK Mehta, P Antao, VC AF Horton, D. Kevin Mehta, Paul Antao, Vinicius C. TI Quantifying a Nonnotifiable Disease in the United States The National Amyotrophic Lateral Sclerosis Registry Model SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Horton, D. Kevin; Mehta, Paul; Antao, Vinicius C.] Agcy Tox Subst & Dis Registry, Atlanta, GA 30341 USA. RP Horton, DK (reprint author), Agcy Tox Subst & Dis Registry, 4770 Buford Hwy,Mailstop F-58, Atlanta, GA 30341 USA. EM dhorton@cdc.gov FU Intramural CDC HHS [CC999999] NR 5 TC 3 Z9 3 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 17 PY 2014 VL 312 IS 11 BP 1097 EP 1098 DI 10.1001/jama.2014.9799 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AO8SN UT WOS:000341624700016 PM 25057819 ER PT J AU Ford, ES Maynard, LM Li, CY AF Ford, Earl S. Maynard, Leah M. Li, Chaoyang TI Trends in Mean Waist Circumference and Abdominal Obesity Among US Adults, 1999-2012 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID UNITED-STATES C1 [Ford, Earl S.; Maynard, Leah M.; Li, Chaoyang] US Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), US Ctr Dis Control & Prevent, 4770 Buford Hwy, Atlanta, GA 30341 USA. EM eford@cdc.gov FU Intramural CDC HHS [CC999999] NR 6 TC 44 Z9 44 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 17 PY 2014 VL 312 IS 11 BP 1151 EP 1153 DI 10.1001/jama.2014.8362 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AO8SN UT WOS:000341624700026 PM 25226482 ER PT J AU Gwinn, M Ioannidis, JP Little, J Khoury, MJ AF Gwinn, Marta Ioannidis, John P. Little, Julian Khoury, Muin J. TI Editorial: Updated Guidance on Human Genome Epidemiology (HuGE) Reviews and Meta-Analyses of Genetic Associations SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Editorial Material ID SYSTEMATIC REVIEWS; CANCER; GWAS; SNP C1 [Gwinn, Marta] McKing Consulting Corp, Atlanta, GA USA. [Ioannidis, John P.] Stanford Univ, Stanford Prevent Res Ctr, Palo Alto, CA 94304 USA. [Little, Julian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, CSELS, OPHSS, Atlanta, GA 30333 USA. RP Khoury, MJ (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, 1600 Clifton Rd,Mailstop E-61, Atlanta, GA 30333 USA. EM MKhoury@cdc.gov NR 18 TC 1 Z9 1 U1 1 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD SEP 15 PY 2014 VL 180 IS 6 BP 559 EP 561 DI 10.1093/aje/kwu196 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ7XK UT WOS:000343033400001 PM 25164421 ER PT J AU Havers, F Thaker, S Clippard, JR Jackson, M McLean, HQ Gaglani, M Monto, AS Zimmerman, RK Jackson, L Petrie, JG Nowalk, MP Moehling, KK Flannery, B Thompson, MG Fry, AM AF Havers, Fiona Thaker, Swathi Clippard, Jessie R. Jackson, Michael McLean, Huong Q. Gaglani, Manjusha Monto, Arnold S. Zimmerman, Richard K. Jackson, Lisa Petrie, Josh G. Nowalk, Mary Patricia Moehling, Krissy K. Flannery, Brendan Thompson, Mark G. Fry, Alicia M. TI Use of Influenza Antiviral Agents by Ambulatory Care Clinicians During the 2012-2013 Influenza Season SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE ambulatory care; antiviral treatment; influenza; neuraminidase inhibitors ID RESPIRATORY-TRACT INFECTIONS; UNITED-STATES; 2009 H1N1; A H1N1; METAANALYSIS; OSELTAMIVIR; CHILDREN; ADULTS; COMPLICATIONS; PREDICTORS AB Background. Early antiviral treatment (<= 2 days since illness onset) of influenza reduces the probability of influenza-associated complications. Early empiric antiviral treatment is recommended for those with suspected influenza at higher risk for influenza complications regardless of their illness severity. We describe antiviral receipt among outpatients with acute respiratory illness (ARI) and antibiotic receipt among patients with influenza. Methods. We analyzed data from 5 sites in the US Influenza Vaccine Effectiveness Network Study during the 2012-2013 influenza season. Subjects were outpatients aged >= 6 months with ARI defined by cough of <= 7 days' duration; all were tested for influenza by polymerase chain reaction (PCR). Medical history and prescription information were collected bymedical and pharmacy records. Four sites collected prescribing data on 3 common antibiotics (amoxicillin-clavulanate, amoxicillin, and azithromycin). Results. Of 6766 enrolled ARI patients, 509 (7.5%) received an antiviral prescription. Overall, 2366 (35%) had PCR-confirmed influenza; 355 (15%) of those received an antiviral prescription. Among 1021 ARI patients at high risk for influenza complications (eg, aged <2 years or >= 65 years or with >= 1 chronic medical condition) presenting to care <= 2 days from symptom onset, 195 (19%) were prescribed an antiviral medication. Among participants with PCR-confirmed influenza and antibiotic data, 540 of 1825 (30%) were prescribed 1 of 3 antibiotics; 297 of 1825 (16%) were prescribed antiviral medications. Conclusions. Antiviral treatment was prescribed infrequently among outpatients with influenza for whom therapy would be most beneficial; in contrast, antibiotic prescribing was more frequent. Continued efforts to educate clinicians on appropriate antibiotic and antiviral use are essential to improve healthcare quality. C1 [Havers, Fiona] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Influenza Div, Atlanta, GA 30333 USA. [Havers, Fiona; Thaker, Swathi; Clippard, Jessie R.; Flannery, Brendan; Thompson, Mark G.; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Jackson, Michael; Jackson, Lisa] Grp Hlth Res Inst, Seattle, WA USA. [McLean, Huong Q.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Gaglani, Manjusha] Texas A&M Univ, Coll Med, Hlth Sci Ctr, Baylor Scott & White Hlth, Temple, TX 76508 USA. [Monto, Arnold S.; Petrie, Josh G.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Zimmerman, Richard K.; Nowalk, Mary Patricia; Moehling, Krissy K.] Univ Pittsburgh, Dept Family Med, Pittsburgh, PA 15260 USA. RP Havers, F (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. EM fhavers@cdc.gov OI Zimmerman, Richard/0000-0001-5941-6092 FU CDC through University of Michigan [U01 IP000474]; CDC through Group Health Research Institute [U01 IP000466]; CDC through Marshfield Clinic Research Foundation [U01 IP000471]; CDC through University of Pittsburgh [U01 IP000467]; CDC through Scott & White Healthcare [U01 IP000473]; National Institutes of Health [UL1 RR024153, UL1TR000005] FX This work was supported by the CDC through co-operative agreements with the University of Michigan (U01 IP000474), Group Health Research Institute (U01 IP000466), Marshfield Clinic Research Foundation (U01 IP000471), University of Pittsburgh (U01 IP000467), and Scott & White Healthcare (U01 IP000473). The project described was also supported by the National Institutes of Health (grant numbers UL1 RR024153 and UL1TR000005). NR 32 TC 13 Z9 13 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2014 VL 59 IS 6 BP 774 EP 782 DI 10.1093/cid/ciu422 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KU UT WOS:000342921700008 PM 25034419 ER PT J AU Liu, B Havers, F Chen, EF Yuan, ZG Yuan, H Ou, JM Shang, M Kang, K Liao, KJ Liu, FQ Li, D Ding, H Zhou, L Zhu, WP Ding, F Zhang, P Wang, XY Yao, JY Xiang, NJ Zhou, SZ Liu, XQ Song, Y Su, HL Wang, R Cai, J Cao, Y Wang, XJ Bai, T Wang, JJ Feng, ZJ Zhang, YP Widdowson, MA Li, Q AF Liu, Bo Havers, Fiona Chen, Enfu Yuan, Zhengan Yuan, Hui Ou, Jianming Shang, Mei Kang, Kai Liao, Kaiju Liu, Fuqiang Li, Dan Ding, Hua Zhou, Lei Zhu, Weiping Ding, Fan Zhang, Peng Wang, Xiaoye Yao, Jianyi Xiang, Nijuan Zhou, Suizan Liu, Xiaoqin Song, Ying Su, Hualin Wang, Rui Cai, Jian Cao, Yang Wang, Xianjun Bai, Tian Wang, Jianjun Feng, Zijian Zhang, Yanping Widdowson, Marc-Alain Li, Qun TI Risk Factors for Influenza A(H7N9) Disease-China, 2013 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE avian influenza; avian influenza A(H7N9) virus; China; H7N9 ID A H7N9 VIRUS; HUMAN INFECTIONS; TRANSMISSION; FERRETS; EPIDEMIOLOGY; MORTALITY; AGE AB Background. The majority of human cases of novel avian influenza A(H7N9), which emerged in China in spring 2013, include reported exposure to poultry. However, specific host and exposure risk factors for disease are unknown, yet critical to design prevention measures. Methods. In April-June 2013, we conducted a case-control study in 8 Chinese provinces. Patients with laboratory-confirmed A(H7N9) (n = 89) were matched by age, sex, and neighborhood to controls (n = 339). Subjects completed a questionnaire on medical history and potential exposures, including poultry markets and other poultry exposure. We used conditional logistic regression to calculate matched and adjusted odds ratios (ORs) for the association of A(H7N9) virus infection with potential risk factors. Results. Fifty-five percent of patients compared with 31% of controls reported any contact with poultry (matched OR [mOR], 7.8; 95% confidence interval [CI], 3.3-18.8). Sixty-seven percent of patients compared with 35% of controls visited a live poultry market (mOR, 5.4; CI, 3.0-9.7). Visiting live poultry markets increased risk of infection even after adjusting for poultry contact and other confounders (adjusted OR, 3.4; CI, 1.8-6.7). Backyard poultry were not associated with increased risk; 14% of cases did not report any poultry exposure or market visit. Obesity (mOR, 4.7; CI, 1.8-12.4), chronic obstructive pulmonary disease (mOR, 2.7; CI, 1.1-6.9), and immunosuppressive medications (mOR, 9.0; CI, 1.7-47.2) were associated with A(H7N9) disease. Conclusion. Exposures to poultry in markets were associated with A(H7N9) virus infection, even without poultry contact. China should consider permanently closing live poultry markets or aggressively pursuing control measures to prevent spread of this emerging pathogen. C1 [Liu, Bo; Liao, Kaiju; Li, Dan; Zhou, Lei; Ding, Fan; Wang, Xiaoye; Yao, Jianyi; Xiang, Nijuan; Wang, Rui; Cao, Yang; Feng, Zijian; Zhang, Yanping; Li, Qun] Chinese Ctr Dis Control & Prevent, Publ Hlth Emergency Ctr, Beijing 102206, Peoples R China. [Havers, Fiona] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Influenza Div, Atlanta, GA USA. [Chen, Enfu; Cai, Jian] Zhejiang Prov Ctr Dis Control & Prevent, Influenza Div, Hangzhou, Zhejiang, Peoples R China. [Yuan, Zhengan] Shanghai Municipal Ctr Dis Control & Prevent, Fuzhou, Peoples R China. [Ou, Jianming] Fujian Prov Ctr Dis Control & Prevent, Fuzhou, Peoples R China. [Shang, Mei; Zhou, Suizan; Song, Ying] US Ctr Dis Control & Prevent, China Off, Beijing, Peoples R China. [Kang, Kai] Henan Prov Ctr Dis Control & Prevent, Zhengzhou, Peoples R China. [Liu, Fuqiang] Hunan Prov Ctr Dis Control & Prevent, Changsha, Hunan, Peoples R China. [Ding, Hua] Zhejiang Hangzhou Ctr Dis Control & Prevent, Hangzhou, Zhejiang, Peoples R China. [Zhu, Weiping] Shanghai Pudong New Area Ctr Dis Control & Preven, Shanghai, Peoples R China. [Zhang, Peng] Zhejiang Huzhou Ctr Dis Control & Prevent, Hangzhou, Zhejiang, Peoples R China. [Yuan, Hui; Liu, Xiaoqin] Jiangxi Prov Ctr Dis Control & Prevent, Nanchang, Peoples R China. [Su, Hualin] Shanghai Minhang Dist Ctr Dis Control & Prevent, Jinan, Peoples R China. [Wang, Xianjun] Shandong Prov Ctr Dis Control & Prevent, Jinan, Peoples R China. [Bai, Tian] Chinese Ctr Dis Control & Prevent, Inst Viral Dis Control & Prevent, Beijing, Peoples R China. [Wang, Jianjun] Anhui Prov Ctr Dis Control & Prevent, Hefei, Peoples R China. [Widdowson, Marc-Alain] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Li, Q (reprint author), Chinese Ctr Dis Control & Prevent, Publ Hlth Emergency Ctr, 155 Changbai Rd, Beijing 102206, Peoples R China. EM liqun@chinacdc.cn FU Ministry of Science and Technology of China, Emergency Technology Research Issue on Prevention and Control for Human Infection with A(H7N9) Avian Influenza Virus; China-US Collaborative Program on Emerging and Re-emerging Infectious Disease FX This study is funded by the Ministry of Science and Technology of China, Emergency Technology Research Issue on Prevention and Control for Human Infection with A(H7N9) Avian Influenza Virus and the China-US Collaborative Program on Emerging and Re-emerging Infectious Disease. NR 28 TC 32 Z9 35 U1 4 U2 20 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2014 VL 59 IS 6 BP 787 EP 794 DI 10.1093/cid/ciu423 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KU UT WOS:000342921700010 PM 24928293 ER PT J AU Cohen, C von Mollendorf, C de Gouveia, L Naidoo, N Meiring, S Quan, V Nokeri, V Fortuin-de Smit, M Malope-Kgokong, B Moore, D Reubenson, G Moshe, M Madhi, SA Eley, B Hallbauer, U Kularatne, R Conklin, L O'Brien, KL Zell, ER Klugman, K Whitney, CG von Gottberg, A AF Cohen, Cheryl von Mollendorf, Claire de Gouveia, Linda Naidoo, Nireshni Meiring, Susan Quan, Vanessa Nokeri, Vusi Fortuin-de Smit, Melony Malope-Kgokong, Babatyi Moore, David Reubenson, Gary Moshe, Mamokgethi Madhi, Shabir A. Eley, Brian Hallbauer, Ute Kularatne, Ranmini Conklin, Laura O'Brien, Katherine L. Zell, Elizabeth R. Klugman, Keith Whitney, Cynthia G. von Gottberg, Anne CA South African Invasive Pneumoco TI Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in HIV-Infected and -Uninfected Children in South Africa: A Matched Case-Control Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE children; HIV; pneumococcus; pneumococcal conjugate vaccine; South Africa ID IMMUNIZATION PROGRAM; INFANTS; IMMUNOGENICITY; TRIAL; 1ST; METAANALYSIS; SCHEDULES; EFFICACY; IMPACT AB Background. South Africa introduced 7-valent pneumococcal conjugate vaccine (PCV7) in April 2009 using a 2 + 1 schedule (6 and 14 weeks and 9 months). We estimated the effectiveness of >= 2 PCV7 doses against invasive pneumococcal disease (IPD) in human immunodeficiency virus (HIV)-infected and -uninfected children. Methods. IPD (pneumococcus identified from a normally sterile site) cases were identified through national laboratory-based surveillance. Specimens were serotyped by Quellung or polymerase chain reaction. Four controls, matched for age, HIV status, and hospital were sought for each case. Using conditional logistic regression, we calculated vaccine effectiveness (VE) as 1 minus the adjusted odds ratio for vaccination. Results. From March 2010 through November 2012, we enrolled 187 HIV-uninfected (48 [26%] vaccine serotype) and 109 HIV-infected (43 [39%] vaccine serotype) cases and 752 HIV-uninfected and 347 HIV-infected controls aged >= 16 weeks. Effectiveness of >= 2 PCV7 doses against vaccine-serotype IPD was 74% (95% confidence interval [CI], 25%-91%) among HIV-uninfected and -12% (95% CI, -449% to 77%) among HIV-infected children. Effectiveness of >= 3 doses against vaccine-serotype IPD was 90% (95% CI, 14%-99%) among HIV-uninfected and 57% (95% CI, -371% to 96%) among HIV-infected children. Among HIV-exposed but -uninfected children, effectiveness of >= 2 doses was 92% (95% CI, 47%-99%) against vaccine-serotype IPD. Effectiveness of >= 2 doses against all-serotype multidrug-resistant IPD was 96% (95% CI, 62%-100%) among HIV-uninfected children. Conclusions. A 2 + 1 PCV7 schedule was effective in preventing vaccine-serotype IPD in HIV-uninfected and HIV-exposed, uninfected children. This finding supports the World Health Organization recommendation for this schedule as an alternative to a 3-dose primary series among HIV-uninfected individuals. C1 [Cohen, Cheryl; von Mollendorf, Claire; de Gouveia, Linda; Naidoo, Nireshni; Nokeri, Vusi; Malope-Kgokong, Babatyi; Madhi, Shabir A.; von Gottberg, Anne] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Ctr Resp Dis & Meningitis, ZA-2131 Johannesburg, South Africa. [Cohen, Cheryl; von Mollendorf, Claire; Naidoo, Nireshni] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, ZA-2050 Johannesburg, South Africa. [Meiring, Susan; Quan, Vanessa; Fortuin-de Smit, Melony] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Div Publ Hlth Surveillance & Response, ZA-2131 Johannesburg, South Africa. [Moore, David; Madhi, Shabir A.] Natl Res Fdn Vaccine Preventable Dis, Dept Sci & Technol, Johannesburg, South Africa. [Reubenson, Gary] Univ Witwatersrand, Fac Hlth Sci, Dept Paediat & Child Hlth, Rahima Moosa Mother & Child Hosp, ZA-2050 Johannesburg, South Africa. [Moshe, Mamokgethi] Medunsa Univ, Dr George Mukhari Hosp, Dept Paediat, Polokwane, Gauteng Provinc, South Africa. [Madhi, Shabir A.; Klugman, Keith; von Gottberg, Anne] Univ Witwatersrand, Sch Pathol, Johannesburg, South Africa. [Madhi, Shabir A.; Klugman, Keith; von Gottberg, Anne] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Eley, Brian] Univ Cape Town, Red Cross War Mem Childrens Hosp, ZA-7700 Rondebosch, South Africa. [Eley, Brian] Univ Cape Town, Dept Paediat & Child Hlth, ZA-7700 Rondebosch, South Africa. [Hallbauer, Ute] Univ Orange Free State, Dept Paediat & Child Hlth, Univ & Pelonomi Hosp, Bloemfontein, South Africa. [Kularatne, Ranmini] Univ Witwatersrand, Fac Hlth Sci, Dept Clin Microbiol, Rahima Moosa Mother & Child Hosp, Johannesburg, South Africa. [Kularatne, Ranmini] Natl Hlth Lab Serv, Johannesburg, South Africa. [Conklin, Laura; Zell, Elizabeth R.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [O'Brien, Katherine L.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Klugman, Keith] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA USA. [Klugman, Keith] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. RP Cohen, C (reprint author), Natl Inst Communicable Dis, Ctr Resp & Meningitis, Private Bag X4, ZA-2131 Johannesburg, South Africa. EM cherylc@nicd.ac.za FU GAVI through PATH FX This work was supported by GAVI through PATH. NR 35 TC 13 Z9 14 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2014 VL 59 IS 6 BP 808 EP 818 DI 10.1093/cid/ciu431 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KU UT WOS:000342921700013 PM 24917657 ER PT J AU Brett, ME Respicio-Kingry, LB Yendell, S Ratard, R Hand, J Balsamo, G Scott-Waldron, C O'Neal, C Kidwell, D Yockey, B Singh, P Carpenter, J Hill, V Petersen, JM Mead, P AF Brett, Meghan E. Respicio-Kingry, Laurel B. Yendell, Stephanie Ratard, Raoult Hand, Julie Balsamo, Gary Scott-Waldron, Christine O'Neal, Catherine Kidwell, Donna Yockey, Brook Singh, Preety Carpenter, Joseph Hill, Vincent Petersen, Jeannine M. Mead, Paul TI Outbreak of Francisella novicida Bacteremia Among Inmates at a Louisiana Correctional Facility SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Francisella novicida; ice; outbreak; prison ID ENVIRONMENTAL-SAMPLES; TULARENSIS; WATER; PCR; IDENTIFICATION; TULAREMIA; STRAINS; DIVERSE; GENUS AB Background. Francisella novicida is a rare cause of human illness despite its close genetic relationship to Francisella tularensis, the agent of tularemia. During April-July 2011, 3 inmates at a Louisiana correctional facility developed F. novicida bacteremia; 1 inmate died acutely. Methods. We interviewed surviving inmates; reviewed laboratory, medical, and housing records; and conducted an environmental investigation. Clinical and environmental samples were tested by culture, real-time polymerase chain reaction (PCR), and multigene sequencing. Isolates were typed by pulsed-field gel electrophoresis (PFGE). Results. Clinical isolates were identified as F. novicida based on sequence analyses of the 16S ribosomal RNA, pgm, and pdpD genes. PmeI PFGE patterns for the clinical isolates were indistinguishable. Source patients were aged 40-56 years, male, and African American, and all were immunocompromised. Two patients presented with signs of bacterial peritonitis; the third had pyomyositis of the thigh. The 3 inmates had no contact with one another; their only shared exposures were consumption of municipal water and of ice that was mass-produced at the prison in an unenclosed building. Swabs from one set of ice machines and associated ice scoops yielded evidence of F. novicida by PCR and sequencing. All other environmental specimens tested negative. Conclusions. To our knowledge, this is the first reported common-source outbreak of F. novicida infections in humans. Epidemiological and laboratory evidence implicate contaminated ice as the likely vehicle of transmission; liver disease may be a predisposing factor. Clinicians, laboratorians, and public health officials should be aware of the potential for misidentification of F. novicida as F. tularensis. C1 [Brett, Meghan E.; Yendell, Stephanie] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Atlanta, GA USA. [Brett, Meghan E.; Respicio-Kingry, Laurel B.; Yockey, Brook; Petersen, Jeannine M.; Mead, Paul] CDC, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Yendell, Stephanie] CDC, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Ratard, Raoult; Hand, Julie; Balsamo, Gary; Scott-Waldron, Christine] Louisiana Off Publ Hlth, New Orleans, LA USA. [O'Neal, Catherine] Louisiana State Univ, Med Ctr, Baton Rouge, LA 70803 USA. [Kidwell, Donna] Shreveport Reg Lab, Louisiana Off Publ Hlth, Shreveport, LA USA. [Singh, Preety] Louisiana Dept Correct, Baton Rouge, LA USA. [Carpenter, Joseph] CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Hill, Vincent] CDC, Waterborne Dis Prevent Branch, Atlanta, GA 30333 USA. RP Mead, P (reprint author), CDC, Bacterial Dis Branch, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM pfm0@cdc.gov RI Hill, Vincent/G-1789-2012 OI Hill, Vincent/0000-0001-7069-7737 FU State of Louisiana; Centers for Disease Control and Prevention FX We thank John Young for laboratory assistance and Kiersten Kugeler and Alison Hinckley for their critical review of the manuscript. This work was conducted as part of public health investigation supported by the State of Louisiana and the Centers for Disease Control and Prevention. NR 28 TC 4 Z9 4 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2014 VL 59 IS 6 BP 826 EP 833 DI 10.1093/cid/ciu430 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KU UT WOS:000342921700015 PM 24944231 ER PT J AU Muehlenbachs, A Fata, CR Lambert, AJ Paddock, CD Velez, JO Blau, DM Staples, JE Karlekar, MB Bhatnagar, J Nasci, RS Zaki, SR AF Muehlenbachs, Atis Fata, Cynthia R. Lambert, Amy J. Paddock, Christopher D. Velez, Jason O. Blau, Dianna M. Staples, J. Erin Karlekar, Mohana B. Bhatnagar, Julu Nasci, Roger S. Zaki, Sherif R. TI Heartland Virus-Associated Death in Tennessee SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE autopsy; Heartland virus; pathology; tick-borne illness; unexplained death ID THROMBOCYTOPENIA SYNDROME; SEVERE FEVER; UNITED-STATES; CHINA; PHLEBOVIRUS; DISEASE AB Background. Heartland virus (HRTV) is a tick-borne phlebovirus recently described in Missouri that is associated with fever, leukopenia, and thrombocytopenia. The virus has also been detected in Ambylomma americanum ticks. Methods. Here we report the first fatal case of HRTV disease in an 80-year-old Tennessee resident. He was hospitalized with fever, confusion, leukopenia, and thrombocytopenia and developed multiorgan failure and hemorrhage. A tick-borne illness was suspected and testing for ehrlichiosis was negative. He died on hospital day 15, and autopsy specimens were tested for various pathogens as part of an unexplained death evaluation. Results. HRTV antigens were detected in postmortem spleen and lymph nodes by immunohistochemistry, and HRTV was detected in premortem blood by reverse transcription polymerase chain reaction and by isolation in cell culture. Conclusions. This case demonstrates that HRTV infection can cause severe disease and death and expands the geographic range of HRTV within the United States. C1 [Muehlenbachs, Atis; Paddock, Christopher D.; Blau, Dianna M.; Bhatnagar, Julu; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30329 USA. [Fata, Cynthia R.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA. [Karlekar, Mohana B.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Lambert, Amy J.; Velez, Jason O.; Staples, J. Erin; Nasci, Roger S.] Ctr Dis Control & Prevent, Arbovirus Dis Branch, Div Vector Borne Infect Dis, Ft Collins, CO USA. RP Muehlenbachs, A (reprint author), Ctr Dis Control & Prevent, Infect Dis Pathol Branch, NCEZID, 1600 Clifton Rd NE,MS G32, Atlanta, GA 30329 USA. EM vkd6@cdc.gov FU CDC FX This work was supported by the CDC. NR 18 TC 17 Z9 17 U1 0 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2014 VL 59 IS 6 BP 845 EP 850 DI 10.1093/cid/ciu434 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KU UT WOS:000342921700018 PM 24917656 ER PT J AU Panneer, N Lontok, E Branson, BM Teo, CG Dan, C Parker, M Stekler, JD DeMaria, A Miller, V AF Panneer, Nivedha Lontok, Erik Branson, Bernard M. Teo, Chong-Gee Dan, Corinna Parker, Monica Stekler, Joanne D. DeMaria, Alfred, Jr. Miller, Veronica TI HIV and Hepatitis C Virus Infection in the United States: Whom and How to Test SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HCV; hepatitis C virus; HIV; nucleic acid test; testing algorithm ID ALL-CAUSE MORTALITY; DIAGNOSTIC ALGORITHM; HCV INFECTION; PREVENTION; PERFORMANCE; POPULATION; DISEASES; UPDATE; HEALTH; ASSAY AB In the United States, of the 1.1 million persons infected with human immunodeficiency virus (HIV) and the 2.7 million infected with hepatitis C virus (HCV), approximately 16% and 50%, respectively, are unaware of their infection. Highly effective treatments have turned both diseases into manageable conditions, and in the case of hepatitis C, a disease that can be cured. Early diagnosis is imperative so that infected persons can take measures to stay healthy, get into care, benefit from therapy, and reduce the risk of transmission. In this report, we review current recommendations provided by the Centers for Disease Control and Prevention (CDC) and the United States Preventive Services Task Force on whom to screen for HIV and HCV infections, and recommendations from the CDC, the Association of Public Health Laboratories, and the Clinical and Laboratory Standards Institute on how to test for these infections. C1 [Panneer, Nivedha; Lontok, Erik; Miller, Veronica] Univ Calif Berkeley, Forum Collaborat HIV Res, Washington, DC 20036 USA. [Branson, Bernard M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Teo, Chong-Gee] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Viral Hepatitis Lab Diagnost, Atlanta, GA USA. [Dan, Corinna] US Dept Hlth & Human Serv, Off HIV AIDS Policy, Washington, DC USA. [Parker, Monica] Wadsworth Ctr, New York State Dept Hlth, Albany, NY USA. [Stekler, Joanne D.] Univ Washington, Dept Med, Seattle, WA USA. [Stekler, Joanne D.] Publ Hlth Seattle, Seattle, WA USA. [Stekler, Joanne D.] King Cty HIV STD Program, Seattle, WA USA. [DeMaria, Alfred, Jr.] Massachusetts Dept Publ Hlth, Bur Infect Dis, Jamaica Plain, MA USA. RP Panneer, N (reprint author), Univ Calif Berkeley, Forum Collaborat HIV Res, 1608 Rhode Isl Ave NW,Ste 212, Washington, DC 20036 USA. EM npanneer@hivforum.org FU AbbVie; Abbott Molecular; Achillion; Boehringer Ingelheim; Bristol-Myers Squibb; Celera; DDL Diagnostic; Genentech; Gilead Sciences; GSK; Idenix; Illumina; Janssen; Kaiser Permanente; Medscape; Merck Laboratories; Monogram; Novartis; Pacific Biosciences; PPD; Quintiles; Roche Molecular; Tobira; Vertex; ViiV Healthcare FX The Forum for Collaborative HIV Research (2013-2014) has received funding from AbbVie, Abbott Molecular, Achillion, Boehringer Ingelheim, Bristol-Myers Squibb, Celera, DDL Diagnostic, Genentech, Gilead Sciences, GSK, Idenix, Illumina, Janssen, Kaiser Permanente, Medscape, Merck Laboratories, Monogram, Novartis, Pacific Biosciences, PPD, Quintiles, Roche Molecular, Tobira, Vertex, and ViiV Healthcare. NR 37 TC 6 Z9 6 U1 2 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2014 VL 59 IS 6 BP 875 EP 882 DI 10.1093/cid/ciu396 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KU UT WOS:000342921700024 PM 24867787 ER PT J AU Blackley, DJ Halldin, CN Laney, AS AF Blackley, David J. Halldin, Cara N. Laney, A. Scott TI Resurgence of a Debilitating and Entirely Preventable Respiratory Disease among Working Coal Miners SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter C1 [Blackley, David J.; Halldin, Cara N.; Laney, A. Scott] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Blackley, David J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA USA. RP Blackley, DJ (reprint author), NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. NR 0 TC 15 Z9 15 U1 1 U2 3 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 15 PY 2014 VL 190 IS 6 BP 708 EP 709 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AP7OM UT WOS:000342266600020 PM 25221884 ER PT J AU Yang, P Thompson, MG Ma, CN Shi, WX Wu, SS Zhang, DT Wang, QY AF Yang, Peng Thompson, Mark G. Ma, Chunna Shi, Weixian Wu, Shuangsheng Zhang, Daitao Wang, Quanyi TI Influenza vaccine effectiveness against medically-attended influenza illness during the 2012-2013 season in Beijing, China SO VACCINE LA English DT Article DE Influenza; Vaccine effectiveness; Influenza-like illness; China ID TEST-NEGATIVE DESIGN; UNITED-STATES; CHILDREN; MORTALITY AB Background: Influenza vaccine coverage remains low in China, and there is limited information on the preventive value of local vaccination programs. Methods: As part of influenza virological surveillance in Beijing, China during the 2012-2013 influenza season, we assessed the vaccine effectiveness (VE) of one or more doses of trivalent inactivated influenza vaccine (IIV3) in preventing medically-attended influenza-like-illness (ILI) associated with laboratory-confirmed influenza virus infection using a test-negative case-control design. Influenza vaccination was determined based on self-report by adult patients or the parents of child patients. Results: Of 1998 patients with ILI, 695 (35%) tested positive for influenza viruses, including 292 (42%) A(H3N2), 398 (57%) A(H1N1)pdm09, and 5 (1%) not (sub)typed influenza viruses. The rate of influenza vaccination among all patients was 4% (71/1998). Among influenza positive patients, 2% (57/1303) were vaccinated compared to 4% (14/695) among influenza negative patients, resulting in VE for one or more doses of vaccine (adjusted forage, sex, week, and days since illness onset) against all circulating influenza viruses of 52% (95% CI = 12-74%). A significant adjusted VE for one or more doses of vaccine for all ages against A(H1N1)pdm09 of 59% (95% Cl, 8-82%) was observed; however, the VE against A(H3N2) was 43% (95% CI, -30% to 75%). The point estimate of VE was 59% (95% CI, 19-79%) for those aged <60 years, but a negative VE point estimate without statistical significance was observed among those aged >= 60 years. Conclusions: IIV3 conferred moderate protection against medically-attended influenza in Beijing, China during the 2012-2013 season, especially against the A(H1N1)pdm09 strain and among those aged <60 years old. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Yang, Peng; Ma, Chunna; Shi, Weixian; Wu, Shuangsheng; Zhang, Daitao; Wang, Quanyi] Beijing Ctr Dis Prevent & Control, Beijing 100013, Peoples R China. [Yang, Peng; Ma, Chunna; Shi, Weixian; Wu, Shuangsheng; Zhang, Daitao; Wang, Quanyi] Beijing Res Ctr Prevent Med, Beijing, Peoples R China. [Thompson, Mark G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Wang, QY (reprint author), Beijing Ctr Dis Prevent & Control, Inst Infect Dis & Endem Dis Control, 16 He Pingli Middle St, Beijing 100013, Peoples R China. EM bjcdcxm@126.com FU Beijing Science and Technology Planning Project of Beijing Science and Technology Commission [Z131100005613048]; Capital Medical Development Research Fund; Beijing Nova Program of the Beijing Science and Technology Commission [Z111107054511062]; National Key Program for Infectious Disease of China [2013ZX10004218] FX This work was supported by grants from the Beijing Science and Technology Planning Project of Beijing Science and Technology Commission (Z131100005613048), Capital Medical Development Research Fund, the Beijing Nova Program of the Beijing Science and Technology Commission (Z111107054511062), and the National Key Program for Infectious Disease of China (2013ZX10004218). NR 28 TC 14 Z9 14 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 15 PY 2014 VL 32 IS 41 BP 5285 EP 5289 DI 10.1016/j.vaccine.2014.07.083 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AP7QS UT WOS:000342272400005 PM 25092635 ER PT J AU Wallace, AS Mantel, C Mayers, G Mansoor, O Gindler, JS Hyde, TB AF Wallace, Aaron S. Mantel, Carsten Mayers, Gill Mansoor, Osman Gindler, Jacqueline S. Hyde, Terri B. TI Experiences with provider and parental attitudes and practices regarding the administration of multiple injections during infant vaccination visits: Lessons for vaccine introduction SO VACCINE LA English DT Article DE Vaccination; Multiple injections; Polio; Measles ID PNEUMOCOCCAL CONJUGATE VACCINE; HEPATITIS-B IMMUNIZATION; HEALTH-CARE PROVIDERS; FAMILY PHYSICIANS; CHILDHOOD VACCINATION; NATIONAL-SURVEY; PEDIATRICIANS; CHILDREN; PROGRAM; IMPACT AB Introduction: An increasing proportion of childhood immunization visits include administration of multiple injections. Future introduction of vaccines to protect against multiple diseases will further increase the number of injections at routine immunization childhood visits, particularly in developing countries that are still scaling up introductions. Parental and healthcare provider attitudes toward multiple injections may affect acceptance of recommended vaccines, and understanding these attitudes may help to inform critical decisions about vaccine introduction. Methods: We conducted a systematic review of the literature to examine factors underlying reported parental and healthcare provider concerns and practices related to administration of multiple injections during childhood vaccination visits. Results: Forty-four articles were identified; 42(95%) were from high income countries, including 27(61%) from the USA. Providers and parents report concerns about multiple injections, which tend to increase with increasing numbers of injections. Common parental and provider concerns included apprehension about the pain experienced by the child, worry about potential side effects, and uncertainty about vaccine effectiveness. Multiple studies reported that a positive provider recommendation to the parent and a high level of concern about the severity of the target disease were significantly associated with parental acceptance of all injections. Providers often significantly overestimated parental concerns about multiple injections. Discussion: Providers may play a critical role in the decision for a child to receive all recommended injections. Their overestimation of parental concerns may lead them to postpone recommended vaccinations, which may result in extra visits and delayed vaccination. More research is needed on interventions to overcome provider and parental concern about multiple injections, particularly in developing countries. Published by Elsevier Ltd. C1 [Wallace, Aaron S.; Gindler, Jacqueline S.; Hyde, Terri B.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30329 USA. [Mantel, Carsten; Mayers, Gill] WHO, Immunizat Vaccines & Biol Programme, CH-1211 Geneva, Switzerland. [Mansoor, Osman] United Natl Childrens Fund, New York, NY USA. RP Wallace, AS (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS-A04, Atlanta, GA 30329 USA. EM awallace@cdc.gov FU World Health Organization [001] NR 60 TC 14 Z9 14 U1 0 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 15 PY 2014 VL 32 IS 41 BP 5301 EP 5310 DI 10.1016/j.vaccine.2014.07.076 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AP7QS UT WOS:000342272400008 PM 25092632 ER PT J AU Agopian, A Lopez, A Wilson, D Peralta, V El Amin, AN Bialek, S AF Agopian, Anya Lopez, Adriana Wilson, Dulmini Peralta, Vi El Amin, Alvin Nelson Bialek, Stephanie TI Varicella hospitalizations in Los Angeles during the varicella vaccination era, 2003-2011: Are they preventable? SO VACCINE LA English DT Article DE Varicella hospitalizations; Varicella vaccination; Varicella complications; Severe varicella ID UNITED-STATES; CHILDREN; EPIDEMIOLOGY; PROGRAM; IMPLEMENTATION; IMPACT AB Characteristics of varicella-related hospitalizations in the mature varicella vaccination era, including the proportion vaccinated and the severity of disease, are not well described. We present the vaccination status, severity and reasons for hospitalization of the hospitalized varicella cases reported to the Los Angeles County Health Department from 2003 to 2011, the period which includes the last 4 years of the mature one-dose program and the first 5 years after introduction of the routine two-dose program. A total of 158 hospitalized varicella cases were reported overall, of which 52.5% were potentially preventable and eligible for vaccination, 41.8% were not eligible for vaccination, and 5.7% were vaccinated. Most hospitalizations (72.2%) occurred among healthy persons, 54.4% occurred among persons >= 20 years of age, and 3.8% of hospitalizations resulted in death. Our data suggest that as many as half of the hospitalized varicella cases, including half of the deaths, may have been preventable given that they occurred in persons who were eligible for vaccination. More complete implementation of the routine varicella vaccination program could further reduce the disease burden of severe varicella. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Agopian, Anya; Wilson, Dulmini; Peralta, Vi; El Amin, Alvin Nelson] Los Angeles Cty, Dept Publ Hlth, Immunizat Program, Los Angeles, CA 90001 USA. [Lopez, Adriana; Bialek, Stephanie] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Agopian, A (reprint author), Los Angeles Cty, Dept Publ Hlth, Immunizat Program, 3530 Wilshire Blvd,Suite 700, Los Angeles, CA 90001 USA. EM Anya.Agopian@gmail.com FU Intramural CDC HHS [CC999999] NR 17 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 15 PY 2014 VL 32 IS 41 BP 5353 EP 5356 DI 10.1016/j.vaccine.2014.07.035 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AP7QS UT WOS:000342272400015 PM 25087675 ER PT J AU Dokubo, EK Shiraishi, RW Young, PW Neal, JJ Aberle-Grasse, J Honwana, N Mbofana, F AF Dokubo, E. Kainne Shiraishi, Ray W. Young, Peter W. Neal, Joyce J. Aberle-Grasse, John Honwana, Nely Mbofana, Francisco TI Awareness of HIV Status, Prevention Knowledge and Condom Use among People Living with HIV in Mozambique SO PLOS ONE LA English DT Article ID SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; DISCORDANT COUPLES; TESTING SERVICES; SOUTH-AFRICA; INFECTION; CARE; UGANDA; RISK; TRANSMISSION AB Objective: To determine factors associated with HIV status unawareness and assess HIV prevention knowledge and condom use among people living with HIV/AIDS (PLHIV) in Mozambique. Design: Cross-sectional household-based nationally representative AIDS Indicator Survey. Methods: Analyses focused on HIV-infected adults and were weighted for the complex sampling design. We identified PLHIV who had never been tested for HIV or received their test results prior to this survey. Logistic regression was used to assess factors associated with HIV status unawareness. Results: Of persons with positive HIV test results (N = 1182), 61% (95% confidence interval [CI] 57-65%) were unaware of their serostatus. Men had twice the odds of being unaware of their serostatus compared with women [adjusted odds ratio (aOR) 2.05, CI 1.40-2.98]. PLHIV in the poorest wealth quintile were most likely to be unaware of their serostatus (aOR 3.15, CI 1.09-9.12) compared to those in the middle wealth quintile. Most PLHIV (83%, CI 79-87%) reported not using a condom during their last sexual intercourse, and PLHIV who reported not using a condom during their last sexual intercourse were more likely to be unaware of their serostatus (aOR 2.32, CI 1.57-3.43) than those who used a condom. Conclusions: Knowledge of HIV-positive status is associated with more frequent condom use in Mozambique. However, most HIV-infected persons are unaware of their serostatus, with men and persons in the poorest wealth quintile being more likely to be unaware. These findings support calls for expanded HIV testing, especially among groups less likely to be aware of their HIV status and key populations at higher risk for infection. C1 [Dokubo, E. Kainne; Shiraishi, Ray W.; Neal, Joyce J.; Aberle-Grasse, John] US Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Young, Peter W.; Honwana, Nely] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Maputo, Mozambique. [Mbofana, Francisco] Minist Hlth, Maputo, Mozambique. RP Dokubo, EK (reprint author), US Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Atlanta, GA 30333 USA. EM kdokubo@cdc.gov FU U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) FX This project was conducted under a grant or cooperative award mechanism from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC). CDC employees were involved in data analysis, decision to publish, and preparation of the manuscript. NR 36 TC 4 Z9 4 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 15 PY 2014 VL 9 IS 9 AR e106760 DI 10.1371/journal.pone.0106760 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AP0SR UT WOS:000341774800025 PM 25222010 ER PT J AU Zhang, YG Brooks, WA Goswami, D Rahman, M Luby, SP Erdman, DD AF Zhang, Yange Brooks, W. Abdullah Goswami, Doli Rahman, Mustafizur Luby, Stephen P. Erdman, Dean D. TI A duplex recombinant viral nucleoprotein microbead immunoassay for simultaneous detection of seroresponses to human respiratory syncytial virus and metapneumovirus infections SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Human respiratory syncytial virus (hRSV); Human metapneumovirus (hMPV); Immunoassay; Serology ID LINKED-IMMUNOSORBENT-ASSAY; GROUP-A; ANTIBODIES; SEROLOGY; CHILDREN; PROTEIN; DIAGNOSIS; SEROPREVALENCE; SURVEILLANCE; STRAINS AB Serologic diagnosis of human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV) infections has been shown to complement virus detection methods in epidemiologic studies. Enzyme immunoassays (EIAs) using cultured virus lysate antigens are often used to diagnose infection by demonstration of a >= 4-fold rises in antibody titer between acute and convalescent serum pairs. In this study, hRSV and hMPV nucleocapsid (recN) proteins were expressed in a baculovirus system and their performance compared with virus culture lysate antigen in EIAs using paired serum specimens collected from symptomatic children. The recN proteins were also used to develop a duplex assay based on the Luminex microbead-based suspension array technology, where diagnostic rises in antibody levels could be determined simultaneously at a single serum dilution. Antibody levels measured by the recN and viral lysate EIAs correlated moderately (hRSV, r(2) = 0.72; hMPV, r(2) = 0.76); the recN EIAs identified correctly 35 of 37 (94.6%) and 48 of 50 (96%) serum pairs showing diagnostic antibody rises by viral lysate EIAs. Purified recN proteins were then coupled to microbeads and serum pairs were tested at a single dilution on a Luminex MAGPIX (R) analyzer. The duplex recN assay identified correctly 33 of 39 (85%) and 41 of 47 (86.7%) serum pairs showing diagnostic rises to hRSV and hMPV, respectively. The recN assay permits simultaneous testing for acute hRSV and hMPV infections and offers a platform for expanded multiplexing of other respiratory virus assays. Published by Elsevier B.V. C1 [Zhang, Yange; Erdman, Dean D.] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Atlanta, GA 30333 USA. [Zhang, Yange] Battelle Mem Inst, Atlanta, GA 30341 USA. [Brooks, W. Abdullah; Goswami, Doli; Rahman, Mustafizur] Int Ctr Diarrheal Dis Res Bangladesh ICDDR B, Dhaka, Bangladesh. [Luby, Stephen P.] Stanford Univ, Woods Inst Environm, Stanford, CA 94305 USA. RP Erdman, DD (reprint author), Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Atlanta, GA 30333 USA. EM dde1@cdc.gov OI Luby, Stephen/0000-0001-5385-899X NR 33 TC 2 Z9 2 U1 2 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD SEP 15 PY 2014 VL 206 BP 55 EP 62 DI 10.1016/j.jviromet.2014.05.008 PG 8 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA AM9RQ UT WOS:000340219100010 PM 24859050 ER PT J AU Cogswell, ME Yuan, KM Gunn, JP Gillespie, C Sliwa, S Galuska, DA Barrett, J Hirschman, J Moshfegh, AJ Rhodes, D Ahuja, J Pehrsson, P Merritt, R Bowman, BA AF Cogswell, Mary E. Yuan, Keming Gunn, Janelle P. Gillespie, Cathleen Sliwa, Sarah Galuska, Deborah A. Barrett, Jan Hirschman, Jay Moshfegh, Alanna J. Rhodes, Donna Ahuja, Jaspreet Pehrsson, Pamela Merritt, Robert Bowman, Barbara A. TI Vital Signs: Sodium Intake Among US School-Aged Children-2009-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID BLOOD-PRESSURE; UNITED-STATES; CONSUMPTION; MORTALITY; HEALTH; TRENDS; ADULTHOOD; CHILDHOOD; BEVERAGES; FOODS AB Background: A national health objective is to reduce average U. S. sodium intake to 2,300 mg daily to help prevent high blood pressure, a major cause of heart disease and stroke. Identifying common contributors to sodium intake among children can help reduction efforts. Methods: Average sodium intake, sodium consumed per calorie, and proportions of sodium from food categories, place obtained, and eating occasion were estimated among 2,266 school-aged (6-18 years) participants in What We Eat in America, the dietary intake component of the National Health and Nutrition Examination Survey, 2009-2010. Results: U.S. school-aged children consumed an estimated 3,279 mg of sodium daily with the highest total intake (3,672 mg/d) and intake per 1,000 kcal (1,681 mg) among high school-aged children. Forty-three percent of sodium came from 10 food categories: pizza, bread and rolls, cold cuts/cured meats, savory snacks, sandwiches, cheese, chicken patties/nuggets/tenders, pasta mixed dishes, Mexican mixed dishes, and soups. Sixty-five percent of sodium intake came from store foods, 13% from fast food/pizza restaurants, 5% from other restaurants, and 9% from school cafeteria foods. Among children aged 14-18 years, 16% of total sodium intake came from fast food/pizza restaurants versus 11% among those aged 6-10 years or 11-13 years (p < 0.05). Among children who consumed a school meal on the day assessed, 26% of sodium intake came from school cafeteria foods. Thirty-nine percent of sodium was consumed at dinner, followed by lunch (29%), snacks (16%), and breakfast (15%). Implications for Public Health Practice: Sodium intake among school-aged children is much higher than recommended. Multiple food categories, venues, meals, and snacks contribute to sodium intake among school-aged children supporting the importance of population wide strategies to reduce sodium intake. New national nutrition standards are projected to reduce the sodium content of school meals by approximately 25%-50% by 2022. Based on this analysis, if there is no replacement from other sources, sodium intake among U. S. school-aged children will be reduced by an average of about 75-150 mg per day and about 220-440 mg on days children consume school meals. C1 [Cogswell, Mary E.; Yuan, Keming; Gunn, Janelle P.; Gillespie, Cathleen; Merritt, Robert; Bowman, Barbara A.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Sliwa, Sarah] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Galuska, Deborah A.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Barrett, Jan] Food & Nutr Serv, Child Nutr Program, USDA, Washington, DC USA. [Barrett, Jan] Food & Nutr Serv, Special Nutr Res & Anal Div, USDA, Washington, DC USA. [Moshfegh, Alanna J.; Rhodes, Donna] ARS, Food Surveys Res Grp, USDA, Washington, DC USA. [Ahuja, Jaspreet; Pehrsson, Pamela] ARS, Food Surveys Res Grp, Nutrient Data Lab, Washington, DC USA. RP Cogswell, ME (reprint author), CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM mcogswell@cdc.gov NR 16 TC 0 Z9 0 U1 1 U2 9 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 12 PY 2014 VL 63 IS 36 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1WB UT WOS:000342573300003 ER PT J AU Lopez, AS Lichtenstein, M Schmid, DS Bialek, S AF Lopez, Adriana S. Lichtenstein, Meredith Schmid, D. Scott Bialek, Stephanie TI Assessment of Varicella Surveillance and Outbreak Control Practices - United States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID VACCINE; IMPACT C1 [Lopez, Adriana S.; Schmid, D. Scott; Bialek, Stephanie] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Lopez, AS (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM alopez@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 12 PY 2014 VL 63 IS 36 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1WB UT WOS:000342573300002 ER PT J AU Midgley, CM Jackson, MA Selvarangan, R Turabelidze, G Obringer, E Johnson, D Giles, BL Patel, A Echols, F Oberste, MS Nix, WA Watson, JT Gerber, SI AF Midgley, Claire M. Jackson, Mary Anne Selvarangan, Rangaraj Turabelidze, George Obringer, Emily Johnson, Daniel Giles, B. Louise Patel, Ajanta Echols, Fredrick Oberste, M. Steven Nix, W. Allan Watson, John T. Gerber, Susan I. TI Severe Respiratory Illness Associated with Enterovirus D68-Missouri and Illinois, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Midgley, Claire M.] CDC, Epidem Intelligence Serv, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Midgley, Claire M.; Oberste, M. Steven; Nix, W. Allan; Watson, John T.; Gerber, Susan I.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Jackson, Mary Anne] Childrens Mercy Hosp, Dept Infect Dis, Kansas City, MO 64108 USA. [Selvarangan, Rangaraj] Childrens Mercy Hosp, Dept Pathol & Lab Med, Kansas City, MO 64108 USA. [Turabelidze, George] Missouri Dept Hlth & Senior Serv, Jefferson City, MO USA. [Obringer, Emily; Johnson, Daniel; Giles, B. Louise; Patel, Ajanta] Missouri Dept Hlth & Senior Serv, Jefferson City, MO USA. [Echols, Fredrick] Illinois Dept Publ Hlth, Springfield, IL 62761 USA. RP Midgley, CM (reprint author), CDC, Epidem Intelligence Serv, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM cmidgley@cdc.gov NR 3 TC 1 Z9 1 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 12 PY 2014 VL 63 IS 36 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1WB UT WOS:000342573300004 ER PT J AU Wendorf, K AF Wendorf, Kristen TI Measles in a Micronesian Community - King County, Washington, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Wendorf, Kristen] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Wendorf, Kristen] Publ Hlth Seattle & King Cty, Seattle, WA USA. RP Wendorf, K (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM kwendorf@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 12 PY 2014 VL 63 IS 36 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1WB UT WOS:000342573300005 ER PT J AU Mathur, MB Patel, RB Gould, M Uyeki, TM Bhattacharya, J Xiao, Y Gillaspie, Y Chae, C Khazeni, N AF Mathur, Maya B. Patel, Rita B. Gould, Michael Uyeki, Timothy M. Bhattacharya, Jay Xiao, Yang Gillaspie, Yoshi Chae, Charlotte Khazeni, Nayer TI Seasonal Patterns in Human A (H5N1) Virus Infection: Analysis of Global Cases SO PLOS ONE LA English DT Article ID PATHOGENIC AVIAN INFLUENZA; OUTBREAKS; ASIA AB Background: Human cases of highly pathogenic avian influenza (HPAI) A (H5N1) have high mortality. Despite abundant data on seasonal patterns in influenza epidemics, it is unknown whether similar patterns exist for human HPAI H5N1 cases worldwide. Such knowledge could help decrease avian-to-human transmission through increased prevention and control activities during peak periods. Methods: We performed a systematic search of published human HPAI H5N1 cases to date, collecting month, year, country, season, hemisphere, and climate data. We used negative binomial regression to predict changes in case incidence as a function of season. To investigate hemisphere as a potential moderator, we used AIC and the likelihood-ratio test to compare the season-only model to nested models including a main effect or interaction with hemisphere. Finally, we visually assessed replication of seasonal patterns across climate groups based on the Koppen-Geiger climate classification. Findings: We identified 617 human cases (611 with complete seasonal data) occurring in 15 countries in Southeast Asia, Africa, and the Middle East. Case occurrence was much higher in winter (n = 285, p = 0.03) than summer (n = 64), and the winter peak occurred across diverse climate groups. There was no significant interaction between hemisphere and season. Interpretation: Across diverse climates, HPAI H5N1 virus infection in humans increases significantly in winter. This is consistent with increased poultry outbreaks and HPAI H5N1 virus transmission during cold and dry conditions. Prioritizing prevention and control activities among poultry and focusing public health messaging to reduce poultry exposures during winter months may help to reduce zoonotic transmission of HPAI H5N1 virus in resource-limited settings. C1 [Mathur, Maya B.] Stanford Univ, Dept Med, Quantitat Sci Unit, Stanford, CA 94305 USA. [Patel, Rita B.; Gillaspie, Yoshi; Chae, Charlotte; Khazeni, Nayer] Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA. [Gould, Michael] Kaiser Permanente So Calif, Pasadena, CA 91101 USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Bhattacharya, Jay; Khazeni, Nayer] Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USA. [Bhattacharya, Jay; Khazeni, Nayer] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA. [Xiao, Yang] Univ S Carolina, Dept Languages Literatures & Cultures, Columbia, SC 29208 USA. RP Mathur, MB (reprint author), Stanford Univ, Dept Med, Quantitat Sci Unit, Stanford, CA 94305 USA. EM mmathur@stanford.edu OI Xiao-Desai, Yang/0000-0002-3609-2758 FU Agency for Healthcare Research and Quality [1K08 HS019816]; Southern California Permanente Medical Group FX This research was supported by the Agency for Healthcare Research and Quality (1K08 HS019816, Dr. Khazeni). See http://www.ahrq.gov/. The Southern California Permanente Medical Group provided support in the form of a salary for author MG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. NR 26 TC 5 Z9 6 U1 2 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 12 PY 2014 VL 9 IS 9 AR e106171 DI 10.1371/journal.pone.0106171 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AP0SM UT WOS:000341774300008 PM 25215608 ER PT J AU Ager, A Burnham, G Checchi, F Gayer, M Grais, RF Henkens, M Massaquoi, MBF Nandy, R Navarro-Colorado, C Spiegel, P AF Ager, A. Burnham, G. Checchi, F. Gayer, M. Grais, R. F. Henkens, M. Massaquoi, M. B. F. Nandy, R. Navarro-Colorado, C. Spiegel, P. TI Strengthening the evidence base for health programming in humanitarian crises SO SCIENCE LA English DT Editorial Material ID EMERGENCIES C1 [Ager, A.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Burnham, G.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Checchi, F.] Save Children UK, London EC1M 4AR, England. [Gayer, M.] WHO, CH-1211 Geneva 27, Switzerland. [Grais, R. F.] Epicentre, F-75012 Paris, France. [Henkens, M.] Med Sans Frontieres Int, B-1090 Brussels, Belgium. [Massaquoi, M. B. F.] Clinton Hlth Access Initiat, Monrovia, Liberia. [Nandy, R.] UNICEF, Jakarta 12920, Indonesia. [Navarro-Colorado, C.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA 30333 USA. [Spiegel, P.] UNHCR, CH-1211 Geneva 2, Switzerland. RP Grais, RF (reprint author), Epicentre, 55 Rue Crozatier, F-75012 Paris, France. EM rebecca.grais@epicentre.msf.org OI Navarro Colorado, Carlos/0000-0002-2185-0157 FU World Health Organization [001] NR 17 TC 5 Z9 5 U1 0 U2 6 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 EI 1095-9203 J9 SCIENCE JI Science PD SEP 12 PY 2014 VL 345 IS 6202 BP 1290 EP 1292 DI 10.1126/science.1254164 PG 3 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AO6TG UT WOS:000341483800048 PM 25214616 ER PT J AU Kourtis, AP Read, JS Jamieson, DJ AF Kourtis, Athena P. Read, Jennifer S. Jamieson, Denise J. TI Pregnancy and Infection Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Kourtis, Athena P.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Read, Jennifer S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Kourtis, AP (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 2 TC 18 Z9 18 U1 1 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 11 PY 2014 VL 371 IS 11 BP 1077 EP 1077 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AO5KD UT WOS:000341382800030 PM 25207782 ER PT J AU O'Dell, S House, M Hall, MA Moore, A Fairley, T AF O'Dell, Sarah House, Marnie Hall, Mary Ann Moore, Angela Fairley, Temeika TI Building the case for expanded support services to young breast cancer survivors: An evaluation of a cooperative agreement SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Breast Cancer Symposium CY SEP 04-06, 2014 CL San Francisco, CA SP Amer Soc Clin Oncol C1 ICF Int, Atlanta, GA USA. Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD SEP 10 PY 2014 VL 32 IS 26 SU S MA 127 PG 1 WC Oncology SC Oncology GA CN2JK UT WOS:000358246700126 ER PT J AU Feng, ZL Glasser, JW Hill, AN Franko, MA Carlsson, RM Hallander, H Tull, P Olin, P AF Feng, Zhilan Glasser, John W. Hill, Andrew N. Franko, Mikael A. Carlsson, Rose-Marie Hallander, Hans Tull, Peet Olin, Patrick TI Modeling rates of infection with transient maternal antibodies and waning active immunity: Application to Bordetella pertussis in Sweden SO JOURNAL OF THEORETICAL BIOLOGY LA English DT Article DE Catalytic modeling; Force of infection; Antibodies to pertussis toxin; Waning immunity; Reproduction number ID SEROLOGICAL SURVEY DATA; CONTROLLED-TRIAL; VACCINE; SEROEPIDEMIOLOGY; MASSACHUSETTS; IMMUNIZATION; 2-COMPONENT; ADOLESCENTS; DISEASES; FIMBRIAE AB Serological surveys provide reliable information from which to calculate forces (instantaneous rates) of infection, but waning immunity and clinical consequences that depend on residual immunity complicate interpretation of results. We devised a means of calculating these rates that accounts for passively acquired maternal antibodies that decay or active immunity that wanes, permitting re-infection. We applied our method to pertussis (whooping cough) in Sweden, where vaccination was discontinued from 1979 to 1995. A national cross-sectional serosurvey of antibodies to pertussis toxin, which peak soon after infection and then decay, was conducted shortly after vaccination resumed. Together with age-specific contact rates in Finland, contemporary forces of infection enable us to evaluate the recent assertion that the probability of infection upon contact is age-independent. We find elevated probabilities among children, adolescents and young adults, whose contacts may be more intimate than others. Products of contact rates and probabilities of infection permit transmission modeling and estimation of the intrinsic reproduction number. In contrast to another recent estimate, ours approximates the ratio of life expectancy and age at first infection. Our framework is sufficiently general to accommodate more realistic sojourn distributions and additional lifetime infections. Published by Elsevier Ltd. C1 [Feng, Zhilan] Purdue Univ, Dept Math, W Lafayette, IN 47907 USA. [Glasser, John W.; Hill, Andrew N.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Franko, Mikael A.; Carlsson, Rose-Marie; Hallander, Hans; Olin, Patrick] Swedish Inst Communicable Dis Control, Solna, Sweden. [Tull, Peet] European Ctr Dis Prevent & Control, Sci Advice Unit, Solna, Sweden. RP Glasser, JW (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM jglasser@cdc.gov FU National Institute of Allergy and Infectious Diseases [N01-AI-15125]; National Science Foundation [DMS-1022758]; Sanofi Pasteur Ltd, Toronto, Ontario, Canada; Sanofi Pasteur MSD, Lyon, France; GlaxoSmithKline Bio, Rixensart, Belgium FX National Institute of Allergy and Infectious Diseases, contract N01-AI-15125; National Science Foundation, grant DMS-1022758; Sanofi Pasteur Ltd, Toronto, Ontario, Canada; Sanofi Pasteur MSD, Lyon, France; and GlaxoSmithKline Bio, Rixensart, Belgium. NR 37 TC 2 Z9 2 U1 2 U2 16 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-5193 EI 1095-8541 J9 J THEOR BIOL JI J. Theor. Biol. PD SEP 7 PY 2014 VL 356 BP 123 EP 132 DI 10.1016/j.jtbi.2014.04.020 PG 10 WC Biology; Mathematical & Computational Biology SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology GA AL4SY UT WOS:000339126300012 PM 24768867 ER PT J AU King, BA Patel, R Babb, SD AF King, Brian A. Patel, Roshni Babb, Stephen D. TI Prevalence of Smokefree Home Rules - United States, 1992-1993 and 2010-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SECONDHAND SMOKE; EXPOSURE C1 [King, Brian A.; Patel, Roshni; Babb, Stephen D.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP King, BA (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM baking@cdc.gov NR 10 TC 17 Z9 17 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 5 PY 2014 VL 63 IS 35 BP 765 EP 769 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1VY UT WOS:000342573000001 PM 25188494 ER PT J AU Sheets, CD Harriman, K Zipprich, J Louie, JK Probert, WS Horowitz, M Prudhomme, JC Gold, D Mayer, L AF Sheets, Channing D. Harriman, Kathleen Zipprich, Jennifer Louie, Janice K. Probert, William S. Horowitz, Michael Prudhomme, Janice C. Gold, Deborah Mayer, Leonard TI Fatal Meningococcal Disease in a Laboratory Worker - California, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID RISK C1 [Horowitz, Michael; Prudhomme, Janice C.; Gold, Deborah] CDC, Calif Div Occupat Safety & Hlth, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Mayer, Leonard] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM channing.sheets@cdph.ca.gov NR 8 TC 2 Z9 2 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 5 PY 2014 VL 63 IS 35 BP 770 EP 772 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1VY UT WOS:000342573000002 PM 25188495 ER PT J AU Haber, P Schembri, CP Lewis, P Hibbs, B Shimabukuro, T AF Haber, Penina Schembri, Christopher P. Lewis, Paige Hibbs, Beth Shimabukuro, Tom TI Reports of Expired Live Attenuated Influenza Vaccine Being Administered - United States, 2007-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Haber, Penina; Schembri, Christopher P.; Lewis, Paige; Hibbs, Beth; Shimabukuro, Tom] CDC, Immunizat Safety Off, Div Healthcare Qual & Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Haber, P (reprint author), CDC, Immunizat Safety Off, Div Healthcare Qual & Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM phaber@cdc.gov NR 4 TC 2 Z9 2 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 5 PY 2014 VL 63 IS 35 BP 773 EP 773 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ1VY UT WOS:000342573000003 PM 25188496 ER PT J AU Breiding, MJ Smith, SG Basile, KC Walters, ML Chen, JR Merrick, MT AF Breiding, Matthew J. Smith, Sharon G. Basile, Kathleen C. Walters, Mikel L. Chen, Jieru Merrick, Melissa T. TI Prevalence and Characteristics of Sexual Violence, Stalking, and Intimate Partner Violence Victimization - National Intimate Partner and Sexual Violence Survey, United States, 2011 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID DATING VIOLENCE; WOMEN AB Problem/Condition: Sexual violence, stalking, and intimate partner violence are public health problems known to have a negative impact on millions of persons in the United States each year, not only by way of immediate harm hut also through negative longterm health impacts. Before implementation of the National Intimate Partner and Sexual Violence Survey (NISVS) in 2010, the most recent detailed national data on the public health burden from these forms of violence were obtained from the National Violence against Women Survey conducted during 1995-1996. This report examines sexual violence, stalking, and intimate partner violence victimization using data from 2011. The report describes the overall prevalence of sexual violence, stalking, and intimate partner violence victimization; racial/ethnic variation in prevalence; how types of perpetrators vary by violence type; and the age at which victimization typically begins. For intimate partner violence, the report also examines a range of negative impacts experienced as a result of victimization, including the need for services. C1 [Breiding, Matthew J.; Smith, Sharon G.; Basile, Kathleen C.; Walters, Mikel L.; Chen, Jieru; Merrick, Melissa T.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Breiding, MJ (reprint author), CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM dvi8@cdc.gov FU Intramural CDC HHS [CC999999] NR 18 TC 65 Z9 66 U1 2 U2 54 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD SEP 5 PY 2014 VL 63 IS 8 BP 1 EP 18 PG 18 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP2AH UT WOS:000341874200001 PM 25188037 ER PT J AU Biggerstaff, M Cauchemez, S Reed, C Gambhir, M Finelli, L AF Biggerstaff, Matthew Cauchemez, Simon Reed, Carrie Gambhir, Manoj Finelli, Lyn TI Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature SO BMC INFECTIOUS DISEASES LA English DT Article DE Reproductive number; Influenza; Pandemics; Zoonotic influenza ID TRANSMISSION DYNAMICS; UNITED-STATES; INFECTIOUS-DISEASES; A/H1N1 INFLUENZA; EPIDEMIOLOGIC CHARACTERIZATION; NOTIFICATION DATA; MORTALITY IMPACT; ASIAN INFLUENZA; TIME VARIATIONS; H1N1 INFLUENZA AB Background: The potential impact of an influenza pandemic can be assessed by calculating a set of transmissibility parameters, the most important being the reproduction number (R), which is defined as the average number of secondary cases generated per typical infectious case. Methods: We conducted a systematic review to summarize published estimates of R for pandemic or seasonal influenza and for novel influenza viruses (e.g. H5N1). We retained and summarized papers that estimated R for pandemic or seasonal influenza or for human infections with novel influenza viruses. Results: The search yielded 567 papers. Ninety-one papers were retained, and an additional twenty papers were identified from the references of the retained papers. Twenty-four studies reported 51 R values for the 1918 pandemic. The median R value for 1918 was 1.80 (interquartile range [IQR]: 1.47-2.27). Six studies reported seven 1957 pandemic R values. The median R value for 1957 was 1.65 (IQR: 1.53-1.70). Four studies reported seven 1968 pandemic R values. The median R value for 1968 was 1.80 (IQR: 1.56-1.85). Fifty-seven studies reported 78 2009 pandemic R values. The median R value for 2009 was 1.46 (IQR: 1.30-1.70) and was similar across the two waves of illness: 1.46 for the first wave and 1.48 for the second wave. Twenty-four studies reported 47 seasonal epidemic R values. The median R value for seasonal influenza was 1.28 (IQR: 1.19-1.37). Four studies reported six novel influenza R values. Four out of six R values were <1. Conclusions: These R values represent the difference between epidemics that are controllable and cause moderate illness and those causing a significant number of illnesses and requiring intensive mitigation strategies to control. Continued monitoring of R during seasonal and novel influenza outbreaks is needed to document its variation before the next pandemic. C1 [Biggerstaff, Matthew; Reed, Carrie; Finelli, Lyn] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Epidemiol & Prevent Branch, Atlanta, GA 30333 USA. [Cauchemez, Simon] Inst Pasteur, Math Modelling Infect Dis Unit, Paris, France. [Gambhir, Manoj] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Biggerstaff, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Epidemiol & Prevent Branch, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. EM mbiggerstaff@cdc.gov FU NIGMS NIH HHS [U54 GM088491] NR 131 TC 22 Z9 22 U1 4 U2 25 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD SEP 4 PY 2014 VL 14 AR 480 DI 10.1186/1471-2334-14-480 PG 20 WC Infectious Diseases SC Infectious Diseases GA AP0VZ UT WOS:000341785300001 PM 25186370 ER PT J AU Stich, RW Blagburn, BL Bowman, DD Carpenter, C Cortinas, MR Ewing, SA Foley, D Foley, JE Gaff, H Hickling, GJ Lash, RR Little, SE Lund, C Lund, R Mather, TN Needham, GR Nicholson, WL Sharp, J Varela-Stokes, A Wang, DM AF Stich, Roger W. Blagburn, Byron L. Bowman, Dwight D. Carpenter, Christopher Cortinas, M. Roberto Ewing, Sidney A. Foley, Desmond Foley, Janet E. Gaff, Holly Hickling, Graham J. Lash, R. Ryan Little, Susan E. Lund, Catherine Lund, Robert Mather, Thomas N. Needham, Glen R. Nicholson, William L. Sharp, Julia Varela-Stokes, Andrea Wang, Dongmei TI Quantitative factors proposed to influence the prevalence of canine tick-borne disease agents in the United States SO PARASITES & VECTORS LA English DT Article DE Anaplasma; Ehrlichia; Borrelia burgdorferi; Tick-borne infections; Prevalence map factors; Ticks; Ixodidae; Prostriata; Metastriata ID DIROFILARIA-IMMITIS; HEARTWORM; REMOVAL AB The Companion Animal Parasite Council hosted a meeting to identify quantifiable factors that can influence the prevalence of tick-borne disease agents among dogs in North America. This report summarizes the approach used and the factors identified for further analysis with mathematical models of canine exposure to tick-borne pathogens. C1 [Stich, Roger W.] Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA. [Blagburn, Byron L.] Auburn Univ, Dept Pathobiol, Auburn, AL 36849 USA. [Bowman, Dwight D.] Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA. [Carpenter, Christopher] Compan Anim Parasite Council, Salem, OR USA. [Cortinas, M. Roberto] Univ Nebraska, Sch Vet Med & Biomed Sci, Lincoln, NE USA. [Ewing, Sidney A.; Little, Susan E.] Oklahoma State Univ, Dept Vet Pathobiol, Stillwater, OK 74078 USA. [Foley, Desmond] Natl Museum Nat Hist, Walter Reed Biosystemat Unit, Washington, DC 20560 USA. [Foley, Janet E.] Univ Calif Davis, Dept Med & Epidemiol, Davis, CA 95616 USA. [Gaff, Holly] Old Dominion Univ, Dept Biol Sci, Norfolk, VA 23529 USA. [Hickling, Graham J.] Univ Tennessee, Dept Forestry Wildlife & Fisheries, Knoxville, TN USA. [Lash, R. Ryan] Univ Georgia, Dept Geog, Athens, GA 30602 USA. [Lund, Catherine] City Kitty Vet Care Cats, Providence, RI USA. [Lund, Robert; Sharp, Julia; Wang, Dongmei] Clemson Univ, Dept Math Sci, Clemson, SC USA. [Mather, Thomas N.] Univ Rhode Isl, Ctr Vector Borne Dis, Kingston, RI 02881 USA. [Needham, Glen R.] Ohio State Univ, Dept Entomol, Columbus, OH 43210 USA. [Nicholson, William L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Varela-Stokes, Andrea] Mississippi State Univ, Coll Vet Med, Dept Basic Sci, Mississippi State, MS 39762 USA. RP Stich, RW (reprint author), Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA. EM stichrw@missouri.edu OI Stich, Roger/0000-0002-9749-2034; Foley, Desmond/0000-0001-7525-4601 FU Companion Animal Parasite Council (CAPC); CAPC; National Science Foundation [DMS-1407480] FX This meeting was supported by the Companion Animal Parasite Council (CAPC), and we are grateful to Sonya Hennessy for assistance in organizing and hosting this meeting. The CAPC is in turn grateful to its sponsors that provide data for Parasite Prevalence Maps: the IDEXX, Antech, Banfield and Abaxis corporations. We are also grateful to the veterinarians across the USA who test their patients for exposure to vector-borne pathogens, especially those who report test results that can eventually be included as data in the CAPC Parasite Prevalence Maps. Robert Lund acknowledges support from the CAPC and from the National Science Foundation Grant DMS-1407480. The opinions and assertions contained herein are those of the authors and are not to be construed as official or reflecting the views of the Department of the Army or the Department of Defense. NR 9 TC 4 Z9 4 U1 3 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD SEP 4 PY 2014 VL 7 AR 417 DI 10.1186/1756-3305-7-417 PG 8 WC Parasitology SC Parasitology GA AO8RH UT WOS:000341621400001 PM 25185829 ER PT J AU Staples, JE Fischer, M AF Staples, J. Erin Fischer, Marc TI Chikungunya Virus in the Americas - What a Vectorborne Pathogen Can Do SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Staples, J. Erin; Fischer, Marc] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO 80521 USA. RP Staples, JE (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO 80521 USA. FU Intramural CDC HHS [CC999999] NR 5 TC 41 Z9 43 U1 0 U2 22 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 4 PY 2014 VL 371 IS 10 BP 887 EP 889 DI 10.1056/NEJMp1407698 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AO5NB UT WOS:000341390600004 PM 25184860 ER PT J AU MacNeil, A Lee, CW Dietz, V AF MacNeil, Adam Lee, Chung-won Dietz, Vance TI Issues and considerations in the use of serologic biomarkers classifying vaccination history in household surveys SO VACCINE LA English DT Review DE Immunization coverage; Vaccination history; Survey; Biomarker; Serology ID EUROPEAN-SEROEPIDEMIOLOGY-NETWORK; ORAL-FLUID; IMMUNIZATION COVERAGE; HEPATITIS-B; ENZYME-IMMUNOASSAY; NORTHERN MALAWI; MIXTURE-MODELS; MEASLES-VIRUS; BLOOD SAMPLES; BCG SCARS AB Accurate estimates of vaccination coverage are crucial for assessing routine immunization program performance. Community based household surveys are frequently used to assess coverage within a country. In household surveys to assess routine immunization coverage, a child's vaccination history is classified on the basis of observation of the immunization card, parental recall of receipt of vaccination, or both; each of these methods has been shown to commonly be inaccurate. The use of serologic data as a biomarker of vaccination history is a potential additional approach to improve accuracy in classifying vaccination history. However, potential challenges, including the accuracy of serologic methods in classifying vaccination history, varying vaccine types and dosing schedules, and logistical and financial implications must be considered. We provide historic and scientific context for the potential use of serologic data to assess vaccination history and discuss in detail key areas of importance for consideration in the context of using serologic data for classifying vaccination history in household surveys. Further studies are needed to directly evaluate the performance of serologic data compared with use of immunization cards or parental recall for classification of vaccination history in household surveys, as well assess the impact of age at the time of sample collection on serologic titers, the predictive value of serology to identify a fully vaccinated child for multi-dose vaccines, and the cost impact and logistical issues on outcomes associated with different types of biological samples for serologic testing. Published by Elsevier Ltd. C1 [MacNeil, Adam; Lee, Chung-won; Dietz, Vance] Ctr Dis Control & Prevent, Strengthening Immunizat Syst Branch, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP MacNeil, A (reprint author), Ctr Dis Control & Prevent, Strengthening Immunizat Syst Branch, Global Immunizat Div, Ctr Global Hlth, 1600 Clifton Rd NE,MS A-04, Atlanta, GA 30333 USA. EM aho3@cdc.gov NR 61 TC 5 Z9 5 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 3 PY 2014 VL 32 IS 39 BP 4893 EP 4900 DI 10.1016/j.vaccine.2014.07.005 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AO7UY UT WOS:000341559300003 PM 25045821 ER PT J AU Verdijk, P Rots, NY van Oijen, MGCT Weldon, WC Oberste, MS Okayasu, H Sutter, RW Bakker, WAM AF Verdijk, Pauline Rots, Nynke Y. van Oijen, Monique G. C. T. Weldon, William C. Oberste, M. Steven Okayasu, Hiromasa Sutter, Roland W. Bakker, Wilfried A. M. TI Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants SO VACCINE LA English DT Article DE Inactivated poliovirus vaccine; Sabin strains; Aluminum hydroxide; Adjuvant; Infants; Safety; Immunogenicity; Clinical trial ID INACTIVATED POLIO VACCINE; TECHNOLOGY-TRANSFER; PHASE-II; STRAINS; POLIOMYELITIS; ERADICATION; TRIAL AB Background: An inactivated poliovirus vaccine (IPV) based on attenuated poliovirus strains (Sabin-1, -2 and -3) was developed for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative. Method: Safety and immunogenicity of Sabin-IPV (sIPV) was evaluated in a double-blind, randomized, controlled, dose-escalation trial in the target population. Healthy infants (n = 20/group) aged 56-63 days, received a primary series of three intramuscular injections with low-, middle- or high-dose sIPV with or without aluminum hydroxide or with the conventional IPV based on wild poliovirus strains (wIPV). Virus-neutralizing titers against both Sabin and wild poliovirus strains were determined before and 28 days after three vaccinations. Results: The incidence of local and systemic reactions was comparable with the wIPV. Seroconversion rates after three vaccinations were 100% for type 2 and type 3 polioviruses (both Sabin and wild strains) and 95-100% for type 1 polioviruses. Median titers were high in all groups. Titers were well above the log(2)(titer) correlated with protection (=3) for all groups. Median titers for Sabin-2 were 9.3 (range 6.8-11.5) in the low-dose sIPV group, 9.2 (range 6.8-10.2) in the low-dose adjuvanted sIPV group and 9.8 (range 5.5-15.0) in the wIPV group, Median titers against MEF-1 (wild poliovirus type 2) were 8.2 (range 4.8-10.8) in the low-dose sIPV group, 7.3 (range 4.5-10.2) in the low-dose adjuvanted Sabin-IPV group and 10.3 (range 8.5-17.0) in the wIPV group. For all poliovirus types the median titers increased with increasing dose levels. Conclusion: sIPV and sIPV adjuvanted with aluminum hydroxide were immunogenic and safe at all dose levels, and comparable with the wIPV. (C) 2014 Published by Elsevier Ltd. C1 [Verdijk, Pauline; van Oijen, Monique G. C. T.; Bakker, Wilfried A. M.] Inst Translat Vaccinol Intravacc, NL-3720 AL Bilthoven, Netherlands. [Rots, Nynke Y.] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands. [Weldon, William C.; Oberste, M. Steven] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Okayasu, Hiromasa; Sutter, Roland W.] WHO, CH-1211 Geneva 27, Switzerland. RP Verdijk, P (reprint author), Inst Translat Vaccinol Intravacc, POB 450, NL-3720 AL Bilthoven, Netherlands. EM pauline.verdijk@intravacc.nl; Nynke.rots@rivm.nl; Monique.van.oijen@intravacc.nl; Wiw4@cdc.gov; Mbo2@cdc.gov; okayasuhi@who.int; sutterr@who.int; Wilfried.bakker@intravacc.nl OI Verdijk, Pauline/0000-0003-2272-2736 FU World Health Organization [001] NR 27 TC 9 Z9 9 U1 5 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 3 PY 2014 VL 32 IS 39 BP 4938 EP 4944 DI 10.1016/j.vaccine.2014.07.029 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AO7UY UT WOS:000341559300009 PM 25043278 ER PT J AU Patel, MK Capeding, RZ Ducusin, JU Castro, MD Garcia, LC Hennessey, K AF Patel, Minal K. Capeding, Rosario Z. Ducusin, Joyce U. de Quiroz Castro, Maricel Garcia, Luzviminda C. Hennessey, Karen TI Findings from a hepatitis B birth dose assessment in health facilities in the Philippines: Opportunities to engage the private sector SO VACCINE LA English DT Article DE Hepatitis B vaccine; Birth dose; Philippines; Private hospitals; Perinatal transmission ID IMMUNIZATION; CAMBODIA; DELIVERY AB Background: Hepatitis B vaccination in the Philippines was introduced in 1992 to reduce the high burden of chronic hepatitis B virus (HBV) infection in the population; in 2007, a birth dose (HepB-BD) was introduced to decrease perinatal HBV transmission. Timely HepB-BD coverage, defined as doses given within 24 h of birth, was 40% nationally in 2011. A first step in improving timely HepB-BD coverage is to ensure that all newborns born in health facilities are vaccinated. Methods: In order to assess ways of improving the Philippines' HepB-BD program, we evaluated knowledge, attitudes, and practices surrounding HepB-BD administration in health facilities. Teams visited selected government clinics, government hospitals, and private hospitals in regions with low reported HepB-BD coverage and interviewed immunization and maternity staff. HepB-BD coverage was calculated in each facility for a 3-month period in 2011. Results: Of the 142 health facilities visited, 12(8%) did not provide HepB-BD; seven were private hospitals and five were government hospitals. Median timely HepB-BD coverage was 90% (IQR 80%-100%) among government clinics, 87% (IQR 50%-97%) among government hospitals, and 50% (IQR 0%-90%) among private hospitals (p = 0.02). The private hospitals were least likely to receive supervision (53% vs. 6%-31%, p = 0.0005) and to report vaccination data to the national Expanded Programme on Immunization (36% vs. 96%-100%, p < 0.0001). Conclusions: Private sector hospitals in the Philippines, which deliver 18% of newborns, had the lowest timely HepB-BD coverage. Multiple avenues exist to engage the private sector in hepatitis B prevention including through existing laws, newborn health initiatives, hospital accreditation processes, and raising awareness of the government's free vaccine program. (C) 2013 World Health Organization (WHO). Published by Elsevier Ltd. All rights reserved. C1 [Patel, Minal K.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. [Capeding, Rosario Z.] Filinvest Corp City, Dept Hlth Compound, Res Inst Trop Med, Muntinlupa 1781, Philippines. [Ducusin, Joyce U.; Garcia, Luzviminda C.] Dept Hlth, Expanded Programme Immunizat, Manila, Philippines. [de Quiroz Castro, Maricel] WHO, Dept Hlth, Off WHO Representat Philippines, Expanded Programme Immunizat, Manila, Philippines. [Hennessey, Karen] WHO, Western Pacific Reg Off, Expanded Programme Immunizat, Manila 1000, Philippines. RP Patel, MK (reprint author), 1600 Clifton Rd,MS A-04, Atlanta, GA 30329 USA. EM hgo9@cdc.gov; lerosecap@yahoo.com.ph; juducusin@yahoo.com; castroma@wpro.who.int; luzcgarcia@gmail.com; hennesseyk@wpro.who.int FU Intramural CDC HHS [CC999999] NR 16 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 3 PY 2014 VL 32 IS 39 BP 5140 EP 5144 DI 10.1016/j.vaccine.2013.11.097 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AO7UY UT WOS:000341559300035 PM 24361121 ER PT J AU Menke, A Rust, KF Fradkin, J Cheng, YLJ Cowie, CC AF Menke, Andy Rust, Keith F. Fradkin, Judith Cheng, Yiling J. Cowie, Catherine C. TI Associations Between Trends in Race/Ethnicity, Aging, and Body Mass Index With Diabetes Prevalence in the United States A Series of Cross-sectional Studies SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID US ADULTS; NATIONAL-HEALTH; PHYSICAL-ACTIVITY; SECULAR CHANGES; AIR-POLLUTION; LIFE-STYLE; OBESITY; MELLITUS; COHORT; ADJUSTMENT AB Background: The increase in the prevalence of diabetes over the past few decades has coincided with an increase in certain risk factors for diabetes, such as a changing race/ethnicity distribution, an aging population, and a rising obesity prevalence. Objective: To determine the extent to which the increase in diabetes prevalence is explained by changing distributions of race/ethnicity, age, and obesity prevalence in U. S. adults. Design: Cross-sectional, using data from 5 NHANES (National Health and Nutrition Examination Surveys): NHANES II (1976-1980), NHANES III (1988-1994), and the continuous NHANES 1999-2002, 2003-2006, and 2007-2010. Setting: Nationally representative samples of the U. S. non-institutionalized civilian population. Patients: 23 932 participants aged 20 to 74 years. Measurements: Diabetes was defined as a self-reported diagnosis or fasting plasma glucose level of 7.0 mmol/L (126 mg/dL) or more. Results: Between 1976 to 1980 and 2007 to 2010, diabetes prevalence increased from 4.7% to 11.2% in men and from 5.7% to 8.7% in women (P for trends for both groups < 0.001). After adjustment for age, race/ethnicity, and body mass index, diabetes prevalence increased in men (6.2% to 9.6%; P for trend < 0.001) but not women (7.6% to 7.5%; P for trend = 0.69). Body mass index was the greatest contributor among the 3 covariates to the change in prevalence estimates after adjustment. Limitation: Some possible risk factors, such as physical activity, waist circumference, and mortality, could not be studied because data on these variables were not collected in all surveys. Conclusion: The increase in the prevalence of diabetes was greater in men than in women in the U. S. population between 1976 to 1980 and 2007 to 2010. After changes in age, race/ethnicity, and body mass index were controlled for, the increase in diabetes prevalence over time was approximately halved in men and diabetes prevalence was no longer increased in women. C1 [Menke, Andy] Social & Sci Syst, Silver Spring, MD 20910 USA. Westat Corp, Rockville, MD 20850 USA. NIDDK, NIH, Bethesda, MD 20892 USA. Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Menke, A (reprint author), Social & Sci Syst, 8757 Georgia Ave,12th Floor, Silver Spring, MD 20910 USA. EM amenke@s-3.com FU Centers for Disease Control and Prevention; National Institutes of Diabetes and Digestive and Kidney Diseases; National Institute of Diabetes and Digestive and Kidney Diseases [GS10F0381L] FX Centers for Disease Control and Prevention and National Institutes of Diabetes and Digestive and Kidney Diseases.; By a contract from the National Institute of Diabetes and Digestive and Kidney Diseases (GS10F0381L; Dr. Menke). NR 42 TC 30 Z9 34 U1 0 U2 13 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 2 PY 2014 VL 161 IS 5 BP 328 EP + DI 10.7326/M14-0286 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA AO7VT UT WOS:000341561400003 PM 25178569 ER PT J AU Cooley, LA Oster, AM Rose, CE Wejnert, C Le, BC Paz-Bailey, G AF Cooley, Laura A. Oster, Alexandra M. Rose, Charles E. Wejnert, Cyprian Le, Binh C. Paz-Bailey, Gabriela CA NHBS Study Grp TI Increases in HIV Testing among Men Who Have Sex with Men - National HIV Behavioral Surveillance System, 20 US Metropolitan Statistical Areas, 2008 and 2011 SO PLOS ONE LA English DT Article ID UNITED-STATES; PERSONS AWARE; RISK; PREVENTION; UNAWARE; CITIES AB In 2011, 62% of estimated new HIV diagnoses in the United States were attributed to male-to-male sexual contact (men who have sex with men, MSM); 39% of these MSM were black or African American. HIV testing, recommended at least annually by CDC for sexually active MSM, is an essential first step in HIV care and treatment for HIV-positive individuals. A variety of HIV testing initiatives, designed to reach populations disproportionately affected by HIV, have been developed at both national and local levels. We assessed changes in HIV testing behavior among MSM participating in the National HIV Behavioral Surveillance System in 2008 and 2011. We compared the percentages tested in the previous 12 months in 2008 and 2011, overall and by race/ethnicity and age group. In unadjusted analyses, recent HIV testing increased from 63% in 2008 to 67% in 2011 overall (P<0.001), from 63% to 71% among black MSM (P<0.001), and from 63% to 75% among MSM of other/multiple races (P<0.001); testing did not increase significantly for white or Hispanic/Latino MSM. Multivariable model results indicated an overall increase in recent HIV testing (adjusted prevalence ratio [aPR] = 1.07, P<0.001). Increases were largest for black MSM (aPR = 1.12, P<0.001) and MSM of other/multiple races (aPR = 1.20, P<0.001). Among MSM aged 18-19 years, recent HIV testing was shown to increase significantly among black MSM (aPR = 1.20, P = 0.007), but not among MSM of other racial/ethnic groups. Increases in recent HIV testing among populations most affected by HIV are encouraging, but despite these increases, improved testing coverage is needed to meet CDC recommendations. C1 [Cooley, Laura A.; Oster, Alexandra M.; Rose, Charles E.; Wejnert, Cyprian; Le, Binh C.; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Cooley, LA (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM LCooley@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX These authors have no support or funding to report. The National HIV Behavioral Surveillance System is funded by the Centers for Disease Control and Prevention (CDC). Study design and data collection are conducted by funded sites in accordance with a standardized protocol developed by CDC. Data analysis and preparation of the manuscript were conducted by CDC staff. NR 31 TC 14 Z9 14 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 2 PY 2014 VL 9 IS 9 AR e104162 DI 10.1371/journal.pone.0104162 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AO3LR UT WOS:000341231500008 PM 25180514 ER PT J AU Desai, M Buff, AM Khagayi, S Byass, P Amek, N van Eijk, A Slutsker, L Vulule, J Odhiambo, FO Phillips-Howard, PA Lindblade, KA Laserson, KF Hamel, MJ AF Desai, Meghna Buff, Ann M. Khagayi, Sammy Byass, Peter Amek, Nyaguara van Eijk, Annemieke Slutsker, Laurence Vulule, John Odhiambo, Frank O. Phillips-Howard, Penelope A. Lindblade, Kimberly A. Laserson, Kayla F. Hamel, Mary J. TI Age-Specific Malaria Mortality Rates in the KEMRI/CDC Health and Demographic Surveillance System in Western Kenya, 2003-2010 SO PLOS ONE LA English DT Article ID CHILD-MORTALITY; AFRICA; IMPACT; NETS AB Recent global malaria burden modeling efforts have produced significantly different estimates, particularly in adult malaria mortality. To measure malaria control progress, accurate malaria burden estimates across age groups are necessary. We determined age-specific malaria mortality rates in western Kenya to compare with recent global estimates. We collected data from 148,000 persons in a health and demographic surveillance system from 2003-2010. Standardized verbal autopsies were conducted for all deaths; probable cause of death was assigned using the InterVA-4 model. Annual malaria mortality rates per 1,000 person-years were generated by age group. Trends were analyzed using Poisson regression. From 2003-2010, in children <5 years the malaria mortality rate decreased from 13.2 to 3.7 per 1,000 person-years; the declines were greatest in the first three years of life. In children 5-14 years, the malaria mortality rate remained stable at 0.5 per 1,000 person-years. In persons >= 15 years, the malaria mortality rate decreased from 1.5 to 0.4 per 1,000 person-years. The malaria mortality rates in young children and persons aged >= 15 years decreased dramatically from 2003-2010 in western Kenya, but rates in older children have not declined. Sharp declines in some age groups likely reflect the national scale up of malaria control interventions and rapid expansion of HIV prevention services. These data highlight the importance of agespecific malaria mortality ascertainment and support current strategies to include all age groups in malaria control interventions. C1 [Desai, Meghna; Phillips-Howard, Penelope A.; Laserson, Kayla F.] Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent, KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya. [Desai, Meghna; Slutsker, Laurence; Lindblade, Kimberly A.; Hamel, Mary J.] CGH, DPDM, Atlanta, GA USA. [Buff, Ann M.] Presidents Malaria Initiat Kenya, CDC, CGH, DPDM, Nairobi, Kenya. [Khagayi, Sammy; Amek, Nyaguara; Odhiambo, Frank O.] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya. [Khagayi, Sammy; Amek, Nyaguara; Vulule, John; Odhiambo, Frank O.] KEMRI Ctr Global Hlth Res, Kisumu, Kenya. [Byass, Peter] Umea Ctr Global Hlth Res, WHO Collaborating Ctr Verbal Autopsy, Umea, Sweden. [van Eijk, Annemieke] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [Phillips-Howard, Penelope A.] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. [Laserson, Kayla F.] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Desai, M (reprint author), Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent, KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya. EM mdesai@cdc.gov OI Byass, Peter/0000-0001-5474-4361; Phillips-Howard, Penelope A/0000-0003-1018-116X FU President's Emergency Plan for AIDS Relief (PEPFAR); U.S. HHS/Centers for Disease Control and Prevention (CDC), Center for Global Health (CGH), Division of Global HIV/AIDS (DGHA) [GH10-1001]; Division of Parasitic Diseases and Malaria (DPDM); HDSS; INDEPTH network FX The KEMRI/CDC HDSS receives funding from the President's Emergency Plan for AIDS Relief (PEPFAR) and the President's Malaria Initiative (PMI) through cooperative agreement No. GH10-1001 from the U.S. HHS/Centers for Disease Control and Prevention (CDC), Center for Global Health (CGH), Division of Global HIV/AIDS (DGHA) and Division of Parasitic Diseases and Malaria (DPDM). Funding has also been received through the studies nested in the HDSS and the INDEPTH network. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 7 Z9 7 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 2 PY 2014 VL 9 IS 9 AR e106197 DI 10.1371/journal.pone.0106197 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AO3LR UT WOS:000341231500058 PM 25180495 ER PT J AU Fein, SB Li, RW Chen, J Scanlon, KS Grummer-Strawn, LM AF Fein, Sara B. Li, Ruowei Chen, Jian Scanlon, Kelley S. Grummer-Strawn, Laurence M. TI Methods for the Year 6 Follow-Up Study of Children in the Infant Feeding Practices Study II SO PEDIATRICS LA English DT Article DE breastfeeding; bottle feeding; infant nutrition; child nutrition; cohort study; health outcomes ID RANDOMIZED-TRIAL; QUESTIONNAIRE; ADJUSTMENT; BEHAVIOR; COHORT; RISK; AGE AB OBJECTIVE: We describe methods used in the Year 6 Follow-Up (Y6FU) of children who participated in the Infant Feeding Practices Study II (IFPSII). This study consists of a questionnaire administered 6 years after the IFPSII to characterize the health, development, and diet quality of the children. METHODS: The Y6FU sample was a subset of those who participated in IFPSII. The IFPSII participants were drawn from a national consumer opinion panel; neither the IFPSII nor the Y6FU sample is nationally representative. The Y6FU sampling frame included all qualified participants who answered at least the first postnatal questionnaire. One questionnaire was administered by mail in 2012, and nonrespondents were contacted for a telephone interview. Survey topics included measures of health, development, diet, physical activity, screen time, and family medical history. We attempted to contact 2958 mothers and obtained completed questionnaires from 1542, a response rate of 52.1%. We conducted 2 sample evaluations, 1 comparing respondents and nonrespondents on data from IFPSII and the other comparing Y6FU respondents with 6-year-old participants in the National Survey of Children's Health. RESULTS: Y6FU mothers are more likely to be white, married, older, and of higher education and income than both nonresponders and nationally representative mothers. Comparisons also revealed health-related differences and similarities. CONCLUSIONS: Although not nationally representative, the Y6FU provides a valuable database because of its wide coverage of diet and health issues and its unique ability to link early feeding patterns with outcomes at age 6 years. C1 [Fein, Sara B.] McKing Consulting Corp, Fairfax, VA USA. [Li, Ruowei; Chen, Jian; Scanlon, Kelley S.; Grummer-Strawn, Laurence M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Li, RW (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, 4770 Buford Hwy,Mail Stop K25, Atlanta, GA 30341 USA. EM ril6@cdc.gov FU US Food and Drug Administration; Centers for Disease Control and Prevention; Office on Women's Health; National Institutes of Health; Maternal and Child Health Bureau in the US Department of Health and Human Services FX This study was funded by the US Food and Drug Administration, Centers for Disease Control and Prevention, Office on Women's Health, National Institutes of Health, and Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 21 TC 12 Z9 12 U1 3 U2 10 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 SU 1 BP S4 EP S12 DI 10.1542/peds.2014-0646C PG 9 WC Pediatrics SC Pediatrics GA CO2NF UT WOS:000358992600002 PM 25183754 ER PT J AU Grimm, KA Kim, SA Yaroch, AL Scanlon, KS AF Grimm, Kirsten A. Kim, Sonia A. Yaroch, Amy L. Scanlon, Kelley S. TI Fruit and Vegetable Intake During Infancy and Early Childhood SO PEDIATRICS LA English DT Article DE fruits; vegetables; frequency of intake; age of introduction; Infant Feeding Practice Study II; Year 6 Follow-Up Study ID FLAVOR EXPERIENCES; FEEDING PRACTICES; TELL US; CONSUMPTION; FOODS; CHILDREN; COHORT; ACCEPTANCE; PATTERNS; RISK AB OBJECTIVES: To examine the association of timing of introduction and frequency of fruit and vegetable intake during infancy with frequency of fruit and vegetable intake at age 6 years in a cohort of US children. METHODS: We analyzed data on fruit and vegetable intake during late infancy, age of fruit and vegetable introduction, and frequency of fruit and vegetable intake at 6 years from the Infant Feeding Practices Study II and the Year 6 Follow-Up (Y6FU) Study. We determined the percent of 6-year-old children consuming fruits and vegetables less than once per day and examined associations with infant fruit and vegetable intake using logistic regression modeling, controlling for multiple covariates (n = 1078). RESULTS: Based on maternal report, 31.9% of 6-year-old children consumed fruit less than once daily and 19.0% consumed vegetables less than once daily. In adjusted analyses, children who consumed fruits and vegetables less than once daily during late infancy had increased odds of eating fruits and vegetables less than once daily at age 6 years (fruit, adjusted odds ratio: 2.48; vegetables, adjusted odds ratio: 2.40). Age of introduction of fruits and vegetables was not associated with intake at age 6 years. CONCLUSIONS: Our study suggests that infrequent intake of fruits and vegetables during late infancy is associated with infrequent intake of these foods at 6 years of age. These findings highlight the importance of infant feeding guidance that encourages intake of fruits and vegetables and the need to examine barriers to fruit and vegetable intake during infancy. C1 [Grimm, Kirsten A.; Kim, Sonia A.; Scanlon, Kelley S.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Yaroch, Amy L.] Gretchen Swanson Ctr Nutr, Omaha, NE USA. RP Scanlon, KS (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F77, Atlanta, GA 30341 USA. EM kxs5@cdc.gov FU US Food and Drug Administration; Centers for Disease Control and Prevention; Office on Women's Health, National Institutes of Health; Maternal and Child Health Bureau in the US Department of Health and Human Services FX This study was funded by the US Food and Drug Administration, Centers for Disease Control and Prevention, Office on Women's Health, National Institutes of Health, and Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 35 TC 13 Z9 13 U1 0 U2 9 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 SU 1 BP S63 EP S69 DI 10.1542/peds.2014-0646K PG 7 WC Pediatrics SC Pediatrics GA CO2NF UT WOS:000358992600010 PM 25183758 ER PT J AU Grummer-Strawn, LM Li, R Perrine, CG Scanlon, KS Fein, SB AF Grummer-Strawn, Laurence M. Li, Ruowei Perrine, Cria G. Scanlon, Kelley S. Fein, Sara B. TI Infant Feeding and Long-Term Outcomes: Results From the Year 6 Follow-Up of Children in the Infant Feeding Practices Study II SO PEDIATRICS LA English DT Editorial Material C1 [Grummer-Strawn, Laurence M.; Li, Ruowei; Perrine, Cria G.; Scanlon, Kelley S.] US Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Grummer-Strawn, Laurence M.; Perrine, Cria G.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. [Fein, Sara B.] McKing Consulting Corp, Fairfax, VA USA. RP Grummer-Strawn, LM (reprint author), 4770 Buford Hwy,Mail Stop F-77, Atlanta, GA 30341 USA. EM lxg8@cdc.gov NR 13 TC 0 Z9 0 U1 1 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 SU 1 BP S1 EP S3 DI 10.1542/peds.2014-0646B PG 3 WC Pediatrics SC Pediatrics GA CO2NF UT WOS:000358992600001 PM 25183749 ER PT J AU Li, RW Scanlon, KS May, A Rose, C Birch, L AF Li, Ruowei Scanlon, Kelley S. May, Ashleigh Rose, Chelsea Birch, Leann TI Bottle-Feeding Practices During Early Infancy and Eating Behaviors at 6 Years of Age SO PEDIATRICS LA English DT Article DE bottle feeding; maternal feeding style; children's eating behaviors; Infant Feeding Practice Study II; Year 6 Follow-Up Study ID MATERNAL CONTROL; SELF-REGULATION; BREAST-MILK; WEIGHT-GAIN; 1ST YEAR; CHILDREN; QUESTIONNAIRE; ADIPOSITY; GROWTH; FOODS AB BACKGROUND: Evidence suggests an association of breastfeeding with a maternal feeding style (MFS) that is less controlling than formula feeding, which, in turn, may improve a child's self-regulation of eating. This study examines associations of bottle-feeding practices during infancy with MFS and children's eating behavior (CEB) at 6 years old. METHODS: We linked data from the Infant Feeding Practices Study II to the Year 6 Follow-Up, which include 8 MFS and CEB measures adapted from previous validated instruments. Bottle-feeding practices during the first 6 months estimated by using the Infant Feeding Practices Study II were bottle-feeding intensity (BFI), mother's encouragement of infant to finish milk in the bottle, and infant finishing all milk in the bottle. Adjusted odds ratios (aORs) for associations of bottle-feeding practices with MFS and CEB at 6 years old were calculated by using multivariable logistic regressions controlling for sociodemographic characteristics and other feeding practices (N = 1117). RESULTS: Frequent bottle emptying encouraged by mothers during infancy increased odds of mothers encouraging their child to eat all the food on their plate (aOR: 2.37; 95% confidence interval [CI]: 1.65-3.41] and making sure their child eats enough (aOR: 1.62; 95% CI: 1.14-2.31) and of children eating all the food on their plate at 6 years old (aOR: 2.01; 95% CI: 1.05-3.83). High BFI during early infancy also increased the odds of mothers being especially careful to ensure their 6-year-old eats enough. CONCLUSIONS: Bottle-feeding practices during infancy may have long-term effects on MFS and CEB. Frequent bottle emptying encouraged by mothers and/or high BFI during early infancy increased the likelihood of mothers pressuring their 6-year-old child to eat and children's low satiety responsiveness. C1 [Li, Ruowei; Scanlon, Kelley S.; May, Ashleigh] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Rose, Chelsea; Birch, Leann] Penn State Univ, Dept Human Dev & Family Studies, State Coll, PA USA. RP Li, RW (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop F77,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM ril6@cdc.gov FU US Food and Drug Administration; Centers for Disease Control and Prevention; Office on Women's Health, National Institutes of Health; Maternal and Child Health Bureau in the US Department of Health and Human Services FX This study was funded by the US Food and Drug Administration, Centers for Disease Control and Prevention, Office on Women's Health, National Institutes of Health, and Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 35 TC 8 Z9 8 U1 5 U2 11 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 SU 1 BP S70 EP S77 DI 10.1542/peds.2014-0646L PG 8 WC Pediatrics SC Pediatrics GA CO2NF UT WOS:000358992600011 PM 25183759 ER PT J AU Li, RW Dee, D Li, CM Hoffman, HJ Grummer-Strawn, LM AF Li, Ruowei Dee, Deborah Li, Chuan-Ming Hoffman, Howard J. Grummer-Strawn, Laurence M. TI Breastfeeding and Risk of Infections at 6 Years SO PEDIATRICS LA English DT Article DE breastfeeding; infection; Infant Feeding Practice Study II; Year 6 Follow-Up Study ID HELICOBACTER-PYLORI INFECTION; OTITIS-MEDIA; PRESCHOOL-CHILDREN; METAANALYSIS; INFANCY; COHORT; HEALTH; SIZE AB BACKGROUND: Previous studies have shown that breastfeeding is associated with reductions in the risk of common infections among infants; however, whether breastfeeding confers longer term protection is inconclusive. METHODS: We linked data from the 2005-2007 IFPS II (Infant Feeding Practices Study II) and follow-up data collected when the children were 6 years old. Multivariable logistic regression was used, controlling for sociodemographic variables, to examine associations of initiation, duration, exclusivity of breastfeeding, timing of supplementing breastfeeding with formula, and breast milk intensity (proportion of milk feedings that were breast milk from age 0-6 months) with maternal reports of infection (cold/upper respiratory tract, ear, throat, sinus, pneumonia/lung, and urinary) and sick visits in the past year among 6-year-olds (N = 1281). RESULTS: The most common past-year infections were colds/upper respiratory tract (66%), ear (25%), and throat (24%) infections. No associations were found between breastfeeding and colds/upper respiratory tract, lung, or urinary tract infections. Prevalence of ear, throat, and sinus infections and number of sick visits differed according to breastfeeding duration, exclusivity, and timing of supplementing breastfeeding with formula (P<.05). Among children ever breastfed, children breastfed for >= 9 months had lower odds of past-year ear (adjusted odds ratio [aOR]: 0.69 [95% confidence interval (95% CI): 0.48-0.98]), throat (aOR: 0.68 [95% CI: 0.47-0.98]), and sinus (aOR: 0.47 [95% CI: 0.30-0.72]) infections compared with those breastfed >0 to <3 months. High breast milk intensity (>66.6%) during the first 6 months was associated with lower odds of sinus infection compared with low breast milk intensity (<33.3%) (aOR: 0.53 [95% CI: 0.35-0.79]). CONCLUSIONS: This prospective longitudinal study suggests that breastfeeding may protect against ear, throat, and sinus infections well beyond infancy. C1 [Li, Ruowei; Grummer-Strawn, Laurence M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Dee, Deborah] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Li, Chuan-Ming; Hoffman, Howard J.] NIDCD, NIH, Div Sci Programs Epidemiol & Stat Program, Bethesda, MD USA. RP Li, RW (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, 4770 Buford Highway NE,Mailstop F77, Atlanta, GA 30341 USA. EM ril6@cdc.gov FU US Food and Drug Administration; Centers for Disease Control and Prevention; Office on Women's Health; National Institutes of Health; Maternal and Child Health Bureau in the US Department of Health and Human Services FX This study was funded by the US Food and Drug Administration, Centers for Disease Control and Prevention, Office on Women's Health, National Institutes of Health, and Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 25 TC 8 Z9 11 U1 0 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 SU 1 BP S13 EP S20 DI 10.1542/peds.2014-0646D PG 8 WC Pediatrics SC Pediatrics GA CO2NF UT WOS:000358992600003 PM 25183750 ER PT J AU Lind, JN Li, RW Perrine, CG Schieve, LA AF Lind, Jennifer N. Li, Ruowei Perrine, Cria G. Schieve, Laura A. TI Breastfeeding and Later Psychosocial Development of Children at 6 Years of Age SO PEDIATRICS LA English DT Article DE breastfeeding; child; social psychology; behavior; Strengths and Difficulties Questionnaire ID DIFFICULTIES QUESTIONNAIRE; MENTAL-HEALTH; BEHAVIOR; COHORT; DEPRESSION; STRENGTHS; DURATION; SCALE AB OBJECTIVE: To examine the association of breastfeeding duration with psychosocial development at 6 years of age. METHODS: We analyzed data from the 2005-2007 Infant Feeding Practices Study II and its 2012 Year 6 Follow-Up (N = 1442). Our breastfeeding duration variable combined overall and exclusive breastfeeding reported during infancy (never breastfed, breastfed <6 months, breastfed >= 6 months + exclusive breastfeeding <3 months, and breastfed >= 6 months + exclusive breastfeeding >= 3 months). Maternal responses to the Strengths and Difficulties Questionnaire were used to create our child psychosocial outcome domains (emotional symptoms, conduct problems, hyperactivity, peer problems, prosocial behavior, and total difficulties). Separate multivariable logistic regression models controlling for maternal sociodemographic characteristics, maternal mental health, and child characteristics were used to assess the likelihood of having difficulties on the 6 domains based on breastfeeding duration. RESULTS: Compared with children who were never breastfed, those who were breastfed for >= 6 months and exclusively breastfed for >= 3 months had decreased odds of difficulties with emotional symptoms (odds ratio [OR]: 0.52; 95% confidence interval [CI]: 0.27-0.99), conduct problems (OR: 0.24; 95% CI: 0.10-0.54), and total difficulties (OR: 0.39; 95% CI: 0.18-0.85) before adjustment. These associations were no longer significant after adjustment. CONCLUSIONS: Although in our unadjusted analyses we observed significant associations between breastfeeding duration and later psychosocial development, including decreased odds of emotional, conduct, and total difficulties at 6 years of age, these findings were no longer detectable after adjusting for the many potential confounding factors that play a role in psychosocial development. C1 [Lind, Jennifer N.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Publ Hlth Sci Serv, Atlanta, GA 30333 USA. [Lind, Jennifer N.; Li, Ruowei; Perrine, Cria G.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Lind, Jennifer N.; Schieve, Laura A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Lind, Jennifer N.; Perrine, Cria G.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. RP Lind, JN (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS E-86, Atlanta, GA 30333 USA. EM jlind@cdc.gov FU Maternal and Child Health Bureau in the US Department of Health and Human Services; US Food and Drug Administration; Centers for Disease Control and Prevention; Office on Women's Health, National Institutes of Health FX This study was funded by the US Food and Drug Administration, Centers for Disease Control and Prevention, Office on Women's Health, National Institutes of Health, and Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 31 TC 6 Z9 6 U1 0 U2 7 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 SU 1 BP S36 EP S41 DI 10.1542/peds.2014-0646G PG 6 WC Pediatrics SC Pediatrics GA CO2NF UT WOS:000358992600006 PM 25183753 ER PT J AU Pan, LP Li, RW Park, SY Galuska, DA Sherry, B Freedman, DS AF Pan, Liping Li, Ruowei Park, Sohyun Galuska, Deborah A. Sherry, Bettylou Freedman, David S. TI A Longitudinal Analysis of Sugar-Sweetened Beverage Intake in Infancy and Obesity at 6 Years SO PEDIATRICS LA English DT Article DE childhood obesity; sugar-sweetened beverages; infancy; population-based studies; public health ID BODY-MASS INDEX; CARDIOVASCULAR RISK-FACTORS; INCOME PRESCHOOL-CHILDREN; CHILDHOOD OBESITY; US CHILDREN; WEIGHT-GAIN; DIET QUALITY; SOFT DRINKS; ADOLESCENTS; CONSUMPTION AB OBJECTIVE: To examine whether sugar-sweetened beverage (SSB) intake during infancy predicts obesity at age 6 years. METHODS: We included 1189 children who participated in the Infant Feeding Practices Study II in 2005-2007 and were followed up at 6 years in 2012. Children's weight and height were measured by mothers. Obesity was defined as gender-specific BMI-for-age >= 95th percentile. We used logistic regression to estimate the associations of any SSB intake and age at SSB introduction before 12 months and mean SSB intake during ages 10 to 12 months with obesity at 6 years controlling for baseline characteristics. RESULTS: The obesity prevalence at 6 years among children who consumed SSBs during infancy was twice as high as that among non-SSB consumers (17.0% vs 8.6%). The adjusted odds of obesity at 6 years was 71% higher for any SSB intake and 92% higher for SSB introduction before 6 months compared with no SSB intake during infancy. Children who consumed SSBs >= 3 times per week during ages 10 to 12 months had twice the odds of obesity compared with those who consumed no SSBs in this period. However, among children who consumed SSBs, the odds of obesity at 6 years did not differ by age at SSB introduction during infancy or by mean weekly SSB intake during ages 10 to 12 months. CONCLUSIONS: Children who consumed SSBs during infancy had higher odds of obesity at 6 years than non-SSB consumers. SSB consumption during infancy may be a risk factor for obesity in early childhood. Whether unmeasured behaviors contributed to the association is unclear. C1 [Pan, Liping; Li, Ruowei; Park, Sohyun; Galuska, Deborah A.; Sherry, Bettylou; Freedman, David S.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Pan, LP (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Hwy,Mail Stop F-77, Atlanta, GA 30341 USA. EM lpan@cdc.gov FU US Food and Drug Administration; Centers for Disease Control and Prevention; Office of Women's Health, National Institutes of Health; Maternal and Child Health Bureau in the US Department of Health and Human Services FX This study was funded by the US Food and Drug Administration, Centers for Disease Control and Prevention, Office of Women's Health, National Institutes of Health, and Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 37 TC 20 Z9 20 U1 3 U2 16 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 SU 1 BP S29 EP S35 DI 10.1542/peds.2014-0646F PG 7 WC Pediatrics SC Pediatrics GA CO2NF UT WOS:000358992600005 PM 25183752 ER PT J AU Park, S Pan, LP Sherry, B Li, RW AF Park, Sohyun Pan, Liping Sherry, Bettylou Li, Ruowei TI The Association of Sugar-Sweetened Beverage Intake During Infancy With Sugar-Sweetened Beverage Intake at 6 Years of Age SO PEDIATRICS LA English DT Article DE sugar-sweetened beverage; children; Infant Feeding Practice Study II ID YOUNG-CHILDREN; UNITED-STATES; BODY-WEIGHT; SODA INTAKE; CONSUMPTION; ADOLESCENTS; CHILDHOOD; FRUIT; PATTERNS; HABITS AB OBJECTIVES: To examine whether sugar-sweetened beverage (SSB) intake during infancy predicts SSB intake at 6 years of age. METHODS: A longitudinal cohort analysis of 1333 US children was conducted by using data from the 2005-2007 Infant Feeding Practices Study II and the 2012 Follow-Up Study at 6 years of age. The exposure variables were maternal-reported SSB intakes during infancy. The outcome variable was maternal-reported SSB intake at age 6 years. Multivariable logistic regression analyses were used to calculate adjusted odds ratios (aOR) for associations of SSB intake during infancy with consuming SSBs >= 1 time/day at 6 years old after controlling for baseline child's and parent's characteristics. RESULTS: Based on maternal recall, approximately one-fifth of children consumed SSBs at least 1 time/day at age 6 years. Adjusted odds of consuming SSBs at age 6 years >= 1 time/day was significantly associated with any SSB intake during infancy (aOR, 2.22 vs none), age at SSB introduction (aOR, 2.33 for age >= 6 months and 2.01 for age <6 months vs never), and mean SSB intake during age 10 to 12 months (aOR, 2.72 for 1 to <2 times/week and 2.57 for >= 3 times/week vs none). CONCLUSIONS: SSB intake during infancy significantly increased the likelihood of consuming SSBs >= 1 time/day at 6 years of age. Our findings suggest that infancy may be an important time for mothers to establish healthy beverage practices for their children and these findings can be used to inform intervention efforts to reduce SSB intake among children. C1 [Park, Sohyun; Pan, Liping; Sherry, Bettylou; Li, Ruowei] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Park, SY (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Highway,Mail Stop F-77, Atlanta, GA 30341 USA. EM spark3@cdc.gov FU US Food and Drug Administration; Centers for Disease Control and Prevention; Office on Women's Health, National Institutes of Health; Maternal and Child Health Bureau in the US Department of Health and Human Services FX This study was funded by the US Food and Drug Administration, Centers for Disease Control and Prevention, Office on Women's Health, National Institutes of Health, and Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 29 TC 16 Z9 16 U1 2 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 SU 1 BP S56 EP S62 DI 10.1542/peds.2014-0646J PG 7 WC Pediatrics SC Pediatrics GA CO2NF UT WOS:000358992600009 PM 25183757 ER PT J AU Perrine, CG Galuska, DA Thompson, FE Scanlon, KS AF Perrine, Cria G. Galuska, Deborah A. Thompson, Frances E. Scanlon, Kelley S. TI Breastfeeding Duration Is Associated With Child Diet at 6 Years SO PEDIATRICS LA English DT Article DE breastfeeding duration; exclusive breastfeeding; diet; fruits; vegetables; sugar-sweetened beverages ID CARDIOVASCULAR RISK; PRESCHOOL-CHILDREN; FOOD NEOPHOBIA; ACCEPTANCE; DETERMINANTS; PATTERNS; INFANT; VEGETABLES; EXPERIENCE; PREDICTORS AB BACKGROUND AND OBJECTIVE: Breastfeeding has been associated with early infant food preferences, but less is known about how breastfeeding is associated with later child diet. The objective of this study was to assess whether any and exclusive breastfeeding duration are associated with child diet at 6 years. METHODS: We linked data from the Infant Feeding Practices Study II and Year 6 Follow-Up. We used approximately monthly questionnaires throughout infancy to calculate any and exclusive breastfeeding duration (n = 1355). We calculated median daily frequency of intake of water, milk, 100% juice, fruits, vegetables, sugar-sweetened beverages, sweets, and savory snacks at 6 years from a dietary screener and examined frequency of consumption of each food or beverage group by any and exclusive breastfeeding duration. We used separate multivariable logistic regression models to calculate odds of consuming more than the median daily frequency of intake of food or beverage items, adjusting for confounders. RESULTS: Intake of milk, sweets, and savory snacks at 6 years was not associated with any or exclusive breastfeeding duration in unadjusted analyses. Frequency of consumption of water, fruits, and vegetables was positively associated, and intake of sugar-sweetened beverages was inversely associated with any and exclusive breastfeeding duration in adjusted models; 100% juice consumption was inversely associated with exclusive breastfeeding duration only. CONCLUSIONS: Among many other health benefits, breastfeeding is associated with a number of healthier dietary behaviors at age 6. The association between breastfeeding and child diet may be an important factor to consider when examining associations between breastfeeding and child obesity and chronic diseases. C1 [Perrine, Cria G.; Galuska, Deborah A.; Scanlon, Kelley S.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Perrine, Cria G.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. [Thompson, Frances E.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Perrine, CG (reprint author), 4770 Buford Hwy NE,Mailstop F-77, Atlanta, GA 30341 USA. EM cperrine@cdc.gov FU US Food and Drug Administration; Centers for Disease Control and Prevention; Office on Women's Health, National Institutes of Health; Maternal and Child Health Bureau in the US Department of Health and Human Services FX This study was funded by the US Food and Drug Administration, Centers for Disease Control and Prevention, Office on Women's Health, National Institutes of Health, and Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 27 TC 13 Z9 13 U1 2 U2 11 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 SU 1 BP S50 EP S55 DI 10.1542/peds.2014-0646I PG 6 WC Pediatrics SC Pediatrics GA CO2NF UT WOS:000358992600008 PM 25183756 ER PT J AU Sharma, AJ Dee, DL Harden, SM AF Sharma, Andrea J. Dee, Deborah L. Harden, Samantha M. TI Adherence to Breastfeeding Guidelines and Maternal Weight 6 Years After Delivery SO PEDIATRICS LA English DT Article DE breastfeeding; benefits; maternal weight; human milk; exclusivity; duration ID BODY-MASS INDEX; ACTIVE MOTHERS POSTPARTUM; OBESE WOMEN; CARDIOVASCULAR-DISEASE; OVARIAN-CANCER; UNITED-STATES; RISK-FACTORS; LATER-LIFE; LACTATION; OVERWEIGHT AB OBJECTIVES: There is a dearth of information on the long-term maternal effects of breastfeeding. The objective of this study was to examine adherence to breastfeeding recommendations of exclusive breastfeeding for >= 4 months and continuation of breastfeeding for >= 1 year and maternal weight retention 6 years after delivery. METHODS: Using data from the Infant Feeding Practices Study II (IFPS II), we categorized women by the degree to which they met breastfeeding recommendations. Mothers' self-reported weight 6 years after delivery (IFPS Year 6 Follow-Up) was compared with self-reported prepregnancy weight from IFPS II. Using linear regression models, adjusting for covariates, we examined associations between breastfeeding recommendation adherence and weight retention. RESULTS: Of the 726 women in our study, 17.9% never breastfed. Among those who initiated breastfeeding, 29.0% breastfed exclusively for >= 4 months, and 20.3% breastfed exclusively for >= 4 months and continued breastfeeding for >= 12 months. Prepregnancy BMI modified the association between breastfeeding recommendation adherence and weight retention. Adjusting for covariates, we found no association between breastfeeding recommendations adherence and weight retention among normal and overweight mothers. Among obese mothers, there was a significant linear trend (P = .03), suggesting that those who fully adhered to breastfeeding recommendations retained less weight (-8.0 kg) than obese women who never breastfed. CONCLUSIONS: This study suggests that improving adherence to breastfeeding recommendations may help reduce long-term maternal weight retention among obese mothers. Larger studies, with diverse populations and similar longitudinal designs, are needed to explore this relationship. C1 [Sharma, Andrea J.; Dee, Deborah L.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. [Sharma, Andrea J.; Dee, Deborah L.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Harden, Samantha M.] Virginia Tech, Dept Human Nutr Foods & Exercise, Blacksburg, VA USA. RP Sharma, AJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Maternal & Infant Hlth Branch, 4770 Buford Hwy NE,MS-F74, Atlanta, GA 30341 USA. EM AJSharma@cdc.gov OI Sharma, Andrea/0000-0003-0385-0011 FU US Food and Drug Administration; Centers for Disease Control and Prevention; Office on Women's Health, National Institutes of Health; Maternal and Child Health Bureau in the US Department of Health and Human Services FX This study was funded by the US Food and Drug Administration, Centers for Disease Control and Prevention, Office on Women's Health, National Institutes of Health, and Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 53 TC 9 Z9 9 U1 1 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 SU 1 BP S42 EP S49 DI 10.1542/peds.2014-0646H PG 8 WC Pediatrics SC Pediatrics GA CO2NF UT WOS:000358992600007 PM 25183755 ER PT J AU Robinson, LR Perou, R Leeb, RT AF Robinson, Lara R. Perou, Ruth Leeb, Rebecca T. TI News from CDC: the Legacy for Children (TM) parenting model, partnering to translate research to practice for children in poverty SO TRANSLATIONAL BEHAVIORAL MEDICINE LA English DT News Item ID INTERACTIVE SYSTEMS FRAMEWORK; BEHAVIORAL INTERVENTIONS; DEVELOPMENTAL OUTCOMES; IMPLEMENTATION; DISSEMINATION; COMPETENCE C1 [Robinson, Lara R.; Perou, Ruth; Leeb, Rebecca T.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Child Dev Studies Team, Atlanta, GA 30329 USA. RP Robinson, LR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Child Dev Studies Team, MS E-88,1600 Clifton Rd, Atlanta, GA 30329 USA. EM lpr0@cdc.gov NR 20 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 1869-6716 EI 1613-9860 J9 TRANSL BEHAV MED JI Transl. Behav. Med. PD SEP PY 2014 VL 4 IS 3 BP 232 EP 233 DI 10.1007/s13142-014-0266-z PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL2PO UT WOS:000356786700002 PM 25264462 ER PT J AU Tate, JE Arora, R Kang, G Parashar, UD AF Tate, Jacqueline E. Arora, Rashmi Kang, Gagandeep Parashar, Umesh D. TI Rotavirus Vaccines at the Threshold of Implementation in India SO NATIONAL MEDICAL JOURNAL OF INDIA LA English DT Editorial Material ID HOSPITAL-BASED SURVEILLANCE; CHILDREN LESS-THAN-5 YEARS; THAN 5 YEARS; INTUSSUSCEPTION RISK; IMMUNIZATION PROGRAM; GASTROENTERITIS; VACCINATION; STRAINS; INFANTS; MULTICENTER C1 [Tate, Jacqueline E.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Arora, Rashmi] Indian Council Med Res, New Delhi, India. [Kang, Gagandeep] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. RP Tate, JE (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 31 TC 4 Z9 4 U1 0 U2 0 PU ALL INDIA INST MEDICAL SCIENCES PI NEW DELHI PA ANSARI NAGAR, NEW DELHI 110 029, INDIA SN 0970-258X J9 NATL MED J INDIA JI Natl. Med. J. India PD SEP-OCT PY 2014 VL 27 IS 5 BP 245 EP 248 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CK2GE UT WOS:000356028000001 PM 26037421 ER PT J AU Flynn, D Schonberger, LB Dodd, RY Steele, WR AF Flynn, D. Schonberger, L. B. Dodd, R. Y. Steele, W. R. TI Twenty Years of the Creutzfeldt-Jakob Disease Look-back Study: No Evidence of Transfusion Transmission SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting CY OCT 25-28, 2014 CL Philadelphia, PA SP AABB C1 [Flynn, D.; Dodd, R. Y.; Steele, W. R.] Amer Red Cross, Rockville, MD USA. [Schonberger, L. B.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2014 VL 54 SU 2 SI SI MA S29-020B BP 28A EP 28A PG 1 WC Hematology SC Hematology GA CB9PX UT WOS:000349965300037 ER PT J AU Leiby, DA Hapip, CA Kenney, JL Mutebi, J Ahmed, A Stramer, SL AF Leiby, D. A. Hapip, C. A. Kenney, J. L. Mutebi, J. Ahmed, A. Stramer, S. L. TI Preliminary Investigations of Donor Exposure to Eastern Equine Encephalitis Virus and Implications for Risk SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting CY OCT 25-28, 2014 CL Philadelphia, PA SP AABB C1 [Kenney, J. L.; Mutebi, J.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO USA. [Leiby, D. A.; Hapip, C. A.] Amer Red Cross Holland Lab, Rockville, MD USA. [Ahmed, A.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. [Stramer, S. L.] Amer Red Cross, Sci Support Off, Gaithersburg, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2014 VL 54 SU 2 SI SI MA SP394 BP 214A EP 214A PG 1 WC Hematology SC Hematology GA CB9PX UT WOS:000349965300486 ER PT J AU Pathak, S Drammeh, B Mpopo, G Haule, D Mahmoud, M Chang, K Sembuche, S Kutaga, RP De, A AF Pathak, S. Drammeh, B. Mpopo, G. Haule, D. Mahmoud, M. Chang, K. Sembuche, S. Kutaga, R. P. De, A. TI Real-Time Quality Control and Data Management for the National Blood Transfusion Needs Study, Tanzania 2013 SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting CY OCT 25-28, 2014 CL Philadelphia, PA SP AABB C1 [Drammeh, B.; De, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mpopo, G.; Haule, D.] Tanzania Natl Blood Transfus Serv, Dar Es Salaam, Tanzania. [Mahmoud, M.] Zanzibar Natl Blood Transfus Serv, Zanzibar, Tanzania. [Chang, K.] US Ctr Dis Control & Prevent, Amer Sch Publ Hlth, Atlanta, GA USA. [Sembuche, S.] Tanzania Field Epidemiol Lab, Training Program, Dar Es Salaam, Tanzania. [Kutaga, R. P.] Ctr Dis Control & Prevent, Dar Es Salaam, Tanzania. [Pathak, S.] ICF Int, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2014 VL 54 SU 2 SI SI MA A4-030B BP 225A EP 226A PG 2 WC Hematology SC Hematology GA CB9PX UT WOS:000349965300518 ER PT J AU Stanley, J Makhmudova, M Nazaretyan, M Jurkevich, I Schecter, K Usmanova, N Pitman, JP Satybaldieva, A Karabaev, B AF Stanley, J. Makhmudova, M. Nazaretyan, M. Jurkevich, I. Schecter, K. Usmanova, N. Pitman, J. P. Satybaldieva, A. Karabaev, B. TI Strengthening Quality Systems in the Blood Services of the Kyrgyz Republic SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting CY OCT 25-28, 2014 CL Philadelphia, PA SP AABB C1 [Stanley, J.; Makhmudova, M.; Jurkevich, I.; Schecter, K.] Amer Int Hlth Alliance, Washington Dc, DC USA. [Nazaretyan, M.] EPOS Hlth Management GmbH, Bishkek, Kyrgyzstan. [Usmanova, N.] Ctr Dis Control & Prevent, Bishkek, Kyrgyzstan. [Satybaldieva, A.; Karabaev, B.] Republican Blood Ctr, Bishkek, Kyrgyzstan. [Pitman, J. P.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2014 VL 54 SU 2 SI SI MA AP62 BP 261A EP 261A PG 1 WC Hematology SC Hematology GA CB9PX UT WOS:000349965300606 ER PT J AU Baloch, MA Sahar, L AF Baloch, Mansoor A. Sahar, Liora TI Development of a Watershed-Based Geospatial Groundwater Specific Vulnerability Assessment Tool SO GROUNDWATER LA English DT Article ID DRASTIC MODEL; GIS; AQUIFER; WELLS AB This study assesses and characterizes the vulnerability of unregulated groundwater systems to microbial contamination in 18 counties in the state of Georgia using a contamination risk screening strategy based on watershed characteristics and elements of the Safe Drinking Water Act's Wellhead Protection program. Environmental data sources analyzed include septic systems, elevation, land use and land cover data, soil, vegetation coverage, demographics, and livestock. A geospatial overlay/index modeling approach was developed to identify areas of higher vulnerability for groundwater pollution by taking into consideration watershed land use, hydrology, and topography (LHT). Sensitivity analysis was used to evaluate the effectiveness of model variables. The results of the model were validated by using field data and output from U.S. EPA's DRASTIC model, a widely used intrinsic vulnerability assessment tool. The validation showed a higher risk of microbial contamination for wells located in a high to medium LHT vulnerability zones. LHT provided a clear distribution of satisfactory and unsatisfactory wells in the three vulnerability zones; however, the majority of wells (>75%), with both satisfactory and unsatisfactory test results, are located in medium DRASTIC vulnerability zone. This difference between LHT and DRASTIC can be attributed to the microbial contamination specific factors incorporated into LHT index. It is concluded that although inclusion of potential contamination sources on adjacent land uses in the vulnerability assessment framework adds to the complexity of the processes involved in a vulnerability assessment, such inclusion provides a meaningful perspective to groundwater protection efforts as an effective screening tool. C1 [Baloch, Mansoor A.] Ctr Dis Control & Prevent, Environm Hlth Specialists Network EHS Net Water, Environm Hlth Serv Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Baloch, Mansoor A.] REB ModelAnalyt LLC, Atlanta, GA 30341 USA. [Sahar, Liora] Hlth Solut, Publ Hlth Div, Northrop Grumman IS, Atlanta, GA 30341 USA. RP Baloch, MA (reprint author), Ctr Dis Control & Prevent, Environm Hlth Specialists Network EHS Net Water, Environm Hlth Serv Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM mansoorbaloch@gmail.com OI Baloch, Mansoor/0000-0002-1502-086X NR 30 TC 0 Z9 0 U1 3 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-467X EI 1745-6584 J9 GROUNDWATER JI Groundwater PD SEP PY 2014 VL 52 SU 1 BP 137 EP 147 DI 10.1111/gwat.12212 PG 11 WC Geosciences, Multidisciplinary; Water Resources SC Geology; Water Resources GA AZ1DU UT WOS:000347981300014 PM 24854156 ER PT J AU Parsons, MB Travis, D Lonsdorf, EV Lipende, I Collins, A Xiao, L Kamenya, S Elchoufi, D Gillespie, TR AF Parsons, M. B. Travis, D. Lonsdorf, E. V. Lipende, I. Collins, A. Xiao, L. Kamenya, S. Elchoufi, D. Gillespie, T. R. TI ECO-EPIDEMIOLOGY OF ZOONOTIC ENTERIC PATHOGENS FROM HUMANS, WILD PRIMATES AND DOMESTICATED ANIMALS IN THE GREATER GOMBE ECOSYSTEM, TANZANIA SO AMERICAN JOURNAL OF PRIMATOLOGY LA English DT Meeting Abstract CT 37th Annual Meeting of the American-Society-of-Primatologists CY SEP 12-15, 2014 CL Decatur, GA SP Amer Soc Primatologists C1 [Parsons, M. B.; Elchoufi, D.; Gillespie, T. R.] Emory Univ, Math & Sci Ctr E526, Program Populat Biol Ecol & Evolut, Atlanta, GA 30322 USA. [Parsons, M. B.; Elchoufi, D.; Gillespie, T. R.] Emory Univ, Math & Sci Ctr E526, Dept Environm Sci, Atlanta, GA 30322 USA. [Parsons, M. B.; Elchoufi, D.; Gillespie, T. R.] Emory Univ, Math & Sci Ctr E526, Dept Environm Hlth, Atlanta, GA 30322 USA. [Parsons, M. B.; Xiao, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Travis, D.] Univ Minnesota, Coll Vet Med, Minneapolis, MN 55455 USA. [Lonsdorf, E. V.] Franklin & Marshall Coll, Dept Psychol, Lancaster, PA 17604 USA. [Lipende, I.; Collins, A.; Kamenya, S.] Jane Goodall Inst, Kigoma, Tanzania. RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0275-2565 EI 1098-2345 J9 AM J PRIMATOL JI Am. J. Primatol. PD SEP PY 2014 VL 76 SU 1 MA 6 BP 38 EP 38 PG 1 WC Zoology SC Zoology GA CB1GE UT WOS:000349374300007 ER PT J AU Travis, DA Lonsdorf, EV Gillespie, TR Lipende, I Raphael, J Terio, KA Murray, CM Mjungu, D Collins, A Parsons, MB Wolf, T Singer, R Hahn, BH Wilson, ML Pusey, AE AF Travis, D. A. Lonsdorf, E. V. Gillespie, T. R. Lipende, I. Raphael, J. Terio, K. A. Murray, C. M. Mjungu, D. Collins, A. Parsons, M. B. Wolf, T. Singer, R. Hahn, B. H. Wilson, M. L. Pusey, A. E. TI SCIENCE-BASED HEALTH MANAGEMENT PLANNING FOR GREAT APES SO AMERICAN JOURNAL OF PRIMATOLOGY LA English DT Meeting Abstract CT 37th Annual Meeting of the American-Society-of-Primatologists CY SEP 12-15, 2014 CL Decatur, GA SP Amer Soc Primatologists C1 [Travis, D. A.; Wolf, T.; Singer, R.; Wilson, M. L.] Univ Minnesota, Coll Vet Med, St Paul, MN 55108 USA. [Lonsdorf, E. V.] Franklin & Marshall Coll, Lancaster, PA 17604 USA. [Gillespie, T. R.; Parsons, M. B.] Emory Univ, Atlanta, GA 30322 USA. [Lipende, I.; Mjungu, D.; Collins, A.] Jane Goodall Inst, Arlington, VA USA. [Terio, K. A.] Univ Illinois, Chicago, IL 60680 USA. [Murray, C. M.] George Washington Univ, Washington, DC 20052 USA. [Parsons, M. B.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Hahn, B. H.] Univ Penn, Philadelphia, PA 19104 USA. [Pusey, A. E.] Duke Univ, Durham, NC 27706 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0275-2565 EI 1098-2345 J9 AM J PRIMATOL JI Am. J. Primatol. PD SEP PY 2014 VL 76 SU 1 MA 9 BP 39 EP 39 PG 1 WC Zoology SC Zoology GA CB1GE UT WOS:000349374300010 ER PT J AU Vazquez-Prokopec, G Parsons, MB Travis, DA Lonsdorf, EV Lipende, I Gilagiza, B Kamenya, S Pintea, L Gillespie, TR AF Vazquez-Prokopec, G. Parsons, M. B. Travis, D. A. Lonsdorf, E. V. Lipende, I. Gilagiza, B. Kamenya, S. Pintea, L. Gillespie, T. R. TI IDENTIFYING HOTSPOTS FOR ZOONOTIC TRANSMISSION: QUANTIFYING FINE-SCALE MOVEMENT OF DOMESTICATED ANIMALS RELATIVE TO CHIMPANZEES AT GOMBE STREAM NATIONAL PARK, TANZANIA SO AMERICAN JOURNAL OF PRIMATOLOGY LA English DT Meeting Abstract CT 37th Annual Meeting of the American-Society-of-Primatologists CY SEP 12-15, 2014 CL Decatur, GA SP Amer Soc Primatologists C1 [Vazquez-Prokopec, G.; Parsons, M. B.; Gillespie, T. R.] Emory Univ, Dept Environm Sci, Atlanta, GA 30322 USA. [Vazquez-Prokopec, G.; Parsons, M. B.; Gillespie, T. R.] Emory Univ, Dept Environm Hlth, Atlanta, GA 30322 USA. [Vazquez-Prokopec, G.; Parsons, M. B.; Gillespie, T. R.] Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Parsons, M. B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Travis, D. A.] Univ Minnesota, Coll Vet Med, Minneapolis, MN 55455 USA. [Lonsdorf, E. V.] Franklin & Marshall Coll, Lancaster, PA 17604 USA. [Lipende, I.; Gilagiza, B.; Kamenya, S.; Pintea, L.] Jane Goodall Inst, Kigoma, Tanzania. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0275-2565 EI 1098-2345 J9 AM J PRIMATOL JI Am. J. Primatol. PD SEP PY 2014 VL 76 SU 1 MA 8 BP 39 EP 39 PG 1 WC Zoology SC Zoology GA CB1GE UT WOS:000349374300009 ER PT J AU Umapathi, T Islam, Z Islam, MB Mohammad, QD Merkies, ISJ Huak, CY Yuki, N Sejvar, J AF Umapathi, T. Islam, Z. Islam, M. B. Mohammad, Q. D. Merkies, I. S. J. Huak, C. Y. Yuki, N. Sejvar, J. TI CAN ANTIBIOTICS IMPROVE THE OUTCOME OF DIARRHEA-ASSOCIATED GUILLAIN-BARRE SYNDROME?: A DOUBLE-BLIND, PLACEBO CONTROLLED RANDOMISED STUDY SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM LA English DT Meeting Abstract CT Meeting of the Inflammatory-Neuropathy-Consortium of the Peripheral-Nerve-Society CY JUL 13-16, 2014 CL Dusseldorf, GERMANY SP Peripheral Nerve Soc, Inflammatory Neuropathy Consortium C1 [Umapathi, T.] Natl Neurosci Inst, Singapore, Singapore. [Islam, Z.; Islam, M. B.] Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh. [Mohammad, Q. D.] Dhaka Med Coll & Hosp, Dhaka, Bangladesh. [Merkies, I. S. J.] Maastricht Univ, Med Ctr, NL-6200 MD Maastricht, Netherlands. [Huak, C. Y.; Yuki, N.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore. [Sejvar, J.] Ctr Dis Control, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1085-9489 EI 1529-8027 J9 J PERIPHER NERV SYST JI J. Peripher. Nerv. Syst. PD SEP PY 2014 VL 19 IS 3 BP 283 EP 284 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AZ8GN UT WOS:000348453500092 ER PT J AU Baseler, LJ Visvesvara, GS Ramos-Vara, JA AF Baseler, Laura J. Visvesvara, Govinda S. Ramos-Vara, Jose A. TI Pathology in Practice SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Editorial Material ID ENTAMOEBA-INVADENS; SNAKES; AMEBIASIS C1 [Baseler, Laura J.; Ramos-Vara, Jose A.] Purdue Univ, Coll Vet Med, Anim Dis Diagnost Lab, W Lafayette, IN 47907 USA. [Baseler, Laura J.; Ramos-Vara, Jose A.] Purdue Univ, Coll Vet Med, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA. [Visvesvara, Govinda S.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Ramos-Vara, JA (reprint author), Purdue Univ, Coll Vet Med, Anim Dis Diagnost Lab, W Lafayette, IN 47907 USA. EM ramosja@purdue.edu NR 11 TC 0 Z9 0 U1 0 U2 4 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD SEP 1 PY 2014 VL 245 IS 5 BP 501 EP 503 PG 3 WC Veterinary Sciences SC Veterinary Sciences GA CA6DB UT WOS:000348997700022 PM 25148090 ER PT J AU Graitcer, SB Kim, D Lindley, M AF Graitcer, Samuel B. Kim, David Lindley, Megan TI Comprehensive efforts to increase healthcare personnel immunization SO HUMAN VACCINES & IMMUNOTHERAPEUTICS LA English DT Article DE healthcare personnel; immunization practices; vaccination requirements; influenza; Tdap; MMR ID UNITED-STATES; VACCINATION; STAFF; RATES AB Vaccination of healthcare personnel (HCP) is an important component of worker and patient safety, yet vaccination rates are lagging. The findings from Taddei et al.'s study of healthcare personnel immunization attitudes and practices in Florence, Italy provides further data of the importance of routine assessment of and recommendations for vaccines for HCP in order to improve coverage. C1 [Graitcer, Samuel B.; Kim, David; Lindley, Megan] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Graitcer, SB (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM SGraitcer@cdc.gov NR 9 TC 0 Z9 0 U1 1 U2 2 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2164-5515 EI 2164-554X J9 HUM VACC IMMUNOTHER JI Human Vaccines Immunother. PD SEP PY 2014 VL 10 IS 9 BP 2625 EP 2626 DI 10.4161/hv.36090 PG 2 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA AZ6GH UT WOS:000348316800027 PM 25483469 ER PT J AU Zhang, L Ko, S Lv, JJ Ji, F Yan, BY Xu, FJ Xu, AQ AF Zhang, Li Ko, Stephen Lv, Jingjing Ji, Feng Yan, Bingyu Xu, Fujie Xu, Aiqiang TI Perinatal hepatitis B prevention program in Shandong Province, China Evaluation and progress SO HUMAN VACCINES & IMMUNOTHERAPEUTICS LA English DT Article DE Hepatitis B; perinatal transmission; prevention; China ID NEWBORN-INFANTS; IMMUNIZATION; MOTHERS; VACCINE; BIRTH; IMMUNOGLOBULIN; TRANSMISSION; EFFICACY; CHILDREN; ANTIGEN AB Post-exposure prophylaxis with hepatitis B vaccine (HepB) alone is highly effective in preventing perinatal hepatitis B virus (HBV) transmission and the World Health Organization recommends administering HepB to all infants within 24 h after delivery. Maternal screening for HBsAg and administration of hepatitis B immune globulin (HBIG) in addition to HepB for infants born to HBsAg-positive pregnant women can increase the effectiveness of post-exposure prophylaxis for perinatal HBV transmission. In Shangdong Province, China which has a high prevalence of chronic HBV infection, HepB birth dose and HBIG were integrated into the routine childhood immunization program in 2002 and July 2011 respectively. We assessed progress toward implementation of these measures. Hospital-based reporting demonstrated an increase in maternal screening from 70.7% to 96.9% from 2004-2012; HepB birth dose coverage (within 24 h) remained high (96.3-97.1%) during this period. For infants with known HBsAg-positive mothers, the coverage of HBIG increased from 85.0% (before July 2011) to 92.1% (after July 2011). However, HBIG coverage in western areas of Shandong Province remained at 81.1% among infants with known HBsAg-positive mothers. Preterm/low-birth-weight and illness after birth were the most commonly reported reasons for delay in the first dose of HepB to >24 h of birth. Additional education on the safety and immune protection from HepB and HBIG might help to correct delays in administering the HepB birth dose and low HBIG coverage in the western areas of the Shandong Province. C1 [Zhang, Li; Lv, Jingjing; Ji, Feng; Yan, Bingyu; Xu, Aiqiang] Shandong Ctr Dis Control & Prevent, Shandong Prov Key Lab Infect Dis Control & Preven, Jinan, Peoples R China. [Zhang, Li; Lv, Jingjing; Ji, Feng; Yan, Bingyu; Xu, Aiqiang] Shandong Univ, Acad Prevent Med, Jinan 250100, Peoples R China. [Ko, Stephen; Xu, Fujie] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Zhang, L (reprint author), Shandong Ctr Dis Control & Prevent, Shandong Prov Key Lab Infect Dis Control & Preven, Jinan, Peoples R China. EM ZL9127@163.Com FU Major Project of National Science and Technology [2012ZX10002-2001]; Shandong Medical and Health Science and Technology Development Programs [2011HD006] FX This study was supported by the grants from the Major Project of National Science and Technology (No. 2012ZX10002-2001) and from the Shandong Medical and Health Science and Technology Development Programs (No. 2011HD006). NR 21 TC 0 Z9 0 U1 1 U2 1 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2164-5515 EI 2164-554X J9 HUM VACC IMMUNOTHER JI Human Vaccines Immunother. PD SEP PY 2014 VL 10 IS 9 BP 2755 EP 2760 DI 10.4161/hv.29648 PG 6 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA AZ6GH UT WOS:000348316800051 PM 25483482 ER PT J AU Issenhuth-Jeanjean, S Roggentin, P Mikoleit, M Guibourdenche, M de Pinna, E Nair, S Fields, PI Weill, FX AF Issenhuth-Jeanjean, Sylvie Roggentin, Peter Mikoleit, Matthew Guibourdenche, Martine de Pinna, Elizabeth Nair, Satheesh Fields, Patricia I. Weill, Francois-Xavier TI Supplement 2008-2010 (no. 48) to the White-Kauffmann-Le Minor scheme SO RESEARCH IN MICROBIOLOGY LA English DT Article DE Salmonella; Serovars; Taxonomy; MLST; White-Kauffmann-Le Minor scheme ID SALMONELLA AB This supplement (no. 48) of the White-Kauffmann-Le Minor scheme reports on the characterization of 63 new Salmonella serovars and 25 new variants of previously described Salmonella serovars recognized by the WHO Collaborating Centre for Reference and Research on Salmonella between 2008 and 2010. Forty-four new serovars were assigned to Salmonella enterica subspecies enterica, 12 to subspecies salamae, two to subspecies arizonae, two to subspecies diarizonae and three to subspecies houtenae. All these new serovars or new variants are described with their multilocus sequence type. (C) 2014 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. C1 [Issenhuth-Jeanjean, Sylvie; Guibourdenche, Martine; Weill, Francois-Xavier] Inst Pasteur, WHO Collaborating Ctr Reference & Res Salmonella, Unite Bacteries Pathogenes Enter, F-75724 Paris 15, France. [Roggentin, Peter] Salmonella Zentrale, Inst Hyg & Umwelt, Hamburg, Germany. [Mikoleit, Matthew; Fields, Patricia I.] Ctr Dis Control & Prevent, Atlanta, GA USA. [de Pinna, Elizabeth; Nair, Satheesh] Publ Hlth England, Gastrointestinal Bacteria Reference Unit, Colindale, England. RP Weill, FX (reprint author), Inst Pasteur, WHO Collaborating Ctr Reference & Res Salmonella, Unite Bacteries Pathogenes Enter, 28 Rue Dr Roux, F-75724 Paris 15, France. EM fxweill@pasteur.fr OI Weill, Francois-Xavier/0000-0001-9941-5799; Nair, Satheesh/0000-0002-7297-1485 NR 8 TC 20 Z9 21 U1 4 U2 28 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0923-2508 EI 1769-7123 J9 RES MICROBIOL JI Res. Microbiol. PD SEP PY 2014 VL 165 IS 7 BP 526 EP 530 DI 10.1016/j.resmic.2014.07.004 PG 5 WC Microbiology SC Microbiology GA AY6KJ UT WOS:000347674900006 PM 25049166 ER PT J AU Schlosser, M Lampasona, V Williams, AJK Mueller, PW Pittman, DL Winter, WE Akolkar, B Achenbach, P AF Schlosser, M. Lampasona, V. Williams, A. J. K. Mueller, P. W. Pittman, D. L. Winter, W. E. Akolkar, B. Achenbach, P. TI Combined appearance of autoantibodies against GAD, IA-2, insulin and ZnT8 in the islet autoantibody standardisation program 2013 proficiency workshop SO DIABETOLOGIA LA English DT Meeting Abstract C1 [Schlosser, M.] Univ Med Ctr Greifswald, Dept Med Biochem & Mol Biol, Karlsburg, Germany. [Lampasona, V.] Ctr Genom Bioinformat & Biostat, Milan, Italy. [Williams, A. J. K.] Univ Bristol, Bristol BS8 1TH, Avon, England. [Mueller, P. W.] Ctr Dis Control & Prevent, Natl Diabet Lab, Atlanta, GA USA. [Pittman, D. L.; Winter, W. E.] Univ Florida, Dept Pathol, Karlsburg, Germany. [Akolkar, B.] Natl Inst Diabet & Digest & Kidney Dis, Div Diabet Endocrinol & Metab Dis, Bethesda, MD USA. [Achenbach, P.] Helmholtz Ctr Munich, Inst Diabet Res, Munich, Germany. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2014 VL 57 SU 1 MA 334 BP S145 EP S145 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AS6PX UT WOS:000344386100334 ER PT J AU Weidle, PJ Lecher, S Botts, LW Jones, L Spach, DH Alvarez, J Jones, R Thomas, V AF Weidle, Paul J. Lecher, Shirley Botts, Linda W. Jones, LaDawna Spach, David H. Alvarez, Jorge Jones, Rhondette Thomas, Vasavi TI HIV testing in community pharmacies and retail clinics: A model to expand access to screening for HIV infection SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION LA English DT Article DE HIV; point-of-care screening; pharmacist; public health ID MISSED OPPORTUNITIES; PERSPECTIVES; PREVENTION; SERVICES; BARRIERS AB Objective: To test the feasibility of offering rapid, point-of-care human immunodeficiency virus (HIV) testing at community pharmacies and retail clinics. Design: Pilot program to determine how to implement confidential HIV testing services in community pharmacies and retail clinics. Setting: 21 community pharmacies and retail clinics serving urban and rural patients in the United States, from August 2011 to July 2013. Participants: 106 community pharmacy and retail clinic staff members. Intervention: A model was developed to implement confidential HIV counseling and testing services using community pharmacy and retail clinic staff as certified testing providers, or through collaborations with organizations that provide HIV testing. Training materials were developed and sites selected that serve patients from urban and rural areas to pilot test the model. Each site established a relationship with its local health department for HIV testing policies, developed referral lists for confirmatory HIV testing/care, secured a CLIA Certificate of Waiver, and advertised the service. Staff were trained to perform a rapid point-of-care HIV test on oral fluid, and provide patients with confidential test results and information on HIV. Patients with a preliminary positive result were referred to a physician or health department for confirmatory testing and, if needed, HIV clinical care. Main outcome measures: Number of HIV tests completed and amount of time required to conduct testing. Results: The 21 participating sites administered 1,540 HIV tests, with 1,087 conducted onsite by staff during regular working hours and 453 conducted at 37 different HIV testing events (e.g., local health fairs). The median amount of time required for pretest counseling/consent, waiting for test results, and posttest counseling was 4, 23, and 3 minutes, respectively. A majority of the sites (17) said they planned to continue HIV testing after the project period ended and would seek assistance or support from the local health department, a community-based organization, or an AIDS service organization. Conclusion: This pilot project established HIV testing in several community pharmacies and retail clinics to be a feasible model for offering rapid, point-of-care HIV testing. It also demonstrated the willingness and ability of staff at community pharmacies and retail clinics to provide confidential HIV testing to patients. Expanding this model to additional sites and evaluating its feasibility and effectiveness may serve unmet needs in urban and rural settings. C1 [Weidle, Paul J.; Lecher, Shirley; Alvarez, Jorge; Jones, Rhondette; Thomas, Vasavi] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, CDC, Atlanta, GA 30333 USA. [Botts, Linda W.; Jones, LaDawna] ASHLIN Management Grp Inc, Greenbelt, MD USA. [Spach, David H.] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA USA. RP Weidle, PJ (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM pweidle@cdc.gov FU CDC [200-2009-30908-00004] FX Funding provided by CDC contract 200-2009-30908-00004 to ASHLIN Management Group, Inc. NR 26 TC 15 Z9 16 U1 1 U2 8 PU AMER PHARMACEUTICAL ASSOC PI WASHINGTON PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037 USA SN 1544-3191 EI 1544-3450 J9 J AM PHARM ASSOC JI J. Am. Pharm. Assoc. PD SEP-OCT PY 2014 VL 54 IS 5 BP 486 EP 492 DI 10.1331/JAPhA.2014.14045 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AU4SC UT WOS:000345600800012 PM 25216878 ER PT J AU Stenglein, MD Jacobson, ER Wozniak, EJ Wellehan, JFX Kincaid, A Gordon, M Porter, BF Baumgartner, W Stahl, S Kelley, K Towner, JS DeRisi, JL AF Stenglein, Mark D. Jacobson, Elliott R. Wozniak, Edward J. Wellehan, James F. X. Kincaid, Anne Gordon, Marcus Porter, Brian F. Baumgartner, Wes Stahl, Scott Kelley, Karen Towner, Jonathan S. DeRisi, Joseph L. TI Ball Python Nidovirus: a Candidate Etiologic Agent for Severe Respiratory Disease in Python regius SO MBIO LA English DT Article ID BEST-FIT MODELS; SYNDROME CORONAVIRUS; PHYLOGENETIC INFERENCE; PROTEIN EVOLUTION; SARS-CORONAVIRUS; CLASSIC RACE; RNA VIRUS; GENOME; IDENTIFICATION; REVEALS AB A severe, sometimes fatal respiratory disease has been observed in captive ball pythons (Python regius) since the late 1990s. In order to better understand this disease and its etiology, we collected case and control samples and performed pathological and diagnostic analyses. Electron micrographs revealed filamentous virus-like particles in lung epithelial cells of sick animals. Diagnostic testing for known pathogens did not identify an etiologic agent, so unbiased metagenomic sequencing was performed. Abundant nidovirus-like sequences were identified in cases and were used to assemble the genome of a previously unknown virus in the order Nidovirales. The nidoviruses, which were not previously known to infect nonavian reptiles, are a diverse order that includes important human and veterinary pathogens. The presence of the viral RNA was confirmed in all diseased animals (n = 8) but was not detected in healthy pythons or other snakes (n = 57). Viral RNA levels were generally highest in the lung and other respiratory tract tissues. The 33.5-kb viral genome is the largest RNA genome yet described and shares canonical characteristics with other nidovirus genomes, although several features distinguish this from related viruses. This virus, which we named ball python nidovirus (BPNV), will likely establish a new genus in Torovirinae subfamily. The identification of a novel nidovirus in reptiles contributes to our understanding of the biology and evolution of related viruses, and its association with lung disease in pythons is a promising step toward elucidating an etiology for this long-standing veterinary disease. IMPORTANCE Ball pythons are popular pets because of their diverse coloration, generally nonaggressive behavior, and relatively small size. Since the 1990s, veterinarians have been aware of an infectious respiratory disease of unknown cause in ball pythons that can be fatal. We used unbiased shotgun sequencing to discover a novel virus in the order Nidovirales that was present in cases but not controls. While nidoviruses are known to infect a variety of animals, this is the first report of a nidovirus recovered from any reptile. This report will enable diagnostics that will assist in determining the role of this virus in the causation of disease, which would allow control of the disease in zoos and private collections. Given its evolutionary divergence from known nidoviruses and its unique host, the study of reptile nidoviruses may further our understanding of related diseases and the viruses that cause them in humans and other animals. C1 [Stenglein, Mark D.; DeRisi, Joseph L.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. [Jacobson, Elliott R.] Univ Florida, Coll Vet Med, Gainesville, FL USA. [Wozniak, Edward J.] Texas Dept State Hlth Serv, Zoonosis Control Unit, Uvalde, TX USA. [Wellehan, James F. X.] Univ Florida, Coll Vet Med, Dept Small Anim Clin Sci, Gainesville, FL 32610 USA. [Kincaid, Anne] Marshfield Labs, Marshfield, WI USA. [Gordon, Marcus] Mayfair Anim Hosp & Emergency Serv, Milwaukee, WI USA. [Porter, Brian F.] Texas A&M Univ, Dept Vet Pathobiol, College Stn, TX USA. [Baumgartner, Wes] Mississippi State Univ, Coll Vet Med, Dept Pathobiol & Populat Med, Mississippi State, MS 39762 USA. [Stahl, Scott] Stahl Exot Anim Vet Serv, Fairfax, VA USA. [Kelley, Karen] Univ Florida, Interdisciplinary Ctr Biotechnol Res, Gainesville, FL USA. [Towner, Jonathan S.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA USA. [DeRisi, Joseph L.] Howard Hughes Med Inst, Chevy Chase, MD USA. RP DeRisi, JL (reprint author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. EM joe@derisilab.ucsf.edu RI Stenglein, Mark/E-3541-2017 OI Stenglein, Mark/0000-0002-0993-813X FU Howard Hughes Medical Institute; NIH [5T32HL007185-34]; Pacific Southwest Regional Center of Excellence (PSWRCE) (NIH) [U54 AI065359] FX J.L.D. is supported by the Howard Hughes Medical Institute. M. D. S. is supported by NIH grant 5T32HL007185-34 and the Pacific Southwest Regional Center of Excellence (PSWRCE) (NIH grant U54 AI065359). NR 88 TC 10 Z9 10 U1 3 U2 16 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 2150-7511 J9 MBIO JI mBio PD SEP-OCT PY 2014 VL 5 IS 5 AR e01484-14 DI 10.1128/mBio.01484-14 PG 16 WC Microbiology SC Microbiology GA AU2OY UT WOS:000345459000014 PM 25205093 ER PT J AU Turner, MC Benke, G Bowman, JD Figuerola, J Fleming, S Hours, M Kincl, L Krewski, D McLean, D Parent, ME Richardson, L Sadetzki, S Schlaefer, K Schlehofer, B Schuz, J Siemiatycki, J van Tongeren, M Cardis, E AF Turner, Michelle C. Benke, Geza Bowman, Joseph D. Figuerola, Jordi Fleming, Sarah Hours, Martine Kincl, Laurel Krewski, Daniel McLean, Dave Parent, Marie-Elise Richardson, Lesley Sadetzki, Siegal Schlaefer, Klaus Schlehofer, Brigitte Schuez, Joachim Siemiatycki, Jack van Tongeren, Martie Cardis, Elisabeth TI Occupational Exposure to Extremely Low-Frequency Magnetic Fields and Brain Tumor Risks in the INTEROCC Study SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID ELECTRIC UTILITY WORKERS; NERVOUS-SYSTEM TUMORS; ELECTROMAGNETIC-FIELDS; CANCER; LEUKEMIA; POPULATION; FRANCE; SWEDEN; GLIOMA; COHORT AB Background: Occupational exposure to extremely low-frequency magnetic fields (ELF) is a suspected risk factor for brain tumors, however the literature is inconsistent. Few studies have assessed whether ELF in different time windows of exposure maybe associated with specific histologic types of brain tumors. This study examines the association between ELF and brain tumors in the large-scale INTEROCC study. Methods: Cases of adult primary glioma and meningioma were recruited in seven countries (Australia, Canada, France, Germany, Israel, New Zealand, and the United Kingdom) between 2000 and 2004. Estimates of mean workday ELF exposure based on a job exposure matrix were assigned. Estimates of cumulative exposure, average exposure, maximum exposure, and exposure duration were calculated for the lifetime, and 1 to 4, 5 to 9, and 10+ years before the diagnosis/reference date. Results: There were 3,761 included brain tumor cases (1,939 glioma and 1,822 meningioma) and 5,404 population controls. There was no association between lifetime cumulative ELF exposure and glioma or meningioma risk. However, there were positive associations between cumulative ELF 1 to 4 years before the diagnosis/reference date and glioma [odds ratio (OR) >= 90th percentile vs. < 25th percentile, 1.67; 95% confidence interval (CI), 1.36-2.07; P-Linear (trend) < 0.0001], and, somewhat weaker associations with meningioma (OR >= 90th percentile vs. < 25th percentile, 1.23; 95% CI, 0.97-1.57; P-Linear trend = 0.02). Conclusions: Results showed positive associations between ELF in the recent past and glioma. Impact: Occupational ELF exposure may play a role in the later stages (promotion and progression) of brain tumorigenesis. (C)2014 AACR. C1 [Turner, Michelle C.; Figuerola, Jordi; Cardis, Elisabeth] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain. [Turner, Michelle C.; Figuerola, Jordi; Cardis, Elisabeth] Univ Pompeu Fabra, Barcelona, Spain. [Turner, Michelle C.; Figuerola, Jordi; Cardis, Elisabeth] CIBER Epidemiol & Salud Publ, Barcelona, Spain. [Turner, Michelle C.; Krewski, Daniel] Univ Ottawa, Inst Populat Hlth, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON, Canada. [Benke, Geza] Monash Univ, Melbourne, Vic 3004, Australia. [Bowman, Joseph D.] NIOSH, Cincinnati, OH 45226 USA. [Fleming, Sarah] Univ Leeds, Leeds, W Yorkshire, England. [Hours, Martine] Univ Lyon 1, IFSTTAR, Unite Mixte Rech Epidemiol Transport Travail Enir, Lyon, France. [Kincl, Laurel] Oregon State Univ, Corvallis, OR 97331 USA. [Krewski, Daniel] Univ Ottawa, Fac Med, Dept Epidemiol & Community Med, Ottawa, ON, Canada. [McLean, Dave] Massey Univ, Wellington, New Zealand. [Parent, Marie-Elise] Univ Quebec, INRS Inst Armand Frappier, Laval, PQ, Canada. [Richardson, Lesley; Siemiatycki, Jack] Univ Montreal, Hosp Res Ctr, Montreal, PQ, Canada. [Sadetzki, Siegal] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel. [Richardson, Lesley] Chaim Sheba Med Ctr, Gertner Inst, Canc & Radiat Epidemiol Unit, IL-52621 Tel Hashomer, Israel. [Schlaefer, Klaus; Schlehofer, Brigitte] German Canc Res Ctr, Unit Environm Epidemiol, Heidelberg, Germany. [Schuez, Joachim] Int Agcy Res Canc, Sect Environm & Radiat, F-69372 Lyon, France. [van Tongeren, Martie] Inst Occupat Med, Edinburgh EH8 9SV, Midlothian, Scotland. RP Turner, MC (reprint author), Parc Recerca Biomed Barcelona, CREAL Ctr Res Environm Epidemiol, Doctor Aiguader 88, Barcelona 08003, Spain. EM mturner@creal.cat RI Cardis, Elisabeth/C-3904-2017; OI Fleming, Sarah/0000-0002-7655-4806 FU NIH [1R01CA124759]; European Fifth Framework Program [100 QLK4-CT-1999901563]; International Union against Cancer (UICC); Mobile Manufacturers' Forum; GSM Association; Australian National Health and Medical Research 5 Council (EME Grant) [219129]; University of Sydney Medical Foundation Program; Cancer Council NSW; Cancer Council Victoria; Canadian Institutes of Health Research [MOP-42525]; Canada Research Chair programme; Guzzo-CRS Chair in Environment and Cancer; Fonds de la recherche en sante du Quebec; Canadian Institutes of Health Research (CIHR); Canadian Wireless Telecommunications Association; NSERC Chair in Risk Science at the University of Ottawa; l'Association pour la Recherche sur le Cancer (ARC) [N85142]; German Mobile Phone Research Program (Deutsches Mobilfunkforschungsprogramm) of the German Federal Ministry for the Environment, Nuclear 45 Safety, and Nature Protection; Ministry for the Environment and Traffic of the state of Baden-Wurttemberg; Ministry for the Environment of the state of North Rhine-Westphalia; MAIFOR Program (Mainzer Forschungsforderungs programm) of the University of Mainz; Health Research Council; Hawkes Bay Medical Research Foundation; Wellington Medical Research Foundation; Waikato Medical Research Foundation; Cancer Society of New Zealand; Mobile Telecommunications, Health and Research (MTHR) program; Health and Safety Executive; Scottish Executive; Government of Canada Banting Postdoctoral Fellowship; Department of Health FX M.C. Turner was supported by a Government of Canada Banting Postdoctoral Fellowship. The INTEROCC study was supported by the NIH Grant No. 1R01CA124759 (PI E. Cardis). Coding of the French occupational data was in part was supported by AFSSET (Convention No. ST-2005-004). The INTERPHONE study was supported by funding from the European Fifth Framework Program, "Quality of Life and Management of Living Resources" (contract 100 QLK4-CT-1999901563) and the International Union against Cancer (UICC). The UICC received funds for this purpose from the Mobile Manufacturers' Forum and GSM Association. In Australia, funding was received from the Australian National Health and Medical Research 5 Council (EME Grant 219129) with funds originally derived from mobile phone service license fees; a University of Sydney Medical Foundation Program; the Cancer Council NSW and The Cancer Council Victoria. In Canada, funding was received from the Canadian Institutes of Health Research (project MOP-42525); the Canada Research Chair programme; the Guzzo-CRS Chair in Environment and Cancer; the Fonds de la recherche en sante du Quebec; the Canadian Institutes of Health Research (CIHR), the latter including partial support from the Canadian Wireless Telecommunications Association; the NSERC Chair in Risk Science at the University of Ottawa. In France, funding was received by l'Association pour la Recherche sur le Cancer (ARC; Contract N85142) and 3 network operators (Orange, SFR, and Bouygues Telecom). In Germany, funding was received from the German Mobile Phone Research Program (Deutsches Mobilfunkforschungsprogramm) of the German Federal Ministry for the Environment, Nuclear 45 Safety, and Nature Protection; the Ministry for the Environment and Traffic of the state of Baden-Wurttemberg; the Ministry for the Environment of the state of North Rhine-Westphalia; the MAIFOR Program (Mainzer Forschungsforderungs programm) of the University of Mainz. In New Zealand, funding was provided by the Health Research Council, Hawkes Bay Medical Research Foundation, the Wellington Medical Research Foundation, the Waikato Medical Research Foundation, and the Cancer Society of New Zealand. Additional funding for the UK study was received from the Mobile Telecommunications, Health and Research (MTHR) program, funding from the Health and Safety Executive, the Department of Health, the UK Network Operators (O2, Orange, T-Mobile, Vodafone, and "3"), and the Scottish Executive. NR 40 TC 12 Z9 12 U1 1 U2 13 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD SEP PY 2014 VL 23 IS 9 BP 1863 EP 1872 DI 10.1158/1055-9965.EPI-14-0102 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA AT9XC UT WOS:000345276100015 PM 24935666 ER PT J AU Kirchberger, PC Turnsek, M Hunt, DE Haley, BJ Colwell, RR Polz, MF Tarr, CL Boucher, Y AF Kirchberger, Paul C. Turnsek, Maryann Hunt, Dana E. Haley, Bradd J. Colwell, Rita R. Polz, Martin F. Tarr, Cheryl L. Boucher, Yan TI Vibrio metoecus sp nov., a close relative of Vibrio cholerae isolated from coastal brackish ponds and clinical specimens SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY LA English DT Article ID RIBOSOMAL-RNA; SEQUENCE; IDENTIFICATION; MIMICUS AB A Gram-staining-negative, curved-rod-shaped bacterium with close resemblance to Vibrio cholerae, the aetiological agent of cholera, was isolated over the course of several years from coastal brackish water (17 strains) and from clinical cases (two strains) in the United States. 16S rRNA gene identity with V. cholerae exceeded 98% yet an average nucleotide identity based on genome data of around 86 % and multi locus sequence analysis of six housekeeping genes (mdh, adk, gyrB, recA, pgi and rpoB) clearly delineated these isolates as a distinct genotypic cluster within the V. cholerae-V. mimicus clade. Most standard identification techniques do not differentiate this cluster of isolates from V. cholerae. Only amplification of the ompW gene using V. cholerae-specific primers and a negative Voges-Proskauer test showed a difference between the two clusters. Additionally, all isolated strains differed phenotypically from V. cholerae in their ability to utilize N-acetyl-D-galactosamine and D-glucuronic acid as sole carbon sources. Furthermore, they were generally unable to infect the slime mould Dictyostelium discoideum, a widespread ability in V. cholerae. Based on these clear phenotypic differences that are not necessarily apparent in standard tests as well as average nucleotide identity and phylogeny of protein-coding genes, we propose the existence of a novel species, Vibrio metoecus sp. nov. with the type strain OP3H(T) (=LMG 27764(T)=CIP 110643(T)). Due to its close resemblance to V. cholerae and the increasing number of strains isolated over the past several years, we suggest that V. metoecus sp. nov. is a relatively common species of the genus Vibrio, isolates of which have been identified as atypical isolates of V. cholerae in the past. Its isolation from clinical samples also indicates that strains of this species, like V. cholerae, are opportunistic pathogens. C1 [Kirchberger, Paul C.; Boucher, Yan] Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada. [Turnsek, Maryann; Tarr, Cheryl L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hunt, Dana E.] Duke Univ, Nicholas Sch Environm, Beaufort, NC USA. [Haley, Bradd J.; Colwell, Rita R.] Univ Maryland, Inst Adv Comp Studies, College Pk, MD 20742 USA. [Haley, Bradd J.; Colwell, Rita R.] Univ Maryland, Maryland Pathogen Res Inst, College Pk, MD 20742 USA. [Colwell, Rita R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth, Baltimore, MD USA. [Polz, Martin F.] MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA. RP Boucher, Y (reprint author), Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada. EM yboucher@ualberta.ca RI Hunt, Dana/A-2051-2012; OI Colwell, Rita R./0000-0001-5432-1502; /0000-0001-9296-3733; Hunt, Dana/0000-0002-8801-9624 FU Integrated Microbial Biodiversity Program of the Canadian Institute for Advanced Research (CIFAR); National Science and Engineering Research Council of Canada (NSERC) FX This work was supported by the Integrated Microbial Biodiversity Program of the Canadian Institute for Advanced Research (CIFAR) and the National Science and Engineering Research Council of Canada (NSERC). NR 20 TC 9 Z9 9 U1 1 U2 5 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1466-5026 EI 1466-5034 J9 INT J SYST EVOL MICR JI Int. J. Syst. Evol. Microbiol. PD SEP PY 2014 VL 64 BP 3208 EP 3214 DI 10.1099/ijs.0.060145-0 PN 9 PG 7 WC Microbiology SC Microbiology GA AT4MA UT WOS:000344912300042 PM 24972615 ER PT J AU Fitzgerald, C Tu, ZC Patrick, M Stiles, T Lawson, AJ Santovenia, M Gilbert, MJ van Bergen, M Joyce, K Pruckler, J Stroika, S Duim, B Miller, WG Loparev, V Sinnige, JC Fields, PI Tauxe, RV Blaser, MJ Wagenaar, JA AF Fitzgerald, Collette Tu, Zheng Chao Patrick, Mary Stiles, Tracy Lawson, Andy J. Santovenia, Monica Gilbert, Maarten J. van Bergen, Marcel Joyce, Kevin Pruckler, Janet Stroika, Steven Duim, Birgitta Miller, William G. Loparev, Vladimir Sinnige, Jan C. Fields, Patricia I. Tauxe, Robert V. Blaser, Martin J. Wagenaar, Jaap A. TI Campylobacter fetus subsp. testudinum subsp. nov., isolated from humans and reptiles SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY LA English DT Article ID GENUS CAMPYLOBACTER; PCR ASSAY; DIFFERENTIATION; IDENTIFICATION; STRAINS; ORIGINS AB A polyphasic study was undertaken to determine the taxonomic position of 13 Campylobacter fetus-like strains from humans (n=8) and reptiles (n=5). The results of matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) MS and genomic data from sap analysis, 16S rRNA gene and hsp60 sequence comparison, pulsed-field gel electrophoresis, amplified fragment length polymorphism analysis, DNA-DNA hybridization and whole genome sequencing demonstrated that these strains are closely related to C. fetus but clearly differentiated from recognized subspecies of C. fetus. Therefore, this unique cluster of 13 strains represents a novel subspecies within the species C. fetus, for which the name Campylobacter fetus subsp. testudinum subsp. nov. is proposed, with strain 03-427(T) (=ATCC BAA-2539(T)=LMG 27499(T)) as the type strain. Although this novel taxon could not be differentiated from C. fetus subsp. fetus and C. fetus subsp. venerealis using conventional phenotypic tests, MALDI-TOF MS revealed the presence of multiple phenotypic biomarkers which distinguish Campylobacter fetus subsp. testudinum subsp. nov. from recognized subspecies of C. fetus. C1 [Fitzgerald, Collette; Patrick, Mary; Santovenia, Monica; Joyce, Kevin; Pruckler, Janet; Stroika, Steven; Loparev, Vladimir; Fields, Patricia I.; Tauxe, Robert V.] CDC, Biotechnol Core Facil Branch, Div Sci Resources, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Tu, Zheng Chao; Blaser, Martin J.] NYU, Dept Med, Sch Med, New York, NY 10016 USA. [Stiles, Tracy] Massachusetts Dept Publ Hlth, Jamaica Plain, MA USA. [Lawson, Andy J.] Publ Hlth England, London, England. [Gilbert, Maarten J.; Duim, Birgitta; Wagenaar, Jaap A.] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Utrecht, Netherlands. [Gilbert, Maarten J.; van Bergen, Marcel; Duim, Birgitta; Wagenaar, Jaap A.] WHO Collaborating Ctr Campylobacter, OIE Reference Lab Campylobacteriosis, Utrecht, Netherlands. [van Bergen, Marcel; Wagenaar, Jaap A.] Cent Vet Inst Wageningen UR, Lelystad, Netherlands. [Miller, William G.] ARS, USDA, WRRC, Prod Safety & Microbiol Res Unit, Albany, CA USA. [Sinnige, Jan C.] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands. RP Fitzgerald, C (reprint author), Ctr Dis Control & Prevent, Natl Campylobacter & Helicobacter Reference Lab, Enter Dis Lab Branch, Div Foodborne Waterborne & Environm Dis,Natl Ctr, 1600 Clifton Rd NE,Mailstop C-03, Atlanta, GA 30329 USA. EM chf3@cdc.gov NR 22 TC 14 Z9 15 U1 1 U2 3 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1466-5026 EI 1466-5034 J9 INT J SYST EVOL MICR JI Int. J. Syst. Evol. Microbiol. PD SEP PY 2014 VL 64 BP 2944 EP 2948 DI 10.1099/ijs.0.057778-0 PN 9 PG 5 WC Microbiology SC Microbiology GA AT4MA UT WOS:000344912300003 PM 24899653 ER PT J AU Contreras-Gutierrez, MA Velez, ID Porter, C Uribe, SI AF Angelica Contreras-Gutierrez, Maria Dario Velez, Ivan Porter, Charles Ines Uribe, Sandra TI An updated checklist of Phlebotomine sand flies (Diptera: Psychodidae: Phlebotominae) from the Colombian Andean coffee-growing region SO BIOMEDICA LA Spanish DT Article DE leishmaniasis; Psychodidae; Lutzomyia; coffee; Colombia ID LEISHMANIA VIANNIA BRAZILIENSIS; AMERICAN CUTANEOUS LEISHMANIASIS; VESICULAR STOMATITIS-VIRUS; VISCERAL LEISHMANIASIS; LUTZOMYIA-EVANSI; RELATIVE ABUNDANCE; UNITED-STATES; COSTA-RICA; VECTORS; FOCUS AB An updated list of phlebotomine sand flies species in coffee growing areas in the Colombian Andean region is presented. Fifty three species were reported from 12 departments. In addition, species distribution in the region was derived from specimens obtained during intensive field work in five departments, from previously published studies and from the taxonomic revision of specimens in the entomological collection of the Programa de Estudio y Control de Enfermedades Tropicales (PECET). The list includes the genera Brumptomyia (2 species), Lutzomyia (50 species) and Warileya (1 species). The updated list contains eleven new records in the region under study, including Lutzomyia panamensis, a species of medical importance not recorded previously in this zone. Eighteen of the species are considered to be anthropophilic, and many of them have been implicated in the transmission of leishmaniasis. C1 [Angelica Contreras-Gutierrez, Maria; Dario Velez, Ivan] Univ Antioquia, Programa Estudio & Control Enfermedades Trop, PECET, Medellin, Colombia. [Angelica Contreras-Gutierrez, Maria; Ines Uribe, Sandra] Univ Nacl Colombia, Fac Ciencias, Grp Invest Sistemat Mol, Lab Biol & Sistemat Insectos Insectario, Medellin, Colombia. [Porter, Charles] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, CDC, Atlanta, GA USA. RP Contreras-Gutierrez, MA (reprint author), Univ Nacl Colombia, Fac Ciencias, Grp Invest Sistemat Mol, Calle 59A 63-20,Bloque 16,Lab 112, Medellin, Colombia. EM maria.contreras@pecet-colombia.org NR 128 TC 4 Z9 4 U1 0 U2 5 PU INST NACIONAL SALUD PI BOGOTA D C PA AVENIDA CALLE 26 NO 51-60, APARTADO AEREO 80334 Y 80080, BOGOTA D C, 00000, COLOMBIA SN 0120-4157 J9 BIOMEDICA JI Biomedica PD SEP PY 2014 VL 34 IS 3 BP 483 EP 498 DI 10.7705/biomedica.v34i3.2121 PG 16 WC Tropical Medicine SC Tropical Medicine GA AS7JZ UT WOS:000344433800017 PM 25504134 ER PT J AU Ferdinands, JM Olsho, LEW Agan, AA Bhat, N Sullivan, RM Hall, M Mourani, PM Thompson, M Randolph, AG AF Ferdinands, Jill M. Olsho, Lauren E. W. Agan, Anna A. Bhat, Niranjan Sullivan, Ryan M. Hall, Mark Mourani, Peter M. Thompson, Mark Randolph, Adrienne G. CA Pediat Acute Lung Injury Sepsis TI Effectiveness of Influenza Vaccine Against Life-threatening RT-PCR-confirmed Influenza Illness in US Children, 2010-2012 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE case-control studies; child; influenza vaccines; intensive care; respiratory failure; influenza infection ID IMMUNIZATION PRACTICES ACIP; TEST-NEGATIVE DESIGN; YOUNG-CHILDREN; UNITED-STATES; ADVISORY-COMMITTEE; A H1N1; SEASON; HOSPITALIZATIONS; RECOMMENDATIONS; PREVENTION AB Background. No studies have examined the effectiveness of influenza vaccine against intensive care unit (ICU) admission associated with influenza virus infection among children. Methods. In 2010-2011 and 2011-2012, children aged 6 months to 17 years admitted to 21 US pediatric intensive care units (PICUs) with acute severe respiratory illness and testing positive for influenza were enrolled as cases; children who tested negative were PICU controls. Community controls were children without an influenza-related hospitalization, matched to cases by comorbidities and geographic region. Vaccine effectiveness was estimated with logistic regression models. Results. We analyzed data from 44 cases, 172 PICU controls, and 93 community controls. Eighteen percent of cases, 31% of PICU controls, and 51% of community controls were fully vaccinated. Compared to unvaccinated children, children who were fully vaccinated were 74% (95% CI, 19% to 91%) or 82% (95% CI, 23% to 96%) less likely to be admitted to a PICU for influenza compared to PICU controls or community controls, respectively. Receipt of 1 dose of vaccine among children for whom 2 doses were recommended was not protective. Conclusions. During the 2010-2011 and 2011-2012 US influenza seasons, influenza vaccination was associated with a three-quarters reduction in the risk of life-threatening influenza illness in children. C1 [Ferdinands, Jill M.; Thompson, Mark] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Ferdinands, Jill M.] Battelle Mem Inst, Atlanta, GA USA. [Olsho, Lauren E. W.] Abt Associates Inc, Cambridge, MA USA. [Agan, Anna A.; Sullivan, Ryan M.; Randolph, Adrienne G.] Boston Childrens Hosp, Dept Anesthesia Perioperat & Pain Med Crit Care, Boston, MA USA. [Bhat, Niranjan] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Hall, Mark] Nationwide Childrens Hosp, Div Crit Care Med, Columbus, OH USA. [Mourani, Peter M.] Univ Colorado, Sch Med, Dept Pediat, Sect Crit Care Med, Aurora, CO USA. [Mourani, Peter M.] Childrens Hosp Colorado, Aurora, CO USA. RP Ferdinands, JM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-20, Atlanta, GA 30333 USA. EM jferdinands@cdc.gov OI Randolph, Adrienne/0000-0002-3084-3071 FU US Centers for Disease Control and Prevention [200-2010-F33396] FX This work was supported by funding from the US Centers for Disease Control and Prevention to Abt Associates, Inc, Cambridge, MA (contract 200-2010-F33396). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 45 TC 26 Z9 27 U1 0 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2014 VL 210 IS 5 BP 674 EP 683 DI 10.1093/infdis/jiu185 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AT0DQ UT WOS:000344607800002 PM 24676207 ER PT J AU Sheth, AN Evans-Strickfaden, T Haaland, R Martin, A Gatcliffe, C Adesoye, A Omondi, MW Lupo, LD Danavall, D Easley, K Chen, CY Pau, CP Hart, C Ofotokun, I AF Sheth, Anandi N. Evans-Strickfaden, Tammy Haaland, Richard Martin, Amy Gatcliffe, Chelsea Adesoye, Adebola Omondi, Michael W. Lupo, L. Davis Danavall, Damien Easley, Kirk Chen, Cheng-Yen Pau, Chou-Pong Hart, Clyde Ofotokun, Igho TI HIV-1 Genital Shedding is Suppressed in the Setting of High Genital Antiretroviral Drug Concentrations Throughout the Menstrual Cycle SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE female genital tract; HIV-1; pharmacology; viral shedding ID HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS; PLASMA VIRAL LOAD; RNA LEVELS; CERVICOVAGINAL HIV-1; INFECTED WOMEN; TYPE-1 RNA; TRACT; THERAPY; SECRETIONS AB Background. It is not known if fluctuations in genital tract antiretroviral drug concentrations correlate with genital virus shedding in human immunodeficiency virus (HIV)-infected women on antiretroviral therapy (ART). Methods. Among 20 HIV-infected women on ART (tenofovir [TFV], emtricitabine [FTC], and ritonavir-boosted atazanavir [ATV]) with suppressed plasma virus loads, blood and cervicovaginal samples collected twice weekly for 3 weeks were tested for antiretroviral concentrations, HIV-1 RNA, and proviral DNA. Results. Cervicovaginal: plasma antiretroviral concentration ratios were highest for FTC (11.9, 95% confidence interval [CI], 8.66-16.3), then TFV (3.52, 95% CI, 2.27-5.48), and ATV (2.39, 95% CI, 1.69-3.38). Within-and between-person variations in plasma and genital antiretroviral concentrations were observed. Low amounts of genital HIV-1 RNA (<50 copies/mL) were detected in 45% of women at 16% of visits. Genital HIV-1 DNA was detected in 70% of women at 35% of visits. Genital virus detection was associated with higher concentrations of mucosal leukocytes but not with genital antiretroviral concentrations, menstrual cycle phase, bacterial vaginosis, genital bleeding, or plasma virus detection. Conclusions. Standard doses of ART achieved higher genital than plasma concentrations across the menstrual cycle. Therapeutic ART suppresses genital virus shedding throughout the menstrual cycle, even in the presence of factors reported to increase virus shedding. C1 [Sheth, Anandi N.; Gatcliffe, Chelsea; Ofotokun, Igho] Emory Univ, Div Infect Dis, Dept Med, Sch Med, Atlanta, GA 30303 USA. [Evans-Strickfaden, Tammy; Haaland, Richard; Martin, Amy; Adesoye, Adebola; Omondi, Michael W.; Lupo, L. Davis; Pau, Chou-Pong; Hart, Clyde] Emory Univ, Sch Publ Hlth, Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30303 USA. [Easley, Kirk] Emory Univ, Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30303 USA. [Danavall, Damien; Chen, Cheng-Yen] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Ofotokun, I (reprint author), Emory Univ, Div Infect Dis, Dept Med, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA. EM iofotok@emory.edu RI Ofotokun, Ighovwerha/L-6545-2015; Easley, Kirk/K-6910-2015 OI Ofotokun, Ighovwerha/0000-0003-2735-1903; Easley, Kirk/0000-0003-4419-2617 FU National Center for Advancing Translational Sciences of the National Institutes of Health [KL2TR000455, UL1TR000454] FX This work was supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health (KL2TR000455 and UL1TR000454). NR 40 TC 7 Z9 7 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2014 VL 210 IS 5 BP 736 EP 744 DI 10.1093/infdis/jiu166 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AT0DQ UT WOS:000344607800010 PM 24643223 ER PT J AU Lowe, BD Albers, J Hudock, SD AF Lowe, Brian D. Albers, James Hudock, Stephen D. TI A biomechanical assessment of hand/arm force with pneumatic nail gun actuation systems SO INTERNATIONAL JOURNAL OF INDUSTRIAL ERGONOMICS LA English DT Article DE Nail gun; Ergonomics; Fatigue ID INJURIES; CARPENTERS; STRESS AB A biomechanical model is presented to estimate user hand/arm force exertion with two pneumatic nail gun trigger systems. The sequential actuation trigger (SAT) is safer than the contact actuation trigger (CAT) but increases the user's exertion of force because the trigger must be actuated after the safety tip is held pressed against the workpiece. Time integrated hand force was calculated for a single user based on direct measurement of nail gun tip force against the workpiece (tip contact) and from estimated force to support the tool weight during transfer between nails and during idle holding. The model shows that hand/arm force increases when nailing with the SAT (relative to CAT) and with a vertically-oriented workpiece (relative to horizontal). Expressed per nail fired, the user exerted 0.13 Ns (horizontal orientation) and 2.88 Ns (vertical orientation) integrated hand force during tip contact with CAT compared to 26.15 Ns (horizontal) and 46.08 Ns (vertical) with SAT. Depending upon idle holding duration, integrated hand force during tip contact was estimated to have been 1-3% of 48-132 Ns total hand force with CAT and 21-44% of 83-167 Ns total hand force with SAT (average of horizontal and vertical orientations). Based on standard time allowances from work measurement systems it is proposed that efficient application of hand force during tip contact with SAT can reduce this contribution to 6-15% of 55-139 Ns total hand force. The model is useful for considering differences in hand/arm force exertion between the SAT and CAT systems Relevance to industry: This paper presents a model of hand/arm force associated with two types of pneumatic nail gun actuation (trigger) systems. The model clarifies differences in user force exertion with the sequential actuation and contact actuation triggers to inform nail gun trigger selection decisions. Published by Elsevier B.V. C1 [Lowe, Brian D.; Albers, James; Hudock, Stephen D.] NIOSH, Cincinnati, OH 45226 USA. RP Lowe, BD (reprint author), NIOSH, 4676 Columbia Pkwy,MS C-24, Cincinnati, OH 45226 USA. EM blowe@cdc.gov; jqa9@cdc.gov; sxh5@cdc.gov FU Intramural CDC HHS [CC999999] NR 15 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0169-8141 EI 1872-8219 J9 INT J IND ERGONOM JI Int. J. Ind. Ergon. PD SEP PY 2014 VL 44 IS 5 BP 715 EP 722 DI 10.1016/j.ergon.2014.06.007 PG 8 WC Engineering, Industrial; Ergonomics SC Engineering GA AS7MH UT WOS:000344439600013 PM 26321780 ER PT J AU Williams, WJ Coca, A Kim, JH Roberge, R AF Williams, W. Jon Coca, Aitor Kim, Jung-Hyun Roberge, Raymond TI Repeatability of physiological responses during two repeated protective clothing performance tests under identical test conditions SO INTERNATIONAL JOURNAL OF INDUSTRIAL ERGONOMICS LA English DT Article DE Repeatability protective clothing; User performance testing; Physiological responses ID UNCOMPENSABLE HEAT-STRESS; CONTAINED BREATHING APPARATUS; FLUID REPLACEMENT; CORE TEMPERATURE; BODY-TEMPERATURE; FIRE FIGHTERS; EXERCISE; TOLERANCE; WORK; FIREFIGHTERS AB Physiological variables were measured in subjects (n = 10) during exercise (50% V O-2max) on two separate occasions while wearing protective clothing under identical controlled conditions (22 degrees C, 50% relative humidity). We hypothesized that there would be no significant difference in measured physiological variables between two separate trials. Rectal temperature and heart rate responses were not statistically different between trials and within subjects (p = 0270; p = 0.85, respectively) whereas mean skin temperature (p = 0.049) and sweat rate ([kg.h(-1)]; 1.31 +/- 0.52 vs. 1.17 +/- 038; p = 0.438) showed a greater variability between trials. We concluded that in general, that heart rate and rectal temperature responses during exercise testing while wearing protective clothing are less variable and more repeatable than sweat rate and skin temperature responses. Relevance to Industry: Comparison of the physiological "burden" of different protective ensembles may aid industry in the proper selection and use of the ensemble that balances both the protective nature against hazards with the least physiological burden to the wearer. Repeatable testing increases the reliability of the selection of the appropriate ensemble. Published by Elsevier B.V. C1 [Williams, W. Jon; Coca, Aitor; Kim, Jung-Hyun; Roberge, Raymond] NIOSH, Natl Personal Protect Technol Lab, CDC, Pittsburgh, PA 15236 USA. RP Williams, WJ (reprint author), NIOSH, Natl Personal Protect Technol Lab, CDC, 626 Cochrans Mill Rd,B29-108, Pittsburgh, PA 15236 USA. EM aun7@cdc.gov FU Department of Defense Technical Support Working Group (TSWG); International Association of Firefighters (IAFF) FX The authors wish to express their gratitude to the Department of Defense Technical Support Working Group (TSWG) and the International Association of Firefighters (IAFF) for the funding (in part) and overall project management of this study. The authors also wish to thank Ms. Nicolette Shriver for her technical support of the study. This research was performed while one of its authors, Dr. Aitor Coca, held a NIOSH National Research Council Resident Research Associateship. Finally, the authors wish to thank the subjects who generously donated their time to participate in this study. NR 31 TC 1 Z9 1 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0169-8141 EI 1872-8219 J9 INT J IND ERGONOM JI Int. J. Ind. Ergon. PD SEP PY 2014 VL 44 IS 5 BP 793 EP 799 DI 10.1016/j.ergon.2014.06.009 PG 7 WC Engineering, Industrial; Ergonomics SC Engineering GA AS7MH UT WOS:000344439600022 ER PT J AU Panos, JJ O'Callaghan, JP Miller, DB Ferguson, SA AF Panos, John J. O'Callaghan, James P. Miller, Diane B. Ferguson, Sherry A. TI Effects of developmental methylphenidate (MPH) treatment on monoamine neurochemistry of male and female rats SO NEUROTOXICOLOGY AND TERATOLOGY LA English DT Article DE Methylphenidate; Rat; Monoamines; Development; Dopamine ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DOPAMINE TRANSPORTER; NEONATAL-RAT; YOUNG-RATS; IN-VIVO; BRAIN; EXPRESSION; STRIATUM; STIMULANTS; PREVALENCE AB Attention Deficit Hyperactivity Disorder (ADHD) is estimated to affect 4-5% of the adult human population (Kessler et al., 2006; Willcutt, 2012). Often prescribed to attenuate ADHD symptoms (Nair and Moss, 2009), methylphenidate hydrochloride (MPH) can have substantial positive effects. However, there is a paucity of literature regarding its use during pregnancy. Thus, adult women with ADHD face a difficult decision when contemplating pregnancy. In this study, pregnant Sprague-Dawley rats were orally treated a total of 0 (water), 6 (low), 18 (medium), or 42 (high) mg MPH/kg body weight/day (divided into three doses) on gestational days 6-21 (i.e., the low dose received 2 mg MPH/kg body weight 3 x/day). Offspring were orally treated with the same daily dose as their dam (divided into two doses) on postnatal days (PNDs) 1-21. One offspring/sex/litter was sacrificed at PND 22 or PND 104 (n = 6-7/age/sex/treatment group) and the striatum was quickly dissected and frozen. High Performance Liquid Chromatography (HPLC) coupled to a Photo Diode Array detector (PDA) was used to analyze monoamine content in the striatum of one side while a sandwich ELISA was used to analyze tyrosine hydroxylase (TH) from the other side. Age significantly affected monoamine and metabolite content as well as turnover ratios (i.e., DA, DOPAC, HVA, DOPAC/DA, HVA/DA, 5-HT and 5-HIAA); however, there were no significant effects of sex. Adult rats of the low MPH group had higher DA levels than control adults (p < 0.05). At both ages, subjects of the low MPH group had higher TH levels than controls (p < 0.05), although neither effect (i.e., higher DA or TH levels) exhibited an apparent dose-response. PND 22 subjects of the high MPH treatment group had higher ratios of HVA/DA and DOPAC/DA than same-age control subjects (p < 0.05). The increased TH levels of the low MPH group may be related to the increased DA levels of adult rats. While developmental MPH treatment appears to have some effects on monoamine system development, further studies are required to determine if these alterations manifest as functional changes in behavior. Published by Elsevier Inc. C1 [Panos, John J.; Ferguson, Sherry A.] US FDA, Natl Ctr Toxicol Res, Div Neurotoxicol, Jefferson, AR 72079 USA. [O'Callaghan, James P.; Miller, Diane B.] CDC, NIOSH, Atlanta, GA 30333 USA. RP Ferguson, SA (reprint author), US FDA, Natl Ctr Toxicol Res, 3900 NCTR Rd, Jefferson, AR 72079 USA. EM Sherry.Ferguson@fda.hhs.gov OI Panos, John/0000-0002-7607-7114; Ferguson, Sherry/0000-0002-5120-0219 FU National Center for Toxicological Research/U.S. Food and Drug Administration [E7318] FX This work was supported by the National Center for Toxicological Research/U.S. Food and Drug Administration [Protocol #E7318 to S.A.F.]. The authors are grateful for the technical expertise provided by the animal care staff of the Priority One Corporation and appreciate the careful study supervision by Mr. C. Delbert Law of the Division of Neurotoxicology. NR 33 TC 0 Z9 0 U1 2 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0892-0362 EI 1872-9738 J9 NEUROTOXICOL TERATOL JI Neurotoxicol. Teratol. PD SEP-OCT PY 2014 VL 45 BP 70 EP 74 DI 10.1016/j.ntt.2014.08.001 PG 5 WC Neurosciences; Toxicology SC Neurosciences & Neurology; Toxicology GA AS7HP UT WOS:000344427900007 PM 25132048 ER PT J AU Jones, BC O'Callaghan, JP Lu, L Williams, RW Alam, G Miller, DB AF Jones, Byron C. O'Callaghan, James P. Lu, Lu Williams, Robert W. Alam, Gelareh Miller, Diane B. TI Genetic correlational analysis reveals no association between MPP+ and the severity of striatal dopaminergic damage following MPTP treatment in BXD mouse strains SO NEUROTOXICOLOGY AND TERATOLOGY LA English DT Article DE Genetic correlational analysis; BXD recombinant inbred mice ID 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; NEUROTOXICITY; INDUCTION; MICE AB 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a pro-neurotoxicant that must be metabolized to 1-methyl-4-phenylpyridinium (MPP+) and taken up into striatal dopaminergic neurons to produce neurodegeneration. Recently, we showed wide genetic variability in MPTP-associated neuronal damage in a panel of recombinant inbred mouse strains. Here we examined the amount of MPP+ produced in the striatum in the same strains of inbred BXD mice. This allowed us to determine if the differences in the dopaminergic neurotoxicity and associated astrogliosis among the BXD mouse strains were due to differential metabolism of MPTP to MPP+. Using the same BXD mouse strains examined previously (Jones et at, 2013) we found that the extent of the striatal damage produced following MPIP treatment is not correlated quantitatively with the production of MPP+ in the striatum. Our findings also extend those of others regarding strain differences in MPTP-induced dopaminergic neurotoxicity. Importantly, our finding suggests that additional factors influence the neurodegenerative response other than the presence and amount of the toxicant at the target site. Published by Elsevier Inc. C1 [Jones, Byron C.; Alam, Gelareh] Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA. [O'Callaghan, James P.; Miller, Diane B.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Lu, Lu; Williams, Robert W.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA. RP Miller, DB (reprint author), NIOSH, CDC, Morgantown, WV 26505 USA. EM dum6@cdc.gov OI Jones, Byron/0000-0002-4985-6729; Williams, Robert/0000-0001-8924-4447 FU UTHSC; CDC-NIOSH; Penn State University; NIAAA Integrative Neuroscience Initiative on Alcoholism [U01AA016662, U01 AA013499]; UTHSC Center for Integrative and Translational Genomics; USPHS [R01 ES022614] FX The intramural funds are from UTHSC, CDC-NIOSH and Penn State University, NIAAA Integrative Neuroscience Initiative on Alcoholism (U01AA016662, U01 AA013499) and the UTHSC Center for Integrative and Translational Genomics. This study is supported in part by USPHS Grant R01 ES022614. NR 9 TC 3 Z9 3 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0892-0362 EI 1872-9738 J9 NEUROTOXICOL TERATOL JI Neurotoxicol. Teratol. PD SEP-OCT PY 2014 VL 45 BP 91 EP 92 DI 10.1016/j.ntt.2014.08.005 PG 2 WC Neurosciences; Toxicology SC Neurosciences & Neurology; Toxicology GA AS7HP UT WOS:000344427900009 PM 25192776 ER PT J AU Cannon, MJ Griffiths, PD Aston, V Rawlinson, WD AF Cannon, Michael J. Griffiths, Paul D. Aston, Van Rawlinson, William D. TI Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit? SO REVIEWS IN MEDICAL VIROLOGY LA English DT Review ID HUMAN CYTOMEGALOVIRUS-INFECTION; SPOKEN LANGUAGE-DEVELOPMENT; SENSORINEURAL HEARING-LOSS; SERVICES-TASK-FORCE; DRIED BLOOD SPOTS; COCHLEAR IMPLANTATION; EARLY INTERVENTION; CONTROLLED-TRIAL; UNITED-STATES; INTELLECTUAL-DEVELOPMENT AB Congenital CMV infection is a leading cause of childhood disability. Many children born with congenital CMV infection are asymptomatic or have nonspecific symptoms and therefore are typically not diagnosed. A strategy of newborn CMV screening could allow for early detection and intervention to improve clinical outcomes. Interventions might include antiviral drugs or nonpharmaceutical therapies such as speech-language therapy or cochlear implants. Using published data from developed countries, we analyzed existing evidence of potential benefit that could result from newborn CMV screening. We first estimated the numbers of children with the most important CMV-related disabilities (i.e. hearing loss, cognitive deficit, and vision impairment), including the age at which the disabilities occur. Then, for each of the disabilities, we examined the existing evidence for the effectiveness of various interventions. We concluded that there is good evidence of potential benefit from nonpharmaceutical interventions for children with delayed hearing loss that occurs by 9 months of age. Similarly, we concluded that there is fair evidence of potential benefit from antiviral therapy for children with hearing loss at birth and from nonpharmaceutical interventions for children with delayed hearing loss occurring between 9 and 24 months of age and for children with CMV-related cognitive deficits. We found poor evidence of potential benefit for children with delayed hearing loss occurring after 24 months of age and for children with vision impairment. Overall, we estimated that in the United States, several thousand children with congenital CMV could benefit each year from newborn CMV screening, early detection, and interventions. Copyright (C) 2014 John Wiley & Sons, Ltd. C1 [Cannon, Michael J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Griffiths, Paul D.] UCL Med Sch, Ctr Virol, London, England. [Aston, Van] Emory Univ, Atlanta, GA 30322 USA. [Rawlinson, William D.] Univ NSW, SOMS, BABS, Sydney, NSW, Australia. [Rawlinson, William D.] Univ NSW, ACPS, Sydney, NSW, Australia. [Rawlinson, William D.] SESLHD, SEALS Microbiol, Virol Div, Sydney, NSW, Australia. RP Cannon, MJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop E-86, Atlanta, GA 30333 USA. EM mcannon@cdc.gov OI Rawlinson, William/0000-0003-0988-7827 FU Intramural CDC HHS [CC999999] NR 111 TC 20 Z9 20 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1052-9276 EI 1099-1654 J9 REV MED VIROL JI Rev. Med. Virol. PD SEP PY 2014 VL 24 IS 5 BP 291 EP 307 DI 10.1002/rmv.1790 PG 17 WC Virology SC Virology GA AS9EC UT WOS:000344544900002 PM 24760655 ER PT J AU Levis, DM Stone-Wiggins, B O'Hegarty, M Tong, VT Polen, KND Cassell, CH Council, M AF Levis, Denise M. Stone-Wiggins, Brenda O'Hegarty, Michelle Tong, Van T. Polen, Kara N. D. Cassell, Cynthia H. Council, Mary TI Women's Perspectives on Smoking and Pregnancy and Graphic Warning Labels SO AMERICAN JOURNAL OF HEALTH BEHAVIOR LA English DT Article DE smoking during pregnancy; graphic warnings; focus groups; women of childbearing age; knowledge, attitudes, and beliefs; tobacco control and policy ID OROFACIAL CLEFTS; UNITED-STATES; LOW-INCOME; HEALTH; CESSATION; SMOKERS; IMPACT; METAANALYSIS; PERCEPTIONS; RISK AB Objectives: To explore women's knowledge, attitudes, and beliefs about adverse outcomes associated with smoking during pregnancy and which outcomes might motivate cessation; to explore reactions to graphic warnings depicting 2 adverse outcomes. Methods: Twelve focus groups were conducted with women of childbearing age who were current smokers. Results: Participants had low to moderate awareness of many outcomes and believed it was acceptable to smoke in the first trimester before knowledge of pregnancy. Perceived susceptibility to outcomes was low. Motivators included risk-focused information, especially serious risks to the baby (eg, stillbirth, SIDS). Graphic warnings produced strong reactions, especially the warning with a real photo. Conclusions: Despite barriers to reducing rates of smoking during pregnancy, educational information and photos depicting babies' risks could motivate women to quit. C1 [Levis, Denise M.; Polen, Kara N. D.; Cassell, Cynthia H.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Stone-Wiggins, Brenda; Council, Mary] RTI Int, Publ Hlth Res Div, Res Triangle Pk, NC USA. [O'Hegarty, Michelle] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. [Tong, Van T.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Levis, DM (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM igc1@cdc.gov OI Tong, Van/0000-0002-3970-1440 FU Intramural CDC HHS [CC999999] NR 33 TC 5 Z9 5 U1 3 U2 6 PU PNG PUBLICATIONS PI OAK RIDGE PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA SN 1945-7359 J9 AM J HEALTH BEHAV JI Am. J. Health Behav. PD SEP PY 2014 VL 38 IS 5 BP 755 EP 764 DI 10.5993/AJHB.38.5.13 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AS1JD UT WOS:000344036500013 PM 24933145 ER PT J AU Zhang, Y Wang, H Xu, S Mao, N Zhu, Z Shi, J Huang, G Liu, C Bo, F Feng, D Lu, P Liu, Y Wang, Y Lei, Y Chen, M Chen, H Wang, C Fu, H Li, C He, J Gao, H Gu, S Wang, S Ling, H Liu, Y Ding, Z Ba, Z Feng, Y Zheng, H Tang, X Lei, Y Xiong, Y Bellini, WJ Rota, PA Jee, Y Xu, W AF Zhang, Y. Wang, H. Xu, S. Mao, N. Zhu, Z. Shi, J. Huang, G. Liu, C. Bo, F. Feng, D. Lu, P. Liu, Y. Wang, Y. Lei, Y. Chen, M. Chen, H. Wang, C. Fu, H. Li, C. He, J. Gao, H. Gu, S. Wang, S. Ling, H. Liu, Y. Ding, Z. Ba, Z. Feng, Y. Zheng, H. Tang, X. Lei, Y. Xiong, Y. Bellini, W. J. Rota, P. A. Jee, Y. Xu, W. CA Measles Virology Surveillance TI Monitoring progress toward measles elimination by genetic diversity analysis of measles viruses in China 2009-2010 SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Article ID MOLECULAR EPIDEMIOLOGY; GLOBAL DISTRIBUTION; UNITED-STATES; ERADICATION; GENOTYPES; OUTBREAK; AMERICA AB With the achievement of high coverage for routine immunization and supplementary immunization activities (SIAs), measles incidence in mainland China reached its lowest level in 2010. The proportion of measles cases in the vaccination-targeted population decreased during 2007-2010 after the SIAs. More than 60% of measles cases were in adults or infants, especially in the coastal and eastern provinces during 2009 and 2010. A total 567 isolates of measles virus were obtained from clinical specimens from 27 of 31 provinces in mainland China during 2009 and 2010. Except for two vaccine-associated cases, one genotypeD4 strain, two genotypeD9 strains, and four genotypeD11 strains, the other 558 strains were genotypeH1 clusterH1a. GenotypeH1 has been the only endemic genotype detected in China since surveillance began in 1993. Only genotypeH1 was found in mainland China during 1993-2008, except for one detection of genotypeH2. More recently, multiple genotypes of imported measles were detected even with the background of endemic genetotypeH1 viruses. Analysis of the 450-nucleotide sequencing window of the measles virus N gene showed that the overall genetic diversity of the recent geneotypeH1 strains decreased between 2008 and 2010. The lower genetic diversity of H1 strains suggested that enhanced vaccination may have reduced the co-circulating lineages of endemic genotypeH1 strains in mainland China. C1 [Zhang, Y.; Wang, H.; Xu, S.; Mao, N.; Zhu, Z.; Shi, J.; Huang, G.; Xu, W.] China Ctr Dis Control & Prevent, WHO WPRO Reg Reference Measles Lab, Natl Inst Viral Dis Control & Prevent, Key Lab Med Virol,Minist Hlth, Beijing 102206, Peoples R China. [Liu, C.] Chinese Acad Med Sci, Inst Pathogen Biol, Beijing 100730, Peoples R China. [Liu, C.] Peking Union Med Coll, Beijing 100021, Peoples R China. [Bo, F.] Heilongjiang Prov Ctr Dis Control & Prevent, Haerbin, Heilongjiang, Peoples R China. [Feng, D.] Henan Prov Ctr Dis Control & Prevent, Zhengzhou, Henan, Peoples R China. [Lu, P.] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China. [Liu, Y.] Hebei Prov Ctr Dis Control & Prevent, Baoding, Hebei, Peoples R China. [Wang, Y.] Liaoning Prov Ctr Dis Control & Prevent, Shenyang, Liaoning, Peoples R China. [Lei, Y.] Tianjin Ctr Dis Control & Prevent, Tianjin, Peoples R China. [Chen, M.] Beijing Ctr Dis Control & Prevent, Beijing, Peoples R China. [Chen, H.] Ningxia Prov Ctr Dis Control & Prevent, Ningxia, Peoples R China. [Wang, C.] Shandong Prov Ctr Dis Control & Prevent, Jinan, Shandong, Peoples R China. [Fu, H.] Gansu Prov Ctr Dis Control & Prevent, Lanzhou, Gansu, Peoples R China. [Li, C.] Shanghai Ctr Dis Control & Prevent, Shanghai, Peoples R China. [He, J.] Sichuan Prov Ctr Dis Control & Prevent, Chengdu, Sichuan, Peoples R China. [Gao, H.] Shanxi Prov Ctr Dis Control & Prevent, Taiyuan, Shanxi, Peoples R China. [Gu, S.] Innermongolia Prov Ctr Dis Control & Prevent, Hohhot, Innermongolia, Peoples R China. [Wang, S.] Jilin Prov Ctr Dis Control & Prevent, Changchun, Jilin, Peoples R China. [Ling, H.] Chongqing Ctr Dis Control & Prevent, Chongqing, Peoples R China. [Liu, Y.] Hunan Prov Ctr Dis Control & Prevent, Changsha, Hunan, Peoples R China. [Ding, Z.] Yunnan Prov Ctr Dis Control & Prevent, Kunming, Yunnan, Peoples R China. [Ba, Z.] Qinghai Prov Ctr Dis Control & Prevent, Xining, Peoples R China. [Feng, Y.] Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou, Zhejiang, Peoples R China. [Zheng, H.] Guangdong Prov Ctr Dis Control & Prevent, Guangzhou, Guangdong, Peoples R China. [Tang, X.] Guizhou Prov Ctr Dis Control & Prevent, Guiyang, Guizhou, Peoples R China. [Lei, Y.] Hubei Prov Ctr Dis Control & Prevent, Wuhan, Hubei, Peoples R China. [Xiong, Y.] Jiangxi Prov Ctr Dis Control & Prevent, Nanchang, Jiangxi, Peoples R China. [Bellini, W. J.; Rota, P. A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Jee, Y.] WHO, Western Pacific Reg Off, Expanded Programme Immunizat, Manila, Philippines. RP Xu, W (reprint author), China Ctr Dis Control & Prevent, WHO WPRO Reg Reference Measles Lab, Natl Inst Viral Dis Control & Prevent, Key Lab Med Virol,Minist Hlth, 155 Changbai Rd, Beijing 102206, Peoples R China. EM wenbo_xu1@aliyun.com FU WHO; WPRO; US CDC; National Natural Science Foundation of China [81371791]; Key Technologies R&D Programme of the National Ministry of Science [2012ZX10004215, 2013ZX10004-101, 2013ZX10004-202, 2012ZX10004401, 2012ZX10004201-003]; WHO Measles Regional Reference Laboratory; WHO [WP CHN AAA 011 XZ 08] FX We thank all of the provincial and prefecture measles laboratory staffs and epidemiologists in mainland China for providing clinical specimens, isolates, and epidemiological data. We thank WHO headquarters, the WPRO and the US CDC for technical and financial support. We also acknowledge anonymous reviewers for their comments, which improved the manuscript. This work was supported by grants from the National Natural Science Foundation of China (81371791) and the Key Technologies R&D Programme of the National Ministry of Science (2012ZX10004215, 2013ZX10004-101, 2013ZX10004-202, 2012ZX10004401, and 2012ZX10004201-003), WHO Measles Regional Reference Laboratory funding, and WHO funding (No. WP CHN AAA 011 XZ 08). NR 38 TC 5 Z9 5 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1198-743X EI 1469-0691 J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD SEP PY 2014 VL 20 IS 9 BP O566 EP O577 DI 10.1111/1469-0691.12530 PG 12 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA AR8KR UT WOS:000343824500007 PM 24438091 ER PT J AU Krahn, GL Fox, MH AF Krahn, Gloria L. Fox, Michael H. TI Health Disparities of Adults with Intellectual Disabilities: What Do We Know? What Do We Do? SO JOURNAL OF APPLIED RESEARCH IN INTELLECTUAL DISABILITIES LA English DT Article DE disparities; life-course model; social determinants ID PUBLIC-HEALTH; MENTAL-RETARDATION; UNITED-STATES; DEVELOPMENTAL-DISABILITIES; OLDER-ADULTS; PEOPLE; CARE; INDIVIDUALS; POPULATION; NEEDS AB Background Recent attention to health of people with intellectual disabilities has used a health disparities framework. Building on historical context, the paper summarizes what is known about health disparities from reports and research and provide direction on what to do to reduce these disparities among adults with intellectual disabilities. Methods The present authors examined literature from 2002 to 2011 on health disparities and people with disabilities looking for broad themes on documenting disparities and on research approaches and methods. Results Multiple countries published reports on health of people with intellectual disabilities. Researchers summarized existing research within a health disparities framework. A number of promising methodologies are identified such as health services research, health indicators, enhanced surveillance and mixed-methods. Conclusions Strategies to reduce health disparities include use of data to educate decision makers, attention to social determinants and a life-course model and emphasis on leveraging inclusion in mainstream services where possible. C1 [Krahn, Gloria L.; Fox, Michael H.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Krahn, GL (reprint author), Ctr Dis Control & Prevent, 404-498-6743,1600 Clifton Rd NE NS E88, Atlanta, GA 30333 USA. EM gfk2@cdc.gov FU Intramural CDC HHS [CC999999] NR 103 TC 16 Z9 16 U1 5 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2322 EI 1468-3148 J9 J APPL RES INTELLECT JI J. Appl. Res. Intellect. Disabil. PD SEP PY 2014 VL 27 IS 5 BP 431 EP 446 DI 10.1111/jar.12067 PG 16 WC Psychology, Educational; Rehabilitation SC Psychology; Rehabilitation GA AR9AY UT WOS:000343864300003 PM 23913632 ER PT J AU Wethington, H Maynard, LM Haltiwanger, C Blanck, HM AF Wethington, Holly Maynard, Leah M. Haltiwanger, Christine Blanck, Heidi M. TI Use of calorie information at fast-food and chain restaurants among US Adults, 2009 SO JOURNAL OF PUBLIC HEALTH LA English DT Article DE Food and nutrition; Individual behaviour; Population-based and preventative services ID NEW-YORK-CITY; NUTRITION INFORMATION; OBESITY EPIDEMIC; AVAILABILITY; SIZE AB The aim of this study was to examine reading and use of calorie information at fast-food/chain restaurants. A cross-sectional analysis was conducted on a sample of 4363 US adults using the 2009 HealthStyles survey. The outcome variable was reading calorie information when available while ordering at fast-food/chain restaurants. Among those who go to fast-food/chain restaurants, we conducted multivariable logistic regression to examine associations between sociodemographic variables and reading calorie information when available. Among those who report reading calorie information when available, we assessed the proportion using calorie information. Among those who reported eating at fast-food/chain restaurants, 36.4% reported reading calorie information when available. Reading calorie information was not related to race/ethnicity, income or education. Compared with men, women had higher odds [adjusted odds ratio (OR) = 1.8; 95% confidence interval (CI) = 1.5-2.1] of reading calorie information when available while those who frequented fast-food/chain restaurants a parts per thousand yen3 times/week (aOR = 0.6; 95% CI = 0.4-0.8) had lower odds compared with those going < 4 times/month. Of those who reported reading calorie information when available, 95.4% reported using calorie information at least sometimes. Almost all who read calorie information when available use the information at least sometimes. Research is needed on how calorie information is being used. C1 [Wethington, Holly; Maynard, Leah M.; Blanck, Heidi M.] US Centers Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr, Obes Prevent & Control Branch, Atlanta, GA 30341 USA. [Haltiwanger, Christine] Univ Georgia, Paul Coverdell Ctr Biomed & Hlth Sci, Athens, GA 30602 USA. RP Wethington, H (reprint author), US Centers Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr, Obes Prevent & Control Branch, Atlanta, GA 30341 USA. EM hwethington@cdc.gov FU Intramural CDC HHS [CC999999] NR 23 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1741-3842 EI 1741-3850 J9 J PUBLIC HEALTH-UK JI J. Public Health PD SEP PY 2014 VL 36 IS 3 BP 490 EP 496 DI 10.1093/pubmed/fdt109 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR6NB UT WOS:000343698900019 PM 24263224 ER PT J AU Azofeifa, A Yeung, LF Alverson, CJ Beltran-Aguilar, E AF Azofeifa, Alejandro Yeung, Lorraine F. Alverson, C. J. Beltran-Aguilar, Eugenio TI Oral Health Conditions and Dental Visits Among Pregnant and Nonpregnant Women of Childbearing Age in the United States, National Health and Nutrition Examination Survey, 1999-2004 SO PREVENTING CHRONIC DISEASE LA English DT Article ID CARE; OUTCOMES; DENTISTS; BARRIERS AB Introduction Oral diseases can be prevented or improved with regular dental visits. Our objective was to assess and compare national estimates on self-reported oral health conditions and dental visits among pregnant women and nonpregnant women of childbearing age by using data from the National Health and Nutrition Examination Survey (NHANES). Methods We analyzed self-reported oral health information on 897 pregnant women and 3,971 nonpregnant women of childbearing age (15-44 years) from NHANES 1999-2004. We used chi(2) and 2-sample t tests to assess statistical differences between groups stratified by age, race/ethnicity, poverty, and education. We applied the Bonferroni adjustment for multiple comparisons. Results Our data show significant differences in self-reported oral health conditions and dental visits among women, regardless of pregnancy status, when stratified by selected sociodemographic char-acteristics. Significant differences were also found in self-reported oral health conditions and dental visits between pregnant and nonpregnant women, especially among young women, women from minority race/ethnicity groups, and women with less than high school education. Conclusion We found disparities in self-reported oral health conditions and use of dental services among women regardless of pregnancy status. Results highlight the need to improve dental service use among US women of childbearing age, especially young pregnant women, those who are non-Hispanic black or Mexican American, and those with low family income or low education level. Prenatal visits could be used as an opportunity to encourage pregnant women to seek preventive dental care during pregnancy. C1 [Azofeifa, Alejandro] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Yeung, Lorraine F.; Alverson, C. J.; Beltran-Aguilar, Eugenio] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Azofeifa, A (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mailstop E-86, Atlanta, GA 30333 USA. EM alejoazo@hotmail.com NR 30 TC 2 Z9 2 U1 0 U2 9 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2014 VL 11 AR E163 DI 10.5888/pcd11.140212 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XL UT WOS:000343522400016 PM 25232750 ER PT J AU Irving, SM Njai, RS Siegel, PZ AF Irving, Shalon M. Njai, Rashid S. Siegel, Paul Z. TI Food Insecurity and Self-Reported Hypertension Among Hispanic, Black, and White Adults in 12 States, Behavioral Risk Factor Surveillance System, 2009 SO PREVENTING CHRONIC DISEASE LA English DT Article ID CHRONIC DISEASE AB Food insecurity is positively linked to risk of hypertension; however, it is not known whether this relationship persists after adjustment for socioeconomic position (SEP). We examined the association between food insecurity and self-reported hypertension among adults aged 35 or older (N = 58,677) in 12 states that asked the food insecurity question in their 2009 Behavioral Risk Factor Surveillance System questionnaire. After adjusting for SEP, hypertension was more common among adults reporting food insecurity (adjusted prevalence ratio, 1.27; 95% confidence interval, 1.19-1.36). Our study found a positive relationship between food insecurity and hypertension after adjusting for SEP and other characteristics. C1 [Irving, Shalon M.] Ctr Dis Control & Prevent, Res Surveillance & Evaluat Branch, Div Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Njai, Rashid S.; Siegel, Paul Z.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Irving, SM (reprint author), Ctr Dis Control & Prevent, Res Surveillance & Evaluat Branch, Div Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-73, Atlanta, GA 30341 USA. EM SIrving@cdc.gov RI Nguyen, Giang/D-9027-2016 NR 11 TC 6 Z9 6 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2014 VL 11 AR E161 DI 10.5888/pcd11.140190 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XL UT WOS:000343522400014 PM 25232748 ER PT J AU Langford, AT Griffith, DM Beasley, DD Braxton, EID AF Langford, Aisha T. Griffith, Derek M. Beasley, Derrick D. Braxton, Effat Id-Deen TI A Cancer Center's Approach to Engaging African American Men About Cancer: The Men's Fellowship Breakfast, Southeastern Michigan, 2008-2014 SO PREVENTING CHRONIC DISEASE LA English DT Article ID HEALTH AB Background Despite disproportionate rates of cancer morbidity and mortality among African American men, few community-based efforts have been developed and sustained to educate African American men about cancer. The University of Michigan Comprehensive Cancer Center implemented a series of breakfasts to improve cancer awareness, screening, and education among African American men. This article describes the rationale for and history of the community intervention. Community Context The 21 breakfasts were held from 2008 through mid-2014 in Ypsilanti and Ann Arbor, Michigan. Ypsilanti ranks below Michigan and the nation on most socioeconomic indicators, although most residents are high school graduates (88% in Ypsilanti and 96.5% in Ann Arbor). African American men in Ypsilanti have higher death rates for diseases associated with poor diet and inadequate physical activity compared with Ypsilanti whites and general populations in Michigan and the nation. Methods We conducted a multicomponent qualitative process evaluation including staff meetings, conversations with participants, and focus groups. We collected 425 post-event surveys to evaluate the breakfasts quantitatively. Outcomes Participants were African American (85%), were aged 51 to 70 years (54%), had health insurance (89%), and had some college education (38%). Fifty-three percent of participants reported interest in the breakfast topics including nutrition; 46%, prostate cancer; 34%, colorectal cancer, and 32%, pain management; 62% reported willingness to participate in a clinical trial. Interpretation African American men are interested in learning about health and are willing to attend a health-focused breakfast series. The Men's Fellowship Breakfast is a promising strategy for bringing men together to discuss cancer screening and risk reduction. C1 [Langford, Aisha T.] Univ Michigan, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA. [Griffith, Derek M.] Vanderbilt Univ, Inst Res Mens Hlth, Nashville, TN 37235 USA. [Beasley, Derrick D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Braxton, Effat Id-Deen] Univ Michigan, Ann Arbor, MI 48109 USA. [Langford, Aisha T.] VA Hlth Serv Res & Dev Serv, Ann Arbor, MI USA. RP Langford, AT (reprint author), Univ Michigan, Ctr Bioeth & Social Sci Med, 2800 Plymouth Rd,Bldg 16,Room 400S-15, Ann Arbor, MI 48109 USA. EM alangfor@umich.edu OI Griffith, Derek/0000-0003-0018-9176; Langford, Aisha/0000-0003-1758-691X FU University of Michigan Comprehensive Cancer Center; MFB FX The authors thank the University of Michigan Comprehensive Cancer Center for its funding and support of the MFB. NR 21 TC 0 Z9 0 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2014 VL 11 AR E164 DI 10.5888/pcd11.140187 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XL UT WOS:000343522400013 PM 25254982 ER PT J AU Wohler, B Qiao, BZ Weir, HK MacKinnon, JA Schymura, MJ AF Wohler, Brad Qiao, Baozhen Weir, Hannah K. MacKinnon, Jill A. Schymura, Maria J. TI Using the National Death Index to Identify Duplicate Cancer Incident Cases in Florida and New York, 1996-2005 SO PREVENTING CHRONIC DISEASE LA English DT Article ID UNITED-STATES; ACCURACY; BURDEN AB Introduction Cancer registries link incidence data to state death certificates to update vital status and identify missing cases; they also link these data to the National Death Index (NDI) to update vital status among patients who leave the state after their diagnosis. This study explored the use of information from NDI linkages to identify potential duplicate cancer cases registered in both Florida and New York. Methods The Florida Cancer Data System (FCDS) and the New York State Cancer Registry (NYSCR) linked incidence data with state and NDI death records from 1996 through 2005. Information for patients whose death occurred in the reciprocal state (the death state) was exchanged. Potential duplicate cases were those that had the same diagnosis and the same or similar diagnosis date. Results NDI identified 4,657 FCDS cancer patients who died in New York and 2,740 NYSCR cancer patients who died in Florida. Matching identified 5,030 cases registered in both states; 508 were death certificate-only (DCO) cases in the death state's registry, and 3,760 (74.8%) were potential duplicates. Among FCDS and NYSCR patients who died and were registered in the registry of the reciprocal state, more than 50% were registered with the same cancer diagnosis, and approximately 80% had similar diagnosis dates (within 1 year). Conclusion NDI identified DCO cases in the death state's cancer registry and a large proportion of potential duplicate cases. Standards are needed for assigning primary residence when multiple registries report the same case. The registry initiating the NDI linkage should consider sharing relevant information with death state registries so that these registries can remove erroneous DCO cases from their databases. C1 [Weir, Hannah K.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Wohler, Brad; MacKinnon, Jill A.] Florida Canc Data Syst, Miami, FL USA. [Qiao, Baozhen; Schymura, Maria J.] New York State Canc Registry, Albany, NY USA. RP Weir, HK (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy,MS F76, Atlanta, GA 30341 USA. EM hbw4@cdc.gov FU CDC [DP003872]; FCDS [DP000783, DP003897]; NYSCR FX We thank Dr Lillian Ingster, director of the NDI at CDC's National Center for Health Statistics, for her review and thoughtful comments on this manuscript. This work was supported by CDC through cooperative agreement DP003872 with the FCDS and cooperative agreements DP000783 and DP003897 with the NYSCR. There are no financial disclosures from any of the authors. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC. NR 26 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2014 VL 11 AR E167 DI 10.5888/pcd11.140200 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XL UT WOS:000343522400015 PM 25254985 ER PT J AU Denison, AM Amin, BD Nicholson, WL Paddock, CD AF Denison, Amy M. Amin, Bijal D. Nicholson, William L. Paddock, Christopher D. TI Detection of Rickettsia rickettsii, Rickettsia parkeri, and Rickettsia akari in Skin Biopsy Specimens Using a Multiplex Real-time Polymerase Chain Reaction Assay SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Rickettsia; real-time PCR; skin biopsies ID MOUNTAIN-SPOTTED-FEVER; NEW-YORK-CITY; UNITED-STATES; AMBLYOMMA-MACULATUM; SWAB SPECIMENS; PCR ASSAY; ESCHAR; IDENTIFICATION; TYPHUS; TICKS AB Background. Rickettsia rickettsii, Rickettsia parkeri, and Rickettsia akari are the most common causes of spotted fever group rickettsioses indigenous to the United States. Infected patients characteristically present with a maculopapular rash, often accompanied by an inoculation eschar. Skin biopsy specimens are often obtained from these lesions for diagnostic evaluation. However, a species-specific diagnosis is achieved infrequently from pathologic specimens because immunohistochemical stains do not differentiate among the causative agents of spotted fever group rickettsiae, and existing polymerase chain reaction (PCR) assays generally target large gene segments that may be difficult or impossible to obtain from formalin-fixed tissues. Methods. This work describes the development and evaluation of a multiplex real-time PCR assay for the detection of these 3 Rickettsia species from formalin-fixed, paraffin-embedded (FFPE) skin biopsy specimens. Results. The multiplex PCR assay was specific at discriminating each species from FFPE controls of unrelated bacterial, viral, protozoan, and fungal pathogens that cause skin lesions, as well as other closely related spotted fever group Rickettsia species. Conclusions. This multiplex real-time PCR demonstrates greater sensitivity than nested PCR assays in FFPE tissues and provides an effective method to specifically identify cases of Rocky Mountain spotted fever, rickettsialpox, and R. parkeri rickettsiosis by using skin biopsy specimens. C1 [Denison, Amy M.; Paddock, Christopher D.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Infect Dis Pathol Branch, Atlanta, GA 30333 USA. [Nicholson, William L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. [Amin, Bijal D.] Montefiore Med Ctr, Dept Pathol, Div Surg Pathol, Bronx, NY 10467 USA. RP Denison, AM (reprint author), Ctr Dis Control & Prevent, Infect Dis Pathol Branch, 1600 Clifton Rd NE,MS G-32, Atlanta, GA 30333 USA. EM crk6@cdc.gov FU Intramural CDC HHS [CC999999] NR 33 TC 10 Z9 10 U1 1 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2014 VL 59 IS 5 BP 635 EP 642 DI 10.1093/cid/ciu358 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KQ UT WOS:000342921100011 PM 24829214 ER PT J AU Gurley, ES Hossain, MJ Paul, RC Sazzad, HMS Islam, MS Parveen, S Faruque, LI Husain, M Ara, K Jahan, Y Rahman, M Luby, SP AF Gurley, Emily S. Hossain, M. Jahangir Paul, Repon C. Sazzad, Hossain M. S. Islam, M. Saiful Parveen, Shahana Faruque, Labib I. Husain, Mushtuq Ara, Khorshed Jahan, Yasmin Rahman, Mahmudur Luby, Stephen P. TI Outbreak of Hepatitis E in Urban Bangladesh Resulting in Maternal and Perinatal Mortality SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Bangladesh; hepatitis E; outbreak; pregnancy; safe water ID E VIRUS-INFECTION; ACUTE VIRAL-HEPATITIS; E EPIDEMIC; PREGNANT-WOMEN; E VACCINE; PAKISTAN; SUDAN; INDIA; WATER; TRANSMISSION AB Background. Hepatitis E virus (HEV) causes outbreaks of jaundice associated with maternal mortality. Four deaths among pregnant women with jaundice occurred in an urban community near Dhaka, Bangladesh, in late 2008 and were reported to authorities in January 2009. We investigated the etiology and risk factors for jaundice and death. Methods. Field workers identified suspected cases, defined as acute onset of yellow eyes or skin, through house-to-house visits. A subset of persons with suspected HEV was tested for immunoglobulin M(IgM) antibodies to HEV to confirm infection. We used logistic regression analysis to identify risk factors for HEV disease and for death. We estimated the increased risk of perinatal mortality associated with jaundice during pregnancy. Results. We identified 4751 suspected HEV cases during August 2008-January 2009, including 17 deaths. IgM antibodies to HEV were identified in 56 of 73 (77%) case-patients tested who were neighbors of the case-patients who died. HEV disease was significantly associated with drinking municipally supplied water. Death among persons with HEV disease was significantly associated with being female and taking paracetamol (acetaminophen). Among women who were pregnant, miscarriage and perinatal mortality was 2.7 times higher (95% confidence interval, 1.2-6.1) in pregnancies complicated by jaundice. Conclusions. This outbreak of HEV was likely caused by sewage contamination of the municipal water system. Longer-term efforts to improve access to safe water and license HEV vaccines are needed. However, securing resources and support for intervention will rely on convincing data about the endemic burden of HEV disease, particularly its role in maternal and perinatal mortality. C1 [Gurley, Emily S.; Hossain, M. Jahangir; Paul, Repon C.; Sazzad, Hossain M. S.; Islam, M. Saiful; Parveen, Shahana; Faruque, Labib I.; Luby, Stephen P.] Icddr B, Dhaka, Bangladesh. [Husain, Mushtuq; Ara, Khorshed; Jahan, Yasmin; Rahman, Mahmudur] Minist Hlth & Family Welf, Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh. [Luby, Stephen P.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. RP Gurley, ES (reprint author), 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh. EM egurley@icddrb.org RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X FU CDC [U01 CI000298]; Ministry of Health and Family Welfare, government of Bangladesh FX This work was supported by the CDC (cooperative agreement U01 CI000298) and the Ministry of Health and Family Welfare, government of Bangladesh. The icddr,b acknowledges with gratitude the contributions of the CDC and the government of Bangladesh to its research efforts. NR 44 TC 10 Z9 10 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2014 VL 59 IS 5 BP 658 EP 665 DI 10.1093/cid/ciu383 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KQ UT WOS:000342921100014 PM 24855146 ER PT J AU Hinckley, AF Connally, NP Meek, JI Johnson, BJ Kemperman, MM Feldman, KA White, JL Mead, PS AF Hinckley, Alison F. Connally, Neeta P. Meek, James I. Johnson, Barbara J. Kemperman, Melissa M. Feldman, Katherine A. White, Jennifer L. Mead, Paul S. TI Lyme Disease Testing by Large Commercial Laboratories in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE lyme disease; infection; United States; diagnostic testing; cost ID NERVOUS-SYSTEM MANIFESTATIONS; BORRELIA-BURGDORFERI; CLINICAL-PRACTICE; ERYTHEMA MIGRANS; PEPTIDE ELISA; SERODIAGNOSIS; DIAGNOSIS; COST; NEUROBORRELIOSIS; EVOLUTION AB Background. Laboratory testing is helpful when evaluating patients with suspected Lyme disease (LD). A 2-tiered antibody testing approach is recommended, but single-tier and nonvalidated tests are also used. We conducted a survey of large commercial laboratories in the United States to assess laboratory practices. We used these data to estimate the cost of testing and number of infections among patients from whom specimens were submitted. Methods. Large commercial laboratories were asked to report the type and volume of testing conducted nationwide in 2008, as well as the percentage of positive tests for 4 LD-endemic states. The total direct cost of testing was calculated for each test type. These data and test-specific performance parameters available in published literature were used to estimate the number of infections among source patients. Results. Seven participating laboratories performed approximately 3.4 million LD tests on approximately 2.4 million specimens nationwide at an estimated cost of $492 million. Two-tiered testing accounted for at least 62% of assays performed; alternative testing accounted for <3% of assays. The estimated frequency of infection among patients from whom specimens were submitted ranged from 10% to 18.5%. Applied to the total numbers of specimens, this yielded an estimated 240 000 to 444 000 infected source patients in 2008. Discussion. LD testing is common and costly, with most testing in accordance with diagnostic recommendations. These results highlight the importance of considering clinical and exposure history when interpreting laboratory results for diagnostic and surveillance purposes. C1 [Hinckley, Alison F.; Johnson, Barbara J.; Mead, Paul S.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Connally, Neeta P.] Western Connecticut State Univ, Connecticut Emerging Infect Program, Dept Biol & Environm Sci, Danbury, CT USA. [Meek, James I.] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA. [Kemperman, Melissa M.] Minnesota Dept Hlth, St Paul, MN USA. [Feldman, Katherine A.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [White, Jennifer L.] New York State Dept Hlth, Albany, NY 12237 USA. RP Hinckley, AF (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM ahinckley@cdc.gov FU CDC Cooperative Agreement/Connecticut Department of Public Health Contract; CDC Emerging Infections Program Grant, TickNet program FX N. P. C., J. L. M., and K. A. F. have received funding from the CDC Cooperative Agreement/Connecticut Department of Public Health Contract. J. L. W. received institutional support through the CDC. M. M. K. received institutional funding through the CDC Emerging Infections Program Grant, TickNet program. NR 39 TC 69 Z9 69 U1 4 U2 17 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2014 VL 59 IS 5 BP 676 EP 681 DI 10.1093/cid/ciu397 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KQ UT WOS:000342921100016 PM 24879782 ER PT J AU Martin, M Vanichseni, S Suntharasamai, P Sangkum, U Mock, PA Gvetadze, RJ Curlin, ME Leethochawalit, M Chiamwongpaet, S Cherdtrakulkiat, T Anekvorapong, R Leelawiwat, W Chantharojwong, N McNicholl, JM Paxton, LA Kittimunkong, S Choopanya, K AF Martin, Michael Vanichseni, Suphak Suntharasamai, Pravan Sangkum, Udomsak Mock, Philip A. Gvetadze, Roman J. Curlin, Marcel E. Leethochawalit, Manoj Chiamwongpaet, Sithisat Cherdtrakulkiat, Thitima Anekvorapong, Rapeepan Leelawiwat, Wanna Chantharojwong, Nartlada McNicholl, Janet M. Paxton, Lynn A. Kittimunkong, Somyot Choopanya, Kachit CA Bangkok Tenofovir Study Grp TI Renal Function of Participants in the Bangkok Tenofovir Study-Thailand, 2005-2012 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE creatinine clearance; glomerular filtration rate; tenofovir disoproxil fumarate ID GLOMERULAR-FILTRATION-RATE; CALCULATED CREATININE CLEARANCE; NEPHROGENIC DIABETES-INSIPIDUS; ANTIRETROVIRAL-NAIVE PATIENTS; INJECTING DRUG-USERS; DISOPROXIL FUMARATE; PREEXPOSURE PROPHYLAXIS; HIV-INFECTION; INTERIM GUIDANCE; TUBULAR DYSFUNCTION AB Background. Tenofovir disoproxil fumarate (tenofovir) has been associated with renal dysfunction in people infected with human immunodeficiency virus (HIV) receiving combination antiretroviral therapy. We reviewed data from an HIV preexposure prophylaxis trial to determine if tenofovir use was associated with changes in renal function in an HIV-uninfected population. Methods. During the trial, 2413 HIV-uninfected people who inject drugs were randomized to receive tenofovir or placebo. We assessed the renal function of trial participants with the Cockcroft-Gault, Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations using t tests for cross-sectional analysis and linear regression for longitudinal analysis. Results. Creatinine clearance and glomerular filtration rate (GFR) results were lower at 24, 36, 48, and 60 months in the tenofovir group compared with the placebo group. Results declined more in the tenofovir group than in the placebo group during follow-up using the Cockcroft-Gault (P < .001) and CKD-EPI (P = .007) equations, but not MDRD (P = .12). Creatinine clearance measured when study drug was stopped was lower in the tenofovir group than the placebo group (P < .001), but the difference resolved when tested a median of 20 months later (P = .12). Conclusions. We found small but significant decreases in cross-sectional measures of creatinine clearance and GFR in the tenofovir group compared with the placebo group and modest differences in downward trends in longitudinal analysis using the Cockcroft-Gault and CKD-EPI equations. These results suggest that with baseline assessments of renal function and routine monitoring of creatinine clearance during follow-up, tenofovir can be used safely for HIV preexposure prophylaxis. C1 [Martin, Michael; Mock, Philip A.; Curlin, Marcel E.; Cherdtrakulkiat, Thitima; Leelawiwat, Wanna; Chantharojwong, Nartlada] Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Nonthaburi, Thailand. [Martin, Michael; Gvetadze, Roman J.; Curlin, Marcel E.; McNicholl, Janet M.; Paxton, Lynn A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Vanichseni, Suphak; Suntharasamai, Pravan; Sangkum, Udomsak; Choopanya, Kachit] Bangkok Tenofovir Study Grp, Nonthaburi, Thailand. [Leethochawalit, Manoj; Chiamwongpaet, Sithisat; Anekvorapong, Rapeepan] Bangkok Metropolitan Adm, Nonthaburi, Thailand. [Kittimunkong, Somyot] Thailand Minist Publ Hlth, Nonthaburi, Thailand. RP Martin, M (reprint author), Minist Publ Hlth, DDC 7 Bldg,4th Floor,Soi 4, Nonthaburi 11000, Thailand. EM znd9@cdc.gov FU US Centers for Disease Control and Prevention; Bangkok Metropolitan Administration FX This work was supported by the US Centers for Disease Control and Prevention and the Bangkok Metropolitan Administration. NR 43 TC 14 Z9 14 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2014 VL 59 IS 5 BP 716 EP 724 DI 10.1093/cid/ciu355 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KQ UT WOS:000342921100023 PM 24829212 ER PT J AU Gardner, LI Giordano, TP Marks, G Wilson, TE Craw, JA Drainoni, ML Keruly, JC Rodriguez, AE Malitz, F Moore, RD Bradley-Springer, LA Holman, S Rose, CE Girde, S Sullivan, M Metsch, LR Saag, M Mugavero, MJ AF Gardner, Lytt I. Giordano, Thomas P. Marks, Gary Wilson, Tracey E. Craw, Jason A. Drainoni, Mari-Lynn Keruly, Jeanne C. Rodriguez, Allan E. Malitz, Faye Moore, Richard D. Bradley-Springer, Lucy A. Holman, Susan Rose, Charles E. Girde, Sonali Sullivan, Meg Metsch, Lisa R. Saag, Michael Mugavero, Michael J. CA Retention Care Study Grp TI Enhanced Personal Contact With HIV Patients Improves Retention in Primary Care: A Randomized Trial in 6 US HIV Clinics SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE behavioral intervention trial; HIV infection; HIV specialty clinics; randomized controlled trial; retention in care ID ACTIVE ANTIRETROVIRAL THERAPY; MEDICAL-CARE; VIRAL SUPPRESSION; INFECTED PERSONS; REMINDER SYSTEMS; FOLLOW-UP; ENGAGEMENT; PREVENTION; ADHERENCE; ACCESS AB Background. The aim of the study was to determine whether enhanced personal contact with human immunodeficiency virus (HIV)-infected patients across time improves retention in care compared with existing standard of care (SOC) practices, and whether brief skills training improves retention beyond enhanced contact. Methods. The study, conducted at 6 HIV clinics in the United States, included 1838 patients with a recent history of inconsistent clinic attendance, and new patients. Each clinic randomized participants to 1 of 3 arms and continued to provide SOC practices to all enrollees: enhanced contact with interventionist (EC) (brief face-to-face meeting upon returning for care visit, interim visit call, appointment reminder calls, missed visit call); EC + skills (organization, problem solving, and communication skills); or SOC only. The intervention was delivered by project staff for 12 months following randomization. The outcomes during that 12-month period were (1) percentage of participants attending at least 1 primary care visit in 3 consecutive 4-month intervals (visit constancy), and (2) proportion of kept/scheduled primary care visits (visit adherence). Results. Log-binomial risk ratios comparing intervention arms against the SOC arm demonstrated better outcomes in both the EC and EC + skills arms (visit constancy: risk ratio [RR], 1.22 [95% confidence interval {CI}, 1.09-1.36] and 1.22 [95% CI, 1.09-1.36], respectively; visit adherence: RR, 1.08 [95% CI, 1.05-1.11] and 1.06 [95% CI, 1.02-1.09], respectively; all Ps < .01). Intervention effects were observed in numerous patient subgroups, although they were lower in patients reporting unmet needs or illicit drug use. Conclusions. Enhanced contact with patients improved retention in HIV primary care compared with existing SOC practices. A brief patient skill-building component did not improve retention further. Additional intervention elements may be needed for patients reporting illicit drug use or who have unmet needs. C1 [Gardner, Lytt I.; Marks, Gary; Craw, Jason A.; Rose, Charles E.; Girde, Sonali] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA. [Wilson, Tracey E.] Suny Downstate Med Ctr, Dept Community Hlth Sci, Sch Publ Hlth, Brooklyn, NY 11203 USA. [Drainoni, Mari-Lynn] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Drainoni, Mari-Lynn] Boston Univ, Sch Med, Ctr Healthcare Org & Implementat Res, Edith Nourse Rogers Mem VA Hosp, Boston, MA 02118 USA. [Drainoni, Mari-Lynn; Sullivan, Meg] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Keruly, Jeanne C.; Moore, Richard D.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Rodriguez, Allan E.] Univ Miami, Miller Sch Med, Div Infect Dis, Coral Gables, FL 33124 USA. [Malitz, Faye] HIV AIDS Bur, Hlth Resources & Serv Adm, Rockville, MD USA. [Bradley-Springer, Lucy A.] Univ Colorado Denver, Sch Med, Aurora, CO USA. [Holman, Susan] Suny Downstate Med Ctr, Coll Med, Brooklyn, NY 11203 USA. [Holman, Susan] Suny Downstate Med Ctr, Coll Nursing, Brooklyn, NY 11203 USA. [Girde, Sonali] ICF Int Inc, Atlanta, GA USA. [Metsch, Lisa R.] Univ Miami, Dept Epidemiol & Publ Hlth, Coral Gables, FL 33124 USA. [Saag, Michael; Mugavero, Michael J.] Univ Alabama Birmingham, HIV AIDS Clin 1917, Birmingham, AL USA. [Saag, Michael; Mugavero, Michael J.] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. RP Gardner, LI (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, MS E-45,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM lig0@cdc.gov FU CDC; Health Resources and Services Administration [200-2007-23685, 200-2007-23690, 200-2007-23689, 200-2007-23687, 200-2007-23684, 200-2007-23692] FX This work was supported by the CDC and the Health Resources and Services Administration (contracts 200-2007-23685, 200-2007-23690, 200-2007-23689, 200-2007-23687, 200-2007-23684, 200-2007-23692). NR 38 TC 34 Z9 34 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2014 VL 59 IS 5 BP 725 EP 734 DI 10.1093/cid/ciu357 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AQ6KQ UT WOS:000342921100024 PM 24837481 ER PT J AU Anderson, PL Glidden, DV Bushman, LR Heneine, W Garcia-Lerma, JG AF Anderson, Peter L. Glidden, David V. Bushman, Lane R. Heneine, Walid Garcia-Lerma, J. Gerardo TI Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE HIV pre-exposure prophylaxis; non-human primate model; intracellular pharmacology; pharmacodynamics; nucleoside analogues ID ANTIRETROVIRAL PREEXPOSURE PROPHYLAXIS; HUMAN-IMMUNODEFICIENCY-VIRUS; DISOPROXIL FUMARATE; INTERMITTENT PROPHYLAXIS; DRUG CONCENTRATIONS; ORAL TENOFOVIR; INFECTION; PREVENTION; EMTRICITABINE; PHARMACOKINETICS AB Objectives: This study evaluated the relationship between intracellular tenofovir diphosphate concentrations in peripheral blood mononuclear cells and prophylactic efficacy in a macaque model for HIV pre-exposure prophylaxis (PrEP). Methods: Macaques were challenged with simian HIV (SHIV) via rectal inoculation once weekly for up to 14 weeks. A control group (n = 34) received no drug, a second group (n = 6) received oral tenofovir disoproxil fumarate/emtricitabine 3 days before each virus challenge and a third group (n = 6) received the same dosing plus another dose 2 h after virus challenge. PBMCs were collected just before each weekly virus challenge. The relationship between tenofovir diphosphate in PBMCs and prophylactic efficacy was assessed with a Cox proportional hazards model. Results: The percentages of animals infected in the control, one-dose and two-dose groups were 97, 83 and 17, respectively. The mean (SD) steady-state tenofovir diphosphate concentration (fmol/10(6) cells) was 15.8 (7.6) in the one-dose group and 30.7 (10.1) in the two-dose group. Each 5 fmol tenofovir diphosphate/10(6) cells was associated with a 40% (95% CI 17%-56%) reduction in risk of SHIV acquisition, P = 0.002. The tenofovir diphosphate concentration associated with a 90% reduction in risk (EC90) was 22.6 fmol/10(6) cells (95% CI 13.8-60.8). Conclusions: The prophylactic EC90 for tenofovir diphosphate identified in macaques exposed rectally compares well with the EC90 previously identified in men who have sex with men (MSM; 16 fmol/10(6) cells, 95% CI 3-28). These results highlight the relevance of this model to inform human PrEP studies of oral tenofovir disoproxil fumarate/emtricitabine for MSM. C1 [Anderson, Peter L.; Bushman, Lane R.] Univ Colorado Denver, Dept Pharmaceut Sci, Aurora, CO 80045 USA. [Glidden, David V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Heneine, Walid; Garcia-Lerma, J. Gerardo] Ctr Dis Control, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. RP Anderson, PL (reprint author), Univ Colorado, Dept Pharmaceut Sci, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus,V20-C238,Room 4101,12850 E, Aurora, CO 80045 USA. EM peter.anderson@ucdenver.edu FU NIH [U01AI84735, Y1-Al-0681-02]; CDC; CDC [Y1-Al-0681-02] FX This work was supported by NIH U01AI84735, CDC intramural funds and Interagency Agreement Y1-Al-0681-02 between CDC and NIH. NR 48 TC 9 Z9 9 U1 2 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD SEP PY 2014 VL 69 IS 9 BP 2470 EP 2476 DI 10.1093/jac/dku162 PG 7 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA AR1DL UT WOS:000343322200023 PM 24862094 ER PT J AU DeAngelo, JW Beitsch, LM Beaudry, ML Corso, LC Estes, LJ Bialek, RG AF DeAngelo, Julia W. Beitsch, Leslie M. Beaudry, Margaret L. Corso, Liza C. Estes, Larissa J. Bialek, Ron G. TI Turning Point Revisited: Launching the Next Generation of Performance Management in Public Health SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE accreditation; health departments; performance management; quality improvement ID QUALITY IMPROVEMENT; CULTURE; SYSTEMS AB A decade ago, the Turning Point Performance Management Excellence Collaborative (Turning Point) developed the first public health-specific performance management (PM) system, with accompanying resource materials, assisted by the Public Health Foundation. Since then, dramatic advancements in PM and quality improvement activities have occurred in public health. Public Health Foundation gathered data that revealed Turning Point was still relevant but difficult to implement within public health. To reflect recent advances and current challenges, Public Health Foundation refreshed the Turning Point model and related guidance tools and developed new resources to facilitate PM implementation. In addition, a new fifth component, "Visible Leadership," was added to the 4-quadrant model and the Self-Assessment Tool. In the future, public health organizations should take an active leadership role in innovating and sustaining PM systems, ensuring they become accountable for producing outcomes, leveraging technology advances, and incorporating best practices from all stakeholders. C1 [DeAngelo, Julia W.; Beaudry, Margaret L.; Bialek, Ron G.] Publ Hlth Fdn, Washington, DC USA. [Beitsch, Leslie M.] Florida State Univ, Coll Med, Tallahassee, FL 32306 USA. [Corso, Liza C.] Ctr Dis Control & Prevent, Off State Tribal Local & Terr Support, Atlanta, GA USA. [Estes, Larissa J.] Houston Dept Hlth & Human Serv, Houston, TX USA. RP Beitsch, LM (reprint author), Florida State Univ, Coll Med, 1115 West Call St, Tallahassee, FL 32306 USA. EM les.beitsch@med.fsu.edu FU Centers for Disease Control and Prevention, Office for State, Tribal, Local and Territorial Support, through the National Public Health Improvement Initiative FX Development of this article was supported by funds made available from the Centers for Disease Control and Prevention, Office for State, Tribal, Local and Territorial Support, through the National Public Health Improvement Initiative. NR 36 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2014 VL 20 IS 5 BP 463 EP 471 DI 10.1097/PHH.0000000000000028 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ8YQ UT WOS:000343127100004 PM 25068709 ER PT J AU Wilcox, LS Majestic, EA Ayele, M Strasser, S Weaver, SR AF Wilcox, Lynne S. Majestic, Elizabeth A. Ayele, Missale Strasser, Sheryl Weaver, Scott R. TI National Survey of Training Needs Reported by Public Health Professionals in Chronic Disease Programs in State, Territorial, and Local Governments SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE chronic disease; cross-sectional surveys; health manpower; public health professional education ID DECISION-MAKING; COMPETENCES; PRACTITIONERS AB Context: In 2009, the National Association of Chronic Disease Directors published desirable competencies for professionals in public health chronic disease programs. Assessing the training needs of these professionals is an important step toward providing appropriate training programs in chronic disease prevention and control competencies. Objectives: Conduct a survey of the chronic disease workforce in state and local health departments to identify professional training needs. Design: We conducted a cross-sectional survey of state, territorial, and local public health professionals who work in chronic disease programs to identify their self-reported training needs, using the membership lists of 3 professional organizations that included practitioners in chronic disease public health programs. Setting: The survey was national, used a convenience sample, and was conducted in 2011. Participants: The survey was developed using an algorithm to select anonymous participants from the membership lists of the National Association of Chronic Disease Directors, the Directors for Health Promotion and Education, and the National Association of County & City Health Officials. Outcome Measures: The survey included questions about professional background, chronic disease activities, confidence about skills, and needs for training. Results: The survey had 567 responses (38% response ratio). The majority of the respondents were female, non-Hispanic white, and 40 years or older. Respondents were not confident of their skills in health economics (38%) and technology and data management (23%). The most requested training topics were assessing the effects of policies, laws, and regulations (70%) and health economics (66%). Conclusions: This survey included local, territorial, and state public health professionals who work in chronic disease programs. These reported training needs in quantitative measurement methods and policy-related topics suggest key subjects for future training and education curricula. C1 [Wilcox, Lynne S.; Ayele, Missale; Strasser, Sheryl; Weaver, Scott R.] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30302 USA. [Majestic, Elizabeth A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Wilcox, LS (reprint author), Georgia State Univ, Sch Publ Hlth, POB 3995, Atlanta, GA 30302 USA. EM lswilcox@lynneswilcox.com FU National Association of Chronic Disease Directors in Atlanta, Georgia; National Institute of Minority Health and Health Disparities of the National Institutes of Health [1P20MD004806] FX This study was supported by the National Association of Chronic Disease Directors in Atlanta, Georgia and partially supported by the National Institute of Minority Health and Health Disparities of the National Institutes of Health under award number 1P20MD004806. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. In addition to the National Association of Disease Directors, the authors thank the Directors of Health Promotion and Education and the National Association of County & City Health Officials, who contributed their membership lists and reviewed drafts of the survey. The authors also thank Helen Leis, Olivia Chan, and Michael Lovdal at Oliver-Wyman, who conducted the study in the field and provided analysis of the data. NR 18 TC 3 Z9 3 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2014 VL 20 IS 5 BP 481 EP 489 DI 10.1097/PHH.0b013e3182a7bdcf PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ8YQ UT WOS:000343127100006 PM 24335714 ER PT J AU Conley, AM Vagi, S Horney, JA AF Conley, Ashley M. Vagi, Sara Horney, Jennifer A. TI Use of the Community Assessment for Public Health Emergency Response to Conduct Community Health Assessments for Public Health Accreditation SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE accreditation; community health assessment; public health ID SAMPLING METHOD AB A community health assessment (CHA) is a collaborative process of collecting and analyzing data to learn about the health status of a community. Community health assessments are also a requirement of public health accreditation for state and local health departments and of the Affordable Care Act for nonprofit hospitals. One element of a CHA is primary data collection. This article describes the use of the Community Assessment for Public Health Emergency Response (CASPER) method for primary data collection to meet public health accreditation requirements in 2 case study communities-Nashua, New Hampshire, and Davidson County, North Carolina; CASPER is a flexible and efficient method for the collection of population-based primary data in an urban or rural setting. C1 [Conley, Ashley M.] City Nashua, NH Div Publ Hlth & Community Serv, Hillsborough, NH USA. [Vagi, Sara] Ctr Dis Control & Prevent, LCDR, US PHS, Atlanta, GA USA. [Vagi, Sara] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Horney, Jennifer A.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA. RP Horney, JA (reprint author), Univ N Carolina, Dept Epidemiol, CB 8165,400 Roberson St, Chapel Hill, NC 27599 USA. EM jen.horney@unc.edu NR 12 TC 1 Z9 1 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2014 VL 20 IS 5 BP 490 EP 497 DI 10.1097/PHH.0b013e3182a99918 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ8YQ UT WOS:000343127100007 PM 24036960 ER PT J AU Cohen, L Coronado, F Folowoshele, C Massoudi, M Koo, D AF Cohen, Laurence Coronado, Fatima Folowoshele, Catherine Massoudi, Mehran Koo, Denise TI Elective Medical and Veterinary Student Rotations in Applied Epidemiology at the Centers for Disease Control and Prevention, 1975-2012 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE curricula; education; epidemiology; medical; preventive medicine; public health; students; veterinary ID POPULATION HEALTH; PUBLIC-HEALTH; UNITED-STATES; EDUCATION; PHYSICIANS; CDC AB Context: Health professionals who can bridge the gap between public health and clinical medicine are needed. The Centers for Disease Control and Prevention Epidemiology Elective Program (EEP) offers a rotation in public health for medical and veterinary students that provides an introduction to public health, preventive medicine, and the principles of applied epidemiology through real-world, hands-on experiential learning. Objective: To describe EEP, including its role in the integration of medicine and public health, and career paths for those who subsequently have enrolled in the Epidemic Intelligence Service (EIS). Design: A review of files of EEP students participating June 1975 to May 2012 and EIS files to determine which EEP participants subsequently enrolled in EIS and their current employment. Results: During January 1975 to May 2012, a total of 1548 students participated in EEP. Six hundred thirty-eight (41.2%) EEP students participated in field-based epidemic-assistance investigations. Among 187 students completing an exit survey implemented during 2007, a total of 175 (93.6%) indicated an increased understanding or competence in applied epidemiology and public health, and 98 (52.4%) indicated that they would apply to EIS. Among the 165 (10.7%) who enrolled in and completed EIS by July 2012, 106 (64.2%) are currently employed in public health and 65 (39.4%) are board-certified in preventive medicine, board eligible, or currently enrolled in the Centers for Disease Control and Prevention Preventive Medicine Residency or Fellowship. Conclusions: The CDC Epidemiology Elective Program offers opportunities for medical and veterinary students to participate in real-world public health learning activities. The Epidemiology Elective Program provides increased understanding and competence in applied epidemiology, provides students with opportunities to learn about population health and health care problems and the tools to help them bridge the gap between clinical medicine and public health, and serves as a source for EIS and other public health-related training and careers. C1 [Cohen, Laurence; Coronado, Fatima; Folowoshele, Catherine; Koo, Denise] Ctr Dis Control & Prevent, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Massoudi, Mehran] Ctr Dis Control & Prevent, Appl Res & Translat Branch, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Cohen, L (reprint author), Ctr Dis Control & Prevent, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd,Mail Stop E-92, Atlanta, GA 30333 USA. EM cbu1@cdc.gov NR 28 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2014 VL 20 IS 5 BP 534 EP 541 DI 10.1097/PHH.0b013e3182aa7dcb PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ8YQ UT WOS:000343127100013 PM 24322840 ER PT J AU Iskander, J Ari, M Chen, B Hall, S Ghiya, N Popovic, T AF Iskander, John Ari, Mary Chen, Bin Hall, Sharon Ghiya, Neelam Popovic, Tanja TI Public Health Grand Rounds at the Centers for Disease Control and Prevention: Evaluation Feedback From a Broad Community of Learners SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE continuing education; evaluation; public health ID CONTINUING MEDICAL-EDUCATION; OPPORTUNITIES; CHALLENGES; IMPACT AB Objective: To evaluate the relevance and educational benefit of monthly Public Health Grand Rounds (GR), an hour-long interactive lecture series featuring 1 current, relevant public health topic. Design: Quantitative and qualitative analysis of data evaluating GR format and content submitted by 2063 continuing education (CE) participants. Setting: Survey data submitted electronically to the Centers for Disease Control and Prevention online CE system from January 2010 through December 2011. Participants: Physicians, nurses, pharmacists, health education specialists, and other health care professionals seeking CE credits for Public Health GR. Main Outcome Measures: Proportion of respondents agreeing or strongly agreeing that GR is using educational strategies that enhance user learning and is meeting preidentified learning objectives. Results: On questions involving instructional strategies and delivery methods, 95.0% and 95.6% of respondents, respectively, agreed or strongly agreed that the GR was conducive to learning. More than 90% of respondents agreed or strongly agreed that they could describe the burden of the disease/condition in question and identify key preventive interventions, knowledge gaps, and measures of public health progress. Conclusions: These evaluation results indicate that the GR is meeting content-specific and educational needs of diverse health care professionals. The GR models organized scientific discussions on evidence and translation into real-world impacts of decreased morbidity, mortality, and health care costs, and links public health to clinical practice. This promotes a greater understanding of the interplay of different health fields and may lead to greater and cross-disciplinary collaborations. C1 [Iskander, John; Ari, Mary; Ghiya, Neelam; Popovic, Tanja] Ctr Dis Control & Prevent, Off Associate Director Sci, Atlanta, GA 30333 USA. [Chen, Bin] Ctr Dis Control & Prevent, Lab Sci Policy & Practice Program Off, Atlanta, GA 30333 USA. [Hall, Sharon] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program, Atlanta, GA 30333 USA. RP Iskander, J (reprint author), Ctr Dis Control & Prevent, Off Associate Director Sci, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM jxi0@cdc.gov FU US government FX We acknowledge the contributions of more than 100 Grand Rounds speakers, CDC subject-matter experts and liaisons, the Grand Rounds communications team, and CDC CE team. This study was funded by the US government. NR 24 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2014 VL 20 IS 5 BP 542 EP 550 DI 10.1097/PHH.0b013e3182aa6560 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ8YQ UT WOS:000343127100014 PM 24100242 ER PT J AU Kuhn, JH Andersen, KG Bao, YM Bavari, S Becker, S Bennett, RS Bergman, NH Blinkova, O Bradfute, S Brister, JR Bukreyev, A Chandran, K Chepurnov, AA Davey, RA Dietzgen, RG Doggett, NA Dolnik, O Dye, JM Enterlein, S Fenimore, PW Formenty, P Freiberg, AN Garry, RF Garza, NL Gire, SK Gonzalez, JP Griffiths, A Happi, CT Hensley, LE Herbert, AS Hevey, MC Hoenen, T Honko, AN Ignatyev, GM Jahrling, PB Johnson, JC Johnson, KM Kindrachuk, J Klenk, HD Kobinger, G Kochel, TJ Lackemeyer, MG Lackner, DF Leroy, EM Lever, MS Muhlberger, E Netesov, SV Olinger, GG Omilabu, SA Palacios, G Panchal, RG Park, DJ Patterson, JL Paweska, JT Peters, CJ Pettitt, J Pitt, L Radoshitzky, SR Ryabchikova, EI Saphire, EO Sabeti, PC Sealfon, R Shestopalov, AM Smither, SJ Sullivan, NJ Swanepoel, R Takada, A Towner, JS van der Groen, G Volchkov, VE Volchkova, VA Wahl-Jensen, V Warren, TK Warfield, KL Weidmann, M Nichol, ST AF Kuhn, Jens H. Andersen, Kristian G. Bao, Yiming Bavari, Sina Becker, Stephan Bennett, Richard S. Bergman, Nicholas H. Blinkova, Olga Bradfute, Steven Brister, J. Rodney Bukreyev, Alexander Chandran, Kartik Chepurnov, Alexander A. Davey, Robert A. Dietzgen, Ralf G. Doggett, Norman A. Dolnik, Olga Dye, John M. Enterlein, Sven Fenimore, Paul W. Formenty, Pierre Freiberg, Alexander N. Garry, Robert F. Garza, Nicole L. Gire, Stephen K. Gonzalez, Jean-Paul Griffiths, Anthony Happi, Christian T. Hensley, Lisa E. Herbert, Andrew S. Hevey, Michael C. Hoenen, Thomas Honko, Anna N. Ignatyev, Georgy M. Jahrling, Peter B. Johnson, Joshua C. Johnson, Karl M. Kindrachuk, Jason Klenk, Hans-Dieter Kobinger, Gary Kochel, Tadeusz J. Lackemeyer, Matthew G. Lackner, Daniel F. Leroy, Eric M. Lever, Mark S. Muehlberger, Elke Netesov, Sergey V. Olinger, Gene G. Omilabu, Sunday A. Palacios, Gustavo Panchal, Rekha G. Park, Daniel J. Patterson, Jean L. Paweska, Janusz T. Peters, Clarence J. Pettitt, James Pitt, Louise Radoshitzky, Sheli R. Ryabchikova, Elena I. Saphire, Erica Ollmann Sabeti, Pardis C. Sealfon, Rachel Shestopalov, Aleksandr M. Smither, Sophie J. Sullivan, Nancy J. Swanepoel, Robert Takada, Ayato Towner, Jonathan S. van der Groen, Guido Volchkov, Viktor E. Volchkova, Valentina A. Wahl-Jensen, Victoria Warren, Travis K. Warfield, Kelly L. Weidmann, Manfred Nichol, Stuart T. TI Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names SO VIRUSES-BASEL LA English DT Letter DE Bundibugyo virus; cDNA clone; cuevavirus; Ebola; Ebola virus; ebolavirus; filovirid; Filoviridae; filovirus; genome annotation; ICTV; International Committee on Taxonomy of Viruses; Lloviu virus; Marburg virus; marburgvirus; mononegavirad; Mononegavirales; mononegavirus; Ravn virus; RefSeq; Reston virus; reverse genetics; Sudan virus; Tai Forest virus; virus classification; virus isolate; virus nomenclature; virus strain; virus taxonomy; virus variant ID INTERFERON INHIBITORY DOMAIN; DOUBLE-STRANDED-RNA; C-TERMINAL DOMAIN; EBOLA-VIRUS VP35; STANDARDIZED NOMENCLATURE; FAMILY FILOVIRIDAE; SPECIES LEVEL; INTERNATIONAL COMMITTEE; ENVELOPE GLYCOPROTEIN; TAXONOMIC PROPOSALS AB Sequence determination of complete or coding-complete genomes of viruses is becoming common practice for supporting the work of epidemiologists, ecologists, virologists, and taxonomists. Sequencing duration and costs are rapidly decreasing, sequencing hardware is under modification for use by non-experts, and software is constantly being improved to simplify sequence data management and analysis. Thus, analysis of virus disease outbreaks on the molecular level is now feasible, including characterization of the evolution of individual virus populations in single patients over time. The increasing accumulation of sequencing data creates a management problem for the curators of commonly used sequence databases and an entry retrieval problem for end users. Therefore, utilizing the data to their fullest potential will require setting nomenclature and annotation standards for virus isolates and associated genomic sequences. The National Center for Biotechnology Information's (NCBI's) RefSeq is a non-redundant, curated database for reference (or type) nucleotide sequence records that supplies source data to numerous other databases. Building on recently proposed templates for filovirus variant naming [ ()////-], we report consensus decisions from a majority of past and currently active filovirus experts on the eight filovirus type variants and isolates to be represented in RefSeq, their final designations, and their associated sequences. C1 [Kuhn, Jens H.; Hensley, Lisa E.; Honko, Anna N.; Jahrling, Peter B.; Johnson, Joshua C.; Kindrachuk, Jason; Lackemeyer, Matthew G.; Olinger, Gene G.; Pettitt, James] NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD 21702 USA. [Andersen, Kristian G.; Gire, Stephen K.; Sabeti, Pardis C.] Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA. [Bao, Yiming; Blinkova, Olga; Brister, J. Rodney] Natl Lib Med, Informat Engn Branch, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA. [Bavari, Sina; Dye, John M.; Garza, Nicole L.; Herbert, Andrew S.; Palacios, Gustavo; Panchal, Rekha G.; Pitt, Louise; Radoshitzky, Sheli R.; Warren, Travis K.] US Army, Med Res Inst Infect Dis, Frederick, MD 21702 USA. [Becker, Stephan; Dolnik, Olga; Klenk, Hans-Dieter] Univ Marburg, Inst Virol, D-35043 Marburg, Germany. [Bennett, Richard S.; Bergman, Nicholas H.; Hevey, Michael C.; Kochel, Tadeusz J.; Lackner, Daniel F.; Wahl-Jensen, Victoria] Natl Biodef Anal & Countermeasures Ctr, Frederick, MD 21702 USA. [Bradfute, Steven] Univ New Mexico, Albuquerque, NM 87131 USA. [Bukreyev, Alexander; Freiberg, Alexander N.; Peters, Clarence J.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Bukreyev, Alexander; Freiberg, Alexander N.; Peters, Clarence J.] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA. [Chandran, Kartik] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA. [Chepurnov, Alexander A.] Russian Acad Sci, Siberian Branch, Inst Clin Immunol, Novosibirsk 630091, Novosibirsk Obl, Russia. [Davey, Robert A.; Griffiths, Anthony; Patterson, Jean L.] Texas Biomed Res Inst, Dept Virol & Immunol, San Antonio, TX 78227 USA. [Dietzgen, Ralf G.] Univ Queensland, Queensland Alliance Agr & Food Innovat, St Lucia, Qld 4072, Australia. [Doggett, Norman A.; Fenimore, Paul W.] Los Alamos Natl Lab, Los Alamos, NM 87545 USA. [Enterlein, Sven] Integrated BioTherapeut Inc, Gaithersburg, MD 20878 USA. [Formenty, Pierre] WHO, CH-1211 Geneva, Switzerland. [Gonzalez, Jean-Paul] Metabiota Inc, San Francisco, CA 94104 USA. [Garry, Robert F.] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA. [Happi, Christian T.] Redeemers Univ, Dept Biol Sci, Coll Nat Sci, Lagos, Ogun State, Nigeria. [Happi, Christian T.] Redeemers Univ, African Ctr Excellence Genom Infect Dis, Lagos, Ogun State, Nigeria. [Hoenen, Thomas] NIAID, Virol Lab, Div Intramural Res, NIH, Hamilton, MT 59840 USA. [Ignatyev, Georgy M.] Minist Hlth Russian Federat, Microgen Sci Ind Co Immunobiol Med, Fed State Unitary Co, Moscow 115088, Russia. [Kobinger, Gary] Publ Hlth Agcy Canada, Natl Microbiol Lab, Special Pathogens Program, Winnipeg, MB R3E 3R2, Canada. [Leroy, Eric M.] Ctr Int Rech Med Franceville, Franceville, Gabon. [Lever, Mark S.; Smither, Sophie J.] Dstl, Dept Biomed Sci, Salisbury SP4 0JQ, Wilts, England. [Muehlberger, Elke] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA. [Muehlberger, Elke] Boston Univ, Sch Med, Natl Emerging Infect Dis Lab, Boston, MA 02118 USA. [Netesov, Sergey V.; Shestopalov, Aleksandr M.] Novosibirsk State Univ, Novosibirsk 630090, Novosibirsk Reg, Russia. [Omilabu, Sunday A.] Univ Lagos, Coll Med, Dept Med Microbiol & Parasitol, Lagos, Nigeria. [Park, Daniel J.] Broad Inst, Cambridge, MA 02142 USA. [Paweska, Janusz T.] Natl Hlth Lab Serv, Ctr Emerging & Zoonot Dis, Natl Inst Communicable Dis, ZA-2192 Sandringham Johannesburg, Gauteng, South Africa. [Ryabchikova, Elena I.] Russian Acad Sci, Siberian Branch, Inst Chem Biol & Fundamental Med, Novosibirsk 630090, Novosibirsk Reg, Russia. [Saphire, Erica Ollmann] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA. [Saphire, Erica Ollmann] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA. [Sealfon, Rachel] MIT, Cambridge, MA 02139 USA. [Sealfon, Rachel] MIT, Artificial Intelligence Lab, Cambridge, MA 02139 USA. [Sullivan, Nancy J.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Swanepoel, Robert] Univ Pretoria, Zoonoses Res Unit, ZA-0028 Pretoria, South Africa. [Takada, Ayato] Hokkaido Univ, Res Ctr Zoonosis Control, Div Global Epidemiol, Kita Ku, Sapporo, Hokkaido, Japan. [Towner, Jonathan S.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [van der Groen, Guido] Prins Leopold Inst Trop Geneeskunde, B-2000 Antwerp, Belgium. [Volchkov, Viktor E.; Volchkova, Valentina A.] Univ Lyon 1, INSERM, U1111, Lab Mol Basis Viral Pathogen,CIRI,Ecole Normale S, F-69365 Lyon 07, France. [Warfield, Kelly L.] Unither Virol LLC, Silver Spring, MD 20910 USA. [Weidmann, Manfred] Univ Stirling, Inst Aquaculture, Stirling FK9 4LA, Scotland. RP Kuhn, JH (reprint author), NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD 21702 USA. EM kuhnjens@mail.nih.gov; kandersen@oeb.harvard.edu; bao@ncbi.nlm.nih.gov; sina.bavari.civ@mail.mil; becker@staff.uni-marburg.de; richard.bennett@nbacc.dhs.gov; nicholas.bergman@nbacc.dhs.gov; olga.blinkova@nih.gov; steven_bradfute@yahoo.com; jamesbr@ncbi.nlm.nih.gov; alexander.bukreyev@utmb.edu; kartik.chandran@einstein.yu.edu; alexa.che.purnov@gmail.com; rdavey@txbiomed.org; r.dietzgen@uq.edu.au; doggett@lanl.gov; Dolnik@staff.uni-marburg.de; john.m.dye1.civ@mail.mil; sven.enterlein@gmail.com; paulf@lanl.gov; formentyp@who.int; anfreibe@utmb.edu; rfgarry@tulane.edu; Nicole.l.lackemeyer.ctr@mail.mil; sgire@oeb.harvard.edu; jpgonzalez@metabiota.com; agriffiths@txbiomed.org; chappi@hsph.harvard.edu; lisa.hensley@nih.gov; anderw.s.herbert.ctr@mail.mil; michael.hevey@nbacc.dhs.gov; thomas.hoenen@nih.gov; anna.honko@nih.gov; g.m.ignatyev@microgen.ru; jahrlingp@niaid.nih.gov; joshua.johnson@nih.gov; microcaddis@gmail.com; kindrachuk.kenneth@nih.gov; klenk@mailer.uni-marburg.de; gary.kobinger@phac-aspc.gc.ca; tadeusz.kochel@nbacc.dhs.gov; matthew.lackemeyer@nih.gov; daniel.lackner@nbacc.dhs.gov; eric.leroy@ird.fr; mslever@mail.dstl.gov.uk; muehlber@bu.edu; nauka@nsu.ru; gene.olinger@nih.gov; omilabusa@yahoo.com; gustavo.f.palacios.ctr@us.army.mil; rekha.g.panchal.civ@mail.mil; dpark@broadinstitute.org; jpatters@txbiomed.org; januszp@nicd.ac.za; cjpeters@UTMB.EDU; james.pettitt@nih.gov; louise.pitt@us.army.mil; sheli.r.radoshitzky.ctr@mail.mil; lenryab@yandex.com; erica@scripps.edu; pardis@broadinstitute.org; sealfon@gmail.com; shestopalov2@mail.ru; SJSMITHER@mail.dstl.gov.uk; njsull@mail.nih.gov; bobswanepoel@gmail.com; atakada@czc.hokudai.ac.jp; jit8@cdc.gov; gvdgroen@scarlet.be; viktor.volchkov@inserm.fr; valentina.volchkova@inserm.fr; victoria.jensen@nbacc.dhs.gov; travis.k.warren.ctr@mail.mil; kellylynwarfield@gmail.com; m.w.weidmann@stir.ac.uk; stn1@cdc.gov RI Volchkov, Viktor/M-7846-2014; Kuhn, Jens H./B-7615-2011; Ryabchikova, Elena /G-3089-2013; Netesov, Sergey/A-3751-2013; Becker, Stephan/A-1065-2010; Palacios, Gustavo/I-7773-2015; Weidmann, Manfred/G-1817-2015; LEROY, Eric/I-4347-2016; OI Volchkov, Viktor/0000-0001-7896-8706; Kuhn, Jens H./0000-0002-7800-6045; Ryabchikova, Elena /0000-0003-4714-1524; Netesov, Sergey/0000-0002-7786-2464; Becker, Stephan/0000-0002-2794-5659; Palacios, Gustavo/0000-0001-5062-1938; Weidmann, Manfred/0000-0002-7063-7491; Johnson, Joshua/0000-0002-5677-3841; LEROY, Eric/0000-0003-0022-0890; Kindrachuk, Jason/0000-0002-3305-7084; Hoenen, Thomas/0000-0002-5829-6305; Honko, Anna/0000-0001-9165-148X; Bennett, Richard/0000-0002-7227-4831 FU Intramural NIH HHS; NIAID NIH HHS [HHSN272200700016I, R01 AI104621, U19 AI115589, UC7 AI094660]; World Health Organization [001] NR 49 TC 20 Z9 20 U1 2 U2 32 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1999-4915 J9 VIRUSES-BASEL JI Viruses-Basel PD SEP PY 2014 VL 6 IS 9 BP 3663 EP 3682 DI 10.3390/v6093663 PG 20 WC Virology SC Virology GA AQ8TW UT WOS:000343107100020 PM 25256396 ER PT J AU Cohen, DL Townsend, RR Angell, SY DiPette, DJ AF Cohen, Debbie L. Townsend, Raymond R. Angell, Sonia Y. DiPette, Donald J. TI The World Health Organization Recognizes Noncommunicable Diseases and Raised Blood Pressure as Global Health Priority for 2025 SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material C1 [Cohen, Debbie L.; Townsend, Raymond R.] Univ Penn, Perelman Sch Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA. [Angell, Sonia Y.] Univ S Carolina, Sch Med, Columbia, SC USA. [DiPette, Donald J.] Ctr Dis Control & Prevent, Global Noncommunicable Dis, Div Global Hlth, Atlanta, GA USA. RP Cohen, DL (reprint author), Univ Penn, Perelman Sch Med, 3400 Spruce St, Philadelphia, PA 19104 USA. EM debbie.cohen@uphs.upenn.edu NR 2 TC 7 Z9 7 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD SEP PY 2014 VL 16 IS 9 BP 624 EP 624 DI 10.1111/jch.12384 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AQ6ZG UT WOS:000342961800002 PM 25087601 ER PT J AU Gonzalez, R Desai, M Macete, E Ouma, P Kakolwa, MA Abdulla, S Aponte, JJ Bulo, H Kabanywanyi, AM Katana, A Maculuve, S Mayor, A Nhacolo, A Otieno, K Pahlavan, G Ruperez, M Sevene, E Slutsker, L Vala, A Williamsom, J Menendez, C AF Gonzalez, Raquel Desai, Meghna Macete, Eusebio Ouma, Peter Kakolwa, Mwaka A. Abdulla, Salim Aponte, John J. Bulo, Helder Kabanywanyi, Abdunoor M. Katana, Abraham Maculuve, Sonia Mayor, Alfredo Nhacolo, Arsenio Otieno, Kephas Pahlavan, Golbahar Ruperez, Maria Sevene, Esperanca Slutsker, Laurence Vala, Anifa Williamsom, John Menendez, Clara TI Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Infected Women Receiving Cotrimoxazole Prophylaxis: A Multicenter Randomized Placebo-Controlled Trial SO PLOS MEDICINE LA English DT Article ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PLASMODIUM-FALCIPARUM MALARIA; SUB-SAHARAN AFRICA; HUMAN-IMMUNODEFICIENCY-VIRUS; SULFADOXINE-PYRIMETHAMINE; PHARMACOKINETIC EXPOSURE; ANTIRETROVIRAL THERAPY; HEALTHY-VOLUNTEERS; PROSPECTIVE COHORT; CLINICAL MALARIA AB Background Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended for malaria prevention in HIV-negative pregnant women, but it is contraindicated in HIV-infected women taking daily cotrimoxazole prophylaxis (CTXp) because of potential added risk of adverse effects associated with taking two antifolate drugs simultaneously. We studied the safety and efficacy of mefloquine (MQ) in women receiving CTXp and long-lasting insecticide treated nets (LLITNs). Methods and Findings A total of 1,071 HIV-infected women from Kenya, Mozambique, and Tanzania were randomized to receive either three doses of IPTp-MQ (15 mg/kg) or placebo given at least one month apart; all received CTXp and a LLITN. IPTp-MQ was associated with reduced rates of maternal parasitemia (risk ratio [RR], 0.47 [95% CI 0.27-0.82]; p=0.008), placental malaria (RR, 0.52 [95% CI 0.29-0.90]; p=0.021), and reduced incidence of non-obstetric hospital admissions (RR, 0.59 [95% CI 0.37-0.95]; p=0.031) in the intention to treat (ITT) analysis. There were no differences in the prevalence of adverse pregnancy outcomes between groups. Drug tolerability was poorer in the MQ group compared to the control group (29.6% referred dizziness and 23.9% vomiting after the first IPTp-MQ administration). HIV viral load at delivery was higher in the MQ group compared to the control group (p=0.048) in the ATP analysis. The frequency of perinatal mother to child transmission of HIV was increased in women who received MQ (RR, 1.95 [95% CI 1.14-3.33]; p=0.015). The main limitation of the latter finding relates to the exploratory nature of this part of the analysis. Conclusions An effective antimalarial added to CTXp and LLITNs in HIV-infected pregnant women can improve malaria prevention, as well as maternal health through reduction in hospital admissions. However, MQ was not well tolerated, limiting its potential for IPTp and indicating the need to find alternatives with better tolerability to reduce malaria in this particularly vulnerable group. MQ was associated with an increased risk of mother to child transmission of HIV, which warrants a better understanding of the pharmacological interactions between antimalarials and antiretroviral drugs. Trial registration ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001813440Please see later in the article for the Editors' Summary Editors' Summary Background Malaria, a mosquito-borne parasitic disease, kills about 600,000 people every year. Most of these deaths occur among young children living in sub-Saharan Africa but pregnant women living in Africa are also very vulnerable to malaria. Infection with malaria during pregnancy can cause severe maternal anemia (reduced red blood cell numbers), stillbirths, and pre-term and low-birthweight babies, and is responsible for the deaths of many African women and their babies. To reduce the loss of life from malaria in pregnancy, the World Health Organization (WHO) recommends that pregnant women living in Africa receive the antimalarial drug sulfadoxine-pyrimethamine (SP) at each scheduled antenatal care visit given at least a month apart (intermittent preventive treatment in pregnancy [IPTp]). In addition, WHO advises pregnant women to sleep under insecticide-treated bed nets to protect themselves from the bites of infected mosquitoes and recommends effective case management of pregnant women with malarial illness. Why Was This Study Done? Pregnant women living in Africa are often infected with HIV, the virus that causes AIDS. HIV infection increases both the risk and severity of malaria infection during pregnancy, and at least one million pregnancies are complicated by co-infection with malaria and HIV in sub-Saharan Africa every year. WHO recommends that HIV-positive pregnant women take cotrimoxazole (CTX) daily to prevent opportunistic infections (CTX prophylaxis [CTXp]). Unfortunately, both CTX and SP are antifolate drugs and taking two drugs of this type increases a woman's risk of developing a severe skin reaction. Moreover, although CTXp protects children and HIV-infected adults against malaria, it is not known whether CTXp alone protects HIV-infected pregnant women adequately against malaria. Thus, evaluations of alternative drugs for use in IPTp in HIV-positive pregnant women are needed. In this randomized placebo-controlled trial, the researchers study the safety and efficacy of the antimalarial drug mefloquine (MQ) in HIV-infected women receiving CTXp. A randomized, placebo-controlled trial compares outcomes among people chosen through the play of chance to receive either the drug under investigation or a dummy (placebo) drug. What Did the Researchers Do and Find? The researchers allocated 1,071 HIV-infected pregnant women from Kenya, Mozambique, and Tanzania to receive three doses of MQ (IPTp-MQ), given at least one month apart, or three doses of placebo. All the women received CTXp and were given an insecticide-treated bed net. In an intention-to-treat analysis (an analysis that considers the outcomes of all trial participants irrespective of whether they receive their allocated treatment), the prevalence of parasitemia (parasites in the blood) at delivery among women given IPTp-MQ was 3.5% whereas the prevalence among women given the placebo was 6.9%. In other words, compared to placebo, IPTp-MQ was associated with a reduced risk of maternal parasitemia. IPTp-MQ was also associated with a reduced rate of placental malaria (parasites in the placenta) and a reduced incidence of hospital admissions for non-pregnancy related causes. There was no difference in adverse pregnancy outcomes such as stillbirth between the intervention groups but drug tolerability was poorer in the MQ group than in the placebo group. Finally, in an exploratory (unplanned) according-to-protocol analysis (an analysis that only considers outcomes in trial participants who receive their allocated intervention), women in the MQ group had a higher HIV viral load at delivery than women in the control group and were nearly twice as likely to transmit HIV to their child around the time of birth. What Do These Findings Mean? These findings suggest that the addition of IPTp-MQ to CTXp and the use of insecticide-treated bed nets can improve malaria prevention and maternal health in HIV-infected pregnant women in Africa. However, the poor tolerability of MQ and the association of MQ treatment with both an increased HIV viral load at delivery and a higher frequency of mother-to-child-transmission of HIV when compared to placebo raise concerns about the use of MQ in IPTp. Because these last two findings came from an exploratory analysis, which is more likely to throw up a chance finding than a pre-planned analysis further studies are needed to confirm these unexpected but potentially important findings. Nevertheless, overall, the findings of this study suggest that MQ should not be recommended for IPTp in HIV-infected pregnant women in Africa and highlight the need to find alternative drugs for malaria prevention in this group of women who are particularly vulnerable to malaria. Additional Information Please access these websites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.1001735. This study is further discussed in a PLOS MedicinePerspective by Richard Steketee. A related PLOS MedicineResearch Article by Gonzalez et al. compares the efficacy of IPTp-MQ and IPTp-SP in HIV-negative women Information is available from the World Health Organization on malaria (in several languages) and on malaria in pregnancy; information on IPTp and the current WHO policy recommendation on IPTp with SP are available; the 2013 World Malaria Report provides details of the current global malaria situation The US Centers for Disease Control and Prevention also provides information on malaria; a personal story about malaria in pregnancy is available Information is available from the Roll Back Malaria Partnership on all aspects of global malaria control, including information on malaria in pregnancy The Malaria in Pregnancy Consortium is undertaking research into the prevention and treatment of malaria in pregnancy MedlinePlus provides links to additional information on malaria (in English and Spanish) More information about the trial protocol is available C1 [Gonzalez, Raquel; Aponte, John J.; Mayor, Alfredo; Pahlavan, Golbahar; Ruperez, Maria; Menendez, Clara] Hosp Clin Univ Barcelona, Barcelona Inst Global Hlth, Barcelona Ctr Int Hlth Res, ISGlobal,CRESIB, Barcelona, Spain. [Gonzalez, Raquel; Macete, Eusebio; Aponte, John J.; Bulo, Helder; Maculuve, Sonia; Mayor, Alfredo; Nhacolo, Arsenio; Ruperez, Maria; Sevene, Esperanca; Vala, Anifa; Menendez, Clara] Manh Hlth Res Ctr CISM, Manhica, Mozambique. [Desai, Meghna; Ouma, Peter; Katana, Abraham; Otieno, Kephas; Williamsom, John] Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent KEMR CDC, Kisumu, Kenya. [Desai, Meghna; Slutsker, Laurence; Williamsom, John] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA USA. [Ouma, Peter; Katana, Abraham; Otieno, Kephas] Kenya Govt Med Res Ctr, KEMRI Ctr Global Hlth Res, Kisumu, Kenya. [Kakolwa, Mwaka A.; Abdulla, Salim; Kabanywanyi, Abdunoor M.] Ifakara Hlth Inst IHI, Dodoma, Tanzania. RP Gonzalez, R (reprint author), Hosp Clin Univ Barcelona, Barcelona Inst Global Hlth, Barcelona Ctr Int Hlth Res, ISGlobal,CRESIB, Barcelona, Spain. EM Menendez@clinic.ub.es FU European Developing Countries Clinical Trials Partnership (EDCTP) [IP.2007.31080.002]; Malaria in Pregnancy Consortium and the Instituto de Salud Carlos III, Spain [PI08/0564]; Spanish Ministry of Health [CM07/0015, CM11/00278]; Spanish Agency for international Cooperation (AECI) FX No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was funded by the European Developing Countries Clinical Trials Partnership (EDCTP; IP.2007.31080.002), the Malaria in Pregnancy Consortium and the Instituto de Salud Carlos III (PI08/0564), Spain. RG and MR were partially supported by grants from the Spanish Ministry of Health (ref. CM07/0015 and CM11/00278, respectively). The CISM receives core funding from the Spanish Agency for international Cooperation (AECI). LLITNs (Permanet) were donated by Vestergaard Fransen and cotrimoxazole tablets (Septrin) by UCB Pharma, Spain. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This publication has been approved by the Director of KEMRI. NR 66 TC 10 Z9 10 U1 3 U2 23 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD SEP PY 2014 VL 11 IS 9 AR e1001735 DI 10.1371/journal.pmed.1001735 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA AQ6FO UT WOS:000342905700036 PM 25247995 ER PT J AU Golnar, AJ Turell, MJ LaBeaud, AD Kading, RC Hamer, GL AF Golnar, Andrew J. Turell, Michael J. LaBeaud, A. Desiree Kading, Rebekah C. Hamer, Gabriel L. TI Predicting the Mosquito Species and Vertebrate Species Involved in the Theoretical Transmission of Rift Valley Fever Virus in the United States SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID WEST-NILE-VIRUS; NORTH-AMERICAN MOSQUITOS; DIPTERA-CULICIDAE; VECTOR COMPETENCE; BUNYAVIRIDAE PHLEBOVIRUS; EXPERIMENTAL-INFECTION; PUBLIC-HEALTH; PATHOGENESIS; DISEASE; BIRDS AB Rift Valley fever virus (RVFV) is a mosquito-borne virus in the family Bunyaviridiae that has spread throughout continental Africa to Madagascar and the Arabian Peninsula. The establishment of RVFV in North America would have serious consequences for human and animal health in addition to a significant economic impact on the livestock industry. Published and unpublished data on RVFV vector competence, vertebrate host competence, and mosquito feeding patterns from the United States were combined to quantitatively implicate mosquito vectors and vertebrate hosts that may be important to RVFV transmission in the United States. A viremia-vector competence relationship based on published mosquito transmission studies was used to calculate a vertebrate host competence index which was then combined with mosquito blood feeding patterns to approximate the vector and vertebrate amplification fraction, defined as the relative contribution of the mosquito or vertebrate host to pathogen transmission. Results implicate several Aedes spp. mosquitoes and vertebrates in the order Artiodactyla as important hosts for RVFV transmission in the U. S. Moreover, this study identifies critical gaps in knowledge which would be necessary to complete a comprehensive analysis identifying the different contributions of mosquitoes and vertebrates to potential RVFV transmission in the U. S. Future research should focus on (1) the dose-dependent relationship between viremic exposure and the subsequent infectiousness of key mosquito species, (2) evaluation of vertebrate host competence for RVFV among North American mammal species, with particular emphasis on the order Artiodactyla, and (3) identification of areas with a high risk for RVFV introduction so data on local vector and host populations can help generate geographically appropriate amplification fraction estimates. C1 [Golnar, Andrew J.; Hamer, Gabriel L.] Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA. [Turell, Michael J.] US Army Med Res Inst Infect Dis, Div Virol, Frederick, MD USA. [LaBeaud, A. Desiree] Childrens Hosp Oakland, Res Inst, Ctr Immunobiol & Vaccine Dev, Oakland, CA 94609 USA. [Kading, Rebekah C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arbovirus Dis Branch, Ft Collins, CO USA. RP Golnar, AJ (reprint author), Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA. EM ghamer@tamu.edu RI Kading, Rebekah/E-5633-2017; OI Kading, Rebekah/0000-0002-4996-915X; Golnar, Andrew/0000-0003-0747-5271 FU National Science Foundation/National Institutes of Health Ecology of Infectious Disease program [EF-0840403]; National Science Foundation [1252521] FX This project was funded through the National Science Foundation/National Institutes of Health Ecology of Infectious Disease program, #EF-0840403 and the National Science Foundation Graduate Research Fellowship program under Grant #1252521. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 80 TC 5 Z9 6 U1 2 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2014 VL 8 IS 9 AR e3163 DI 10.1371/journal.pntd.0003163 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AQ4UZ UT WOS:000342796600044 PM 25211133 ER PT J AU Groseth, A Mampilli, V Weisend, C Dahlstrom, E Porcella, SF Russell, BJ Tesh, RB Ebihara, H AF Groseth, Allison Mampilli, Veena Weisend, Carla Dahlstrom, Eric Porcella, Stephen F. Russell, Brandy J. Tesh, Robert B. Ebihara, Hideki TI Molecular Characterization of Human Pathogenic Bunyaviruses of the Nyando and Bwamba/Pongola Virus Groups Leads to the Genetic Identification of Mojui dos Campos and Kaeng Khoi Virus SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID ARTHROPOD-BORNE VIRUSES; NEIGHBOR-JOINING METHOD; CDNA ENDS RACE; GENUS ORTHOBUNYAVIRUS; INDIGENOUS RESIDENTS; RAPID AMPLIFICATION; INFECTIOUS-DISEASES; FAMILY BUNYAVIRIDAE; PHYLOGENIES; ANTIBODIES AB Background: Human infection with Bwamba virus (BWAV) and the closely related Pongola virus (PGAV), as well as Nyando virus (NDV), are important causes of febrile illness in Africa. However, despite seroprevalence studies that indicate high rates of infection in many countries, these viruses remain relatively unknown and unstudied. In addition, a number of unclassified bunyaviruses have been isolated over the years often with uncertain relationships to human disease. Methodology/Principal Findings: In order to better understand the genetic and evolutionary relationships among orthobunyaviruses associated with human disease, we have sequenced the complete genomes for all 3 segments of multiple strains of BWAV (n = 2), PGAV (n = 2) and NDV (n = 4), as well as the previously unclassified Mojui dos Campos (MDCV) and Kaeng Khoi viruses (KKV). Based on phylogenetic analysis, we show that these viruses populate 2 distinct branches, one made up of BWAV and PGAV and the other composed of NDV, MDCV and KKV. Interestingly, the NDV strains analyzed form two distinct clades which differed by >10% on the amino acid level across all protein products. In addition, the assignment of two bat-associated bunyaviruses into the NDV group, which is clearly associated with mosquito-borne infection, led us to analyze the ability of these different viruses to grow in bat (RE05 and Tb 1 Lu) and mosquito (C6/36) cell lines, and indeed all the viruses tested were capable of efficient growth in these cell types. Conclusions/Significance: On the basis of our analyses, it is proposed to reclassify the NDV strains ERET147 and YM176-66 as a new virus species. Further, our analysis definitively identifies the previously unclassified bunyaviruses MDCV and KKV as distinct species within the NDV group and suggests that these viruses may have a broader host range than is currently appreciated. C1 [Groseth, Allison; Mampilli, Veena; Weisend, Carla; Ebihara, Hideki] NIAID, Mol Virol & Host Pathogen Interact Unit, Virol Lab, Div Intramural Res,NIH, Hamilton, MT 59840 USA. [Dahlstrom, Eric; Porcella, Stephen F.] NIAID, RML Genom Unit, Res Technol Branch, NIH, Hamilton, MT USA. [Russell, Brandy J.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA. [Tesh, Robert B.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Tesh, Robert B.] Univ Texas Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA. RP Groseth, A (reprint author), NIAID, Mol Virol & Host Pathogen Interact Unit, Virol Lab, Div Intramural Res,NIH, Hamilton, MT 59840 USA. EM ebiharah@niaid.nih.gov FU National Institutes of Health; NIH [HHSN272201000040I/HHSN200004/D04] FX This work was supported by the Intramural Research Program of the National Institutes of Health. RBT was supported by NIH contract HHSN272201000040I/ HHSN200004/D04. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the National Institutes of Health. NR 55 TC 3 Z9 3 U1 5 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2014 VL 8 IS 9 AR e3147 DI 10.1371/journal.pntd.0003147 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AQ4UZ UT WOS:000342796600036 PM 25188437 ER PT J AU Khan, SU Salje, H Hannan, A Islam, MA Bhuyan, AAM Islam, MA Rahman, MZ Nahar, N Hossain, MJ Luby, SP Gurley, ES AF Khan, Salah Uddin Salje, Henrik Hannan, A. Islam, Md. Atiqul Bhuyan, A. A. Mamun Islam, Md. Ariful Rahman, M. Ziaur Nahar, Nazmun Hossain, M. Jahangir Luby, Stephen P. Gurley, Emily S. TI Dynamics of Japanese Encephalitis Virus Transmission among Pigs in Northwest Bangladesh and the Potential Impact of Pig Vaccination SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID WEST-NILE; EPIDEMIOLOGY; INFECTION; SWINE; ECOLOGY AB Background: Japanese encephalitis (JE) virus infection can cause severe disease in humans, resulting in death or permanent neurologic deficits among survivors. Studies indicate that the incidence of JE is high in northwestern Bangladesh. Pigs are amplifying hosts for JE virus (JEV) and a potentially important source of virus in the environment. The objectives of this study were to describe the transmission dynamics of JEV among pigs in northwestern Bangladesh and estimate the potential impact of vaccination to reduce incidence among pigs. Methodology/Principal Findings: We conducted a comprehensive census of pigs in three JE endemic districts and tested a sample of them for evidence of previous JEV infection. We built a compartmental model to describe JEV transmission dynamics in this region and to estimate the potential impact of pig vaccination. We identified 11,364 pigs in the study area. Previous JEV infection was identified in 30% of pigs with no spatial differences in the proportion of pigs that were seropositive across the study area. We estimated that JEV infects 20% of susceptible pigs each year and the basic reproductive number among pigs was 1.2. The model suggest that vaccinating 50% of pigs each year resulted in an estimated 82% reduction in annual incidence in pigs. Conclusions/Significance: The widespread distribution of historic JEV infection in pigs suggests they may play an important role in virus transmission in this area. Future studies are required to understand the contribution of pig infections to JE risk in humans and the potential impact of pig vaccination on human disease. C1 [Khan, Salah Uddin; Islam, Md. Atiqul; Bhuyan, A. A. Mamun; Islam, Md. Ariful; Rahman, M. Ziaur; Nahar, Nazmun; Hossain, M. Jahangir; Luby, Stephen P.; Gurley, Emily S.] I Cddr B, Ctr Communicable Dis, Dhaka, Bangladesh. [Khan, Salah Uddin] Univ Florida, Dept Environm & Global Hlth, Coll Publ Hlth & Hlth Profess, Gainesville, FL USA. [Salje, Henrik] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Hannan, A.] Minist Fisheries & Livestock, Dept Livestock Serv, Dhaka, Bangladesh. [Luby, Stephen P.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. RP Khan, SU (reprint author), I Cddr B, Ctr Communicable Dis, Dhaka, Bangladesh. EM sukhanbd@gmail.com RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X; Salje, Henrik/0000-0003-3626-4254 FU Centers for Disease Control and Prevention, USA [U01/C1000298]; Research and Policy on Infectious Disease Dynamics (RAPIDD), Fogarty International Center, National Institutes of Health FX This study was conducted with support from the Centers for Disease Control and Prevention, USA, cooperative agreement U01/C1000298, and Research and Policy on Infectious Disease Dynamics (RAPIDD), Fogarty International Center, National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 7 Z9 7 U1 2 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2014 VL 8 IS 9 AR e3166 DI 10.1371/journal.pntd.0003166 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AQ4UZ UT WOS:000342796600047 PM 25255286 ER PT J AU Mues, KE Deming, M Kleinbaum, DG Budge, PJ Klein, M Leon, JS Prakash, A Rout, J Fox, LM AF Mues, Katherine E. Deming, Michael Kleinbaum, David G. Budge, Philip J. Klein, Mitch Leon, Juan S. Prakash, Aishya Rout, Jonathan Fox, LeAnne M. TI Impact of a Community-Based Lymphedema Management Program on Episodes of Adenolymphangitis (ADLA) and Lymphedema Progression - Odisha State, India SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID PREVENTING ACUTE ADENOLYMPHANGITIS; PAPUA-NEW-GUINEA; BANCROFTIAN FILARIASIS; LYMPHATIC FILARIASIS; BRUGIAN FILARIASIS; LOCAL TREATMENT; AFFECTED LIMB; ACUTE ATTACKS; EFFICACY; ORISSA AB Background: Lymphedema management programs have been shown to decrease episodes of adenolymphangitis (ADLA), but the impact on lymphedema progression and of program compliance have not been thoroughly explored. Our objectives were to determine the rate of ADLA episodes and lymphedema progression over time for patients enrolled in a community-based lymphedema management program. We explored the association between program compliance and ADLA episodes as well as lymphedema progression. Methodology/Principal Findings: A lymphedema management program was implemented in Odisha State, India from 2007-2010 by the non-governmental organization, Church's Auxiliary for Social Action, in consultation with the Centers for Disease Control and Prevention. A cohort of patients was followed over 24 months. The crude 30-day rate of ADLA episodes decreased from 0.35 episodes per person-month at baseline to 0.23 at 24 months. Over the study period, the percentage of patients who progressed to more severe lymphedema decreased (P-value = 0.0004), while those whose lymphedema regressed increased over time (P-value < 0.0001). Overall compliance to lymphedema management, lagged one time point, appeared to have little to no association with the frequency of ADLA episodes among those without entry lesions (RR = 0.87 (0.69, 1.10)) and was associated with an increased rate (RR = 1.44 (1.11, 1.86)) among those with entry lesions. Lagging compliance two time points, it was associated with a decrease in the rate of ADLA episodes among those with entry lesions (RR = 0.77 (95% CI: 0.59, 0.99)) and was somewhat associated among those without entry lesions (RR = 0.83 (95% CI: 0.64, 1.06)). Compliance to soap was associated with a decreased rate of ADLA episodes among those without inter-digital entry lesions. Conclusions/Significance: These results indicate that a community-based lymphedema management program is beneficial for lymphedema patients for both ADLA episodes and lymphedema. It is one of the first studies to demonstrate an association between program compliance and rate of ADLA episodes. C1 [Mues, Katherine E.; Kleinbaum, David G.; Klein, Mitch; Leon, Juan S.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Mues, Katherine E.] Emory Univ, Laney Grad Sch, Atlanta, GA 30322 USA. [Deming, Michael; Budge, Philip J.; Fox, LeAnne M.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Prakash, Aishya; Rout, Jonathan] Churchs Auxiliary Social Act, Odisha, India. RP Mues, KE (reprint author), Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. EM kmues@emory.edu RI Leon, Juan/E-9674-2012 FU USAID [OGH99-005]; Centers for Disease Control and Prevention; Emory University, Laney Graduate School; National Institute Of Allergy And Infectious Diseases of the National Institutes of Health [K01AI087724] FX Funding for this work came from USAID Grant No. OGH99-005 (http://www.usaid.gov) to the Centers for Disease Control and Prevention and IMA World Health and the Centers for Disease Control and Prevention. KEM was supported in part by Emory University, Laney Graduate School. Research reported in this publication was supported in part (to JSL) by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number K01AI087724. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control and Prevention or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 5 Z9 5 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2014 VL 8 IS 9 AR e3140 DI 10.1371/journal.pntd.0003140 PG 14 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AQ4UZ UT WOS:000342796600030 PM 25211334 ER PT J AU O'Neal, SE Moyano, LM Ayvar, V Rodriguez, S Gavidia, C Wilkins, PP Gilman, RH Garcia, HH Gonzalez, AE AF O'Neal, Seth E. Moyano, Luz M. Ayvar, Viterbo Rodriguez, Silvia Gavidia, Cesar Wilkins, Patricia P. Gilman, Robert H. Garcia, Hector H. Gonzalez, Armando E. CA Cysticercosis Working Grp Peru TI Ring-Screening to Control Endemic Transmission of Taenia solium SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; PORCINE CYSTICERCOSIS; MASS CHEMOTHERAPY; TAPEWORM CARRIERS; NEUROCYSTICERCOSIS; PIGS; EPILEPSY; PERU; INFECTIONS; DIAGNOSIS AB Background: Taenia solium is a major cause of preventable epilepsy in developing nations. Screening and treatment of human intestinal stage infection (taeniasis) within high-risk foci may reduce transmission and prevent epilepsy by limiting human exposure to infective eggs. We piloted a ring-strategy that involves screening and treatment for taeniasis among households located nearby pigs heavily-infected with the larval stage (cysticercosis). These pigs mark areas of increased transmission and can be identified by tongue examination. Methodology: We selected two villages in northern Peru for a controlled prospective interventional cohort pilot study. In the intervention village (1,058 residents) we examined the tongues of all pigs every 4 months for nodules characteristic of cysticercosis. We then screened all residents living within 100-meters of any tongue-positive pig using enzyme-linked immunosorbent assay to detect Taenia antigens in stool. Residents with taeniasis were treated with niclosamide. In both the intervention and control (753 residents) we measured incidence of exposure by sampling the pig population every 4 months for serum antibodies against cysticercosis using enzyme-linked immunoelectrotransfer blot. Principal Findings: Baseline seroincidence among pigs born during the study was 22.6 cases per 100 pigs per-month (95% confidence interval [CI] 17.0-30.0) in the intervention and 18.1 (95% CI 12.7-25.9) in the control. After one year we observed a 41% reduction in seroincidence in the intervention village compared to baseline (incidence rate ratio 0.59, 95% CI 0.41-0.87) while the seroincidence in the control village remained unchanged. At study end, the prevalence of taeniasis was nearly 4 times lower in the intervention than in the control (prevalence ratio 0.28, 95% CI 0.08-0.91). Conclusions/Significance: Ring-screening reduced transmission of T. solium in this pilot study and may provide an effective and practical approach for regions where resources are limited. However, this strategy requires validation in larger populations over a greater period of time. C1 [O'Neal, Seth E.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Moyano, Luz M.; Ayvar, Viterbo; Garcia, Hector H.] Univ Peruana Cayetano Heredia, Cysticercosis Eliminat Program, Tumbes, Peru. [Moyano, Luz M.; Ayvar, Viterbo; Garcia, Hector H.] Univ Peruana Cayetano Heredia, Ctr Global Hlth Tumbes, Tumbes, Peru. [Rodriguez, Silvia; Garcia, Hector H.] Inst Ciencias Neurol, Lima, Peru. [Gavidia, Cesar; Gonzalez, Armando E.] Univ Nacl Mayor San Marcos, Sch Vet Med, Lima 14, Peru. [Wilkins, Patricia P.] Ctr Dis Control, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Gilman, Robert H.] Johns Hopkins Univ, Dept Int Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Gilman, Robert H.; Garcia, Hector H.] Univ Peruana Cayetano Heredia, Sch Sci, Dept Microbiol, Lima, Peru. RP O'Neal, SE (reprint author), Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. EM oneals@ohsu.edu OI Gavidia, Cesar Miguel/0000-0003-3936-5077 FU Fogarty International Center (FIC); National Institute of Neurologic Disorders and Stroke (NINDS), National Institutes of Health (NIH) [R21NS069275]; Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH [5KL2 RR024141-04]; NIH Roadmap for Medical Research; Fogarty International Center [TW001140]; Bill and Melinda Gates Foundation through the Cysticercosis Elimination Demonstration Program FX This research was made possible with support from the Fogarty International Center (FIC) and the National Institute of Neurologic Disorders and Stroke (NINDS), National Institutes of Health (NIH) grant number R21NS069275. Additional support was provided by the Oregon Clinical and Translational Research Institute (OCTRI), grant number 5KL2 RR024141-04 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH and the NIH Roadmap for Medical Research. Partial support from Training grant TW001140 from the Fogarty International Center in training of study team members is also acknowledged. Partial support from the Bill and Melinda Gates Foundation through the Cysticercosis Elimination Demonstration Program is also acknowledged. HHG is now a Wellcome Trust International Senior Research Fellow in Public Health and Tropical Medicine. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 34 TC 4 Z9 4 U1 0 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2014 VL 8 IS 9 AR e3125 DI 10.1371/journal.pntd.0003125 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AQ4UZ UT WOS:000342796600019 PM 25210748 ER PT J AU Lopiano, KK Young, LJ Gotway, CA AF Lopiano, Kenneth K. Young, Linda J. Gotway, Carol A. TI A Pseudo-Penalized Quasi-Likelihood Approach to the Spatial Misalignment Problem with Non-Normal Data SO BIOMETRICS LA English DT Article DE Berkson Error; Generalized linear models; Kriging; Spatial Misalignment ID LINEAR MIXED MODELS; REGRESSION-MODELS; INFERENCE; ERROR AB Spatially referenced datasets arising from multiple sources are routinely combined to assess relationships among various outcomes and covariates. The geographical units associated with the data, such as the geographical coordinates or areal-level administrative units, are often spatially misaligned, that is, observed at different locations or aggregated over different geographical units. As a result, the covariate is often predicted at the locations where the response is observed. The method used to align disparate datasets must be accounted for when subsequently modeling the aligned data. Here we consider the case where kriging is used to align datasets in point-to-point and point-to-areal misalignment problems when the response variable is non-normally distributed. If the relationship is modeled using generalized linear models, the additional uncertainty induced from using the kriging mean as a covariate introduces a Berkson error structure. In this article, we develop a pseudo-penalized quasi-likelihood algorithm to account for the additional uncertainty when estimating regression parameters and associated measures of uncertainty. The method is applied to a point-to-point example assessing the relationship between low-birth weights and PM2.5 levels after the onset of the largest wildfire in Florida history, the Bugaboo scrub fire. A point-to-areal misalignment problem is presented where the relationship between asthma events in Florida's counties and PM2.5 levels after the onset of the fire is assessed. Finally, the method is evaluated using a simulation study. Our results indicate the method performs well in terms of coverage for 95% confidence intervals and naive methods that ignore the additional uncertainty tend to underestimate the variability associated with parameter estimates. The underestimation is most profound in Poisson regression models. C1 [Lopiano, Kenneth K.] Stat & Appl Math Sci Inst, Res Triangle Pk, NC 27709 USA. [Young, Linda J.] Univ Florida, Dept Stat, Gainesville, FL 32611 USA. [Gotway, Carol A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Lopiano, KK (reprint author), Stat & Appl Math Sci Inst, Res Triangle Pk, NC 27709 USA. EM klopiano@gmail.com NR 26 TC 2 Z9 2 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0006-341X EI 1541-0420 J9 BIOMETRICS JI Biometrics PD SEP PY 2014 VL 70 IS 3 BP 648 EP 660 DI 10.1111/biom.12175 PG 13 WC Biology; Mathematical & Computational Biology; Statistics & Probability SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology; Mathematics GA AQ3AI UT WOS:000342660700019 PM 24749487 ER PT J AU Gilboa, SM Lee, KA Cogswell, ME Traven, FK Botto, LD Riehle-Colarusso, T Correa, A Boyle, CA AF Gilboa, Suzanne M. Lee, Kyung A. Cogswell, Mary E. Traven, Flavia K. Botto, Lorenzo D. Riehle-Colarusso, Tiffany Correa, Adolfo Boyle, Coleen A. CA Natl Birth Defects Prevention TI Maternal Intake of Vitamin E and Birth Defects, National Birth Defects Prevention Study, 1997 to 2005 SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE birth defects; congenital heart defects; vitamin E ID CONGENITAL HEART-DEFECTS; E SUPPLEMENTATION; PREGNANT-WOMEN; PRETERM BIRTH; MALFORMATIONS; PREECLAMPSIA; RISKS; TRIAL; DIET AB BACKGROUND In a recent study, high maternal periconceptional intake of vitamin E was found to be associated with risk of congenital heart defects (CHDs). To explore this association further, we investigated the association between total daily vitamin E intake and selected birth defects. METHODS: We analyzed data from 4525 controls and 8665 cases from the 1997 to 2005 National Birth Defects Prevention Study. We categorized estimated periconceptional energy-adjusted total daily vitamin E intake from diet and supplements into quartiles (referent, lowest quartile). Associations between quartiles of energy-adjusted vitamin E intake and selected birth defects were adjusted for demographic, lifestyle, and nutritional factors. RESULTS: We observed a statistically significant association with the third quartile of vitamin E intake (odds ratio [OR], 1.17; 95% confidence interval [CI], 1.01-1.35) and all CHDs combined. Among CHD sub-types, we observed associations with left ventricular outflow tract obstruction defects, and its sub-type, coarctation of the aorta and the third quartile of vitamin E intake. Among defects other than CHDs, we observed associations between anorectal atresia and the third quartile of vitamin E intake (OR, 1.66; 95% CI, 1.01-2.72) and hypospadias and the fourth quartile of vitamin E intake (OR, 1.42; 95% CI, 1.09-1.87). CONCLUSION: Selected quartiles of energy-adjusted estimated total daily vitamin E intake were associated with selected birth defects. However, because these few associations did not exhibit exposure-response patterns consistent with increasing risk associated with increasing intake of vitamin E, further studies are warranted to corroborate our findings. (C) 2014 Wiley Periodicals, Inc. C1 [Gilboa, Suzanne M.; Riehle-Colarusso, Tiffany; Boyle, Coleen A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Lee, Kyung A.] Northrop Grumman Informat Syst, Atlanta, GA USA. [Lee, Kyung A.; Traven, Flavia K.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Cogswell, Mary E.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. [Traven, Flavia K.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Botto, Lorenzo D.] Univ Utah, Dept Pediat, Salt Lake City, UT USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA. RP Gilboa, SM (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Mailstop E-86,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM sgilboa@cdc.gov FU Centers for Disease Control and Prevention [PA 96043, PA 02081, FOA DD09-001]; Nutrition Epidemiology Core of the University of North Carolina Clinical Nutrition Research Center [DK56350] FX This work was supported through cooperative agreements under PA 96043, PA 02081 and FOA DD09-001 from the Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study. This work was also supported by grant number DK56350 from the Nutrition Epidemiology Core of the University of North Carolina Clinical Nutrition Research Center. Presented at the 16th Annual Meeting of the National Birth Defects Prevention Network, Atlanta, GA, February 25-27, 2013 and the 26th Annual Meeting of the Society for Pediatric and Perinatal Epidemiologic Research, Boston, MA, June 1718, 2013. NR 29 TC 1 Z9 1 U1 4 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD SEP PY 2014 VL 100 IS 9 BP 647 EP 657 DI 10.1002/bdra.23247 PG 11 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA AQ2OC UT WOS:000342625200001 PM 24740457 ER PT J AU in 't Woud, SG van Rooij, IALM van Gelder, MMHJ Olney, RS Carmichael, SL Roeleveld, N Reefhuis, J AF in 't Woud, Sander Groen van Rooij, Iris A. L. M. van Gelder, Marleen M. H. J. Olney, Richard S. Carmichael, Suzan L. Roeleveld, Nel Reefhuis, Jennita CA Natl Birth Defects Prevention TI Differences in Risk Factors for Second and Third Degree Hypospadias in the National Birth Defects Prevention Study SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE hypospadias; risk factors; birth defects; pregnancy ID DIFFERENT PHENOTYPES; MEDICATION USE; TRENDS; EPIDEMIOLOGY; CLOMIPHENE; WEIGHT; GROWTH; LIFE AB Background: Hypospadias is a frequent birth defect with three phenotypic subtypes. With data from the National Birth Defects Prevention Study, a large, multi-state, population-based, case-control study, we compared risk factors for second and third degree hypospadias. Methods: A wide variety of data on maternal and pregnancy-related risk factors for isolated second and third degree hypospadias was collected by means of computer-assisted telephone interviews to identify potential etiological differences between the two phenotypes. Logistic regression was used to calculate odds ratios including a random effect by study center. Results: In total, 1547 second degree cases, 389 third degree cases, and 5183 male controls were included in our study. Third degree cases were more likely to have a non-Hispanic black or Asian/Pacific Islander mother, be delivered preterm, have a low birth weight, be small for gestational age, and be conceived with fertility treatments than second degree cases and controls. Associations with both second and third degree hypospadias were observed for maternal age, family history, parity, plurality, and hypertension during pregnancy. Risk estimates were generally higher for third degree hypospadias except for family history. Conclusion: Most risk factors were associated with both or neither phenotype. Therefore, it is likely that the underlying mechanism is at least partly similar for both phenotypes. However, some associations were different between second and third degree hypospadias, and went in opposite directions for second and third degree hypospadias for Asian/Pacific Islander mothers. Effect estimates for subtypes of hypospadias may be over-or underestimated in studies without stratification by phenotype. (C) 2014 Wiley Periodicals, Inc. C1 [in 't Woud, Sander Groen; Olney, Richard S.; Reefhuis, Jennita] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30033 USA. [in 't Woud, Sander Groen; van Rooij, Iris A. L. M.; van Gelder, Marleen M. H. J.; Roeleveld, Nel] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, NL-6525 ED Nijmegen, Netherlands. [Carmichael, Suzan L.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA. [Roeleveld, Nel] Radboud Univ Nijmegen, Med Ctr, Dept Pediat, NL-6525 ED Nijmegen, Netherlands. RP Reefhuis, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mail Stop E-86, Atlanta, GA 30033 USA. EM nzr5@cdc.gov RI van Gelder, Marleen/P-9473-2015; Roeleveld, Nel/B-4242-2008; Rooij, van, Iris/A-5705-2014 OI van Gelder, Marleen/0000-0003-4853-4434; Roeleveld, Nel/0000-0002-3390-4466; Rooij, van, Iris/0000-0002-9519-966X FU Centers for Disease Control and Prevention [PA 96043, PA 02081, FOA DD09-001]; NIH grant [R01 ES017060] FX This work was supported through cooperative agreements under PA 96043, PA 02081 and FOA DD09-001 from the Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study, and NIH grant R01 ES017060. NR 30 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD SEP PY 2014 VL 100 IS 9 BP 703 EP 711 DI 10.1002/bdra.23296 PG 9 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA AQ2OC UT WOS:000342625200008 ER PT J AU Mehal, JM Holman, RC Steiner, CA Bartholomew, ML Singleton, RJ AF Mehal, Jason M. Holman, Robert C. Steiner, Claudia A. Bartholomew, Michael L. Singleton, Rosalyn J. TI Epidemiology of Asthma Hospitalizations Among American Indian and Alaska Native People and the General United States Population SO CHEST LA English DT Article ID RESPIRATORY-TRACT; CHILDHOOD ASTHMA; RURAL ALASKA; RISK-FACTORS; HEALTH-CARE; CHILDREN; PREVALENCE; TRENDS; BRONCHIOLITIS; INFECTIONS AB BACKGROUND: Asthma, a common chronic disease among adults and children in the United States, results in nearly one-half million hospitalizations annually. There has been no evaluation of asthma hospitalizations for American Indian and Alaska Native (AI/AN) people since a previous study using data for 1988-2002. In this study, we describe the epidemiology and trends for asthma hospitalizations among AI/AN people and the general US population for 2003-2011. METHODS: Hospital discharge records with a first-listed diagnosis of asthma for 2003-2011 were examined for AI/AN people, using Indian Health Service (IHS) data, and for the general US population, using the Nationwide Inpatient Sample. Average annual crude and age-adjusted hospitalization rates were calculated. RESULTS: The average annual asthma hospitalization rates for AI/AN people and the general US population decreased from 2003-2005 to 2009-2011 (32% and 11% [SE, 3%], respectively). The average annual age-adjusted rate for 2009-2011 was lower for AI/AN people (7.6 per 10,000 population) compared with the general US population (13.2 per 10,000; 95% CI, 12.8-13.6). Age-specific AI/AN rates were highest among infants and children 1 to 4 years of age. IHS regional rates declined in all regions except Alaska. CONCLUSIONS: Asthma hospitalization rates are decreasing for AI/AN people and the general US population despite increasing prevalence rates. AI/AN people experienced a substantially lower age-adjusted asthma hospitalization rate compared with the general US population. Although the rates for AI/AN infants and children 1 to 4 years of age have declined substantially, they remain higher compared with other age groups. Improved disease management and awareness should help to further decrease asthma hospitalizations, particularly among young children. C1 [Mehal, Jason M.; Holman, Robert C.] Ctr Dis Control & Prevent CDC, Div High Consequence Pathogens & Pathol, NCEZID, DHHS, Atlanta, GA 30333 USA. [Steiner, Claudia A.] Ctr Delivery Organizat & Markets, Agcy Healthcare Res & Qual, DHHS, Healthcare Cost & Utilizat Project, Rockville, MD USA. [Bartholomew, Michael L.] DHHS, Indian Hlth Serv, Rockville, MD USA. [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Singleton, Rosalyn J.] CDC, Arct Investigat Program, Div Preparedness & Emerging Infect, NCEZID,DHHS, Anchorage, AK USA. RP Mehal, JM (reprint author), Ctr Dis Control & Prevent, 1600 Clift Rd NE,MS A-30, Atlanta, GA 30333 USA. EM jmehal@cdc.gov NR 40 TC 3 Z9 3 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD SEP PY 2014 VL 146 IS 3 BP 624 EP 632 DI 10.1378/chest.14-0183 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AP9UM UT WOS:000342425800041 PM 24810971 ER PT J AU Redding, GJ Singleton, RJ Valery, PC Williams, H Grimwood, K Morris, PS Torzillo, PJ McCallum, GB Chikoyak, L Holman, RC Chang, AB AF Redding, Gregory J. Singleton, Rosalyn J. Valery, Patricia C. Williams, Hayley Grimwood, Keith Morris, Peter S. Torzillo, Paul J. McCallum, Gabrielle B. Chikoyak, Lori Holman, Robert C. Chang, Anne B. TI Respiratory Exacerbations in Indigenous Children From Two Countries With Non-Cystic Fibrosis Chronic Suppurative Lung Disease/Bronchiectasis SO CHEST LA English DT Article ID ALASKA NATIVE CHILDREN; CONTROLLED-TRIAL; BRONCHIECTASIS; DISEASE; CHILDHOOD; AZITHROMYCIN AB BACKGROUND: Acute respiratory exacerbations (AREs) cause morbidity and lung function decline in children with chronic suppurative lung disease (CSLD) and bronchiectasis. In a prospective longitudinal cohort study, we determined the patterns of AREs and factors related to increased risks for AREs in children with CSLD/bronchiectasis. METHODS: Ninety-three indigenous children aged 0.5 to 8 years with CSLD/bronchiectasis in Australia (n = 57) and Alaska (n 5 36) during 2004 to 2009 were followed for >3 years. Standardized parent interviews, physical examinations, and medical record reviews were undertaken at enrollment and every 3 to 6 months thereafter. RESULTS: Ninety-three children experienced 280 AREs (median 5 2, range = 0-11 per child) during the 3-year period; 91 (32%) were associated with pneumonia, and 43 (15%) resulted in hospitalization. Of the 93 children, 69 (74%) experienced more than two AREs over the 3-year period, and 28 (30%) had more than one ARE in each study year. The frequency of AREs declined significantly over each year of follow-up. Factors associated with recurrent (two or more) AREs included age <3 years, ARE-related hospitalization in the first year of life, and pneumonia or hospitalization for ARE in the year preceding enrollment. Factors associated with hospitalizations for AREs in the first year of study included age <3 years, female care-giver education, and regular use of bronchodilators. CONCLUSIONS: AREs are common in children with CSLD/bronchiectasis, but with clinical care and time AREs occur less frequently. All children with CSLD/bronchiectasis require comprehensive care; however, treatment strategies may differ for these patients based on their changing risks for AREs during each year of care. C1 [Redding, Gregory J.] Seattle Childrens Hosp, Pulm & Sleep Med Div, Seattle, WA 98105 USA. [Redding, Gregory J.] Univ Washington, Seattle, WA 98195 USA. [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Singleton, Rosalyn J.] Natl Ctr Emerging & Zoonot Infect Dis, Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Arct Invest Program, Anchorage, AK USA. [Valery, Patricia C.; Williams, Hayley; Morris, Peter S.; McCallum, Gabrielle B.; Chang, Anne B.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia. [Grimwood, Keith] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia. [Grimwood, Keith] Royal Childrens Hosp, Queensland Paediat Infect Dis Lab, Brisbane, Qld, Australia. [Torzillo, Paul J.] Univ Sydney, Royal Prince Alfred Hosp, Sydney, NSW 2006, Australia. [Chikoyak, Lori] Yukon Kuskokwim Hlth Corp, Bethel, AK USA. [Holman, Robert C.] Natl Ctr Emerging & Zoonot Infect Dis, Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Chang, Anne B.] Queensland Univ Technol, Royal Childrens Hosp, Queensland Resp Ctr, Queensland Childrens Med Res Inst, Brisbane, Qld 4001, Australia. RP Redding, GJ (reprint author), Seattle Childrens Hosp, Pulm & Sleep Med Div, Room OC-7-720, Seattle, WA 98105 USA. EM gredding@u.washington.edu FU National Health and Medical Research Council of Australia (NHMRC) [389837, 1040830]; Telstra Foundation; Australian Research Council Future Fellowship [100100511]; Australian NHMRC fellowship [545216]; National Institutes of Health, National Heart, Lung, and Blood Institute [U26IHS3000001/01] FX This work was supported by the National Health and Medical Research Council of Australia (NHMRC) [Grants 389837, 1040830], Telstra Foundation [seeding grant - Telstra Community Development Grant, 2004]. Dr Valery was supported by an Australian Research Council Future Fellowship [100100511], and Dr Chang was supported by Australian NHMRC fellowship [545216]. Dr Singleton received funding from the National Institutes of Health, National Heart, Lung, and Blood Institute [Grant U26IHS3000001/01]. This work was produced as part of the In-Kind activities of the Lowitja Institute incorporating the Cooperative Research Centre for Aboriginal and Torres Strait Islander Health. NR 28 TC 9 Z9 9 U1 1 U2 1 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD SEP PY 2014 VL 146 IS 3 BP 762 EP 774 DI 10.1378/chest.14-0126 PG 13 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AP9UM UT WOS:000342425800053 PM 24811693 ER PT J AU Li, CY Li, CH AF Li, Chunyu Li, Chenghui TI Patient-Reported Mental Health Services Utilization and Expenditures among Cancer Survivors in the United States SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS LA English DT Meeting Abstract C1 [Li, Chunyu] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Li, Chenghui] Univ Arkansas Med Sci, Coll Pharm, Div Pharmaceut Evaluat & Policy, Little Rock, AR 72205 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE PI MILANO PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY SN 1091-4358 J9 J MENT HEALTH POLICY JI J. Ment. Health Policy Econ. PD SEP PY 2014 VL 17 SU 1 BP S12 EP S12 PG 1 WC Health Policy & Services; Psychiatry SC Health Care Sciences & Services; Psychiatry GA AQ3ZF UT WOS:000342731300024 ER PT J AU Dunford, JC Stoops, CA Estep, AS Britch, SC Richardson, AG Walker, TW Farooq, M Hoel, DF Platt, RR Smith, VL Wirtz, RA Kerce, JD AF Dunford, James C. Stoops, Craig A. Estep, Alden S. Britch, Seth C. Richardson, Alec G. Walker, Todd W. Farooq, Muhammad Hoel, David F. Platt, Raymond R. Smith, Vincent L. Wirtz, Robert A. Kerce, Jerry D. TI SR450 AND SUPERHAWK XP APPLICATIONS OF BACILLUS THURINGIENSIS ISRAELENSIS AGAINST CULEX QUINQUEFASCIATUS SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION LA English DT Article DE Larval control; container-inhabiting; backpack sprayer; thermal fogger ID VAR. ISRAELENSIS; ALBOPICTUS SKUSE; MOSQUITO-CONTROL; AEDES-AEGYPTI; FORMULATIONS; BTI; ULV; CONTAINERS; MALAYSIA; STRAIN AB Sprayer comparisons and larval morality assays were conducted following SR450 backpack mist blower and Superhawk XP thermal fogger applications of Vectobac (R) WDG Bacillus thuringiensis israelensis (Bti) against Culex quinquefasciatus. Bacillus thuringiensis israelensis was applied at maximum label rate in a 232.26-m(2) field plot located in north-central Florida with containers placed at 2 heights (ground level and 1.52 m above ground) on stakes positioned 3.04, 6.09, 9.14, 12.19, and 15.24 m from the spray line. Results indicated that there was no significant (P > 0.05) difference in 24- and 48-h larval mortality between the 2 sprayers or between the 2 heights. There was significant difference (P < 0.05) among the 5 rows, with mortality continuously decreasing with increasing distance from sprayer. Both sprayers provided on average >70% larval mortality 3.04-9.14 m from the spray line, and <60% mortality at 12.19 and 15.24 m. The data suggest that the SR450 and Superhawk XP may be comparable sprayers for use with Bti to control mosquito larvae. C1 [Dunford, James C.; Hoel, David F.] Ctr Dis Control & Prevent, Navy & Marine Corps Publ Hlth Ctr Detachment, Atlanta, GA 30329 USA. [Stoops, Craig A.] USDA ARS, Navy & Marine Corps Publ Hlth Ctr Detachment, Ctr Med Agr & Vet Entomol, Gainesville, FL 32608 USA. [Estep, Alden S.; Richardson, Alec G.; Walker, Todd W.; Farooq, Muhammad; Platt, Raymond R.; Smith, Vincent L.] Naval Air Stn, Navy Entomol Ctr Excellence, Jacksonville, FL 32212 USA. [Britch, Seth C.] USDA ARS, Ctr Med Agr & Vet Entomol, Gainesville, FL 32608 USA. [Wirtz, Robert A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Kerce, Jerry D.] Camp Blanding Joint Training Ctr, Starke, FL 32091 USA. RP Dunford, JC (reprint author), Ctr Dis Control & Prevent, Navy & Marine Corps Publ Hlth Ctr Detachment, Atlanta, GA 30329 USA. FU Department of Defense Deployed War Fighter Protection Program FX We greatly appreciate assistance provided by Camp Blanding Joint Training Center personnel for arranging field site location and installation access. We also thank J. Andrews and P. DeChant (Valent BioSciences) for providing VectoBac WDG Bti and Curtis Dyna-Fog for loan of the Superhawk XP. Assistance in the field and lab was kindly provided by J. Bertrand, A. Lloyd, R. Pomales, and A. Hanley. Earlier versions of this manuscript were greatly improved by reviews provided by H. Arimoto, C. Doud, J. Harwood, P. Nunn, and P. Obenauer (NECE). This study was conducted by NECE as part of its mission in developing field expedient vector control technologies and techniques to better protect deployed war fighters from insect-borne diseases, with financial, technical, and field support provided by the Department of Defense Deployed War Fighter Protection Program. NR 25 TC 3 Z9 3 U1 0 U2 2 PU AMER MOSQUITO CONTROL ASSOC PI MOUNT LAUREL PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA SN 8756-971X EI 1943-6270 J9 J AM MOSQUITO CONTR JI J. Am. Mosq. Control Assoc. PD SEP PY 2014 VL 30 IS 3 BP 191 EP 198 PG 8 WC Entomology SC Entomology GA AQ1IO UT WOS:000342535300005 PM 25843094 ER PT J AU Burns, RE Bicknese, EJ Qvarnstrom, Y DeLeon-Carnes, M Drew, CP Gardiner, CH Rideout, BA AF Burns, Rachel E. Bicknese, Elizabeth J. Qvarnstrom, Yvonne DeLeon-Carnes, Marlene Drew, Clifton P. Gardiner, Chris H. Rideout, Bruce A. TI Cerebral Angiostrongylus cantonensis infection in a captive African pygmy falcon (Polihierax semitorquatus) in southern California SO JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION LA English DT Article DE Angiostrongylus cantonensis; falcons; meningoencephalitis; polymerase chain reaction; rat lungworm ID FROGMOUTHS PODARGUS-STRIGOIDES; NEUROANGIOSTRONGYLIASIS; RATS AB A 10-month-old, female African pygmy falcon (Polihierax semitorquatus) hatched and housed at the San Diego Zoo developed neurologic signs and died from a cerebral infection with the rat lungworm Angiostrongylus cantonensis. There was an associated mild nonsuppurative meningoencephalitis. This infection was diagnosed on histology and confirmed by detection of species-specific A. cantonensis DNA in formalin-fixed and frozen brain tissue by a polymerase chain reaction assay. To the authors' knowledge, this infection has not previously been reported in a bird in the United States and has not been known to be naturally acquired in any species in this region of the world. The source of the infection was not definitively determined but was possibly feeder geckos (Hemidactylus frenatus) imported from Southeast Asia where the parasite is endemic. C1 [Burns, Rachel E.; Rideout, Bruce A.] San Diego Zoo Global, Wildlife Dis Labs, Inst Conservat Res, San Diego, CA USA. [Bicknese, Elizabeth J.] San Diego Zoo, Vet Serv, San Diego, CA USA. [Qvarnstrom, Yvonne] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [DeLeon-Carnes, Marlene; Drew, Clifton P.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Gardiner, Chris H.] Joint Pathol Serv, Vet Pathol Serv, Silver Spring, MD USA. RP Burns, RE (reprint author), Univ Connecticut, Dept Pathobiol & Vet Sci, Coll Agr Hlth & Nat Resources, 61 North Eagleville Rd,Unit 3089, Storrs, CT 06269 USA. EM burnre02@yahoo.com NR 14 TC 3 Z9 3 U1 2 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1040-6387 EI 1943-4936 J9 J VET DIAGN INVEST JI J. Vet. Diagn. Invest. PD SEP PY 2014 VL 26 IS 5 BP 695 EP 698 DI 10.1177/1040638714544499 PG 4 WC Veterinary Sciences SC Veterinary Sciences GA AQ2RB UT WOS:000342634700018 PM 25085869 ER PT J AU Dantonio, PD Stevens, G Hagar, A Ludvigson, D Green, D Hannon, H Vogt, RF AF Dantonio, Paul D. Stevens, Germaine Hagar, Arthur Ludvigson, David Green, Daron Hannon, Harry Vogt, Robert F. TI Comparative evaluation of newborn bloodspot specimen cards by experienced laboratory personnel and by an optical scanning instrument SO MOLECULAR GENETICS AND METABOLISM LA English DT Article DE Newbom bloodspot screening; Automation; Evaluation; Specimen quality; Training; Dried blood spots ID NEONATAL HYPOTHYROIDISM; DRIED BLOOD; RADIOIMMUNOASSAY; PHENYLKETONURIA; INFANTS AB A major factor in determining the suitability of a dried blood spot (DBS) specimen is the subjective nature of evaluation by laboratory personnel. Using newborn screening DBS specimen cards as they were submitted to a public health NBS program, we conducted a systematic pilot study of DBS evaluation by multiple experienced laboratory personnel (ELP) and by an automated optical scanning instrument (OSI) (CardScan (tm), BSD Robotics). OSI confirmed the satisfactory status of all newborn DBS specimen cards that passed initial review by the first ELP. Among the questionable cards selected for further review, 58% passed multiple ELP consensus assessment, and 62% passed OSI evaluation. The overall agreement between ELP and OS! was 86%. Among questionable specimen cards, ELP and OSI were more strongly correlated when multiple ELP assessment was unanimous. We conclude that subjective assessment by ELP is essential and that 051 evaluation is a useful adjunct when ELP assessment does not reach consensus. OSI further allows the selection of optimal locations for punching DBS from unsatisfactory or questionable specimens, optimizing the quality of interim analyses that may be conducted while repeat specimens are being collected. Instrument evaluation of specimen cards would also be valuable as an independent reference method for training laboratory and specimen collection personnel. OSI technology merits further studies to confirm and extend our findings. Published by Elsevier Inc. C1 [Dantonio, Paul D.; Vogt, Robert F.] CDC, Newborn Screening & Mol Biol Branch, Atlanta, GA 30341 USA. [Stevens, Germaine; Hagar, Arthur; Ludvigson, David] Georgia Dept Publ Hlth, Newborn Screening Lab, Decatur, GA 30030 USA. [Green, Daron] BSD Robot, Brisbane, Qld, Australia. [Hannon, Harry] CDC Fdn, Newborn Screening Translat Res Initiat, Atlanta, GA 30303 USA. RP Vogt, RF (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, 4770 Buford Highway, Atlanta, GA 30341 USA. EM rvogt@cdc.gov FU Georgia Department of Public Health; Centers for Disease Control and Prevention (CDC) FX This collaborative study was supported by operational funds from the Georgia Department of Public Health and from the Centers for Disease Control and Prevention (CDC) without further support from grants or sponsors. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Instrumentation was provided without charge for evaluation purposes by BSD Robotics, a Luminex Company. One of the authors (DG) was an employee of BSD Robotics during the time this study was conducted. NR 9 TC 2 Z9 2 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 EI 1096-7206 J9 MOL GENET METAB JI Mol. Genet. Metab. PD SEP-OCT PY 2014 VL 113 IS 1-2 SI SI BP 62 EP 66 DI 10.1016/j.ymgme.2014.07.007 PG 5 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA AQ1KG UT WOS:000342539700013 PM 25095725 ER PT J AU De Jesus, VR Adam, BW Mandel, D Cuthbert, CD Matern, D AF De Jesus, Victor R. Adam, Barbara W. Mandel, Daniel Cuthbert, Carla D. Matern, Dietrich TI Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs SO MOLECULAR GENETICS AND METABOLISM LA English DT Article DE Tyrosinemia type I; Succinylacetone; Newborn screening; US Recommended Uniform Screening Panel; Tyrosine; HHS Secretary's (Discretionary) Advisory; Committee on Heritable Disorders in Newborns and Children ID DRIED-BLOOD SPOTS; TANDEM MASS-SPECTROMETRY; HEREDITARY TYROSINEMIA; HEPATORENAL TYROSINEMIA; LIVER-TRANSPLANTATION; AMINO-ACIDS; DISEASE; QUEBEC; NTBC AB Tyrosinemia type I (TYR I) is caused by autosomal recessive fumarylacetoacetate hydrolase deficiency and is characterized by development of severe liver disease in infancy and neurologic crises. If left untreated, most patients die of liver failure in the first years of life. Intervention with medication is effective when initiated during the first month of life. This improvement in the treatment of TYR I patients influenced the decision to include TYR I in the US Secretary of the Department of Health and Human Services' (HHS) Recommended Uniform Screening Panel. However, while tyrosine is routinely measured in newborn screening (NBS) by tandem mass spectrometry (MS/MS), elevated tyrosine levels are not specific to TYR I. To improve the specificity of NBS for TYR I, several assays were developed to measure succinylacetone (SUAC) in dried blood spots (DBS). SUAC is a pathognomonic marker of TYR I, and its detection by NBS MS/MS is possible. This review of the current status of NBS for TYR I in the US is the result of discussions at the HHS Secretary's (Discretionary) Advisory Committee on Heritable Disorders in Newborns and Children about the inconsistent implementation of effective NBS for TYR I in the US. We sought to understand the different TYR I screening practices in US NBS programs. Results indicate that 50 out of 51 NBS programs in the US screen for TYR I, and a successful SUAC performance evaluation scheme is available from the Centers for Disease Control and Prevention. Programmatic and methodological barriers were identified that prevent widespread adoption of SUAC measurements in NBS laboratories. However, since SUAC detection is currently the best approach to NBS for TYR I, a further delay of the addition of SUAC measurement into NBS procedures is discouraged. SUAC measurement should improve both the false positive and false negative rate in NBS for TYR I thereby yielding the desired benefits for affected patients at no expense to the overall population served. Published by Elsevier Inc. C1 [De Jesus, Victor R.; Adam, Barbara W.; Mandel, Daniel; Cuthbert, Carla D.] Ctr Dis Control & Prevent, Newborn Screening & Mol Biol Branch, Atlanta, GA 30341 USA. [Matern, Dietrich] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA. [Matern, Dietrich] Mayo Clin, Dept Med Genet, Rochester, MN 55905 USA. [Matern, Dietrich] Mayo Clin, Dept Pediat, Rochester, MN 55905 USA. RP De Jesus, VR (reprint author), 4770 Buford Hwy,Mail Stop F-19, Atlanta, GA 30341 USA. EM vdejesus@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 2 Z9 2 U1 3 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 EI 1096-7206 J9 MOL GENET METAB JI Mol. Genet. Metab. PD SEP-OCT PY 2014 VL 113 IS 1-2 SI SI BP 67 EP 75 DI 10.1016/j.ymgme.2014.07.010 PG 9 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA AQ1KG UT WOS:000342539700014 PM 25066104 ER PT J AU Rice, BL Acosta, MM Pacheco, MA Carlton, JM Barnwell, JW Escalante, AA AF Rice, Benjamin L. Acosta, Monica M. Pacheco, M. Andreina Carlton, Jane M. Barnwell, John W. Escalante, Ananias A. TI The origin and diversification of the merozoite surface protein 3 (msp3) multi-gene family in Plasmodium vivax and related parasites SO MOLECULAR PHYLOGENETICS AND EVOLUTION LA English DT Article DE Homology; Merozoite surface protein 3; Multi-gene family; Plasmodium; Plasmodium vivax; Plasmodium falciparum ID HUMAN MALARIA PARASITE; MAXIMUM-LIKELIHOOD; SEQUENCE ALIGNMENT; GENETIC DIVERSITY; FALCIPARUM; GENOME; EVOLUTION; POLYMORPHISM; ANTIBODIES; INVASION AB The genus Plasmodium is a diversified group of parasites with more than 200 known species that includes those causing malaria in humans. These parasites use numerous proteins in a complex process that allows them to invade the red blood cells of their vertebrate hosts. Many of those proteins are part of multi-gene families; one of which is the merozoite surface protein-3 (msp3) family. The msp3 multi-gene family is considered important in the two main human parasites, Plasmodium vivax and Plasmodium falciparum, as its paralogs are simultaneously expressed in the blood stage (merozoite) and are immunogenic. There are large differences among Plasmodium species in the number of paralogs in this family. Such differences have been previously explained, in part, as adaptations that allow the different Plasmodium species to invade their hosts. To investigate this, we characterized the array containing msp3 genes among several Plasmodium species, including P. falciparum and P. vivax. We first found no evidence indicating that the msp3 family of P. falciparum was homologous to that of P. vivax. Subsequently, by focusing on the diverse clade of nonhuman primate parasites to which P. vivax is closely related, where homology was evident, we found no evidence indicating that the interspecies variation in the number of paralogs was an adaptation related to changes in host range or host switches. Overall, we hypothesize that the evolution of the msp3 family in P. vivax is consistent with a model of multi-allelic diversifying selection where the paralogs may have functionally redundant roles in terms of increasing antigenic diversity. Thus, we suggest that the expressed MSP3 proteins could serve as "decoys", via antigenic diversity, during the critical process of invading the host red blood cells. (C) 2014 Elsevier Inc. All rights reserved. C1 [Rice, Benjamin L.; Acosta, Monica M.; Pacheco, M. Andreina; Escalante, Ananias A.] Arizona State Univ, Biodesign Inst, Ctr Evolutionary Med & Informat, Tempe, AZ USA. [Carlton, Jane M.] NYU, Dept Biol, Ctr Genom & Syst Biol, New York, NY 10003 USA. [Barnwell, John W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Escalante, Ananias A.] Arizona State Univ, Sch Life Sci, Tempe, AZ USA. RP Escalante, AA (reprint author), POB 875401, Tempe, AZ 85287 USA. EM Benjamin.Rice@asu.edu; mmacost1@asu.edu; Maria.Pacheco@asu.edu; Jane.Carlton@nyu.edu; wzb3@cdc.gov; Ananias.Escalante@asu.edu FU US National Institutes of Health [R01 GM080586, U19AI089688]; US NIH [R25GM071798]; ASU PREP FX This work was supported by the US National Institutes of Health (R01 GM080586 and U19AI089688 to AAE). We thank the DNA laboratory at the School of Life Sciences for their technical support and David Fisher for computational support. BLR and MMA were supported in part by the US NIH: Grant R25GM071798, ASU PREP for Biomedical Research. The content is solely the responsibility of the authors and does not represent the official views of the NIH or the Centers for Disease Control and Prevention. NR 63 TC 19 Z9 19 U1 1 U2 10 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1055-7903 EI 1095-9513 J9 MOL PHYLOGENET EVOL JI Mol. Phylogenet. Evol. PD SEP PY 2014 VL 78 BP 172 EP 184 DI 10.1016/j.ympev.2014.05.013 PG 13 WC Biochemistry & Molecular Biology; Evolutionary Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Evolutionary Biology; Genetics & Heredity GA AQ0NQ UT WOS:000342480400015 PM 24862221 ER PT J AU van Gelder, MMHJ Donders, ART Devine, O Roeleveld, N Reefhuis, J AF van Gelder, Marleen M. H. J. Donders, A. Rogier T. Devine, Owen Roeleveld, Nel Reefhuis, Jennita CA Natl Birth Defects Prevention Stud TI Using Bayesian Models to Assess the Effects of Under-reporting of Cannabis Use on the Association with Birth Defects, National Birth Defects Prevention Study, 1997-2005 SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE Anencephaly; Bayes theorem; Bias (epidemiology); Birth defects; Cannabis; Diaphragmatic hernia; Epidemiologic methods; Esophageal atresia; Gastroschisis; Maternal exposure ID ILLICIT DRUG-USE; MARIJUANA USE; COCAINE USE; NONDIFFERENTIAL MISCLASSIFICATION; EXPOSURE MISCLASSIFICATION; SENSITIVITY-ANALYSIS; MATERNAL MARIJUANA; RISK-FACTORS; PREGNANCY; RECALL AB BackgroundStudies on associations between periconceptional cannabis exposure and birth defects have mainly relied on self-reported exposure. Therefore, the results may be biased due to under-reporting of the exposure. The aim of this study was to quantify the potential effects of this form of exposure misclassification. MethodsUsing multivariable logistic regression, we re-analysed associations between periconceptional cannabis use and 20 specific birth defects using data from the National Birth Defects Prevention Study from 1997-2005 for 13859 case infants and 6556 control infants. For seven birth defects, we implemented four Bayesian models based on various assumptions concerning the sensitivity of self-reported cannabis use to estimate odds ratios (ORs), adjusted for confounding and under-reporting of the exposure. We used information on sensitivity of self-reported cannabis use from the literature for prior assumptions. ResultsThe results unadjusted for under-reporting of the exposure showed an association between cannabis use and anencephaly (posterior OR 1.9 [95% credible interval (CRI) 1.1, 3.2]) which persisted after adjustment for potential exposure misclassification. Initially, no statistically significant associations were observed between cannabis use and the other birth defect categories studied. Although adjustment for under-reporting did not notably change these effect estimates, cannabis use was associated with esophageal atresia (posterior OR 1.7 [95% CRI 1.0, 2.9]), diaphragmatic hernia (posterior OR 1.8 [95% CRI 1.1, 3.0]), and gastroschisis (posterior OR 1.7 [95% CRI 1.2, 2.3]) after correction for exposure misclassification. ConclusionsUnder-reporting of the exposure may have obscured some cannabis-birth defect associations in previous studies. However, the resulting bias is likely to be limited. C1 [van Gelder, Marleen M. H. J.; Donders, A. Rogier T.; Roeleveld, Nel] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, Nijmegen, Netherlands. [Roeleveld, Nel] Radboud Univ Nijmegen, Med Ctr, Dept Pediat, Nijmegen, Netherlands. [Devine, Owen; Reefhuis, Jennita] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Reefhuis, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE MS E-86, Atlanta, GA 30333 USA. EM nzr5@cdc.gov RI Donders, A.R.T./L-4277-2015; van Gelder, Marleen/P-9473-2015; Roeleveld, Nel/B-4242-2008 OI Donders, A.R.T./0000-0002-0484-1419; van Gelder, Marleen/0000-0003-4853-4434; Roeleveld, Nel/0000-0002-3390-4466 FU Centers for Disease Control and Prevention; Netherlands Organisation for Scientific Research [021.001.008] FX The Centers for Disease Control and Prevention provided funding for the National Birth Defects Prevention Study. MMHJvG was supported by grant 021.001.008 from the Netherlands Organisation for Scientific Research. NR 32 TC 1 Z9 1 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD SEP PY 2014 VL 28 IS 5 BP 424 EP 433 DI 10.1111/ppe.12140 PG 10 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA AQ3IW UT WOS:000342686500011 PM 25155701 ER PT J AU Groenewold, MR Masterson, EA Themann, CL Davis, RR AF Groenewold, Matthew R. Masterson, Elizabeth A. Themann, Christa L. Davis, Rickie R. TI Do Hearing Protectors Protect Hearing? SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE noise; hearing protection; occupational hearing loss; noise-induced hearing loss ID NOISE EXPOSURE; CONSTRUCTION WORKERS; LOGISTIC-REGRESSION; OCCUPATIONAL NOISE; UNITED-STATES; WORKPLACE; PROGRAMS; INDUSTRY; DEVICES AB Background We examined the association between self-reported hearing protection use at work and incidence of hearing shifts over a 5-year period. Methods Audiometric data from 19,911 workers were analyzed. Two hearing shift measures-OSHA standard threshold shift (OSTS) and high-frequency threshold shift (HFTS)-were used to identify incident shifts in hearing between workers' 2005 and 2009 audiograms. Adjusted odds ratios were generated using multivariable logistic regression with multi-level modeling. Results The odds ratio for hearing shift for workers who reported never versus always wearing hearing protection was nonsignificant for OSTS (OR 1.23, 95% CI 0.92-1.64) and marginally significant for HFTS (OR 1.26, 95% CI 1.00-1.59). A significant linear trend towards increased risk of HFTS with decreased use of hearing protection was observed (P = 0.02). Conclusion The study raises concern about the effectiveness of hearing protection as a substitute for noise control to prevent noise-induced hearing loss in the workplace. Published 2014. This article is a U. S. Government work and is in the public domain in the USA. C1 [Groenewold, Matthew R.; Masterson, Elizabeth A.] NIOSH, Surveillance Branch, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent CDC, Cincinnati, OH 45226 USA. [Themann, Christa L.; Davis, Rickie R.] NIOSH, Hearing Loss Prevent Team, Engn & Phys Hazards Branch, Div Appl Res & Technol,CDC, Cincinnati, OH 45226 USA. RP Groenewold, MR (reprint author), 275 E Main St MS HS1-EJ, Frankfort, KY 40621 USA. EM gyr5@cdc.gov FU Intramural CDC HHS [CC999999] NR 33 TC 1 Z9 2 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD SEP PY 2014 VL 57 IS 9 BP 1001 EP 1010 DI 10.1002/ajim.22323 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP7UA UT WOS:000342281000004 PM 24700499 ER PT J AU Kaur, H Luckhaupt, SE Li, J Alterman, T Calvert, GM AF Kaur, Harpriya Luckhaupt, Sara E. Li, Jia Alterman, Toni Calvert, Geoffrey M. TI Workplace Psychosocial Factors Associated With Hypertension in the U.S. Workforce: A Cross-Sectional Study Based on the 2010 National Health Interview Survey SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE hypertension; occupational health; occupational exposures; national survey ID CORONARY-HEART-DISEASE; LONG WORKING HOURS; AMBULATORY BLOOD-PRESSURE; JOB INSECURITY; UNITED-STATES; CARDIOVASCULAR-DISEASES; POLICE OFFICERS; RISK-FACTORS; WORKERS; STRESS AB Objective To explore associations between self-reported hypertension and workplace psychosocial factors that are common among U. S. workers and to identify industries and occupations (I&Os) that are associated with a high prevalence of hypertension, even after adjustment for common known risk factors. Methods Data from the 2010 National Health Interview Survey were used to examine relationships between the prevalence of self-reported hypertension and job insecurity, hostile work environment, work-family imbalance, work hours and I&O. Results Job insecurity (adjusted prevalence ratio (aPR): 1.11; 95% confidence interval (CI): 1.04-1.19)) and hostile work environment (aPR: 1.15; 95% CI: 1.03-1.29) were significantly associated with hypertension. Hypertension prevalence was significantly elevated among those employed in Healthcare Support occupations and Public Administration industries. Conclusion Addressing hostile work environments and the stress associated with job insecurity may improve workers' health. Other occupational factors that contribute to the variation in prevalence of hypertension by I&O should be sought. (C) 2014 Wiley Periodicals, Inc. C1 [Kaur, Harpriya] Univ Nebraska Med Ctr, Omaha, NE USA. [Luckhaupt, Sara E.; Li, Jia; Alterman, Toni; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Luckhaupt, SE (reprint author), NIOSH, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM sluckhaupt@cdc.gov OI Alterman, Toni/0000-0003-1512-4367 FU U.S. Government FX The authors express their appreciation to the many other persons, both within and outside of NIOSH and NCHS, who contributed to study planning, questionnaire development, and/or review of previous drafts of this paper. All authors are federal government employees or were training with the federal government at the time of this study (H. K.), and the NHIS and preparation of this manuscript were completely funded by the U.S. Government. NR 59 TC 2 Z9 2 U1 5 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD SEP PY 2014 VL 57 IS 9 BP 1011 EP 1021 DI 10.1002/ajim.22345 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP7UA UT WOS:000342281000005 PM 25137617 ER PT J AU Hernandez, L Hanson, KM Martel, LD AF Hernandez, Luis Hanson, Kimberly M. Martel, Lise D. TI GUATEMALA'S MINISTRY OF HEALTH RAPID RESPONSE TEAM MANUALS SO BIOSECURITY AND BIOTERRORISM-BIODEFENSE STRATEGY PRACTICE AND SCIENCE LA English DT Article AB The function of public health rapid response teams (RRTs) is to quickly identify, investigate, and control an outbreak before it can spread. The Central America Regional Office in Guatemala provided assistance to the Guatemalan Ministry of Health and Social Assistance (MSPAS) to develop RRT manuals at the district and regional levels. The manuals are divided into 4 sections: background, activity lists, standard operating procedures, and annexes. The manuals outline Guatemala's RRT members' responsibilities and will be tested in the near future through tabletop exercises. The development of the manuals is a concrete and significant step toward the attainment of Guatemala's IHR goals and should be integrated into a larger emergency management system to promote "a world safe and secure from global health threats posed by infectious diseases.'' C1 [Hernandez, Luis] Ctr Dis Control & Prevent, Ctr Global Hlth, Guatemala City, Guatemala. [Hanson, Kimberly M.] Ctr Dis Control & Prevent, ORISE Res, Ctr Global Hlth, Atlanta, GA USA. [Martel, Lise D.] Ctr Dis Control & Prevent, Int Emergency Preparedness Team, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Martel, LD (reprint author), Ctr Dis Control & Prevent, Int Emergency Preparedness Team, Ctr Global Hlth, Atlanta, GA 30333 USA. EM diz0@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1538-7135 EI 1557-850X J9 BIOSECUR BIOTERROR JI Biosecur. Bioterror. PD SEP-OCT PY 2014 VL 12 IS 5 BP 292 EP 297 DI 10.1089/bsp.2014.0043 PG 6 WC Public, Environmental & Occupational Health; International Relations SC Public, Environmental & Occupational Health; International Relations GA AP7ZO UT WOS:000342297600011 PM 25254918 ER PT J AU Arango, CM Parra, DC Gomez, LF Lema, L Lobelo, F Ekelund, U AF Arango, Carlos M. Parra, Diana C. Gomez, Luis F. Lema, Lucia Lobelo, Felipe Ekelund, Ulf TI Screen time, cardiorespiratory fitness and adiposity among school-age children from Monteria, Colombia SO JOURNAL OF SCIENCE AND MEDICINE IN SPORT LA English DT Article DE Sedentary lifestyle; Physical fitness; Abdominal fat; Adolescent; Developing countries ID PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; RISK-FACTORS; MEDIA USE; TELEVISION; ADOLESCENTS; OBESITY; YOUTH AB Objectives: To explore the association between electronic media exposure (television viewing time, personal computer/video game use, total screen time), and waist circumference and body mass index, and study whether this association is independent of cardiorespiratory fitness, in a representative sample of adolescents from Monteria, Colombia. Design: Cross-sectional study analyzing data from 546 students aged 11-18 years, from fourteen randomly selected schools. Z-scores for WC and BMI were calculated. Methods: The physical activity module of the Global School Health Survey 2007 was used to determine EME, and the shuttle run test was used to assess CRF. Linear regression models adjusted by age, school location, physical activity level, type of institution (public or private), consumption of sweetened beverages, fast food, and fried food were used. Results: Among boys, independently of cardiorespiratory fitness, high television viewing time (>= 2 h/day) (beta = +0.22; p<0.02), was positively associated with waist circumference. High total screen time (>3 h/day) was positively associated with waist circumference (beta = +0.34; p<0.01), and body mass index (beta = +0.39; p<0.01). Among girls, sedentary behavior was not associated with adiposity, but cardiorespiratory fitness (beta = -0.04; p<0.02) was negatively associated with body mass index. Conclusions: These findings support the evidence on the negative impact of excessive electronic media exposure and low cardiorespiratory fitness, and highlight the need for interventions, and prevention strategies. (C) 2013 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved. C1 [Arango, Carlos M.; Parra, Diana C.] Washington Univ, George Warren Brown Sch Social Work, Prevent Res Ctr St Louis, St Louis, MO 63130 USA. [Gomez, Luis F.] Pontificia Univ Javeriana, Dept Med Prevent & Social, Bogota, Colombia. [Lema, Lucia] Univ Cordoba, Dept Cultura Fis, Cordoba, Colombia. [Lobelo, Felipe] Ctr Dis Control & Prevent, Global Hlth Promot Off, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Ekelund, Ulf] Dept Sport Med, Oslo, Norway. [Ekelund, Ulf] Inst Metab Sci, MRC, Epidemiol Unit, Tehran, Iran. RP Arango, CM (reprint author), Washington Univ, George Warren Brown Sch Social Work, Prevent Res Ctr St Louis, St Louis, MO 63130 USA. EM carangopaternina@go.wustl.edu RI Parra, Diana/B-7761-2015; OI Parra, Diana/0000-0002-9797-6231; Lobelo, Felipe/0000-0003-4185-7193 FU Medical Research Council [MC_U106179473] NR 30 TC 4 Z9 5 U1 0 U2 20 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1440-2440 EI 1878-1861 J9 J SCI MED SPORT JI J. Sci. Med. Sport PD SEP PY 2014 VL 17 IS 5 BP 491 EP 495 DI 10.1016/j.jsams.2013.09.010 PG 5 WC Sport Sciences SC Sport Sciences GA AP9MZ UT WOS:000342405200009 PM 24211150 ER PT J AU Cullen, KA Stokley, S Markowitz, LE AF Cullen, Karen A. Stokley, Shannon Markowitz, Lauri E. TI Uptake of Human Papillomavirus Vaccine Among Adolescent Males and Females: Immunization Information System Sentinel Sites, 2009-2012 SO ACADEMIC PEDIATRICS LA English DT Article DE adolescent; human papillomavirus vaccine; immunization ID AGED 13-17 YEARS; UNITED-STATES; INFLUENZA SEASON; SURVEY-TEEN; COVERAGE; GIRLS; HPV AB OBJECTIVE: The Advisory Committee on Immunization Practices (ACIP) has recommended routine human papillomavirus (HPV) vaccination at age 11 or 12 years for girls since 2006 and for boys since 2011. We sought to describe adolescent HPV vaccination coverage, doses administered from 2009 to 2012, and age at first vaccination by sex. METHODS: Aggregate data were analyzed from 8 Immunization Information System sentinel sites on HPV vaccinations in children and adolescents aged 11 to 12 years, 13 to 15 years, and 16 to 18 years. Vaccination coverage by age group was reported for 2009 to 2012, and weekly doses administered were determined. Age at first HPV vaccination was calculated for girls in 2007 and 2011 and for boys in 2011. RESULTS: This analysis included data on 2 9 million adolescents aged 11 to 18 years. There were small increases in coverage for girls, with receipt of >= 1 dose of HPV vaccine reaching 27.1% of ages 11 to 12, 47.9% of ages 13 to 15, and 57.1% of ages 16 to 18 by December 31, 2012. Uptake of >= 1 dose in boys reached similar to 18% for all age groups. Doses administered showed seasonal variation, with highest uptake before back to school among girls and steady increases in boys after the 2009 ACIP recommendation for permissive use. Doses administered to boys surpassed those administered to girls by September 2012. Among vaccinated girls, more received vaccine at the recommended age of 11 to 12 years in 2011 (74.2%) compared to 2007 (9.9%). In 2011, 27.3% of vaccinated boys received their first dose at age 11 to 12 years. CONCLUSIONS: HPV vaccination coverage increased among adolescents between 2009 and 2012. However, increases among girls were small, and coverage for boys and girls remained below target levels. C1 [Cullen, Karen A.; Stokley, Shannon] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Markowitz, Lauri E.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Cullen, KA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A-06, Atlanta, GA 30333 USA. EM kcullen@cdc.gov FU Intramural CDC HHS [CC999999] NR 39 TC 12 Z9 12 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 EI 1876-2867 J9 ACAD PEDIATR JI Acad. Pediatr. PD SEP-OCT PY 2014 VL 14 IS 5 BP 497 EP 504 PG 8 WC Pediatrics SC Pediatrics GA AP2KD UT WOS:000341900200013 PM 24954170 ER PT J AU Foldy, S Grannis, S Ross, D Smith, T AF Foldy, Seth Grannis, Shaun Ross, David Smith, Torney TI A Ride in the Time Machine: Information Management Capabilities Health Departments Will Need SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID PUBLIC-HEALTH; POPULATION HEALTH; CARE; RECORD; SYSTEMS; NETWORK; ALERTS; IMPACT AB We have proposed needed information management capabilities for future US health departments predicated on trends in health care reform and health information technology. Regardless of whether health departments provide direct clinical services (and many will), they will manage unprecedented quantities of sensitive information for the public health core functions of assurance and assessment, including population-level health surveillance and metrics. Absent improved capabilities, health departments risk vestigial status, with consequences for vulnerable populations. Developments in electronic health records, interoperability and information exchange, public information sharing, decision support, and cloud technologies can support information management if health departments have appropriate capabilities. The need for national engagement in and consensus on these capabilities and their importance to health department sustainability make them appropriate for consideration in the context of accreditation. C1 [Foldy, Seth] Ctr Dis Control & Prevent, Publ Hlth Surveillance & Informat Program Off, Atlanta, GA USA. [Grannis, Shaun] Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA. [Grannis, Shaun] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Ross, David] Publ Hlth Informat Inst, Atlanta, GA USA. [Smith, Torney] Reg Hlth Dept, Spokane, WA USA. RP Foldy, S (reprint author), 3061 N Marietta Ave, Milwaukee, WI 53211 USA. EM sfoldy@sbcglobal.net FU Public Health Accreditation Board FX The Public Health Accreditation Board funded the think tank meetings where we were tasked with forecasting longer-range future informatics needs of health departments. NR 77 TC 5 Z9 5 U1 0 U2 8 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2014 VL 104 IS 9 BP 1592 EP 1600 DI 10.2105/AJPH.2014.301956 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1XB UT WOS:000341864400020 PM 25033122 ER PT J AU Singh, S Hu, XH Wheeler, W Hall, HI AF Singh, Sonia Hu, Xiaohong Wheeler, William Hall, H. Irene TI HIV Diagnoses Among Men Who Have Sex With Men and Women-United States and 6 Dependent Areas, 2008-2011 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID RISK BEHAVIORS; BISEXUAL MEN; TRANSMISSION; AIDS AB Objectives. We sought to describe HIV diagnoses among men who have sex with men and women (MSMW), who have the potential to bridge HIV transmission risk from men who have sex with men (MSM) to women. Methods. Applying National HIV Surveillance System data for persons aged 13 years and older, we examined estimated numbers and percentages of HIV diagnoses among MSMW and MSM only (MSMO) from 2008 to 2011, and estimated the annual percentage change and 95% confidence intervals, by age and race/ethnicity. Results. In 2011, 26.4% of 30 896 MSM diagnosed with HIV infection also had had sex with women. A larger percentage of MSMW were Black/African American (44.5%) compared with MSMO (36.0%), and fewer MSMW were White (26.4%) compared with MSMO (36.2%); similar percentages were classified as either MWMW or MSMO among other racial/ethnic groups. Among MSMW, HIV diagnoses were relatively stable and MSMO increased more than 6% annually among those aged 13 to 29 years. Conclusions. Many MSM diagnosed with HIV infection had also had sex with women. Intensified interventions are needed to decrease HIV infections overall for MSMW and reverse the increasing trends among young MSMO. C1 [Singh, Sonia; Hu, Xiaohong; Hall, H. Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30329 USA. [Wheeler, William] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA. RP Singh, S (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-47, Atlanta, GA 30329 USA. EM ssingh3@cdc.gov NR 21 TC 3 Z9 3 U1 2 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2014 VL 104 IS 9 BP 1700 EP 1706 DI 10.2105/AJPH.2014.301990 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1XB UT WOS:000341864400037 PM 25033139 ER PT J AU Canfield, MA Mai, CT Wang, Y O'Halloran, A Marengo, LK Olney, RS Borger, CL Rutkowski, R Fornoff, J Irwin, N Copeland, G Flood, TJ Meyer, RE Rickard, R Alverson, CJ Sweatlock, J Kirby, RS AF Canfield, Mark A. Mai, Cara T. Wang, Ying O'Halloran, Alissa Marengo, Lisa K. Olney, Richard S. Borger, Christopher L. Rutkowski, Rachel Fornoff, Jane Irwin, Nila Copeland, Glenn Flood, Timothy J. Meyer, Robert E. Rickard, Russel Alverson, C. J. Sweatlock, Joseph Kirby, Russell S. CA Natl Birth Defects Prevention TI The Association Between Race/Ethnicity and Major Birth Defects in the United States, 1999-2007 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID CONGENITAL HEART-DEFECTS; DESCRIPTIVE EPIDEMIOLOGY; ORAL CLEFTS; SPINA-BIFIDA; PREVALENCE; TEXAS; CALIFORNIA; POPULATION; GASTROSCHISIS; MALFORMATIONS AB Objectives. We investigated the relationship between race/ethnicity and 27 major birth defects. Methods. We pooled data from 12 population-based birth defects surveillance systems in the United States that included 13.5million live births (1 of 3 of US births) from 1999 to 2007. Using Poisson regression, we calculated prevalence estimates for each birth defect and 13 racial/ethnic groupings, along with crude and adjusted prevalence ratios (aPRs). Non-Hispanic Whites served as the referent group. Results. American Indians/Alaska Natives had a significantly higher and 50% or greater prevalence for 7 conditions (aPR = 3.97; 95% confidence interval [CI] = 2.89, 5.44 for anotia or microtia); aPRs of 1.5 to 2.1 for cleft lip, trisomy 18, and encephalocele, and lower, upper, and any limb deficiency). Cubans and Asians, especially Chinese and Asian Indians, had either significantly lower or similar prevalences of these defects compared with non-Hispanic Whites, with the exception of anotia or microtia among Chinese (aPR = 2.08; 95% CI = 1.30, 3.33) and Filipinos (aPR = 1.90; 95% CI = 1.10, 3.30) and tetralogy of Fallot among Vietnamese (aPR = 1.60; 95% CI = 1.11, 2.32). Conclusions. This is the largest population-based study to our knowledge to systematically examine the prevalence of a range of major birth defects across many racial/ethnic groups, including Asian and Hispanic subgroups. The relatively high prevalence of birth defects in American Indians/Alaska Natives warrants further attention. C1 [Canfield, Mark A.; Marengo, Lisa K.] Texas Dept State Hlth Serv, Austin, TX 78714 USA. [Mai, Cara T.; O'Halloran, Alissa; Olney, Richard S.; Alverson, C. J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Wang, Ying] New York State Dept Hlth, Albany, NY 12237 USA. [Borger, Christopher L.] Massachusetts Dept Publ Hlth, Boston, MA USA. [Rutkowski, Rachel] Florida Dept Hlth, Tallahassee, FL USA. [Fornoff, Jane] Illinois Dept Publ Hlth, Springfield, IL 62761 USA. [Irwin, Nila] Nebraska Dept Hlth & Human Serv, Lincoln, NE USA. [Copeland, Glenn] Michigan Dept Community Hlth, Michigan Birth Defects Registry, Lansing, MI USA. [Flood, Timothy J.] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Meyer, Robert E.] North Carolina Birth Defects Monitoring Program, Raleigh, NC USA. [Rickard, Russel] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Sweatlock, Joseph] New Jersey Dept Hlth, Trenton, NJ USA. [Kirby, Russell S.] Univ S Florida, Dept Community & Family Hlth, Tampa, FL USA. RP Canfield, MA (reprint author), Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, POB 149347,MC 1964, Austin, TX 78714 USA. EM mark.canfield@dshs.state.tx.us FU Intramural CDC HHS [CC999999] NR 37 TC 15 Z9 15 U1 0 U2 12 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2014 VL 104 IS 9 BP E14 EP E23 DI 10.2105/AJPH.2014.302098 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1XB UT WOS:000341864400005 PM 25033129 ER PT J AU Kucik, JE Cassell, CH Alverson, CJ Donohue, P Tanner, JP Minkovitz, CS Correia, J Burke, T Kirby, RS AF Kucik, James E. Cassell, Cynthia H. Alverson, Clinton J. Donohue, Pamela Tanner, Jean Paul Minkovitz, Cynthia S. Correia, Jane Burke, Thomas Kirby, Russell S. TI Role of Health Insurance on the Survival of Infants With Congenital Heart Defects SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID LOW-BIRTH-WEIGHT; UNITED-STATES; DOWN-SYNDROME; FETAL DIAGNOSIS; RACIAL/ETHNIC DISPARITIES; METROPOLITAN ATLANTA; RACIAL DISPARITIES; ETHNIC DISPARITIES; MORTALITY; DISEASE AB Objectives. We examined the association between health insurance and survival of infants with congenital heart defects (CHDs), and whether medical insurance type contributed to racial/ethnic disparities in survival. Methods. We conducted a population-based, retrospective study on a cohort of Florida resident infants born with CHDs between 1998 and 2007. We estimated neonatal, post-neonatal, and infant survival probabilities and adjusted hazard ratios (AHRs) for individual characteristics. Results. Uninsured infants with critical CHDs had 3 times the mortality risk (AHR = 3.0; 95% confidence interval = 1.3, 6.9) than that in privately insured infants. Publicly insured infants had a 30% reduced mortality risk than that of privately insured infants during the neonatal period, but had a 30% increased risk in the post-neonatal period. Adjusting for insurance type reduced the Black-White disparity in mortality risk by 50%. Conclusions. Racial/ethnic disparities in survival were attenuated significantly, but not eliminated, by adjusting for payer status. C1 [Kucik, James E.; Cassell, Cynthia H.; Alverson, Clinton J.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA USA. [Donohue, Pamela] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA. [Tanner, Jean Paul; Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Birth Defects Surveillance Program, Tampa, FL USA. [Minkovitz, Cynthia S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA. [Correia, Jane] Florida Dept Hlth, Florida Birth Defects Registry, Bur Epidemiol, Div Dis Control & Hlth Protect, Tallahassee, FL USA. [Burke, Thomas] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. RP Kucik, JE (reprint author), CDC, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM jkucik@cdc.gov FU Intramural CDC HHS [CC999999] NR 55 TC 8 Z9 8 U1 1 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2014 VL 104 IS 9 BP E62 EP E70 DI 10.2105/AJPH.2014.301969 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1XB UT WOS:000341864400011 PM 25033158 ER PT J AU Simon, AE Schoendorf, KC AF Simon, Alan E. Schoendorf, Kenneth C. TI Medicaid Enrollment Gap Length and Number of Medicaid Enrollment Periods Among US Children SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HEALTH-INSURANCE; UNITED-STATES; COVERAGE AB Objectives. We examined gap length, characteristics associated with gap length, and number of enrollment periods among Medicaid-enrolled children in the United States. Methods. We linked the 2004 National Health Interview Survey to Medicaid Analytic eXtract files for 1999 through 2008. We examined linkage-eligible children aged 5 to 13 years in the 2004 National Health Interview Survey who disenrolled from Medicaid. We generated Kaplan-Meier curves of time to reenrollment. We used Cox proportional hazards models to assess the effect of sociodemographic variables on time to reenrollment. We compared the percentage of children enrolled 4 or more times across sociodemographic groups. Results. Of children who disenrolled from Medicaid, 35.8%, 47.1%, 63.5%, 70.8%, and 79.1% of children had reenrolled in Medicaid by 6 months, 1, 3, 5, and 10 years, respectively. Children who were younger, poorer, or of minority race/ethnicity or had lower educated parents had shorter gaps in Medicaid and were more likely to have had 4 or more Medicaid enrollment periods. Conclusions. Nearly half of US children who disenrolled from Medicaid reenrolled within 1 year. Children with traditionally high-risk demographic characteristics had shorter gaps in Medicaid enrollment and were more likely to have more periods of Medicaid enrollment. C1 [Simon, Alan E.; Schoendorf, Kenneth C.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Schoendorf, Kenneth C.] US PHS, Rockville, MD USA. RP Simon, AE (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Rm 6122, Hyattsville, MD 20782 USA. EM fpa8@cdc.gov NR 24 TC 1 Z9 1 U1 1 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2014 VL 104 IS 9 BP E55 EP E61 DI 10.2105/AJPH.2014.301976 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1XB UT WOS:000341864400010 PM 25033135 ER PT J AU Fettig, J Swaminathan, M Murrill, CS Kaplan, JE AF Fettig, Jade Swaminathan, Mahesh Murrill, Christopher S. Kaplan, Jonathan E. TI Global Epidemiology of HIV SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE HIV; Global health; Epidemiology; Antiretroviral therapy; Risk behavior ID SUB-SAHARAN AFRICA; MALE CIRCUMCISION; SOUTH-AFRICA; PREVENTION; MEN; TRANSMISSION; SEX; INFECTION; HIV/AIDS; COVERAGE AB The number of persons living with HIV worldwide reached approximately 35.3 million in 2012. Meanwhile, AIDS-related deaths and new HIV infections have declined. Much of the increase in HIV prevalence is from rapidly increasing numbers of people on antiretroviral treatment who are now living longer. There is regional variation in epidemiologic patterns, major modes of HIV transmission, and HIV program response. It is important to focus on HIV incidence, rather than prevalence, to provide information about HIV transmission patterns and populations at risk. Expanding HIV treatment will function as a preventive measure through decreasing horizontal and vertical transmission of HIV. C1 [Fettig, Jade; Swaminathan, Mahesh; Murrill, Christopher S.] Ctr Global Hlth, Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Epidemiol & Strateg Informat Branch, Atlanta, GA 30333 USA. [Kaplan, Jonathan E.] Ctr Global Hlth, Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, HIV Care & Treatment Branch, Atlanta, GA 30333 USA. RP Kaplan, JE (reprint author), Ctr Global Hlth, Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, HIV Care & Treatment Branch, 1600 Clifton Rd,Northeast,MS E-04, Atlanta, GA 30333 USA. EM jxk2@cdc.gov FU Intramural CDC HHS [CC999999] NR 38 TC 11 Z9 11 U1 2 U2 20 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 EI 1557-9824 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD SEP PY 2014 VL 28 IS 3 BP 323 EP + DI 10.1016/j.idc.2014.05.001 PN 1 PG 16 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AP2JS UT WOS:000341899100004 PM 25151559 ER PT J AU Reed, C Bruden, D Byrd, KK Veguilla, V Bruce, M Hurlburt, D Wang, D Holiday, C Hancock, K Ortiz, JR Klejka, J Katz, JM Uyeki, TM AF Reed, Carrie Bruden, Dana Byrd, Kathy K. Veguilla, Vic Bruce, Michael Hurlburt, Debby Wang, David Holiday, Crystal Hancock, Kathy Ortiz, Justin R. Klejka, Joe Katz, Jacqueline M. Uyeki, Timothy M. TI Characterizing wild bird contact and seropositivity to highly pathogenic avian influenza A (H5N1) virus in Alaskan residents SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Alaska; H5N1; influenza ID HEALTH-CARE WORKERS; TO-HUMAN TRANSMISSION; HONG-KONG; ANTIBODY-RESPONSE; ANTI-H5 ANTIBODY; BRITISH-COLUMBIA; POULTRY WORKERS; ANAS-ACUTA; INFECTION; OUTBREAK AB BackgroundHighly pathogenic avian influenza A (HPAI) H5N1 viruses have infected poultry and wild birds on three continents with more than 600 reported human cases (59% mortality) since 2003. Wild aquatic birds are the natural reservoir for avian influenza A viruses, and migratory birds have been documented with HPAI H5N1 virus infection. Since 2005, clade 2.2 HPAI H5N1 viruses have spread from Asia to many countries. ObjectivesWe conducted a cross-sectional seroepidemiological survey in Anchorage and western Alaska to identify possible behaviors associated with migratory bird exposure and measure seropositivity to HPAI H5N1. MethodsWe enrolled rural subsistence bird hunters and their families, urban sport hunters, wildlife biologists, and a comparison group without bird contact. We interviewed participants regarding their exposures to wild birds and collected blood to perform serologic testing for antibodies against a clade 2.2 HPAI H5N1 virus strain. ResultsHunters and wildlife biologists reported exposures to wild migratory birds that may confer risk of infection with avian influenza A viruses, although none of the 916 participants had evidence of seropositivity to HPAI H5N1. ConclusionsWe characterized wild bird contact among Alaskans and behaviors that may influence risk of infection with avian influenza A viruses. Such knowledge can inform surveillance and risk communication surrounding HPAI H5N1 and other influenza viruses in a population with exposure to wild birds at a crossroads of intercontinental migratory flyways. C1 [Reed, Carrie; Byrd, Kathy K.; Ortiz, Justin R.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Reed, Carrie; Veguilla, Vic; Wang, David; Holiday, Crystal; Hancock, Kathy; Katz, Jacqueline M.; Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Bruden, Dana; Byrd, Kathy K.; Bruce, Michael; Hurlburt, Debby] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. [Ortiz, Justin R.] Univ Washington, Dept Med, Seattle, WA USA. [Ortiz, Justin R.] Univ Washington, Dept Global Hlth, Seattle, WA USA. [Klejka, Joe] Yukon Kuskokwim Hlth Corp, Bethel, AK USA. RP Reed, C (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE MS A-32, Atlanta, GA 30333 USA. EM CReed1@cdc.gov NR 40 TC 5 Z9 5 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2014 VL 8 IS 5 BP 516 EP 523 DI 10.1111/irv.12253 PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AP4RX UT WOS:000342067200002 PM 24828535 ER PT J AU Tarnagda, Z Yougbare, I Ilboudo, AK Kagone, T Sanou, AM Cisse, A Medah, I Yelbeogo, D Nzussouo, NT AF Tarnagda, Zekiba Yougbare, Issaka Ilboudo, Abdoul K. Kagone, Therese Sanou, Armel M. Cisse, Assana Medah, Isaie Yelbeogo, Denis Nzussouo, Ndahwouh Talla TI Sentinel surveillance of influenza in Burkina Faso: identification of circulating strains during 2010-2012 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Burkina Faso; influenza-like illness; sentinel surveillance ID VIRUS SUBTYPE H1N1; PANDEMIC INFLUENZA; WEST-AFRICA; WILD BIRDS; PREPAREDNESS; MORTALITY; H5N1; MENINGITIS; INFECTION; OUTBREAKS AB BackgroundAlthough influenza surveillance has recently been improved in some sub-Saharan African countries, no information is yet available from Burkina Faso. ObjectivesOur study was the first to determine the prevalence of influenza viruses circulating in Burkina Faso through a sentinel surveillance system. MethodsWe conducted sentinel surveillance with oropharyngeal (OP) swabs collected from outpatients (1month to 83years) from six sites in Bobo-Dioulasso and Ouagadougou, among patients meeting the WHO/CDC case definition for influenza-like illness (ILI; fever 38 degrees C, and cough and/or sore throat in the absence of other diagnosis) from July 2010 to May 2012. Influenza viruses were detected by real-time RT-PCR using CDC primers, probes, and protocols. ResultsThe first three ILI cases were enrolled each day; of 881 outpatients with ILI enrolled and sampled, 58 (66%) tested positive for influenza viruses (29 influenza A and 29 influenza B). Among the influenza A viruses, 552% (16/29) were influenza A (H1N1)pdm09 and 448% (13/29) were seasonal A (H3N2). No cases of seasonal A/H1N1 were detected. Patients within 0-5years and 6-14years were the most affected, comprising 414% and 224% laboratory-confirmed influenza cases, respectively. Influenza infections occurred during both the dry, dusty Harmattan months from November to March and the rainy season from June to October with peaks in January and August. ConclusionsThis surveillance was the first confirming the circulation of influenza A (H1N1)pdm09, A/H3N2, and influenza B viruses in humans in Burkina Faso. C1 [Tarnagda, Zekiba; Ilboudo, Abdoul K.; Sanou, Armel M.; Cisse, Assana] Ctr Natl Reference Grippe, Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso. [Tarnagda, Zekiba] Univ Ouagadougou, West African Master Field Epidemiol & Lab Trainin, Ouagadougou, Burkina Faso. [Yougbare, Issaka] St Michaels Hosp LKSKI Keenan Res Ctr, Toronto, ON, Canada. [Kagone, Therese] Ctr Muraz, Bobo Dioulasso, Burkina Faso. [Medah, Isaie; Yelbeogo, Denis] Minist Sante, DLM, Ouagadougou, Burkina Faso. [Nzussouo, Ndahwouh Talla] US Ctr Dis Control & Prevent CDC, Influenza Div, Atlanta, GA USA. RP Tarnagda, Z (reprint author), IRSS, 399 Ave Liberte,BP 545 Bobo Dioulasso, Ouagadougou, Burkina Faso. EM zekiba@hotmail.com FU U.S. Naval Medical Research Unit [3 (NAMRU-3), N 61751-10-M-0254] FX Swabs and virus transport medium were donated by the USAID. Reagents, primers, and probes were kindly provided by the WHOCC, CDC, Atlanta. Centre National de Reference pour la Grippe received a Grant from the U.S. Naval Medical Research Unit No. 3 (NAMRU-3), Contract No. N 61751-10-M-0254 to support influenza surveillance in Burkina Faso. NR 27 TC 3 Z9 3 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2014 VL 8 IS 5 BP 524 EP 529 DI 10.1111/irv.12259 PG 6 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AP4RX UT WOS:000342067200003 PM 25074591 ER PT J AU Pretorius, MA Tempia, S Treurnicht, FK Walaza, S Cohen, AL Moyes, J Hellferscee, O Variava, E Dawood, H Chhagan, M Haffjee, S Madhi, SA Cohen, C Venter, M AF Pretorius, Marthi A. Tempia, Stefano Treurnicht, Florette K. Walaza, Sibongile Cohen, Adam L. Moyes, Jocelyn Hellferscee, Orienka Variava, Ebrahim Dawood, Halima Chhagan, Meera Haffjee, Sumayya Madhi, Shabir A. Cohen, Cheryl Venter, Marietjie TI Genetic diversity and molecular epidemiology of human rhinoviruses in South Africa SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Disease association; genetic diversity; rhinovirus; South Africa ID ACUTE RESPIRATORY ILLNESS; MAXIMUM-LIKELIHOOD; CHILDREN; INFECTION; VIRUSES; ASTHMA; PCR AB BackgroundRhinoviruses (RV) are a well-established cause of respiratory illness. RV-C has been associated with more severe illness. We aimed to characterize and compare the clinical presentations and disease severity of different RV type circulating in South Africa. MethodWe performed two analyses of RV-positive specimens identified through surveillance in South Africa across all age groups. First, RV-positive specimens identified through severe acute respiratory illness (SARI) surveillance in four provinces was randomly selected from 2009 to 2010 for molecular characterization. Second, RV-positive specimens identified through SARI, influenza-like illness (ILI) and control surveillance at hospitals and outpatient clinics in during 2012-2013 were used to determine the association of RV type with severe disease. Selected specimens were sequenced, and phylogenetic analysis was performed. ResultsAmong the 599 sequenced specimens from 2009 to 2010 and 2012 to 2013, RV-A (285, 48%) and RV-C (247, 41%) were more commonly identified than RV-B (67, 11%), with no seasonality and a high genetic diversity. A higher prevalence of RV infection was identified in cases with SARI [515/962 (26%); aRRR=16; 95% CI 121; 22] and ILI [356/962 (28%); aRRR=19; 95% CI 137; 26] compared with asymptomatic controls (91/962, 22%). There was no difference in disease severity between the different type when comparing SARI, ILI and controls. ConclusionAll three type of RV were identified in South Africa, although RV-A and RV-C were more common than RV-B. RV was associated with symptomatic respiratory illness; however, there was no association between RV type and disease severity. C1 [Pretorius, Marthi A.; Treurnicht, Florette K.; Walaza, Sibongile; Moyes, Jocelyn; Hellferscee, Orienka; Madhi, Shabir A.; Cohen, Cheryl; Venter, Marietjie] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Pretorius, Marthi A.; Venter, Marietjie] Univ Pretoria, Dept Med Virol, ZA-0001 Pretoria, South Africa. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Div, Pretoria, South Africa. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent South Africa, Influenza Programme, Pretoria, South Africa. [Moyes, Jocelyn; Cohen, Cheryl] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa. [Variava, Ebrahim] Klerksdorp Tshepong Hosp, Dept Med, Klerksdorp, South Africa. [Variava, Ebrahim] Univ Witwatersrand, Dept Med, Fac Hlth Sci, ZA-2001 Johannesburg, South Africa. [Dawood, Halima] Pietermaritzburg Metropolitan Hosp, Dept Med, Pietermaritzburg, South Africa. [Dawood, Halima] Univ KwaZulu Natal, Dept Med, Pietermaritzburg, South Africa. [Chhagan, Meera] Univ KwaZulu Natal, Dept Paediat, Pietermaritzburg, South Africa. [Haffjee, Sumayya] Univ KwaZulu Natal, Sch Pathol, Pietermaritzburg, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, Med Res Council, Resp & Meningeal Pathogens Res Unit, Fac Hlth Sci, Johannesburg, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn, Johannesburg, South Africa. [Venter, Marietjie] Ctr Dis Control & Prevent, Pretoria, South Africa. RP Venter, M (reprint author), US Ctr Dis Control & Prevent, Pretoria, South Africa. EM yds8@cdc.gov RI Venter, Marietjie/P-9604-2016 OI Venter, Marietjie/0000-0003-2696-824X FU United States Centers for Disease Control and Prevention, Atlanta, Georgia, USA [5U51IP000155] FX This work was supported by the United States Centers for Disease Control and Prevention, Atlanta, Georgia, USA [cooperative agreement number: 5U51IP000155]. The corresponding author has full access to all data in the study and final responsibility for the decision to submit this publication. NR 23 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2014 VL 8 IS 5 BP 567 EP 573 DI 10.1111/irv.12264 PG 7 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AP4RX UT WOS:000342067200009 PM 24990601 ER PT J AU Hampton, LM Daubresse, M Chang, HY Alexander, GC Budnitz, DS AF Hampton, Lee M. Daubresse, Matthew Chang, Hsien-Yen Alexander, G. Caleb Budnitz, Daniel S. TI Emergency Department Visits by Adults for Psychiatric Medication Adverse Events SO JAMA PSYCHIATRY LA English DT Article ID OFFICE-BASED TREATMENT; UNITED-STATES; ANTIPSYCHOTIC USE; OLDER-PEOPLE; DRUG EVENTS; SURVEILLANCE; RESIDENTS; DISORDER; ZOLPIDEM; BENEFITS AB IMPORTANCE In 2011, an estimated 26.8 million US adults used prescription medications for mental illness. OBJECTIVE To estimate the numbers and rates of adverse drug event (ADE) emergency department (ED) visits involving psychiatric medications among US adults between January 1, 2009, and December 31, 2011. DESIGN AND SETTING Descriptive analyses of active, nationally representative surveillance of ADE ED visits using the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance system and of drug prescribing during outpatient visits using the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. PARTICIPANTS Medical records from national probability samples of ED and outpatient visits by adults 19 years or older were reviewed and analyzed. EXPOSURES Antidepressants, antipsychotics, lithium salts, sedatives and anxiolytics, and stimulants. MAIN OUTCOMES AND MEASURES National estimates of ADE ED visits resulting from therapeutic psychiatric medication use and of psychiatric medication ADE ED visits per 10 000 outpatient visits at which psychiatric medications were prescribed. RESULTS From 2009 through 2011, there were an estimated 89 094 (95% CI, 68 641-109 548) psychiatric medication ADE ED visits annually, with 19.3%(95% CI, 16.3%-22.2%) resulting in hospitalization and 49.4%(95% CI, 46.5%-52.4%) involving patients aged 19 to 44 years. Sedatives and anxiolytics, antidepressants, antipsychotics, lithium salts, and stimulants were implicated in an estimated 30 707 (95% CI, 23 406-38 008), 25 377 (95% CI, 19 051-31 704), 21 578 (95% CI, 16 599-26 557), 3620 (95% CI, 2311-4928), and 2779 (95% CI, 1764-3794) respective ADE ED visits annually. Antipsychotics and lithium salts were implicated in 11.7 (95% CI, 10.1-13.2) and 16.4 (95% CI, 13.0-19.9) ADE ED visits per 10 000 outpatient prescription visits, respectively, compared with 3.6 (95% CI, 3.2-4.1) for sedatives and anxiolytics, 2.9 (95% CI, 2.3-3.5) for stimulants, and 2.4 (95% CI, 2.1-2.7) for antidepressants. The commonly used sedative zolpidem tartrate was implicated in 11.5%(95% CI, 9.5%-13.4%) of all adult psychiatric medication ADE ED visits and in 21.0%(95% CI, 16.3%-25.7%) of visits involving adults 65 years or older, in both cases significantly more than any other psychiatric medication. CONCLUSIONS AND RELEVANCE Psychiatric medications are implicated in many ADEs treated in US EDs. Efforts to reduce ADEs should include adults of all ages but might prioritize medications causing high numbers and rates of ED visits. C1 [Hampton, Lee M.; Budnitz, Daniel S.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Daubresse, Matthew; Chang, Hsien-Yen; Alexander, G. Caleb] Johns Hopkins Univ, Ctr Drug Safety & Effectiveness, Baltimore, MD USA. [Daubresse, Matthew; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Chang, Hsien-Yen] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Alexander, G. Caleb] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. RP Hampton, LM (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,Mail Stop A-24, Atlanta, GA 30329 USA. EM lhampton@cdc.gov RI Chang, Hsien-Yen/E-4627-2014 OI Chang, Hsien-Yen/0000-0002-7997-4822 FU Intramural CDC HHS [CC999999] NR 44 TC 23 Z9 24 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD SEP PY 2014 VL 71 IS 9 BP 1006 EP 1014 DI 10.1001/jamapsychiatry.2014.436 PG 9 WC Psychiatry SC Psychiatry GA AP0SV UT WOS:000341775300006 PM 25006837 ER PT J AU Xu, ST Zhang, Y Rivailler, P Wang, HL Ji, YX Zhen, Z Mao, NY Li, CS Bellini, WJ Xu, WB Rota, PA AF Xu, Songtao Zhang, Yan Rivailler, Pierre Wang, Huiling Ji, Yixin Zhen, Zhu Mao, Naiying Li, Chongshan Bellini, William J. Xu, Wenbo Rota, Paul A. TI Evolutionary genetics of genotype H1 measles viruses in China from 1993 to 2012 SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID MOLECULAR EPIDEMIOLOGY; MAXIMUM-LIKELIHOOD; HEMAGGLUTININ; SEQUENCES; PRESSURE; DYNAMICS AB Virologic surveillance is a critical component of measles management. One of the criteria for verification of elimination of endemic measles is genetic analysis of wild-type viruses to demonstrate lack of an indigenous genotype. Measles is yet to be eliminated in China, and genotype H1 has been detected continuously since virologic surveillance was initiated in 1993. Virologic surveillance has been very active in China, providing a unique opportunity to conduct a detailed study of the evolution of a single, endemic genotype over a timespan of nearly two decades. Phylogenetic analysis performed on the 450 nt coding sequence for the C-terminal 150 amino acids of the nucleoprotein (N-450), fusion (F) gene and haemagglutinin (H) gene confirmed the continued circulation of genotype H1 viruses for 19 years. No evidence of selective pressure for the H protein was found. The substitution rates ranged from 0.75x10(-3) substitutions site(-1) year(-1) for H to 1.65x10(-3) substitutions site(-1) year(-1) for N-450. The time of most recent common ancestor (TMRCA) for genotype H1 was estimated as approximately 1985 (95 % highest probability density, 1979-1989). Finally, the overall diversity of measles sequences from China decreased from 2005 to 2012, coincident with a substantial decrease in measles cases. The results suggest that detailed evolutionary analyses should facilitate the documentation of eventual measles elimination in China. Moreover, the molecular approaches used in this study can be applied in other countries approaching measles elimination. C1 [Xu, Songtao; Zhang, Yan; Wang, Huiling; Ji, Yixin; Zhen, Zhu; Mao, Naiying; Xu, Wenbo] China Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, WHO Reg Reference Lab Measles Western Pacific Reg, Beijing 102206, Peoples R China. [Rivailler, Pierre; Bellini, William J.; Rota, Paul A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Li, Chongshan] Shanghai Ctr Dis Control & Prevent, Shanghai, Peoples R China. RP Rota, PA (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. EM wenbo_xu1@aliyun.com; prota@cdc.gov FU WHO headquarters; WPRO; US CDC; National Natural Science Foundation of China [81371791]; Key Technologies R&D Program of National Ministry of Science [2013ZX10004-202, 2012ZX10004215, 2013ZX10004-101, 2012YQ03026104, 2012ZX10004201-003, 2012ZX10004401]; WHO Measles Regional Reference Laboratory; WHO [WP CHN AAA 011 XZ 08] FX We thank all the provincial and prefecture measles laboratory staff and epidemiologists in mainland China for providing clinical specimens, isolates and epidemiological data. We are grateful to WHO headquarters, WPRO and US CDC for technical and financial support. We additionally acknowledge anonymous reviewers for comments that improved the manuscript. This work is supported by a grant from the National Natural Science Foundation of China (grant no. 81371791), the Key Technologies R&D Program of National Ministry of Science (2013ZX10004-202, 2012ZX10004215, 2013ZX10004-101, 2012YQ03026104, 2012ZX10004201-003, 2012ZX10004401), WHO Measles Regional Reference Laboratory funding and WHO funding (no. WP CHN AAA 011 XZ 08). NR 36 TC 5 Z9 6 U1 0 U2 4 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 EI 1465-2099 J9 J GEN VIROL JI J. Gen. Virol. PD SEP PY 2014 VL 95 BP 1892 EP 1899 DI 10.1099/vir.0.066746-0 PN 9 PG 8 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA AP1BD UT WOS:000341800500005 PM 24914068 ER PT J AU Hackbarth, AD Munier, WB Eldridge, N Jordan, J Richards, C Brennan, NJ Wagner, D McGann, P AF Hackbarth, Andrew D. Munier, William B. Eldridge, Noel Jordan, Jack Richards, Chesley Brennan, Niall J. Wagner, Dennis McGann, Paul TI An Overview of Measurement Activities in the Partnership for Patients SO JOURNAL OF PATIENT SAFETY LA English DT Article DE partnership for patients; measurement; adverse events ID ADVERSE EVENTS; SAFETY; TRENDS; CARE AB The Partnership for Patients, launched in April 2011, is a national quality improvement initiative from the Department of Health and Human Services that has set ambitious goals for U. S. providers to improve patient safety and care transitions. This paper outlines the initiative's measurement strategy, describing four measurement-related objectives: (1) to track national progress toward the program goals that U. S. hospitals reduce preventable adverse events by 40% and readmissions by 20%; (2) to support local quality improvement measurement in participating hospitals by providing the appropriate tools, training, and programmatic structure; (3) to obtain feedback on hospital and contractor progress, in close to real time, so the project can be effectively managed; and (4) to evaluate the program's impact on adverse event and readmission rates. C1 [Hackbarth, Andrew D.; Jordan, Jack; Brennan, Niall J.; Wagner, Dennis; McGann, Paul] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. [Munier, William B.; Eldridge, Noel] Agcy Healthcare Res & Qual, Rockville, MD USA. [Richards, Chesley] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hackbarth, AD (reprint author), Ctr Medicare & Medicaid Serv, 200 Independence Ave SW, Washington, DC 20201 USA. EM andrew.hackbarth@cms.hhs.gov NR 13 TC 2 Z9 2 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1549-8417 EI 1549-8425 J9 J PATIENT SAF JI J. Patient Saf. PD SEP PY 2014 VL 10 IS 3 BP 125 EP 132 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AP7AW UT WOS:000342230900002 PM 25119788 ER PT J AU Leiby, DA Johnson, ST Won, KY Nace, EK Slemenda, SB Pieniazek, NJ Cable, RG Herwaldt, BL AF Leiby, David A. Johnson, Stephanie T. Won, Kimberly Y. Nace, Eva K. Slemenda, Susan B. Pieniazek, Norman J. Cable, Ritchard G. Herwaldt, Barbara L. TI A longitudinal study of Babesia microti infection in seropositive blood donors SO TRANSFUSION LA English DT Article ID TRANSFUSION-TRANSMITTED BABESIOSIS; TRANSMISSION; PARASITEMIA; PERSISTENT; EXPERIENCE; STATES; AREA AB BackgroundBabesia infection is caused by intraerythrocytic tick-borne parasites. Cases of transfusion-transmitted babesiosis have been increasingly recognized. To date, no Babesia test has been licensed for screening US blood donors. We conducted a longitudinal study to assess the course and markers of Babesia infection among seropositive donors identified in a seroprevalence study. Study Design and MethodsEligible donors had B.microti indirect fluorescent antibody (IFA) titers of 64 or greater. Enrollees were monitored up to 3years, by IFA and three methods for evidence of parasitemia: B.microti nested polymerase chain reaction (PCR) analysis (at two laboratories), hamster inoculation, and blood-smear examination. ResultsAmong 115 eligible donors, 84 (73%) enrolled. Eighteen enrollees (21%) had evidence of parasitemia for 30 total specimens (17% of 181), which were collected in 9 different months and tested positive by various approaches: PCR (25 specimens/16 persons), hamster inoculation (13 specimens/8 persons), and blood smear (one specimen positive by all three approaches). Overall, 14 persons had one or more specimen with positive PCR results at both laboratories (12 persons) and/or had parasitologically confirmed infection (eight persons). Three of nine persons who had more than one specimen with evidence of parasitemia had nonconsecutive positives. Several enrollees likely had been infected at least 1 year when their last positive specimen was collected. The final three specimens for seven persons tested negative by all study methods, including IFA. ConclusionSeropositive blood donors can have protracted low-level parasitemia that is variably and intermittently detected by parasitologic and molecular methods. Donor-screening algorithms should include serologic testing and not solely rely on molecular testing. C1 [Leiby, David A.; Johnson, Stephanie T.] Amer Red Cross, Transmissible Dis Dept, Holland Lab, Rockville, MD 20855 USA. [Johnson, Stephanie T.; Cable, Ritchard G.] Amer Red Cross, Biomed Serv, Northeast Div, Farmington, CT USA. [Won, Kimberly Y.; Nace, Eva K.; Slemenda, Susan B.; Pieniazek, Norman J.; Herwaldt, Barbara L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Leiby, DA (reprint author), Amer Red Cross, Transmissible Dis Dept, 15601 Crabbs Branch Way, Rockville, MD 20855 USA. EM david.leiby@redcross.org FU Centers for Disease Control and Prevention [UR9/CCU316878]; American Red Cross Biomedical Services FX This work was supported in part by the Centers for Disease Control and Prevention (Cooperative Agreement UR9/CCU316878) and by the American Red Cross Biomedical Services. NR 31 TC 10 Z9 10 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2014 VL 54 IS 9 BP 2217 EP 2225 DI 10.1111/trf.12622 PG 9 WC Hematology SC Hematology GA AP5TJ UT WOS:000342141300013 PM 24673297 ER PT J AU Horton, KC Wasfy, M Samaha, H Abdel-Rahman, B Safwat, S Fadeel, MA Mohareb, E Dueger, E AF Horton, Katherine C. Wasfy, Momtaz Samaha, Hamed Abdel-Rahman, Bassem Safwat, Sameh Fadeel, Moustafa Abdel Mohareb, Emad Dueger, Erica TI Serosurvey for Zoonotic Viral and Bacterial Pathogens Among Slaughtered Livestock in Egypt SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Zoonoses; Rift Valley Fever virus; Crimean; Congo hemorrhagic fever virus; Coxiella burnetii; Brucella; Leptospira; Abattoir; Livestock; Egypt ID CONGO HEMORRHAGIC-FEVER; RIFT-VALLEY FEVER; SEROLOGICAL EVIDENCE; DOMESTIC-ANIMALS; FEBRILE ILLNESS; LEPTOSPIROSIS; SURVEILLANCE; DISEASE; PREVALENCE; INFECTION AB Introduction: Zoonotic diseases are an important cause of human morbidity and mortality. Animal populations at locations with high risk of transmission of zoonotic pathogens offer an opportunity to study viral and bacterial pathogens of veterinary and public health concern. Methods: Blood samples were collected from domestic and imported livestock slaughtered at the Muneeb abattoir in central Egypt in 2009. Samples were collected from cattle (n = 161), buffalo (n = 153), sheep (n = 174), and camels (n = 10). Samples were tested for antibodies against Leptospira spp. by a microscopy agglutination test, Coxiella burnetii by enzyme immunoassay, Brucella spp. by standard tube agglutination, and Rift Valley Fever virus (RVFV), Crimean-Congo hemorrhagic fever virus (CCHFV), sandfly fever Sicilian virus (SFSV), and sandfly fever Naples virus (SFNV) by enzyme-linked immunosorbent assay. Results: Antibodies against Leptospira spp. were identified in 64 (40%) cattle, 45 (29%) buffalo, 71 (41%) sheep, and five (50%) camels; antibodies against C. burnetii in six (4%) buffalo, 14 (8%) sheep, and seven (70%) camels; and antibodies against Brucella spp. in 12 (8%) cattle, one (1%) buffalo, seven (4%) sheep, and one (10%) camel. Antibodies against RVFV were detected in two (1%) cattle and five (3%) buffalo, and antibodies against CCHFV in one (1%) cow. No antibodies against SFSV or SFNV were detected in any species. Discussion: Results indicate that livestock have been exposed to a number of pathogens, although care must be taken with interpretation. It is not possible to determine whether antibodies against Leptospira spp. and RVFV in cattle and buffalo are due to prior vaccination or natural exposure. Similarly, antibodies identified in animals less than 6 months of age may be maternal antibodies transferred through colostrum rather than evidence of prior exposure. Results provide baseline evidence to indicate that surveillance within animal populations may be a useful tool to monitor the circulation of pathogens of veterinary and public health concern in Egypt. C1 [Horton, Katherine C.; Wasfy, Momtaz; Abdel-Rahman, Bassem; Fadeel, Moustafa Abdel; Dueger, Erica] US Naval Med Res Unit 3, Global Dis Detect Reg Ctr Egypt, Cairo, Egypt. [Samaha, Hamed] Minist Agr & Land Reclamat, Gen Org Vet Serv, Cairo, Egypt. [Samaha, Hamed] Univ Alexandria, Fac Vet Med, Alexandria, Egypt. [Safwat, Sameh; Mohareb, Emad] US Naval Med Res Unit 3, Viral & Zoonot Dis Res Program, Cairo, Egypt. [Dueger, Erica] US Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. RP Horton, KC (reprint author), PSC 452 Box 5000, FPO, AE 09835 USA. EM katherinehorton12@gmail.com FU Department of Defense Global Emerging Infections System (GEIS), work unit [847705.82000.25GB.E0018] FX The views expressed herein are those of the authors and do not necessarily reflect the official policy or position of the U. S. Department of the Navy, U. S. Department of Defense, U. S. Government, or Government of the Arab Republic of Egypt. This project was funded by the Department of Defense Global Emerging Infections System (GEIS), work unit 847705.82000.25GB.E0018, and was conducted in compliance with the Animal Welfare Act and in accordance with the principles set forth in the "Guide for the Care and Use of Laboratory Animals,'' Institute of Laboratory Animals Resources, National Research Council, National Academy Press, 1996. NR 39 TC 3 Z9 3 U1 6 U2 17 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD SEP PY 2014 VL 14 IS 9 BP 633 EP 639 DI 10.1089/vbz.2013.1525 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AP5VQ UT WOS:000342147200002 PM 25198525 ER PT J AU Geissler, AL Thorp, E Van Houten, C Lanciotti, RS Panella, N Cadwell, BL Murphy, T Staples, JE AF Geissler, Aimee L. Thorp, Emily Van Houten, Clayton Lanciotti, Robert S. Panella, Nicolas Cadwell, Betsy L. Murphy, Tracy Staples, J. Erin TI Infection with Colorado Tick Fever Virus Among Humans and Ticks in a National Park and Forest, Wyoming, 2010 SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Wyoming; Colorado tick fever; Dermacentor andersoni ID DERMACENTOR-ANDERSONI ACARI; ADULT LIFE STAGE; LYME-DISEASE; RISK; IXODIDAE; ECOLOGY AB Background: Colorado tick fever (CTF) is an underreported tick-borne viral disease occurring in the western United States. CTF illness includes fever, headache, and severe myalgia lasting for weeks. Wyoming has one of the highest CTF incidence rates with approximately 30% of infected persons reporting tick exposure in a Wyoming National Park or Forest before symptom onset. We assessed CTF virus infections among humans and Dermacentor andersoni ticks in Grand Teton National Park (GRTE) and Bridger-Teton National Forest (BTNF). Methods: In June of 2010, 526 eligible employees were approached to participate in a baseline and 3-month follow-up serosurvey and risk behavior survey. Seropositivity was defined as antibody titers against CTF virus >= 10, as measured by the plaque reduction neutralization test. Ticks were collected at 27 sites within GRTE/BTNF and tested by RT-PCR for the CTF virus. Results: A total of 126 (24%) employees participated in the baseline and follow-up study visits. Three (2%) employees were seropositive for CTF virus infection at baseline. During the study, 47 (37%) participants found unattached ticks on themselves, and 12 (10%) found attached ticks; however, no participants seroconverted against CTF virus. Walking through sagebrush (p = 0.04) and spending time at >= 7000 feet elevation (p < 0.01) were significantly associated with tick exposure. Ninety-nine percent (174/176) of ticks were D. andersoni, and all were found at >= 7000 feet elevation in sagebrush areas; 37 (21%) ticks tested positive for CTF virus and were found at 10 (38%) of 26 sites sampled. Conclusions: Although no GRTE or BTNF employees were infected with CTF virus during the study period, high rates of infected ticks were identified in areas with sagebrush at >= 7000 feet. CTF education and personal protection measures against tick exposure should be targeted to visitors and employees traveling to the high-risk environs identified in this study. C1 [Geissler, Aimee L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Geissler, Aimee L.; Thorp, Emily; Van Houten, Clayton; Murphy, Tracy] Wyoming Dept Hlth, Cheyenne, WY USA. [Lanciotti, Robert S.; Panella, Nicolas; Staples, J. Erin] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO USA. [Cadwell, Betsy L.] Ctr Dis Control & Prevent, Div Appl Sci, Atlanta, GA 30333 USA. RP Geissler, AL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, CDC Mailstop C-06,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ageissler@cdc.gov FU Centers for Disease Control and Prevention; Wyoming Department of Health FX This research was funded by the Centers for Disease Control and Prevention and the Wyoming Department of Health. The funders had a role in study design, data collection and analysis, decision to publish, and manuscript preparation. NR 26 TC 3 Z9 3 U1 1 U2 13 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD SEP PY 2014 VL 14 IS 9 BP 675 EP 680 DI 10.1089/vbz.2013.1568 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AP5VQ UT WOS:000342147200007 PM 25229706 ER PT J AU Lambert, AJ Huhtamo, E Di Fatta, T De Andrea, M Borella, A Vapalahti, O Kosoy, O Ravanini, P AF Lambert, Amy J. Huhtamo, Eili Di Fatta, Tiziana De Andrea, Marco Borella, Alberto Vapalahti, Olli Kosoy, Olga Ravanini, Paolo TI Serological Evidence of Batai Virus Infections, Bovines, Northern Italy, 2011 SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Batai virus; Bovines; Italy ID REASSORTMENT; MOSQUITOS; INDIA AB Batai virus (BATV) was identified in mosquitoes in the Caltignaga region of Novarra, northern Italy in 2009. Here, we report the identification of antibodies to BATV in serum samples that were taken from healthy bovines in that region in 2011. BATV has been associated with a mild febrile human illness and identified as the likely parental segment donor in a reassortment event that resulted in the generation of the virulent progeny, Ngari virus. The possible veterinary disease associations of BATV are unknown. The presence of antibodies to BATV in bovine populations confirms local transmission in northern Italy. Given its likely role as a segment donor, an understanding of the geographic and host distributions of BATV is of veterinary and human public health interest. C1 [Lambert, Amy J.; Kosoy, Olga] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Huhtamo, Eili] Univ Helsinki, Dept Virol, Haartman Inst, Fac Med, Helsinki, Finland. [Di Fatta, Tiziana; Ravanini, Paolo] AOU Maggiore Carita, Mol Virol Lab, Novara, Italy. [De Andrea, Marco] Univ Turin, Dept Publ Hlth & Pediat Sci, I-10124 Turin, Italy. [Borella, Alberto] ASL13, Anim Hlth Serv, Novara, Italy. [Vapalahti, Olli] Univ Helsinki, Dept Virol, Haartman Inst, Infect Biol Res Program,Fac Med, Helsinki, Finland. [Vapalahti, Olli] Helsinki Univ Cent Hosp Lab, Dept Virol & Immunol, Helsinki, Finland. [Vapalahti, Olli] Univ Helsinki, Fac Vet Med, Dept Vet Biosci, Helsinki, Finland. RP Lambert, AJ (reprint author), Ctr Dis Control & Prevent, Arbovirus Dis Branch, Div Vector Borne Dis, 3150 Rampart Rd,Foothills Res Campus, Ft Collins, CO 80521 USA. EM ahk7@cdc.gov OI De Andrea, Marco/0000-0002-3188-5783; Vapalahti, Olli/0000-0003-2270-6824 FU Emil Aaltonen Foundation FX We would like to thank the Emil Aaltonen Foundation for their financial support of Eili Huhtamo in this work. NR 11 TC 2 Z9 2 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD SEP PY 2014 VL 14 IS 9 BP 688 EP 689 DI 10.1089/vbz.2014.1596 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AP5VQ UT WOS:000342147200010 PM 25198523 ER PT J AU Seo, S Xie, H Karron, RA Thumar, B Englund, JA Leisenring, WM Stevens-Ayers, T Boeckh, M Campbell, AP AF Seo, S. Xie, H. Karron, R. A. Thumar, B. Englund, J. A. Leisenring, W. M. Stevens-Ayers, T. Boeckh, M. Campbell, A. P. TI Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes SO BONE MARROW TRANSPLANTATION LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RECONSTITUTION; TRACT DISEASE; RISK-FACTORS; NEUTRALIZING ANTIBODIES; YOUNG-CHILDREN; INFECTIONS; OUTBREAK; MORTALITY; OUTPATIENT AB Parainfluenza virus type 3 (PIV-3) can cause severe respiratory illness among hematopoietic cell transplantation (HCT) recipients. Factors associated with PIV-3-specific Ab level, and the association between PIV-3 Ab levels and clinical outcomes in HCT recipients who acquire PIV-3 infection, are unknown. We evaluated PIV-3-specific hemagglutination inhibition Ab levels and clinical outcomes among 172 patients with PIV-3 infection following HCT. In a multivariable linear regression model, high post-transplantation Ab levels were independently associated with higher pre-transplantation recipient titer (mean difference 0.38 (95% confidence interval (CI), 0.26, 0.50), P < 0.001). Significant associations between pre-HCT Ab titers in both patients and donors and occurrence of lower respiratory tract disease (LRD) after HCT were not observed. In conclusion, low pre-transplantation titers are associated with low Ab levels after HCT. The relationship between PIV-3 Ab levels and outcomes remain uncertain. Further study is needed to prospectively evaluate the dynamics of PIV-3-specific Ab responses and the relative contribution of PIV-3-specific Ab to protection from infection acquisition and progression to LRD. C1 [Seo, S.; Englund, J. A.; Stevens-Ayers, T.; Boeckh, M.; Campbell, A. P.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA. [Xie, H.; Leisenring, W. M.; Boeckh, M.; Campbell, A. P.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Karron, R. A.; Thumar, B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Immunizat Res, Baltimore, MD USA. [Englund, J. A.; Campbell, A. P.] Seattle Childrens Hosp, Seattle, WA USA. [Englund, J. A.; Campbell, A. P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Boeckh, M.] Univ Washington, Dept Med, Seattle, WA USA. RP Campbell, AP (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A32, Atlanta, GA 30329 USA. EM apeck@fhcrc.org FU NIH [CA18029, CA15704, HL081595, HL93294, K23HL091059, L40AI071572]; Joel Meyers Memorial Fund; Seattle Children's Center for Clinical and Translational Research; CTSA grant [ULI RR025014] FX We thank Chris Davis, George Counts and Zachary Stednick for data management, Tera Matson, Elsa Garnace and Jessica Yi for laboratory assistance, and Ikuyo Imayama for statistical advice. This work was partially supported by NIH grants CA18029, CA15704, HL081595, HL93294, K23HL091059 and L40AI071572. SS is a recipient of a fellowship from the Joel Meyers Memorial Fund. APC also received support from the Seattle Children's Center for Clinical and Translational Research and CTSA grant ULI RR025014. NR 32 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD SEP PY 2014 VL 49 IS 9 BP 1205 EP 1211 DI 10.1038/bmt.2014.124 PG 7 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA AP0WN UT WOS:000341786700012 PM 24978141 ER PT J AU Mahajan, R Kuehnert, MJ AF Mahajan, Reena Kuehnert, Matthew J. TI How can we improve tracking of transplanted tissue in the United States? SO CELL AND TISSUE BANKING LA English DT Article DE Tissue; Transplantation; Tracking; Safety AB Currently an estimated two million tissues are distributed for transplantation annually. With increasing use of recovered tissue, clusters of transplant-transmitted infection have shown the difficulty of tracking tissues from an infected donor to the recipient. The challenge of tissue tracking to multiple transplant recipients was illustrated in a recent investigation of transmission of hepatitis C virus infection from a donor of organs and tissues. When a tissue bank issued a recall of the donated tissue, the Centers for Disease Control and Prevention was notified to assist public health authorities; the mean time to locate and notify the physicians who had transplanted the tissue was 13 days, while the mean time to notify, inform, and test the patients was 29 days. Lack of common coding and nomenclature was one of the key challenges in tracking tissue to the recipient. Some changes that could improve timeliness in the event of a recall includes: (1) standardized tissue nomenclature and coding through unique donor identifiers; (2) tissue traceability requirements using systems similar to that used for blood products; (3) a surveillance system for adverse events that provides feedback at the provider level. C1 [Mahajan, Reena; Kuehnert, Matthew J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Kuehnert, Matthew J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA 30333 USA. RP Kuehnert, MJ (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Dis, 1600 Clifton Rd,Mailstop A-07, Atlanta, GA 30333 USA. EM rmahajan1120@yahoo.com; mkuehnert@cdc.gov NR 7 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1389-9333 EI 1573-6814 J9 CELL TISSUE BANK JI Cell Tissue Banking PD SEP PY 2014 VL 15 IS 3 BP 287 EP 289 DI 10.1007/s10561-013-9408-7 PG 3 WC Cell Biology; Engineering, Biomedical SC Cell Biology; Engineering GA AO5WM UT WOS:000341417100001 PM 24281916 ER PT J AU Keck, JW Bulkow, LR Raczniak, GA Negus, SE Zanis, CL Bruce, MG Spradling, PR Teshale, EH McMahon, BJ AF Keck, James W. Bulkow, Lisa R. Raczniak, Gregory A. Negus, Susan E. Zanis, Carolyn L. Bruce, Michael G. Spradling, Philip R. Teshale, Eyasu H. McMahon, Brian J. TI Hepatitis B Virus Antibody Levels 7 to 9 Years after Booster Vaccination in Alaska Native Persons SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID PROTECTION; CHILDREN; MEMORY; IMPACT AB Hepatitis B antibody persistence was assessed in individuals who had previously received a vaccine booster. We measured hepatitis B surface antigen antibody (anti-HBs) levels 7 to 9 years post-hepatitis B booster in individuals with primary vaccination at birth. While 95 (91.3%) of 104 participants had detectable anti-HBs (minimum, 0.1 mIU/ml; maximum, 1,029 mIU/ml), only 43 (41%) had protective levels of >= 10 mIU/ml. Pre- and week 4 postbooster anti-HBs levels were significant predictors of hepatitis B immunity at follow-up (P < 0.001). Almost all participants had detectable anti-HBs 7 to 9 years after the hepatitis B vaccine booster, but less than half had levels >= 10 mIU/ml. C1 [Keck, James W.; Raczniak, Gregory A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Keck, James W.; Bulkow, Lisa R.; Raczniak, Gregory A.; Zanis, Carolyn L.; Bruce, Michael G.; McMahon, Brian J.] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. [Negus, Susan E.; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Spradling, Philip R.; Teshale, Eyasu H.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Keck, JW (reprint author), Tufts Univ, Sch Med, Boston, MA 02111 USA. EM jameswkeck@gmail.com; bdm9@cdc.gov NR 13 TC 6 Z9 6 U1 4 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD SEP PY 2014 VL 21 IS 9 BP 1339 EP 1342 DI 10.1128/CVI.00263-14 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AO8SO UT WOS:000341624800020 PM 25056363 ER PT J AU Caceres, DH Scheel, CM Tobon, AM Cleveland, AA Restrepo, A Brandt, ME Chiller, T Gomez, BL AF Caceres, Diego H. Scheel, Christina M. Tobon, Angela M. Cleveland, Angela Ahlquist Restrepo, Angela Brandt, Mary E. Chiller, Tom Gomez, Beatriz L. TI Validation of an Enzyme-Linked Immunosorbent Assay That Detects Histoplasma capsulatum Antigenuria in Colombian Patients with AIDS for Diagnosis and Follow-Up during Therapy SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID HIV-INFECTED PATIENTS; FUNGAL-INFECTIONS; AMERICA; IMMUNOASSAY; PROGNOSIS; MYCOSES AB We validated an antigen capture enzyme-linked immunosorbent assay ( ELISA) in Colombian persons with AIDS and proven histoplasmosis and evaluated the correlation between antigenuria and clinical improvement during follow-up. The sensitivity of the Histoplasma capsulatum ELISA was 86%, and the overall specificity was 94%. The antigen test successfully monitored the response to therapy. C1 [Caceres, Diego H.; Tobon, Angela M.; Restrepo, Angela; Gomez, Beatriz L.] CIB, Med & Expt Mycol Grp, Medellin, Colombia. [Scheel, Christina M.; Cleveland, Angela Ahlquist; Brandt, Mary E.; Chiller, Tom] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Tobon, Angela M.] Hosp La Maria, Medellin, Colombia. [Gomez, Beatriz L.] Univ Rosario, Sch Med & Hlth Sci, Bogota, Colombia. RP Gomez, BL (reprint author), CIB, Med & Expt Mycol Grp, Medellin, Colombia. EM beatrizlgomez@hotmail.com FU Global Disease Detection Program, CDC (Atlanta, GA, USA); Corporacion para Investigaciones Biologicas (CIB), Medellin, Colombia; Fondo de Investigaciones de la Universidad del Rosario (FIUR), Bogota, Colombia; Colciencias, Colombia FX This work was supported in part by the Global Disease Detection Program, CDC (Atlanta, GA, USA), Colciencias, Colombia, via the program for young investigators (Scholarships Virginia Gutierrez de Pineda), the Corporacion para Investigaciones Biologicas (CIB), Medellin, Colombia, and the Fondo de Investigaciones de la Universidad del Rosario (FIUR), Bogota, Colombia. NR 17 TC 4 Z9 5 U1 2 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD SEP PY 2014 VL 21 IS 9 BP 1364 EP 1368 DI 10.1128/CVI.00101-14 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AO8SO UT WOS:000341624800025 PM 25008902 ER PT J AU Gavin, L Moskosky, S AF Gavin, Lorrie Moskosky, Susan TI Developing new federal guidelines on family planning for the United States SO CONTRACEPTION LA English DT Editorial Material ID INTERPREGNANCY INTERVAL; PRECONCEPTION CARE; CLINICAL CONTENT; BIRTH; QUALITY; HEALTH C1 [Gavin, Lorrie] US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. [Moskosky, Susan] US Off Populat Affairs, Rockville, MD USA. RP Gavin, L (reprint author), US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. EM lcg6@cdc.gov NR 21 TC 2 Z9 2 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD SEP PY 2014 VL 90 IS 3 BP 207 EP 210 DI 10.1016/j.contraception.2014.06.034 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AP0GF UT WOS:000341738600003 PM 25173781 ER PT J AU Tortolero, SR Peskin, MF Baumler, ER Cuccaro, PM Elliott, MN Davies, SL Lewis, TH Banspach, SW Kanouse, DE Schuster, MA AF Tortolero, Susan R. Peskin, Melissa F. Baumler, Elizabeth R. Cuccaro, Paula M. Elliott, Marc N. Davies, Susan L. Lewis, Terri H. Banspach, Stephen W. Kanouse, David E. Schuster, Mark A. TI Daily Violent Video Game Playing and Depression in Preadolescent Youth SO CYBERPSYCHOLOGY BEHAVIOR AND SOCIAL NETWORKING LA English DT Article ID AGGRESSIVE-BEHAVIOR; COMMUNITY VIOLENCE; PROSOCIAL BEHAVIOR; HOSTILE FEELINGS; MEDIA VIOLENCE; HEALTH; ADOLESCENTS; EXPOSURE; CHILDREN; METAANALYSIS AB Most studies on the impact of playing violent video games on mental health have focused on aggression. Relatively few studies have examined the relationship between playing violent video games and depression, especially among preadolescent youth. In this study, we investigated whether daily violent video game playing over the past year is associated with a greater number of depressive symptoms among preadolescent youth, after controlling for several well-known correlates of depression among youth. We analyzed cross-sectional data collected from 5,147 fifth-grade students and their primary caregivers who participated in Wave I (2004-2006) of Healthy Passages, a community-based longitudinal study conducted in three U.S. cities. Linear regression was conducted to determine the association between violent video game exposure and number of depressive symptoms, while controlling for gender, race/ethnicity, peer victimization, witnessing violence, being threatened with violence, aggression, family structure, and household income level. We found that students who reported playing high-violence video games for >= 2 hours per day had significantly more depressive symptoms than those who reported playing low-violence video games for <2 hours per day (p < 0.001). The magnitude of this association was small (Cohen's d = 0.16), but this association was consistent across all racial/ethnic subgroups and among boys (Cohen's d values ranged from 0.12 to 0.25). Our findings indicate that there is an association between daily exposure to violent video games and number of depressive symptoms among preadolescent youth. More research is needed to examine this association and, if confirmed, to investigate its causality, persistence over time, underlying mechanisms, and clinical implications. C1 [Tortolero, Susan R.; Peskin, Melissa F.; Baumler, Elizabeth R.; Cuccaro, Paula M.] Univ Texas Hlth Sci Ctr Houston UTHlth, Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, Houston, TX 77030 USA. [Elliott, Marc N.; Kanouse, David E.; Schuster, Mark A.] RAND Corp, Santa Monica, CA USA. [Davies, Susan L.; Lewis, Terri H.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL 35294 USA. [Banspach, Stephen W.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Schuster, Mark A.] Boston Childrens Hosp, Div Gen Pediat, Dept Med, Boston, MA USA. [Schuster, Mark A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. RP Tortolero, SR (reprint author), Univ Texas Hlth Sci Ctr Houston UTHlth, Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, 7000 Fannin,Suite 2080, Houston, TX 77030 USA. EM susan.tortolero@uth.tmc.edu OI Cuccaro, Paula/0000-0002-9551-4789 FU NCCDPHP CDC HHS [U19DP002663, U19DP002664, U19DP002665, U48DP000046, U48DP000056, U48DP000057]; PHS HHS [CCU409679, CCU609653, CCU915773] NR 43 TC 4 Z9 4 U1 4 U2 59 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2152-2715 EI 2152-2723 J9 CYBERPSYCH BEH SOC N JI Cyberpsychology Behav. Soc. Netw. PD SEP PY 2014 VL 17 IS 9 BP 609 EP 615 DI 10.1089/cyber.2014.0091 PG 7 WC Psychology, Social SC Psychology GA AP1KC UT WOS:000341827000007 PM 25007237 ER PT J AU Pires, SM Vieira, AR Hald, T Cole, D AF Pires, Sara M. Vieira, Antonio R. Hald, Tine Cole, Dana TI Source Attribution of Human Salmonellosis: An Overview of Methods and Estimates SO FOODBORNE PATHOGENS AND DISEASE LA English DT Review ID EXPERT ELICITATION SURVEY; UNITED-STATES; FOODBORNE ILLNESS; OUTBREAK DATA; FOOD-SOURCES; NEW-ZEALAND; SURVEILLANCE DATA; DISEASE; BURDEN; CAMPYLOBACTERIOSIS AB Reducing the burden of foodborne salmonellosis is challenging. It requires identification of the most important food sources causing disease and prioritization of effective intervention strategies. For this purpose, a variety of methods to estimate the relative contribution of different sources of Salmonella infections have been applied worldwide. Each has strengths and limitations, and the usefulness of each depends on the public health questions being addressed. In this study, we reviewed the source attribution methods and outcomes of several studies developed in different countries and settings, comparing approaches and regional differences in attribution estimates. Reviewed results suggest that illnesses and outbreaks are most commonly attributed to exposure to contaminated food, and that eggs, broiler chickens, and pigs are among the top sources. Although most source attribution studies do not attribute salmonellosis to produce, outbreak data in several countries suggest that exposure to raw vegetables is also an important source. International travel was also a consistently important exposure in several studies. Still, the relative contribution of specific sources to human salmonellosis varied substantially between studies. Although differences C1 [Pires, Sara M.; Hald, Tine] Tech Univ Denmark, Natl Food Inst, DK-2860 Soborg, Denmark. [Vieira, Antonio R.; Cole, Dana] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA USA. RP Pires, SM (reprint author), Tech Univ Denmark, Natl Food Inst, Morkhoj Bygade 19, DK-2860 Soborg, Denmark. EM smpi@food.dtu.dk RI Hald, Tine/B-5477-2016 NR 42 TC 20 Z9 21 U1 4 U2 30 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 EI 1556-7125 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD SEP PY 2014 VL 11 IS 9 BP 667 EP 676 DI 10.1089/fpd.2014.1744 PG 10 WC Food Science & Technology SC Food Science & Technology GA AP0RG UT WOS:000341770000001 PM 24885917 ER PT J AU Bruce, MG Morris, J Bruden, D Reasonover, A Hurlburt, D McMahon, B AF Bruce, M. G. Morris, J. Bruden, D. Reasonover, A. Hurlburt, D. McMahon, B. TI ANTIMICROBIAL RESISTANCE OF HELICOBACTER PYLORI ISOLATES IN ALASKA NATIVE PERSONS FROM 2000 TO 2013: RESULTS FROM THE ALASKA SENTINEL SURVEILLANCE PROJECT SO HELICOBACTER LA English DT Meeting Abstract CT European-Helicobacter-Study-Group 27th International Workshop on Helicobacter and Microbiota in Chronic Digestive Inflammation and Gastric Cancer CY SEP 11-13, 2014 CL Rome, ITALY SP European Helicobacter Study Grp C1 [Bruce, M. G.; Morris, J.; Bruden, D.; Reasonover, A.; Hurlburt, D.] Ctr Dis Control & Prevent, Anchorage, AK USA. [McMahon, B.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1083-4389 EI 1523-5378 J9 HELICOBACTER JI Helicobacter PD SEP PY 2014 VL 19 SU 1 SI SI MA W3.1 BP 81 EP 81 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA AO8SG UT WOS:000341623900025 ER PT J AU Taylor, MM Ebrahim, S Abiola, N Kinkodi, DK Mpingulu, M Kabuayi, JP Ekofo, F Newman, DR Peterman, TA Kamb, ML Sidibe, K AF Taylor, Melanie M. Ebrahim, Shahul Abiola, Nadine Kinkodi, Didine Kaba Mpingulu, Minlangu Kabuayi, Jean Pierre Ekofo, Felly Newman, Daniel R. Peterman, Thomas A. Kamb, Mary L. Sidibe, Kassim TI Correlates of syphilis seropositivity and risk for syphilis-associated adverse pregnancy outcomes among women attending antenatal care clinics in the Democratic Republic of Congo SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE Syphilis; congenital syphilis; antenatal care; Democratic Republic of Congo; STD; STI; screening; prevention; seroprevalence ID SEXUALLY-TRANSMITTED INFECTIONS; HIV; PREVALENCE; MORTALITY; PROGRAMS; KINSHASA AB Screening and treatment for syphilis among pregnant women is the primary means of prevention of congenital syphilis. Sentinel surveillance for syphilis can inform these prevention efforts. We reviewed antenatal syphilis screening results to assess trends and to identify correlates of seropositivity among women attending antenatal care clinics in the Democratic Republic of Congo during 2011. Syphilis seropositivity among the 17,669 women attending the antenatal care clinics during 2011 was 4.2% (range 0.4%-16.9%). Syphilis seropositivity was significantly higher among women attending rural clinics (5.0%) as compared to urban clinics (3.0%) and those tested in antenatal care clinics in the provinces of Equateur (7.6%) and Orientale (7.7%) as compared to other provinces (p<0.001). Based on the antenatal care syphilis seroprevalence and national pregnancy estimates, we estimate that approximately 128,591 pregnant women countrywide would have tested seropositive for syphilis during 2011. Over 85,000 adverse pregnancy outcomes would have resulted from these maternal infections, assuming prenatal syphilis diagnosis and treatment were not available. The prevalence of syphilis was highest in rural areas, but exceeded 1% in every area, indicating a need to assure screening and treatment throughout Democratic Republic of Congo. These sentinel surveillance estimates can be used to guide national congenital syphilis prevention efforts. C1 [Taylor, Melanie M.; Newman, Daniel R.; Peterman, Thomas A.; Kamb, Mary L.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Ebrahim, Shahul; Abiola, Nadine; Mpingulu, Minlangu; Sidibe, Kassim] Ctr Dis Control & Prevent, Global AIDS Program, Kinshasa, Zaire. [Kinkodi, Didine Kaba] Kinshasa Sch Publ Hlth, Kinshasa, Zaire. [Kabuayi, Jean Pierre; Ekofo, Felly] Minist Sante Publ, Program Natl Lutte VIH SIDA, Kinshasa, Zaire. RP Taylor, MM (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. EM MDT7@CDC.GOV NR 29 TC 0 Z9 0 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD SEP PY 2014 VL 25 IS 10 BP 716 EP 725 DI 10.1177/0956462413518194 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AP1FP UT WOS:000341813000003 PM 24452733 ER PT J AU Pleil, JD Stiegel, MA Fent, KW AF Pleil, Joachim D. Stiegel, Matthew A. Fent, Kenneth W. TI Exploratory breath analyses for assessing toxic dermal exposures of firefighters during suppression of structural burns SO JOURNAL OF BREATH RESEARCH LA English DT Article DE adverse outcome pathway; exposome; firefighter; JP-8 jet fuel; PAHs; benzene; heatmap ID VOLATILE ORGANIC-COMPOUNDS; EXHALED BREATH; BIOMARKERS; SCIENCE; EXHAUST; RISK AB Firefighters wear fireproof clothing and self-contained breathing apparatus (SCBA) during rescue and fire suppression activities to protect against acute effects from heat and toxic chemicals. Fire services are also concerned about long-term health outcomes from chemical exposures over a working lifetime, in particular about low-level exposures that might serve as initiating events for adverse outcome pathways (AOP) leading to cancer. As part of a larger US National Institute for Occupational Safety and Health (NIOSH) study of dermal exposure protection from safety gear used by the City of Chicago firefighters, we collected pre- and post-fire fighting breath samples and analyzed for single-ring and polycyclic aromatic hydrocarbons as bioindicators of occupational exposure to gas-phase toxicants. Under the assumption that SCBA protects completely against inhalation exposures, any changes in the exhaled profile of combustion products were attributed to dermal exposures from gas and particle penetration through the protective clothing. Two separate rounds of firefighting activity were performed each with 15 firefighters per round. Exhaled breath samples were collected onto adsorbent tubes and analyzed with gas-chromatography-mass spectrometry (GC-MS) with a targeted approach using selective ion monitoring. We found that single ring aromatics and some PAHs were statistically elevated in post-firefighting samples of some individuals, suggesting that fire protective gear may allow for dermal exposures to airborne contaminants. However, in comparison to a previous occupational study of Air Force maintenance personnel where similar compounds were measured, these exposures are much lower suggesting that firefighters' gear is very effective. This study suggests that exhaled breath sampling and analysis for specific targeted compounds is a suitable method for assessing systemic dermal exposure in a simple and non-invasive manner. C1 [Pleil, Joachim D.] US EPA, Human Exposure & Atmospher Sci Div, NERL ORD, Res Triangle Pk, NC 27711 USA. [Stiegel, Matthew A.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Fent, Kenneth W.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. RP Pleil, JD (reprint author), US EPA, Human Exposure & Atmospher Sci Div, NERL ORD, Res Triangle Pk, NC 27711 USA. EM pleil.joachim@epa.gov FU NIOSH FX The authors are thankful for the volunteer subjects from the Chicago Fire Department. This research has been subjected to EPA review and approved for publication. This study was internally funded by NIOSH and approved by the NIOSH Human Subjects Review Board. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of NIOSH. NR 41 TC 7 Z9 7 U1 3 U2 19 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 1752-7155 EI 1752-7163 J9 J BREATH RES JI J. Breath Res. PD SEP PY 2014 VL 8 IS 3 SI SI AR 037107 DI 10.1088/1752-7155/8/3/037107 PG 9 WC Biochemical Research Methods; Respiratory System SC Biochemistry & Molecular Biology; Respiratory System GA AP0SO UT WOS:000341774500012 PM 25190461 ER PT J AU Nguyen, AV Cohen, NJ Gao, HJ Fishbein, DB Keir, J Ocana, JM Senini, L Flores, A Waterman, SH AF Nguyen, An V. Cohen, Nicole J. Gao, Hongjiang Fishbein, Daniel B. Keir, Jane Ocana, J. Miguel Senini, Lori Flores, Aleta Waterman, Stephen H. TI Knowledge, Attitudes, and Practices among Border Crossers during Temporary Enforcement of a Formal Entry Requirement for Mexican-Style Soft Cheeses, 2009 SO JOURNAL OF FOOD PROTECTION LA English DT Article ID SURVEILLANCE NETWORK FOODNET; LISTERIA-MONOCYTOGENES; UNITED-STATES; MYCOBACTERIUM-BOVIS; HUMAN BRUCELLOSIS; QUESO FRESCO; SALMONELLA; OUTBREAKS; CONSUMPTION; CALIFORNIA AB Mexican-style soft cheese known as queso fresco (QF), which is often unpasteurized, has been implicated in outbreaks of foodborne illness in the United States. The U.S. Food and Drug Administration (FDA) exercises discretion in enforcement of noncommercial importation of cheese. To test control measures aimed at decreasing unlawful QF importation, in 2009 the FDA temporarily enforced a requirement for formal commercial entry for all cheeses over 5 lb (2.3 kg) at the San Diego-Tijuana border. Enforcement was combined with educational outreach. Border crossers importing cheese and those not importing cheese were surveyed at the beginning and end of the temporary enforcement period. Data collected included participant demographic information, knowledge of QF-associated health risks, and attitudes and practices regarding QF consumption and importation. We surveyed 306 importers and 381 nonimporters. Compared with nonimporters, importers had a lower level of knowledge regarding QF-associated health risks (P < 0.0001). Border crossers carrying cheese were more likely to have less education, be U.S. or dual residents, consume QF more frequently, and cross the border less often. Importation and consumption of unpasteurized QF remained prevalent among border crossers during the temporary enforcement period, and the level of knowledge regarding QF-associated risks remained low among these crossers. More vigorous, sustained messaging targeted at high-risk groups is needed to change behaviors. Definition and consistent enforcement of limits will likely be needed to reduce QF importation and the risk of QF-associated diseases along the U.S.-Mexico border; however, public health benefits will need to be balanced against the cost of enforcement. C1 [Nguyen, An V.; Cohen, Nicole J.; Gao, Hongjiang; Fishbein, Daniel B.; Keir, Jane; Ocana, J. Miguel; Waterman, Stephen H.] US Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Nguyen, An V.] Council State & Terr Epidemiologists, Atlanta, GA 30341 USA. [Keir, Jane] SRA Int, Atlanta, GA 30329 USA. [Senini, Lori] Hlth & Human Serv Agcy, San Diego Cty Off Publ Hlth Serv, San Diego, CA 92101 USA. [Flores, Aleta] US FDA, Alameda, CA 94502 USA. RP Cohen, NJ (reprint author), US Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. EM ncohen@cdc.gov FU Intramural CDC HHS [CC999999] NR 32 TC 1 Z9 1 U1 2 U2 15 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD SEP PY 2014 VL 77 IS 9 BP 1571 EP 1578 DI 10.4315/0362-028X.JFP-13-395 PG 8 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA AP1UE UT WOS:000341856300015 PM 25198849 ER PT J AU Graham, CB Woods, ME Vetter, SM Petersen, JM Montenieri, JA Holmes, JL Maes, SE Bearden, SW Gage, KL Eisen, RJ AF Graham, Christine B. Woods, Michael E. Vetter, Sara M. Petersen, Jeannine M. Montenieri, John A. Holmes, Jennifer L. Maes, Sarah E. Bearden, Scott W. Gage, Kenneth L. Eisen, Rebecca J. TI Evaluation of the Effect of Host Immune Status on Short-Term Yersinia pestis Infection in Fleas With Implications for the Enzootic Host Model for Maintenance of Y. pestis During Interepizootic Periods SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Yersinia pestis; plague; flea; enzootic ID EARLY-PHASE TRANSMISSION; PASTEURELLA-PESTIS; UNITED-STATES; PLAGUE; VECTOR; PIGMENTATION; STRAINS; VACCINE; SIPHONAPTERA; EPIZOOTICS AB Plague, a primarily flea-borne disease caused by Yersinia pestis, is characterized by rapidly spreading epizootics separated by periods of quiescence. Little is known about how and where Y. pestis persists between epizootics. It is commonly proposed, however, that Y. pestis is maintained during interepizootic periods in enzootic cycles involving flea vectors and relatively resistant host populations. According to this model, while susceptible individuals serve as infectious sources for feeding fleas and subsequently die of infection, resistant hosts survive infection, develop antibodies to the plague bacterium, and continue to provide bloodmeals to infected fleas. For Y. pestis to persist under this scenario, fleas must remain infected after feeding on hosts carrying antibodies to Y. pestis. Studies of other vector-borne pathogens suggest that host immunity may negatively impact pathogen survival in the vector. Here, we report infection rates and bacterial loads for fleas (both Xenopsylla cheopis (Rothschild) and Oropsylla montana (Baker)) that consumed an infectious bloodmeal and subsequently fed on an immunized or age-matched naive mouse. We demonstrate that neither the proportion of infected fleas nor the bacterial loads in infected fleas were significantly lower within 3 d of feeding on immunized versus naive mice. Our findings thus provide support for one assumption underlying the enzootic host model of interepizootic maintenance of Y. pestis. C1 [Graham, Christine B.; Woods, Michael E.; Vetter, Sara M.; Petersen, Jeannine M.; Montenieri, John A.; Holmes, Jennifer L.; Maes, Sarah E.; Bearden, Scott W.; Gage, Kenneth L.; Eisen, Rebecca J.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect, Ft Collins, CO 80521 USA. RP Graham, CB (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM hyb4@cdc.gov FU Centers for Disease Control and Prevention FX We thank Christopher Sexton, John Young, and Ryan Pappert for technical assistance, and Rebecca Clark for helpful discussion with regard to statistical analyses. This research was supported in part by an appointment to the Emerging Infectious Diseases Fellowship Program administered by the Association of Public Health Laboratories and funded by the Centers for Disease Control and Prevention. NR 54 TC 1 Z9 1 U1 4 U2 22 PU ENTOMOLOGICAL SOC AMER PI ANNAPOLIS PA 3 PARK PLACE, STE 307, ANNAPOLIS, MD 21401-3722 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD SEP PY 2014 VL 51 IS 5 BP 1079 EP 1086 DI 10.1603/ME14080 PG 8 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA AO8ZL UT WOS:000341644600026 PM 25276941 ER PT J AU Salazar, LF Vivolo-Kantor, A Hardin, J Berkowitz, A AF Salazar, Laura F. Vivolo-Kantor, Alana Hardin, James Berkowitz, Alan TI A Web-Based Sexual Violence Bystander Intervention for Male College Students: Randomized Controlled Trial SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE Internet; sex offenses; rape; universities; students; public health ID HEALTH BEHAVIOR-CHANGE; REDUCING RISK-FACTORS; ASSAULT PREVENTION; SOCIAL NORMS; PSYCHOEDUCATIONAL PROGRAM; EATING-DISORDERS; PROBLEM DRINKERS; SELF-HELP; INTERNET; WOMEN AB Background: Bystander intervention approaches offer promise for reducing rates of sexual violence on college campuses. Most interventions are in-person small-group formats, which limit their reach and reduce their overall public health impact. Objective: This study evaluated the efficacy of RealConsent, a Web-based bystander approach to sexual violence prevention, in enhancing prosocial intervening behaviors and preventing sexual violence perpetration. Methods: A random probability sample of 743 male undergraduate students (aged 18 to 24 years) attending a large, urban university located in the southeastern United States was recruited online and randomized to either RealConsent (n=376) or a Web-based general health promotion program (n=367). Participants were surveyed online at baseline, postintervention, and 6-months postintervention. RealConsent was delivered via a password-protected Web portal that contained six 30-minute media-based and interactive modules covering knowledge of informed consent, communication skills regarding sex, the role of alcohol and male socialization in sexual violence, empathy for rape victims, and bystander education. Primary outcomes were self-reported prosocial intervening behaviors and sexual violence perpetration. Secondary outcomes were theoretical mediators (eg, knowledge, attitudes). Results: At 6-month follow-up RealConsent participants intervened more often (P=.04) and engaged in less sexual violence perpetration (P=.04) compared to controls. In addition, RealConsent participants reported greater legal knowledge of sexual assault (P<.001), greater knowledge of effective consent (P<.001), less rape myths (P<.001), greater empathy for rape victims (P<.001), less negative date rape attitudes (P<.001), less hostility toward women (P=.01), greater intentions to intervene (P=.04), less hyper-gender ideology (P<.001), less positive outcome expectancies for nonconsensual sex (P=.03), more positive outcome expectancies for intervening (P<.001), and less comfort with other men's inappropriate behaviors (P<.001). Conclusions: Our results support the efficacy of RealConsent. Due to its Web-based format, RealConsent has potential for broad-based dissemination thereby increasing its overall public health impact on sexual violence. C1 [Salazar, Laura F.] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30302 USA. [Vivolo-Kantor, Alana] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. [Hardin, James] Univ S Carolina, Dept Epidemiol & Biostat, Columbia, SC 29208 USA. RP Salazar, LF (reprint author), Georgia State Univ, Sch Publ Hlth, POB 3984, Atlanta, GA 30302 USA. EM lsalazar1@gsu.edu RI Hardin, James/Q-7617-2016 OI Hardin, James/0000-0003-0506-5500 FU National Center for Injury Prevention and Control, Centers for Disease Control and Prevention [R49 CE000892] FX This study was funded by the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Grant #R49 CE000892. The authors also wish to acknowledge the significant contributions and talents of Jody Kaufman, Nichole Daluga-Guenther, and Kira McGroarty Koon to intervention development, survey development, and preliminary testing of the program. NR 72 TC 4 Z9 4 U1 10 U2 53 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD SEP PY 2014 VL 16 IS 9 AR e203 DI 10.2196/jmir.3426 PG 16 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA AO6BL UT WOS:000341433000001 PM 25198417 ER PT J AU Connor, TH Lawson, CC Polovich, M McDiarmid, MA AF Connor, Thomas H. Lawson, Christina C. Polovich, Martha McDiarmid, Melissa A. TI Reproductive Health Risks Associated With Occupational Exposures to Antineoplastic Drugs in Health Care Settings A Review of the Evidence SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID DIETHYLSTILBESTROL IN-UTERO; SURFACE CONTAMINATION; HOSPITAL PERSONNEL; TRANSFER DEVICE; ECTOPIC PREGNANCY; CYTOSTATIC DRUGS; CANCER-TREATMENT; TARGETED AGENTS; UNITED-STATES; PART I AB Objectives: Antineoplastic drugs are known reproductive and developmental toxicants. Our objective was to review the existing literature of reproductive health risks to workers who handle antineoplastic drugs. Methods: A structured literature review of 18 peer-reviewed, English language publications of occupational exposure and reproductive outcomes was performed. Results: Although effect sizes varied with study size and population, occupational exposure to antineoplastic drugs seems to raise the risk of both congenital malformations and miscarriage. Studies of infertility and time to pregnancy also suggested an increased risk for subfertility. Conclusions: Antineoplastic drugs are highly toxic in patients receiving treatment, and adverse reproductive effects have been well documented in these patients. Health care workers with long-term, low-level occupational exposure to these drugs also seem to have an increased risk of adverse reproductive outcomes. Additional precautions to prevent exposure should be considered. C1 [Connor, Thomas H.] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Lawson, Christina C.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Polovich, Martha] Georgia State Univ, Byrdine F Lewis Sch Nursing & Hlth Profess, Atlanta, GA 30303 USA. [McDiarmid, Melissa A.] Univ Maryland, Sch Med, Div Occupat & Environm Med, Baltimore, MD 21201 USA. RP Connor, TH (reprint author), NIOSH, Div Appl Res & Technol, MS C-23,1090 Tusculum Ave, Cincinnati, OH 45226 USA. EM tconnor@cdc.gov FU Intramural CDC HHS [CC999999] NR 96 TC 8 Z9 8 U1 2 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2014 VL 56 IS 9 BP 901 EP 910 DI 10.1097/JOM.0000000000000249 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1JB UT WOS:000341824000008 PM 25153300 ER PT J AU Wirth, MD Burch, J Shivappa, N Violanti, JM Burchfiel, CM Fekedulegn, D Andrew, ME Hartley, TA Miller, DB Mnatsakanova, A Charles, LE Steck, SE Hurley, TG Vena, JE Hebert, JR AF Wirth, Michael D. Burch, James Shivappa, Nitin Violanti, John M. Burchfiel, Cecil M. Fekedulegn, Desta Andrew, Michael E. Hartley, Tara A. Miller, Diane B. Mnatsakanova, Anna Charles, Luenda E. Steck, Susan E. Hurley, Thomas G. Vena, John E. Hebert, James R. TI Association of a Dietary Inflammatory Index With Inflammatory Indices and Metabolic Syndrome Among Police Officers SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CARDIOVASCULAR-DISEASE; SHIFT WORK; MARKERS; STATEMENT; STRESS; HEALTH; SCORES; ADULTS AB Objectives: To determine whether the dietary inflammatory index (DII) is associated with inflammatory or metabolic biomarkers and metabolic syndrome (MetSyn) among police officers. Methods: Cross-sectional data from the Buffalo Cardio-Metabolic Occupational Police Stress study were derived from saliva and fasting blood samples, anthropometric measurements, long-term shiftwork histories, and demographic, stress/depression, and food frequency questionnaires (FFQs). Metabolic syndrome was defined using standard criteria. Results: Officers in DII quartiles 2 to 4 were more likely to exceed a threshold of 3.0 mg/L for C-reactive protein (odds ratio [OR] = 1.88; 95% confidence interval [95% CI] = 1.02 to 3.45; OR = 2.17; 95% CI = 1.19 to 3.95; OR= 1.57; 95% CI= 0.85 to 2.88, respectively) compared with quartile 1. The glucose intolerance component of MetSyn was more prevalent among officers in DII quartile 4 than among those in quartile 1 (OR = 2.03; 95% CI = 1.08 to 3.82). Conclusions: A pro-inflammatory diet was associated with elevated CRP and with the glucose intolerance component of MetSyn. C1 [Wirth, Michael D.; Burch, James; Shivappa, Nitin; Steck, Susan E.; Hurley, Thomas G.; Hebert, James R.] Univ S Carolina, Canc Prevent & Control Program, Columbia, SC 29208 USA. [Burch, James; Shivappa, Nitin; Steck, Susan E.; Hebert, James R.] Univ S Carolina, Dept Epidemiol & Biostat, Columbia, SC 29208 USA. [Burch, James] WJB Dorn VA Med Ctr, Columbia, SC USA. [Violanti, John M.] SUNY Buffalo, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA. [Burchfiel, Cecil M.; Fekedulegn, Desta; Andrew, Michael E.; Hartley, Tara A.; Mnatsakanova, Anna; Charles, Luenda E.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Spokane, WA USA. [Miller, Diane B.] NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Spokane, WA USA. [Vena, John E.] Univ Georgia, Dept Epidemiol & Biostat, Coll Publ Hlth, Athens, GA 30602 USA. Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC USA. RP Wirth, MD (reprint author), Univ S Carolina, Canc Prevent & Control Program, 915 Greene St,Suite 200, Columbia, SC 29208 USA. EM wirthm@mailbox.sc.edu RI Wirth, Michael/C-6330-2013 FU National Institute for Occupational Safety and Health [200-2003-01580]; ASPIRE-II Grant from the University of South Carolina Office of Research; South Carolina Cancer Prevention and Control Research Network under Centers for Disease Control and Prevention [3U48DP001936-01]; National Cancer Institute; Cancer Training Branch of the National Cancer Institute [K05 CA136975] FX This work was supported by the National Institute for Occupational Safety and Health contract number 200-2003-01580. Dr Wirth's participation was supported through an ASPIRE-II Grant from the University of South Carolina Office of Research and by the South Carolina Cancer Prevention and Control Research Network funded under Cooperative Agreement Number 3U48DP001936-01 from the Centers for Disease Control and Prevention and the National Cancer Institute. Dr. Hebert is supported by an Established Investigator Award in Cancer Prevention and Control from the Cancer Training Branch of the National Cancer Institute (K05 CA136975). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, or the National Cancer Institute. The authors declare no conflicts of interest. NR 20 TC 52 Z9 53 U1 8 U2 24 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2014 VL 56 IS 9 BP 986 EP 989 DI 10.1097/JOM.0000000000000213 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP1JB UT WOS:000341824000019 PM 25046320 ER PT J AU Kroelinger, CD Jones, J Barfield, WD Kogan, MD AF Kroelinger, Charlan D. Jones, Jessica Barfield, Wanda D. Kogan, Michael D. TI Recognizing Excellence in Maternal and Child Health (MCH) Epidemiology: The 2012 Co-hosted 18th MCH Epidemiology Conference and 22nd CityMatCH Urban MCH Leadership Conference, the 25th Anniversary of the MCH Epidemiology Program, and the National MCH Epidemiology Awards SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT News Item DE National Maternal and Child Health Epidemiology Awards; Building capacity; Leadership; Workforce development AB In December 2012, multiple leading agencies in the field of Maternal and Child Health (MCH) partnered to co-host a national MCH Epidemiology Conference. The Conference offered opportunities for peer exchange; presentation of new scientific methodologies, programs, and policies; dialogue on changes in the MCH field; and discussion of emerging MCH issues relevant to the work of MCH professionals. During the Conference, the MCH Epidemiology Program celebrated 25 years of success and partnership, and 16 MCH agencies presented six deserving health researchers and leaders with national awards in the areas of advancing knowledge, effective practice, outstanding leadership, excellence in teaching and mentoring, and young professional achievement. In September 2014, building on knowledge gained and changes in the field of MCH, leading agencies including the Centers for Disease Control and Prevention, the Health Resources and Services Administration, CityMatCH, and the Association of MCH Programs plan to replicate the achievements of 2012 through the implementation of a fully integrated national conference: the CityMatCH Leadership and MCH Epidemiology Conference. C1 [Kroelinger, Charlan D.] Ctr Dis Control & Prevent, Natl MCH Epidemiol Awards Select Comm, Maternal & Child Hlth Epidemiol Program, Div Reprod Hlth, Atlanta, GA 30341 USA. [Jones, Jessica; Kogan, Michael D.] US Hlth Resources & Serv Adm, Natl MCH Epidemiol Awards Select Comm, Maternal & Child Hlth Bur, Rockville, MD 20857 USA. [Barfield, Wanda D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Kroelinger, CD (reprint author), Ctr Dis Control & Prevent, Natl MCH Epidemiol Awards Select Comm, Maternal & Child Hlth Epidemiol Program, Div Reprod Hlth, 4770 Buford Hwy,NE MS K-22, Atlanta, GA 30341 USA. EM ckroelinger@cdc.gov FU Intramural CDC HHS [CC999999] NR 2 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD SEP PY 2014 VL 18 IS 7 BP 1553 EP 1557 DI 10.1007/s10995-014-1567-z PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO9RM UT WOS:000341693900001 PM 25091642 ER PT J AU Kroelinger, CD Rankin, KM Chambers, DA Roux, AVD Hughes, K Grigorescu, V AF Kroelinger, Charlan D. Rankin, Kristin M. Chambers, David A. Roux, Ana V. Diez Hughes, Karen Grigorescu, Violanda TI Using the Principles of Complex Systems Thinking and Implementation Science to Enhance Maternal and Child Health Program Planning and Delivery SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Implementation science; Complex systems thinking; Quality assurance; Public health; Theory ID EPIDEMIOLOGY AB Traditionally, epidemiologic methodologies have focused on measurement of exposures, outcomes, and program impact through reductionistic, yet complex statistical modeling. Although not new to the field of epidemiology, two frameworks that provide epidemiologists with a foundation for understanding the complex contexts in which programs and policies are implemented were presented to maternal and child health (MCH) professionals at the 2012 co-hosted 18th Annual MCH Epidemiology Conference and 22nd CityMatCH Urban Leadership Conference. The complex systems approach offers researchers in MCH the opportunity to understand the functioning of social, medical, environmental, and behavioral factors within the context of implemented public health programs. Implementation science provides researchers with a framework to translate the evidence-based program interventions into practices and policies that impact health outcomes. Both approaches offer MCH epidemiologists conceptual frameworks with which to re-envision how programs are implemented, monitored, evaluated, and reported to the larger public health audience. By using these approaches, researchers can begin to understand and measure the broader public health context, account for the dynamic interplay of the social environment, and ultimately, develop more effective MCH programs and policies. C1 [Kroelinger, Charlan D.; Grigorescu, Violanda] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Chamblee, GA 30341 USA. [Rankin, Kristin M.] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA. [Chambers, David A.] NIMH, Div Serv & Intervent Res, NIH, Bethesda, MD 20892 USA. [Roux, Ana V. Diez] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Hughes, Karen] Ohio Dept Hlth, Div Family & Community Hlth Serv, Columbus, OH 43266 USA. RP Kroelinger, CD (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-74, Chamblee, GA 30341 USA. EM ckroelinger@cdc.gov FU Intramural CDC HHS [CC999999] NR 10 TC 0 Z9 0 U1 1 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD SEP PY 2014 VL 18 IS 7 BP 1560 EP 1564 DI 10.1007/s10995-014-1586-9 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO9RM UT WOS:000341693900003 PM 25108501 ER PT J AU Arellano, DE Goodman, DA Howlette, T Kroelinger, CD Law, M Phillips, D Jones, J Brantley, MD Fitzgerald, M AF Arellano, Danielle E. Goodman, David A. Howlette, Travis Kroelinger, Charlan D. Law, Mark Phillips, Donna Jones, Jessica Brantley, Mary D. Fitzgerald, Maureen TI Evaluation of the 2012 18th Maternal and Child Health (MCH) Epidemiology and 22nd CityMatCH MCH Urban Leadership Conference: Six Month Impact on Science, Program, and Policy SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE MCH; Capacity building; Impact assessment; Conference evaluation AB The 18th Maternal and Child Health (MCH) Epidemiology and 22nd CityMatCH MCH Urban Leadership Conference took place in December 2012, covering MCH science, program, and policy issues. Assessing the impact of the Conference on attendees' work 6 months post-Conference provides information critical to understanding the impact and the use of new partnerships, knowledge, and skills gained during the Conference. Evaluation assessments, which included collection of quantitative and qualitative data, were administered at two time points: at Conference registration and 6 months post-Conference. The evaluation files were merged using computer IP address, linking responses from each assessment. Percentages of attendees reporting Conference impacts were calculated from quantitative data, and common themes and supporting examples were identified from qualitative data. Online registration was completed by 650 individuals. Of registrants, 30 % responded to the 6 month post-Conference assessment. Between registration and 6 month post-Conference evaluation, the distribution of respondents did not significantly differ by organizational affiliation. In the 6 months following the Conference, 65 % of respondents reported pursuing a networking interaction; 96 % shared knowledge from the Conference with co-workers and others in their agency; and 74 % utilized knowledge from the Conference to translate data into public health action. The Conference produced far-reaching impacts among Conference attendees. The Conference served as a platform for networking, knowledge sharing, and attaining skills that advance the work of attendees, with the potential of impacting organizational and workforce capacity. Increasing capacity could improve MCH programs, policies, and services, ultimately impacting the health of women, infants, and children. C1 [Arellano, Danielle E.; Goodman, David A.; Kroelinger, Charlan D.; Phillips, Donna; Brantley, Mary D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Arellano, Danielle E.; Howlette, Travis] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Arellano, Danielle E.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Chamblee, GA 30341 USA. [Law, Mark; Fitzgerald, Maureen] Univ Nebraska Med Ctr, CityMatCH, Omaha, NE USA. [Jones, Jessica] US Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, Washington, DC USA. RP Arellano, DE (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-74, Chamblee, GA 30341 USA. EM hiz6@cdc.gov OI Law, Mark/0000-0001-5938-2785 FU Intramural CDC HHS [CC999999] NR 9 TC 1 Z9 1 U1 1 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD SEP PY 2014 VL 18 IS 7 BP 1565 EP 1571 DI 10.1007/s10995-014-1585-x PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO9RM UT WOS:000341693900004 PM 25107597 ER PT J AU Ailes, EC Newsome, K Williams, JL McIntyre, AF Jamieson, DJ Finelli, L Honein, MA AF Ailes, Elizabeth C. Newsome, Kimberly Williams, Jennifer L. McIntyre, Anne F. Jamieson, Denise J. Finelli, Lyn Honein, Margaret A. TI CDC Pregnancy Flu Line: Monitoring Severe Illness Among Pregnant Women with Influenza SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Influenza, Human; Influenza A virus; H1N1 subtype; Pregnancy; Surveillance ID UNITED-STATES AB The Centers for Disease Control and Prevention implemented the Pregnancy Flu Line (PFL) during the influenza A(H1N1)pdm09 (pH1N1) pandemic and continued operation through the 2010-2011 influenza season to collect reports of intensive care unit (ICU) admissions and deaths among pregnant women with influenza. The system documented the severe impact of influenza on pregnant women during both seasons with 181 ICU/survivals and 37 deaths reported during the 2009 fall pandemic wave and 69 ICU/survivals and ten deaths reported in the subsequent influenza season (2010-2011). A health department survey suggests PFL participants perceived public health benefits and minimum time burdens. C1 [Ailes, Elizabeth C.; Newsome, Kimberly; Williams, Jennifer L.; Honein, Margaret A.] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Ailes, Elizabeth C.] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [McIntyre, Anne F.; Finelli, Lyn] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Jamieson, Denise J.] Ctr Dis Control & Prevent CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Newsome, K (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM kan3@cdc.gov FU Intramural CDC HHS [CC999999] NR 12 TC 4 Z9 5 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD SEP PY 2014 VL 18 IS 7 BP 1578 EP 1582 DI 10.1007/s10995-013-1415-6 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO9RM UT WOS:000341693900006 PM 24368408 ER PT J AU Oza-Frank, R Ko, JY Wapner, A Rodgers, L Bouchard, JM Conrey, EJ AF Oza-Frank, Reena Ko, Jean Y. Wapner, Andrew Rodgers, Loren Bouchard, Jo M. Conrey, Elizabeth J. TI Improving Care for Women with a History of Gestational Diabetes: A Provider Perspective SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Gestational diabetes; Diabetes prevention; Postpartum care ID LIFE-STYLE; PREVENTION PROGRAM; GLUCOSE-TOLERANCE; RISK-FACTORS; MELLITUS; PREGNANCY; MOTHERS; INTERVENTIONS; MANAGEMENT; HEALTH AB To identify perceived roles with regard to care for women with gestational diabetes mellitus (GDM) history and resources for improving care among women with a history of GDM from the perspective of obstetrician/gynecologists (OB/GYNs), certified nurse midwives (CNM), family practitioners, and internists. In 2010, a survey was sent to a random sample of OB/GYNs, CNM, family practitioners, and internists (n = 2,375) in Ohio to assess knowledge, attitudes, and postpartum practices regarding diabetes prevention for women with a history of GDM. A total of 904 practitioners completed the survey (46 %). Over 70 % of CNMs strongly agreed it is part of their job to help women with GDM history improve diet and increase exercise, compared with 60 % of family practitioners/internists and 55 % of OB/GYNs (p < 0.001). More OB/GYNs and CNMs identified a need for more local nutrition specialists and patient education materials, compared with family practitioners/ internists. Between 60 and 70 % of OB/GYNs and CNMs reported lifestyle modification programs and corresponding reimbursement would better support them to provide improved care. Health care providers giving care to women with GDM history have varying perceptions of their roles, however, there was agreement on resources needed to improve care. C1 [Oza-Frank, Reena] Ohio State Univ, Dept Pediat, Ctr Perinatal Res, Res Inst,Nationwide Childrens Hosp, Columbus, OH 43205 USA. [Ko, Jean Y.; Rodgers, Loren] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Ko, Jean Y.; Conrey, Elizabeth J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Wapner, Andrew; Rodgers, Loren; Bouchard, Jo M.; Conrey, Elizabeth J.] Ohio Dept Hlth, Columbus, OH 43266 USA. [Rodgers, Loren] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA. RP Oza-Frank, R (reprint author), Ohio State Univ, Dept Pediat, Ctr Perinatal Res, Res Inst,Nationwide Childrens Hosp, 700 Childrens Dr,Res Bldg 3, Columbus, OH 43205 USA. EM reena.oza-frank@nationwidechildrens.org NR 41 TC 2 Z9 2 U1 1 U2 23 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD SEP PY 2014 VL 18 IS 7 BP 1683 EP 1690 DI 10.1007/s10995-013-1410-y PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO9RM UT WOS:000341693900018 PM 24343308 ER PT J AU Sun, XJ Cao, WP Pappas, C Liu, F Katz, JM Tumpey, TM AF Sun, Xiangjie Cao, Weiping Pappas, Claudia Liu, Feng Katz, Jacqueline M. Tumpey, Terrence M. TI Effect of receptor binding specificity on the immunogenicity and protective efficacy of influenza virus A H1 vaccines SO VIROLOGY LA English DT Article DE Influenza virus; Immunogenicity; Receptor binding specificity; Inactivated whole virus vaccine ID HEMAGGLUTININ-SPECIFIC ANTIBODIES; A H5N1 VACCINE; HUMAN INFECTION; MANNOSE RECEPTOR; MOLECULAR-BASIS; A/H5N1 VACCINE; HUMAN AIRWAY; FERRETS; SAFETY; TRANSMISSION AB The biological basis for the poor immunogenicity of unadjuvanted avian influenza A virus vaccines in mammals is not well understood. Here, we mutated the hemagglutinin (HA) of two HI NI virus vaccines to determine whether virus receptor binding specificity contributes to the low immunogenicity of avian influenza virus vaccines. Mutations were introduced into the HA of an avian influenza virus, A/Duck/New York/15024-21/96 (Dk/96) which switched the binding preference from alpha 2,3- to alpha 2,6-linked sialic acid (SA). A switch in receptor specificity of the human A/South Carolina/1/18 (SC/18) virus generated a mutant virus with alpha 2,3 SA (avian) binding preference. Inactivated vaccines were generated and administered to mice and ferrets intramuscularly. We found that the vaccines with human receptor binding preference induced slightly higher antibody titers and cell-mediated immune responses compared to their isogenic viruses with avian receptor binding specificity. Upon challenge with DK/96 or SC18 virus, differences in lung virus titers between the vaccine groups with different receptor-binding specificities were minimal. Overall, our data suggest that receptor binding specificity contributes only marginally to the immunogenicity of avian influenza vaccines and that other factors may also be involved. Published by Elsevier Inc. C1 [Sun, Xiangjie; Cao, Weiping; Pappas, Claudia; Liu, Feng; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunol & Resp Dis, Atlanta, GA 30333 USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunol & Resp Dis, 1600 Clifton Rd,MS G16, Atlanta, GA 30333 USA. EM tft9@cdc.gov NR 53 TC 2 Z9 2 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD SEP PY 2014 VL 464 BP 156 EP 165 DI 10.1016/j.virol.2014.07.004 PG 10 WC Virology SC Virology GA AO7RJ UT WOS:000341550000016 PM 25078114 ER PT J AU Hughes, LJ Goldstein, J Pohl, J Hooper, JW Pitts, RL Townsend, MB Bagarozzi, D Damon, IK Karem, KL AF Hughes, Laura J. Goldstein, Jason Pohl, Jan Hooper, Jay W. Pitts, R. Lee Townsend, Michael B. Bagarozzi, Dennis Damon, Inger K. Karem, Kevin L. TI A highly specific monoclonal antibody against monkeypox virus detects the heparin binding domain of A27 SO VIROLOGY LA English DT Article DE Monkeypox virus; Vaccinia virus; Orthopoxvirus; Antibody; Heparin binding ID ENVELOPE PROTEIN A27L; MEDIATED CELL-FUSION; TIME PCR ASSAYS; VACCINIA VIRUS; SMALLPOX VACCINES; STABLE COMPLEX; DNA VACCINE; IDENTIFICATION; MEMBRANE; IMMUNITY AB The eradication of smallpox and the cessation of global vaccination led to the increased prevalence of human infections in Central Africa. Serologic and protein-based diagnostic assay for MPXV detection is difficult due to cross-reactive antibodies that do not differentiate between diverse orthopoxvirus (OPXV) species. A previously characterized monoclonal antibody (mAb 69-126-3-7) against MPXV [1] was retested for cross-reactivity with various OPXVs. The 14.5 kDa band protein that reacted with mAb 69-126-3 was identified to be MPXV A29 protein (homolog of vaccinia virus Copenhagen A27). Amino acid sequence analysis of the MPXV A29 with other OPXV homologs identified four amino acid changes. Peptides corresponding to these regions were designed and evaluated for binding to mAb 69-126-3 by ELISA and Biolayer Interferometry (BLI). Further refinement and truncations mapped the specificity of this antibody to a single amino acid difference in a 30-mer peptide compared to other OPXV homologs. This particular residue is proposed to be essential for heparin binding by VACV A27 protein. Despite this substitution, MPXV A29 bound to heparin with similar affinity to that of VACV A27 protein, suggesting flexibility of this motif for heparin binding. Although binding of mAb 69-126-3-7 to MPXV A29 prevented interaction with heparin, it did not have any effect on the infectivity of MPXV. Characterization of 69-126-3-7 mAb antibody allows for the possibility of the generation of a serological based species-specific detection of OPXVs despite high proteomic homology. Published by Elsevier Inc. C1 [Hughes, Laura J.; Goldstein, Jason; Pohl, Jan; Pitts, R. Lee; Townsend, Michael B.; Bagarozzi, Dennis; Damon, Inger K.; Karem, Kevin L.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Hooper, Jay W.] USAMRIID, Frederick, MD USA. RP Hughes, LJ (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM bkz2@cdc.gov OI Hooper, Jay/0000-0002-4475-0415 NR 37 TC 2 Z9 2 U1 1 U2 16 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD SEP PY 2014 VL 464 BP 264 EP 273 DI 10.1016/j.virol.2014.06.039 PG 10 WC Virology SC Virology GA AO7RJ UT WOS:000341550000028 PM 25108113 ER PT J AU Zhou, Y Lobo, NF Wolkon, A Gimnig, JE Malishee, A Stevenson, J Sulistyawati Collins, FH Madey, G AF Zhou, Ying Lobo, Neil F. Wolkon, Adam Gimnig, John E. Malishee, Alpha Stevenson, Jennifer Sulistyawati Collins, Frank H. Madey, Greg TI PGMS: A Case Study of Collecting PDA-Based Geo-Tagged Malaria-Related Survey Data SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID FIELD DATA-COLLECTION; PAPER DATA-COLLECTION; HAND-HELD COMPUTERS; INTEGRATED CAMPAIGN; NETS; POPULATIONS; ZANZIBAR; FORMS AB Using mobile devices, such as personal digital assistants (PDAs), smartphones, tablet computers, etc., to electronically collect malaria-related field data is the way for the field questionnaires in the future. This case study seeks to design a generic survey framework PDA-based geo-tagged malaria-related data collection tool (PGMS) that can be used not only for large-scale community-level geo-tagged electronic malaria-related surveys, but also for a wide variety of electronic data collections of other infectious diseases. The framework includes two parts: the database designed for subsequent cross-sectional data analysis and the customized programs for the six study sites (two in Kenya, three in Indonesia, and one in Tanzania). In addition to the framework development, we also present our methods used when configuring and deploying the PDAs to 1) reduce data entry errors, 2) conserve battery power, 3) field install the programs onto dozens of handheld devices, 4) translate electronic questionnaires into local languages, 5) prevent data loss, and 6) transfer data from PDAs to computers for future analysis and storage. Since 2008, PGMS has successfully accomplished quite a few surveys that recorded 10,871 compounds and households, 52,126 persons, and 17,100 bed nets from the six sites. These numbers are still growing. C1 Univ Notre Dame, Dept Comp Sci & Engn, Notre Dame, IN 46556 USA. Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA. [Wolkon, Adam; Gimnig, John E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Malishee, Alpha] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Stevenson, Jennifer] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England. [Sulistyawati] Univ Ahmad Dahlan, Dept Publ Hlth, Yogyakarta, Indonesia. [Zhou, Ying] ArcSight HP Enterprise Secur, Sunnyvale, CA USA. [Lobo, Neil F.; Collins, Frank H.; Madey, Greg] Univ Notre Dame, Notre Dame, IN 46556 USA. RP Zhou, Y (reprint author), 7179 Blue Hill Dr, San Jose, CA 95129 USA. EM nancyzhou04@gmail.com; Neil.F.Lobo.2@nd.edu; aow5@cdc.gov; hzg1@cdc.gov; maligana@gmail.com; jennycstevenson80@gmail.com; sulistyawatipuci@yahoo.co.id; frank@nd.edu; gmadey@nd.edu FU Bill and Melinda Gates Foundation Malaria Transmission Consortium [45114] FX This study was funded by the Bill and Melinda Gates Foundation Malaria Transmission Consortium grant No. 45114. NR 31 TC 1 Z9 1 U1 0 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2014 VL 91 IS 3 BP 496 EP 508 DI 10.4269/ajtmh.13-0652 PG 13 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AO4WQ UT WOS:000341342500011 PM 25048377 ER PT J AU Njau, JD Stephenson, R Menon, MP Kachur, SP McFarland, DA AF Njau, Joseph D. Stephenson, Rob Menon, Manoj P. Kachur, S. Patrick McFarland, Deborah A. TI Investigating the Important Correlates of Maternal Education and Childhood Malaria Infections SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID DEVELOPING-COUNTRIES; MOTHERS EDUCATION; NET USE; HOUSEHOLD EXPENDITURE; OAXACA DECOMPOSITION; HEALTH-EDUCATION; TREATED NETS; DETERMINANTS; MORTALITY; SURVIVAL AB The relationship between maternal education and child health has intrigued researchers for decades. This study explored the interaction between maternal education and childhood malaria infection. Cross-sectional survey data from three African countries were used. Descriptive analysis and multivariate logistic regression models were completed in line with,identified correlates. Marginal effects and Oaxaca decomposition analysis on maternal education and childhood malaria infection were also estimated. Children with mothers whose education level was beyond primary school were 4.7% less likely to be malaria-positive (P < 0.001). The Oaxaca decomposition analysis exhibited an 8% gap in childhood malaria infection for educated and uneducated mothers. Over 60% of the gap was explained by differences in household wealth (26%), household place of domicile (21%), malaria transmission intensities (14%), and media exposure (12%). All other correlates accounted for only 27%. The full adjusted model showed a robust and significant relationship between maternal education and childhood malaria infection. C1 [Njau, Joseph D.] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. [Njau, Joseph D.; Menon, Manoj P.; Kachur, S. Patrick] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Div Global Immunizat,Ctr Global Hlth, Atlanta, GA USA. [Stephenson, Rob; McFarland, Deborah A.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Menon, Manoj P.] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Div Med Oncol, Seattle, WA 98195 USA. RP Njau, JD (reprint author), 1600 Clifton Rd 16NE, Atlanta, GA 30333 USA. EM jnjau@cdc.gov; rbsteph@emory.edu; manoj@u.washington.edu; spk0@cdc.gov; dmcfarl@emory.edu NR 73 TC 5 Z9 5 U1 2 U2 8 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2014 VL 91 IS 3 BP 509 EP 519 DI 10.4269/ajtmh.13-0713 PG 11 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AO4WQ UT WOS:000341342500012 PM 25002302 ER PT J AU Paddock, CD Denison, AM Lash, RR Liu, L Bollweg, BC Dahlgren, FS Kanamura, CT Angerami, RN dos Santos, FCP Martines, RB Karpathy, SE AF Paddock, Christopher D. Denison, Amy M. Lash, R. Ryan Liu, Lindy Bollweg, Brigid C. Dahlgren, F. Scott Kanamura, Cristina T. Angerami, Rodrigo N. Pereira dos Santos, Fabiana C. Martines, Roosecelis Brasil Karpathy, Sandor E. TI Phylogeography of Rickettsia rickettsii Genotypes Associated with Fatal Rocky Mountain Spotted Fever SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID TICK HAEMAPHYSALIS-LEPORISPALUSTRIS; TIME PCR ASSAY; UNITED-STATES; CLINICAL-SAMPLES; RISK-FACTORS; COSTA-RICA; VIRULENCE; STRAINS; TYPHUS; VIRUS AB Rocky Mountain spotted fever (RMSF), a tick-borne zoonosis caused by Rickettsia rickettsii, is among the deadliest of all infectious diseases. To identify the distribution of various genotypes of R. rickettsii associated with fatal RMSF, we applied molecular typing methods to samples of DNA extracted from formalin-fixed, paraffin-embedded tissue specimens obtained at autopsy from 103 case-patients from seven countries who died of RMSF. Complete sequences of one or more intergenic regions were amplified from tissues of 30 (29%) case-patients and revealed a distribution of genotypes consisting of four distinct clades, including the Hip clade, regarded previously as a non-pathogenic strain of R. rickettsii. Distinct phylogeographic patterns were identified when composite case-patient and reference strain data were mapped to the state and country of origin. The phylogeography of R. rickettsii is likely determined by ecological and environmental factors that exist independently of the distribution of a particular tick vector. C1 Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Infect Dis Pathol Branch, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. Adolfo Lutz Inst, Ctr Patol, Nucleo Anat Patol, Sao Paulo, Brazil. [Angerami, Rodrigo N.] Secretaria Municipal Saude Campinas, Dept Vigilancia Saude, Sao Paulo, Brazil. [Paddock, Christopher D.; Dahlgren, F. Scott; Karpathy, Sandor E.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. [Denison, Amy M.; Liu, Lindy; Bollweg, Brigid C.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA 30333 USA. [Lash, R. Ryan] Ctr Dis Control & Prevent, Travelers Hlth Branch, Atlanta, GA 30333 USA. [Kanamura, Cristina T.; Pereira dos Santos, Fabiana C.; Martines, Roosecelis Brasil] Adolfo Lutz Inst, Nucelo Anat Patol, Sao Paulo, Brazil. RP Paddock, CD (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Mailstop G-13,1600 Clifton Rd, Atlanta, GA 30333 USA. EM cdp9@cdc.gov; crk6@cdc.gov; gnk6@cdc.gov; fuz3@cdc.gov; fvt6@cdc.gov; iot0@cdc.gov; criskanamura@yahoo.com.br; rodrigo.angerami@gmail.com; fabianacp@yahoo.com; roosebrasil@hotmail.com; evu2@cdc.gov RI Angerami, Rodrigo/A-8926-2013 OI Angerami, Rodrigo/0000-0002-4976-9238 FU U.S. Department of Health and Human Services FX We thank Theodore Tzianabos (CDC), for producing the antiserum used in the immunohistochemical assay, and for providing access to several of the archival cases evaluated in this study; Onyekachukwu Nwankwo, for assistance with cataloguing the archival paraffin blocks; Marcus Nashelsky (University of Iowa Carver College of Medicine, Iowa City, Iowa), Kimberly Goble (Spearfish Regional Hospital, Spearfish, South Dakota), Sonia Montiel (San Diego County Health Department, San Diego, California), and Joanna Regan, Steven Waterman, Wun-Ju Shieh, Clifton Drew, Jana Ritter, Atis Muehlenbachs, and Sherif Zaki, (CDC) for their assistance in the clinical characterization and pathologic assessment of many of the case-patients evaluated in this series. This work was funded by the U.S. Department of Health and Human Services. The findings and conclusions are those of the authors and do not necessarily represent the official position of the U.S. Department of Health and Human Services. NR 52 TC 7 Z9 9 U1 0 U2 17 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2014 VL 91 IS 3 BP 589 EP 597 DI 10.4269/ajtmh.14-0146 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AO4WQ UT WOS:000341342500027 PM 24957541 ER PT J AU Williams, M Mayer, SV Johnson, WL Chen, RB Volkova, E Vilcarromero, S Widen, SG Wood, TG Suarez-Ognio, L Long, KC Hanley, KA Morrison, AC Vasilakis, N Halsey, ES AF Williams, Maya Mayer, Sandra V. Johnson, William L. Chen, Rubing Volkova, Evgeniya Vilcarromero, Stalin Widen, Steven G. Wood, Thomas G. Suarez-Ognio, Luis Long, Kanya C. Hanley, Kathryn A. Morrison, Amy C. Vasilakis, Nikos Halsey, Eric S. TI Lineage II of Southeast Asian/American DENV-2 Is Associated with a Severe Dengue Outbreak in the Peruvian Amazon SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ADJUSTED LIFE YEARS; HEMORRHAGIC-FEVER; ECONOMIC-IMPACT; VIRUS TYPE-2; FEBRILE ILLNESSES; SHOCK SYNDROME; PUERTO-RICO; 3 DECADES; AMERICA; INFECTION AB During 2010 and 2011, the Loreto region of Peru experienced a dengue outbreak of unprecedented magnitude and severity for the region. This outbreak coincided with the reappearance of dengue virus-2 (DENV-2) in Loreto after almost 8 years. Whole-genome sequence indicated that DENV-2 from the outbreak belonged to lineage II of the southeast Asian/American genotype and was most closely related to viruses circulating in Brazil during 2007 and 2008, whereas DENV-2 previously circulating in Loreto grouped with lineage I (DENV-2 strains circulating in South America since 1990). One amino acid substitution (NS5 A811V) in the 2010 and 2011 isolates resulted from positive selection. However, the 2010 and 2011 DENV-2 did not replicate to higher titers in monocyte-derived dendritic cells and did not infect or disseminate in a higher proportion of Aedes aegypti than DENV-2 isolates previously circulating in Loreto. These results suggest that factors other than enhanced viral replication played a role in the severity of this outbreak. C1 US Naval Med Res Unit 6, Dept Virol, Lima, Peru. [Mayer, Sandra V.; Chen, Rubing] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Mayer, Sandra V.; Chen, Rubing] Univ Texas Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA. [Hanley, Kathryn A.] New Mexico State Univ, Dept Biol, Las Cruces, NM 88003 USA. [Vilcarromero, Stalin; Morrison, Amy C.] US Naval Med Res Unit 6, Dept Virol, Iquitos, Peru. [Widen, Steven G.; Wood, Thomas G.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA. Minist Salud Peru, Direcc Gen Epidemiol, Lima, Peru. [Morrison, Amy C.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA. [Vasilakis, Nikos] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA. [Vasilakis, Nikos] Univ Texas Med Branch, Ctr Trop Dis, Galveston, TX 77555 USA. [Williams, Maya] Naval Med Res Ctr, Viral & Rickettsial Dis Dept, Silver Spring, MD 20910 USA. [Johnson, William L.] Colorado Sch Publ Hlth, Ft Collins, CO USA. [Volkova, Evgeniya] US FDA, Lab Emerging Pathogens, Ctr Biol Evaluat & Res, Div Emerging & Transfus Transmitted Dis, Bethesda, MD 20014 USA. [Suarez-Ognio, Luis] Univ Ciencias Aplicadas, Fac Hlth Sci, Lima, Peru. [Long, Kanya C.] Andrews Univ, Dept Biol, Berrien Springs, MI 49104 USA. [Vasilakis, Nikos] Univ Texas Med Branch, Dept Pathol, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA. [Halsey, Eric S.] US Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. RP Williams, M (reprint author), Naval Med Res Ctr, Viral & Rickettsial Dis Dept, 503 Robert Grant Ave,Room 3A14, Silver Spring, MD 20910 USA. EM maya.williams@med.navy.mil; samayer@utmb.edu; w.johnson@rams.colostate.edu; ruchen@utmb.edu; Evgeniya.volkova@fda.hhs.gov; stalinf@yahoo.com; sgwiden@utmb.edu; tgwood@utmb.edu; luis.suarez@upc.edu.pe; kanya@andrews.edu; khanley@nmsu.edu; amy.aegypti@gmail.com; nivasila@utmb.edu; ehalsey@cdc.gov OI Vilcarromero, Stalin/0000-0002-9097-0638 FU Global Emerging Infections Surveillance and Response System, a Division of the Armed Forces Health Surveillance Center [800000.82000.25GB.B0016]; Military Infectious Diseases Research Program [6000 RAD1.S.B0302]; National Center for Research Resources Grant [5P20RR016480-12]; National Institute of General Medical Sciences Grant [8 P20 GM103451-12]; Department of Pathology, University of Texas Medical Branch; NIH [HHSN272201000040I/HHSN27200004/D04] FX This work was supported by the Global Emerging Infections Surveillance and Response System, a Division of the Armed Forces Health Surveillance Center (Work Unit Number 800000.82000.25GB.B0016) and the Military Infectious Diseases Research Program (Work Unit Number 6000 RAD1.S.B0302). W.L.J. and K.A.H. were supported by National Center for Research Resources Grant 5P20RR016480-12 and National Institute of General Medical Sciences Grant 8 P20 GM103451-12. N.V. was supported by start-up funds provided by the Department of Pathology, University of Texas Medical Branch and NIH contract HHSN272201000040I/HHSN27200004/D04. NR 62 TC 10 Z9 11 U1 1 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2014 VL 91 IS 3 BP 611 EP 620 DI 10.4269/ajtmh.13-0600 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AO4WQ UT WOS:000341342500029 PM 25002298 ER PT J AU Moss, JA Srinivasan, P Smith, TJ Butkyavichene, I Lopez, G Brooks, AA Martin, A Dinh, CT Smith, JM Baum, MM AF Moss, John A. Srinivasan, Priya Smith, Thomas J. Butkyavichene, Irina Lopez, Gilbert Brooks, Amanda A. Martin, Amy Dinh, Chuong T. Smith, James M. Baum, Marc M. TI Pharmacokinetics and Preliminary Safety Study of Pod-Intravaginal Rings Delivering Antiretroviral Combinations for HIV Prophylaxis in a Macaque Model SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID TENOFOVIR DISOPROXIL FUMARATE; IMMUNODEFICIENCY-VIRUS TYPE-1; PIG-TAILED MACAQUES; PREEXPOSURE PROPHYLAXIS; RHESUS MACAQUES; DRUG CONCENTRATIONS; VAGINAL RINGS; MARAVIROC; PREVENTION; INFECTION AB Preexposure prophylaxis using oral regimens involving the HIV nucleoside reverse transcriptase inhibitors tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) demonstrated efficacy in three clinical trials. Adherence was determined to be a key parameter for success. Incorporation of the TDF-FTC combination into intravaginal rings (IVRs) for sustained mucosal delivery could increase product adherence and efficacy compared with those of oral and vaginal gel formulations. A novel pod-IVR technology capable of delivering multiple drugs is described; this constitutes the first report of an IVR delivering TDF and FTC, as well as a triple-combination IVR delivering TDF, FTC, and the entry inhibitor maraviroc (MVC). The pharmacokinetics and preliminary local safety of the two combination pod-IVRs were evaluated in the pig-tailed macaque model. The devices exhibited sustained release at controlled rates over the 28-day study period. Median steady-state drug levels in vaginal tissues in the TDF-FTC group were 30 mu g g(-1) (tenofovir [TFV], in vivo hydrolysis product of TDF) and 500 mu g g(-1) (FTC) and in the TDF-FTC-MVC group were 10 mu g g(-1) (TFV), 150 mu g g(-1) (FTC), and 20 mu g g(-1) (MVC). No adverse events were observed, and there were no toxicological findings. Mild-to-moderate increases in inflammatory infiltrates were observed in the vaginal tissues of some animals in both the presence and the absence of the IVRs. The IVRs did not disturb the vaginal microbiota, and levels of proinflammatory cytokines remained stable throughout the study. Pod-IVR candidates based on the TDF-FTC combination have potential for the prevention of vaginal HIV acquisition and merit clinical investigation. C1 [Moss, John A.; Smith, Thomas J.; Brooks, Amanda A.; Baum, Marc M.] Oak Crest Inst Sci, Dept Chem, Pasadena, CA 91107 USA. [Srinivasan, Priya; Martin, Amy; Smith, James M.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Branch Lab, Atlanta, GA USA. [Smith, Thomas J.; Butkyavichene, Irina; Lopez, Gilbert] Auritec Pharmaceut Inc, Pasadena, CA USA. [Dinh, Chuong T.] Total Solut Inc, Atlanta, GA USA. RP Baum, MM (reprint author), Oak Crest Inst Sci, Dept Chem, Pasadena, CA 91107 USA. EM m.baum@oak-crest.org FU National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R33AI079791, R43AI098743, R01AI100744, R43HD075636, R44AI081552] FX Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, under grants R33AI079791 (development of TDF-MVC pod-IVRs), R43AI098743 and R01AI100744 (development of TDF-FTC pod-IVRs), R43HD075636 (investigational new drug studies for TDF-FTC-MVC pod-IVRs), and R44AI081552 (fabrication of TDF pod-IVRs). NR 59 TC 11 Z9 11 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2014 VL 58 IS 9 BP 5125 EP 5135 DI 10.1128/AAC.02871-14 PG 11 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AO3UV UT WOS:000341262700016 PM 24936594 ER PT J AU Olson, VA Smith, SK Foster, S Li, Y Lanier, ER Gates, I Trost, LC Damon, IK AF Olson, Victoria A. Smith, Scott K. Foster, Scott Li, Yu Lanier, E. Randall Gates, Irina Trost, Lawrence C. Damon, Inger K. TI In Vitro Efficacy of Brincidofovir against Variola Virus SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID DNA POLYMERASE; SMALLPOX-VIRUS; CIDOFOVIR; CMX001 AB Brincidofovir (CMX001), a lipid conjugate of the acyclic nucleotide phosphonate cidofovir, is under development for smallpox treatment using "the Animal Rule," established by the FDA in 2002. Brincidofovir reduces mortality caused by orthopoxvirus infection in animal models. Compared to cidofovir, brincidofovir has increased potency, is administered orally, and shows no evidence of nephrotoxicity. Here we report that the brincidofovir half-maximal effective concentration (EC50) against five variola virus strains in vitro averaged 0.11 mu M and that brincidofovir was therefore nearly 100-fold more potent than cidofovir. C1 [Olson, Victoria A.; Smith, Scott K.; Li, Yu; Gates, Irina; Damon, Inger K.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. [Foster, Scott; Lanier, E. Randall; Trost, Lawrence C.] Chimerix Inc, Durham, NC USA. RP Damon, IK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. EM iad7@cdc.gov NR 12 TC 6 Z9 7 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2014 VL 58 IS 9 BP 5570 EP 5571 DI 10.1128/AAC.02814-14 PG 2 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AO3UV UT WOS:000341262700066 PM 24957837 ER PT J AU Cromeans, T Park, GW Costantini, V Lee, D Wang, Q Farkas, T Lee, A Vinje, J AF Cromeans, Theresa Park, Geun Woo Costantini, Veronica Lee, David Wang, Qiuhong Farkas, Tibor Lee, Alvin Vinje, Jan TI Comprehensive Comparison of Cultivable Norovirus Surrogates in Response to Different Inactivation and Disinfection Treatments SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID HIGH HYDROSTATIC-PRESSURE; INTESTINAL EPITHELIAL-CELLS; COMMONLY USED DISINFECTANTS; MURINE NOROVIRUS; FELINE CALICIVIRUS; UNITED-STATES; TULANE VIRUS; GII.4 NOROVIRUS; ROMAINE LETTUCE; GASTROENTERITIS AB Human norovirus is the leading cause of epidemic and sporadic acute gastroenteritis. Since no cell culture method for human norovirus exists, cultivable surrogate viruses (CSV), including feline calicivirus (FCV), murine norovirus (MNV), porcine enteric calicivirus (PEC), and Tulane virus (TuV), have been used to study responses to inactivation and disinfection methods. We compared the levels of reduction in infectivities of CSV and Aichi virus (AiV) after exposure to extreme pHs, 56 degrees C heating, alcohols, chlorine on surfaces, and high hydrostatic pressure (HHP), using the same matrix and identical test parameters for all viruses, as well as the reduction of human norovirus RNA levels under these conditions. At pH 2, FCV was inactivated by 6 log(10) units, whereas MNV, TuV, and AiV were resistant. All CSV were completely inactivated at 56 degrees C within 20 min. MNV was inactivated 5 log(10) units by alcohols, in contrast to 2 and 3 log(10) units for FCV and PEC, respectively. TuV and AiV were relatively insensitive to alcohols. FCV was reduced 5 log(10) units by 1,000 ppm chlorine, in contrast to 1 log(10) unit for the other CSV. All CSV except FCV, when dried on stainless steel surfaces, were insensitive to 200 ppm chlorine. HHP completely inactivated FCV, MNV, and PEC at >= 300 MPa, and TuV at 600 MPa, while AiV was completely resistant to HHP up to 800 MPa. By reverse transcription- quantitative PCR (RT-qPCR), genogroup I (GI) noroviruses were more sensitive than GII noroviruses to alcohols, chlorine, and HHP. Although inactivation profiles were variable for each treatment, TuV and MNV were the most resistant CSV overall and therefore are the best candidates for studying the public health outcomes of norovirus infections. C1 [Cromeans, Theresa; Park, Geun Woo; Costantini, Veronica; Lee, David; Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Cromeans, Theresa] CDC Fdn, Atlanta, GA USA. [Costantini, Veronica] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Wang, Qiuhong] Ohio State Univ, Dept Vet Prevent Med, Wooster, OH USA. [Farkas, Tibor] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Farkas, Tibor] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Lee, Alvin] IIT, Inst Food Safety & Hlth, Bedford Pk, IL USA. RP Vinje, J (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jvinje@cdc.gov OI Costantini, Veronica/0000-0002-1532-4345 FU Agriculture and Food Research Initiative Competitive Grant from the U.S. Department of Agriculture, National Institute of Food and Agriculture [2011-68003-30395] FX This study was supported by Agriculture and Food Research Initiative Competitive Grant 2011-68003-30395 from the U.S. Department of Agriculture, National Institute of Food and Agriculture. NR 72 TC 34 Z9 34 U1 0 U2 25 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 EI 1098-5336 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD SEP PY 2014 VL 80 IS 18 BP 5743 EP 5751 DI 10.1128/AEM.01532-14 PG 9 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA AO6UV UT WOS:000341488200020 PM 25015883 ER PT J AU Ferucci, ED Johnston, JM Gaddy, JR Sumner, L Posever, JO Choromanski, TL Gordon, C Lim, SS Helmick, CG AF Ferucci, Elizabeth D. Johnston, Janet M. Gaddy, Jasmine R. Sumner, Lisa Posever, James O. Choromanski, Tammy L. Gordon, Caroline Lim, S. Sam Helmick, Charles G. TI Prevalence and Incidence of Systemic Lupus Erythematosus in a Population-Based Registry of American Indian and Alaska Native People, 2007-2009 SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID RHEUMATIC-DISEASES; REVISED CRITERIA; CLASSIFICATION; EPIDEMIOLOGY; RATES AB Objective. Few studies have investigated the epidemiology of systemic lupus erythematosus (SLE) in American Indian and Alaska Native populations. The objective of this study was to determine the prevalence and incidence of SLE in the Indian Health Service (IHS) active clinical population in 3 regions of the US. Methods. For this population-based registry within the IHS, the denominator consisted of individuals in the IHS active clinical population in 2007, 2008, and/or 2009 and residing in a community in 1 of 3 specified regions. Potential SLE cases were identified based on the presence of a diagnostic code for SLE or related disorder in the IHS National Data Warehouse. Detailed medical record abstraction was performed for each potential case. The primary case definition was documentation in the medical record of >= 4 of the revised American College of Rheumatology criteria for the classification of SLE. Prevalence was calculated for 2007, and the mean annual incidence was calculated for the years 2007 through 2009. Results. The age-adjusted prevalence and incidence of SLE according to the primary definition were 178 per 100,000 person-years (95% confidence interval [95% CI] 157-200) and 7.4 per 100,000 person-years (95% CI 5.1-10.4). Among women, the age-adjusted prevalence was 271, and the age-adjusted incidence was 10.4. The prevalence was highest in women ages 50-59 years and in the Phoenix Area IHS. Conclusion. The first population-based lupus registry in the US American Indian and Alaska Native population has demonstrated that the prevalence and incidence of SLE are high. Our estimates are as high as or higher than the rates reported in the US black population. C1 [Ferucci, Elizabeth D.; Choromanski, Tammy L.] Alaska Native Tribal Hlth Consortium, Anchorage, AK 99508 USA. [Johnston, Janet M.] Univ Alaska Anchorage, Anchorage, AK USA. [Gaddy, Jasmine R.] Oklahoma City Area Indian Hlth Serv, Oklahoma City, OK USA. [Sumner, Lisa; Posever, James O.] Phoenix Indian Med Ctr, Phoenix, AZ USA. [Gordon, Caroline] Univ Birmingham, Birmingham, W Midlands, England. [Lim, S. Sam] Emory Univ, Atlanta, GA 30322 USA. [Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ferucci, ED (reprint author), Alaska Native Tribal Hlth Consortium, ANC HEP, Community Hlth Serv, 4315 Diplomacy Dr, Anchorage, AK 99508 USA. EM edferucci@anthc.org FU interagency agreement award from the CDC [IAA 10FED1003070] FX Supported by an interagency agreement award from the CDC to the Indian Health Service (IAA 10FED1003070). NR 22 TC 10 Z9 10 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD SEP PY 2014 VL 66 IS 9 BP 2494 EP 2502 DI 10.1002/art.38720 PG 9 WC Rheumatology SC Rheumatology GA AO3RD UT WOS:000341251100021 PM 24891315 ER PT J AU Voisin, DR King, KM Diclemente, RJ Carry, M AF Voisin, Dexter R. King, Kelly M. Diclemente, Ralph J. Carry, Monique TI Correlates of gang involvement and health-related factors among African American females with a detention history SO CHILDREN AND YOUTH SERVICES REVIEW LA English DT Article DE gang involved; psychocontextual factors; health-related factors; detained girls ID SEXUAL-BEHAVIOR; DRUG-USE; ADOLESCENTS; MEMBERSHIP; VIOLENCE; RISK; VICTIMIZATION; AGGRESSION; QUALITY AB Background: Prior studies have assessed relationships between gang membership and health-related factors. However, the existing literature has largely failed to consider how individual and broader social contextual factors might be related to such gang involvement among African American females. Thus, the aim of the present study was to identify empirically driven correlates of gang involvement and then better understand the relationship between gang membership and health-related behaviors for African American females, after controlling for covariates of gang involvement. Methods: Data were collected from a convenience sample of detained African American adolescents females, between the ages of 13-17, currently incarcerated in a short-term detention facility in Atlanta, Georgia (n = 188). After obtaining written informed assent and parental permission, participants answered survey questions using A-CASI procedures that assessed socio-contextual factors and health-related behaviors. Results: Multiple logistic regression models controlling for age and SES documented that low self-esteem, emotional dysregulation, trauma history, deviant peers, low parental monitoring, infrequent parental communication, housing instability and poor neighborhood quality were correlates of gang involvement. In addition, multiple linear and logistic regression models, controlling for these constructs, revealed that gang involvement was independently associated with lower STD prevention knowledge, a higher likelihood of having a gang-involved boyfriend, a greater risk of having current casual sexual partnerships, higher rates of substance abuse, higher incidences of condom misuse and a lower likelihood of ever having been tested for HIV. Conclusions: These results provide information that can help service providers target certain profiles of African American females who may be at risk for joining gangs and address the health risk behaviors that may be associated with such memberships. (c) 2014 Elsevier Ltd. All rights reserved. C1 [Voisin, Dexter R.] Univ Chicago, Sch Social Serv Adm, Chicago, IL 60637 USA. [Voisin, Dexter R.; Diclemente, Ralph J.] STI HIV Intervent Network, Chicago, IL USA. [King, Kelly M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA. [Diclemente, Ralph J.] Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. [Diclemente, Ralph J.] Emory Ctr AIDS Res, Atlanta, GA USA. [Diclemente, Ralph J.] Indiana Univ, Rural Ctr AIDS STD Prevent, Bloomington, IN USA. [Diclemente, Ralph J.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Carry, Monique] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Prevent Res Branch, Atlanta, GA USA. RP Diclemente, RJ (reprint author), Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd, Atlanta, GA 30322 USA. EM rdiclem@emory.edu NR 54 TC 3 Z9 3 U1 2 U2 21 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0190-7409 EI 1873-7765 J9 CHILD YOUTH SERV REV JI Child. Youth Serv. Rev. PD SEP PY 2014 VL 44 BP 120 EP 125 DI 10.1016/j.childyouth.2014.05.001 PG 6 WC Family Studies; Social Work SC Family Studies; Social Work GA AO6NG UT WOS:000341468200016 ER PT J AU Basavaraju, SV Kuehnert, MJ Zaki, SR Sejvar, JJ AF Basavaraju, Sridhar V. Kuehnert, Matthew J. Zaki, Sherif R. Sejvar, James J. TI Encephalitis Caused by Pathogens Transmitted through Organ Transplants, United States, 2002-2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID WEST-NILE-VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; BALAMUTHIA-MANDRILLARIS; BLOOD-TRANSFUSION; PROCUREMENT ORGANIZATIONS; RABIES VIRUS; TRANSMISSION; INFECTION; DONOR AB The cause of encephalitis among solid organ transplant recipients may be multifactorial; the disease can result from infectious or noninfectious etiologies. During 2002-2013, the US Centers for Disease Control and Prevention investigated several encephalitis clusters among transplant recipients. Cases were caused by infections from transplant-transmitted pathogens: West Nile virus, rabies virus, lymphocytic choriomeningitis virus, and Balamuthia mandrillaris amebae. In many of the clusters, identification of the cause was complicated by delayed diagnosis due to the rarity of the disease, geographic distance separating transplant recipients, and lack of prompt recognition and reporting systems. Establishment of surveillance systems to detect illness among organ recipients, including communication among transplant center physicians, organ procurement organizations, and public health authorities, may enable the rapid discovery and investigation of infectious encephalitis clusters. These transplant-transmitted pathogen clusters highlight the need for greater awareness among clinicians, pathologists, and public health workers, of emerging infectious agents causing encephalitis among organ recipients. C1 [Basavaraju, Sridhar V.; Kuehnert, Matthew J.; Zaki, Sherif R.; Sejvar, James J.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Basavaraju, SV (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A07, Atlanta, GA 30329 USA. EM etu7@cdc.gov NR 40 TC 11 Z9 11 U1 0 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2014 VL 20 IS 9 BP 1443 EP 1451 DI 10.3201/eid2009.131332 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AO3JY UT WOS:000341226700002 PM 25148201 ER PT J AU Deng, XY Desai, PT den Bakker, HC Mikoleit, M Tolar, B Trees, E Hendriksen, RS Frye, JG Porwollik, S Weimer, BC Wiedmann, M Weinstock, GM Fields, PI McClelland, M AF Deng, Xiangyu Desai, Prerak T. den Bakker, Henk C. Mikoleit, Matthew Tolar, Beth Trees, Eija Hendriksen, Rene S. Frye, Jonathan G. Porwollik, Steffen Weimer, Bart C. Wiedmann, Martin Weinstock, George M. Fields, Patricia I. McClelland, Michael TI Genomic Epidemiology of Salmonella enterica Serotype Enteritidis based on Population Structure of Prevalent Lineages SO EMERGING INFECTIOUS DISEASES LA English DT Article ID TANDEM REPEAT ANALYSIS; UNITED-STATES; EVOLUTIONARY; RECOMBINATION; PHYLOGENETICS; TRANSMISSION; PATHOGENS; OUTBREAKS; SELECTION; ORIGINS AB Salmonella enterica serotype Enteritidis is one of the most commonly reported causes of human salmonellosis. Its low genetic diversity, measured by fingerprinting methods, has made subtyping a challenge. We used whole-genome sequencing to characterize 125 S. enterica Enteritidis and 3 S. enterica serotype Nitra strains. Single-nucleotide polymorphisms were filtered to identify 4,887 reliable loci that distinguished all isolates from each other. Our whole-genome single-nucleotide polymorphism typing approach was robust for S. enterica Enteritidis subtyping with combined data for different strains from 2 different sequencing platforms. Five major genetic lineages were recognized, which revealed possible patterns of geographic and epidemiologic distribution. Analyses on the population dynamics and evolutionary history estimated that major lineages emerged during the 17th-18th centuries and diversified during the 1920s and 1950s. C1 [Deng, Xiangyu] Univ Georgia, Griffin, GA 30223 USA. [Desai, Prerak T.; Porwollik, Steffen; McClelland, Michael] Univ Calif Irvine, Irvine, CA USA. [den Bakker, Henk C.; Wiedmann, Martin] Cornell Univ, Ithaca, NY USA. [Mikoleit, Matthew; Tolar, Beth; Trees, Eija; Fields, Patricia I.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hendriksen, Rene S.] Tech Univ Denmark, DK-2800 Lyngby, Denmark. [Frye, Jonathan G.] USDA, Athens, GA USA. [Weimer, Bart C.] Univ Calif Davis, Davis, CA 95616 USA. [Weinstock, George M.] Washington Univ, Sch Med, St Louis, MO USA. RP Deng, XY (reprint author), Univ Georgia, Ctr Food Safety, 1109 Expt St, Griffin, GA 30223 USA. EM xdeng@uga.edu RI Wiedmann, Martin/A-9683-2008; den Bakker, Henk/A-8136-2010; OI Wiedmann, Martin/0000-0002-4168-5662; den Bakker, Henk/0000-0002-4086-1580; Frye, Jonathan/0000-0002-8500-3395; McClelland, Michael/0000-0003-1788-9347 FU American Society for Microbiology/Centers for Disease Control and Prevention Fellowship; University of Georgia; National Institutes of Health [AI039557 AI052237, AI073971, AI075093, AI077645 AI083646, HHSN272200900040C]; US Department of Agriculture (USDA) [2009-03579, 2011-67017-30127]; Binational Agricultural Research and Development Fund; Center for Produce Safety; USDA Agricultural Research Services project [6612-32000-006-00]; USDA [2010-34459-20756] FX X.D. was supported in part by an American Society for Microbiology/Centers for Disease Control and Prevention Fellowship and startup funds from University of Georgia. M.M., S.P., and P.D. were supported in part by National Institutes of Health grant nos. AI039557 AI052237, AI073971, AI075093, AI077645 AI083646, and HHSN272200900040C; US Department of Agriculture (USDA) grant nos. 2009-03579 and 2011-67017-30127; the Binational Agricultural Research and Development Fund; and a grant from the Center for Produce Safety. J.G.F was supported by USDA Agricultural Research Services project no. 6612-32000-006-00. H.dB. and M.W. were supported in part by USDA grant no. 2010-34459-20756 NR 40 TC 14 Z9 16 U1 2 U2 14 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2014 VL 20 IS 9 BP 1481 EP 1489 DI 10.3201/eid2009.131095 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AO3JY UT WOS:000341226700006 PM 25147968 ER PT J AU Pham, CD Reiss, E Hagen, F Meis, JF Lockhart, SR AF Pham, Cau D. Reiss, Errol Hagen, Ferry Meis, Jacques F. Lockhart, Shawn R. TI Passive Surveillance for Azole-Resistant Aspergillus fumigatus, United States, 2011-2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID CYP51A GENE; TRIAZOLE RESISTANCE; CYSTIC-FIBROSIS; ANTIFUNGAL RESISTANCE; HIGH PREVALENCE; IN-VITRO; ITRACONAZOLE; SUSCEPTIBILITY; MUTATIONS; TR/L98H AB Emergence of Aspergillus fumigatus strains containing mutations that lead to azole resistance has become a serious public health threat in many countries. Nucleotide polymorphisms leading to amino acid substitutions in the lanosterol demethylase gene (cyp51A) are associated with reduced susceptibility to azole drugs. The most widely recognized mutation is a lysine to histidine substitution at aa 98 (L98H) and a duplication of the untranscribed promoter region, together known as TR34/L98H. This mechanism of resistance has been reported in Europe, Asia, and the Middle East, and is associated with resistance to all azole drugs and subsequent treatment failures. To determine whether isolates with this mutation are spreading into the United States, we conducted a passive surveillance based study of 1,026 clinical isolates of A. fumigatus from 22 US states during 2011-2013. No isolates harboring the TR34/L98H mutation were detected, and MICs of itraconazole were generally low. C1 [Pham, Cau D.; Reiss, Errol; Lockhart, Shawn R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Hagen, Ferry; Meis, Jacques F.] Canisius Wilhelmina Hosp, Nijmegen, Netherlands. [Hagen, Ferry; Meis, Jacques F.] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands. RP Pham, CD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G11, Atlanta, GA 30333 USA. EM whi4@cdc.gov RI Hagen, Ferry/B-9044-2009; Meis, J.F.G.M./L-4518-2015 OI Hagen, Ferry/0000-0002-5622-1916; FU Office of Antimicrobial Resistance at the Centers for Disease Control and Prevention FX This study was supported by the Office of Antimicrobial Resistance at the Centers for Disease Control and Prevention. NR 40 TC 23 Z9 24 U1 0 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2014 VL 20 IS 9 BP 1498 EP 1503 DI 10.3201/eid2009.140142 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AO3JY UT WOS:000341226700008 PM 25148217 ER PT J AU Patrick, ME Mahon, BE Greene, SA Rounds, J Cronquist, A Wymore, K Boothe, E Lathrop, S Palmer, A Bowen, A AF Patrick, Mary E. Mahon, Barbara E. Greene, Sharon A. Rounds, Joshua Cronquist, Alicia Wymore, Katie Boothe, Effie Lathrop, Sarah Palmer, Amanda Bowen, Anna TI Incidence of Cronobacter spp. Infections, USA, 2003-2009 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ENTEROBACTER-SAKAZAKII; INFANT FORMULA; FOOD AB During 2003-2009, we identified 544 cases of Cronobacter spp. infection from 6 US states. The highest percentage of invasive infections occurred among children <5 years of age; urine isolates predominated among adults. Rates of invasive infections among infants approximate earlier estimates. Overall incidence of 0.66 cases/100,000 population was higher than anticipated. C1 [Patrick, Mary E.; Mahon, Barbara E.; Greene, Sharon A.; Bowen, Anna] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Rounds, Joshua] Minnesota Dept Hlth, St Paul, MN USA. [Cronquist, Alicia] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Wymore, Katie] Calif Emerging Infect Program, Oakland, CA USA. [Boothe, Effie] Tennessee Dept Hlth, Nashville, TN USA. [Lathrop, Sarah] New Mexico Emerging Infect Program, Albuquerque, NM USA. [Palmer, Amanda] Maryland Dept Hlth, Baltimore, MD USA. RP Patrick, ME (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30329 USA. EM mepatrick@cdc.gov NR 15 TC 18 Z9 18 U1 0 U2 18 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2014 VL 20 IS 9 BP 1520 EP 1523 DI 10.3201/eid2009.140545 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AO3JY UT WOS:000341226700012 PM 25148394 ER PT J AU Thapa, NK Tenzin Wangdi, K Dorji, T Migma Dorjee, J Marston, CK Hoffmaster, AR AF Thapa, Nirmal K. Tenzin Wangdi, Karma Dorji, Tshering Migma Dorjee, Jambay Marston, Chung K. Hoffmaster, Alex R. TI Investigation and Control of Anthrax Outbreak at the Human-Animal Interface, Bhutan, 2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID BACILLUS-ANTHRACIS; CUTANEOUS ANTHRAX; BANGLADESH AB In 2010, we investigated anthrax outbreak in Bhutan. A total of 43 domestic animals died, and cutaneous anthrax developed in 9 persons, and 1 died. All affected persons had contact with the carcasses of infected animals. Comprehensive preparedness and response guidelines are needed to increase public awareness of anthrax in Bhutan. C1 [Thapa, Nirmal K.; Tenzin; Migma; Dorjee, Jambay] Natl Ctr Anim Hlth, Thimphu, Bhutan. [Wangdi, Karma; Dorji, Tshering] Minist Hlth, Thimphu, Bhutan. [Marston, Chung K.; Hoffmaster, Alex R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Tenzin (reprint author), Natl Ctr Anim Hlth, Vet Publ Hlth Sect, Dept Livestock, Dis Prevent & Control Unit, Thimphu, Bhutan. EM tenzinvp@gmail.com OI Tenzin, Tenzin/0000-0002-4326-3623 NR 15 TC 6 Z9 7 U1 2 U2 23 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2014 VL 20 IS 9 BP 1524 EP 1526 DI 10.3201/eid2009.140181 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AO3JY UT WOS:000341226700013 PM 25147965 ER PT J AU Abroug, F Slim, A Ouanes-Besbes, L Kacem, MAH Dachraoui, F Ouanes, I Lu, XY Tao, Y Paden, C Caidi, H Miao, CR Al-Hajri, MM Zorraga, M Ghaouar, W BenSalah, A Gerber, SI AF Abroug, Fekri Slim, Amine Ouanes-Besbes, Lamia Kacem, Mohamed-Ali Hadj Dachraoui, Fahmi Ouanes, Islem Lu, Xiaoyan Tao, Ying Paden, Clinton Caidi, Hayat Miao, Congrong Al-Hajri, Mohammed Mohammed Zorraga, Mokhtar Ghaouar, Wissem BenSalah, Afif Gerber, Susan I. CA World Hlth Org Global Outbreak Ale TI Family Cluster of Middle East Respiratory Syndrome Coronavirus Infections, Tunisia, 2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article AB In 2013 in Tunisia, 3 persons in 1 family were infected with Middle East respiratory syndrome coronavirus (MERS-CoV). The index case-patient's respiratory tract samples were negative for MERS-CoV by reverse transcription PCR, but diagnosis was retrospectively confirmed by FOR of serum. Sequences clustered with those from Saudi Arabia and United Arab Emirates. C1 [Abroug, Fekri; Ouanes-Besbes, Lamia; Dachraoui, Fahmi; Ouanes, Islem] CHU F Bourguiba, Intens Care Unit, Monastir 5000, Tunisia. [Slim, Amine; Kacem, Mohamed-Ali Hadj] Ctr Hosp Univ Charles Nicolle, Tunis, Tunisia. [Lu, Xiaoyan; Tao, Ying; Paden, Clinton; Caidi, Hayat; Miao, Congrong; Gerber, Susan I.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Zorraga, Mokhtar; Ghaouar, Wissem; BenSalah, Afif] Direct Soins Sante Base, Tunis, Tunisia. RP Abroug, F (reprint author), CHU F Bourguiba, Intens Care Unit, Rue 1er Juin 1955, Monastir 5000, Tunisia. EM f.abroug@rns.tn NR 10 TC 20 Z9 23 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2014 VL 20 IS 9 BP 1527 EP 1530 DI 10.3201/eid2009.140378 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AO3JY UT WOS:000341226700014 PM 25148113 ER PT J AU Imanishi, M Manikonda, K Murthy, BP Gould, LH AF Imanishi, Maho Manikonda, Karunya Murthy, Bhavini P. Gould, L. Hannah TI Factors Contributing to Decline in Foodborne Disease Outbreak Reports, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article AB The number of foodborne disease outbreaks reported in the United States declined substantially in 2009, when the surveillance system transitioned from reporting only foodborne disease outbreaks to reporting all enteric disease outbreaks. A 2013 survey found that some outbreaks that would have been previously reported as foodborne are now reported as having other transmission modes. C1 [Imanishi, Maho; Manikonda, Karunya; Murthy, Bhavini P.; Gould, L. Hannah] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Manikonda, K (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM hum6@cdc.gov NR 4 TC 2 Z9 2 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2014 VL 20 IS 9 BP 1551 EP 1553 DI 10.3201/eid2009.140044 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AO3JY UT WOS:000341226700020 PM 25147912 ER PT J AU Jones, JL Shvachko, VA Wilkins, EE Bergen, R Manos, MM AF Jones, Jeffrey L. Shvachko, Valentina A. Wilkins, E. Elizabeth Bergen, Randy Manos, M. Michele TI Rate of Congenital Toxoplasmosis in Large Integrated Health Care Setting, California, USA, 1998-2012 SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID GONDII INFECTION C1 [Jones, Jeffrey L.; Wilkins, E. Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Shvachko, Valentina A.; Bergen, Randy; Manos, M. Michele] Kaiser Permanente, Div Res, Oakland, CA USA. RP Jones, JL (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A06, Atlanta, GA 30329 USA. EM jlj1@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2014 VL 20 IS 9 BP 1573 EP 1574 DI 10.3201/eid2009.131919 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AO3JY UT WOS:000341226700029 PM 25151860 ER PT J AU Lankau, EW Turner, PV Mullan, RJ Galland, GG AF Lankau, Emily W. Turner, Patricia V. Mullan, Robert J. Galland, G. Gale TI Worker Health and Safety Practices in Research Facilities Using Nonhuman Primates, North America SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID INFECTION C1 [Lankau, Emily W.; Mullan, Robert J.; Galland, G. Gale] Ctr Dis Control & Prevent, Atlanta, GA USA. [Turner, Patricia V.] Univ Guelph, Guelph, ON N1G 2W1, Canada. RP Lankau, EW (reprint author), LandCow Consulting, POB 7403, Athens, GA 30604 USA. EM landcow.ecohealth@gmail.com RI Lankau, Emily/C-8057-2011 OI Lankau, Emily/0000-0002-7094-7780 NR 9 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2014 VL 20 IS 9 BP 1589 EP 1590 DI 10.3201/eid2009.140420 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AO3JY UT WOS:000341226700038 PM 25153090 ER PT J AU Breedlove, B Chuengsatiansup, K AF Breedlove, Byron Chuengsatiansup, Komatra TI The Art of Intertwining Life and Work SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Breedlove, Byron] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Chuengsatiansup, Komatra] Minist Publ Hlth, Nonthaburi, Thailand. RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E41, Atlanta, GA 30329 USA. EM wbb1@cdc.gov OI Breedlove, Byron/0000-0002-1026-1963 NR 6 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2014 VL 20 IS 9 BP 1598 EP 1599 DI 10.3201/eid2009.AC2009 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AO3JY UT WOS:000341226700043 PM 25295334 ER PT J AU Kissin, DM Kawwass, JF Monsour, M Boulet, SL Session, DR Jamieson, DJ AF Kissin, Dmitry M. Kawwass, Jennifer F. Monsour, Michael Boulet, Sheree L. Session, Donna R. Jamieson, Denise J. CA Natl Art Surveillance Syst NASS TI Assisted hatching: trends and pregnancy outcomes, United States, 2000-2010 SO FERTILITY AND STERILITY LA English DT Article DE Assisted hatching; assisted reproductive technology (ART); in vitro fertilization (IVF); live birth rate; pregnancy outcome ID IN-VITRO FERTILIZATION; EMBRYO QUALITY; CYCLES; CRYOPRESERVATION; IMPLANTATION; RISK AB Objective: To assess trends and outcomes of assisted hatching among assisted reproductive technology (ART) cycles. Design: Retrospective cohort analysis using National ART Surveillance System (NASS) data. Setting: U.S. fertility centers reporting to NASS. Patient(s): Fresh autologous noncanceled ART cycles conducted from 2000-2010. Intervention(s): None. Main Outcome Measure(s): Implantation, clinical pregnancy, live-birth, miscarriage, multiple gestation. Result(s): Assisted hatching use statistically significantly increased in absolute number (from 25,724 to 35,518 cycles), percentages of day-3 (from 50.7% to 56.3%) and day-5 transfers (from 15.9% to 22.8%), and percentage of transfers among women >= 38 years (from 17.8% to 21.8%) or women with >= 2 prior ART cycles and no live birth(s) (from 4.3% to 7.4%). Both day-3 and day-5 cycles involving assisted hatching were associated with lower odds of implantation (adjusted odds ratios [aOR] 0.7 and 0.6, respectively), clinical pregnancy (aOR 0.8 and 0.7, respectively), live birth (aOR 0.8 and 0.7, respectively), and increased odds of miscarriage (aOR 1.4 and 1.4, respectively), as compared with cycles without assisted hatching. Assisted hatching was associated with lower odds of multiple gestation in day-5 cycles (aOR 0.8). In cycles for women with a "poor prognosis," the association of assisted hatching with pregnancy outcomes was not statistically significant. Conclusion(s): Assisted hatching use had an increasing trend but was not associated with improved pregnancy outcomes, even in poor-prognosis patients. Prospective studies are needed to identify the patients who may benefit from assisted hatching. (C)2014 by American Society for Reproductive Medicine. C1 [Kissin, Dmitry M.; Kawwass, Jennifer F.; Monsour, Michael; Boulet, Sheree L.; Jamieson, Denise J.] Emory Univ, Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30322 USA. [Kissin, Dmitry M.; Kawwass, Jennifer F.; Session, Donna R.; Jamieson, Denise J.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA USA. RP Kissin, DM (reprint author), Emory Univ, Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30322 USA. EM dkissin@cdc.gov OI Monsour, Michael/0000-0003-3029-476X FU Intramural CDC HHS [CC999999] NR 16 TC 7 Z9 8 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2014 VL 102 IS 3 BP 795 EP 801 DI 10.1016/j.fertnstert.2014.06.013 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AO5DU UT WOS:000341363300031 PM 25044084 ER PT J AU Adams, E Deutsche, J Okoroh, E Owens-McAlister, S Majumdar, S Ullman, M Damiano, ML Recht, M AF Adams, E. Deutsche, J. Okoroh, E. Owens-McAlister, S. Majumdar, S. Ullman, M. Damiano, M. L. Recht, M. CA Hlth Weight Working Grp TI An inventory of healthy weight practices in federally funded haemophilia treatment centres in the United States SO HAEMOPHILIA LA English DT Article DE body mass index; healthy weight practices; obesity ID CARE; OBESITY; PREVALENCE; OVERWEIGHT; MALES; BOYS AB In the haemophilia population, obesity has an adverse effect on health care cost, chronic complications and joint disease. Although staff of federally funded Hemophilia Treatment Centers in the United States (HTCs) anecdotally recognize these outcomes, practices to promote healthy weights have not been reported. This evaluation identifies routine practices among HTCs in body mass index (BMI) assessment, perceptions about need to address obesity and roles in offering evidence-based strategies to promote healthy weights. A telephone survey was developed to assess HTCs practices including patient BMI assessment and counselling, perceptions about the importance of healthy patient weights, and HTCs roles in weight management. Ninety of the 130 federally funded HTCs contacted elected to participate and completed the telephone survey. Of these, 67% routinely calculated BMI and 48% provided results to patients. Approximately one-third classified obesity correctly for children (30%) and adults (32%), using the Centers for Disease Control and Preventions BMI cut-offs. Most HTCs (87%) reported obesity as an issue of big' or moderate' concern and 98% indicated HTC responsibility to address this issue. Most centres (64%) address patient weight during comprehensive visits. One-third (33%) of centres include a nutritionist; of those without, 61% offer nutrition referrals when needed. Most (89%) HTCs do not have a protocol in place to address healthy weights; 53% indicated that guidelines are needed. HTCs offer services to help improve weight outcomes. Training programmes for calculating and interpreting BMI as well as identifying appropriate guidelines to apply to the HTC patient population are needed. C1 [Adams, E.; Deutsche, J.; Recht, M.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97239 USA. [Okoroh, E.; Owens-McAlister, S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Majumdar, S.] Univ Mississippi, Div Pediat Hematol Oncol, Jackson, MS 39216 USA. [Ullman, M.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Damiano, M. L.] Univ Arizona, Hemophilia & Thrombosis Ctr, Tucson, AZ USA. RP Recht, M (reprint author), Oregon Hlth & Sci Univ, Hemophilia Ctr, 3181 SW Sam Jackson Pk Rd,Mail Code CDRC, Portland, OR 97239 USA. EM rechtm@ohsu.edu FU Intramural CDC HHS [CC999999] NR 14 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD SEP PY 2014 VL 20 IS 5 BP 639 EP 643 DI 10.1111/hae.12385 PG 5 WC Hematology SC Hematology GA AO8HS UT WOS:000341595700013 PM 24629074 ER PT J AU Lane, H Siddiqi, AEA Ingram-Rich, R Tobase, P Ward, RS AF Lane, H. Siddiqi, A. -E. -A. Ingram-Rich, R. Tobase, P. Ward, R. Scott CA Universal Data Collection Joint Hemophilia Treatment Ctr Network TI Functional outcomes following ankle arthrodesis in males with haemophilia: analyses using the CDC's Universal Data Collection surveillance project SO HAEMOPHILIA LA English DT Article DE ankle arthrodesis; ankle fusion; arthropathy; haemophilia; outcomes; range of motion ID ARTHROPATHY; MOTION; MANAGEMENT; RANGE AB In persons with haemophilia (PWH), repeated ankle haemarthroses lead to pain, loss of joint range of motion (ROM), and limitations in activity and participation in society. PWH are offered ankle arthrodesis (AA) to eliminate pain. In our experience, PWH are hesitant to proceed to AA due to concerns regarding gait anomalies, functional decline and complete loss of ROM. The aim of this study was to report outcomes in ROM, assistive device (AD)/wheelchair use, activity scale and work/school absenteeism for participants in the CDC's Universal Data Collection surveillance project (UDC) pre- and post- AA. Males with haemophilia enrolled in the UDC with first report of AA (1998-2010) were selected. Descriptive statistics were calculated using data from the annual study visit pre-AA and the follow-up visit (similar to 12-24months) post-AA. The 68 subjects who fulfilled the criteria were: mean age 36.9years (SD=12.9); 85.3% white; 85.3% haemophilia A; 72% severe, 20.6% moderate; and 10.3% with inhibitor once during the study period. Mean loss in total arc of ankle motion was 17.02 degrees (SD=21.8, P0.01) pre- compared to post-AA. For 61.8%, there was no change in use of AD for ambulation/mobility. For 85.3%, there was no change in use of a wheelchair. On a self-reported activity scale, 11.8% improved, 8.8% worsened and 79.4% did not change. Work/school absenteeism averaged 2.7 (SD=6.4) pre- and 1.5 (SD=6.4, P=0.26) days per year post-AA. While ankle ROM was significantly reduced post-AA, for most subjects, there was no change in use of AD/wheelchair for ambulation/mobility. Physical activity was maintained and work/school absenteeism remained stable. C1 [Lane, H.] Primary Childrens Med Ctr, Intermt Hemophilia & Thrombosis Ctr, Salt Lake City, UT 84113 USA. [Siddiqi, A. -E. -A.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. [Ingram-Rich, R.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA. [Tobase, P.] Univ Calif San Francisco, Hemophilia Treatment Ctr, San Francisco, CA 94143 USA. [Ward, R. Scott] Univ Utah, Dept Phys Therapy, Salt Lake City, UT USA. RP Lane, H (reprint author), Primary Childrens Med Ctr, Intermt Hemophilia & Thrombosis Ctr, Salt Lake City, UT 84113 USA. EM heidi.lane@hsc.utah.edu RI Kerlin, Bryce/E-3369-2011 OI Kerlin, Bryce/0000-0002-1756-8271 FU National Hemophilia Foundation: Physical Therapy Excellence Fellowship Award FX The authors thank the Joint Outcomes Committee of the Universal Data Collection and the Hemophilia Treatment Center Network for their assistance in the preparation of this manuscript. This work was supported in part by a grant from the National Hemophilia Foundation: Physical Therapy Excellence Fellowship Award. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 18 TC 4 Z9 4 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD SEP PY 2014 VL 20 IS 5 BP 709 EP 715 DI 10.1111/hae.12398 PG 7 WC Hematology SC Hematology GA AO8HS UT WOS:000341595700023 PM 24629136 ER PT J AU Wheeler, SB Kuo, TM Goyal, RK Meyer, AM Lich, KH Gillen, EM Tyree, S Lewis, CL Crutchfield, TM Martens, CE Tangka, F Richardson, LC Pignone, MP AF Wheeler, Stephanie B. Kuo, Tzy-Mey Goyal, Ravi K. Meyer, Anne-Marie Lich, Kristen Hassmiller Gillen, Emily M. Tyree, Seth Lewis, Carmen L. Crutchfield, Trisha M. Martens, Christa E. Tangka, Florence Richardson, Lisa C. Pignone, Michael P. TI Regional variation in colorectal cancer testing and geographic availability of care in a publicly insured population SO HEALTH & PLACE LA English DT Article DE Colorectal cancer screening; Medicaid; Medicare; Regional variation; Multilevel modeling; Disabled ID SERVICES TASK-FORCE; PREVENTIVE SERVICES; UNITED-STATES; AVERAGE-RISK; MEDICARE; DISPARITIES; DISABILITY; BREAST; INSURANCE; RECEIPT AB Despite its demonstrated effectiveness, colorectal cancer (CRC) testing is suboptimal, particularly in vulnerable populations such as those who are publicly insured. Prior studies provide an incomplete picture of the importance of the intersection of multilevel factors affecting CRC testing across heterogeneous geographic regions where vulnerable populations live. We examined CRC testing across regions of North Carolina by using population-based Medicare and Medicaid claims data from disabled individuals who turned 50 years of age during 2003-2008. We estimated multilevel models to examine predictors of CRC testing, including distance to the nearest endoscopy facility, county-level endoscopy procedural rates, and demographic and community contextual factors. Less than 50% of eligible individuals had evidence of CRC testing; men, African-Americans, Medicaid beneficiaries, and those living furthest away from endoscopy facilities had significantly lower odds of CRC testing, with significant regional variation. These results can help prioritize intervention strategies to improve CRC testing among publicly insured, disabled populations. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Wheeler, Stephanie B.; Lich, Kristen Hassmiller; Gillen, Emily M.] Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC 27599 USA. [Wheeler, Stephanie B.; Kuo, Tzy-Mey; Goyal, Ravi K.; Meyer, Anne-Marie; Tyree, Seth; Lewis, Carmen L.; Martens, Christa E.; Pignone, Michael P.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Wheeler, Stephanie B.; Lewis, Carmen L.; Crutchfield, Trisha M.; Pignone, Michael P.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA. [Wheeler, Stephanie B.; Crutchfield, Trisha M.; Pignone, Michael P.] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC 27599 USA. [Lewis, Carmen L.; Pignone, Michael P.] Univ N Carolina, Div Gen Med & Clin Epidemiol, Chapel Hill, NC 27599 USA. [Tangka, Florence; Richardson, Lisa C.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Wheeler, SB (reprint author), 135 Dauer Dr,CB 7411, Chapel Hill, NC 27516 USA. EM stephanie_wheeler@unc.edu OI Pignone, Michael/0000-0002-6657-7342; Crutchfield, Trisha/0000-0002-6266-8976 FU Centers for Disease Control and Prevention (CDC), Special Interest Project [11-041]; Agency for Healthcare Research and Quality (AHRQ), Mentored Clinical Scientists Comparative Effectiveness Development Award [1-K-12 HS019468-01]; National Institutes of Health (NIH) [K05 CA129166]; State of North Carolina through the University Cancer Research Fund FX This study was funded by the Centers for Disease Control and Prevention (CDC), Special Interest Project 11-041 "Behavioral economics of colorectal cancer screening in underserved populations" (Co-PIs: Pignone and Wheeler). Additionally, Dr. Wheeler's time on this project was further supported by the Agency for Healthcare Research and Quality (AHRQ), 1-K-12 HS019468-01 Mentored Clinical Scientists Comparative Effectiveness Development Award (PI: Weinberger; Scholar: Wheeler), and Dr. Pignone's time on this project was further supported by the National Institutes of Health (NIH), K05 CA129166 Established Investigator Award in Cancer Prevention and Control: Improving Cancer-Related Patient Decision Making (PI: Pignone). Finally, data, programming, analytic, and systems support were provided by the Integrated Cancer Information and Surveillance System (ICISS), a UNC Lineberger Comprehensive Cancer Center resource funded by the State of North Carolina through the University Cancer Research Fund. NR 37 TC 4 Z9 4 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8292 EI 1873-2054 J9 HEALTH PLACE JI Health Place PD SEP PY 2014 VL 29 BP 114 EP 123 DI 10.1016/j.healthplace.2014.07.001 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO5MI UT WOS:000341388500014 PM 25063908 ER PT J AU Gelanew, T Hailu, A Schonian, G Lewis, MD Miles, MA Yeo, M AF Gelanew, Tesfaye Hailu, Asrat Schonian, Gabriele Lewis, Michael D. Miles, Michael A. Yeo, Matthew TI Multi locus sequence and microsatellite identification of intra-specific hybrids and ancestor-like donors among natural Ethiopian isolates of Leishmania donovani SO INTERNATIONAL JOURNAL FOR PARASITOLOGY LA English DT Article DE Hybridisation; Leishmania; MLMT; MLST; Recombination; Genetic exchange ID POPULATION-STRUCTURE; VISCERAL LEISHMANIASIS; INFANTUM; BRAZILIENSIS; STRAINS; VIANNIA; SEX AB Protozoan parasites of the genus Leishmania (Kinetoplastida: Trypanosomatidae) cause widespread and devastating human diseases. Visceral leishmaniasis is endemic in Ethiopia where it has also been responsible for fatal epidemics. It is postulated that genetic exchange in Leishmania has implications for heterosis (hybrid vigour), spread of virulent strains, resistance to chemotherapeutics, and exploitation of different hosts and vectors. Here we analyse 11 natural Ethiopian Leishmania donovani isolates consisting of four putative hybrids, seven parent-like isolates and over 90 derived biological clones. We apply a novel combination of high resolution multilocus microsatellite typing (five loci) and multilocus sequence typing (four loci) that together distinguish parent-like and hybrid L donovani strains. Results indicate that the four isolates (and their associated biological clones) are genetic hybrids, not the results of mixed infections, each possessing heterozygous markers consistent with inheritance of divergent alleles from genetically distinct Ethiopian L. donovani lineages. The allelic profiles of the putative hybrids may have arisen from a single hybridisation event followed by inbreeding or gene conversion, or alternatively from two or more hybridisation events. Mitochondrial sequencing showed uniparental maxicircle inheritance for all of the hybrids, each possessing a single mitochondria! genotype. Fluorescence activated cell sorting analysis of DNA content demonstrated that all hybrids and their associated clones were diploid. Together the data imply that intra-specific genetic exchange is a recurrent feature of natural L donovani populations, with substantial implications for the phyloepidemiology of Leishmania. (C) 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/). C1 [Gelanew, Tesfaye] Ctr Dis Control & Prevent, Serol Diagnost & Res Lab, Div Vector Bome Dis Dengue Branch, San Juan, PR USA. [Hailu, Asrat] Univ Addis Ababa, Fac Med, Addis Ababa, Ethiopia. [Schonian, Gabriele] Charite, Inst Microbiol & Hyg, D-13353 Berlin, Germany. [Gelanew, Tesfaye; Lewis, Michael D.; Miles, Michael A.; Yeo, Matthew] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England. RP Yeo, M (reprint author), Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Keppel St, London WC1E 7HT, England. EM Matthew.yeo@lshtm.ac.uk FU Wellcome Trust FX We wish to thank Bethlehem Getachew (Leishmaniasis Research and Diagnostic Laboratory, School of Medicine, Addis Ababa University, Ethiopia) for her help with parasite cultivation. We also thank the Leishmaniasis Research and Treatment Centres in Gondar University and Arba Minch Hospital, Ethiopia. We specifically thank Dr Zewdu Hurissa and Dr Workagegnehu Hailu (Gondar University) and Dr. Teklu Weldegebreal (Arba Minch Hospital) for their help during field studies. This work was supported by the Wellcome Trust. NR 25 TC 2 Z9 2 U1 1 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-7519 EI 1879-0135 J9 INT J PARASITOL JI Int. J. Parasit. PD SEP PY 2014 VL 44 IS 10 BP 751 EP 757 DI 10.1016/j.ijpara.2014.05.008 PG 7 WC Parasitology SC Parasitology GA AO6QI UT WOS:000341476200010 PM 24995620 ER PT J AU Stormo, AR Saraiya, M Hing, E Henderson, JT Sawaya, GF AF Stormo, Analia R. Saraiya, Mona Hing, Esther Henderson, Jillian T. Sawaya, George F. TI Women's Clinical Preventive Services in the United States: Who Is Doing What? SO JAMA INTERNAL MEDICINE LA English DT Letter ID VISITS C1 [Stormo, Analia R.; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Hing, Esther] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Henderson, Jillian T.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. [Sawaya, George F.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. RP Saraiya, M (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,MS K 76, Atlanta, GA 30341 USA. EM msaraiya@cdc.gov NR 4 TC 10 Z9 10 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD SEP PY 2014 VL 174 IS 9 BP 1512 EP 1514 DI 10.1001/jamainternmed.2014.3003 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA AO8AL UT WOS:000341574400024 PM 25003954 ER PT J AU Wortham, JM Shapiro, DJ Hersh, AL Hicks, LA AF Wortham, Jonathan M. Shapiro, Daniel J. Hersh, Adam L. Hicks, Lauri A. TI Burden of Ambulatory Visits and Antibiotic Prescribing Patterns for AdultsWith Community-Acquired Pneumonia in the United States, 1998 Through 2009 SO JAMA INTERNAL MEDICINE LA English DT Letter ID GUIDELINES; MANAGEMENT C1 [Wortham, Jonathan M.; Hicks, Lauri A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Resp Dis Branch, Atlanta, GA USA. [Shapiro, Daniel J.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Hersh, Adam L.] Univ Utah, Div Pediat Infect Dis, Salt Lake City, UT USA. RP Wortham, JM (reprint author), 1600 Clifton Rd,NE MS E-10, Atlanta, GA 30333 USA. EM vij5@cdc.gov NR 6 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD SEP PY 2014 VL 174 IS 9 BP 1520 EP 1522 DI 10.1001/jamainternmed.2014.3456 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA AO8AL UT WOS:000341574400028 PM 25070593 ER PT J AU Akinbami, LJ Moorman, JE Simon, AE Schoendorf, KC AF Akinbami, Lara J. Moorman, Jeanne E. Simon, Alan E. Schoendorf, Kenneth C. TI Trends in racial disparities for asthma outcomes among children 0 to 17 years, 2001-2010 SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Asthma; child; race; disparities; prevalence; emergency room; hospitalization; mortality; epidemiology ID CHILDHOOD ASTHMA; MEDICATION USE; CARE AB Background: Racial disparities in childhood asthma have been a long-standing target for intervention, especially disparities in hospitalization and mortality. Objectives: Describe trends in racial disparities in asthma outcomes using both traditional population-based rates and at-risk rates (based on the estimated number of children with asthma) to account for prevalence differences between race groups. Methods: Estimates of asthma prevalence and outcomes (emergency department [ED] visits, hospitalizations, and deaths) were calculated from national data for 2001 to 2010 for black and white children. Trends were calculated using weighted loglinear regression, and changes in racial disparities over time were assessed using Joinpoint. Results: Disparities in asthma prevalence between black and white children increased from 2001 to 2010; at the end of this period, black children were twice as likely as white children to have asthma. Population-based rates showed that disparities in asthma outcomes remained stable (ED visits and hospitalizations) or increased (asthma attack prevalence, deaths). In contrast, analysis with at-risk rates, which account for differences in asthma prevalence, showed that disparities in asthma outcomes remained stable (deaths), decreased (ED visits, hospitalizations), or did not exist (asthma attack prevalence). Conclusions: Using at-risk rates to assess racial disparities in asthma outcomes accounts for prevalence differences between black and white children, and adds another perspective to the population-based examination of asthma disparities. An at-risk rate analysis shows that among children with asthma, there is no disparity for asthma attack prevalence and that progress has been made in decreasing disparities in asthma ED visit and hospitalization rates. C1 [Akinbami, Lara J.; Simon, Alan E.; Schoendorf, Kenneth C.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Infant, Child & Womens Hlth Stat Branch, Hyattsville, MD 20782 USA. [Akinbami, Lara J.; Schoendorf, Kenneth C.] US PHS, Rockville, MD USA. [Moorman, Jeanne E.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA USA. RP Akinbami, LJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Infant, Child & Womens Hlth Stat Branch, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM lea8@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 28 Z9 28 U1 0 U2 10 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD SEP PY 2014 VL 134 IS 3 BP 547 EP + DI 10.1016/j.jaci.2014.05.037 PG 12 WC Allergy; Immunology SC Allergy; Immunology GA AO5GR UT WOS:000341372400005 PM 25091437 ER PT J AU Xia, Y Wong, LY Bunker, BC Bernert, JT AF Xia, Yang Wong, Lee-Yang Bunker, Brandon C. Bernert, John T. TI Comparison of Creatinine and Specific Gravity for Hydration Corrections on Measurement of the Tobacco-Specific Nitrosamine 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol (NNAL) in Urine SO JOURNAL OF CLINICAL LABORATORY ANALYSIS LA English DT Article DE tobacco-specific nitrosamine; 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL); creatinine; specific gravity ID DIETARY-SUPPLEMENT USE; NATIONAL-HEALTH; N-NITROSAMINES; US POPULATION; COTININE CONCENTRATIONS; TOXIC-SUBSTANCES; SECONDHAND SMOKE; F344 RATS; ADJUSTMENT; EXPOSURE AB Background: Tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) was measured in all participants aged 6 years and older from the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey 2007-2008. The suitability of using creatinine or specific gravity for urinary NNAL correction in exposure assessment is examined in this study. Methods: Effects of both specific gravity and creatinine correction on urinary NNAL among smokers were investigated with multiple linear regression models using either normalization or the fitting of creatinine and specific gravity in the model as covariates. Results: When log-scaled NNAL was normalized by either creatinine or specific gravity, R-2 was slightly higher for creatinine than for specific gravity (R-2 = 0.1694 and 0.1439, for creatinine and specific gravity, respectively). When log-scaled NNAL was normalized by both factors, the R-2 was improved (R-2 = 0.2068). When specific gravity or creatinine was included as a covariate separately in the models, they were highly significant factors (P < 0.001, R-2 = 0.2226 and 0.1681 for creatinine and specific gravity, respectively). However, when both were included in the model as covariates, creatinine remained highly significant (P < 0.001), whereas the significance of specific gravity was eliminated (P = 0.4294). Conclusion: This study confirms significant relationships between NNAL concentrations and both urine creatinine and specific gravity. We conclude that creatinine is the more influential and preferred variable to account for urine dilution in tobacco-specific nitrosamine exposure assessment. (C) 2014 Wiley Periodicals, Inc. C1 [Xia, Yang; Wong, Lee-Yang; Bernert, John T.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Bunker, Brandon C.] Univ Louisville, Sch Med, Abell Adm Ctr, Louisville, KY 40292 USA. RP Xia, Y (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway MS F47, Atlanta, GA 30341 USA. EM yxia@cdc.gov NR 44 TC 1 Z9 1 U1 0 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0887-8013 EI 1098-2825 J9 J CLIN LAB ANAL JI J. Clin. Lab. Anal. PD SEP PY 2014 VL 28 IS 5 BP 353 EP 363 DI 10.1002/jcla.21693 PG 11 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AO8XK UT WOS:000341638900003 PM 24648246 ER PT J AU Litvintseva, AP Hurst, S Gade, L Frace, MA Hilsabeck, R Schupp, JM Gillece, JD Roe, C Smith, D Keim, P Lockhart, SR Changayi, S Weil, MR MacCannell, DR Brandt, ME Engelthaler, DM AF Litvintseva, Anastasia P. Hurst, Steven Gade, Lalitha Frace, Michael A. Hilsabeck, Remy Schupp, James M. Gillece, John D. Roe, Chandler Smith, David Keim, Paul Lockhart, Shawn R. Changayi, Shankar Weil, M. Ryan MacCannell, Duncan R. Brandt, Mary E. Engelthaler, David M. TI Whole-Genome Analysis of Exserohilum rostratum from an Outbreak of Fungal Meningitis and Other Infections SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CONTAMINATED METHYLPREDNISOLONE INJECTIONS; MULTISTATE OUTBREAK; UNITED-STATES; DNA; IDENTIFICATION; SOFTWARE AB Exserohilum rostratum was the cause of most cases of fungal meningitis and other infections associated with the injection of contaminated methylprednisolone acetate produced by the New England Compounding Center (NECC). Until this outbreak, very few human cases of Exserohilum infection had been reported, and very little was known about this dematiaceous fungus, which usually infects plants. Here, we report using whole-genome sequencing (WGS) for the detection of single nucleotide polymorphisms (SNPs) and phylogenetic analysis to investigate the molecular origin of the outbreak using 22 isolates of E. rostratum retrieved from 19 case patients with meningitis or epidural/spinal abscesses, 6 isolates from contaminated NECC vials, and 7 isolates unrelated to the outbreak. Our analysis indicates that all 28 isolates associated with the outbreak had nearly identical genomes of 33.8 Mb. A total of 8 SNPs were detected among the outbreak genomes, with no more than 2 SNPs separating any 2 of the 28 genomes. The outbreak genomes were separated from the next most closely related control strain by similar to 136,000 SNPs. We also observed significant genomic variability among strains unrelated to the outbreak, which may suggest the possibility of cryptic speciation in E. rostratum. C1 [Litvintseva, Anastasia P.; Hurst, Steven; Gade, Lalitha; Lockhart, Shawn R.; Brandt, Mary E.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. [Frace, Michael A.] Ctr Dis Control & Prevent, Biotechnol Core Facil, Div Sci Resources, Atlanta, GA USA. [Changayi, Shankar; Weil, M. Ryan; MacCannell, Duncan R.] Ctr Dis Control & Prevent, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Hilsabeck, Remy; Schupp, James M.; Gillece, John D.; Roe, Chandler; Smith, David; Keim, Paul; Engelthaler, David M.] Translat Genom Res Inst, Flagstaff, AZ USA. RP Litvintseva, AP (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. EM frq8@cdc.gov NR 37 TC 11 Z9 11 U1 0 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2014 VL 52 IS 9 BP 3216 EP 3222 DI 10.1128/JCM.00936-14 PG 7 WC Microbiology SC Microbiology GA AO5CL UT WOS:000341359300013 PM 24951807 ER PT J AU Magomani, V Wolter, N Tempia, S du Plessis, M de Gouveia, L von Gottberg, A AF Magomani, Victoria Wolter, Nicole Tempia, Stefano du Plessis, Mignon de Gouveia, Linda von Gottberg, Anne TI Challenges of Using Molecular Serotyping for Surveillance of Pneumococcal Disease SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID REAL-TIME PCR; STREPTOCOCCUS-PNEUMONIAE; BACTERIAL-MENINGITIS; CAPSULAR SEROTYPES; INVASIVE DISEASE; MULTIPLEX PCR; CHILDREN; CULTURE; BURDEN; INFLUENZA AB Recent advances in the molecular identification and serotyping of Streptococcus pneumoniae are useful for culture-negative samples; however, there are limitations associated with these methods. We aimed to assess the value of molecular assays for invasive pneumococcal disease (IPD) surveillance in South Africa from 2010 through 2012. Nonviable isolates and culture-negative clinical specimens were tested for the lytA gene and, if positive, were serotyped, using real-time PCRs. Multinomial regression analysis was used to determine the maximum lytA cycle threshold (C-T) value useful for predicting the ability to detect a serotype for the sample. The chi(2) test was used to compare the prevalence of serotypes between viable/nonviable isolates and culture-negative clinical specimens. Of 11,224 IPD cases reported, 1,091 (10%) were culture-negative samples and 981 (90%) of these were lytA positive. Samples with a lytA CT value of >= 35 were significantly less likely to be serotyped. A serotype/group was determined for 87% (737/844) of samples with a lytA CT value of < 35, of which 60% (443/737) were identified as individual serotypes. The serotype prevalence did not differ significantly between isolates and culture-negative specimens. Although molecular serotyping added 7% (737/11,224) serotyping data, the inability to resolve 40% of samples to single serotypes remains a challenge for serotype-specific data analysis. C1 [Magomani, Victoria; Wolter, Nicole; Tempia, Stefano; du Plessis, Mignon; de Gouveia, Linda; von Gottberg, Anne] Natl Inst Communicable Dis NICD, Johannesburg, South Africa. [Magomani, Victoria; Wolter, Nicole; du Plessis, Mignon; von Gottberg, Anne] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa. [Magomani, Victoria; Wolter, Nicole; du Plessis, Mignon; de Gouveia, Linda; von Gottberg, Anne] MRC, Johannesburg, South Africa. [Tempia, Stefano] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Wolter, N (reprint author), Natl Inst Communicable Dis NICD, Johannesburg, South Africa. EM nicolew@nicd.ac.za FU Medical Research Council of South Africa; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), South Africa FX This work was supported by the Medical Research Council of South Africa and the National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), South Africa. NR 25 TC 10 Z9 10 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2014 VL 52 IS 9 BP 3271 EP 3276 DI 10.1128/JCM.01061-14 PG 6 WC Microbiology SC Microbiology GA AO5CL UT WOS:000341359300021 PM 24958802 ER PT J AU Karim, MR Dong, HJ Yu, FC Jian, FC Zhang, LX Wang, RJ Zhang, SM Rume, FI Ning, CS Xiao, LH AF Karim, Md Robiul Dong, Haiju Yu, Fuchang Jian, Fuchun Zhang, Longxian Wang, Rongjun Zhang, Sumei Rume, Farzana Islam Ning, Changshen Xiao, Lihua TI Genetic Diversity in Enterocytozoon bieneusi Isolates from Dogs and Cats in China: Host Specificity and Public Health Implications SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID HIV-INFECTED PATIENTS; GIARDIA-DUODENALIS; ANTIRETROVIRAL THERAPY; FECAL SAMPLES; GENOTYPES; CRYPTOSPORIDIUM; ANIMALS; MICROSPORIDIOSIS; PARASITES; COLOMBIA AB To explore the genetic diversity, host specificity, and zoonotic potential of Enterocytozoon bieneusi, feces from 348 stray and pet dogs and 96 pet cats from different locations in China were examined by internal transcribed spacer (ITS)-based PCR. E. bieneusi was detected in 15.5% of the dogs, including 20.5% of stray dogs and 11.7% of pet dogs, and in 11.5% of the pet cats. Higher infection rates were recorded in the >2-year and the 1- to 2-year age groups in dogs and cats, respectively. Altogether, 24 genotypes, including 11 known and 13 new, were detected in 65 infected animals. In 54 positive dogs, 18 genotypes, 9 known (PtE-bIX, O, D, CM1, EbpA, Peru8, type IV, EbpC, and PigEBITS5) and 9 new (CD1 to CD9), were found. In contrast, 8 genotypes, 4 known (D, BEB6, I, and PtEbIX) and 4 new (CC1 to CC4), were identified in 11 infected cats. The dominant genotype in dogs was PtEbIX (26/54). Phylogenetic analysis revealed that 8 known genotypes (D, Peru8, type IV, CM1, EbpC, PigEBITS5, O, and EbpA) and 7 new genotypes (CD1 to CD4 and CC2 to CC4) were the members of zoonotic group 1, whereas genotypes CD7, CD8, and CD9 together with PtEbIX belonged to the dog-specific group, and genotypes CD6 and CC1 were placed in group 2 with BEB6 and I. Conversely, genotype CD5 clustered with CM4 without belonging to any previous groups. We conclude that zoonotic genotypes are common in dogs and cats, as are host-specific genotypes in dogs. C1 [Karim, Md Robiul; Dong, Haiju; Yu, Fuchang; Jian, Fuchun; Zhang, Longxian; Wang, Rongjun; Zhang, Sumei; Ning, Changshen] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou, Peoples R China. [Rume, Farzana Islam] Patuakhali Sci & Technol Univ, Dept Microbiol, Patuakhali, Bangladesh. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Zhang, LX (reprint author), Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou, Peoples R China. EM zhanglx8999@gmail.com; lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU State Key Program of the National Natural Science Foundation of China [31330079]; Innovation Scientists and Technicians Troop Construction Projects of Henan Province [134200510012]; International Cooperation and Exchange Projects of the National Natural Science Foundation of China [31110103901]; Key National Science and Technology Specific Projects [2012ZX10004220] FX This study was supported in part by the State Key Program of the National Natural Science Foundation of China (grant 31330079), the Innovation Scientists and Technicians Troop Construction Projects of Henan Province (grant 134200510012), the International Cooperation and Exchange Projects of the National Natural Science Foundation of China (grant 31110103901), and the Key National Science and Technology Specific Projects (grant 2012ZX10004220). NR 32 TC 28 Z9 28 U1 0 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2014 VL 52 IS 9 BP 3297 EP 3302 DI 10.1128/JCM.01352-14 PG 6 WC Microbiology SC Microbiology GA AO5CL UT WOS:000341359300025 PM 24989604 ER PT J AU Nagalingam, S Lisgaris, M Rodriguez, B Jacobs, MR Lederman, M Salata, RA Hujer, AM Muehlenbachs, A DeLeon-Carnes, M Farrell, JJ Sampath, R Bonomo, RA AF Nagalingam, Sudha Lisgaris, Michelle Rodriguez, Benigno Jacobs, Michael R. Lederman, Michael Salata, Robert A. Hujer, Andrea M. Muehlenbachs, Atis DeLeon-Carnes, Marlene Farrell, John J. Sampath, Rangarajan Bonomo, Robert A. TI Identification of Occult Fusobacterium nucleatum Central Nervous System Infection by Use of PCR-Electrospray Ionization Mass Spectrometry SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID RAPID IDENTIFICATION; PATHOGENS AB Anaerobic bacteria are often difficult to detect, especially after the initiation of antibiotics. We describe the application of PCR-electrospray ionization mass spectrometry (PCR/ESI-MS) using a sample of cerebrospinal fluid to identify an anaerobic Gram-negative bacillus, Fusobacterium nucleatum, in a patient with "culture-negative" meningitis and cerebral abscesses. C1 [Nagalingam, Sudha; Lisgaris, Michelle; Rodriguez, Benigno; Lederman, Michael; Salata, Robert A.; Hujer, Andrea M.] Case Western Reserve Univ, Dept Med, Div Infect Dis & HIV Med, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA. [Jacobs, Michael R.] Case Western Reserve Univ, Dept Pathol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA. [Muehlenbachs, Atis; DeLeon-Carnes, Marlene] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Farrell, John J.] Univ Illinois, Sch Med, Dept Med, Peoria, IL USA. [Sampath, Rangarajan] Ibis Biosci, Carlsbad, CA USA. [Hujer, Andrea M.; Bonomo, Robert A.] Vet Affairs Med Ctr, Res Serv, Louis Stokes Cleveland Dept, Cleveland, OH 44106 USA. [Sampath, Rangarajan] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA. [Sampath, Rangarajan] Case Western Reserve Univ, Dept Microbiol, Cleveland, OH 44106 USA. [Sampath, Rangarajan] Case Western Reserve Univ, Dept Mol Biol, Cleveland, OH 44106 USA. RP Bonomo, RA (reprint author), Vet Affairs Med Ctr, Res Serv, Louis Stokes Cleveland Dept, Cleveland, OH 44106 USA. EM Robert.bonomo@va.gov RI Rodriguez, Benigno/C-3365-2009 OI Rodriguez, Benigno/0000-0001-9736-7957 FU Cleveland Department of Veterans Affairs; Veterans Affairs Merit Review Program [1I01BX001974]; Geriatric Research Education and Clinical Center VISN [10]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI063517, R01AI100560]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health through the Antibiotic Resistance Leadership Group under National Institutes of Health [UM1AI104681]; STERIS Corporation; AstraZeneca; Merck; Pfizer; Rib-X Pharmaceuticals FX Funds and facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program award number 1I01BX001974, and the Geriatric Research Education and Clinical Center VISN 10 to R. A. B. supported this work. This work was also supported by funds from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AI063517 and R01AI100560 to R. A. B. and through the Antibiotic Resistance Leadership Group under National Institutes of Health award number UM1AI104681.; R.A.B. has received grant funding from STERIS Corporation, AstraZeneca, Merck, Pfizer, and Rib-X Pharmaceuticals. R.S. is a salaried employee of Ibis Biosciences, a division of Abbott. NR 8 TC 1 Z9 1 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2014 VL 52 IS 9 BP 3462 EP 3464 DI 10.1128/JCM.01082-14 PG 3 WC Microbiology SC Microbiology GA AO5CL UT WOS:000341359300056 PM 24966358 ER PT J AU Gilchrist, J Parker, EM AF Gilchrist, Julie Parker, Erin M. TI Racial and ethnic disparities in fatal unintentional drowning among persons less than 30 years of age United States, 1999-2010 SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE Swimming pool; Natural water; Children; Young adults AB Background: In the U.S., almost 4,000 persons die from drowning annually. Among those 0-29 years, drowning is in the top three causes of unintentional injury death. Methods: To describe racial/ethnic differences in drowning rates by age of decedent and drowning setting, CDC analyzed 12 years of mortality data from 1999 through 2010 for those..29 years. Results: Compared to whites, American Indians/Alaska Natives were twice, and blacks were 1.4 times, as likely to drown. Disparities were greatest in swimming pool settings, with drowning rates among blacks aged 5-19 years 5.5 times higher than those among whites. Conclusions: Drowning rates for black children and teens are higher than those of other race/ethnicities, especially in swimming pools. Practical application: The practicality and effectiveness of current drowning prevention strategies varies by setting; however, basic swimming skills can be beneficial across all settings and may help reduce racial disparities. (C) 2014 National Safety Council and Elsevier Ltd. All rights reserved. C1 [Gilchrist, Julie; Parker, Erin M.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Gilchrist, J (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy,Mailstop F62, Atlanta, GA 30341 USA. EM jrg7@cdc.gov; eparker@cdc.gov NR 9 TC 1 Z9 1 U1 3 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 EI 1879-1247 J9 J SAFETY RES JI J. Saf. Res. PD SEP PY 2014 VL 50 BP 139 EP 142 DI 10.1016/J.jsr.2014.06.001 PG 4 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA AO6QT UT WOS:000341477300016 PM 25142370 ER PT J AU Sarmiento, K Hoffman, R Dmitrovsky, Z Lee, R AF Sarmiento, Kelly Hoffman, Rosanne Dmitrovsky, Zoe Lee, Robin TI A 10-year review of the Centers for Disease Control and Prevention's Heads Up initiatives: Bringing concussion awareness to the forefront SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE CDC; Concussion; Heads Up ID HIGH-SCHOOL; CDC HEADS; SPORTS; COACHES AB TheJournal of Safety Research has partnered with the Office of the Associate Director for Science, Division of 16 Unintentional Injury Prevention in the National Center for Injury Prevention & Control at the Centers for Disease 17 Control and Prevention (CDC) in Atlanta, Georgia, USA, to briefly report on some of the latest findings in the re- 18 search and practice community. This report is the 32nd in a series of CDC articles. C1 [Sarmiento, Kelly; Lee, Robin] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30041 USA. [Hoffman, Rosanne; Dmitrovsky, Zoe] ICF Int, Strateg Commun & Mkt Div, Fairfax, VA USA. RP Sarmiento, K (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30041 USA. EM KSarmiento@cdc.gov FU Intramural CDC HHS [CC999999] NR 20 TC 8 Z9 8 U1 1 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 EI 1879-1247 J9 J SAFETY RES JI J. Saf. Res. PD SEP PY 2014 VL 50 BP 143 EP 147 DI 10.1016/j.jsr.2014.05.003 PG 5 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA AO6QT UT WOS:000341477300017 PM 25142371 ER PT J AU Newton, PN Tabernero, P Dwivedi, P Culzoni, MJ Monge, ME Swamidoss, I Mildenhall, D Green, MD Jahnke, R de Oliveira, MD Simao, J White, NJ Fernandez, FM AF Newton, Paul N. Tabernero, Patricia Dwivedi, Prabha Culzoni, Maria J. Monge, Maria Eugenia Swamidoss, Isabel Mildenhall, Dallas Green, Michael D. Jaehnke, Richard de Oliveira, Miguel dos Santos Simao, Julia White, Nicholas J. Fernandez, Facundo M. TI Falsified medicines in Africa: all talk, no action SO LANCET GLOBAL HEALTH LA English DT Letter C1 [Newton, Paul N.; Tabernero, Patricia] Lao Oxford Mahosot Hosp Wellcome Trust, Mahosot Hosp, Res Unit, Microbiol Lab, Viangchan, Laos. [Newton, Paul N.; Tabernero, Patricia; White, Nicholas J.] Univ Oxford, Churchill Hosp, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England. [Newton, Paul N.; Tabernero, Patricia; White, Nicholas J.] Univ Oxford, Worldwide Antimalarial Resistance Network, Churchill Hosp, Oxford, England. [Newton, Paul N.] London Sch Hyg & Trop Med, London WC1, England. [Dwivedi, Prabha; Culzoni, Maria J.; Monge, Maria Eugenia; Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Culzoni, Maria J.] Univ Nacl Litoral, Fac Bioquim & Ciencias Biol, Catedra Quim Analit 1, Lab Desarrollo Analit Quimiometria, Santa Fe, Argentina. [Culzoni, Maria J.] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina. [Monge, Maria Eugenia] Consejo Nacl Invest Cient & Tecn, Ctr Invest Bionanociencias, Godoy Cruz, Argentina. [Swamidoss, Isabel; Green, Michael D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mildenhall, Dallas] GNS Sci, Lower Hutt, New Zealand. [Jaehnke, Richard] Global Pharma Hlth Fund, Frankfurt, Germany. [de Oliveira, Miguel dos Santos; Simao, Julia] Inspeccao Geral Saude, Luanda, Angola. [White, Nicholas J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Res Unit, Bangkok, Thailand. RP Newton, PN (reprint author), Lao Oxford Mahosot Hosp Wellcome Trust, Mahosot Hosp, Res Unit, Microbiol Lab, Viangchan, Laos. EM paul@tropmedres.ac FU Wellcome Trust [093956] NR 10 TC 16 Z9 16 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2214-109X J9 LANCET GLOB HEALTH JI Lancet Glob. Health PD SEP PY 2014 VL 2 IS 9 BP E509 EP E510 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO5EB UT WOS:000341364400015 PM 25304415 ER PT J AU Osorio, JE Velez, ID Thomson, C Lopez, L Jimenez, A Haller, AA Silengo, S Scott, J Boroughs, KL Stovall, JL Luy, BE Arguello, J Beatty, ME Santangelo, J Gordon, GS Huang, CYH Stinchcomb, DT AF Osorio, Jorge E. Velez, Ivan D. Thomson, Cynthia Lopez, Liliana Jimenez, Alejandra Haller, Aurelia A. Silengo, Shawn Scott, Jaclyn Boroughs, Karen L. Stovall, Janae L. Luy, Betty E. Arguello, John Beatty, Mark E. Santangelo, Joseph Gordon, Gilad S. Huang, Claire Y-H Stinchcomb, Dan T. TI Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study SO LANCET INFECTIOUS DISEASES LA English DT Article ID VIRUS-VACCINE; HUMAN VOLUNTEERS; CLINICAL-TRIAL; I TRIAL; FORMULATIONS; CANDIDATE; CHILDREN; ADOLESCENTS; EFFICACY; PDK-53 AB Background Dengue virus is the most serious mosquito-borne viral threat to public health and no vaccines or antiviral therapies are approved for dengue fever. The tetravalent DENVax vaccine contains a molecularly characterised live attenuated dengue serotype-2 virus (DENVax-2) and three recombinant vaccine viruses expressing the prM and E structural genes for serotypes 1, 3, and 4 in the DENVax-2 genetic backbone. We aimed to assess the safety and immunogenicity of tetravalent DENVax formulations. Methods We undertook a randomised, double-blind, phase 1, dose-escalation trial between Oct 11, 2011, and Nov 9, 2011, in the Rionegro, Antioquia, Colombia. The first cohort of participants (aged 18-45 years) were randomly assigned centrally, via block randomisation, to receive a low-dose formulation of DENvax, or placebo, by either subcutaneous or intradermal administration. After a safety assessment, participants were randomly assigned to receive a high-dose DENVax formulation, or placebo, by subcutaneous or intradermal administration. Group assignment was not masked from study pharmacists, but allocation was concealed from participants, nurses, and investigators. Primary endpoints were frequency and severity of injection-site and systemic reactions within 28 days of each vaccination. Secondary endpoints were the immunogenicity of DENVax against all four dengue virus serotypes, and the viraemia due to each of the four vaccine components after immunisation. Analysis was by intention to treat for safety and per protocol for immunogenicity. Because of the small sample size, no detailed comparison of adverse event rates were warranted. The trial is registered with ClinicalTrials.gov, number NCT01224639. Findings We randomly assigned 96 patients to one of the four study groups: 40 participants (42%) received low-dose vaccine and eight participants (8%) received placebo in the low-dose groups; 39 participants (41%) received high-dose vaccine, with nine (9%) participants assigned to receive placebo. Both formulations were well tolerated with mostly mild and transient local or systemic reactions. No clinically meaningful differences were recorded in the overall incidence of local and systemic adverse events between patients in the vaccine and placebo groups; 68 (86%) of 79 participants in the vaccine groups had solicited systemic adverse events compared with 13 (76%) of 17 of those in the placebo groups. By contrast, 67 participants (85%) in the vaccine group had local solicited reactions compared with five (29%) participants in the placebo group. Immunisation with either high-dose or low-dose DENVax formulations induced neutralising antibody responses to all four dengue virus serotypes; 30 days after the second dose, 47 (62%) of 76 participants given vaccine seroconverted to all four serotypes and 73 (96%) participants seroconverted to three or more dengue viruses. Infectious DENVax viruses were detected in only ten (25%) of 40 participants in the low-dose group and 13 (33%) of 39 participants in the high-dose group. Interpretation Our findings emphasise the acceptable tolerability and immunogenicity of the tetravalent DENVax formulations in healthy, flavivirus-naive adults. Further clinical testing of DENVax in different age groups and in dengue-endemic areas is warranted. C1 [Osorio, Jorge E.; Haller, Aurelia A.; Silengo, Shawn; Scott, Jaclyn; Arguello, John; Gordon, Gilad S.; Stinchcomb, Dan T.] Takeda Vaccines, Deerfield, IL USA. [Velez, Ivan D.; Lopez, Liliana; Jimenez, Alejandra] Univ Antioquia, Programa Estudio & Control Enfermedades Trop, Medellin, Colombia. [Thomson, Cynthia; Santangelo, Joseph] Takeda Vaccines Ptd, Singapore, Singapore. [Boroughs, Karen L.; Stovall, Janae L.; Luy, Betty E.; Huang, Claire Y-H] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Beatty, Mark E.] Dengue Vaccine Initiat, Seoul, South Korea. RP Osorio, JE (reprint author), Takeda Vaccines, Madison, WI 53719 USA. EM jorge.osorio@takeda.com OI Stinchcomb, Dan/0000-0002-3634-7503 FU Takeda Vaccines FX Takeda Vaccines. NR 51 TC 33 Z9 34 U1 0 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD SEP PY 2014 VL 14 IS 9 BP 830 EP 838 DI 10.1016/S1473-3099(14)70811-4 PG 9 WC Infectious Diseases SC Infectious Diseases GA AO4WS UT WOS:000341342700026 PM 25087476 ER PT J AU Leshem, E Lopman, B Glass, R Gentsch, J Banyai, K Parashar, U Patel, M AF Leshem, Eyal Lopman, Ben Glass, Roger Gentsch, Jon Banyai, Krisztian Parashar, Umesh Patel, Manish TI Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis SO LANCET INFECTIOUS DISEASES LA English DT Article ID GROUP-A ROTAVIRUS; 1ST 2 YEARS; MOLECULAR EPIDEMIOLOGY; PROVIDES PROTECTION; POTENTIAL IMPACT; AFRICAN INFANTS; SEVERE DIARRHEA; DOUBLE-BLIND; US CHILDREN; PENTAVALENT AB Background Concerns exist about whether monovalent (RV1) and pentavalent (RV5) rotavirus vaccines provide adequate protection against diverse strains and whether vaccine introduction will lead to selective pressure. We aimed to investigate the distribution of rotavirus strains and strain-specific rotavirus vaccine effectiveness after vaccine introduction. Methods We did a systematic review of published work to assess the strain-specific effectiveness of RV1 and RV5 rotavirus vaccines. We classified strains as homotypic, partly heterotypic, and fully heterotypic based on the amount of antigen-matching between strain and vaccine. When studies reported vaccine effectiveness against single antigens (G-type or P-type), we categorised them as either single-antigen vaccine type or single-antigen non-vaccine type. Our primary outcome was strain-specific vaccine effectiveness, comparing effectiveness of homotypic strains with fully or partly heterotypic strains. A secondary outcome was the prevalence of rotavirus strains after vaccine introduction. We estimated pooled odds ratios using random-effect regression models, stratified by country income level and vaccine type, and tested for differences in strain-specific vaccine effectiveness. We assessed strain distribution trends from surveillance reports. Findings In high-income countries, RV1 pooled vaccine effectiveness was 94% (95% CI 80-98) against homotypic strains, 71% (39-86) against partly heterotypic strains, and 87% (76-93) against fully heterotypic strains. In middle-income settings, respective pooled data were 59% (36-73), 72% (58-81), and 47% (28-61). In high-income countries, RV5 vaccine effectiveness was 83% (78-87) against homotypic strains, 82% (70-89) against single-antigen vaccine type strains, 82% (70-89) against partly heterotypic strains, and 75% (47-88) against single-antigen non-vaccine type strains. In middle-income settings, RV5 vaccine effectiveness was 70% (58-78) against single-antigen vaccine type strains, 37% (10-56) against partly heterotypic strains, and 87% (38-97) against single-antigen non-vaccine type strains. No difference was noted in vaccine effectiveness for either RV1 or RV5 in any setting (all p>0-05). Prevalent strains in countries using RV1 were G2P[4] (2198 of 4428,50%) and G1P[8] (953,22%), and those in countries using RV5 were G1P[8] (1280 of 3875, 33%) and G2P[4] (1169,30%). Sustained predominance of a single strain was not recorded. Interpretation RV1 and RV5 exert similar effectiveness against homotypic and heterotypic rotavirus strains. Persistence of specific strains was not recorded, suggesting vaccine-induced selective pressure did not occur. Expansion of rotavirus surveillance efforts to low-income countries and ongoing surveillance are crucial to identify emergence of new strains and to assess strain-specific vaccine effectiveness in various settings. C1 [Leshem, Eyal; Lopman, Ben; Gentsch, Jon; Parashar, Umesh; Patel, Manish] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Leshem, Eyal] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA. [Glass, Roger] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Banyai, Krisztian] Hungarian Acad Sci, Vet Med Res Inst, Agr Res Ctr, H-1581 Budapest, Hungary. RP Leshem, E (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM eleshem@cdc.gov OI Leshem, Eyal/0000-0003-1267-6131; Banyai, Krisztian/0000-0002-6270-1772 NR 52 TC 33 Z9 35 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD SEP PY 2014 VL 14 IS 9 BP 847 EP 856 DI 10.1016/S1473-3099(14)70832-1 PG 10 WC Infectious Diseases SC Infectious Diseases GA AO4WS UT WOS:000341342700028 PM 25082561 ER PT J AU Hakizimana, E Cyubahiro, B Rukundo, A Kabayiza, A Mutabazi, A Beach, R Patel, R Tongren, JE Karema, C AF Hakizimana, Emmanuel Cyubahiro, Beatus Rukundo, Alphonse Kabayiza, Allan Mutabazi, Alphonse Beach, Raymond Patel, Roopal Tongren, Jon E. Karema, Corine TI Monitoring long-lasting insecticidal net (LLIN) durability to validate net serviceable life assumptions, in Rwanda SO MALARIA JOURNAL LA English DT Article DE LLIN; Serviceable life; Durability; Survivorship/attrition; Fabric integrity; Loss; Distribution/replacement time AB Background: To validate assumptions about the length of the distribution-replacement cycle for long-lasting insecticidal nets (LLINs) in Rwanda, the Malaria and other Parasitic Diseases Division, Rwanda Ministry of Health, used World Health Organization methods to independently confirm the three-year LLIN serviceable life span recommendation of WHO. Methods: Approximately 3,000 coded LLINs, distributed as part of a national campaign, were monitored in six sites, by means of six-monthly visits to selected houses. Two indicators, survivorship/attrition, a measure of the number of nets remaining, and fabric integrity, the proportion of remaining nets in either 'good', 'serviceable' or 'needs replacement' condition, based on holes in the net material, were tracked. To validate the assumption that the intervention would remain effective for three years, LLIN coverage, calculated using either survivorship, or integrity, by removing nets in the 'needs replacement' category from the survivorship total, was compared with the predicted proportion of nets remaining, derived from a net loss model, that assumes an LLIN serviceable life of three years. Results: After two years, there was close agreement between estimated LLIN survivorship at all sites, 75% (range 64-84%), and the predicted proportion of nets remaining, 75%. However, when integrity was considered, observed survivorship at all sites, declined to 42% (range 10-54%). Conclusions: More than half, 58%, of the LLINs fell into the 'needs replacement' category after two years. While these nets were counted for survivorship, they were judged to be of little-to-no benefit to a user. Therefore, when integrity was taken into account, survivorship was significantly lower than predicted, suggesting that net serviceable life was actually closer to two, rather than three years, and, by extension, that the impact of the intervention during year three of the LLIN distribution-replacement cycle could be well below that seen in years one and two. C1 [Hakizimana, Emmanuel; Cyubahiro, Beatus; Rukundo, Alphonse; Kabayiza, Allan; Mutabazi, Alphonse; Karema, Corine] Minist Hlth, Rwanda Biomed Ctr, Malaria & Other Parasit Dis Div, Kigali, Rwanda. [Beach, Raymond] Ctr Dis Control & Prevent, Entomol Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Patel, Roopal; Tongren, Jon E.] US Agcy Int Dev, Presidents Malaria Initiat, Ctr Dis Control, Kigali, Rwanda. [Hakizimana, Emmanuel] Wageningen Univ, Entomol Lab, NL-6700 AP Wageningen, Netherlands. RP Beach, R (reprint author), Ctr Dis Control & Prevent, Entomol Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. EM rfb1@cdc.gov FU Government of Rwanda; President's Malaria Initiative (PMI) via the Bureau for Global Health, United States Agency for International Development (USAID); Global Fund malaria SSF FX Our thanks are addressed to the Ministry of Health, local leaders, health providers, community health workers and residents at the LLIN monitoring sites. This work was supported by the Government of Rwanda and funded by the President's Malaria Initiative (PMI) via the Bureau for Global Health, United States Agency for International Development (USAID) and the Global Fund malaria SSF. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the Government of Rwanda or USAID. NR 7 TC 11 Z9 11 U1 2 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD SEP 1 PY 2014 VL 13 AR 344 DI 10.1186/1475-2875-13-344 PG 8 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AP0CX UT WOS:000341729700001 PM 25174414 ER PT J AU Schauer, GL Agaku, IT King, BA Malarcher, AM AF Schauer, Gillian L. Agaku, Israel T. King, Brian A. Malarcher, Ann M. TI Health Care Provider Advice for Adolescent Tobacco Use: Results From the 2011 National Youth Tobacco Survey SO PEDIATRICS LA English DT Article DE tobacco use cessation; smoking cessation; counseling; adolescent; questionnaires ID SELF-REPORTED SMOKING; HIGH-SCHOOL-STUDENTS; UNITED-STATES; INTERVENTIONS; CESSATION; MIDDLE AB BACKGROUND: Health care providers play an important role in promoting tobacco use abstinence among adolescents. This study aimed to provide nationally representative data on the prevalence of provider tobacco use screening and advice delivered to adolescents. Cessation behaviors and correlates of past year quit attempts among current smokers are also explored. METHODS: Data came from the 2011 National Youth Tobacco Survey, a nationally representative school-based survey of adolescents in grades 6 through 12 (n = 18 385). Provider screening and advice were assessed by smoking status and demographic characteristics. Logistic regression was used to assess the association between advice and past year quit attempt. RESULTS: The overall prevalence of current tobacco use was 16.6%; 10.8% were current cigarette smokers (3.6% were established smokers, 7.2% were nonestablished smokers); 17.3% were former smokers; and 71.9% were never smokers (22.6% high susceptibility, 77.4% low susceptibility). Among all respondents, the prevalence of being asked about tobacco use by a health care provider was 32.2%; the prevalence of being advised to quit or avoid tobacco was 31.4%. Established smokers were more likely than other groups to report provider assessment of tobacco use and advice. Receipt of advice was associated with a higher adjusted odds of having made a past year quit attempt (odds ratio: 1.47, 95% confidence interval: 1.18-1.82). CONCLUSIONS: Less than one-third of adolescents report being asked about tobacco use or being advised not to use tobacco. Increased tobacco use intervention by health care providers is needed to prevent initiation and increase cessation. C1 [Schauer, Gillian L.] Carter Consulting Inc, Atlanta, GA USA. [Schauer, Gillian L.] US Ctr Dis Control & Prevent, Georgia Contractor Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Schauer, Gillian L.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. [Agaku, Israel T.; King, Brian A.; Malarcher, Ann M.] US Ctr Dis Control & Prevent, Contractor Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Agaku, Israel T.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Div Appl Sci, Epidem Intelligence Serv, Atlanta, GA USA. RP Schauer, GL (reprint author), US Ctr Dis Control & Prevent, Carter Consulting Inc, Contractor Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Mailstop F-79, Atlanta, GA 30341 USA. EM gschauer@cdc.gov NR 29 TC 7 Z9 7 U1 3 U2 9 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 IS 3 BP 446 EP 455 DI 10.1542/peds.2014-0458 PG 10 WC Pediatrics SC Pediatrics GA AO5DN UT WOS:000341362600043 PM 25136037 ER PT J AU Greenbaum, AH Chen, JF Reed, C Beavers, S Callahan, D Christensen, D Finelli, L Fry, AM AF Greenbaum, Adena H. Chen, Jufu Reed, Carrie Beavers, Suzanne Callahan, David Christensen, Deborah Finelli, Lyn Fry, Alicia M. TI Hospitalizations for Severe Lower Respiratory Tract Infections SO PEDIATRICS LA English DT Article DE severe respiratory tract infection; hospitalizations; children ID YOUNG-CHILDREN; NATIVE CHILDREN; INFLUENZA; DISEASE; PNEUMONIA; MORTALITY; INFANTS; ILLNESS; BURDEN; TRENDS AB BACKGROUND: Hospitalization for lower respiratory tract infections (LRTIs) among children have been well characterized. We characterized hospitalizations for severe LRTI among children. METHODS: We analyzed claims data from commercial and Medicaid insurance enrollees (MarketScan) ages 0 to 18 years from 2007 to 2011. LRTI hospitalizations were identified by the first 2 listed International Classification of Diseases, Ninth Revision discharge codes; those with ICU admission and/or receiving mechanical ventilation were defined as severe LRTI. Underlying conditions were determined from out- and inpatient discharge codes in the preceding year. We report insurance specific and combined rates that used both commercial and Medicaid rates and adjusted for age and insurance status. RESULTS: During 2007-2011, we identified 16 797 and 12 053 severe LRTI hospitalizations among commercial and Medicaid enrollees, respectively. The rates of severe LRTI hospitalizations per 100 000 person-years were highest in children aged <1 year (commercial: 244; Medicaid: 372, respectively), and decreased with age. Among commercial enrollees, >= 1 condition increased the risk for severe LRTI (1 condition: adjusted relative risk, 2.68; 95% confidence interval, 2.58-2.78; 3 conditions: adjusted relative risk, 4.85; 95% confidence interval, 4.65-5.07) compared with children with no medical conditions. Using commercial/Medicaid combined rates, an estimated 31 289 hospitalizations for severe LRTI occurred each year in children in the United States. CONCLUSIONS: Among children, the burden of hospitalization for severe LRTI is greatest among children aged <1 year. Children with underlying medical conditions are at greatest risk for severe LRTI hospitalization. C1 [Greenbaum, Adena H.; Chen, Jufu; Reed, Carrie; Finelli, Lyn; Fry, Alicia M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. [Greenbaum, Adena H.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Epidem Intelligence Serv, Influenza Div, Atlanta, GA 30333 USA. [Christensen, Deborah] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA 30333 USA. [Callahan, David] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. [Christensen, Deborah] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Fry, AM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop A-32, Atlanta, GA 30333 USA. EM afry@cdc.gov NR 27 TC 6 Z9 7 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 IS 3 BP 546 EP 554 DI 10.1542/peds.2014-0244 PG 9 WC Pediatrics SC Pediatrics GA AO5DN UT WOS:000341362600056 PM 25113302 ER PT J AU Ervin, RB Fryar, CD Wang, CY Miller, IM Ogden, CL AF Ervin, R. Bethene Fryar, Cheryl D. Wang, Chia-Yih Miller, Ivey M. Ogden, Cynthia L. TI Strength and Body Weight in US Children and Adolescents SO PEDIATRICS LA English DT Article DE strength; youth; physical activity; NHANES; NNYFS ID KNEE EXTENSION STRENGTH; ISOMETRIC MUSCLE FORCE; CARDIORESPIRATORY FITNESS; PHYSICAL-ACTIVITY; NORMATIVE DATA; RISK-FACTORS; VALUES; YOUTH; OBESE; MASS AB BACKGROUND AND OBJECTIVES: Regular aerobic and muscle-strengthening physical activity in youth has been positively associated with health and may help prevent obesity. The purpose of this study is to provide reference values on 4 core, upper, and lower body measures of muscle strength among US children and adolescents and to investigate the association between these measures of strength and weight status. METHODS: We assessed muscular strength using 4 different tests (plank, modified pull-up, knee extension, and grip strength) in 1224 youth aged 6 to 15 years collected during the 2012 National Health and Nutrition Examination Survey National Youth Fitness Survey. Mean and median estimates are provided by gender, age, and weight status. Weight status was defined based on standard categories of obesity, overweight, normal weight, and underweight using the gender-specific BMI-for-age Centers for Disease Control and Prevention growth charts. RESULTS: There were significant positive trends with age for each of the strength tests (P < .001) except the modified pull-up among girls. The length of time the plank was held decreased as weight status increased for both girls and boys (P < .001). As weight status increased the number of modified pull-ups decreased (P < .001 boys and girls). Scores on the knee extension increased as weight status increased (P < .01). Grip strength increased as weight status increased (P < .01). CONCLUSIONS: Increasing weight status had a negative association with measures of strength that involved lifting the body, but was associated with improved performances on tests that did not involve lifting the body. C1 [Ervin, R. Bethene; Fryar, Cheryl D.; Wang, Chia-Yih; Miller, Ivey M.; Ogden, Cynthia L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Ogden, CL (reprint author), CDC, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4415, Hyattsville, MD 20782 USA. EM cogden@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 15 Z9 15 U1 2 U2 12 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 IS 3 BP E782 EP E789 DI 10.1542/peds.2014-0794 PG 8 WC Pediatrics SC Pediatrics GA AO5DN UT WOS:000341362600019 PM 25157016 ER PT J AU Gaensbauer, JT Lindsey, NP Messacar, K Staples, JE Fischer, M AF Gaensbauer, James T. Lindsey, Nicole P. Messacar, Kevin Staples, J. Erin Fischer, Marc TI Neuroinvasive Arboviral Disease in the United States: 2003 to 2012 SO PEDIATRICS LA English DT Article DE arboviruses; epidemiology; child; United States ID WEST-NILE-VIRUS; EASTERN EQUINE ENCEPHALITIS; LA-CROSSE ENCEPHALITIS; CENTRAL-NERVOUS-SYSTEM; RISK-FACTORS; INFECTION; CHILDREN; EPIDEMIOLOGY; CALIFORNIA; USA AB OBJECTIVE: To describe the epidemiologic and clinical syndromes associated with pediatric neuroinvasive arboviral infections among children in the United States from 2003 through 2012. METHODS: We reviewed data reported by state health departments to ArboNET, the national arboviral surveillance system, for 2003 through 2012. Children (<18 years) with neuroinvasive arboviral infections (eg, meningitis, encephalitis, or acute flaccid paralysis) were included. Demographic, clinical syndrome, outcome, geographic, and temporal data were analyzed for all cases. RESULTS: During the study period, 1217 cases and 22 deaths due to pediatric neuroinvasive arboviral infection were reported from the 48 contiguous states. La Crosse virus (665 cases; 55%) and West Nile virus (505 cases; 41%) were the most common etiologies identified. Although less common, Eastern equine encephalitis virus (30 cases; 2%) resulted in 10 pediatric deaths. La Crosse virus primarily affected younger children, whereas West Nile virus was more common in older children and adolescents. West Nile virus disease cases occurred throughout the country, whereas La Crosse and the other arboviruses were more focally distributed. CONCLUSIONS: Neuroinvasive arboviral infections were an important cause of pediatric disease from 2003 through 2012. Differences in the epidemiology and clinical disease result from complex interactions among virus, vector, host, and the environment. Decreasing the morbidity and mortality from these agents depends on vector control, personal protection to reduce mosquito and tick bites, and blood donor screening. Effective surveillance is critical to inform clinicians and public health officials about the epidemiologic features of these diseases and to direct prevention efforts. C1 [Gaensbauer, James T.; Messacar, Kevin] Univ Colorado, Sch Med, Dept Pediat, Div Pediat Infect Dis, Aurora, CO USA. [Lindsey, Nicole P.; Staples, J. Erin; Fischer, Marc] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO 80521 USA. RP Fischer, M (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM mfischer@cdc.gov FU Centers for Disease Control and Prevention FX Drs Gaensbauer and Messacar received funding from the Centers for Disease Control and Prevention for this study. NR 60 TC 15 Z9 15 U1 0 U2 6 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD SEP PY 2014 VL 134 IS 3 BP E642 EP E650 DI 10.1542/peds.2014-0498 PG 9 WC Pediatrics SC Pediatrics GA AO5DN UT WOS:000341362600002 PM 25113294 ER PT J AU Grow, D Kawwass, JF Kulkarni, AD Durant, T Jamieson, DJ Macaluso, M AF Grow, Daniel Kawwass, Jennifer F. Kulkarni, Aniket D. Durant, Tonji Jamieson, Denise J. Macaluso, Maurizio TI GnRH agonist and GnRH antagonist protocols: comparison of outcomes among good-prognosis patients using national surveillance data SO REPRODUCTIVE BIOMEDICINE ONLINE LA English DT Article DE agonist; antagonist; implantation rate; live birth rate; good prognosis ID GONADOTROPIN-RELEASING-HORMONE; IN-VITRO FERTILIZATION; OVARIAN STIMULATION; IMPLANTATION; PREGNANCY; TRIAL; WOMEN AB Implantation and live birth rates resulting from IVF cycles using gonadotropin-releasing hormone (GnRH) agonist and (GnRH) antagonist IVF protocols were compared among good-prognosis patients using the Centers for Disease Control and Prevention's National Assisted Reproductive Technology Surveillance System 2009-2010 data (n = 203,302 fresh, autologous cycles). Bivariable and multivariable analyses were conducted between cycles to compare outcomes. Cycles were restricted as follows: age younger than 35 years, maximum FSH less than 10 mIU/mL, first assisted reproduction technology cycle and FSH dose less than 3601 IU. A subgroup analysis including only elective single embryo transfer was also carried out. Among good-prognosis patients, the GnRH-agonist protocol was associated with a lower risk of cancellation before retrieval (4.3 versus 5.2%; P < 0.05) or transfer (5.5 versus 6.8%; P < 0.05), and a higher live birth rate per transfer (adjusted odds ratio [OR] 1.13, confidence interval [CI] 1.03 to 1.25) than the GnRH-antagonist group. Among the elective single embryo transfer group, the GnRH-agonist protocol was associated with a higher implantation rate (adjusted odds ratio [OR] 1.36, CI 1.08 to 1.73) and a higher live birth rate (adjusted OR 1.33, CI 1.07 to 1.66) compared with the GnRH-antagonist protocol. The GnRH-antagonist group had lower rates of ovarian hyperstimulation syndrome. Among good-prognosis patients, agonist protocols decreased cancellation risk and increased odds of implantation and live birth. Antagonist protocols may confer decreased risk of hyperstimulation. (C) 2014 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved. C1 [Grow, Daniel] Baystate Med Ctr, Dept Obstet & Gynecol, Springfield, MA USA. [Kawwass, Jennifer F.; Kulkarni, Aniket D.; Durant, Tonji; Jamieson, Denise J.; Macaluso, Maurizio] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Kawwass, Jennifer F.; Jamieson, Denise J.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Endocrinol & Infertil, Atlanta, GA USA. RP Kawwass, JF (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM jennifer.kawwass@emory.edu NR 15 TC 7 Z9 7 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1472-6483 EI 1472-6491 J9 REPROD BIOMED ONLINE JI Reprod. Biomed. Online PD SEP PY 2014 VL 29 IS 3 BP 299 EP 304 DI 10.1016/j.rbmo.2014.05.007 PG 6 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AO5IT UT WOS:000341378500007 PM 25043892 ER PT J AU Dawson, AL Riehle-Colarusso, T Reefhuis, J Arena, JF AF Dawson, April L. Riehle-Colarusso, Tiffany Reefhuis, Jennita Arena, J. Fernando CA Natl Birth Defects Prevention TI Maternal Exposure to Methotrexate and Birth Defects: A Population-Based Study SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE methotrexate; birth defects; congenital heart defects ID LOW-DOSE METHOTREXATE; RHEUMATOID-ARTHRITIS; ECTOPIC PREGNANCY; EMBRYOPATHY; PREVENTION; BLOOD AB Methotrexate is an anti-folate medication that is associated with increased risk of multiple birth defects. Using data from the National Birth Defects Prevention Study, a case-control study of major birth defects in the United States, we examined mothers exposed to methotrexate. The study population included mothers of live-born infants without major birth defects (controls) and mothers of fetuses or infants with a major birth defect (cases), with expected dates of delivery between October 1997 and December 2009. Mothers of cases and controls were asked detailed questions concerning pregnancy history, demographic information, and exposures in a telephone interview. Approximately 0.06%(n = 16/27,623) of case and 0.04%(n = 4/10,113) of control mothers reported exposure to methotrexate between 3 months prior to conception through the end of pregnancy. Of the 16 case infants, 11 (68.8%) had a congenital heart defect (CHD). The observed CHDs included atrial septal defects, tetralogy of Fallot, valvar pulmonary stenosis, ventricular septal defects (VSDs), and total anomalous pulmonary venous return. One case infant had microtia in addition to a VSD and another had VACTER association. Exposed cases without a CHD had one of the following birth defects: cleft palate, hypospadias, congenital diaphragmatic hernia, or craniosynostosis. Based on a limited number of methotrexate-exposed mothers, our findings support recent case reports suggesting an association between early pregnancy exposure to methotrexate and CHDs. Because of the rarity of maternal periconceptional exposure to methotrexate, long-term, population-based case-control studies are needed to confirm these findings and better evaluate the association between methotrexate and birth defects. (C) 2014 Wiley Periodicals, Inc. C1 [Dawson, April L.; Riehle-Colarusso, Tiffany; Reefhuis, Jennita; Arena, J. Fernando; Natl Birth Defects Prevention] CDC, NCBDDD, Atlanta, GA 30333 USA. RP Dawson, AL (reprint author), CDC, NCBDDD, 1600 Clifton Rd MS-E86, Atlanta, GA 30333 USA. EM isp3@cdc.gov FU Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention [PA96043, PA02081, FOA DD09-001] FX Grant sponsor: Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention; Grant numbers: PA96043, PA02081, FOA DD09-001. NR 20 TC 6 Z9 6 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD SEP PY 2014 VL 164 IS 9 BP 2212 EP 2216 DI 10.1002/ajmg.a.36625 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA AN5YO UT WOS:000340669200011 PM 24898111 ER PT J AU Broussard, CS Frey, MT Hernandez-Diaz, S Greene, MF Chambers, CD Sahin, L Sharp, BAC Honein, MA AF Broussard, Cheryl S. Frey, Meghan T. Hernandez-Diaz, Sonia Greene, Michael F. Chambers, Christina D. Sahin, Leyla Sharp, Beth A. Collins Honein, Margaret A. TI Developing a systematic approach to safer medication use during pregnancy: summary of a Centers for Disease Control and Prevention-convened meeting SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE Centers for Disease Control and Prevention; expert review; medications; pregnancy; teratogens ID RECOMMENDATIONS; WOMEN; LACTATION; INFECTION; FETAL; BIRTH; RISK; CDC AB To address information gaps that limit informed clinical decisions on medication use in pregnancy, the Centers for Disease Control and Prevention (CDC) solicited expert input on a draft prototype outlining a systematic approach to evaluating the quality and strength of existing evidence for associated risks. The draft prototype outlined a process for the systematic review of available evidence and deliberations by a panel of experts to inform clinical decision making for managing health conditions in pregnancy. At an expert meeting convened by the CDC in January 2013, participants divided into working groups discussed decision points within the prototype. This report summarizes their discussions of best practices for formulating an expert review process, developing evidence summaries and treatment guidance, and disseminating information. There is clear recognition of current knowledge gaps and a strong collaboration of federal partners, academic experts, and professional organizations willing to work together toward safer medication use during pregnancy. C1 [Broussard, Cheryl S.; Frey, Meghan T.; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Frey, Meghan T.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Greene, Michael F.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Greene, Michael F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Chambers, Christina D.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA. [Chambers, Christina D.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Sahin, Leyla] US FDA, Ctr Drug Evaluat & Res, Off New Drugs, Maternal Hlth Team,Pediat & Maternal Hlth Staff, Silver Spring, MD USA. [Sharp, Beth A. Collins] Agcy Healthcare Res & Qual, Rockville, MD USA. RP Broussard, CS (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. FU Centers for Disease Control and Prevention (CDC) FX This work was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC (M.T.F.). NR 35 TC 11 Z9 11 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD SEP PY 2014 VL 211 IS 3 BP 208 EP U667 DI 10.1016/j.ajog.2014.05.040 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AO4HO UT WOS:000341297900007 PM 24881821 ER PT J AU Callaghan, WM AF Callaghan, William M. TI Geographic variation of reproductive health indicators and outcomes in the United States: place matters SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE disparity; infant mortality rate; preterm birth; social determinant of health ID PRETERM BIRTH AB The social determinants of health are the circumstances in which people are born, grow up, live, work, and age and the systems put in place to deal with illness. These circumstances, in turn, are shaped by a wider set of forces: economics, social policies, and politics. Reproductive health indicators and conditions that are germane to obstetricians and gynecologists vary across states and regions in the United States as well as within regions and states. The aim of this article is to illustrate this variation with the use of examples of gynecologic malignancies, sexually transmitted infections, teen birth rates, preterm birth rates, and infant mortality rates. Using the example of infant death, the difficulties in "unpacking" the construct of place will be discussed, and a special emphasis is placed on the interaction of race, place, and disparities in shaping perinatal outcomes. Finally, readily available and easy-to-use online data resources will be provided so that obstetricians and gynecologists will be able to assess geographic variation in health indicators and outcomes in their own localities. C1 [Callaghan, William M.] Ctr Dis Control, Div Reprod Hlth, Atlanta, GA 30333 USA. [Callaghan, William M.] Ctr Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Callaghan, WM (reprint author), Ctr Dis Control, Div Reprod Hlth, Atlanta, GA 30333 USA. EM wgc0@cdc.gov FU Intramural CDC HHS [CC999999] NR 9 TC 1 Z9 1 U1 0 U2 10 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD SEP PY 2014 VL 211 IS 3 BP 278 EP + DI 10.1016/j.ajog.2014.06.043 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AO4HO UT WOS:000341297900033 PM 24956548 ER PT J AU Smith, BD Yartel, AK AF Smith, Bryce D. Yartel, Anthony K. TI Comparison of Hepatitis C Virus Testing Strategies Birth Cohort Versus Elevated Alanine Aminotransferase Levels SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID LIVER-FUNCTION TESTS; UNITED-STATES; PRIMARY-CARE; SERUM ALANINE; UPPER LIMITS; COST-EFFECTIVENESS; VIRAL-HEPATITIS; RISK BEHAVIOR; BLOOD-DONORS; DRUG-USERS AB Background: Hepatitis C virus (HCV) infection is unidentified in an estimated 40%-85% of infected adults. Surveillance and modeling data have found significant increases in HCV-associated morbidity and mortality. Purpose: To compare two HCV antibody (anti-HCV) testing strategies based on (1) elevated alanine aminotransferase levels (ALT) and (2) a birth cohort approach for people born during 1945-1965. Methods: Data from 19,055 adults aged 20-70 years who completed the National Health and Nutrition Examination Survey in 1999-2008 were analyzed in 2013. Two independent models were evaluated, based on membership in the 1945-1965 birth cohort or elevated ALT, to compare the number of identified anti-HCV-positive (anti-HCV+) individuals; proportion of total identified cases; and the number of people that would be tested using either strategy. Results: The prevalence of anti-HCV among adults aged 20-70 years was estimated at 2.0% (95% CI=1.8%, 2.3%), representing about 3.6 million people. The birth cohort strategy would result in testing about 85.4 million people and identifying nearly 2.8 million anti-HCV+ people with a sensitivity of 76.6%. The ALT strategy would test about 21.5 million adults and identify approximately 1.8 million anti-HCV+ people with a sensitivity of 50.0%. Implementing both strategies concurrently would identify 87.3% of anti-HCV+ adults. Conclusions: The birth cohort strategy, which is recommended by both the CDC and the U.S. Preventive Services Task Force, would identify 1 million more anti-HCV+ people than the elevated ALT approach. Concurrent implementation would identify an even larger number of individuals ever infected. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Smith, Bryce D.] CDC, Atlanta, GA 30333 USA. [Yartel, Anthony K.] CDC Fdn, Atlanta, GA USA. RP Smith, BD (reprint author), CDC, 1600 Clifton Rd,MS G-37, Atlanta, GA 30333 USA. EM bsmith6@cdc.gov NR 75 TC 5 Z9 5 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2014 VL 47 IS 3 BP 233 EP 241 DI 10.1016/j.amepre.2014.05.011 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AN6WH UT WOS:000340738600001 PM 25145616 ER PT J AU Ekwueme, DU Uzunangelov, VJ Hoerger, TJ Miller, JW Saraiya, M Benard, VB Hall, IJ Royalty, J Li, CY Myers, ER AF Ekwueme, Donatus U. Uzunangelov, Vladislav J. Hoerger, Thomas J. Miller, Jacqueline W. Saraiya, Mona Benard, Vicki B. Hall, Ingrid J. Royalty, Janet Li, Chunyu Myers, Evan R. TI Impact of the National Breast and Cervical Cancer Early Detection Program on Cervical Cancer Mortality Among Uninsured Low-Income Women in the US, 1991-2007 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SQUAMOUS-CELL CARCINOMA; SERVICES TASK-FORCE; UNITED-STATES; PREVENTIVE SERVICES; HEALTH; CYTOLOGY; TRENDS; ADENOCARCINOMA; INTERVENTIONS; SCREEN AB Background: The benefits of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) on cervical cancer screening for participating uninsured low-income women have never been measured. Purpose: To estimate the benefits in life-years (LYs) gained; quality-adjusted life-years (QALYs) gained; and deaths averted. Methods: A cervical cancer simulation model was constructed based on an existing cohort model. The model was applied to NBCCEDP participants aged 18-64 years. Screening habits for uninsured low-income women were estimated using National Health Interview Survey data from 1990 to 2005 and NBCCEDP data from 1991 to 2007. The study was conducted during 2011-2012 and covered all 68 NBCCEDP grantees in 50 states, the District of Columbia, five U.S. territories, and 12 tribal organizations. Separate simulations were performed for the following three scenarios: (1) women who received NBCCEDP (Program) screening; (2) women who received screening without the program (No Program); and (3) women who received no screening (No Screening). Results: Among 1.8 million women screened in 1991-2007, the Program added 10,369 LYs gained compared to No Program, and 101,509 LYs gained compared to No Screening. The Program prevented 325 women from dying of cervical cancer relative to No Program, and 3,829 relative to No Screening. During this time period, the Program accounted for 15,589 QALYs gained when compared with No Program, and 121,529 QALYs gained when compared with No Screening. Conclusions: These estimates suggest that NBCCEDP cervical cancer screening has reduced Mortality among medically underserved low-income women who participated in the program. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Ekwueme, Donatus U.; Miller, Jacqueline W.; Saraiya, Mona; Benard, Vicki B.; Hall, Ingrid J.; Royalty, Janet; Li, Chunyu] CDC, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Uzunangelov, Vladislav J.] Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA. [Hoerger, Thomas J.] RTI Int, Res Triangle Pk, NC USA. [Myers, Evan R.] Duke Univ, Dept Obstet & Gynecol, Durham, NC USA. RP Ekwueme, DU (reprint author), CDC, Div Canc Prevent & Control, 4770 Buford Highway,Chamblee Bldg 107,MS F-76, Atlanta, GA 30341 USA. EM dce3@cdc.gov NR 40 TC 5 Z9 5 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2014 VL 47 IS 3 BP 300 EP 308 DI 10.1016/j.amepre.2014.05.016 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AN6WH UT WOS:000340738600008 PM 25015564 ER PT J AU Cooper, CP Saraiya, M AF Cooper, Crystale Purvis Saraiya, Mona TI Opting Out of Cervical Cancer Screening Physicians Who Do Not Perform Pap Tests SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID WOMEN; CARE; MEMBERS; SEX AB Background: Some primary care physicians choose not to provide cervical cancer screening. Purpose: To investigate the characteristics and screening beliefs of family practitioners and internists who treat adult women in outpatient settings but perform no routine Pap tests. Methods: A survey of U.S. primary care physicians (N=892) was conducted and analyzed in 2012. Results: Participants who performed no Pap tests during a typical month (17.2% of family practitioners and 44.3% of internists) generally reported that they referred patients to gynecologists for cervical cancer screening. The most significant predictor of Pap test non-provision was agreement that patients are best served by having Pap tests performed by gynecologists (AOR=8.80, 95% CI=5.58, 13.88, p<0.001). Conclusions: The perception that patients benefit from cervical cancer screening administered by gynecologists may deter screening in primary care settings, resulting in missed opportunities to offer screening to women who are never or rarely screened. (C) 2014 American Journal of Preventive Medicine. All rights reserved. C1 [Cooper, Crystale Purvis] Soltera Ctr Canc Prevent & Control, Tucson, AZ USA. [Saraiya, Mona] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Saraiya, M (reprint author), CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,MS K76, Atlanta, GA 30341 USA. EM yzs2@cdc.gov FU CDC's Inside Knowledge: Get the Facts About Gynecologic Cancer Campaign FX This study was funded by the CDC's Inside Knowledge: Get the Facts About Gynecologic Cancer Campaign (cdc.gov/cancer/knowledge). NR 18 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2014 VL 47 IS 3 BP 315 EP 319 DI 10.1016/j.amepre.2014.04.018 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AN6WH UT WOS:000340738600010 PM 24953518 ER PT J AU Jeffries, WL AF Jeffries, William L. TI Beyond the Bisexual Bridge Sexual Health Among US Men Who Have Sex with Men and Women SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID AFRICAN-AMERICAN MEN; MARKETING HIV PREVENTION; IDENTIFIED LATINO MEN; UNITED-STATES; BLACK-MEN; RISK BEHAVIORS; REDUCTION INTERVENTION; SECONDARY SYPHILIS; ADOLESCENT MALES; CONDOM USE AB Context: Men who have sex with both men and women (MSMW) experience health problems in ways that distinguish them from men who only have sex with men (MSM) and men who only have sex with women (MSW). Historically, an undue focus on MSMW's potential role in transmitting HIV to women has resulted in limited understanding of these men's unique sexual health needs. This article discusses the sexual health of MSMW in the U.S. Evidence acquisition: The author searched PubMed, Sociological Abstracts, PsycINFO, and GoogleScholar to acquire peer-reviewed studies pertaining to MSMW that were published during January 2008 and December 2013. Reference lists for these studies provided additional studies not acquired through this search. Evidence synthesis: MSMW are more likely than MSW to be infected with HIV. MSMW may be at increased risk for some other sexually transmitted infections (STIs) compared with both MSW and MSM. Some factors that affect their sexual health include unprotected sex, early sexual debut, forced sexual encounters, increased numbers of sexual partners, substance use, exchange sex, risk behaviors of their male and female partners, and pregnancy-related considerations. These factors uniquely shape MSMW's vulnerability to HIV/STIs and other sexual health problems. Anti-bisexual sentiment, socioeconomic marginalization, culturally specific masculine ideologies, and sexual identity can negatively influence their sexual partnerships and likelihood of disease acquisition. Conclusions: Risk-reduction interventions alone are likely insufficient to improve MSMW's sexual health. Efforts should also address the social contexts affecting MSMW in order to decrease HIV/STI vulnerability and mitigate other barriers to MSMW's sexual health. (Am J Prey Med 2014;47(3):320-329) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Jeffries, William L.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Jeffries, WL (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E37, Atlanta, GA 30333 USA. EM wjeffries@cdc.gov NR 78 TC 12 Z9 12 U1 4 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2014 VL 47 IS 3 BP 320 EP 329 DI 10.1016/j.amepre.2014.05.002 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AN6WH UT WOS:000340738600011 PM 24970239 ER PT J AU Jacob, V Chattopadhyay, SK Elder, RW Robinson, MN Tansil, KA Soler, RE Labre, MP Mercer, SL AF Jacob, Verughese Chattopadhyay, Sajal K. Elder, Randy W. Robinson, Maren N. Tansil, Kristin A. Soler, Robin E. Labre, Magdala P. Mercer, Shawna L. CA Community Preventive Serv Task For TI Economics of Mass Media Health Campaigns with Health-Related Product Distribution A Community Guide Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID COST-EFFECTIVENESS; PROGRAM; INTERVENTION; ADOLESCENTS; PROMOTION AB Context: The objective of this systematic review was to determine the costs, benefits, and overall economic value of communication campaigns that included mass media and distribution of specified health-related products at reduced price or free of charge. Evidence acquisition: Economic evaluation studies from a literature search from January 1980 to December 2009 were screened and abstracted following systematic economic review methods developed by The Community Guide. Data were analyzed in 2011. Evidence synthesis: The economic evidence was grouped and assessed by type of product distributed and health risk addressed. A total of 15 evaluation studies were included in the economic review, involving campaigns promoting the use of child car seats or booster seats, pedometers, condoms, recreational safety helmets, and nicotine replacement therapy. Conclusions: Economic merits of the intervention could not be determined for health communication campaigns associated with use of recreational helmets, child car seats, and pedometers, primarily because available economic information and analyses were incomplete. There is some evidence that campaigns with free condom distribution to promote safer sex practices were cost-effective among high-risk populations and the cost per quit achieved in campaigns promoting tobacco cessation with nicotine replacement therapy products may translate to a cost per quality-adjusted life-year less than $50,000. Many interventions were publicly funded trials or programs, and the failure to properly evaluate their economic cost and benefit is a serious gap in the science and practice of public health. (Am J Prey Med 2014;47(3):348-359) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Jacob, Verughese; Chattopadhyay, Sajal K.; Elder, Randy W.; Robinson, Maren N.; Tansil, Kristin A.; Soler, Robin E.; Labre, Magdala P.; Mercer, Shawna L.; Community Preventive Serv Task For] CDC, Community Guide Branch, Div Epidemiol Anal & Lib Serv, Atlanta, GA 30333 USA. RP Jacob, V (reprint author), CDC, Community Guide Branch, 1600 Clifton Rd,Mailstop E69, Atlanta, GA 30333 USA. EM hir0@cdc.gov OI Jacob, Verughese/0000-0001-6833-6588 FU Intramural CDC HHS [CC999999] NR 24 TC 2 Z9 2 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2014 VL 47 IS 3 BP 348 EP 359 DI 10.1016/j.amepre.2014.05.031 PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AN6WH UT WOS:000340738600014 PM 25145619 ER PT J AU Robinson, MN Tansil, KA Elder, RW Soler, RE Labre, MP Mercer, SL Eroglu, D Baur, C Lyon-Daniel, K Fridinger, F Sokler, LA Green, LW Miller, T Dearing, JW Evans, WD Snyder, LB Viswanath, KK Beistle, DM Chervin, DD Bernhardt, JM Rimer, BK AF Robinson, Maren N. Tansil, Kristin A. Elder, Randy W. Soler, Robin E. Labre, Magdala P. Mercer, Shawna L. Eroglu, Dogan Baur, Cynthia Lyon-Daniel, Katherine Fridinger, Fred Sokler, Lynn A. Green, Lawrence W. Miller, Therese Dearing, James W. Evans, William D. Snyder, Leslie B. Viswanath, K. Kasisomayajula Beistle, Diane M. Chervin, Doryn D. Bernhardt, Jay M. Rimer, Barbara K. CA Community Prevent Serv Task Force TI Mass Media Health Communication Campaigns Combined with Health-Related Product Distribution A Community Guide Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID BICYCLE HELMET USE; HIV-PREVENTION; CONTROLLED-TRIAL; INTERVENTION; QUITLINE; BEHAVIOR; ADOLESCENTS; PROMOTION; SERVICES; EXPOSURE AB Context: Health communication campaigns including mass media and health-related product distribution have been used to reduce mortality and morbidity through behavior change. The intervention is defined as having two core components reflecting two social marketing principles: (1) promoting behavior change through multiple communication channels, one being mass media, and (2) distributing a free or reduced-price product that facilitates adoption and maintenance of healthy behavior change, sustains cessation of harmful behaviors, or protects against behavior-related disease or injury. Evidence acquisition: Using methods previously developed for the Community Guide, a systematic review (search period, January 1980-December 2009) was conducted to evaluate the effectiveness of health communication campaigns that use multiple channels, including mass media, and distribute health-related products. The primary outcome of interest was use of distributed health-related products. Evidence synthesis: Twenty-two studies that met Community Guide quality criteria were analyzed in 2010. Most studies showed favorable behavior change effects on health-related product use (a median increase of 8.4 percentage points). By product category, median increases in desired behaviors ranged from 4.0 percentage points for condom promotion and distribution campaigns to 10.0 percentage points for smoking-cessation campaigns. Conclusions: Health communication campaigns that combine mass media and other communication channels with distribution of free or reduced-price health-related products are effective in improving healthy behaviors. This intervention is expected to be applicable across U.S. demographic groups, with appropriate population targeting. The ability to draw more specific conclusions about other important social marketing practices is constrained by limited reporting of intervention components and characteristics. (Am J Prey Med 2014;47(3):360-371) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Robinson, Maren N.; Tansil, Kristin A.; Elder, Randy W.; Soler, Robin E.; Labre, Magdala P.; Mercer, Shawna L.] CDC, Community Guide Branch, Div Epidemiol Anal & Lib Serv, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Eroglu, Dogan; Baur, Cynthia; Lyon-Daniel, Katherine; Fridinger, Fred; Sokler, Lynn A.] CDC, Off Assoc Director Commun, Off Director, Atlanta, GA 30333 USA. [Beistle, Diane M.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Green, Lawrence W.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Miller, Therese] Agcy Healthcare Res & Qual, Rockville, MD USA. [Dearing, James W.] Michigan State Univ, E Lansing, MI 48824 USA. [Evans, William D.] George Washington Univ, St Louis, MO USA. [Snyder, Leslie B.] Univ Connecticut, Storrs Mansfield, CT USA. [Chervin, Doryn D.] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. [Chervin, Doryn D.] SciMetrika, Durham, NC USA. [Rimer, Barbara K.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Bernhardt, Jay M.] Univ Florida, Gainesville, FL USA. RP Elder, RW (reprint author), Guide Community Prevent Serv, 1600 Clifton Rd,Mailstop E-69, Atlanta, GA 30333 USA. EM relder1@cdc.gov OI Bernhardt, Jay/0000-0002-2045-4005 NR 58 TC 10 Z9 11 U1 3 U2 34 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2014 VL 47 IS 3 BP 360 EP 371 DI 10.1016/j.amepre.2014.05.034 PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AN6WH UT WOS:000340738600015 PM 25145620 ER PT J AU Kaye, WE Sanchez, M Wu, J AF Kaye, Wendy E. Sanchez, Marchelle Wu, Jennifer TI Feasibility of creating a National ALS Registry using administrative data in the United States SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION LA English DT Article DE Amyotrophic lateral sclerosis; prevalence studies; epidemiology; registry ID AMYOTROPHIC-LATERAL-SCLEROSIS; HEALTH INFORMATION-SYSTEMS; HOSPITAL DISCHARGE DATA; MEDICARE CLAIMS DATA; NEURON DISEASE; RISK-FACTORS; ACCURACY; DIAGNOSES; VETERANS; SENSITIVITY AB Uncertainty about the incidence and prevalence of amyotrophic lateral sclerosis (ALS), as well as the role of the environment in the etiology of ALS, supports the need for a surveillance system/registry for this disease. Our aim was to evaluate the feasibility of using existing administrative data to identify cases of ALS. The Agency for Toxic Substances and Disease Registry (ATSDR) funded four pilot projects at tertiary care facilities for ALS, HMOs, and state based organizations. Data from Medicare, Medicaid, the Veterans Health Administration, and Veterans Benefits Administration were matched to data available from site-specific administrative and clinical databases for a five-year time-period (1 January 2001-31 December 2005). Review of information in the medical records by a neurologist was considered the gold standard for determining an ALS case. We developed an algorithm using variables from the administrative data that identified true cases of ALS (verified by a neurologist). Individuals could be categorized into ALS, possible ALS, and not ALS. The best algorithm had sensitivity of 87% and specificity of 85%. We concluded that administrative data can be used to develop a surveillance system/registry for ALS. These methods can be explored for creating surveillance systems for other neurodegenerative diseases. C1 [Kaye, Wendy E.] McKing Consulting Corp, Atlanta, GA 30341 USA. [Sanchez, Marchelle; Wu, Jennifer] Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. RP Kaye, WE (reprint author), McKing Consulting Corp, 2900 Chamblee Tucker Rd,Bldg 10,Suite 100, Atlanta, GA 30341 USA. EM wek1@cdc.gov FU Intramural CDC HHS [CC999999] NR 36 TC 4 Z9 4 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 2167-8421 EI 2167-9223 J9 AMYOTROPH LAT SCL FR JI Amyotroph. Lateral Scher. Frontotemp. Degenerat. PD SEP PY 2014 VL 15 IS 5-6 BP 433 EP 439 DI 10.3109/21678421.2014.887119 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA AN8BY UT WOS:000340827800016 PM 24597459 ER PT J AU Djomand, G Quaye, S Sullivan, PS AF Djomand, Gaston Quaye, Silas Sullivan, Patrick S. TI HIV epidemic among key populations in west Africa SO CURRENT OPINION IN HIV AND AIDS LA English DT Review DE concentrated epidemics; female sex workers; key populations; men who have sex with men; west Africa ID FEMALE SEX WORKERS; SEXUALLY-TRANSMITTED INFECTIONS; UNPROTECTED ANAL INTERCOURSE; PLACEBO-CONTROLLED TRIAL; RISK BEHAVIORS; NIGERIA IMPLICATIONS; COTE-DIVOIRE; CONDOM USE; MEN; PREVALENCE AB Purpose of review Globally, HIV infection remains a significant issue for key populations such as men who have sex with men (MSM) and female sex workers. A review of recent articles was conducted for west African countries to assess the burden of disease among female sex workers and MSM, access to services and identify barriers to implementation of services for key populations. Recent findings In west Africa, key populations engage in high-risk practices for the acquisition of HIV and other sexually transmitted infections. Available HIV prevalence data fluctuate across and within countries for both MSM and female sex workers and may be five to ten times as high as that of the general population. HIV prevalence varied from 15.9% in The Gambia to 68% in Benin among female sex workers, whereas it ranged from 9.8% in The Gambia to 34.9% in Nigeria for MSM. Yet, important data gaps exist, including key populations size estimations in several countries as well as HIV prevalence, incidence and other biomarkers of HIV risk. Because of sociocultural, legal, political and economic challenges, exacerbated by a poor health system infrastructure, the HIV response is not strategically directed toward programs for key populations in countries with concentrated epidemics. Noteworthy is the low coverage of prevention care and treatment interventions offered to key populations. Summary Sufficient planning and political will with legal and structural frameworks that reconcile public health and human rights are needed to prioritize HIV prevention, care and treatment programming for key populations programs in west Africa. C1 [Djomand, Gaston] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Quaye, Silas] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Accra, Ghana. [Sullivan, Patrick S.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Djomand, G (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, 1600 Clifton Rd,MS-E04, Atlanta, GA 30333 USA. EM gdd7@cdc.gov FU Intramural CDC HHS [CC999999] NR 65 TC 8 Z9 8 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1746-630X EI 1746-6318 J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD SEP PY 2014 VL 9 IS 5 BP 506 EP 513 DI 10.1097/COH.0000000000000090 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AN4NU UT WOS:000340565600012 PM 25010898 ER PT J AU Espeland, MA Glick, HA Bertoni, A Brancati, FL Bray, GA Clark, JM Curtis, JM Egan, C Evans, M Foreyt, JP Ghazarian, S Gregg, EW Hazuda, HP Hill, JO Hire, D Horton, ES Hubbard, V Jakicic, JM Jeffery, RW Johnson, KC Kahn, SE Killean, T Kitabchi, AE Knowler, WC Kriska, A Lewis, CE Miller, M Montez, MG Murillo, A Nathan, DM Nyenwe, E Patricio, J Peters, AL Pi-Sunyer, X Pownall, H Redmon, B Rushing, J Ryan, DH Safford, M Tsai, AG Wadden, TA Wing, RR Yanovski, SZ Zhang, P AF Espeland, Mark A. Glick, Henry A. Bertoni, Alain Brancati, Frederick L. Bray, George A. Clark, Jeanne M. Curtis, Jeffrey M. Egan, Caitlin Evans, Mary Foreyt, John P. Ghazarian, Siran Gregg, Edward W. Hazuda, Helen P. Hill, James O. Hire, Don Horton, Edward S. Hubbard, Van S. Jakicic, John M. Jeffery, Robert W. Johnson, Karen C. Kahn, Steven E. Killean, Tina Kitabchi, Abbas E. Knowler, William C. Kriska, Andrea Lewis, Cora E. Miller, Marsha Montez, Maria G. Murillo, Anne Nathan, David M. Nyenwe, Ebenezer Patricio, Jennifer Peters, Anne L. Pi-Sunyer, Xavier Pownall, Henry Redmon, Bruce Rushing, Julia Ryan, Donna H. Safford, Monika Tsai, Adam G. Wadden, Thomas A. Wing, Rena R. Yanovski, Susan Z. Zhang, Ping CA Look AHEAD Res Grp TI Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services Among Overweight and Obese Adults With Type 2 Diabetes: The Action for Health in Diabetes SO DIABETES CARE LA English DT Article ID DISEASE RISK-FACTORS; LOOK-AHEAD ACTION; WEIGHT-LOSS; CARDIOVASCULAR-DISEASE; CLINICAL-TRIAL; MELLITUS; INDIVIDUALS; PREVENTION; METFORMIN; SAVINGS AB OBJECTIVE To assess the relative impact of an intensive lifestyle intervention (ILI) on use and costs of health care within the Look AHEAD trial. RESEARCH DESIGN AND METHODS A total of 5,121 overweight or obese adults with type 2 diabetes were randomly assigned to an ILI that promoted weight loss or to a comparison condition of diabetes support and education (DSE). Use and costs of health-care services were recorded across an average of 10 years. RESULTS ILI led to reductions in annual hospitalizations (11%, P = 0.004), hospital days (15%, P = 0.01), and number of medications (6%, P < 0.001), resulting in cost savings for hospitalization (10%, P = 0.04) and medication (7%, P < 0.001). ILI produced a mean relative per-person 10-year cost savings of $5,280 (95% CI 3,385-7,175); however, these were not evident among individuals with a history of cardiovascular disease. CONCLUSIONS Compared with DSE over 10 years, ILI participants had fewer hospitalizations, fewer medications, and lower health-care costs. C1 [Espeland, Mark A.; Hire, Don; Rushing, Julia] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC 27157 USA. [Glick, Henry A.; Wadden, Thomas A.] Univ Penn, Weight & Eating Disorder Program, Philadelphia, PA 19104 USA. [Bertoni, Alain] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA. [Brancati, Frederick L.; Clark, Jeanne M.] Johns Hopkins Sch Med, Baltimore, MD USA. [Bray, George A.; Ryan, Donna H.] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Curtis, Jeffrey M.; Killean, Tina; Knowler, William C.] NIDDK, Southwest Amer Indian Ctr, Phoenix, AZ USA. [Egan, Caitlin; Wing, Rena R.] Miriam Hosp, Brown Med Sch, Weight Control & Diabet Res Ctr, Providence, RI 02906 USA. [Evans, Mary; Hubbard, Van S.; Yanovski, Susan Z.] NIDDK, NIH, Bethesda, MD USA. [Foreyt, John P.; Pownall, Henry] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Ghazarian, Siran; Peters, Anne L.] Roybal Comprehens Hlth Ctr, Los Angeles, CA USA. [Gregg, Edward W.; Zhang, Ping] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hazuda, Helen P.; Montez, Maria G.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Hill, James O.; Miller, Marsha] Univ Colorado, Hlth Sci Ctr, Anschutz Hlth & Wellness Ctr, Aurora, CO USA. [Horton, Edward S.] Joslin Diabet Ctr, Dept Clin Epidemiol, Boston, MA 02215 USA. [Jakicic, John M.; Kriska, Andrea] Univ Pittsburgh, Diabet Unit, Dept Hlth & Phys Act, Pittsburgh, PA USA. [Jeffery, Robert W.; Redmon, Bruce] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Johnson, Karen C.; Kitabchi, Abbas E.; Nyenwe, Ebenezer] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Kahn, Steven E.; Murillo, Anne] Univ Washington, Dept Med, Seattle, WA USA. [Lewis, Cora E.; Safford, Monika] Univ Alabama Birmingham, Birmingham, AL USA. [Nathan, David M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Patricio, Jennifer; Pi-Sunyer, Xavier] St Lukes Roosevelt Hosp, Div Dept Med, New York, NY 10025 USA. [Tsai, Adam G.] Univ Colorado, Hlth Sci Ctr, Div Internal Med, Aurora, CO USA. RP Espeland, MA (reprint author), Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC 27157 USA. EM mespelan@wakehealth.edu OI Redmon, J. Bruce/0000-0002-1883-9467; Kriska, Andrea/0000-0002-3522-0869; Kahn, Steven/0000-0001-7307-9002 FU Merck; Amgen; Amylin Pharmaceuticals, LLC; Bristol-Myers Squibb/AstraZeneca; GI Dynamic, Inc.; Gilead Sciences, Inc.; International Medical Press Global Partnership for Effective Diabetes Management; Janssen Pharmaceuticals, Inc.; Merck Research Laboratories, Inc.; Sanofi, Inc.; Vivus, Inc.; Theracos Pharmaceuticals, Inc.; Takeda Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Medtronic MiniMed; Medscape; Novo Nordisk; Janssen; Takeda; Vivus; Eisai; diaDexus FX M.A.E. serves on monitoring boards for Terumo Medical Corporation and the Kowa Research Institute. He serves on a steering committee for Boehringer Ingelheim and has recently served on an advisory committee for Takeda Global Research. H. A. G. has twice been a sponsored lecturer by Merck. J.O.H. serves on advisory boards for Takeda and Novo Nordisk. E. S. H. has received consulting, advisory board, monitoring board, and speakers' board support from Amgen; Amylin Pharmaceuticals, LLC; Bristol-Myers Squibb/AstraZeneca; GI Dynamic, Inc.; Gilead Sciences, Inc.; International Medical Press Global Partnership for Effective Diabetes Management; Janssen Pharmaceuticals, Inc.; Merck Research Laboratories, Inc.; Sanofi, Inc.; Vivus, Inc.; Theracos Pharmaceuticals, Inc.; and Takeda Pharmaceuticals, Inc. E.N. has received research support from Eli Lilly and Company and GlaxoSmithKline. A. L. P. has consulted for Abbott Diabetes Care, Becton Dickinson, Bristol-Myers Squibb, Boehringer Ingelheim, Janssen, Lilly, Medtronic MiniMed, and Sanofi; has been on the speakers' bureau for Bristol-Myers Squibb/AstraZeneca and Novo Nordisk; has received research grant funding from Medtronic MiniMed; and has received editorial fees from Medscape. D. H. R. was a paid consultant/advisor to Novo Nordisk, Janssen, Takeda, Vivus, and Eisai and has an equity position in Scientific Intake. M. S. has received salary support from Amgen and diaDexus and has served as a consultant for diaDexus. T. A. W. serves on advisory boards for Novo Nordisk and Orexigen and is a consultant to Boehringer Ingelheim. No other potential conflicts of interest relevant to this article were reported. NR 32 TC 39 Z9 39 U1 5 U2 13 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD SEP PY 2014 VL 37 IS 9 BP 2548 EP 2556 DI 10.2337/dc14-0093 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AN8HX UT WOS:000340846300029 PM 25147253 ER PT J AU Zhuo, XH Zhang, P Barker, L Albright, A Thompson, TJ Gregg, E AF Zhuo, Xiaohui Zhang, Ping Barker, Lawrence Albright, Ann Thompson, Theodore J. Gregg, Edward TI The Lifetime Cost of Diabetes and Its Implications for Diabetes Prevention SO DIABETES CARE LA English DT Article ID STYLE INTERVENTION; MEDICAL COSTS; UNITED-STATES; WEIGHT-LOSS; CARE COSTS; PROGRAM; RISK; OVERWEIGHT; STRATEGIES; MORTALITY AB OBJECTIVE To assess the cost implications of diabetes prevention, it is important to know the lifetime medical cost of people with diabetes relative to those without. We derived such estimates using data representative of the U.S. national population. RESEARCH DESIGN AND METHODS We aggregated annual medical expenditures from the age of diabetes diagnosis to death to determine lifetime medical expenditure. Annual medical expenditures were estimated by sex, age at diagnosis, and diabetes duration using data from 2006-2009 Medical Expenditure Panel Surveys, which were linked to data from 2005-2008 National Health Interview Surveys. We combined survival data from published studies with the estimated annual expenditures to calculate lifetime spending. We then compared lifetime spending for people with diabetes with that for those without diabetes. Future spending was discounted at 3% annually. RESULTS The discounted excess lifetime medical spending for people with diabetes was $124,600 ($211,400 if not discounted), $91,200 ($135,600), $53,800 ($70,200), and $35,900 ($43,900) when diagnosed with diabetes at ages 40, 50, 60, and 65 years, respectively. Younger age at diagnosis and female sex were associated with higher levels of lifetime excess medical spending attributed to diabetes. CONCLUSIONS Having diabetes is associated with substantially higher lifetime medical expenditures despite being associated with reduced life expectancy. If prevention costs can be kept sufficiently low, diabetes prevention may lead to a reduction in long-term medical costs. C1 [Zhuo, Xiaohui; Zhang, Ping; Barker, Lawrence; Albright, Ann; Thompson, Theodore J.; Gregg, Edward] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Zhuo, XH (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM xzhuo@cdc.gov NR 36 TC 28 Z9 28 U1 2 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD SEP PY 2014 VL 37 IS 9 BP 2557 EP 2564 DI 10.2337/dc13-2484 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AN8HX UT WOS:000340846300030 PM 25147254 ER PT J AU Divi, RL Lindeman, TE Shockley, ME Keshava, C Weston, A Poirier, MC AF Divi, R. L. Lindeman, T. E. Shockley, M. E. Keshava, C. Weston, A. Poirier, M. C. TI Correlation between CYP1A1 RNA Transcript, Protein Level, Enzyme Activity, and DNA Adducts in Primary Normal Human Mammary Epithelial Cells Exposed to Benzo[a]pyrene SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Meeting Abstract CT 45th Annual Meeting of the Environmental-Mutagenesis-and-Genomics-Society (EMGS) CY SEP 13-17, 2014 CL Orlando, FL SP Environm Mutagenesis & Genom Soc C1 [Divi, R. L.; Lindeman, T. E.; Shockley, M. E.; Poirier, M. C.] NCI, Bethesda, MD 20892 USA. [Keshava, C.] US EPA, Natl Ctr Environm Assessment, Res Triangle Pk, NC 27711 USA. [Weston, A.] NIOSH, Div Resp Dis Studies, CDC, Morgantown, WV 26505 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0893-6692 EI 1098-2280 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PD SEP PY 2014 VL 55 SU 1 MA P68 BP S56 EP S56 PG 1 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA AO2ST UT WOS:000341176900159 ER PT J AU Rasmussen, SA AF Rasmussen, S. A. TI Protecting Pregnant Women and Their Babies from Seasonal and Pandemic Influenza SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Meeting Abstract CT 45th Annual Meeting of the Environmental-Mutagenesis-and-Genomics-Society (EMGS) CY SEP 13-17, 2014 CL Orlando, FL SP Environm Mutagenesis & Genom Soc C1 [Rasmussen, S. A.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0893-6692 EI 1098-2280 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PD SEP PY 2014 VL 55 SU 1 MA L1 BP S18 EP S18 PG 1 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA AO2ST UT WOS:000341176900003 ER PT J AU Philippat, C Botton, J Calafat, AM Ye, XY Charles, MA Slama, R AF Philippat, Claire Botton, Jeremie Calafat, Antonia M. Ye, Xiaoyun Charles, Marie-Aline Slama, Remy CA EDEN Study Grp TI Prenatal Exposure to Phenols and Growth in Boys SO EPIDEMIOLOGY LA English DT Article ID BISPHENOL-A; URINARY CONCENTRATIONS; PERINATAL EXPOSURE; NEONATAL THYROXINE; PARABENS; VARIABILITY; PREGNANCY; FETAL; BODY; DIFFERENTIATION AB Background: Phenols interact with nuclear receptors implicated in growth and adipogenesis regulation. Only a few studies have explored their effects on growth in humans. Objectives: We studied the associations of maternal exposure to phenols during pregnancy with prenatal and postnatal growth of male newborns. Methods: Within a cohort of women recruited during pregnancy, we selected 520 mother-son pairs and quantified 9 phenols in spot urine samples collected during pregnancy. We used ultrasonography during pregnancy, together with birth measurements, to assess fetal growth. We modeled individual postnatal growth trajectories from repeated measures of weight and height in the first 3 years of life. Results: Triclosan concentration was negatively associated with growth parameters measured at the third ultrasound examination but not earlier in pregnancy. At birth, this phenol tended to be negatively associated with head circumference (-1.2 mm for an interquartile range [IQR] increase in ln-transformed triclosan concentration [95% confidence interval = -2.6 to 0.3]) but not with weight or height. Parabens were positively associated with weight at birth. This positive association remained for 3 years for methylparaben (beta = 193 g [-4 to 389]) for an IQR increase in ln-transformed concentrations. Conclusion: We relied on only 1 spot urine sample to assess exposure; because of the high variability in phenol urinary concentrations reported during pregnancy, using only 1 sample may result in exposure misclassification, in particular for bisphenol A. Our study suggested associations between prenatal exposure to parabens and triclosan and prenatal or early postnatal growth. C1 [Philippat, Claire; Slama, Remy] INSERM, IAB, Team Environm Epidemiol Appl Reprod & Resp Hlth, F-38042 Grenoble 9, France. [Philippat, Claire; Slama, Remy] Univ Grenoble Alpes, IAB, Grenoble, France. [Botton, Jeremie; Charles, Marie-Aline] INSERM, U1018, Ctr Res Epidemiol & Populat Hlth, Team Epidemiol Diabet Obes & Renal Dis Lifelong A, Villejuif, France. [Botton, Jeremie; Charles, Marie-Aline] Univ Paris 11, Fac Pharm, F-92290 Chatenay Malabry, France. [Calafat, Antonia M.; Ye, Xiaoyun] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Philippat, C (reprint author), INSERM, UJF U823, Inst Albert Bonniot, Ctr Rech, UJF Site Sante,BP 170, F-38042 Grenoble 9, France. EM cphilippat@ucdavis.edu RI Slama, Remy/M-1755-2013; OI Slama, Remy/0000-0002-8980-8529; Botton, Jeremie/0000-0002-4814-6370 FU ANSES; FRM; Inserm; IReSP; Nestle; French Ministry of health; ANR; Univ. Paris-Sud; InVS; MGEN FX Supported by ANSES. The Eden cohort is supported by grants from FRM, Inserm, IReSP, Nestle, French Ministry of health, ANR, Univ. Paris-Sud, InVS, ANSES, and MGEN. NR 34 TC 26 Z9 26 U1 0 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD SEP PY 2014 VL 25 IS 5 BP 625 EP 635 DI 10.1097/EDE.0000000000000132 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AN6RA UT WOS:000340722600002 PM 25061923 ER PT J AU Liberman, RF Stern, JE Luke, B Reefhuis, J Anderka, M AF Liberman, Rebecca F. Stern, Judy E. Luke, Barbara Reefhuis, Jennita Anderka, Marlene TI Validating Assisted Reproductive Technology Self-Report SO EPIDEMIOLOGY LA English DT Letter ID UNITED-STATES; BIRTH-DEFECTS; SURVEILLANCE; RISK C1 [Liberman, Rebecca F.; Anderka, Marlene] Massachusetts Dept Publ Hlth, Boston, MA 02108 USA. [Stern, Judy E.] Geisel Sch Med Dartmouth, Lebanon, NH USA. [Luke, Barbara] Michigan State Univ, E Lansing, MI 48824 USA. [Reefhuis, Jennita] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Liberman, RF (reprint author), Massachusetts Dept Publ Hlth, Boston, MA 02108 USA. EM rebecca.liberman@state.ma.us FU NCBDD CDC HHS [1U01DD000493, U01 DD000493]; NICHD NIH HHS [R01 HD064595, R01 HD067270] NR 8 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD SEP PY 2014 VL 25 IS 5 BP 773 EP 775 DI 10.1097/EDE.0000000000000153 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AN6RA UT WOS:000340722600024 PM 25076154 ER PT J AU Cherry, JD Paddock, CD AF Cherry, James D. Paddock, Christopher D. TI Pathogenesis and histopathology of pertussis: implications for immunization SO EXPERT REVIEW OF VACCINES LA English DT Review DE histopathology; immunization; pathogenesis; pertussis; vaccine ID BAPC AUTOTRANSPORTER PROTEIN; COMPONENT DTP VACCINE; BORDETELLA-PERTUSSIS; COUGH ILLNESSES; VIRULENCE DETERMINANT; COMPARATIVE EFFICACY; UNIVERSITY-STUDENTS; DTAP VACCINE; ADULTS; INFECTIONS AB Pertussis is a unique infectious disease in that it can be severe and fatal but occurs without fever and other evidence of an inflammatory illness. The authors with others have studied the histopathology of fatal pertussis and also the unique characteristics of severe pertussis in young infants. Histopathologic observations from approximately 100 years ago, and from recent evaluation, indicate that the histopathologic changes of the upper respiratory tract of patients with fatal pertussis are often relatively normal unless there is a secondary bacterial infection. Bordetella pertussis contains many protein antigens and perhaps a polysaccharide capsule which contribute to the infectious process. However, only two of these antigens contribute to clinical illness. These antigens are pertussis toxin and the yet to be identified 'cough toxin'. The authors speculate as to the nature of the 'cough toxin' and discuss the implications of their observations and concepts for the future control of pertussis. C1 [Cherry, James D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Paddock, Christopher D.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA 30333 USA. RP Cherry, JD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, 10833 Le Conte Ave,MDCC 22-442, Los Angeles, CA 90095 USA. EM jcherry@mednet.ucla.edu NR 67 TC 10 Z9 12 U1 1 U2 7 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1476-0584 EI 1744-8395 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD SEP PY 2014 VL 13 IS 9 SI SI BP 1115 EP 1123 DI 10.1586/14760584.2014.935766 PG 9 WC Immunology SC Immunology GA AN6TW UT WOS:000340731900006 PM 24992986 ER PT J AU Satten, GA Biswas, S Papachristou, C Turkmen, A Konig, IR AF Satten, Glen A. Biswas, Swati Papachristou, Charalampos Turkmen, Asuman Koenig, Inke R. TI Population-Based Association and Gene by Environment Interactions in Genetic Analysis Workshop 18 SO GENETIC EPIDEMIOLOGY LA English DT Article DE association; haplotype; rare variants; gene-environment interaction ID LOGISTIC BAYESIAN LASSO; COMMON VARIANTS; RARE VARIANTS; TESTS; INFERENCE AB In the past decade, genome-wide association studies have been successful in identifying genetic loci that play a role in many complex diseases. Despite this, it has become clear that for many traits, investigation of single common variants does not give a complete picture of the genetic contribution to the phenotype. Therefore a number of new approaches are currently being investigated to further the search for susceptibility loci or regions. We summarize the contributions to Genetic Analysis Workshop 18 (GAW18) that concern this search using methods for population-based association analysis. Many of the members of our GAW18 working group made use of data types that have only recently become available through the use of next-generation sequencing technologies, with many focusing on the investigation of rare variants instead of or in combination with common variants. Some contributors used a haplotype-based approach, which to date has been used relatively infrequently but may become more important for analyzing rare variant association data. Others analyzed gene-gene or gene-environment interactions, where novel statistical approaches were needed to make the best use of the available information without requiring an excessive computational burden. GAW18 provided participants with the chance to make use of state-of-the-art data, statistical techniques, and technology. We report here some of the experiences and conclusions that were reached by workshop participants who analyzed the GAW18 data as a population-based association study. (C) 2014 Wiley Periodicals, Inc. C1 [Satten, Glen A.] Ctr Dis Control & Prevent, Atlanta, GA 30345 USA. [Biswas, Swati] Univ Texas Dallas, Dept Math Sci, Richardson, TX 75083 USA. [Papachristou, Charalampos] Allegheny Univ Hlth Sci, Dept Math Phys & Stat, Philadelphia, PA 19102 USA. [Turkmen, Asuman] Ohio State Univ, Dept Stat, Newark, OH USA. [Koenig, Inke R.] Med Univ Lubeck, Inst Med Biometrie & Stat, Univ Klinikum Schleswig Holstein, D-23538 Lubeck, Germany. RP Satten, GA (reprint author), Ctr Dis Control & Prevent, Mailstop K-23,4770 Buford Highway, Atlanta, GA 30345 USA. EM gas0@cdc.gov RI Konig, Inke/A-4544-2009 FU National Cancer Institute [R03CA171011-01]; National Institutes of Health [R01 GM031575] FX SB was partially supported by the National Cancer Institute through grant R03CA171011-01. The Genetic Analysis Workshops are funded by the National Institutes of Health through grant R01 GM031575. NR 39 TC 1 Z9 1 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0741-0395 EI 1098-2272 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PD SEP PY 2014 VL 38 SU 1 SI SI BP S49 EP S56 DI 10.1002/gepi.21825 PG 8 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA AN5DR UT WOS:000340610500008 PM 25112188 ER PT J AU Yokoe, DS Anderson, DJ Berenholtz, SM Calfee, DP Dubberke, ER Ellingson, K Gerding, DN Haas, J Kaye, KS Klompas, M Lo, E Marschall, J Mermel, LA Nicolle, L Salgado, C Bryant, K Classen, D Crist, K Foster, N Humphreys, E Padberg, J Podgorny, K VanAmringe, M Weaver, T Wise, R Maragakis, LL AF Yokoe, Deborah S. Anderson, Deverick J. Berenholtz, Sean M. Calfee, David P. Dubberke, Erik R. Ellingson, Katherine Gerding, Dale N. Haas, Janet Kaye, Keith S. Klompas, Michael Lo, Evelyn Marschall, Jonas Mermel, Leonard A. Nicolle, Lindsay Salgado, Cassandra Bryant, Kristina Classen, David Crist, Katrina Foster, Nancy Humphreys, Eve Padberg, Jennifer Podgorny, Kelly VanAmringe, Margaret Weaver, Tom Wise, Robert Maragakis, Lisa L. TI Introduction to "A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 Updates" SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Editorial Material AB Since the publication of "A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals" in 2008, prevention of healthcare-associated infections (HAIs) has become a national priority. Despite improvements, preventable HAIs continue to occur. The 2014 updates to the Compendium were created to provide acute care hospitals with up-to-date, practical, expert guidance to assist in prioritizing and implementing their HAI prevention efforts. It is the product of a highly collaborative effort led by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), the American Hospital Association (AHA), the Association for Professionals in Infection Control and Epidemiology (APIC), and The Joint Commission, with major contributions from representatives of a number of organizations and societies with content expertise, including the Centers for Disease Control and Prevention (CDC), the Institute for Healthcare Improvement (IHI), the Pediatric Infectious Diseases Society (PIDS), the Society for Critical Care Medicine (SCCM), the Society for Hospital Medicine (SHM), and the Surgical Infection Society (SIS). C1 [Yokoe, Deborah S.; Klompas, Michael] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yokoe, Deborah S.; Klompas, Michael] Harvard Univ, Sch Med, Boston, MA USA. [Anderson, Deverick J.] Duke Univ, Med Ctr, Durham, NC USA. [Berenholtz, Sean M.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Calfee, David P.] Weill Cornell Med Coll, New York, NY USA. [Dubberke, Erik R.; Marschall, Jonas] Washington Univ, Sch Med, St Louis, MO USA. [Ellingson, Katherine] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Chicago, IL USA. [Haas, Janet] Westchester Med Ctr, Valhalla, NY USA. [Haas, Janet] New York Med Coll, Valhalla, NY 10595 USA. [Kaye, Keith S.] Detroit Med Ctr, Detroit, MI USA. [Kaye, Keith S.] Wayne State Univ, Detroit, MI USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Lo, Evelyn] St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada. [Lo, Evelyn; Nicolle, Lindsay] Univ Manitoba, Winnipeg, MB, Canada. [Marschall, Jonas] Univ Hosp Bern, CH-3010 Bern, Switzerland. [Marschall, Jonas] Univ Bern, Bern, Switzerland. [Mermel, Leonard A.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Mermel, Leonard A.] Rhode Isl Hosp, Providence, RI USA. [Nicolle, Lindsay] Hlth Sci Ctr, Winnipeg, MB, Canada. [Salgado, Cassandra] Med Univ S Carolina, Charleston, SC 29425 USA. [Bryant, Kristina] Univ Louisville, Louisville, KY 40292 USA. [Classen, David] Univ Utah, Sch Med, Salt Lake City, UT USA. [Crist, Katrina; Weaver, Tom] Assoc Profess Infect Control & Epidemiol, Washington, DC USA. [Foster, Nancy] Amer Hosp Assoc, Washington, DC USA. [Humphreys, Eve] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Padberg, Jennifer] Infect Dis Soc Amer, Arlington, VA USA. [Podgorny, Kelly; VanAmringe, Margaret; Wise, Robert] Joint Commiss, Oak Brook Terrace, IL USA. [Maragakis, Lisa L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Yokoe, DS (reprint author), 181 Longwood Ave, Boston, MA 02115 USA. EM dyokoe@partners.org NR 12 TC 0 Z9 0 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2014 VL 35 SU 2 BP 455 EP 459 DI 10.1086/675819 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AO0QB UT WOS:000341014500001 ER PT J AU Lo, E Nicolle, LE Coffin, SE Gould, C Maragakis, LL Meddings, J Pegues, DA Pettis, AM Saint, S Yokoe, DS AF Lo, Evelyn Nicolle, Lindsay E. Coffin, Susan E. Gould, Carolyn Maragakis, Lisa L. Meddings, Jennifer Pegues, David A. Pettis, Ann Marie Saint, Sanjay Yokoe, Deborah S. TI Strategies to Prevent Catheter-Associated Urinary Tract Infections in Acute Care Hospitals: 2014 Update SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; CONTROL CONSORTIUM INICC; NOSOCOMIAL INFECTIONS; DEVELOPING-COUNTRIES; UNITED-STATES; RATES; BACTERIURIA; QUALITY; EPIDEMIOLOGY; RECOMMENDATIONS C1 [Lo, Evelyn] St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada. [Lo, Evelyn; Nicolle, Lindsay E.] Univ Manitoba, Winnipeg, MB, Canada. [Nicolle, Lindsay E.] Hlth Sci Ctr, Winnipeg, MB, Canada. [Coffin, Susan E.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Gould, Carolyn] Ctr Dis Control & Prevent, Atlanta, GA USA. [Maragakis, Lisa L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Meddings, Jennifer] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Pegues, David A.] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Pegues, David A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Pettis, Ann Marie] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Saint, Sanjay] Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI USA. [Saint, Sanjay] Univ Michigan, Ann Arbor, MI 48109 USA. [Yokoe, Deborah S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yokoe, Deborah S.] Harvard Univ, Sch Med, Boston, MA USA. RP Nicolle, LE (reprint author), GG 443 Hlth Sci Ctr, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada. EM lnicolle@exchange.hsc.mb.ca FU Cangene Corporation FX Authors report the following. E.L.-research grants/contracts: Cangene Corporation, antibody responses to C. difficile-associated diarrhea; research with Virox Industries, HAI response to environmental disinfection. L.E.N.-advisory/consultant role: Cerena, Johnson & Johnson. D.A.P.-advisory/consultant role: InVentiv; honoraria: Health Research and Educational Trust/American Hospital Association, Rand Health. A.M.P.-served as a speaker for Bard; served as a speaker and author for Covidien. S.S.-honoraria and speaking fees for lectures on healthcare-associated infection prevention, implementation science, and patient safety from hospitals, academic medical centers, professional societies, and non-profit foundations (none of these activities are related to speakers' bureaus); medical advisory board: Doximity (a new social networking site for physicians), Jvion (a healthcare technology company). S.E.C., C.G., L.L.M., J.M., D.S.Y.-nothing to disclose. NR 77 TC 0 Z9 0 U1 1 U2 15 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2014 VL 35 SU 2 BP 464 EP 479 DI 10.1086/675718 PG 16 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AO0QB UT WOS:000341014500007 ER PT J AU Anderson, DJ Podgorny, K Berrios-Torres, SI Bratzler, DW Dellinger, EP Greene, L Nyquist, AC Saiman, L Yokoe, DS Maragakis, LL Kaye, KS AF Anderson, Deverick J. Podgorny, Kelly Berrios-Torres, Sandra I. Bratzler, Dale W. Dellinger, E. Patchen Greene, Linda Nyquist, Ann-Christine Saiman, Lisa Yokoe, Deborah S. Maragakis, Lisa L. Kaye, Keith S. TI Strategies to Prevent Surgical Site Infections in Acute Care Hospitals: 2014 Update SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; RESISTANT STAPHYLOCOCCUS-AUREUS; STERNAL WOUND INFECTIONS; GENTAMICIN-COLLAGEN SPONGE; BYPASS GRAFT-SURGERY; SUPPLEMENTAL PERIOPERATIVE OXYGEN; TRICLOSAN-COATED SUTURES; TOTAL HIP-ARTHROPLASTY; OPEN-HEART-SURGERY; CARDIAC-SURGERY C1 [Anderson, Deverick J.] Duke Univ, Med Ctr, Durham, NC 27710 USA. [Podgorny, Kelly] Joint Commiss, Oak Brook Terrace, IL USA. [Berrios-Torres, Sandra I.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bratzler, Dale W.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Dellinger, E. Patchen] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Greene, Linda] Highland Hosp, Rochester, NY USA. [Greene, Linda] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Nyquist, Ann-Christine] Childrens Hosp Colorado, Aurora, CO USA. [Nyquist, Ann-Christine] Univ Colorado, Sch Med, Aurora, CO USA. [Saiman, Lisa] Columbia Univ, Med Ctr, New York, NY USA. [Yokoe, Deborah S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yokoe, Deborah S.] Harvard Univ, Sch Med, Boston, MA USA. [Maragakis, Lisa L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Kaye, Keith S.] Detroit Med Ctr, Detroit, MI USA. [Kaye, Keith S.] Wayne State Univ, Detroit, MI USA. RP Anderson, DJ (reprint author), Duke Univ, Med Ctr, Div Infect Dis, Box 102359, Durham, NC 27710 USA. EM deverick.anderson@duke.edu FU Tetraphase; Sage Products FX E.P.D. reports serving as an advisor/consultant for Merck, Baxter, Ortho-McNeil, Targanta, Rib-X, Affinium, 3M, Schering-Plough, Astellas, CareFusion, Durata, Pfizer, and Applied Medical and receiving grant support from Tetraphase. L.G. reports receiving honoraria from Premier, CareFusion, and Infection Control Today. K.S.K. reports receiving grant support and serving as an advisor/consultant for Sage Products. D.J.A., K.P., D.W.B., S.I.B.-T., A.-C.N., L.L.M., L.S., and D.S.Y. report no relevant conflicts of interest. NR 231 TC 0 Z9 0 U1 2 U2 18 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2014 VL 35 SU 2 BP 605 EP 627 DI 10.1086/676022 PG 23 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AO0QB UT WOS:000341014500009 ER PT J AU Dubberke, ER Carling, P Carrico, R Donskey, CJ Loo, VG McDonald, LC Maragakis, LL Sandora, TJ Weber, DJ Yokoe, DS Gerding, DN AF Dubberke, Erik R. Carling, Philip Carrico, Ruth Donskey, Curtis J. Loo, Vivian G. McDonald, L. Clifford Maragakis, Lisa L. Sandora, Thomas J. Weber, David J. Yokoe, Deborah S. Gerding, Dale N. TI Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals: 2014 Update SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; HIGH-RISK ANTIBIOTICS; ENVIRONMENTAL CONTAMINATION; HYPOCHLORITE SOLUTION; COLONIZED PATIENTS; CONTACT ISOLATION; TOXIN PRODUCTION; ISOLATION ROOMS; UNITED-STATES; NORTH-AMERICA C1 [Dubberke, Erik R.] Washington Univ, Sch Med, St Louis, MO 63110 USA. [Carling, Philip] Boston Univ, Sch Med, Boston, MA 02118 USA. [Carrico, Ruth] Univ Louisville, Sch Med, Div Infect Dis, Louisville, KY 40292 USA. [Donskey, Curtis J.] Case Western Reserve Univ, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA. [Loo, Vivian G.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. [McDonald, L. Clifford] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Maragakis, Lisa L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Sandora, Thomas J.] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA. [Weber, David J.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Yokoe, Deborah S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yokoe, Deborah S.] Harvard Univ, Sch Med, Boston, MA USA. [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Gerding, Dale N.] Loyola Univ, Stritch Sch Med, Chicago, IL 60611 USA. RP Dubberke, ER (reprint author), Washington Univ, Sch Med, 660 South Euclid Ave,Box 8051, St Louis, MO 63110 USA. EM edubberk@dom.wustl.edu FU Sanofi Pasteur; ViroPharma; Optimer; Merck; Rebiotix; Steris; Pfizer; GOJO Industries FX E.R.D. reports serving as an advisor/consultant for Sanofi Pasteur, Merck, and Pfizer and receiving research grants/contracts from Sanofi Pasteur, ViroPharma, Optimer, Merck, and Rebiotix. P.C. reports serving as an advisor/consultant for Steris and holding a patent/copyright/license with Ecolab. R.C. reports serving on the speakers' bureau for Sanofi Pasteur, MedImmune, Abbott Diabetes Care, and 3M; performing technical writing for Ketchum; and receiving research grants/contracts from Sanofi Pasteur. C.J.D. reports serving as an advisor/consultant for Steris, GOJO Industries, and 3M; receiving honoraria from Ecolab; and receiving research grants/contracts from Merck, ViroPharma, Steris, and Pfizer. V.G.L. reports serving as an advisor/consultant for Optimer Pharmaceuticals. D.J.W. reports serving as an advisor/consultant for Johnson & Johnson and Clorox. D.N.G. reports serving as an advisor/consultant for Merck, Cubist, Novartis, Cangene, Actelion, ViroPharma, Rebiotix, and Sanofi Pasteur; receiving honoraria from Robert Michael; holding a patent/license (no royalties) with ViroPharma; and receiving research grant/contracts from GOJO Industries. L.C.M., L.L.M., T.J.S., and D.S.Y. report no conflicts of interest. NR 120 TC 0 Z9 0 U1 1 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2014 VL 35 SU 2 BP 628 EP 645 DI 10.1086/676023 PG 18 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AO0QB UT WOS:000341014500008 ER PT J AU Marschall, J Mermel, LA Fakih, M Hadaway, L Kallen, A O'Grady, NP Pettis, AM Rupp, ME Sandora, T Maragakis, LL Yokoe, DS AF Marschall, Jonas Mermel, Leonard A. Fakih, Mohamad Hadaway, Lynn Kallen, Alexander O'Grady, Naomi P. Pettis, Ann Marie Rupp, Mark E. Sandora, Thomas Maragakis, Lisa L. Yokoe, Deborah S. TI Strategies to Prevent Central Line-Associated Bloodstream Infections in Acute Care Hospitals: 2014 Update SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID CENTRAL VENOUS CATHETERS; RANDOMIZED-CONTROLLED-TRIAL; CRITICALLY-ILL PATIENTS; NEONATAL INTENSIVE-CARE; OF-THE-LITERATURE; STERILE BARRIER PRECAUTIONS; DOUBLE-BLIND TRIAL; NEEDLELESS INTRAVASCULAR CONNECTOR; ANTIMICROBIAL-COATED CATHETERS; PULMONARY-ARTERY CATHETERS C1 [Marschall, Jonas] Washington Univ, Sch Med, St Louis, MO USA. [Marschall, Jonas] Univ Hosp Bern, CH-3010 Bern, Switzerland. [Marschall, Jonas] Univ Bern, Bern, Switzerland. [Mermel, Leonard A.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Mermel, Leonard A.] Rhode Isl Hosp, Providence, RI 02903 USA. [Fakih, Mohamad] St John Hosp & Med Ctr, Detroit, MI USA. [Fakih, Mohamad] Wayne State Univ, Sch Med, Detroit, MI USA. [Hadaway, Lynn] Lynn Hadaway Associates Inc, Milner, GA USA. [Kallen, Alexander] Ctr Dis Control & Prevent, Atlanta, GA USA. [O'Grady, Naomi P.] NIH, Bethesda, MD 20892 USA. [Pettis, Ann Marie] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Rupp, Mark E.] Univ Nebraska Med Ctr, Omaha, NE USA. [Sandora, Thomas] Boston Childrens Hosp, Boston, MA USA. [Sandora, Thomas] Harvard Univ, Sch Med, Boston, MA USA. RP Mermel, LA (reprint author), Rhode Isl Hosp, Div Infect Dis, 593 Eddy St, Providence, RI 02903 USA. EM lmermel@lifespan.org FU Bard FX J.M. reports receiving a speaker honorarium from Gilead Sciences Switzerland. L.A.M. reports serving as an advisor/consultant for ICU Medical, Fresenius Medical Care, Bard Access Systems, Marvao Medical Devices, CareFusion, 3M Healthcare, Catheter Connections, Semprus Biosciences, and Sharklet Technologies. L.H. reports serving as an advisor/consultant for B Braun Medical, BD Medical, Excelsior Medical, Ivera Medical, Access Scientific, 3M, and Baxter Healthcare. A.M.P. reports receiving speaking fees from Bard and serving as a speaker and author for Covidien. M.E.R reports serving as an advisor/consultant for 3M, Ariste, Semprus, and Sharklet Technologies and receiving honoraria from Baxter and CareFusion. All other authors report no relevant conflicts of interest. NR 250 TC 0 Z9 0 U1 6 U2 13 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2014 VL 35 SU 2 BP 753 EP 771 DI 10.1086/676533 PG 19 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AO0QB UT WOS:000341014500010 ER PT J AU Calfee, DP Salgado, CD Milstone, AM Harris, AD Kuhar, DT Moody, J Aureden, K Huang, SS Maragakis, LL Yokoe, DS AF Calfee, David P. Salgado, Cassandra D. Milstone, Aaron M. Harris, Anthony D. Kuhar, David T. Moody, Julia Aureden, Kathy Huang, Susan S. Maragakis, Lisa L. Yokoe, Deborah S. TI Strategies to Prevent Methicillin-Resistant Staphylococcus aureus Transmission and Infection in Acute Care Hospitals: 2014 Update SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID SURGICAL-SITE INFECTIONS; BLOOD-STREAM INFECTIONS; NASAL MUPIROCIN OINTMENT; CRITICALLY-ILL CHILDREN; HYDROGEN-PEROXIDE VAPOR; CHROMAGAR MRSA MEDIUM; INTENSIVE-CARE; SURVEILLANCE CULTURES; ACTIVE SURVEILLANCE; ENVIRONMENTAL CONTAMINATION C1 [Calfee, David P.] Weill Cornell Med Coll, New York, NY 10065 USA. [Salgado, Cassandra D.] Med Univ S Carolina, Charleston, SC 29425 USA. [Milstone, Aaron M.; Maragakis, Lisa L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Harris, Anthony D.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Kuhar, David T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Moody, Julia] Hosp Corp Amer, Nashville, TN USA. [Aureden, Kathy] Advocate Sherman Hosp, Elgin, IL USA. [Huang, Susan S.] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA. [Yokoe, Deborah S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yokoe, Deborah S.] Harvard Univ, Sch Med, Boston, MA USA. RP Calfee, DP (reprint author), Weill Cornell Med Coll, 525 East 68th St,Box 265, New York, NY 10065 USA. EM dpc9003@med.cornell.edu FU Sage Products FX A.M. reports receiving a research grant/contract from Sage Products. A.D.H. reports serving in an advisory/consultant role for Cubist, UpToDate, and Premier. S.S.H. reports leading a clinical trial in which participating hospitals received contributed product from Sage Products. J.M. reports conducting a clinical trial in which participating hospitals received contributed product from Sage Products. S.S.H. and J.M. report conducting a clinical trial in which participating hospitals receive contributed product from Sage Products and Molnlycke; this disclosure arose after the manuscript was completed but before publication. C.S., D.C., D.K., K.A., D.S.Y., and L.L.M. report no conflicts of interest. NR 189 TC 0 Z9 0 U1 1 U2 12 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2014 VL 35 SU 2 BP 772 EP 796 DI 10.1086/676534 PG 25 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AO0QB UT WOS:000341014500011 ER PT J AU Klompas, M Branson, R Eichenwald, EC Greene, LR Howell, MD Lee, G Magill, SS Maragakis, LL Priebe, GP Speck, K Yokoe, DS Berenholtz, SM AF Klompas, Michael Branson, Richard Eichenwald, Eric C. Greene, Linda R. Howell, Michael D. Lee, Grace Magill, Shelley S. Maragakis, Lisa L. Priebe, Gregory P. Speck, Kathleen Yokoe, Deborah S. Berenholtz, Sean M. TI Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals: 2014 Update SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID CRITICALLY-ILL PATIENTS; RANDOMIZED CONTROLLED-TRIAL; RECEIVING MECHANICAL VENTILATION; SUBGLOTTIC SECRETION DRAINAGE; ACUTE RESPIRATORY-FAILURE; STRESS-ULCER PROPHYLAXIS; ACUTE LUNG INJURY; POSITIVE-PRESSURE VENTILATION; SACCHAROMYCES-CEREVISIAE FUNGEMIA; PERFORMANCE-IMPROVEMENT PROJECT C1 [Klompas, Michael; Lee, Grace] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA. [Klompas, Michael; Lee, Grace] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Klompas, Michael; Priebe, Gregory P.; Yokoe, Deborah S.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Branson, Richard] Univ Cincinnati, Dept Surg, Cincinnati, OH 45221 USA. [Eichenwald, Eric C.] Univ Texas Med Sch Houston, Div Neonatal Perinatal Med, Houston, TX USA. [Greene, Linda R.] Univ Rochester, Med Ctr Affiliate, Highland Hosp, Rochester, NY USA. [Howell, Michael D.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Lee, Grace; Priebe, Gregory P.] Boston Childrens Hosp, Dept Med, Boston, MA USA. [Magill, Shelley S.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Maragakis, Lisa L.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Priebe, Gregory P.] Boston Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA. [Speck, Kathleen; Berenholtz, Sean M.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA. [Berenholtz, Sean M.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA. [Berenholtz, Sean M.] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. RP Klompas, M (reprint author), Harvard Univ, Sch Med, Dept Populat Med, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA. EM mklompas@partners.org RI Howell, Michael/B-8065-2009 OI Howell, Michael/0000-0001-7003-6971 NR 239 TC 0 Z9 0 U1 3 U2 14 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2014 VL 35 SU 2 BP 915 EP 936 DI 10.1086/677144 PG 22 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AO0QB UT WOS:000341014500012 ER PT J AU Ellingson, K Haas, JP Aiello, AE Kusek, L Maragakis, LL Olmsted, RN Perencevich, E Polgreen, PM Schweizer, ML Trexler, P VanAmringe, M Yokoe, DS AF Ellingson, Katherine Haas, Janet P. Aiello, Allison E. Kusek, Linda Maragakis, Lisa L. Olmsted, Russell N. Perencevich, Eli Polgreen, Philip M. Schweizer, Marin L. Trexler, Polly VanAmringe, Margaret Yokoe, Deborah S. TI Strategies to Prevent Healthcare-Associated Infections through Hand Hygiene SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID RANDOMIZED CLINICAL-TRIAL; ALCOHOL-BASED HANDRUB; VANCOMYCIN-RESISTANT ENTEROCOCCUS; CLOSTRIDIUM-DIFFICILE SPORES; SURGICAL SITE INFECTION; AUTOMATED MONITORING-SYSTEM; INTENSIVE-CARE; NOSOCOMIAL TRANSMISSION; STAPHYLOCOCCUS-AUREUS; FELINE CALICIVIRUS C1 [Ellingson, Katherine] Ctr Dis Control & Prevent, Atlanta, GA USA. [Haas, Janet P.] Westchester Cty Med Ctr, Valhalla, NY 10595 USA. [Haas, Janet P.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA. [Aiello, Allison E.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Kusek, Linda; VanAmringe, Margaret] Joint Commiss, Oak Brook Terrace, IL USA. [Maragakis, Lisa L.; Trexler, Polly] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Olmsted, Russell N.] St Joseph Mercy Hlth Syst, Ann Arbor, MI USA. [Perencevich, Eli; Polgreen, Philip M.; Schweizer, Marin L.] Univ Iowa, Carver Coll Med, Iowa City, IA USA. [Perencevich, Eli; Schweizer, Marin L.] Iowa City Vet Adm Healthcare Syst, Iowa City, IA USA. [Yokoe, Deborah S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yokoe, Deborah S.] Harvard Univ, Sch Med, Boston, MA USA. RP Haas, JP (reprint author), Westchester Med Ctr Infect Prevent & Control, Macy Pavil SW 246,100 Woods Rd, Valhalla, NY 10595 USA. EM haasj@wcmc.com FU 3M; Sanofi Pasteur; Baxter Healthcare; GOJO industries FX J.P.H. reports receiving research grant/contract support from 3M. A.E.A. reports serving as an advisor/consultant for the Tork Green Hygiene Council of SCA Tork and Grant & Eisenhofer. L.K. reports being an employee of The Joint Commission and receiving grant/contract support from Sanofi Pasteur and Baxter Healthcare. R.N.O. reports serving on the speakers' bureau for Ethicon and Avid Education Partners and serving as an advisor/consultant for Premier. E.P. reports serving as an advisor/consultant for Pur Thread. P.M.P. reports receiving grant/contract support from GOJO industries in the form of a gift to the University of Iowa Foundation. K.E., L.L.M., M.L.S., P.T., M.V.A., and D.S.Y. report no relevant conflicts of interest. NR 253 TC 0 Z9 0 U1 11 U2 38 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2014 VL 35 SU 2 BP 937 EP 960 DI 10.1086/677145 PG 24 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AO0QB UT WOS:000341014500013 ER PT J AU Yokoe, DS Anderson, DJ Berenholtz, SM Calfee, DP Dubberke, ER Ellingson, KD Gerding, DN Haas, JP Kaye, KS Klompas, M Lo, E Marschall, J Mermel, LA Nicolle, LE Salgado, CD Bryant, K Classen, D Crist, K Deloney, VM Fishman, NO Foster, N Goldmann, DA Humphreys, E Jernigan, JA Padberg, J Perl, TM Podgorny, K Septimus, EJ VanAmringe, M Weaver, T Weinstein, RA Wise, R Maragakis, LL AF Yokoe, Deborah S. Anderson, Deverick J. Berenholtz, Sean M. Calfee, David P. Dubberke, Erik R. Ellingson, Katherine D. Gerding, Dale N. Haas, Janet P. Kaye, Keith S. Klompas, Michael Lo, Evelyn Marschall, Jonas Mermel, Leonard A. Nicolle, Lindsay E. Salgado, Cassandra D. Bryant, Kristina Classen, David Crist, Katrina Deloney, Valerie M. Fishman, Neil O. Foster, Nancy Goldmann, Donald A. Humphreys, Eve Jernigan, John A. Padberg, Jennifer Perl, Trish M. Podgorny, Kelly Septimus, Edward J. VanAmringe, Margaret Weaver, Tom Weinstein, Robert A. Wise, Robert Maragakis, Lisa L. TI A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 Updates SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID CLOSTRIDIUM-DIFFICILE INFECTIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; VENTILATOR-ASSOCIATED PNEUMONIA; BLOOD-STREAM INFECTIONS; TRANSMISSION AB Since the publication of "A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals" in 2008, prevention of healthcare-associated infections (HAIs) has become a national priority. Despite improvements, preventable HAIs continue to occur. The 2014 updates to the Compendium were created to provide acute care hospitals with up-to-date, practical, expert guidance to assist in prioritizing and implementing their HAI prevention efforts. They are the product of a highly collaborative effort led by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), the American Hospital Association (AHA), the Association for Professionals in Infection Control and Epidemiology (APIC), and The Joint Commission, with major contributions from representatives of a number of organizations and societies with content expertise, including the Centers for Disease Control and Prevention (CDC), the Institute for Healthcare Improvement (IHI), the Pediatric Infectious Diseases Society (PIDS), the Society for Critical Care Medicine (SCCM), the Society for Hospital Medicine (SHM), and the Surgical Infection Society (SIS). C1 [Yokoe, Deborah S.; Klompas, Michael] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yokoe, Deborah S.; Klompas, Michael; Goldmann, Donald A.] Harvard Univ, Sch Med, Boston, MA USA. [Anderson, Deverick J.] Duke Univ, Med Ctr, Durham, NC USA. [Berenholtz, Sean M.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Berenholtz, Sean M.; Perl, Trish M.; Maragakis, Lisa L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Calfee, David P.] Weill Cornell Med Coll, New York, NY USA. [Dubberke, Erik R.; Marschall, Jonas] Washington Univ, Sch Med, St Louis, MO USA. [Ellingson, Katherine D.; Jernigan, John A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gerding, Dale N.] Edward Hines Jr Vet Affairs Hosp, Hines, IL USA. [Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Chicago, IL USA. [Haas, Janet P.] Westchester Med Ctr, Valhalla, NY USA. [Haas, Janet P.] New York Med Coll, Valhalla, NY 10595 USA. [Kaye, Keith S.] Detroit Med Ctr, Detroit, MI USA. [Kaye, Keith S.] Wayne State Univ, Detroit, MI USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Lo, Evelyn] St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada. [Lo, Evelyn; Nicolle, Lindsay E.] Univ Manitoba, Winnipeg, MB, Canada. [Marschall, Jonas] Univ Hosp Bern, CH-3010 Bern, Switzerland. [Marschall, Jonas] Univ Bern, Bern, Switzerland. [Mermel, Leonard A.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Mermel, Leonard A.] Rhode Isl Hosp, Providence, RI USA. [Nicolle, Lindsay E.] Hlth Sci Ctr, Winnipeg, MB, Canada. [Salgado, Cassandra D.] Med Univ S Carolina, Charleston, SC 29425 USA. [Bryant, Kristina] Univ Louisville, Louisville, KY 40292 USA. [Classen, David] Univ Utah, Sch Med, Salt Lake City, UT USA. [Crist, Katrina; Weaver, Tom] Assoc Profess Infect Control & Epidemiol, Washington, DC USA. [Deloney, Valerie M.; Humphreys, Eve] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Fishman, Neil O.] Univ Penn Hlth Syst, Philadelphia, PA USA. [Foster, Nancy] Amer Hosp Assoc, Washington, DC USA. [Goldmann, Donald A.] Inst Healthcare Improvement, Cambridge, MA USA. [Goldmann, Donald A.] Boston Childrens Hosp, Boston, MA USA. [Jernigan, John A.] Emory Univ, Sch Med, Atlanta, GA USA. [Padberg, Jennifer] Infect Dis Soc Amer, Arlington, VA USA. [Podgorny, Kelly; VanAmringe, Margaret; Wise, Robert] Joint Commiss, Oak Brook Terrace, IL USA. [Septimus, Edward J.] Texas A&M Hlth Sci Ctr, Coll Med, Houston, TX USA. [Septimus, Edward J.] Hosp Corp Amer, Nashville, TN USA. [Weinstein, Robert A.] Stroger Hosp, Chicago, IL USA. [Weinstein, Robert A.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. RP Yokoe, DS (reprint author), 181 Longwood Ave, Boston, MA 02115 USA. EM dyokoe@partners.org FU Society for Healthcare Epidemiology of America FX Support for this Compendium was provided by the Society for Healthcare Epidemiology of America. NR 19 TC 0 Z9 0 U1 1 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2014 VL 35 SU 2 BP 967 EP 977 DI 10.1086/677216 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AO0QB UT WOS:000341014500006 ER PT J AU Hocevar, SN Lessa, FC Gallagher, L Conover, C Gorwitz, R Iwamoto, M AF Hocevar, Susan N. Lessa, Fernanda C. Gallagher, Lauren Conover, Craig Gorwitz, Rachel Iwamoto, Martha TI Infection Prevention Practices in Neonatal Intensive Care Units Reporting to the National Healthcare Safety Network SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID BLOOD-STREAM INFECTIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; EPIDEMIOLOGY; BUNDLES; FUTURE; MODEL; US AB BACKGROUND. Patients in the neonatal intensive care unit (NICU) are at high risk for healthcare-associated infections. Variability in reported infection rates among NICUs exists, possibly related to differences in prevention strategies. A better understanding of current prevention practices may help identify prevention gaps and areas for further research. METHODS. We surveyed infection control staff in NICUs reporting to the National Healthcare Safety Network (NHSN) to assess strategies used to prevent methicillin-resistant Staphylococcus aureus (MRSA) transmission and central line-associated bloodstream infections in NICUs. RESULTS. Staff from 162 of 342 NICUs responded (response rate, 47.3%). Most (92.3%) NICUs use central line insertion and maintenance bundles, but maintenance practices varied, including agents used for antisepsis and frequency of dressing changes. Forty-two percent reported routine screening for MRSA colonization upon admission for all patients. Chlorhexidine gluconate (CHG) use for central line care for at least 1 indication (central line insertion, dressing changes, or port/cap antisepsis) was reported in 82 NICUs (51.3%). Among sixty-five NICUs responding to questions on CHG use restrictions, 46.2% reported no restrictions. CONCLUSIONS. Our survey illustrated heterogeneity of CLABSI and MRSA prevention practices and underscores the need for further research to define optimal strategies and evidence-based prevention recommendations for neonates. C1 [Hocevar, Susan N.; Lessa, Fernanda C.; Gorwitz, Rachel; Iwamoto, Martha] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA USA. [Hocevar, Susan N.] Ctr Dis Control & Prevent, Off Workforce & Career Dev, Epidem Intelligence Serv, Atlanta, GA USA. [Gallagher, Lauren] Illinois Dept Publ Hlth, Chicago, IL USA. [Conover, Craig] Illinois Dept Publ Hlth, Springfield, IL 62761 USA. RP Hocevar, SN (reprint author), 1600 Clifton Rd NE,MS A-35, Atlanta, GA 30333 USA. EM shocevar@cdc.gov FU Intramural CDC HHS [CC999999] NR 22 TC 4 Z9 4 U1 1 U2 7 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2014 VL 35 IS 9 BP 1126 EP 1132 DI 10.1086/677636 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AN6TI UT WOS:000340729900006 PM 25111920 ER PT J AU Dharmadhikari, AS Mphahlele, M Venter, K Stoltz, A Mathebula, R Masotla, T van der Walt, M Pagano, M Jensen, P Nardell, E AF Dharmadhikari, A. S. Mphahlele, M. Venter, K. Stoltz, A. Mathebula, R. Masotla, T. van der Walt, M. Pagano, M. Jensen, P. Nardell, E. TI Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE multidrug-resistant tuberculosis; impact of treatment; transmission; extensively drug-resistant tuberculosis ID MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; TUBERCLE-BACILLI; SOUTH-AFRICA; CHEMOTHERAPY; INFECTION; VARIABILITY; SETTINGS; WARD AB BACKGROUND: Effective treatment for drug-susceptible tuberculosis (TB) rapidly renders patients noninfectious, long before conversion of sputum acid-fast smear or culture to negative. Multidrug-resistant TB (MDR-TB) patients on treatment are currently assumed to remain infectious for months. While the resources required for prolonged hospitalization are a barrier to the scale-up of MDR-TB treatment, the safety of community treatment is clear. OBJECTIVES: To estimate the impact of treatment on infectiousness among MDR-TB patients. METHODS: A series of five human-to-guinea pig TB transmission studies was conducted to test various interventions for infection control. Guinea pigs in adjacent chambers were exposed to exhaust air from a hospital ward occupied by mostly sputum smear- and culture-positive MDR-TB patients. The guinea pigs then underwent tuberculin skin testing for infection. Only the control groups of guinea pigs from each study (no interventions used) provide the data for this analysis. The number of guinea pigs infected in each study is reported and correlated with Mycobacterium tuberculosis drug susceptibility relative to treatment. RESULTS: Despite exposure to presumably infectious MDR-TB patients, infection percentages among guinea pigs ranged from 1% to 77% in the five experiments conducted. In one experiment in which guinea pigs were exposed to 27 MDR-TB patients newly started on effective treatment for 3 months, there was minimal transmission. In four other experiments with greater transmission, guinea pigs had been exposed to patients with unsuspected extensively drug-resistant tuberculosis who were not on effective treatment. CONCLUSIONS: In this model, effective treatment appears to render MDR-TB patients rapidly noninfectious. Further prospective studies on this subject are needed. C1 [Dharmadhikari, A. S.; Nardell, E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Dharmadhikari, A. S.; Nardell, E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. [Mphahlele, M.; Venter, K.; Mathebula, R.; Masotla, T.; van der Walt, M.] South African Med Res Council, Pretoria, South Africa. [Stoltz, A.] Univ Pretoria, ZA-0002 Pretoria, South Africa. [Pagano, M.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Jensen, P.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Dharmadhikari, AS (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, 641 Huntington Ave,Suite 3A03, Boston, MA 02115 USA. EM adharmadhikari@partners.org FU NIOSH [R01OH009050] FX Sources of support/funding: NIOSH R01OH009050. NR 32 TC 36 Z9 36 U1 0 U2 10 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD SEP PY 2014 VL 18 IS 9 BP 1019 EP 1025 DI 10.5588/ijtld.13.0834 PG 7 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA AO4CM UT WOS:000341283800003 PM 25189547 ER PT J AU Menzies, HJ Moalosi, G Anisimova, V Gammino, V Sentle, C Bachhuber, MA Bile, E Radisowa, K Kachuwaire, O Basotli, J Maribe, T Makombe, R Shepherd, J Kim, B Samandari, T El-Halabi, S Chirenda, J Cain, KR AF Menzies, H. J. Moalosi, G. Anisimova, V. Gammino, V. Sentle, C. Bachhuber, M. A. Bile, E. Radisowa, K. Kachuwaire, O. Basotli, J. Maribe, T. Makombe, R. Shepherd, J. Kim, B. Samandari, T. El-Halabi, S. Chirenda, J. Cain, K. R. TI Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance Survey SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; drug resistance; surveillance ID TUBERCULOSIS PATIENTS; MULTIDRUG-RESISTANT; SPUTUM SMEARS; HIV; EPIDEMIOLOGY; RISK AB SETTING: Although approximately 0.5 million cases of multidrug-resistant tuberculosis (MDR-TB) occur globally each year, surveillance data are limited. Botswana is one of the few high TB burden countries to have carried out multiple anti-tuberculosis drug resistance surveys (in 1995-1996, 1999 and 2002). OBJECTIVE: In 2007-2008, we conducted the fourth national survey of anti-tuberculosis drug resistance in Botswana to assess anti-tuberculosis drug resistance, including trends over time. In the previous survey, 0.8% (95%CI 0.4-1.5) of new patients and 10.4% (95%CI 5.6-17.3) of previously treated patients had MDR-TB. DESIGN: During the survey period, eligible specimens from all new sputum-smear positive TB patients and from all TB patients with history of previous anti-tuberculosis treatment underwent mycobacterial culture and anti-tuberculosis drug susceptibility testing (DST). RESULTS: Of 924 new TB patients and 137 with previous anti-tuberculosis treatment with DST results, respectively 23 (2.5%, 95% CI 1.6-3.7) and 9 (6.6%, 95%CI 3.3-11.7) had MDR-TB. The proportion of new TB patients with MDR-TB has tripled in Botswana since the previous survey. CONCLUSION: Combatting drug-resistant TB will require the scale-up of MDR-TB diagnosis and treatment to prevent the transmission of MDR-TB and strengthening of general TB control to prevent the emergence of resistance. C1 [Menzies, H. J.; Gammino, V.; Bile, E.; Kim, B.; Samandari, T.; Cain, K. R.] US Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Moalosi, G.; Sentle, C.; Chirenda, J.] Botswana Natl TB Program, Gaborone, Botswana. [Anisimova, V.] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Anisimova, V.; Kachuwaire, O.] KNCV TB Fdn, The Hague, Netherlands. [Anisimova, V.; Radisowa, K.; Kachuwaire, O.; Basotli, J.; Maribe, T.] Botswana Natl TB Reference Lab, Gaborone, Botswana. [Bachhuber, M. A.; Bile, E.; Basotli, J.; Makombe, R.; Shepherd, J.; Samandari, T.] CDC Botswana, Gaborone, Botswana. [El-Halabi, S.] Botswana Minist Hlth, Gaborone, Botswana. RP Menzies, HJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM hmenzies@cdc.gov NR 18 TC 2 Z9 2 U1 0 U2 6 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD SEP PY 2014 VL 18 IS 9 BP 1026 EP 1033 DI 10.5588/ijtld.13.0749 PG 8 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA AO4CM UT WOS:000341283800004 PM 25189548 ER PT J AU Parija, D Patra, TK Kumar, AMV Swain, BK Satyanarayana, S Sreenivas, A Chadha, VK Moonan, PK Oeltmann, JE AF Parija, D. Patra, T. K. Kumar, A. M. V. Swain, B. K. Satyanarayana, S. Sreenivas, A. Chadha, V. K. Moonan, P. K. Oeltmann, J. E. TI Impact of awareness drives and community-based active tuberculosis case finding in Odisha, India SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE active case finding; outreach; surveillance; awareness drives; Revised National Tuberculosis Control Programme AB India's Revised National Tuberculosis Control programme employs passive case detection. The new sputum smear-positive case detection rate is less than 70% in Odisha State. During April June 2012, active case finding (ACF) was conducted through awareness drives and field-based tuberculosis (TB) screening in select communities with the lowest case detection rates. During the campaign, 240 sputum smear-positive TB cases were detected. The number of smear-positive cases detected increased by 11% relative to April June 2011 in intervention communities compared to an 0.8% increase in non-intervention communities. ACF brought TB services closer to the community and increased TB case detection. C1 [Parija, D.; Sreenivas, A.] World Hlth Org Country Off India, New Delhi, India. [Patra, T. K.; Swain, B. K.] Govt Odisha, Dept Hlth, Bhubaneswar, Orissa, India. [Kumar, A. M. V.; Satyanarayana, S.] South East Asia Reg Off, Int Union TB & Lung Dis, New Delhi, India. [Chadha, V. K.] Natl TB Inst, Bangalore, Karnataka, India. [Moonan, P. K.; Oeltmann, J. E.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Parija, D (reprint author), Directorate Hlth Serv, State TB Cell, Heads Dept Bldg, Bhubaneswar, Orissa, India. EM parijad@gmail.com OI Moonan, Patrick/0000-0002-3550-2065 FU Health and Family Welfare Department, Government of Odisha, Bhubaneshwar, India; Union from Global Fund Round 9 India TB Project funds; WHO-India from United States Agency for International Development funds; Tamil Nadu State Heath Society, Chennai, India (RNTCP) FX The authors would like to thank the staff of the Health Department, Odisha, for participating and contributing to this study. We would also like to thank E Pevzner and S Shah for their thoughtful review of the manuscript. We are grateful to the Health and Family Welfare Department, Government of Odisha, Bhubaneshwar, India, for supporting us in carrying out the study, providing access to reports and official documents, and funding the project.; Funding support was provided, in part, by The Union from Global Fund Round 9 India TB Project funds and by WHO-India from United States Agency for International Development funds, and the Tamil Nadu State Heath Society, Chennai, India (RNTCP) under research head. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 4 TC 5 Z9 5 U1 0 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD SEP PY 2014 VL 18 IS 9 BP 1105 EP 1107 DI 10.5588/ijtld.13.0918 PG 3 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA AO4CM UT WOS:000341283800016 PM 25189560 ER PT J AU Olsen, EO Kann, L Vivolo-Kantor, A Kinchen, S McManus, T AF Olsen, Emily O'Malley Kann, Laura Vivolo-Kantor, Alana Kinchen, Steve McManus, Tim TI School Violence and Bullying Among Sexual Minority High School Students, 2009-2011 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE School violence; School bullying; LGBT youth; Sexual minority students; Youth Risk Behavior Surveys ID RISK BEHAVIOR SURVEILLANCE; PEER VICTIMIZATION; SUICIDE ATTEMPTS; SOCIAL SUPPORT; UNITED-STATES; YOUTH; GAY; ADOLESCENTS; HEALTH; ORIENTATION AB Purpose: School-based victimization has short-and long-term implications for the health and academic lives of sexual minority students. This analysis assessed the prevalence and relative risk of school violence and bullying among sexual minority and heterosexual high school students. Methods: Youth Risk Behavior Survey data from 10 states and 10 large urban school districts that assessed sexual identity and had weighted data in the 2009 and/or 2011 cycle were combined to create two large population-based data sets, one containing state data and one containing district data. Prevalence of physical fighting, being threatened or injured with a weapon, weapon carrying, and being bullied on school property and not going to school because of safety concerns was calculated. Associations between these behaviors and sexual identity were identified. Results: In the state data, sexual minority male students were at greater risk for being threatened or injured with a weapon, not going to school because of safety concerns and being bullied than heterosexual male students. Sexual minority female students were at greater risk than heterosexual female students for all five behaviors. In the district data, with one exception, sexual minority male and female students were at greater risk for all five behaviors than heterosexual students. Conclusions: Sexual minority students still routinely experience more school victimization than their heterosexual counterparts. The implementation of comprehensive, evidence-based programs and policies has the ability to reduce school violence and bullying, especially among sexual minority students. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Olsen, Emily O'Malley; Kann, Laura; Kinchen, Steve; McManus, Tim] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30329 USA. [Vivolo-Kantor, Alana] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30329 USA. RP Olsen, EO (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Mailstop E-75,1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM eolsen@cdc.gov NR 39 TC 7 Z9 7 U1 9 U2 62 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD SEP PY 2014 VL 55 IS 3 BP 432 EP 438 DI 10.1016/j.jadohealth.2014.03.002 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA AO2HE UT WOS:000341138400021 ER EF